ishlt.org/ishlt2023
#ISHLT2023

ISHLT 2023

43rd ANNUAL MEETING & SCIENTIFIC SESSIONS

Wednesday, 19 April – Saturday, 22 April 2023
Colorado Convention Center | Denver, CO, USA

FINAL PROGRAM

@ISHLT
@TheISHLT
@TheISHLT
/company/ishlt

ANNUAL MEETING GENERAL INFORMATION

Meeting Location

The ISHLT 43rd Annual Meeting & Scientific Sessions will be held in person at the Colorado Convention Center in Denver, CO USA. Full details about the meeting are available at ishlt.org/ishlt2023.

Continuing Education Information

Please visit the ISHLT2023 Continuing Education Information page for full details.

2022-2023 Board Of Directors

Andreas Zuckerman, MD, Austria, President
Jason D Christie, MD, MS, USA, President-Elect
Lara Danziger-Isakov, MD, MPH, USA, Past President
Martin Goddard, FRCS, MRCPa, United Kingdom, Secretary
Peter Hopkins, FRACP, Australia, Treasurer
Caron Burch, RN, MSN, FNP, CCTC, USA, Director
Edward Cantu, MD, MSCE, USA, Director
Marc De Perrot, MD, MSc, Canada, Director
Daniel Dilling, MD, USA, Director
Mardi Gomberg-Maitland, MD, MSc, USA, Director
Are Holm, MD, PhD, Norway, Director
Kiran Khush, MD, USA, Director
Angela Lorts, MD, MBA, USA, Director
Tereza Martinu, MD, MHS, Canada, Director
Jignesh Patel, MD, PhD, USA, Director
Diyar Saeed, MD, PhD, Germany, Director

ISHLT Staff

Greg Schultz, CAE, Chief Executive Officer
Aaron Adair, Chief Operating Officer
Sue Bessner, Director of Education and Research
Jess Burke, CAE, IOM, Director of Marketing and Communications
Jacky Schweinzger, CMP, Director of Meetings and Industry Partnerships
Megan Barrett, Programs Manager
Lisa Collins, Meetings and Industry Partnerships Manager
Susie Newton, Scientific Programs Manager
Alyssa Simpson, Marketing and Communications Manager
Juliet Osazemwinde, Governance and Communities Administrator
Olivia Taylor, Education Program Administrator

141 West Jackson Suite 1340
Chicago, IL 60604 USA
Phone: +1-312-224-1277
www.ishlt.org

ISHLT2023 ANNUAL MEETING SCIENTIFIC PROGRAM PLANNING COMMITTEE

The ISHLT would like to thank the following individuals who worked tirelessly to build an outstanding scientific program for the ISHLT Annual Meeting and Scientific Sessions.

❖ Denotes Team Leader

EXECUTIVE PROGRAM COMMITTEE

Howard Eisen, MD, USA, ISHLT2023 Scientific Program Chair
Andreas Zuckermann, MD, Austria, ISHLT President
Laurie Snyder, MD, USA, ISHLT2022 Scientific Program Chair
Goran Dellgren, MD, PhD, Sweden, ISHLT2024 Scientific Program Chair

ADVANCED HEART FAILURE AND TRANSPLANTATION TEAM:

❖ Angela Velleca, RN, BSN, MHDS, CCTC, USA
Estela Azeka, MD, PhD, Brazil
Javier Carbone, MD, PhD, Spain
Kevin Daly, MD, USA
Emily Granger, MBBS, Australia
Kyung-Hee Kim, MD, PhD, South Korea
Ivan Knezevic, MD, PhD, Slovenia
Rebecca Kumar, MD, USA
Arne Neyrinck, MD, PhD, Belgium
Dylan Miller, MD, USA
Sonia Mirabet-Perez, MD, PhD, Spain
Yael Peled, MD, Israel
Lynn Punnoose, MD, USA
Tara Veasey, PharmD, USA

ADVANCED LUNG FAILURE AND TRANSPLANTATION TEAM:

❖ Ciara Shaver, MD, PhD, USA
Daniel Calabrese, MD, USA
Silvia Campos, PhD, Brazil
Joshua Diamond, MD, USA
Asvin Ganapathi, MD, USA
David Hwang, MD, PhD, Canada
Steven Ivulich, BPharm, Australia
Monique Malouf, FRACP, Australia
Archer Martin, MD, USA
Marc Schecter, MD, USA
Patrick Smith, PhD, MPH, USA
Wiebke Sommer, MD, Germany

MECHANICAL CIRCULATORY SUPPORT TEAM:

❖ David Baran, MD, USA
Alexander Bernhardt, MD, Germany
Melissa Cousino, PhD, USA
Paolo Grossi, MD, PhD, Italy
Amanda Ingemi, PharmD, MPH, USA
Jamila Kremer, MD, Germany
Kiran Mirza, MD, Denmark
Sanem Nalbantgil, MD, Turkey
David Peng, MD, USA
Jaimin Trivedi, MD, MPH, USA
Peter Von Homeyer, MD, FASE, USA
Katharina Wassilew, MD, MHBA, UK

PULMONARY VASCULAR DISEASE (PAH & CTEPH) TEAM:

❖ Manreet Kanwar, MD, USA
Maurice Beghetti, MD, Switzerland
Carol Farver, MD, USA
Patricia Ging, MSc, Ireland
Shahid Husain, MD, MS, Canada
Brittany Koons, PhD, USA
Micheal McInnis, MD, Canada
Olaf Mercier, MD, PhD, France
Michael Perch, MD, Denmark
Alessandra Verzelloni Sef, MD, UK

SYMPOSIUM PROPOSAL SUBMITTERS:

The ISHLT would like to thank the following individuals who submitted symposium proposals for consideration to the meeting.

Mustafa Ahmed, USA
Sophia Airhart, USA
Peta Alexander, Australia
Kaushik Amancherla, USA
Ambalavanan Arunachalam, USA
William Auger, USA
Nicholas Avdimiretz Canada
Meghan Aversa, Canada
Dipanjan Banerjee, USA
Neha Bansal, USA
Yaron Barac, Israel
Christopher Barnett, USA
Alberto Benazzo, Austria
Luke Benvenuto, USA
Anju Bhardwaj, USA
Kadir Caliskan, Netherlands
Manuela Camino Lopez, Spain
Pedro Catarino, USA
Richard Cheng, USA
Colin Church, UK
Paolo Colombo, USA
Hannah Copeland, USA
Richard Cosgrove, USA
Andrew Courtwright, USA
Adrian daSilva-deAbreu, USA
Kavita Dave, UK
Ersilia DeFilippis, USA
Eugene DePasquale, USA
Nhue DO, USA
Sam Emmanuel, Australia
Charles Fauvel, USA
Paulo Pego Fernandes, Brazil
Julien Fessler, France
Nadia Fida, USA
Nitheesha Ganta, USA
Puneet Garcha, USA
Andrew Gelman, USA
Vasiliki Gerovasili, UK
Livia Goldraich, Brazil
Daniel R. Goldstein, USA
Rohan Goswami, USA
John Greenland, USA
Harpreet Grewal, USA
Donna Guadiz, USA
Courtney Harris, USA
Jaime Hernandez Montfort, USA
Konrad Hoetzenecker, Austria
Edward Horn, USA
Eileen Hsich, USA
Mandisa-Maia Jones, USA
Arun Jose, USA
Forum Kamdar, USA
Nandkishore Kapadia, India
Darshak Karia, USA
Hayah Kassis, USA
Rachna Kataria, USA
Amy Kiskaddon, USA
Nicholas Kolaitis, USA
Sheila Krishnan, USA
Christiane Kugler, Germany
Matthew Lander, USA
Erika D. Lease, USA
Candice Lee, USA
Deborah Levine, USA
Gregory Lewis, USA
Sern Lim, UK
Shin Lin, USA
Christopher Link, USA
Tereza Martinu, Canada
Hansie Mathelier, USA
Yasbanoo Moayedi, Canada
Andrew Morley-Smith, UK
Mrudula Munagala, USA
Nandini Nair, USA
Emil Najjar, Sweden
Joshua Newman, USA
Jignesh Patel, USA
Stephanie Pouch, USA
Mahyar Pourriahi, USA
Ann Punnoose, USA
Rajalingam Raja, USA
Aniket Rali, USA
Allison Ramsey, USA
Varinder Randhawa, USA
Ravi Kumar Ratnagiri, India
Anna Reed, UK
María Renedo, Argentina
Anja Roden, USA
Stefan Roest, Netherlands
Justin Rosenheck, USA
Lorenzo Rosso, Italy
Ana Roussoulieres, Belgium
Sandeep Sahay, USA
Maria-Nieves Sanz, Switzerland
Kelly Schlendorf, USA
Thomas Schloeglhofer, Austria
Sarah Schroeder, USA
Palak Shah, USA
Xin Si, USA
Marc Simon, USA
Shashank Sinha, USA
Kristin Stawiarski, USA
Gerin Stevens, USA
Dong Tian, China
Marian Urban, USA
Nir Uriel, USA
Jean-Luc Vachiery, Belgium
Maryam Valapour, USA
Nicole Valenzuela, USA
Georgina Waldman, USA
Amin Yehya, USA
Rayan Yousefzai, USA
Melana Yuzefpolskaya, USA
Lorenzo Zaffiri, USA

ABSTRACT REVIEWERS

The ISHLT would like to thank the following individuals who reviewed abstracts submitted to the meeting.

Rayid Abdulqawi, Saudi Arabia
Mohammad Abuannadi, USA
Deepak Acharya, USA
Rosalyn Adigun, USA
Maxwell Afari, USA
Neha Agarwal, USA
Miriam Aguilar Perez, Spain
Mustafa Ahmed, USA
Clemens Aigner, Austria
Nathan Airhart, USA
Sophia Airhart, USA
Mohammad Al-Ani, USA
Ana Alba, Canada
Nael Aldweib, USA
Juan Alejos, USA
Natasha Aleksova, Canada
Kevin Alexander, USA
Tamas Alexy, USA
Hazim AL-Haideri, UK
Rami Alharethi, USA
Hakim Ali, USA
Omaima Ali, USA
Othman Aljohani, USA
Jesus Almendral, USA
Stacy Al-Saleh, USA
Sammar Alsunaid, USA
Elvis Amao, Spain
Cristiano Amarelli, Italy
Amrut Ambardekar, USA
Shahnawaz Amdani, USA
Allen Anderson, USA
Ambar Andrade, USA
Annalisa Angelini, Italy
Fatima Anjum, USA
Samantha Anthony, Canada
Beatrice Aramini, Italy
Selim Arcasoy, USA
Chandrasekaran Arumugam, India
Ambalavanan Arunachalam, USA
Shambhu Aryal, USA
Saima Aslam, USA
Carl Atkinson, USA
William Auger, USA
Nicholas Avdimiretz, Canada
Kamal Ayyat, USA
Fernando Bacal, Brazil
Esther Bae, USA
Nataliya Bahatyrevich, USA
Dipanjan Banerjee, USA
Maria Bano, USA
Neha Bansal, USA
Yaron Barac, Israel
Markus Barten, Germany
Sylvie Baudart, USA
David Bearl, USA
Jennifer Bell, USA
Elizabeth Belloli, USA
Christian Benden, Switzerland
David Bennett, Italy
Celine Bergeron, Canada
Alessandro Bertani, Italy
Sai Bhagra, UK
Anju Bhardwaj, USA
Sanjeeb Bhattacharya, USA
Arvind Bhimaraj, USA
Filio Billia, Canada
Abbas Bitar, USA
Katharine Black, USA
Peggy Blood, USA
Matthew Bock, USA
Udo Boeken, Germany
Brent Boettcher, USA
Carmel Bogle, USA
Indra Bole, USA
Vaibhav Bora, USA
Brandi Bottiger, USA
Robert Boucek, USA
Andrew Boyle, USA
Gerard Boyle, USA
Yevgeniy Brailovsky, USA
Stacey Brann, USA
Heidi Brink, USA
Nicholas Brown, USA
Nicolas Brozzi, USA
Marie Budev, USA
Caron Burch, USA
Michael Burke, USA
Arene Butto, USA
Marco Caccamo, USA
Kadir Caliskan, Netherlands
Jose Campo-Canaeral de la Cruz, Spain
Marlene Cano, USA
Charles Canter, USA
Charles Canver, USA
Michael Carboni, USA
Michele Carboni, Italy
Waldemar Carlo, USA
Anthony Carnicelli, USA
Philip Carrott, USA
Alfred Casillan, USA
Francesco Castagna, USA
Maria Castel, Spain
Natalia Castillo Almeida, USA
Javier Castrodeza, Spain
Pedro Catarino, USA
Kevin Chan, USA
Michael Chan, Canada
Wandy Chan, Australia
Sandra Chaparro, USA
Prangthip Charoenpong, USA
Nathalie Chateauvert, Canada
Khaled Chatila, USA
Vinh Chau, USA
Sanjay Chaudhary, USA
Sunit-Preet Chaudhry, USA
Patricia Chavez, USA
Leway Chen, USA
Robert Chen, USA
Richard Cheng, USA
Lin-Chiang Chou, USA
Jennifer Chow, USA
Jose Cifrian, Spain
Tamara Claridge, USA
Stephen Clark, UK
Emily Clausen, USA
Kevin Clerkin, USA
Adam Cochrane, USA
Erin Coglianese, USA
Robert Cole, USA
Stephane Collaud, Germany
Bailey Colvin, USA
Michael Combs, USA
Johanna Contreras, USA
Jennifer Conway, Canada
Hannah Copeland, USA
Maria Dolores Cosio, Spain
Jenalee Coster, USA
Andrew Courtwright, USA
Guillaume Coutance, France
Laura Coyle, USA
Maria Crespo, USA
Maria Currie, USA
Jennifer Dan, USA
Friederike Danne, Germany
Bibhuti Das, USA
Adrian daSilva-deAbreu, USA
Kavita Dave, UK
Ryan Davies, USA
Jennifer Day, USA

Nicolaas De Jonge, Netherlands
Teresa De Marco, USA
Michel De Pauw, Belgium
Marc De Perrot, Canada
Susan Denfield, USA
Eugene DePasquale, USA
Oliver Dewald, Germany
Anne Dipchand, Canada
Chandima Divithotawela, Australia
Nhue Do, USA
Fabienne Dobbels, Belgium
Karen Doucette, Canada
Robert Dowling, USA
Anique Ducharme, Canada
Juan Duero Posada, Canada
Debi Dumas-Hicks, USA
Imo Ebong, USA
Dawn Eck, USA
Peter Eckman, USA
Harald Eichstaedt, Germany
Magdy El-Sayed Ahmed, USA
Jean Elwing, USA
Sam Emmanuel, Australia
Fabian Emrich, Germany
Amir Emtiazjoo, USA
Eric Epailly, France
Paul Esteso, USA
Melanie Everitt, USA
Patrick Evrard, Belgium
Gregory Ewald, USA
Elie Fadel, France
Gloria Faerber, Germany
Christine Falk, Germany
David Faraoni, USA
Alexander Fardman, Israel
Marta Farrero Torres, Spain
Savitri Fedson, USA
Julien Fessler, France
Andreas Fiene, Australia
Stephen Forest, USA
Erik Frandsen, USA
Meg Fregoso, USA
Miriam Freundt, USA
Joshua Friedland-Little, USA
Ashley Fritz, USA
Laura Frye, USA
Sheng Fu, USA
Takeo Fujino, Japan
Louise Fuller, Australia
Masaki Funamoto, USA
Erik Fung, Canada
Tji Gan, Netherlands
Puneet Garcha, USA
Jose Garcia, USA
Bradley Gardiner, Australia
Sonia Garg, USA
Theresa Gelzinis, USA
Vasiliki Gerovasili, UK
Hussam Ghalib, USA
Gerard Giblin, USA
Claudia Gidea, USA
Allan Glanville, Australia
Laurent Godinas, Belgium
Justin Godown, USA
Siew Goh New Zealand
Livia Goldraich, Brazil
Oscar Gonzalez Fernandez, UK
Jose Gonzalez-Costello, Spain
Matthew Goodwin, USA
Jeffrey Gossett, USA
Jens Gottlieb, Germany
Kathleen Grady, USA
Alice Gray, USA
Mark Greer, Germany
Cynthia Gries, USA
Eric Griffiths, USA
Cesar Guerrero-Miranda, USA
Ashrith Guha, USA
Julien Guihaire, France
Yizhan Guo, USA
Dipankar Gupta, USA
Ramsey Hachem, USA
Amy Hackmann, USA
Jennifer Hajj, USA
Shelley Hall, USA
Kieran Halloran, Canada
Eman Hamad, USA
Michele Hamilton, USA
Jonathan Hand, USA
Thomas Hanff, USA
Rajinder Singh Harjit Singh, Australia
Courtney Harris, USA
Matthew Hartwig, USA
Reema Hasan, USA
Z. Hashmi, USA
Don Hayes, USA
Stephanie Heeney, USA
Christian Heim, Germany
Erik Henricksen, USA
Donna Hickling, Australia
Lutz Hilker, Germany
Kelley Hitchman, USA
Osami Honjo, Canada
Robert Hooker, USA
Kyle Hope, USA
Peter Hopkins, Australia
David Hormuth, USA
Edward Horn, USA
Brian Houston, USA
Molly Howsare, USA
Michael Hsin Hong Kong
Chih-Hsin Hsu Taiwan
Stephen Huddleston, USA
Maya Ignaszewski, USA
Onyedika Ilonze, USA
Teruhiko Imamura, Japan
Debra Isaac, Canada
Ilker Iskender, Belgium
Michael Ison, USA
Peter Ivak, Czech Republic
Renea Jablonski, USA
Gregory Jackson, USA
Samuel Jacob, USA
Peter Jaksch, Austria
Gina Jamero, USA
Daniel Jane-Wit, USA
George Javorsky, Australia
Khalil Jawad, Canada
David Jenkins, UK
Mylvaganam Jeyakanthan, UK
Jonathan Johnson, USA
Maryl Johnson, USA
Mandisa-Maia Jones, USA
Arun Jose, USA
Namita Joseph, USA
Anand Jothidasan, UK
Jose Ernesto Juarez Leon, Mexico
Stephen Juvet, Canada
Soma Jyothula, USA
Annemarie Kaan, Canada
Dima Kabbani, Canada
David Kaczorowski, USA
Thomas Kaleekal, USA
Markus Kamler, Germany
Andrew Kao, USA
Nandkishore Kapadia, India
Darshak Karia, USA
Mahwash Kassi, USA
Hayah Kassis, USA
Rachna Kataria, USA
Tomoko Kato, Japan
Beth Kaufman, USA
Vaidehi Kaza, USA
Katherine Kearney, Australia
Brian Keller, USA
Jamie Kennedy, USA

Umit Kervan Turkey
Suresh Keshavamurthy, USA
Wissam Khalife, USA
Basha Khan, India
Michael Khoury, Canada
Sean Kiley, USA
Ahmet Kilic, USA
Gene Kim, USA
In-Cheol Kim South Korea
Ju Kim, USA
Miae Kim, USA
Steven Kindel, USA
Christopher King, USA
Kaan Kirali Turkey
Amy Kiskaddon, USA
Audrey Kleet, USA
Liviu Klein, USA
Rebecca Klingbeil, USA
Ken Knecht, USA
Christoph Knosalla, Germany
Michael Koerner, USA
Kevin Koomalsingh, USA
Benjamin Kopecky, USA
Katherine Kozarek, USA
Deborah Kozik, USA
Annemarie Krauss, Germany
Selim Krim, USA
Kewal Krishan, USA
Jill Krisl, USA
Bartosz Kubisa, Poland
Christiane Kugler, Germany
Hanneke Kwakkel-van Erp, Belgium
Anna Kydd, USA
Jacqueline Lamour, USA
Matthew Lander, USA
Caroline Landry, Canada
Kathryn Langley, USA
Sharon Larson, USA
Bilal Lashari, USA
Jacob Lavee, Israel
Tatyana Lawrecki, USA
Adrian Lawrence, USA
Lorriana Leard, USA
Erika D. Lease, USA
Roy Lee, USA
Sangjin Lee, USA
Karl Lemstrom Finland
Andrew Lenneman, USA
Laurie Letarte, USA
George Letsou, USA
Deborah Levine, USA
Heang Lim, USA
Sern Lim, UK
Jules Lin, USA
Shin Lin, USA
Sandra Lindstedt, Sweden
Antonio Loforte, Italy
Cathy Logan, USA
Erin Lowery, USA
Brian Lowes, USA
Renzo Loyaga-Rendon, USA
Lucian Lozonschi, USA
Francesca Lunardi, Italy
Scott Lundgren, USA
Fatima Lunze, USA
Me-Linh Luong, Canada
Aine Lynch, Canada
Haifa Lyster, UK
Irene Lytrivi, USA
Dennis Lyu, USA
Robroy MacIver, USA
John Mackintosh, Australia
Shivank Madan, USA
Brian Madden, USA
Jesper Magnusson, Sweden
Julia Maheshwari, USA
Jorge Mallea, USA
Chirantan Mangukia, USA
Olivier Manintveld, Netherlands
Yosef Manla United Arab Emirates
Charles Marboe, USA
Cindy Martin, USA
Sofia Martin-Suarez, Italy
Tereza Martinu, Canada
Marco Masetti, Italy
Sofia Masri, USA
Ligia Matos, Brazil
Simon Maybaum, USA
Matylda Mazur, USA
Amanda McCormick, USA
Allison McLarty, USA
Bruno Meiser, Germany
Vojtech Melenovsky, Czech Republic
Ernestina Melicoff-Portillo, USA
Aurelie Merlo, USA
Kumi Mesaki, Canada
Anna Meyer, Germany
Sebastian Michel, Germany
Levent Midyat, USA
Robert Miller, Canada
Andrea Miltiades, USA
Assi Milwidsky, USA
Yasbanoo Moayedi, Canada
Kanika Mody, USA
Selma Mohammed, USA
Thalachallour Mohanakumar, USA
Muhammad Mohiuddin, USA
Ezequiel Molina, USA
Nandan Mondal, USA
Jiyong Moon, USA
Joshua Mooney, USA
Charles Moore, USA
Clifford Moore, USA
Sarka Moravcova, UK
Paola Morejon Barragan, Ecuador
David Moreno McNeill, USA
Letizia Corinna Morlacchi, Italy
Robert Morlend, USA
Andrew Morley-Smith, United Kingdom
Eric Morrell, USA
Matthew Morrell, USA
Tina Morris, USA
Madeline Morrison, USA
Catherine Orla Morrissey, Australia
Nicolas Mueller, Switzerland
Mrudula Munagala, USA
Catherine Murks, USA
Margaret Murray, USA
Michelle Murray Ireland
Kavitha Muthiah, Australia
Arun Nair, UK
Nandini Nair, USA
Emil Najjar, Sweden
Sravanthi Nandavaram, USA
Deipanjan Nandi, USA
Vinodh Nanjayya, Australia
Tathagat Narula, USA
Kristen Nelson McMillan, USA
Peter Neuburger, USA
Alina Nicoara, USA
Lazaros Nikolaidis, USA
Kentaro Noda, USA
Pierre-Emmanuel Noly, USA
Alan Nyquist, USA
Matthew O'Connor, USA
Michal Odermarsky, Sweden
Marish Oerlemans, Netherlands
Anne Olland, France
Minoru Ono, Japan
Juan Ortega-Legaspi, USA
Carlos Ortiz-Bautista, Spain
Jamel Ortoleva, USA
Francis Pagani, USA
Siddharth Pahwa, USA
Octavio Pajaro, USA

Alessandro Palleschi, Italy
Stephen Pan, USA
Anthony Panos, USA
Luca Paoletti, USA
Maria Papathanasiou, Germany
John Parent, USA
Chetan Pasrija, USA
Shravani Pasupneti, USA
Pujan Patel, USA
Snehal Patel, USA
Caroline Patterson, UK
Amit Pawale, USA
Simon Pecha, Germany
Megan Pelter, USA
Matthias Peltz, USA
Nitipong Permpalung, USA
Stephen Pettit, UK
Michael Pham, USA
Richard Pierson, USA
Nina Pilat, Austria
Sean Pinney, USA
Barbara Pisani, USA
Michelle Ploutz, USA
Gregor Poglajen, Slovenia
Jack Price, USA
Tomas Pulido, Mexico
Kriti Puri, USA
Adam Putschoegl, USA
Vijil Rahulan, India
Eugenia Raichlin, USA
Jayant Raikhelkar, USA
Amresh Raina, USA
Rajalingam Raja, USA
Navin Rajagopalan, USA
Indranee Rajapreyar, USA
Bhavadharini Ramu, USA
Varinder Randhawa, USA
Roopa Rao, USA
Sriram Rao, USA
Ravi Kumar Ratnagiri, India
Yazhini Ravi, India
Ashwin Ravichandran, USA
Filip Rega, Belgium
João Eurico Reis, Portugal
Benjamin Renaud-Picard, France
María Renedo Argentina
Nosheen Reza, USA
Gustavo Ribeiro, Brazil
Alexandra Rice, UK
Marc Richmond, USA
Ilaria Righi, Italy
Ivan Robbins, USA
Desiree Robson, Australia
Yogita Rochlani, USA
Anja Roden, USA
Benjamin Rohrer, USA
Nicola Ronan Ireland
Filippos Paschalis Rorris Greece
Andrew Rosenbaum, USA
Justin Rosenheck, USA
Joseph Rossano, USA
Victor Rossel Chile
Ana Roussoulieres, Belgium
Darya Rudym, USA
Siavosh Saatee, USA
Marwa Sabe, USA
Sahar Saddoughi, USA
Andrew Sage, Canada
Sandeep Sahay, USA
Satoshi Saito, Japan
Marcos Samano, Brazil
Rohan Samson, USA
Melissa Sanchez, UK
Pablo Sanchez, USA
Elena Sandoval, Spain
Ricardo Sandoval, Mexico
Pedro Santos, USA
David Sayah, USA
Michael Scala, USA
Janet Scheel, USA
Sarah Schettle, USA
Kelly Schlendorf, USA
Thomas Schloeglhofer, Austria
Bruno Schnegg, Switzerland
Stephan Schueler, UK
Macé Schuurmans, Switzerland
Stefan Schwarz, Austria
Martin Schweiger, Switzerland
Javier Segovia-Cubero, Spain
Kristen Sell-Dottin, USA
Elena Seminari, Italy
Dipesh Shah, USA
Esther Shao, USA
Ashish Sharma, USA
Fawwaz Shaw, USA
Tao Shen, USA
Renata Shih, USA
Akira Shimamoto, Japan
Nabin Shrestha, USA
Yasuhiro Shudo, USA
Bhavana Siddegowda Bangalore, USA
Aleem Siddique, USA
Kirandeep Sidhu, USA
Daniel Silverman, USA
Daniel Sims, USA
Jonathan Singer, USA
Nikki Singh, USA
Sanjeet Singh, UK
Cumara Sivathasan Singapore
Bronwyn Small, USA
Melissa Smallfield, USA
Joshua Smith, USA
Mark Snyder, USA
Pallavi Solanki, USA
Osama Soliman Ireland
Tae Song, USA
James St. Louis, USA
Kristin Stawiarski, USA
Josef Stehlik, USA
Gerin Stevens, USA
Ulrich Stock, UK
Douglas Stoller, USA
Heather Strah, USA
Swethika Sundaravel, USA
David Sutcliffe, USA
Jose Tallaj, USA
Satona Tanaka, Japan
Daniel Tang, USA
W.H. Wilson Tang, USA
Inna Tchoukina, USA
Jeffrey Teuteberg, USA
Sarumathi Thangavel, USA
Brandi Thoma, USA
Debra Thomas, UK
Josef Thul, Germany
Dong Tian, China
Rade Tomic, USA
Van-Khue Ton, USA
Laurens Tops, Netherlands
Madeleine Townsend, Canada
John Trahanas, USA
Howie Tran, USA
Maxime Tremblay-Gravel, Canada
Anil Trindade, USA
Dirk Troitzsch, Germany
Anna Tsirka, USA
Sebastian Tume, USA
Grant Turner, USA
Patricia Uber, USA
Izabella Uchmanowicz, Poland
Marian Urban, USA
Nir Uriel, USA
Simon Urschel, Canada
Piedad Ussetti, Spain
Jean-Luc Vachiery, Belgium
Ajay Vaidya, USA

Maryam Valapour, USA
Cassandra Vale, Australia
Adrian Van Bakel, USA
Caroline Van De Wauwer, Netherlands
Linda Van Laake, Netherlands
Mrinalini Venkata Subramani, USA
Veronique Verplancke, Belgium
Erik Verschuuren, Netherlands
Amanda Vest, USA
Jorge Villalpando, USA
Andre Vincentelli, France
Jan von der Thusen, Netherlands
Robin Vos, Belgium
Bojan Vrtovec, Slovenia
Julie Wacker, Switzerland
Georgina Waldman, USA
Rajat Walia, USA
Krishnan Warrior, USA
Tatsuaki Watanabe, Japan
Shawn West, USA
Helen Whitford, Australia
Markus Wilhelm, Switzerland
Barbara Wilkey, USA
Chad Witt, USA
Carol Wittlieb-Weber, USA
Cameron Wolfe, USA
Yu Wu, USA
Yoshito Yamada, Japan
Roh Yanagida, USA
Xiucheng Yang, China
Amin Yehya, USA
Daniel Yip, USA
Rayan Yousefzai, USA
David Youssef, Australia
Melana Yuzefpolskaya, USA
Lorenzo Zaffiri, USA
Martin Zamora, USA
Xiaohai (Sam) Zhang, USA
Xin Zhang, China
Tomasz Zielinski, Poland
Daniel Zimpfer, Austria
Warren Zuckerman, USA

SCIENTIFIC CONTENT

For the most up to date version of the scientific program, download the **ISHLT2023** Mobile App.

ISHLT 2023

Looking for CME Information?

Visit ishlt.org/ishlt2023 and look for the CME Information page.

Still have questions? Send an email to meetings@ishlt.org

WEDNESDAY, 19 APRIL, 2023

8:00 – 9:30 a.m.

GENERAL SESSION (PLENARY) I

Location: Four Seasons Ballroom

Core Therapies: ALL
Practice Areas: ALL

Co-Chairs: Howard Eisen, MD, Penn State Hershey Medical Center, Hershey, PA United States
Andreas Zuckermann, MD, Medical University of Vienna, Vienna Austria

8:00 a.m. ***ISHLT Scientific Program Chair Report***
Howard Eisen, MD, Penn State Hershey Medical Center, Hershey, PA USA

8:10 a.m. ***ISHLT President's Report***
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

8:25 a.m. ***FEATURED PRESENTATION:*** **(1)** ***Severe Pediatric Pulmonary Arterial Hypertension. Long-Term Outcomes of Reverse Potts Shunt and Transplantation***; E. Valdeolmillos[1], J. Le Pavec[2], M. Audie[3], L. Savale[4], X. Jais[5], S. Feuillet[6], O. Sitbon[7], O. Mercier[8], J. Petit[3], M. Humbert[9], E. Fadel[10], E. Belli[11], S. Hascoet[3]. *[1]Department of Congenital Heart Diseases, Marie Lannelongue Hospital Groupe Hospitalier Paris-Saint Joseph, Plessis Robinson, France, [2]Department of Pulmology, Hôpital Marie Lannelongue, Groupe Hospitalier Paris-Saint Joseph, Le Plessis-Robinson, France, [3]Marie Lannelongue Hospital Groupe Hospitalier Paris-Saint Joseph, Plessis Robinson, France, [4]Hospital Bicetre, Le Kremlin-Bicêtre, France, [5]Le Kremlin-Bicêtre, France, [6]Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France, [7]Hopital Antoine Beclere, Clamart Paris, France, [8]Department of Thoracic and Vascular Surgery, Marie Lannelongue Hospital Groupe Hospitalier Paris-Saint Joseph, Plessis Robinson, France, [9]Hospital De Bicetre, Le Kremlin-Bicêtre, France, [10]Hospital Marie Lannelongue, Le Plessis-Robinson, France, [11]Marie Lannelongue Hopsital Groupe Hospitalier Paris-Saint Joseph, Plessis Robinson, France*

8:35 a.m. ***Q&A with Interactive Discussant***
Lori West, MD, DPhil, University of Alberta, Edmonton, AB Canada

8:40 a.m. ***Forced Organ Procurement in China***
Ethan Gutmann, China Studies Research Fellow, Victims of Communism Memorial Foundation; Co-Founder, International Coalition to End Transplant Abuse in China, Washington, DC USA

9:05 a.m. ***Commentary on Ethics in Thoracic Organ Transplantation***
Are Holm, MD, PhD, Oslo University Hospital, Oslo, Norway

9:15 a.m. ***FEATURED PRESENTATION:*** **(2)** ***Subgroup Safety Analyses in Solid Organ Transplant (SOT) Recipients in a Phase 3 Trial of Maribavir (MBV) versus Investigator-Assigned Therapy (IAT) for Cytomegalovirus (CMV) Infection (Refractory with or without Resistance; R/R)***; R. M. La Hoz[1], D. Florescu[2], D. Kumar[3], F. Saliba[4], J. Gu[5], A. Sundberg[5]. *[1]University of Texas Southwestern Medical Center, Dallas, TX, [2]University of Nebraska Medical Center, Omaha, NE, [3]University Health Network, Toronto, ON, Canada, [4]University Paris Saclay, Villejuif, France, [5]Takeda Development Center Americas, Inc., Lexington, MA*

9:25 a.m. ***Q&A with Interactive Discussant***
Ann Woolley, MD, MPH, Brigham & Women's Hospital, Boston, MA USA

10:00 – 11:00 a.m.

SESSION 01: A BRIDGE TOO FAR? ETHICS OF ORGAN PROCUREMENT USING THORACIC NORMOTHERMIC REGIONAL PERFUSION

Location: Four Seasons Ballroom

Core Therapies: HEART, LUNG, MCS
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pediatrics, Pulmonology

Session Summary: Thoracic normothermic regional perfusion (T-NRP) allows for controlled heart and lung procurement following circulatory determination of death. T-NRP employs an extracorporeal circuit to restart the heart after circulatory death; however, brain perfusion is surgically prevented prior to during restoration of circulation. Ethical concerns have been raised regarding the use of extracorporeal circuits to produce heart-beating, brain dead donors, including whether T-NRP violates the dead donor rule. Co-Chairs will lead speakers in a 15-minute panel discussion and Q&A at the end of the session, addressing the controversial questions pertaining to T-NRP and then opening the session to general Q&A from the audience.

Co-Chairs: Andrew Courtwright, MD, PhD, Hospital of the University of Pennsylvania, Philadelphia, PA USA
Anne Olland, MD, PhD, University Hospital Strasbourg, Strasbourg France
Arne Neyrinck, MD, PhD, Leuven University Hospitals, Leuven Belgium

10:00 a.m. ***Introduction to Thoracic Normothermic Regional Perfusion: Technical and Legal Considerations***
Dirk Van Raemdonck, MD, PhD, University Hospitals Leuven, Leuven, Belgium

Speaker will overview technical aspects of different T-NRP procedures, including transition from death by circulatory criteria to death by brain-death criteria. Speaker will describe outcomes of organs procured with T-NRP, also disclosing potential differences between hearts and lungs harvested with this technique. In addition, the current regulatory status of T-NRP in relevant ISHLT-member countries will be reviewed.

10:15 a.m. ***Ethical Concerns in T-NRP Organ Procurement with Focus on the Donor***
Savitri Fedson, MD, MA, Michael E. DeBakey VA Medical Center, Houston, TX USA

The speaker will highlight primary ethical considerations around T-NRP with focus on the donors (i.e. discussions with donor family, definition of death, comfort care during removal of life support, community perceptions, etc.) including potential violation of dead donor rule, ascertainment of donor death, respect for donor autonomy, distinction between permanent and irreversible, between adults and pediatrics, disclosure to surrogate decision makers, and trust in organ procurement systems.

10:30 a.m. ***Ethical Concerns with Focus on the Recipient in T-NRP Organ Procurement***
Pedro Catarino, MD, Cedars-Sinai Heart Institute, Los Angeles, CA USA

The speaker will highlight primary ethical considerations around T-NRP, with focus on organ recipients (what to tell family, effect on allocation, equity issues as some centers do this and other don't, competing interest for heart/lung/abdominal organs), and beneficence in both adults and pediatrics, as well as trust in organ transplant systems.

10:45 a.m. ***Panel Discussion***

WEDNESDAY, 19 APRIL, 2023

10:00 – 11:00 a.m.

SESSION 02: DIVING INTO THE ROLE OF MITOCHONDRIA IN HEART TRANSPLANTATION

Location: Rooms 603-605

Core Therapies: HEART, LUNG
Practice Areas: Research and Immunology, Cardiology, Cardiothoracic Surgery, Pediatrics, Pharmacy

Session Summary: Mitochondria are more than the powerhouse of our cells. They are the largest cellular producers of oxygen free radicals, they contain their own DNA, and they can be produced or recycled according to cellular needs. This session will highlight unique features of mitochondrial components and parameters as potential biomarkers of heart quality and cardiac rejection and will introduce new cardioprotective therapies acting through mitochondrial mechanisms. The session will conclude with a moderated panel discussion led by the co-chairs.

Co-Chairs: Christine Lau, MD, MBA, University of Maryland, Baltimore, MD USA
Javier Carbone, MD, PhD, Hospital General Universitario Gregorio Marañón, Madrid, Spain

10:00 a.m. ***Mitochondrial Components: A New Generation of Biomarkers in Heart Transplantation***
Sarah Longnus, PhD, University Hospital, Berne, Switzerland

This talk will introduce the relevance of mitochondria in heart transplantation. Novel mitochondrial components, such as, cytochrome c, succinate and mitochondrial DNA, will be described and their potential use as biomarkers of hearts status prior to transplantation will be discussed

10:15 a.m. ***Mitochondria Have Something Important to Tell You About Heart Rejection and You Did Not Know***
Martin Cadeiras, MD, University of California Davis, Sacramento, CA USA

Mitochondria are emerging as potent immunomodulators agents. In this talk, recent evidence pointing out mitochondrial parameters and/or components as robust markers of heart rejection will be described. Attention will be given to markers assessed in biopsies and cell-free mitochondrial DNA. The potential association of mitochondrial dysfunction and CAV will also be included.

10:30 a.m. ***Let's Put Something New in the Box: How Mitochondrial Therapies Can Improve the Quality of Organs***
James McCully, PhD, Boston Children's Hospital, Boston, MA USA

Innovative therapies targeting mitochondrial parameters, as well as mitochondrial transplantation, are emerging in pre-clinical models of heart transplantation and will be reviewed during the talk.

10:45 a.m. ***Panel Discussion***

10:00 – 11:00 a.m.

SESSION 03: BACK TO THE FUTURE OF AMR: A MULTIDISCIPLINARY SYMPOSIUM

Location: Rooms 401-404

Core Therapies: LUNG
Practice Areas: Cardiothoracic Surgery, Pathology, Pharmacy and Pharmacology, Pulmonology, Research and Immunology

Session Summary: The aim of this symposium is twofold: to present the current state of knowledge on the detection, pathogenesis, and treatment of antibody-mediated rejection and to analyze knowledge gaps to inform future directions. The session begins with a case of donor:recipient selection and then continues with detailed discussion of the complex pathological and serological presentation of AMR, new advances in detection of deleterious antibodies, and novel therapeutics in the pipeline. A multidisciplinary approach will present AMR in its complexity and promote knowledge exchange between different fields. Following each talk, co-chairs will lead a brief Q&A segment with the speaker and encourage questions from the audience.

Co-Chairs: Glen Westall, FRACP, PhD, Alfred Hospital, Melbourne, VIC Australia
Meghan Aversa, MD, University of Toronto, Toronto, ON Canada

10:00 a.m. ***Case Presentation: To Treat or Not to Treat? That is the Question***
Jake Natalini, MD, MSCE, NYU Langone Health, New York, NY USA

This short talk will introduce a case of a lung transplant recipient with a 15% decline in FEV1 from baseline and biopsy negative for acute cellular rejection who is found to have both class I and class II donor-specific antibodies. This case will set the stage for the session addressing ongoing challenges in AMR diagnostics and treatment.

10:06 a.m. ***Pulmonary AMR: Meeting the Challenge in 2023***
Deborah Levine, MD, Stanford University, Palo Alto, CA USA

This talk will summarize the updates from the AMR Working Group including information on standardizing surveillance, monitoring and testing for Pulmonary AMR based on risk assessment and stratification.

10:18 a.m. ***Q&A***

10:24 a.m. ***Updates in DSA: Evaluation and Detection of Pulmonary AMR***
Adriana Zeevi, PhD, University of Pittsburgh, Pittsburgh, PA USA

This talk will discuss advances in the detection of donor-specific antibodies (HLA and non-HLA) using innovative techniques as well as new opportunities for detection of pulmonary AMR in biopsy specimens.

10:36 a.m. ***Q&A***

10:42 a.m. ***The Present and the Future of AMR Treatment***
Adam Cochrane, PharmD, MPH, Inova Fairfax Hospital, Falls Church, VA USA

This presentation will provide a comprehensive overview of current and future AMR therapeutic strategies. To promote a multidisciplinary approach, special attention will be given to the immunological rationale behind them. In addition, relevant clinical trials in this field will be discussed.

10:54 a.m. ***Q&A***

10:00 – 11:00 a.m.

SESSION 04: PULMONARY ARTERIAL HYPERTENSION IS RISKY BUSINESS!

Location: Rooms 501-504

Core Therapies: PVD, HEART, LUNG
Practice Areas: Cardiology, Pediatrics, Pulmonology

Session Summary: This session will review recent updates and clinical aspects of risk-stratification in PAH.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: Risk stratification in PAH requires a comprehensive intake of clinical, hemodynamic and imaging parameters which will be presented in this session.

Co-Chairs: Jason Weatherald, MD, MSc, University of Alberta, Edmonton, AB Canada
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA USA

10:00 a.m. ***Real-Life Risk Stratification in PAH: When and How and How Often***
Sandeep Sahay, MD, Houston Methodist Hospital, Houston, TX USA

Review the clinical practice and methods of risk-stratification in PAH, including recommended time-points during the course of the disease

10:08 a.m. ***3-Risk Strata System in PAH***
Laurent Savale, MD, PhD, Hospital Bicetre, Le Kremlin-Bicêtre, France

Review the 3-risk strata stratification in PAH, with focus on recent ESC/ERS recommendation.

10:16 a.m. ***RV Imaging and Risk-Stratification in PAH***
Roberto Badagliacca, MD, PhD, University of Rome Sapienza, Roma, Italy

Review the role of RV imaging in risk-stratification in PAH

10:24 a.m. ***Hemodynamics That Predict Outcomes in PAH***
Charles Fauvel, MD, The Ohio State University, Columbus, OH USA

Review the role of hemodynamics that predict outcomes in PAH

10:32 a.m. ***Risk Stratification in Pediatric PH: Where Are We, With the Kids?***
Allen Everett, MD, Johns Hopkins University School of Medicine, Baltimore, MD USA

Review updates in risk-stratification in PAH in pediatric patient population

10:40 a.m. ***Panel Discussion and Audience Vote***

10:00 – 11:00 a.m.

SESSION 05: SHOTS! SHOTS! SHOTS! COVID-19 VACCINES IN HEART TRANSPLANT RECIPIENTS

Location: Rooms 205-207

Core Therapies: HEART
Practice Areas: Infectious Diseases, Cardiology, Cardiothoracic Surgery, Research and Immunology

Session Summary: This session will discuss the latest data in heart transplant recipients for COVID-19 vaccine strategies, immune response to vaccine, and the bivalent booster.

Co-Chairs: Jonathan Hand, MD, Ochsner Medical Center, New Orleans, LA USA
Rebecca Kumar, MD, Georgetown University Hospital Center, Washington, DC USA

10:00 a.m. **(5)** ***COVID-19 Vaccination Strategies in Solid Organ Transplant Recipients: A Living Systematic Review and Network Meta-Analysis***; D. G. Rayner[1], J. T. Nunes[2], A. Chu[1], A. Orchanian-Cheff[2], F. Foroutan[2], C. Rotstein[2], H. J. Ross[2], N. Aleksova[2]. *[1]McMaster University, Hamilton, ON, Canada, [2]Toronto General Hospital, Toronto, ON, Canada*

10:15 a.m. **(6)** ***BNT162b2-Vaccine-Induced Neutralization Responses are Immune Correlates of Clinical Protection Against SARS-CoV-2 in Heart Transplant Recipients***; Y. Peled[1], J. Patel[2], E. Raanani[1], A. Segev[1], S. Matezki[1], E. Ram[1], A. Fardman[1], R. Beigel[1], N. Atari[3], L. Kliker[3], B. Abd Elkader[3], M. Mandelboim[3], A. Afek[1]. *[1]Sheba Medical Center and Tel Aviv University, Ramat Gan, Israel, [2]Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, [3]Ministry of Health, Ramat Gan, Israel*

10:30 a.m. **(7)** ***Cellular and Humoral Responses to Vaccination Before or after SARS-CoV-2 Infection - Bridging the Knowledge Gap to End the Pandemic for Heart Transplant Recipients***; Y. Peled[1], J. Patel[2], E. Raanani[1], A. Segev[1], S. Matezki[1], E. Ram[1], A. Fardman[1], R. Beigel[1], N. Atari[3], L. Kliker[3], B. Abd Elkader[3], A. Afek[1], M. Mandelboim[3]. *[1]Sheba Medical Center and Tel Aviv University, Ramat Gan, Israel, [2]Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, [3]Ministry of Health, Ramat Gan, Israel*

10:45 a.m. **(8)** ***5th Dose Bivalent Omicron-Containing Booster Vaccine Against Covid-19 in Heart Transplant Recipients***; Y. Peled[1], J. Patel[2], E. Raanani[1], A. Segev[1], S. Matezki[1], E. Ram[1], A. Fardman[1], R. Beigel[1], N. Atari[3], L. Kliker[3], B. Abd Elkader[3], A. Afek[1], M. Mandelboim[3]. *[1]Sheba Medical Center and Tel Aviv University, Ramat Gan, Israel, [2]Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, [3]Ministry of Health, Ramat Gan, Israel*

10:00 – 11:00 a.m.

SESSION 06: PEDIATRIC M.C.S. = MULTI-CENTER COLLABORATIVE SUCCESS!

Location: Rooms 405-407

Core Therapies: MCS
Practice Areas: Pediatrics, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health

Session Summary: Important collaborative research in the pediatric VAD field will be presented in this session. New technology and outcomes for the most challenging pediatric patient populations will be covered.

Co-Chairs: Joseph Spinner, MD, Baylor College of Medicine, Houston, TX USA
Deipanjan Nandi, MD, Nationwide Children's Hospital, Columbus, OH USA

10:00 a.m. **(9)** ***Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Outcomes Report***; C. Bonilla Ramirez[1], M. Shezad[2], C. J. VanderPluym[3], M. Bleiweis[4], H. Tunuguntla[5], A. Joong[6], D. Rosenthal[7], A. Lorts[1], S. Auerbach[8], I. Adachi[9], R. Davies[10], M. O'Connor[11]. *[1]Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [2]Cincinnati Children's Hospital, Cincinnati, OH, [3]Boston Children's Hospital, Boston, MA, [4]UF Health Congenital Heart Center, Gainesville, FL, [5]Texas Children's Hospital, Houston, TX, [6]Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, [7]stanford, Portland, OR, [8]University of Colorado, Denver, [9]Children's Hospital, Houston, TX, [10]Children's Health, UT Southwestern, Dallas, TX, [11]Children's Hospital of Philadelphia, Wynnewood, PA*

10:15 a.m. **(10)** ***Size Isn't Everything: Survival for Very Small Infants Supported by VAD***; E. L. Frandsen[1], M. Shezad[2], N. Shwaish[3], M. O'Connor[4], A. Lorts[5], J. Philip[6], M. Bleiweis[7], P. McConnell[8], J. Friedland-Little[9]. *[1]Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA, [2]Cincinnati Children's Hospital, Cincinnati, OH, [3]Loma Linda University, Redlands, CA, [4]Children's Hospital of Philadelphia, Wynnewood, PA, [5]Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [6]Congenital Heart Center-UF Health, Gainesville, FL, [7]UF Health Congenital Heart Center, Gainesville, FL, [8]Nationwide Children's Hospital, Hilliard, OH, [9]Seattle Children's Hospital, Seattle, WA*

10:30 a.m. **(11)** ***A Novel Mobile Driving System Improves the Quality of Life of Children Treated with a Paracorporeal Ventricular Assist Device***; O. Miera[1], E. Sandica[2], A. Kamphues[3], M. Schweiger[4], B. Stiller[5], R. Kozlik-Feldmann[6], M. Perez[7], S. Schubert[8], D. Zimpfer[9]. *[1]Congenital Heart Disease / Pediatric Cardiology, German Heart Center Berlin, Berlin, Germany, [2]Center for Congenital Heart Disease/Dep. of Surgery for Congenital Heart Defects, Heart- and Diabetescenter NRW, Bad Oeynhausen, Germany, [3]Pediatric Cardiology and Intensive Care, Ludwig Maximilian University of Munich, Munich, Germany, [4]Children's Hospital Zurich, Zürich, ZH, Switzerland, [5]University of Freiburg, Germany, Freiberg, Germany, [6]Clinic for Children's Heart Medicine and Adults with Congenital Heart Disease, University Heart & Vascular Center, Hamburg, Germany, [7]Women-Mother-Child Department, University Hospital of Lausanne, Lausanne, Switzerland, [8]Herz- und Diabeteszentrum NRW and German Heart Center Berlin, Bad Oeynhausen, Germany, [9]Medical University Vienna, Vienna, Austria*

10:45 a.m. **(12)** ***Post-Stage 2 Palliation Single Ventricular Assist Device Outcomes: An Advanced Cardiac Therapies Improving Outcomes Network (Action) Registry Analysis***; E. J. Rabinowitz[1], M. Mehegan[2], A. Joong[3], M. Shezad[4], E. Griffiths[5], M. J. O'Connor[6], D. Mokshagundam[1], A. S. Said[1]. *[1]Washington University in St Louis, St Louis, MO, [2]St Louis Children's Hos, Saint Louis, MO, [3]Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, [4]Cincinnati Children's Hospital, Cincinnati, OH, [5]University of Utah, Salt Lake City, UT, [6]Children's Hospital of Philadelphia, Wynnewood, PA*

10:00 – 11:00 a.m.

SESSION 07: THERE AND BACK AGAIN: SCIENCE OF LUNG ISCHEMIA-REPERFUSION INJURY AND PRIMARY GRAFT DYSFUNCTION

Location: Rooms 201-203

Core Therapies: LUNG
Practice Areas: Research and Immunology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Pathology, Pediatrics, Pharmacy, Pulmonology

Session Summary: This session describes basic mechanisms of IRI and PGD after lung transplantation, including potential therapeutic targets.

Co-Chairs: John McDyer, MD, University of Pittsburgh, Pittsburgh, PA USA
Mena Botros, MD, Houston Methodist Hospital, Houston, TX USA

10:00 a.m. **(13)** ***A Single Nucleotide Polymorphism in Donor MICB Protects from NKG2D-Mediated Primary Graft Dysfunction and Death***; O. A. Aguilar[1], A. E. Qualls[1], M. D. Gonzalez-Hinojosa[1], J. Singer[2], W. Raymond[1], S. Hays[3], J. Golden[4], J. Kukreja[5], J. Diamond[6], J. Christie[6], L. L. Lanier[1], J. Greenland[1], D. R. Calabrese[1]. *[1]University of California, San Francisco, San Francisco, CA, [2]UC San Francisco, San Francisco, CA, [3]UCSF Medical Center, San Francisco, CA, [4]UCSF, San Francisco, CA, [5]University of California San Francisco, San Francisco, CA, [6]University of Pennsylvania, Philadelphia, PA*

10:15 a.m. **(14)** ***CCR5 Mediates Natural Killer Cell Airway Trafficking in Lung Ischemia Reperfusion Injury***; J. Santos, S. Cleary, P. Wang, A. Shemesh, T. Tsao, E. Aminian, M. R. Looney, J. R. Greenland, D. R. Calabrese. *University of California, San Francisco, San Francisco, CA*

10:30 a.m. **(15)** ***The Role of Heparanase Activation on Ischemia-Reperfusion Injury in Mice***; K. Noda[1], P. Sanchez[2]. *[1]University of Pittsburgh, Pittsburgh, PA, [2]University of Pittsburgh Medical Center, Pittsburgh, PA*

10:45 a.m. **(16)** ***WITHDRAWN***

10:45 a.m. **(372)** ***Increased Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Expression in Epithelial Club Cells in Acute Lung Allograft Dysfunction***; O. Mekhael[1], A. Duong[2], M. Dianti[3], A. Tian[4], B. Renaud-Picard[5], T. Daigneault[4], S. Juvet[2], T. Martinu[6]. *[1]Toronto Lung Transplant Program, Ajmera Transplant Centre, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, [2]University Health Network, Toronto, ON, Canada, [34]Toronto, ON, Canada, [5]Nouvel Hopital Civil, Strasbourg, France, [6]Toronto General Hospital/UHN, Toronto, ON, Canada*

11:30 a.m. – 12:30 p.m.

SPECIAL SESSION: ISHLT EN ESPAÑOL: ABORDAJE DEL SHOCK CARDIOPULMONAR (STRATEGIES TO MANAGE CARDIOPULMONARY SHOCK)

Location: Rooms 603-605

Core Therapies: MCS, HEART, LUNG
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing & Allied Health, Pharmacy and Pharmacology, Pulmonology

Esta sesión se llevará a cabo en español. (This session will be conducted in Spanish.)

Resumen de la sesión: La sesión discutirá estrategias para manejar el shock cardiopulmonar. Se discutirá las intervenciones médicas y quirúrgicas, incluidas las indicaciones para los pacientes, qué pacientes y el momento para iniciar estas modalidades de tratamiento. La sesión también discutirá el manejo de los pacientes en estos diversos tratamientos. Esta sesión se llevará a cabo en español.

*(**Session Summary**: The session will discuss strategies to manage cardiopulmonary shock. It will discuss medical and surgical interventions including indications for patients, which patients and the timing to initiate these treatment modalities. The session will also discuss the management of patients once on these various treatments.)*

Formato Pecha Kucha: El término japonés para el sonido de la conversación ("charla"), el estilo del simposio está diseñado para mantener presentaciones concisas y de ritmo rápido. La sesión comenzará con una breve descripción del Tema Unificador, seguida por cinco disertantes, cada uno de los cuales tendrá 8 minutos para discutir el tema, usando 20 diapositivas en total y sólo dedicando 20 segundos por diapositiva. Los últimos 20 minutos serán para preguntas y respuestas de la audiencia y un voto para el disertante ganador.

*(**Pecha Kucha Format**: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.)*

Tema unificador: Los países pueden abordar el shock cardiopulmonar desde diferentes perspectivas. Nos centraremos en estos enfoques e intentaremos identificar el vínculo común que podría mejorar la identificación y el manejo.
*(**Unifying Theme**: Countries may approach cardiopulmonary shock from different perspectives. We will focus on these approaches and try to identify the common link that could improve the identification, and management.)*

CME no se ofrece para esta sesión. ***(CME is not offered for this session.)***

Co-Chairs: Hannah Copeland, MD, Lutheran Medical Group, Fort Wayne, IN USA
Paola Morejon Barragan, MD, Clinica Guayaquil, Guayaquil, Ecuador

11:30 a.m. ***Tema: ¿ Cómo Lo Hacen? Modelos Organizativos Para El Shock Cardiogénico En Todo El Mundo (Topic: How Do They Do It? Organizational Models For Cardiogenic Shock Across The World)***
Jaime Hernandez Montfort, MD, MPH, MSc. Baylor Scott and White Health, Austin, TX USA

Descripción del tema: el disertante analizará los diferentes modelos de equipos de choque cardiogénico en todo el mundo. El orador discutirá quiénes componen estos equipos, es decir, cirujanos, intensivistas, cardiólogos, etc. El orador discutirá el papel de cada miembro del equipo y su contribución al equipo.

(The speaker will discuss various models of cardiogenic shock teams across the world. The speaker will discuss who makes up these teams, ie surgeons, intensivists, cardiologists etc. The speaker will discuss each team members role and contribution to the team.)

11:38 a.m.

Tema: Allí Estaré: Experiencias ECMO Móviles
(Topic: I Will Be There: Mobile ECMO Experiences)
Adriana Torres, MD, Los Cobos Medical Center, Bogotá, Colombia

El disertante hablará sobre varias experiencias de ECMO móvil en todo el mundo, desde poner a los pacientes en ECMO en el campo, en las calles de la ciudad, en otro hospital y luego transferir al paciente al hospital de origen. El manejo del paciente en campo previo a su llegada al hospital.

(The speaker will discuss various Mobile ECMO experiences across the world, from putting patients on ECMO in the field, the streets of the city, in another hospital and then transferring the patient to the home hospital. The management of the patient in the field prior to arrival at the hospital.)

11:46 a.m.

Tema: Shock Cardiogénico en PAH: La Última Frontera
(Cardiogenic Shock in PAH: The Last Frontier)
Christian Bermudez, MD, Hospital of the University of Pennsylvania, Philadelphia, PA USA

El disertante abordará cómo manejar el shock cardiogénico en el paciente con HAP - identificar la HAP, cuándo no conoce al paciente y cómo manejar al paciente con terapia médica, versus diferentes intervenciones quirúrgicas.

(The speaker will address how to manage cardiogenic shock in the PAH patient - identifying PAH, when you do not know the patient, and how to manage the patient with medical therapy, versus different surgical interventions.)

11:54 a.m.

Tema: No Me Detengas Ahora: Manejo del Shock Debido a Una Embolia Pulmonar
(Don't Stop Me Now: Management of Shock Due to Pulmonary Embolism)
Maria Crespo, MD, Hospital of the University of Pennsylvania, Philadelphia, PA USA

El disertante discutirá el diagnóstico temprano del paciente con embolia pulmonar aguda, PERT (equipo de respuesta a la embolia pulmonar), manejo médico con anticoagulación, cuándo escalar a ECMO-VA, soporte para la falla del ventrículo derecho y embolectomía pulmonar aguda.

(The speaker will discuss early diagnosis of the acute pulmonary embolism patient, PERT (pulmonary embolism response team), medical management with anticoagulation, when to escalate to VA ECMO, RVAD support, and acute pulmonary embolectomy.)

12:02 p.m.

Tema: Todo en un Nombre: Choque en Poblaciones Menos Favorecidas - ¿ Misma Enfermedad Pero Diferentes Oportunidades?
(All In a Name: Shock in Less Favoured Populations - Same Disease But Different Opportunities?)
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain

El disertante discutirá el shock cardiogénico en varias poblaciones, es decir, la mujer pequeña (problemas de acceso vascular), frágil (paciente delgado, caquéctico), obeso mórbido (acceso difícil), pacientes embarazadas y aquellos con falta de acceso a la atención (desiertos de salud).

(The speaker will discuss cardiogenic shock in various populations ie the small female (vascular access issues), frail (thin, cachectic patient), morbidly obese (difficult access), pregnant patients and those with lack of access to care (health deserts).)

12:10 p.m.

Panel Discussion and Audience Vote

WEDNESDAY, 19 APRIL, 2023

1:00 – 2:00 p.m.

SESSION 08: *JHLT* YEAR IN REVIEW

Location: Rooms 603-605

Core Therapies: ALL
Practice Areas: ALL

Session Summary: The JHLT Editors will introduce some of the most influential papers published in JHLT from 2022. These papers will be selected by the editors in early 2023. The "Top 4" original research papers, one from each area of heart transplant, lung transplant, MCS, and pulmonary arterial hypertension, will be presented by Early Career Editors, who will discuss the key findings of the study and describe the importance of the paper in moving the field forward. A senior editor from each area will co-chair the session and lead a brief Q&A discussion with the presenter following each presentation, with the goal of bringing out key additional learning points for the audience.

Co-Chairs:
Michelle Kittleson, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA USA
Marcelo Cypel, MD, University Health Network, Toronto, ON Canada
Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Ryan Tedford, MD, Medical University of South Carolina, Charleston, SC USA

1:00 p.m. ***The Most Influential JHLT Mechanical Circulatory Support Paper in 2022***
Aditi Nayak, MD, MS, Emory University, Atlanta, GA USA

This presentation will describe one of the most influential JHLT papers in the MCS space. The presenter will go over the rationale for the study, the key findings, and how it moves the field forward.

1:10 p.m. ***Q&A led by Senior Editor***

1:15 p.m. ***The Most Influential JHLT Lung Failure/Transplantation Paper in 2022***
Laurent Godinas, MD, PhD, UZ Leuven, Leuven, Belgium

This presentation will describe one of the most influential JHLT papers in the lung transplant space. The presenter will go over the rationale for the study, the key findings, and how it moves the field forward.

1:25 p.m. ***Q&A led by Senior Editor***

1:30 p.m. ***The Most Influential JHLT Pulmonary Arterial Hypertension Paper in 2022***
Carles Diez-Lopez, MD, Bellvitge University Hospital, Barcelona, Spain

This presentation will describe one of the most influential JHLT papers in the area of PAH. The presenter will go over the rationale for the study, the key findings, and how it moves the field forward.

1:40 p.m. ***Q&A led by Senior Editor***

1:45 p.m. ***The Most Influential JHLT Heart Failure/Transplantation Paper in 2022***
Kriti Puri, MBBS, Baylor College of Medicine, Houston, TX USA

This presentation will describe one of the most influential JHLT papers in the heart transplant space. The presenter will go over the rationale for the study, the key findings, and how it moves the field forward.

1:55 p.m. ***Q&A led by Senior Editor***

1:00 – 2:00 p.m.

SESSION 09: DIAGNOSIS OF HEART TRANSPLANT REJECTION: OUT WITH THE OLD, IN WITH THE NEW

Location: Rooms 401-404

Core Therapies: HEART
Practice Areas: Cardiology, Nursing & Allied Health, Pathology, Pediatrics, Research and Immunology

Session Summary: This session, in Pecha Kucha format, will provide an update on recent advances in the diagnosis of cardiac rejection including an update on current histological techniques, biopsy and blood-based genetic technologies.

Pecha Kucha Format: The Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: This session will bring together the latest technological advances in the diagnosis of cardiac allograft rejection (both ACR and AMR).

Co-Chairs: Jignesh Patel, MD, PhD, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA USA
Annalisa Angelini, MD, University of Padua, Padova, Italy

1:00 p.m. ***Through the Looking Glass: Advances in Histology***
Carolyn Glass, MD, PhD, Duke University Medical Center, Durham, NC USA
Discuss the potential of "computer-vision" technology and "artificial intelligence" to enhance diagnostic performance in improving the reliability and accuracy of EMB interpretation; Phenotyping the inflammatory cells using immunohistochemistry; Reassessing histopathology and the contribution of various structural myocardial injuries to allograft dysfunction or prognostic stratification (myocardial injury, "minimal rejection' and vasculitis).

1:08 p.m. ***Going Small: MicroRNA Analysis for the Diagnosis of Cardiac Allograft Rejection***
Palak Shah, MD, MS, Inova Heart and Vascular Institute, Falls Church, VA USA
Discuss the potential microRNAs (miRNAs) as biomarkers; Next-Generation Sequencing (NGS) technology in FFPE EMBs to explore miRNA expression profiles; The utility of intragraft miRNA profiles & signature to distinguish patients with rejection from patients without rejection to distinguish different types of ACR, pAMR, and mixed rejection.

1:16 p.m. ***Delving Deeper into the Biopsy: Intragraft Gene Profiling***
Daniel Kim, MD, University of Alberta, Edmonton, AB Canada
Discuss the molecular microscope diagnostic technique and the potential clinical implications.

1:24 p.m. ***Gene Expression Profiling: What's in a Score?***
Luciano Potena, MD, PhD, Bologna University Hospital, Bologna, Italy
Discuss the potential use of gene expression profiling variability to predict the probability of future clinical events in heart transplant recipients and the clinically validated data.

1:32 p.m. ***Capturing the Escaped: Cell Free DNA and Donor-Derived Exosomal Analysis***
Kiran Khush, MD, MAS, Stanford University, Stanford, CA USA
Techniques in development of Donor-derived cell-free DNA and Donor-derived Exosomal Analysis; Their potential as noninvasive use markers of rejection and discuss the data supporting clinically validate use in rejection diagnosis, Expand on the utility beyond that of rejection (sensitization, allograft vasculopathy).

1:40 p.m. ***Panel Discussion and Audience Vote***

1:00 – 2:00 p.m.

SESSION 10: MULTIDISCIPLINARY AVENGERS: DEFEATING THE LUNG PRIMARY GRAFT DYSFUNCTION HYDRA

Location: Four Seasons Ballroom

Core Therapies: LUNG, HEART, PVD, MCS
Practice Areas: Pulmonology, Cardiothoracic Surgery, Anesthesiology and Critical Care, Nursing & Allied Health

Session Summary: This session will discuss new approaches to reduce primary graft dysfunction with a focus on patient optimization before surgery and in the operating room, ending with a lively debate on whether intraoperative ECMO is beneficial or detrimental in terms of PGD risk.

Co-Chairs:	Archer Martin, MD, Mayo Clinic Florida, Jacksonville, FL USA Sandra Lindstedt, MD, PhD, Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden
1:00 p.m.	***Preoperative Optimization: Prehabilitation Program*** Jonathan Singer, MD, MS, University of California San Francisco, San Francisco, CA USA *Discuss pre-operative rehabilitation strategies to address frailty and explore its impact on development of PGD*
1:10 p.m.	***Q&A***
1:15 p.m.	***OR Extubation: Non-ECLS Approach to Improving PGD*** Julien Fessler, MD, Foch Lung Transplant Group, Paris, France *Review new data and approaches regarding early extubation that may reduce the risk of PGD.*
1:25 p.m.	***Q&A***
1:30 p.m.	***DEBATE: Intraoperative Per Protocol VA ECMO Attenuates PGD (PRO)*** Brandi Bottiger, MD, Duke University, Durham, NC USA *The speaker will argue that intraoperative ECMO is helpful in terms of protecting from PGD development/risk.*
1:40 p.m.	***DEBATE: Intraoperative Per Protocol VA ECMO Attenuates PGD (CON)*** Gabriel Loor, MD, Baylor College of Medicine, Houston, TX USA *The speaker will argue that intraoperative ECMO is harming in terms of protecting from PGD development/risk.*
1:50 p.m.	***Q&A***

1:00 – 2:00 p.m.

SESSION 11: A MILE HIGH IN DENVER: ELEVATING OUR UNDERSTANDING AND MANAGEMENT OF PEDIATRIC AND ADULT MCS INFECTIONS

Location: Rooms 501-504

Core Therapies: MCS, HEART
Practice Areas: Infectious Diseases, Cardiology, Cardiothoracic Surgery, Nursing & Allied Health, Pediatrics, Pharmacy and Pharmacology

Session Summary: This session is intended to provide a wide audience with important updates in the pathogenesis of device infections, novel adjuvant therapies for prevention and treatment of VAD infections, and 2023 ISHLT Definitions of Infections of Mechanical Circulatory Support. The session will conclude with a moderated panel discussion led by the co-chairs.

Co-Chairs: Stephanie Pouch, MD, MS, Emory University, Atlanta, GA USA
Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital Medical Center, Cincinnati, OH USA

1:00 p.m. ***Name that Infection: 2023 ISHLT Definitions for Infections of Mechanical Circulatory Support Devices***
Ezequiel Molina, MD, Piedmont Heart Institute/Samsky Advanced Heart Failure Center, Atlanta, GA USA

The speaker will provide an overview of the 2023 ISHLT Definitions of Infections of Mechanical Circulatory Support, including those relevant to percutaneous devices and ECMO.

1:12 p.m. ***Tiny Humans, Big Devices: Incidence and Impact of Infections in Pediatric MCS***
Scott Auerbach, MD, University of Colorado, Denver, CO USA

This talk will review the infection-related complications in pediatric MCS patients, especially related to the exit site. The discussion will include both traditional durable devices, as well as "temporary used as durable devices".

1:24 p.m. ***Make It Go Away: Lotions, Potions and Phages***
Saima Aslam, MD, MS, University of California San Diego, San Diego, CA USA

This talk will describe advances in phage isolation and treatment in general, as well as concentrating on the potential roles for patients with ventricular assist devices.

1:36 p.m. ***All It Takes is a Knife: Surgical Perspective on VAD Infections***
Ivan Knezevic, MD, PhD, University Medical Centre, Ljubljana, Slovenia

The presenter will review the outcomes of surgical management of durable MCS infections and the role of device replacement.

1:48 p.m. ***Panel Discussion***

WEDNESDAY, 19 APRIL, 2023

1:00 – 2:00 p.m.

SESSION 12: FOUR TO GO: WHO GROUP 4/CTEPH

Location: Rooms 205-207

Core Therapies: PVD
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pulmonology

Session Summary: This session will highlight research abstracts in the field of RV physiology with focus on chronic thromboembolic pulmonary hypertension (CTEPH).

Co-Chairs: Isabelle Opitz, MD, University Hospital, Zurich, Switzerland
Ivan Robbins, MD, Vanderbilt University Medical Center, Nashville, TN USA

1:00 p.m. **(17)** ***MicroRNA Expression Correlates with Clinical Presentation of Chronic Thromboembolic Pulmonary Hypertension***; I. Martínez López[1], T. Papasotiropoulos[1], F. Schlaepfer[1], S. Ulrich[2], I. Opitz[1], M. B. Kirschner[1]. *[1]Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, [2]Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland*

1:15 p.m. **(18)** ***Role of Endothelial-to-Mesenchymal Transition in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)***; M. Asghar[1], j. Man[2], L. Wu[2], M. De Perrot[3]. *[1]University Health Network, Toronto, ON, Canada, [2]Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada, [3]Toronto General Hospital, Toronto, ON, Canada*

1:30 p.m. **(19)** ***Grading Severity of Right Ventricular Dysfunction in Pulmonary Hypertension, a Mechanical Analysis***; B. Celestin[1], K. Ichimura[2], A. J. Sweatt[3], L. Chun[4], F. Haddad[5]. *[1]Cardiovascular Medecine, Stanford, Palo Alto, CA, [23]Medecine-Pulmonary Allergy and critical Care Medecine, Stanford, Palo Alto, CA, [4]Stanford, Palo Alto, CA, [5]Stanford University, Palo Alto, CA*

1:45 p.m. **(20)** ***Early Experience with Minimally Invasive Pulmonary Thromboendarterectomy for High-Risk Patients***; A. M. Vekstein[1], J. Armstrong[2], J. Haney[3]. *[1]Surgery, Duke University Medical Center, Durham, NC, [2]Duke University School of Medicine, Durham, NC, [3]Duke University, Durham, NC*

WEDNESDAY, 19 APRIL, 2023

1:00 – 2:00 p.m.

SESSION 13: RINGS OF POWER: CARDIOPULMONARY EFFECTS OF EVLP

Location: Rooms 405-407

Core Therapies: LUNG
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Pulmonology, Research and Immunology

Session Summary: This session reviews the latest insights into how EVLP has the ability to impact cardiopulmonary outcomes throughout the peri-operative period.

Co-Chairs: Wiebke Sommer, MD, University of Heidelberg, Heidelberg, Germany
Sue Braithwaite, MD, University Medical Center Utrecht, Utrecht, Netherlands

1:00 p.m. **(23)** ***First Report of the Organ Care System (OCS) Thoracic Organ Perfusion (TOP) Post-Approval Registry***; G. Loor[1], P. Garcha[2], S. Huddleston[3], M. Hertz[4], M. Hartwig[5], L. Snyder[6], A. Siddique[7], H. Strah[7], J. Kukreja[8], T. Song[9], R. Jablonski[10], M. Smith[11], R. Walia[12], A. Arjuna[13], L. Lozonschi[14], K. Patel[15], G. Katlaps[16], H. Nemeh[17], E. Suarez[18], H. Huang[19], N. Langer[20], J. Madsen[21], A. Lee[22], G. Dhillon[23], J. MacArthur[24], S. Keshavamurthy[25], S. Nandavaram[26], M. Daneshmand[27], D. Neujahr[28], E. Bush[29], D. Joyce[30], A. Ardehali[31], M. Budev[32], K. McCurry[33]. *[1]Cardiothoracic Surgery, Baylor St. Luke's Medical Center, Houston, TX, [2]Baylor College of Medicine, Houston, TX, [3]Cardiothoracic Surgery, University of Minnesotta, Minneapolis, MN, [4]University of Minnesota, Minneapolis, MN, [5]Duke University Medical Center, Durham, NC, [6]Duke University, Durham, NC, [7]University of Nebraska Medical Center, Omaha, NE, [8]University of California San Francisco, San Francisco, CA, [9]University of Chicago, Chicago, IL, [10]The University of Chicago, Chicago, IL, [11]St. Joseph's Hosp & Med Center Norton Thoracic Institute, Phoenix, AZ, [12]St. Joseph's Hospital and Medical Center Norton Thoracic Institute, Phoenix, AZ, [13]University of Florida, Phoenix, AZ, [14]University of South Florida, Tampa General Hospital, Tampa, FL, [15]USF Morsani College of Medicine, Tampa, FL, [16]University of South Florida, Tampa General Hospital, St Pete Beach, FL, [17]Henry Ford Hospital, Troy, MI, [18]Houston, TX, [19]Houston Methodist J.C. Walter Jr. Transplant Center, Houston, TX, [20]Massachusetts General Hospital, Wellesley, MA, [21]Massachusetts General Hospital, Charlestown, MA, [2223]Stanford University, Stanford, CA, [24]Stanford University, Palo Alto, CA, [25]University Of Kentucky, Lexington, Lexington, KY, [26]University of Kentucky, Lexington, KY, [27]Emory University, Durham, NC 27710, NC, [28]Emory Univesity, Atlanta, GA, [29]Johns Hopkins, Baltimore, MD, [30]Froedtert & the Med College of Wisconsin, Milwaukee, WI, [31]UCLA School of Medicine, Los Angeles, CA, [32]Cleveland Clinic, Pepper Pike, OH, [33]Cleveland Clinic, Solon, OH*

1:15 p.m. **(22)** ***A Computational Approach to Breath-By-Breath Ventilator Waveform Data Extraction and Analysis During Ex Vivo Lung Perfusion Enables Enhanced Physiological Lung Assessment***; X. Zhou[1], L. Del Sorbo[1], O. Hough[1], B. T. Chao[1], A. Ali[1], E. Brambate[1], R. V. Ribeiro[1], B. Gomes[1], M. Di Nardo[1], J. C. Yeung[1], M. Liu[1], M. Cypel[1], B. Wang[2], S. Keshavjee[1], A. T. Sage[1]. *[1]Toronto Lung Transplant Program and Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, [2]Department of Laboratory Medicine and Pathobiology and Department of Computer Science, University of Toronto, Toronto, ON, Canada*

1:30 p.m. **(21)** ***Negative Pressure Ventilation Ex-Situ Lung Perfusion Successfully Preserves Porcine Lungs and Rejected Human Lungs for 36-Hours***; K. A. Forgie[1], A. Ribano[2], K. Du[2], A. Watkins[2], D. Freed[3], J. Nagendran[2]. *[1]Cardiac Surgery, University of Alberta, Edmonton, AB, Canada, [2]University of Alberta, Edmonton, AB, Canada, [3]Stollery Children's Hospital, Edmonton, AB, Canada*

1:45 p.m. **(24)** ***Pseudo Cardiomyopathy in End-Stage Lung Disease With Elevated Pulmonary Vascular Resistance and/or Right Ventricular Dysfunction That Improves Following Lung Transplantation***; D. Blake[1], A. Patel[1], S. Hopkins[1], A. G. Del Pozo[2], J. Marx[2], M. Ibrahim[1], E. Hamad[1]. *[1]Temple University Hospital, Philadelphia, PA, [2]Lewis Katz School of Medicine, Temple University Hospital, Philadelphia, PA*

1:00 – 2:00 p.m.

SESSION 14: MUCH ADO ABOUT NOTHING? USING ARTIFICIAL INTELLIGENCE FOR THE BEST HEART TRANSPLANTATION OUTCOMES

Location: Rooms 201-203

Core Therapies: HEART
Practice Areas: Cardiology, Pathology, Pediatrics, Research and Immunology

Session Summary: Don't be scared using Artificial Intelligence (AI). This session explores its potential beneficial effect on heart transplantation outcomes.

Co-Chairs: Kyung-Hee Kim, MD, PhD, Incheon Sejong Hospital, Incheon, South Korea
Nir Uriel, MD, New York Presbyterian, New York, NY USA

1:00 p.m. **(25)** ***Machine Learning Ensemble Models for Predicting Post- Transplant Lymphoproliferative Disorder in Heart Transplant Recipients***; N. Nair[1], H. Johnston[2], D. Du[2]. *[1]Texas Tech University Health Sciences Center, Lubbock, TX, [2]Industrial and Structural Engineering, TTU, Lubbock, TX*

1:15 p.m. **(26)** ***Predicting Health Outcomes Using Machine Learning in Pediatric Heart Transplantation Using UNOS Data***; M. O. Killian[1], S. Tian[1], A. Xing[1], D. Gupta[2], Z. He[1]. *[1]Florida State University, Tallahassee, FL, [2]UF College of Medicine, Gainesville, FL*

1:30 p.m. **(27)** ***Explainable Machine Learning to Improve Donor-Recipient Matching at Time of Heart Transplant***; J. Xu[1], W. Dai[2], J. Goldberg[3], P. Shah[4], I. Hu[2], C. Chen[1], C. R. deFilippi[4], J. Sun[2]. *[1]Systems Engineering and Operations Research, George Mason University, Fairfax, VA, [2]Statistics, George Mason University, Fairfax, VA, [3]George Mason University, Inova L.J. Murphy Children's Hospital, Fairfax, VA, [4]Inova Heart and Vascular Institute, Falls Church, VA*

1:45 p.m. **(28)** ***Artificial Intelligence to Predict Death or Transplant in ATTR Amyloidosis Cardiomyopathy***; R. Goswami, J. Jang, J. Ruiz, S. Desai, S. Paghdar, S. Malkani, D. Yip, J. Leoni, P. Patel, M. Lyle, J. Nativi. *Transplant, Mayo Clinic, Jacksonville, FL*

2:15 – 3:45 p.m.

SESSION 15: LA VIDA LOCA: EXPANDING THE HEART DONOR POOL WITH DCD – PEARLS AND PITFALLS

Location: Four Seasons Ballroom

Core Therapies: ALL
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Pediatrics

Session Summary: Heart transplantation is a curative therapy for patients with end stage heart failure, however, the number of available organs continues to fall short of the number awaiting transplant. Donation after circulatory death (DCD), which is a common method of procuring kidneys, livers, and lungs for organ donation, has not had as widespread a role in heart transplantation. Countries with DCD heart transplant programs have significantly expanded their donor pool, with excellent post-transplant outcomes. These programs have developed complex procurement strategies whilst navigating ethical, technical and resource challenges. This session aims to review the logistics, pearls, and pitfalls for DCD heart transplantation. Can DCD heart transplantation go mainstream?

Co-Chairs: Gerin Stevens, MD, PhD, Northwell Health, New York, NY USA
Amy Fiedler, MD, University of California San Francisco, San Francisco, CA USA
Are Holm, MD, PhD, Oslo University Hospital, Oslo, Norway

2:15 p.m. ***Rolling the Dice: How to Start a DCD Heart Transplant Program***
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

To start at the beginning, a strong foundation must be built! This presentation will cover the challenges of starting a DCD heart transplantation program. Specifically, identification of key participants, needed resources, informed consent, avoiding conflicts of interest, and managing ethical considerations are critical to building a DCD heart program What is the 'ideal time-line' for establishing a program, how should outcomes be measured and is success guaranteed?

2:25 p.m. ***Playing One's Hand: Donor and Recipient Selection for DCD***
Emily Granger, MBBS, St. Vincent's Hospital, Sydney, NSW Australia

You've got to know when to hold 'em, know when to fold 'em, know when to walk away, and know when to run. Who is the ideal DCD heart donor and who is the ideal DCD heart recipient? This presentation will dive into the expanded donor pool of DCD hearts. The talk will explore the different donors who now may be considered, specifically the concept of 'warm/cold ischaemic time'?. How long can we wait for circulatory death, and what constitutes significant donor heart ischaemia, and how do we then assess the impact on donor heart? Furthermore, is there a preferred recipient for the DCD heart or do we now have a 'winning hand' for all! Once you roll the dice, what is the best strategy for managing the DCD heart beyond the operating theatre and into the intensive care. The talk will also advise on specific tips for managing typical challenges in the immediate peri-operative period: haemodynamics, bleeding, rejection and other bad cards!

2:35 p.m. ***Keeping Your Cards Close: Selecting and Prognosticating the DCD Donor***
Arne Neyrinck, MD, PhD, Leuven University Hospitals, Leuven, Belgium

This discussion looks at selection of DCD donors and their management. How can intensive care units predict the progression to circulatory death in the devastating brain

injury donors? What can be done to optimize outcomes for the potential organ recipient, yet still respect the needs and care of the donor patient?

2:45 - 3:15 p.m. ***DEBATE: Normothermic Regional Perfusion or Direct Procurement and Perfusion for DCD Heart Transplantation?***

Discussion in a pro-con style, with a 2-member pro team and 2-member con team. Moderators will pose a controversial question to the teams. Each team will have 5 minutes to respond to the question and present their team's argument. The moderator will then allow each team a 2-minute rebuttal of the opposition's argument. Question 1: The donor defines the technique: Donor choice, donor management, donor assessment: which technique is the superior? Question 2: The recipient outcome makes the difference: Recipient choice, recipient outcome: can I choose which is better for my patient?

2:45 p.m. ***PRO TEAM: Going With the Flow: NRP Rules - Real Time Retrieval is the Real Thing!***
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria
Ashish Shah, MD, Vanderbilt University Medical Center, Nashville, TN USA

3:00 p.m. ***CON TEAM: Rush and Retrieve: DPP is the Way to Go!***
Are Holm, MD, PhD, Oslo University Hospital, Oslo, Norway
Emily Granger, MBBS, St. Vincent's Hospital, Sydney, NSW Australia

3:15 p.m. ***Panel Discussion with Audience Q&A***

2:15 – 3:45 p.m.

SESSION 16: IF AT FIRST YOU DON'T SUCCEED, TRY, TRY AGAIN! HEART FAILURE AND TRANSPLANTATION IN FONTAN PATIENTS

Location: Rooms 603-605

Core Therapies: HEART, MCS, PVD
Practice Areas: Pediatrics, Anesthesiology & Critical Care, Cardiology, Cardiothoracic Surgery, Pharmacy, Pulmonology

Session Summary: This session will discuss the heart failure therapies and challenges of heart transplantation in patients with failing Fontan physiology. The session will conclude with a moderated panel discussion led by the co-chairs.

Co-Chairs: Neha Bansal, MD, Children's Hospital at Montefiore, Bronx, NY USA
David Peng, MD, University of Michigan, Ann Arbor, MI USA
Rayan Yousefzai, Houston Methodist Hospital, Houston, TX USA

2:15 p.m. ***Failure is Not an Option: Complications of Fontan Physiology***
Estela Azeka, MD, University of Sao Paulo, São Paulo, Brazil

This talk will discuss the chronic heart failure a single ventricle patient faces from the time of Fontan operation. The speaker will also discuss the unique physiologic state and how both systolic and diastolic ventricular dysfunction are frequently seen.

2:30 p.m. ***Not Good Enough! Using Conventional Heart Failure Therapies in Fontan Circulatory Failure***
Amy Kiskaddon, PharmD, Johns Hopkins All Children's Hospital, St. Petersburg, FL USA

This talk will discuss how standard adult heart failure pharmacotherapies are frequently employed in management of heart failure and discuss the little evidence supporting their efficacy in Fontan patients.

2:45 p.m. ***Under Pressure: Elevated Pulmonary Vascular Resistance in Fontan Patients***
Claire Irving, MBChB, MRCPCH, MD, Children's Hospital Westmead, Sydney, NSW Australia

Elevated pulmonary vascular resistance (PVR) plays a critical role in the failing Fontan, with even mild elevations in PVR resulting in detrimental effects. This talk will address the elevated Pulmonary Vascular resistance in Fontan patients: diagnostics, therapy and impact on transplant.

3:00 p.m. ***Peri- and Post-Operative Challenges and Strategies in the Heart Recipient with Fontan Circulation***
Viviane Nasr, MD, MPH, FASA. Boston Children's Hospital, Boston, MA USA

Vasoplegia, collateral flow, protein losing enteropathy, chronic drainage, and other unique post-transplant challenges in the heart recipient with Fontan circulation will be described. Best practices to address these complications will be shared.

3:15 p.m. ***Jury Still Out? Heart-Liver vs. Heart-Only Transplantation in Fontan Patients***
Kathleen Simpson, MD, University of Colorado Denver, Denver, CO USA

The speaker will discuss the difficulty in assessment of need of liver transplantation in Fontan patients, especially as work up for heart only vs heart-liver transplantation.

3:30 p.m. ***Panel Discussion***

2:15 – 3:45 p.m.

SESSION 17: DONOR LUNG ALLOCATION: PRIORITIZING URGENCY, ACCESS OR OUTCOMES - WHAT MATTERS MOST?

Location: Rooms 401-404

Core Therapies: LUNG
Practice Areas: Pulmonology, Nursing & Allied Health, Research and Immunology

Session Summary: The session will provide an overview of three donor lung allocation systems including the new continuous allocation system in the United States using the composite allocation system, France's relatively new lung allocation system utilizing supply and demand, and Scandiatransplant's Urgent Lung Allocation system (ScULAS). Finally, the session will end by reviewing the challenges faced by different countries and organ allocation systems and a discussion of the tradeoffs and benefits of each system.

Co-Chairs: Carli Lehr, MD, PhD, Cleveland Clinic Foundation, Cleveland, OH USA
Luke Benvenuto, MD, Columbia University, New York, NY USA

2:15 p.m. ***Composite Allocation System (CAS): What to Expect***
Maryam Valapour, MD, MPP, Cleveland Clinic, Cleveland, OH USA

Describe the framework of the new US lung allocation system and the projected impact of the system on the transplant population

2:30 p.m. ***Supply-Demand Ratio for Lung Allocation in France***
Antoine Roux, MD, PhD, Foch Hospital, Paris, France

The speaker will provide a general overview of allocation in France, why it was set up like it was, and how it is working (ie the pros/cons of such a system, equitability, and/or opportunities for improvement).

2:42 p.m. ***Multinational Urgent Lung Allocation in Scandiatransplant***
Hans Henrik Schultz, MD, PhD, Rigshospitalet, Copenhagen, Denmark

The Scandiatransplant Urgent Lung Allocation System (ScULAS) was introduced in 2009 to facilitate donor lung allocation across 4 countries. The talk will provide an overview of the system and review the benefits and limitations of the current system.

2:54 p.m. ***How the Lessons Learned From the US LAS Can Be Used to Inform International Models***
Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

Discuss impact of the LAS system on international transplant systems and if/how the expected changes to the US system may be useful to other countries

3:06 p.m. ***Pediatric Organ Allocation: Similarities and Differences Around the World***
Christian Benden, MD, MBA, FCCP, University of Zürich, Zurich, Switzerland

Discuss how organs are allocated to pediatric recipients in the US and internationally and highlight considerations unique to the pediatric population

3:18 p.m. ***Panel Discussion***

2:15 – 3:45 p.m.

SESSION 18: CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: A DECADE OF PROGRESS

Location: Rooms 501-504

Core Therapies: PVD, HEART, LUNG
Practice Areas: Cardiothoracic Surgery, Cardiology, Nursing & Allied Health, Pulmonology

Session Summary: Chronic thromboembolic pulmonary hypertension (CTEPH) is regarded as a potentially curable form of pulmonary vascular disease. This session provides a range of topics describing the ongoing clinical challenges, for both operable and inoperable CTEPH patients, as a result of advances in pulmonary endarterectomy surgery, the availability of approved PH targeted medical therapy, and the resurgence of balloon pulmonary angioplasty.

Co-Chairs: Joanna Pepke-Zaba, PhD, FRCP, Royal Papworth Hospital NHS Trust, Cambridge, United Kingdom
Marc De Perrot, MD, MSc, FRCSC, Toronto General Hospital, Toronto, ON Canada
William Auger, MD, University of California San Diego, San Diego, CA USA

2:15 p.m. ***What Are We Learning From Our CTEPH Registries?***
Marion Delcroix, MD, PhD, UZ Leuven, Leuven, Belgium

Over the past 10 years, several CTEPH-related registries from Europe/Canada, US, Japan and China have provided valuable insight into the diagnosis and management of CTEPH. This lecture will review results from the Global CTEPH registry (ICA) and longitudinal outcome data from the US CTEPH Registry.

2:30 p.m. ***Q&A***

2:33 p.m. ***PEA as a Cure for CTEPH: Re-examining Outcomes***
Michael Madani, MD, University of California San Diego, La Jolla, CA USA

Pulmonary endarterectomy often provides marked pulmonary hemodynamic and survival benefits in select CTEPH patients. This lecture will examine other patient-important outcomes post PEA, where additional non-surgical therapy may be appropriate.

2:48 p.m. ***Q&A***

2:51 p.m. ***Multimodality Approach in CTEPH: Choosing the Best Strategy for Segmental Disease***
Elie Fadel, MD, Hospital Marie Lannelongue, Le Plessis-Robinson, France

The option of a technically more challenging endarterectomy as opposed to the PH medical therapy and BPA treatment plan for patients with segmental level CTEPH will be discussed in this presentation.

3:06 p.m. ***Q&A***

3:09 p.m. ***BPA: The Search for Equipoise with PEA***
Hiromi Matsubara, MD, PhD, National Hospital Organization, Okayama Medical Center, Okayama, Japan

A critical examination of the possibility that Balloon Pulmonary Angioplasty might eventually result in comparable clinical outcomes in CTEPH patients to those achieved with PEA surgery

3:24 p.m. ***Q&A***

3:27 p.m. ***The Expansion of CTEPH Centers Around the World: Defining Capability and Credibility***
Isabelle Opitz, MD, University Hospital Zurich, Zurich, Switzerland
Beyond annual patient numbers, this lecture will review programmatic needs to become a CTEPH Center of Excellence, providing PH medical care, PEA and BPA services.

3:42 p.m. ***Q&A***

WEDNESDAY, 19 APRIL, 2023

2:15 – 3:45 p.m.

SESSION 19: A SHORT BRIDGE TO HEART TRANSPLANTATION: ARE WE BUILDING IT RIGHT?

Location: Rooms 205-207

Core Therapies: MCS
Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health

Session Summary: This session focuses on the perioperative use of short-term devices in the setting of heart transplantation

Co-Chairs: Claudius Mahr, DO, University of Washington, Seattle, WA USA
Emil Najjar, MD, PhD, Karolinska University Hospital, Stockholm, Sweden

2:15 p.m. **(29)** ***Use of Mechanical Circulatory Support in Orthotopic Heart Transplantation: A 10-Year Analysis***; C. P. Echieh[1], M. Hamidi[2], M. Rogers[3], T. Kazui[4], R. Hooker[5]. *[1]Department of Surgery, University of Calabar, Calabar, Nigeria, [2]Department of Surgery, University of Arizona, Tucson, AZ, [3]University of South Florida Morsani College of Medicine, Tampa, FL, [4]Banner University Medical Center Tucson, Tucson, AZ, [5]University of Arizona, Banner Tucson, Tucson, AZ*

2:30 p.m. **(30)** ***Prehabilitation Maximizing Functional Mobility in Patient with Cardiogenic Shock Supported on Axillary Impella***; I. Salas-De-Armas[1], A. Bhardwaj[1], A. Bergeron[2], C. B. Gilley[2], K. M. Reeves[2], S. Kumar[1], M. Patarroyo Aponte[1], M. Patel[1], J. Patel[1], J. M. Marcano[1], Z. Seal[3], S. Nathan[1], I. Gregoric[1], B. Kar[4]. *[1]Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, TX, [2]Memorial Hermann Hospital-Texas Medical Center, Houston, TX, [3]The University of Texas Health Science Center at Houston, Houston, TX, [4]Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, TX*

2:45 p.m. **(31)** ***Mid-Term Survival in Patients with Advanced Heart Failure Receiving an Impella Device Intended as Bridge to Transplantation***; J. Jang[1], J. Ruiz[1], S. Desai[1], B. Sareyyupoglu[2], S. Paghdar[1], S. Malkani[1], K. Landolfo[2], P. Patel[1], J. Nativi[1], D. Yip[1], M. Lyle[1], J. Leoni[1], S. Pham[2], R. Goswami[1]. *[1]Transplant, Mayo Clinic, Jacksonville, FL, [2]Cardiothoracic surgery, Mayo Clinic, Jacksonville, FL*

3:00 p.m. **(32)** ***Impact of Heart Failure Etiology and ECMO on Heart Transplant Outcomes***; M. Shah, H. Rando, A. Kilic. *The Johns Hopkins University, Baltimore, MD*

3:15 p.m. **(33)** ***Extracorporeal Membrane Oxygenation Bridging to Orthotopic Heart Transplantation: Updated Analysis Following the 2018 Allocation Change***; N. Hess[1], Y. Hong[2], L. Ziegler[1], M. Keebler[3], G. Hickey[4], J. Huston[1], M. Mathier[5], D. Kaczorowski[6]. *[1]University of Pittsburgh Medical Center, Pittsburgh, PA, [2]University of Pittsburgh, Pittsburgh, PA, [3]UPMC, Pittsburgh, PA, [4]UPMC Pittsburgh, Murrysville, PA, [5]Heart and Vascular Institute, Pittsburgh, PA, [6]UPMC, Venetia, PA*

3:30 p.m. **(34)** ***Waitlist and Transplant Outcomes in Heart Transplant Candidates Bridged with Temporary Right Ventricular Assist Devices***; J. H. Kwon, K. Bhandari, A. Carnicelli, J. Yourshaw, K. Shorbaji, A. Kilic. *Medical University of South Carolina, Charleston, SC*

WEDNESDAY, 19 APRIL, 2023

2:15 – 3:45 p.m.

SESSION 20: CLAD THE INHALER: NOVEL BIOMARKERS OF CLAD PATHOGENESIS

Location: Rooms 405-407

Core Therapies: LUNG
Practice Areas: Research and Immunology, Infectious Diseases, Pharmacy, Pulmonology

Session Summary: This session will investigate human translational studies of immune and non-immune markers and mediators of chronic lung allograft dysfunction (CLAD).

Co-Chairs: Tereza Martinu, MD, MHS, Toronto General Hospital/UHN, Toronto, ON Canada
Geert Verleden, MD, PhD, FERS, University Hospital Leuven, Leuven, Belgium

2:15 p.m. **(35)** ***Donor-Derived Lymphocyte Chimerism is Associated with Protection from Chronic Lung Allograft Dysfunction***; K. Parsons[1], G. Snell[2], A. Brooks[1], G. Westall[2], Y. Cristiano[2], B. Levvey[2], L. Sullivan[3], S. Stankovic[2]. *[1]Department of Microbiology and Immunology, University of Melbourne at Peter Doherty Institute for Infection and Immunity, Melbourne, Australia, [2]Alfred Hospital, Melbourne, Australia, [3]South Australian Transplantation and Immunogenetics Service, Australian Red Cross Lifeblood, Women's and Children's Hospital, Adelaide, Australia*

2:30 p.m. **(36)** ***Molecular Drivers of Tissue Resident Memory T Cell Formation in Lung Allografts***; K. Moghbeli[1], A. Craig[2], A. Bondonese[3], L. Fan[2], K. Chen[2], J. McDyer[2], M. Snyder[2]. *[1]Medicine, University of Pittsburgh, Pittsburgh, PA, [2]University of Pittsburgh, Pittsburgh, PA, [3]*

2:45 p.m. **(37)** ***Exosomal-MiRNas Expression, Cytokines and Growth Factors Levels Released by Peripheral Blood Mononuclear Cells of CLAD Patients In Response to Extracorporeal Photoapheresis***; S. Bozzini[1], C. Bagnera[1], E. Bozza[1], C. Del Fante[2], M. De Amici[3], G. Testa[4], V. Vertui[5], G. Viarengo[2], C. Perotti[2], F. Meloni[6]. *[1]Laboratory of Respiratory Disease, Section of Cell Biology, UOS Transplant Center IRCCS Policlinico San Matteo Foundation, Pavia, Italy, [2]Immunohaematology and Transfusion Service, Apheresis and Cell Therapy Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, [3]Immuno-Allergology Laboratory of the Clinical Chemistry Unit and Pediatric Clinic Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, [4]Pediatric Clinic Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, [5]University of Pavia, Pavia, PV, Italy, [6]Policlinico San Matteo di Pavia, Pavia, PV, Italy*

3:00 p.m. **(38)** ***Distinct Airway Virome Signatures are Associated with CLAD and Modulate Airway Interferon Responses***; M. Banday[1], K. Patel[2], M. Qureshi[3], N. Movval[4], N. Sharma[5]. *[1]Brigham and Womens, Boston, MA, [2]USF Morsani College of Medicine, Tampa, FL, [3]Universoty of South Florida / Tampa General Hospital, Wesley Chapel, FL, [4]BWH, Boston, MA, [5]Brigham & Women's Hospital, Boston, MA*

3:15 p.m. **(39)** ***Airway Pepsinogen A4 is a Specific Marker of Gastric Aspiration and Predicts Chronic Lung Allograft Dysfunction in Lung Transplant Recipients***; R. Ramendra[1], A. Duong[2], K. Zhang[3], J. Havlin[4], M. Ahmed[5], J. Yeung[3], A. Sage[6], S. Keshavjee[7], T. Martinu[8]. *[1]Ajmera Transplant, University Health Network, Toronto, ON, Canada, [2]University Health Network, Toronto, ON, Canada, [3]University of Toronto, Toronto, ON, Canada, [4]University Hospital Motol, Praha 8, Czech Republic, [5]Winnipeg, MB, Canada, [6]Toronto General Hospital, Toronto, ON, Canada, [7]UHN, Toronto, ON, Canada, [8]Toronto General Hospital/UHN, Toronto, ON, Canada*

3:30 p.m. **(40)** ***Chronic Lung Allograft Dysfunction is Associated with an Increased Number of Autoantibodies***; Q. Xu[1], A. Roux[2], M. Elrefaei[3], K. Hitchman[4], J. TAUPIN[5], A. Gareau[6], D. Lucas[6], M. Bettinotti[6], M. Marrari[7], T. Narula[3], F. Alvarez[3], C. Iasella[7], P. Sanchez[1], D. Levine[4], A. Zeevi[7]. *[1]University of Pittsburgh Medical Center, Pittsburgh, PA, [2]Foch Hospital, Suresnes, France, [3]Mayo Clinic, Jacksonville, FL, [4]University of Texas, San Antonio, TX, [5]Hôpital Saint Louis, Paris, France, [6]Johns Hopkins University, Baltimore, MD, [7]University of Pittsburgh, Pittsburgh, PA*

WEDNESDAY, 19 APRIL, 2023

2:15 – 3:45 p.m.

SESSION 21: CARDIAC ALLOGRAFT VASCULOPATHY: FROM BENCH TO BEDSIDE

Location: Rooms 201-203

Core Therapies: HEART
Practice Areas: Cardiology, Cardiothoracic Surgery, Pathology, Research and Immunology

Session Summary: This session includes topics related to Cardiac Allograft Vasculopathy (CAV) development and new tools for CAV assessment.

Co-Chairs: Sonia Mirabet, MD, PhD, Hospital Sant Pau, Barcelona, Spain
Maria Dolores Cosio, MD, PhD, Hospital 12 Octubre, Madrid, Spain

2:15 p.m. **(41)** ***Cardiac Allograft Vasculopathy is Characterized by a Diverse and Unique Cellular Landscape***; B. Kopecky[1], J. Amrute[1], H. Dun[2], K. Lavine[3]. *[1]Washington University in St. Louis, St. Louis, MO, [2]Washington University School of Medicine, Saint Louis, MO, [3]Washington University, Saint Louis, MO*

2:30 p.m. **(42)** ***Restrictive Physiology : Playing with Rhc Between Cav and Amr***; M. Masetti[1], M. Scuppa[1], L. Giovannini[1], M. Sabatino[1], S. Martin Suarez[2], L. Potena[1]. *[1]Heart Failure and Heart Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, [2]Cardiac Surgery, IRCCS AOU Bologna, Bologna, Italy*

2:45 p.m. **(43)** ***Cardiac Pet Flow Quantification Assessment of Early Cardiac Allograft Vasculopathy***; S. Chih[1], A. Tavoosi[1], V. Nair[2], A. Chong[1], V. Džavík[3], N. Aleksova[3], D. Y. So[1], I. Amara[1], G. A. Wells[1], J. Bernick[1], C. B. Overgaard[3], L. M. Mielniczuk[1], E. Stadnick[1], H. J. Ross[3], R. S. Beanlands[1]. *[1]University of Ottawa Heart Institute, Ottawa, ON, Canada, [2]The Ottawa Hospital, Ottawa, ON, Canada, [3]Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre, Toronto, ON, Canada*

3:00 p.m. **(44)** ***Lipoprotein(a) Levels Predict Development of Cardiac Allograft Vasculopathy***; K. Patel, A. Yadalam, R. DeStefano, Z. Almuwaqqat, S. Desai, A. Alkhoder, K. Ejaz, Z. Alvi, W. Book, D. Gupta, A. A. Quyyumi. *Emory University, Atlanta, GA*

3:15 p.m. **(45)** ***Influence of Donor Transmitted Coronary Artery Disease in Cardiac Allograft Vasculopathy: Results of the Donor Transmitted Coronary Artery Disease (DONOR-CAD) Study***; D. Couto-Mallon[1], V. Donoso-Trenado[2], E. Barge-Caballero[1], F. Hernandez Perez[3], J. López-Azor García[4], T. Domingo Gardeta[5], M. A. Castel[6], S. Mirabet Perez[7], I. Garrido Bravo[8], C. Diez-Lopez[9], R. Manrique Anton[10], A. López Granados[11], J. Muñiz[12], M. G. Crespo-Leiro[1]. *[1]Cardiology, Hospital Universitario A Coruña. Instituto de Investigación Biomédica de A Coruña (INIBIC). CIBERCV., A Coruña, Spain, [2]Hospital Universitario y Politécnico La Fe, Valencia, Spain, [3]Hospital Universitario Puerta de Hierro, Majadahonda, Spain, [4]Hospital Universitario 12 de Octubre, Madrid, Spain, [5]Hospital General Universitario Gregorio Marañón, Madrid, Spain, [6]Hospital Clínic, Barcelona, Spain, [7]Hospital Sant Pau. IIB SANT PAU. CIBERCV, Barcelona, Spain, [8]H Virgen de la Arrixaca, Murcia, Spain, [9]Bellvitge University Hospital, Barcelona, Spain, [10]Clinica Universidad Navarra, Pamplona/Iruña, Spain, [11]Hospital Universitario Reina Sofía, Córdoba, Spain, [12]Universidade de A Coruña. Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain*

3:30 p.m. **(46)** ***One Year Cardiac Allograft Vasculopathy (cav) Outcomes in Donor after Circulatory Death (dcd) Heart Transplant Recipients***; Q. Bui[1], Y. Gernhofer[2], A. Duran[3], A. Lin[1], J. Ding[3], A. Birs[3], G. Ma[1], R. White[4], K. Sharaf[3], D. Cookish[3], N. Wettersten[3], J. Cruz Rodriguez[3], H. Tran[1], K. Hong[3], E. Adler[3], J. Silva Enciso[3], M. Urey[1], M. Kearns[1], V. Pretorius[3]. *[1]UC San Diego, San Diego, CA, [2]University of the Incarnate Word School of Osteopathic Medicine, San Antonio, TX, [3]UC San Diego, La Jolla, CA*

4:15 – 5:15 p.m.

SESSION 22: PREGNANCY AND BEYOND: REPRODUCTIVE HEALTH IN HEART AND LUNG FAILURE

Location: Four Seasons Ballroom

Core Therapies: HEART, LUNG, MCS
Practice Areas: Cardiology, Pharmacy and Pharmacology, Pulmonology

Session Summary: The ISHLT Consensus Statement on Reproductive Health in Thoracic Transplantation will be published in the Journal of Heart and Lung Transplantation in late 2022 or early 2023. This comprehensive document spans preconception counseling; risk assessment, management, and outcomes in lung transplantation and heart transplantation; and pregnancy in patients with durable mechanical circulatory support (MCS). This session, in Pecha Kucha format, will highlight the important content of this document.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: Pregnancy in patients with end-stage heart and / or lung disease is considered high and often poses a clinical and ethical dilemma for the patient and the provider. This session will discuss controversial topics related to pregnancy in this high risk population.

Co-Chairs: Jesper Magnusson, MD, PhD, Sahlgrenska University Hospital, Göteborg, Sweden
Anique Ducharme, MD, MSC, Université de Montréal, Montreal, QC Canada

4:15 p.m. ***Pregnancy in Pulmonary Arterial Hypertension***
Jennifer Haythe, MD, Columbia University Medical Center, New York, NY USA

The speaker will discuss the sequelae and consequences of pregnancy in patients with Pulmonary Hypertension and how to mitigate these risks

4:23 p.m. ***Pregnancy after Transplantation (Heart/Lung)***
Lynn Punnoose, MD, Vanderbilt University Medical Center, Nashville, TN USA

Discussion of timing, risk assessment, assessment of graft function, and outcomes of pregnancy in lung/ heart transplantation. Include immune-suppression's impact on decision making as well.

4:31 p.m. ***Pregnancy in Patients with Left Ventricular Assist Devices***
Francesca Macera, MD, Erasmus Medical Center, Brussels, Belgium

The speaker will discuss complications of pregnancies in patients with LVADs, how the LVADs impact pregnancy and vice versa. There will also be discussion of successful strategies used to manage pregnancy in patients with LVADs.

4:39 p.m. ***Pregnancy in High-Risk Population in the Era of Abortion Bans***
Mary Walsh, MD, St. Vincent Heart and Vascular Institute, Indianapolis, IN USA

Medical recommendations for termination of pregnancy in patients with end stage heart and lung failure where the risk of maternal mortality is high.

4:47 p.m. ***Assisted Reproduction in High-Risk Populations (Heart and Lung Failure)***
Patricia Ging, MSc, Mater Misericordiae, Dublin, Ireland

Overview of recommendations for assisted reproduction in patients with end stage heart and lung failure.

4:55 p.m. ***Panel Discussion and Audience Vote***

4:15 – 5:15 p.m.

SESSION 23: DIFFERENT CONTINENTS, SAME PROBLEMS: GLOBAL PERSPECTIVE ON CARDIOGENIC SHOCK

Location: Rooms 603-605

Core Therapies: MCS, HEART
Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing & Allied Health, Pediatrics

Session Summary: This session will highlight global perspectives on various aspects of cardiogenic shock care, from optimizing systems of care and shock team compositions to delivering care in low resource settings and highlighting the global uptake of the SCAI stage shock classification scheme.

Co-Chairs: Bart Meyns, MD, PhD, UZ Leuven, Leuven, Belgium
Jamila Kremer, MD, St. Vincent's Hospital, Sydney, NSW Australia

4:15 p.m. ***Shock Networks of Care: Which Fits Best?***
Rachna Kataria, MD, Massachusetts General Hospital, Boston, MA USA

This talk will discuss the pros and cons of different models of cardiogenic shock care, including the hub and spoke vs tier-based systems. As well, how these differing systems influence delivery of care in high vs low resource countries will be discussed.

4:30 p.m. ***The Bottom Line: Shock Teams and Infrastructure in Low vs. High Resource Settings***
Talha Meeran, MD, Sir HN Reliance Foundation Hospital, Mumbai, India

This talk will discuss the impact of resource infrastructure and shock team compositions on cardiogenic shock management, with particular emphasis on low resource settings.

4:45 p.m. ***Look at the SCAI: Forecast for Cardiogenic Shock Patients in Europe and Beyond***
Stephan Ensminger, MD, DPhil, Univeristy of Lubeck, Lubeck, Germany

This talk will discuss the uptake of the SCAI classification for cardiogenic shock staging in countries outside of the US, and whether this uptake has altered cardiogenic shock management and/or outcomes.

5:00 p.m. ***Panel Discussion***

4:15 – 5:15 p.m.

SESSION 24: TOP LUNG: I FEEL THE NEED FOR SPEED -- TO GET YOU EATING AND DRINKING

Location: Rooms 401-404

Core Therapies: LUNG
Practice Areas: Pulmonology, Nursing & Allied Health, Pharmacy and Pharmacology

Session Summary: Providing adequate nutrition and achieving sufficient drug absorption are required for patients to thrive after lung transplantation. A multidisciplinary approach is necessary to manage dysphagia, aspiration, nutritional delivery, and drug absorption in lung transplant recipients.

Co-Chairs: Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO USA
Peter Jaksch, MD, Medical University of Vienna, Vienna Austria

4:15 p.m. ***Highway to the Danger Zone: The Oesophagus***
Matthew Hartwig, MD, Duke University Medical Center, Durham, NC USA

This talk will review data regarding pre- and post-transplant assessment of esophageal function, including patient-centered risk factors that may predict recovery of esophageal function after transplant. Discussion of predictors of recovery of esophageal dysfunction after transplantation will also be included.

4:25 p.m. ***Q&A***

4:30 p.m. ***You've Lost That Loving Feeling: When Your Patient Aspirates***
Vasiliki Gerovasili, MD, Royal Brompton and Harefield Hospitals UK, Harefield, United Kingdom

This talk will discuss prevention, management, and sequelae of aspiration.

4:40 p.m. ***Q&A***

4:45 p.m. ***When to Call the Top Gun Team: Pharmaceutical Management When Not Absorbing***
Fay Burrows, BPharm, St. Vincent's Hospital, Sydney, NSW Australia

This talk will discuss challenges with polypharmacy, as well as strategies to optimize drug delivery in the setting of gastroparesis or esophageal dysfunction.

4:55 p.m. ***Q&A***

5:00 p.m. ***Take My Breath Away: Costs and Considerations of Prolonged NPO Status***
Katie Stratton, MA, RD, LDN, University of Pennsylvania, Philadelphia, PA USA

This talk will focus on data regarding utility of prolonged NPO status to minimize the impact of esophageal/gastric dysfunction and discuss pathways for multidisciplinary management of GI issues after lung transplant.

5:10 p.m. ***Q&A***

4:15 – 5:15 p.m.

SESSION 25: TRANSPLANTS AND PULMONARY HYPERTENSION
Location: Rooms 501-504

Core Therapies: PVD, LUNG
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Pulmonology

Session Summary: This session will go through the considerations for timing and listing for transplantation, discuss the need for bilateral versus single lung transplantation, and describe the postoperative handling all to improve outcomes.

Co-Chairs: Ilaria Righi, MD, Cà Granda Foundation Policlinico Hospital, Milan, Italy
Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Göteborg, Sweden

4:15 p.m. ***Timing Listing Criteria for Patients with iPAH in the Pulmonary Vasodilator Era: How Do We Optimize Pre- and Post-Transplant Survival?***
Vikramjit Khangoora, MD, Inova Fairfax Hospital, Fairfax, VA USA

Timing Listing criteria for patients with iPAH in the pulmonary vasodilator era: How do we optimize pre and post-transplant survival? Assessment of the complex factors and decision making around timing for listing. Criteria that should elevate urgency status on the lung transplant waiting list.

4:30 p.m. ***Single vs. Double Lung or Heart-Lung Transplant?***
Konrad Hoetzenecker, MD, Medical University of Vienna, Vienna, Austria

Single versus double lung or heart-lung transplant?High rates of PGD following lung transplant for pulmonary hypertension have led to a generalized preference to perform bilateral lung transplant. Patient selection for single versus double lung transplant + H-L transplant for those with severe RV dysfunction

4:45 p.m. ***Role of Liver vs. Lung-Liver Transplantation in Porto-Pulmonary Hypertension***
Laurent Savale, MD, PhD, Hospital Bicetre, Le Kremlin-Bicêtre, France

Role of liver versus lung-liver transplantation in porto-pulmonary hypertension. This presentation will focus on surgical management of patients with severe pulmonary hypertension in the setting of porto-pulmonary disease, including optimal patient selection, peri-operative concerns and outcomes.

5:00 p.m. ***Panel Discussion***

4:15 – 5:15 p.m.

SESSION 26: ORGAN ALLOCATION STRATEGY: ALGORITHMS TO IMPLEMENT EQUITY

Location: Rooms 205-207

Core Therapies: HEART
Practice Areas: Cardiology, Cardiothoracic Surgery

Session Summary: This session will explore how organ allocation strategies can influence waitlist outcomes including mortality and improve equity in access to transplantation.

Co-Chairs: Savitri Fedson, MD, Baylor College of Medicine, Houston, TX USA
Jacob Lavee, MD, Sheba Medical Center, Ramat Gan, Israel

4:15 p.m. **(47)** ***Association of High-Priority Exceptions with Mortality Among Heart Transplant Candidates***; D. Y. Johnson[1], D. Ahn[2], K. Lazenby[1], K. Zhang[3], N. Narang[4], K. Khush[5], W. F. Parker[3]. *[1]Pritzker School of Medicine, University of Chicago, Chicago, IL, [2]Department of Surgery, Stanford University, Stanford, CA, [3]Department of Medicine, University of Chicago, Chicago, IL, [4]Advocate Heart Institute, Advocate Christ Medical Center, Oak Lawn, IL, [5]Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA*

4:30 p.m. **(48)** ***Geographic Variation Exists in Heart Transplantation for Status One and Two Patients after the 2018 Heart Allocation Policy Change***; M. T. Hassanein[1], S. Singh[1], D. Spragan[1], Y. Kaku[1], P. Kurlansky[1], F. Latif[1], G. Sayer[1], N. Uriel[2], K. Takeda[1]. *[1]Columbia University, New York, NY, [2]New York Presbyterian-Columbia University Medical Center, New York, NY*

4:45 p.m. **(49)** ***Heart Transplant Allocation Policy Using an Algorithm: Putting the Pieces Together***; C. Jasseron[1], B. Audry[1], C. Legeai[1], C. Jacquelinet[1], G. Coutance[2], L. Sebbag[3], F. kerbaul[1], C. Henin[4], R. Dorent[1]. *[1]Agence de la Biomédecine, Saint-Denis, France, [2]Pitié-Salpetrière Hospital, Paris, 75, France, [3]Hospices Civils De Lyon Hopital Louis Pradel, Bron, France, [4]INRIA, Paris, France*

5:00 p.m. **(50)** ***Recipient Outcomes with Extended Criteria Donors: An Analysis of the Guardian Heart Registry***; R. Moayedifar[1], Y. Shudo[2], M. Kawabori[3], S. Silvestry[4], J. Schroder[5], D. Meyer[6], D. D'Alessandro[7], A. Zuckermann[8]. *[1]Medical University Vienna General Hospital Vienna, Wien, Austria, [2]Stanford University, Menlo Park, CA, [3]Tufts Medical Center, Brookline, MA, [4]AdventHealth Transplant Institute, Orlando, FL, [5]Duke University Medical Center, Durham, NC, [6]Baylor Scott and White Health, Health Texas Provider Network, Cardiac and Thoracic Surgery at Baylor, Dallas, TX, [7]MGH, Weston, MA, [8]Medical University of Vienna, Wien, Austria*

4:15 – 5:15 p.m.

SESSION 27: NEW TOOLS FOR THE KIDS: DIAGNOSIS OF HEART TRANSPLANT REJECTION AND REGISTRIES FOR HEART FUNCTION IN PEDIATRICS

Location: Rooms 405-407

Core Therapies: HEART
Practice Areas: Pediatrics, Cardiology, Pathology

Session Summary: This session will explore how blood biomarkers and molecular pathology can be used to help screen for rejection in children after heart transplant. The session will also report on the findings of a prospective registry of boys with dystrophinopathy.

Co-Chairs: Kevin Daly, MD, Boston Children's Hospital, Boston, MA USA
Melanie Everitt, MD, Children's Hospital Colorado, Aurora, CO USA

4:15 p.m. **(51)** ***Taking ACTION. Creation of a Prospective Registry of Boys with Dystrophinopathy and Ventricular Dysfunction to Define Cardiac Medication Use and Optimize Guideline Directed Medical Therapy***; C. A. Wittlieb-Weber[1], B. Birnbaum[2], C. Castleberry[3], P. Esteso[4], K. Gambetta[5], E. Hayes[6], D. Hsu[7], B. Kaufman[8], A. Lal[9], A. Lorts[10], H. Martinez[11], D. Mokshagundam[12], D. Nandi[13], J. Parent[14], F. Raucci[15], N. Soares[16], M. Shezad[17], R. Shih[18], S. Shugh[19], C. Villa[20], S. Wilkens[21], B. L. Wisotzkey[22], J. Conway[23]. *[1]Children's Hospital of Philadelphia, Philadelphia, PA, [2]Children 's Mercy Hospital, Kansas City, MO, [3]Dell Children's Hospital, Austin, TX, [4]Boston Children's Hospital, Brookline, MA, [5]Lurie Children's Hosp, Chicago, IL, [6]Nationwide Children's Hospital, Bexley, OH, [7]Montefiore Medical Center, Ardsley, NY, [8]Stanford University, San Francisco, CA, [9]University of Utah, Salt Lake City, UT, [10]Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [11]Le Bonheur Children's Hospital, Memphis, TN, [12]Washington University in St Louis, St Louis, MO, [13]Nationwide Children's Hospital, Columbus, OH, [14]Indiana Univ Sch of Med, Indianapolis, IN, [15]Virginia Commonwealth University, Richmond, VA, [16]UT Southwestern Medical Center, Dallas, TX, [17]Cincinnati Children's Hospital, Cincinnati, OH, [18]UF Health Congenital Heart Center, Gainesville, FL, [19]Joe DiMaggio Children's Hospital, Hollywood, FL, [20]Cincinnati Children's Hosp, Montgomery, OH, [21]University of Louisville, Norton Children's Hospital, Louisville, KY, [22]Phoenix Children's, Phoenix, AZ, [23]Stollery Children's Hospital, Edmonton, AB, Canada*

4:30 p.m. **(52)** ***High Sensitivity Troponin-I is Associated with Acute Rejection in Pediatric Heart Transplant Recipients***; D. A. Magnetta[1], L. Jackson[2], A. Zeevi[3], H. R. Turnquist[4], S. A. Miller[5], S. West[5], G. Murtagh[2], B. Feingold[5]. *[1]Pediatric Cardiology, Lurie Children's Hospital of Chicago, Chicago, IL, [2]Abbott Laboratories, Abbott Park, IL, [3]Pathology, University of Pittsburgh, Pittsburgh, PA, [4]Surgery, University of Pittsburgh, Pittsburgh, PA, [5]Pediatrics, University of Pittsburgh, Pittsburgh, PA*

4:45 p.m. **(53)** ***Utility of Molecular Microscope Diagnostic System (mmdx) in Addition to Histopathology for Rejection Surveillance in Pediatric Heart Transplantation***; C. O'Halloran, D. Magnetta, P. Thrush, M. Monge, A. Joong, P. Tannous. *Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL*

5:00 p.m. **(54)** ***Association Between Histopathology, Molecular Microscope Diagnostics, and Donor-Derived Cell-Free DNA for Rejection Surveillance in Pediatric Heart Transplantation***; D. Magnetta[1], C. O'Halloran[1], M. C. Monge[2], P. T. Thrush[1], P. Tannous[1], A. Joong[1]. *[1]Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, [2]Pediatric Cardiovascular Surgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL*

4:15 – 5:15 p.m.

SESSION 28: THE FIFTH ELEMENT: GENETIC ENGINEERING IN LUNG TRANSPLANTATION

Location: Rooms 201-203

Core Therapies: LUNG
Practice Areas: Research and Immunology, Anesthesiology and Critical Care, Cardiothoracic Surgery

Session Summary: This session includes impactful talks applying molecular techniques in lung transplant experimental models.

Co-Chairs: Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, QLD Australia
Daniel Calabrese, MD, University of California, San Francisco, CA USA

4:15 p.m. **(55)** ***Genetic Engineering for Combined Early and Long-Term Immunomodulation in the Donor Lung after Transplantation***; K. Mesaki[1], S. Juvet[1], J. Yeung[2], H. Mangat[1], C. Dickie[1], Z. Guan[1], P. Shathasivam[1], J. Hu[2], A. Davidson[2], B. Kleinstiver[3], M. Cypel[1], M. Liu[4], S. Keshavjee[5]. *[1]University Health Network, Toronto, ON, Canada, [2]University of Toronto, Toronto, ON, Canada, [3]Massachusetts General Hospital & Harvard Medical School, Boston, MA, [4]Toronto Gen Hosp, Toronto, ON, Canada, [5]UHN, Toronto, ON, Canada*

4:30 p.m. **(56)** ***A Preclinical Study of CRISPR Porcine Cell Gene Editing Combined with IL-10 Gene Delivery for Donor Lung Immunomodulation***; N. Yoshiyasu[1], K. Mesaki[1], Z. Guan[1], S. Juvet[1], B. Kleinstiver[2], M. Cypel[1], M. Liu[1], S. Keshavjee[1]. *[1]Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, [2]Center for Genomic Medicine and Department of Pathology, Massachusetts General Hospital, Boston, MA*

4:45 p.m. **(57)** ***The Effect of Recombinant Human (rh) CC10 Protein Treatment in a Mouse Model of Chronic Lung Allograft Dysfunction (CLAD)***; F. Liao[1], T. Martinu[2], A. Pilon[3], A. E. Gelman[4]. *[1]Surgery, Washington University, St. Louis, MO, [2]Toronto General Hospital/UHN, Toronto, ON, Canada, [3]APCBio Innovations, Rockville, MD, [4]Surgery, Washington University School of Medicine, Saint Louis, MO*

5:00 p.m. **(58)** ***Repeated but Not Single Dose of Early Passage Mesenchymal Stem Cells Regenerated Aspirated Damaged Donor Lungs and Reduced Primary Graft Dysfunction***; F. Olm[1], D. Edström[1], M. Mittendorfer[1], H. Ghaidan[1], A. Niroomand[2], G. Hirdman[1], E. Boden[1], M. Stenlo[1], L. Pierre[3], S. Hyllen[1], S. Lindstedt[4]. *[1]Lund University, Lund, Sweden, [2]Rutgers University, Piscataway, NJ, [3]Skane Univ Hosp, Lund, Sweden, [4]Cardiothoracic Surgery, Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden*

WEDNESDAY, 19 APRIL, 2023

5:30 – 6:30 p.m.

MINI ORAL 01: SCANNING THE (ROCKY MOUNTAIN) HORIZON: BIOMARKER DISCOVERY AND UNDERSTANDING OUTCOMES IN HEART TRANSPLANTATION

Location: Rooms 603-605

Core Therapies: HEART
Practice Areas: Research and Immunology, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Pathology, Pharmacy

Session Summary: In this rapid fire session, abstracts focus on omics approaches to marker discovery and exploring factors impacting heart transplant outcomes.

Co-Chairs: Katharina Wassilew, Dr med, DScmed, MHBA, Royal Brompton Hospital, London, United Kingdom
Kentaro Noda, PhD, University of Pittsburgh, Pittsburgh, PA USA

5:30 p.m. **(241)** ***Early Metabolomics Alterations in Recipient Plasma Predict the Outcome of Cardiac Transplantation***; R. S. Krebs, K. Dhaygude, R. Krebs, K. Lemstrom. *University of Helsinki, Helsinki, Finland*

5:36 p.m. **(242)** ***Donor Plasma Serine Levels and Its Connection to Heart Transplant Mitochondrial Dysfunction and Acute Rejection***; K. Dhaygude[1], R. Krebs[1], A. Nykanen[2], K. Lemstrom[2]. *[1]Translational Immunology Research Program and Transplantation Laboratory, University of Helsinki, Helsinki, Finland, [2]Department of Cardiothoracic Surgery, Helsinki University Hospital, Helsinki, Finland*

5:42 p.m. **(243)** ***Inhaled Nitric Oxide is Associated with Decreased Incidence of Acute Rejections after Heart Transplantation in 5-Year Follow-Up***; E. Holmstrom[1], K. Dhaygude[1], S. Syrjala[2], R. Krebs[1], A. Nykanen[2], K. Lemstrom[2]. *[1]University of Helsinki, Helsinki, Finland, [2]Helsinki University Hospital, Helsinki, Finland*

5:48 p.m. **(244)** ***Intracellular Cardiac Preservation Solution May Have Superior Clinical Outcomes to Extracellular Solution for Adult Heart Transplantation***; R. J. Chen, C. Ruaengsri, H. He, Y. Shudo, D. Neto, A. Malki, D. M. Bethencourt, P. R. Theodore, J. Woo. *Cardiothoracic Surgery, Stanford University SoM, Palo Alto, CA*

5:54 p.m. **(245)** ***Proteins Released During Ex-Vivo Perfusion are Promising Biomarkers for Cardiac Graft Quality: Studies in an Isolated Rat Heart Model of DCD***; A. Clavier[1], M. Arnold[1], A. Segiser[1], N. Mendez-Carmona[1], R. Wyss[1], A. Uldry[2], M. Heller[2], M. Siepe[1], S. Longnus[1]. *[1]Department of Cardiac Surgery, Inselspital, Bern, Switzerland, [2]Department for Biomedical Research, University of Bern, Bern, Switzerland*

6:00 p.m. **(246)** ***Transcriptomic Profiling of Acute Cellular Rejection after Heart Transplantation***; M. Wang[1], A. Nair[1], B. Smith[1], T. Nguyen[1], N. Kehoe[2], H. Vyas[1], D. Liu[1], V. Murthy[1], D. Yip[3], D. Steidley[4], A. Clavell[1], S. Kushwaha[1], W. Park[1], H. Eisen[5], M. Stegall[1], N. Pereira[1]. *[1]Mayo Clinic, Rochester, MN, [2]Univ of Wisconsin, Madison, WI, [3]Mayo Clinic, Jacksonville, FL, [4]Mayo Clinic, Phoenix, AZ, [5]Penn State Milton S. Hershey MC, Hershey, PA*

6:06 p.m. **(247)** ***The Varied Rna Transcript Isoform Landscape During Human Donor Heart Preservation***; I. Lei[1], W. Huang[1], S. Naik[1], H. Maqsood[1], J. He[1], P. C. Tang[2]. *[1]Cardiac Surgery, University of Michigan-Ann Arbor, Ann Arbor, MI, [2]Cardiac Surgery, University of Michigan, Ann Arbor, MI*

6:12 p.m. **(248)** ***Early Graft Function by Hemodynamics is Similar Between Brain Death (DBD) and Circulatory Death Donors (DCD)***; A. Duran[1], R. Rubarth[2], D. Agdashian[2], A. Kumar[2], Q. Bui[3], M. McLenon[4], J. Cruz Rodriguez[5], M. Urey[6], E. Adler[7], N. Wettersten[8], H. Tran[9], M. Kearns[6], V. Pretorius[10], J. Silva Enciso[10]. *[1]UCSD, San Diego, CA, [2]Texas Tech University Health Sciences Center, El Paso, TX*

6:18 p.m. **(249)** ***Cumulative Incidence and Risk Factors for Early Post-Transplant Lymphoproliferative Disorder in Adult Heart Transplant Recipients: Single-Centre Experience***; M. A. Peterzan, H. Lyster, A. Grover, F. Imam, J. Kwinta, A. Hall, S. Murthy, O. Dar, V. Rial Baston, A. Morley-Smith, J. Dunning, F. Riesgo Gil. *Cardiothoracic Transplantation. Harefield Hospital. Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom*

6:24 p.m. **(250)** ***Clinical and Histopathological Cardiomyopathy Diagnosis Discrepancies in Heart Transplant***; N. Gorrie[1], D. Sivasubramaniam[1], K. Muthiah[1], E. Kotlyar[1], A. Jabbour[2], C. Hayward[1], P. MacDonald[1], N. Bart[1]. *[1]St Vincent's Hospital, Sydney, Australia, [2]Victor Chang Cardiac Research Institute St Vincent's Hospital, Darlinghurst, Australia*

5:30 – 6:30 p.m.

MINI ORAL 02: THE FORCE AWAKENS: ADVANCES IN LUNG PRESERVATION TO IMPROVE DONOR SELECTION AND RECIPIENT OUTCOMES

Location: Rooms 401-404

Core Therapies: LUNG
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Pharmacy, Pulmonology, Research and Immunology

Session Summary: This rapid fire session will highlight recent advances in donor lung preservation including better characterization of cold storage and ischemia-reperfusion injury as well as highlighting new aspects of donor and recipient selection. In addition, the important topic of DCD lung donation including implications on utilization when the heart is also procured will be discussed.

Co-Chairs: Varun Puri, MD, MSCI, Washington Univesity School of Medicine, St. Louis, MO USA
Puneet Garcha, MD, Baylor College of Medicine, Houston, TX USA

5:30 p.m. **(251)** ***A Machine Learning Approach to Processing and Interpreting Ex Vivo Lung Radiographs Predicts Transplant Outcomes***; B. T. Chao[1], J. Ma[2], X. Zhou[1], M. McInnis[3], J. Yeung[1], M. Cypel[1], M. Liu[1], A. Sage[1], B. Wang[2], S. Keshavjee[1]. *[1]Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, [2]Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, [3]Department of Medical Imaging, University Health Network, Toronto, ON, Canada*

5:36 p.m. **(252)** ***Pressure Controlled Hypothermic Lung Perfusion is not Better Than Cold Storage for Lung Preservation***; G. Fadel[1], A. Akamkam[1], J. Guihaire[2], J. Adam[3], J. Menager[4], E. Fadel[4], F. Antigny[1], O. Mercier[4]. *[1]Inserm U999, Marie Lannelongue Hospital, Le-Plessis-Robinson, France, [2]Department of Cardiac and Vascular Surgery, Marie Lannelongue Hospital, Le Plessis-Robinson, France, [3]Department of Pathology, Groupe Hospitalier Paris Saint-Joseph, Paris, France, [4]Department of Thoracic and Heart-Lung Transplantation, Marie Lannelongue Hospital, Le-Plessis-Robinson, France*

5:42 p.m. **(253)** ***Ice is Not 4c: Thermodynamic Characterization of Lungs and Hearts Preserved on Ice***; P. Patel[1], B. Bulka[1], L. Churchill[1], M. Tajima[1], L. Anderson[1], F. Rega[2]. [1]Paragonix Technologies, Inc., Cambridge, MA, [2]University Hospitals, Leuven, Belgium

5:48 p.m. **(254)** ***24-Hour Negative Pressure Ventilation Ex-Situ Lung Perfusion with Transplantation in a Porcine Model***; K. A. Forgie[1], A. Watkins[2], K. Du[2], A. Ribano[2], D. Freed[3], J. Nagendran[2]. *[1]Cardiac Surgery, University of Alberta, Mazankowski Alberta Heart Institute, Edmonton, AB, Canada, [2]University of Alberta, Edmonton, AB, Canada, [3]Stollery Children's Hospital, Edmonton, AB, Canada*

5:54 p.m. **(255)** ***Does Donor Age Impact Survival Outcome of Increased-Risk Lung Transplantation?***; M. Brown, A. Kashem, H. Zhao, K. Cheng, H. Kehara, S. Mokashi, R. Yanagida, N. Shigemura, Y. Toyoda. *Temple University, Lewis Katz School of Medicine, Philadelphia, PA*

6:00 p.m. **(256)** ***Ex-Vivo Lung Perfusion May Have a Detrimental Impact on Lung Transplants from Donation after Circulatory Death Donors***; Y. Xia[1], S. T. Kim[2], J. Maloney[3], M. DeCamp[1], E. Lowery[4], D. McCarthy[3], A. Ardehali[2]. *[1]Surgery, University of WIsconsin, Madison, WI, [2]UCLA School of Medicine, Los Angeles, CA, [3]University of Wisconsin, Madison, WI, [4]University of Wisconsin School of Medicine and Public Health, Madison, WI*

6:06 p.m. **(257)** ***National Trends of Lung Allograft Utilization During Donation-After-Circulatory-Death (dcd) Heart Procurement in the United States***; K. Choi[1], C. Spadaccio[1], M. Villavicencio[1], B. Langlais[1], K. Pennington[1], R. Ribeiro[1], P. Spencer[1], R. Daly[1], J. Mallea[2], S. Keshavjee[3], M. Cypel[4], S. Saddoughi[1]. *[1]Mayo Clinic, Rochester, MN, [2]Mayo Clinic Florida, Jacksonville, FL, [3]UHN, Toronto, ON, Canada, [4]Univ Health Network, Toronto, ON, Canada*

6:12 p.m. **(258)** ***Histidine-Rich Glycoprotein Ameliorates Lung Ischemia-Reperfusion Injury in a Mouse***; Y. Kubo, S. Sugimoto, H. Choshi, H. Ujike, S. Kawana, D. Shimizu, K. Matsubara, K. Hashimoto, S. Tanaka, K. Shien, K. Suzawa, K. Miyoshi, H. Yamamoto, M. Okazaki, S. Toyooka. *Okayama University Hospital, Okayama, Japan*

6:18 p.m. **(259)** ***Are We Discarding too Many DCD Lung Allografts for the Wrong Reasons?***; T. Malik[1], J. J. Miggins[2], R. M. Reul[3], A. Rana[4]. *[1]New York University, New York, NY, [2]Baylor College of Medicine, Houston, TX, [3]Emory University School of Medicine, Atlanta, GA, [4]Division of Abdominal Transplantation, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX*

6:24 p.m. **(260)** ***Results of ECLS Support Comparing DCD and DBD Lung Transplantation***; A. Kashem[1], M. Villavicencio[2], F. Ius[3], G. Loor[4], M. Hartwig[5], K. Ghadimi[6], J. Salman[3], S. Chandrashekaran[7], T. Machuca[8], P. Sanchez[9], K. Subramaniam[10], D. Van Raemdonck[11], A. Neyrinck[12], M. Warnick[13], S. Huddleston[14], A. Osho[15], E. D'Silva[4], U. Ramamurthy[4], A. Leon Pena[4], A. Shaffer[16], N. Langer[17], A. Emtiazjoo[18], Y. Toyoda[19]. *[1]Temple University School of Med, Philadelphia, PA, [2]Mayo Clinic, Rochester, Rochester, MN, [3]Hannover Medical School, Hannover, Germany, [4]Baylor College of Medicine, Houston, TX, [5]Duke University Medical Center, Durham, NC, [6]Duke Unversity, Raleigh, NC, [7]Emory University Hospital, Gainesville, FL, [8]University of Miami, Gainesville, FL, [9]University of Pittsburgh Medical Center, Pittsburgh, PA, [10]Univ of Pittsburgh Med Ctr Presbyterian Hospital, Sewickley, PA, [11]University Hospitals Leuven, Leuven, Belgium, [12]Leuven University Hospitals, Leuven, Belgium, [13]Temple University School of Medicine, Philadelphia, PA, [14]University of Minnesota, Minneapolis, MN, [15]Duke University Medical Center, Boston, MA, [16]Univ of Minnesota, Minneapolis, MN, [17]Massachusetts General Hospital, Wellesley, MA, [18]University of Florida, Gainesville, FL, [19]Temple Univ Sch of Med, Philadelphia, PA*

WEDNESDAY, 19 APRIL, 2023

5:30 – 6:30 p.m.

MINI ORAL 03: BUGS, DRUGS, AND THUGS: FIGHTING INFECTION IN VADS ANY WAY WE CAN

Location: Rooms 501-504

Core Therapies: MCS
Practice Areas: Infectious Diseases, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pharmacy, Research and Immunology

Session Summary: Infections remain a major cause of adverse events and represent a significant therapeutic challenge in mechanical circulatory support patients. In this rapid fire session, epidemiology and impact of infections on patient survival as well as new strategies for prevention and treatment of driveline infections will be presented.

Co-Chairs: James Kirklin, MD, University of Alabama Birmingham, Birmingham, AL USA
Cumara Sivathasan, MBBS, FRCS, National Heart Center, Singapore, Singapore

5:30 p.m. **(261)** ***Development of Fever in Lvad Patients: Systemic Inflammatory Response or Right Ventricular Strain***; S. Marek-Iannucci, R. Wildemann, Y. Brailovsky, R. Alvarez, J. Rame, G. Gibson, E. Storozynsky, H. Massey, V. Tchantchaleishvili, B. Thoma, I. Rajapreyar. *Thomas Jefferson University Hospital, Philadelphia, PA*

5:36 p.m. **(262)** ***Microbiology and Antimicrobial Resistance of Clinical Isolates Early Post Left Ventricular Device Implantation***; A. Merlo, N. Kumar, R. Watkins, P. Tessmann, M. Byku, L. Bartelt, M. Bhatia. *University of North Carolina, Chapel Hill, NC*

5:42 p.m. **(263)** ***Bloodstream Infection in Pre-Heart Transplant Patients on Temporary Mechanical Circulatory Support***; E. Eichenberger, S. Satola, D. Gupta, S. Pouch. *Emory University School of Medicine, Atlanta, GA*

5:48 p.m. **(264)** ***Impact of Perioperative Dysphagia and Oral Microbiome on Postoperative Pneumonia after LVAD***; M. R. Carey[1], A. Ladanyi[1], B. Bohn[2], M. Nishikawa[1], G. M. Mondellini[1], A. Pinsino[1], E. Goldberg[1], A. Kleet[1], G. T. Sayer[1], N. Uriel[3], J. G. Aaron[1], A. Uhlemann[1], K. Takeda[1], R. T. Demmer[2], P. C. Colombo[1], M. Yuzefpolskaya[1]. *[1]Columbia University Irving Medical Center, New York, NY, [2]University of Minnesota, Minneapolis, MN, [3]New York Presbyterian Hospital, New York, NY*

5:54 p.m. **(265)** ***Effects of ICU Infection on Durable LVAD Patient Outcomes***; O. Chubrikova, A. Ramsay, K. Drezek, S. Verma, T. Winship, J. Barnes, J. Guiry, A. Pico, D. D'Alessandro, V. Ton, E. Coglianese. *Massachusetts General Hospital, Boston, MA*

6:00 p.m. **(266)** ***Microtrauma - A Common Cause for Driveline Infection***; J. L. Tan[1], K. Kerk[1], J. Tay[2], C. Neo[1], T. Tan[1], C. Sivathasan[1]. *[1]National Heart Centre, Singapore, Singapore, [2]n/a*

6:06 p.m. **(267)** ***Cold Atmospheric Plasma Therapy: A Powerful Tool for Treating Driveline Infections in Left Ventricular Assist Device Patients***; T. Schloeglhofer[1], M. Socha[2], S. Shen[2], T. Abart[2], J. Riebandt[2], H. Schima[1], C. Marko[2], G. Laufer[2], D. Wiedemann[2], D. Zimpfer[2]. *[1]Department of Cardiac Surgery, Center for Med. Physics and Biomed. Eng.; LBI Cardiovasc. Research, Medical University of Vienna, Vienna, Austria, [2]Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria*

6:12 p.m. **(268)** ***Prevention of Driveline Infections with Cold Atmospheric Argon Plasma: A Randomized Trial Comparing Two Surgical Techniques***; V. Lauenroth[1], S. Lucke[1], H. Fox[1], S. P. Günther[1], M. Morshuis[2], R. Schramm[2], J. F. Gummert[2], S. V. Rojas[2]. *[1]Cardiothoracic Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany, [2]Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany*

6:18 p.m. **(269)** ***Treatment Concept of Chronic Ventricular Assist Device Driveline Infections with Vacuum Assisted Closure Therapy as Bridge to Transplant Strategy***; C. Volgmann, Y. Al Assar, M. Barten, H. Grahn, H. Reichenspurner, A. Bernhardt. *University Heart and Vascular Center Hamburg, Hamburg, Germany*

6:24 p.m. **(270)** ***Silverlon: A Weapon Against Driveline Infections in Lvad Patients***; K. R. Barrett, B. Ebert, M. Remaly. *Lehigh Valley Health Network, Allentown, PA*

WEDNESDAY, 19 APRIL, 2023

5:30 – 6:30 p.m.

MINI ORAL 04: OUTCOMES, PREDICTIONS, AND MONITORING, OH MY! IN THE WONDERFUL WORLD OF HEART TRANSPLANT

Location: Rooms 205-207

Core Therapies: HEART
Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Research and Immunology

Session Summary: This rapid fire session will include research on various topics related to monitoring and predicting outcomes after heart transplantation.

Co-Chairs: Omaima Ali, MD, Penn State Milton S. Hershey Medical Center, Hershey, PA USA
Erik Henricksen, PharmD, Stanford Healthcare, Palo Alto, CA USA

5:30 p.m. **(271)** ***Bye-Bye Biopsy? Comparing Short and Long-Term Outcomes after Adopting Early Non-Invasive Rejection Surveillance***; E. Henricksen[1], D. T. Kim[2], H. Luikart[2], Y. Moayedi[3], R. Lee[1], J. Han[4], B. Wayda[2], S. Hsiao[2], B. M. Zhang[2], B. Guenthart[2], K. Khush[2], J. Teuteberg[2]. *[1]Transplant, Stanford Medicine, Stanford, CA, [2]Stanford University, Stanford, CA, [3]UHN, Toronto, ON, Canada, [4]University of Chicago MC, Chicago, IL*

5:36 p.m. **(272)** ***Isolated Microvascular Cardiac Allograft Vasculopathy is Associated with an Increased Risk of Death or Retransplantation***; E. S. Harris, L. Sewanan, V. Topkara, J. Fried, J. Raikhelkar, P. Colombo, M. Yuzefpolskaya, E. DeFilippis, F. Latif, M. Castillo, E. Y. Lam, K. Takeda, M. Chernovolenko, A. Einstein, L. Johnson, N. Uriel, G. Sayer, K. Clerkin. *Columbia University Irving Medical Center, New York, NY*

5:42 p.m. **(273)** ***Postoperative Renal Failure in Patients Undergoing Isolated Heart Transplantation: What are the Outcomes?***; S. T. Kim[1], Y. Xia[2], J. K. Ho[1], A. Ardehali[1]. *[1]University of California, Los Angeles, Los Angeles, CA, [2]UCLA, Los Angeles, CA*

5:48 p.m. **(274)** ***The Impact of Donor-Recipient Age Difference on Graft Survival after Heart Transplant in Adults with Congenital Heart Disease***; W. H. Marshall[1], D. Nandi[2], C. J. Daniels[1], L. Wright[2]. *[1]The Ohio State University & Nationwide Children's Hospital, Columbus, OH, [2]Nationwide Children's Hospital, Columbus, OH*

5:54 p.m. **(275)** ***Early Renal Outcomes Following Cardiac Transplantation Using Organs Procured after Circulatory Death***; J. C. Zhou[1], M. E. Sise[2], D. A. D'Alessandro[3], S. B. Wolfe[3], A. A. Osho[3], K. Drezek[3], M. N. Prario[3], S. Rabi[3], E. Michel[3], L. Tsao[4], E. Coglianese[4], M. Doucette[4], C. Newton-Cheh[4], S. Thomas[4], V. Ton[4], N. Sutaria[4], M. W. Schoenike[4], A. M. Christ[4], D. C. Paneitz[3], M. Villavicencio[5], J. C. Madsen[3], R. Pierson[3], G. D. Lewis[4], D. A. Zlotoff[4]. *[1]Department of Medicine, Massachusetts General Hospital, Boston, MA, [2]Nephrology Division, Massachusetts General Hospital, Boston, MA, [3]Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, [4]Cardiology Division, Massachusetts General Hospital, Boston, MA, [5]Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN*

6:00 p.m. **(276)** ***Donor-Derived Cell-Free Dna in Heart Transplant Recipients with Microvascular Cardiac Allograft Vasculopathy***; D. Oren, C. Moeller, D. Lotan, G. Rubinstein, S. Slomovich, J. Fried, J. Raikhelkar, K. Oh, V. Topkara, E. M. DeFilippis, P. C. Colombo, M. Yuzefpolskaya, E. Lin, S. Lee, F. Latif, G. Sayer, N. Uriel, K. Clerkin. *Division of Cardiology -Center for Advanced Cardiac Care, Columbia University Irving Medical Center – New York Presbyterian Hospital, New York, NY*

6:06 p.m. **(277)** ***Association of Early Testing of Donor Derived Cell-Free DNA with the Risk of Antibody Mediated Rejection in Heart Transplant Recipients***; J. Han[1], A. Nguyen[2], M. Zhou[3], A. Nguyen[4], Y. Fu[3], L. Shen[3], S. Patel[5], E. DePasquale[6]. *[1]University of Chicago Medical Center, Chicago, IL, [2]University of Chicago Medicine, Chicago, IL, [3]Biostatistics and Data Sciences, CareDx, Brisbane, CA, [4]CareDx, Brisbane, CA, [5]Montefiore-Einstein, Bronx, NY, [6]University of Southern California, Valley Village, CA*

6:12 p.m. **(278)** ***Elevated Lipoprotein A Levels and Development of Moderate or Severe Cardiac Allograft Vasculopathy***; D. Rangel Sousa, M. Gonzalez-Quijano, A. Grande-Trillo, I. Esteve-Ruiz, A. Aranda-Dios, J. Sobrino-Márquez. *Heart Failure and Heart Transplantation Unit, Virgen del Rocío University Hospital, Seville, Spain*

6:18 p.m. **(279)** ***WITHDRAWN***

6:24 p.m. **(280)** ***Comparison of Two Commercially Available Donor-Derived Cell-Free DNA Assays for Surveillance of Rejection in Heart Transplant Recipients***; E. M. DeFilippis[1], D. Oren[2], D. Lotan[3], E. Harris[1], K. Clerkin[4], J. Fried[5], J. Raikhelkar[3], M. Yuzefpolskaya[5], P. Colombo[3], E. Lin[6], K. T. Oh[1], F. Latif[7], N. Uriel[8], G. Sayer[9]. *[1]Columbia University Irving Medical Center, New York, NY, [2]New York Presbyterian, Columbia University, Los Altos Hills, CA, [3]Columbia University, New York, NY, [4]Columbia University Irving Medical Center, Ridgewood, NJ, [5]Columbia University Medical Center, New York, NY, [6]Columbia Univ Med Ctr, New York, NY, [7]NY Presbyterian Hospital, New York, NY, [8]New York Presbyterian, New York, NY, [9]Columbia University Irving Medical Center, Hartsdale, NY*

5:30 – 6:30 p.m.

MINI ORAL 05: AFTER THE DUST SETTLES: LONG-TERM MCS OUTCOMES

Location: Rooms 405-407

Core Therapies: MCS
Practice Areas: Cardiology, Cardiothoracic Surgery

Session Summary: This rapid fire session highlights mid-term and long-term outcomes of mechanical circulatory support devices and associated factors in the recent era.

Co-Chairs: Jennifer Cowger, MD, MS, Henry Ford Hospitals, Detroit, MI USA
Christopher Salerno, MD, University of Chicago, Carmel, IN USA

5:30 p.m. **(281)** ***Impact on Non-Cardiac Surgery for Patients with Lvad Support***; T. Watanabe, A. Nemoto, A. Nguyen, J. Grinstein, B. Chung, B. Smith, S. Kalantari, N. Sarswat, G. Kim, S. Pinney, D. Onsager, T. Song, C. Salerno, V. Jeevanandam, T. Ota. *University of Chicago Medicine, Chicago, IL*

5:36 p.m. **(282)** ***Comparing Patients Bridged to Transplant with a Fully Magnetically Levitated Left Ventricular Assist Device Before and after the UNOS/OPTN Allocation Change: An STS-Intermacs Registry Analysis***; D. K. Phan[1], S. J. Forest[1], J. P. Skendelas[1], R. Cantor[2], L. Deng[2], J. Kirklin[2], A. J. Weiss[3], J. Milena[4], J. P. Jacobs[5], P. Atluri[6], D. Goldstein[1]. *[1]Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, [2]University of Alabama at Birmingham (UAB), Birmingham, AL, [3]Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, [4]Spectrum Health, Grand Rapids, MI, [5]University of Florida, St. Petersburg, FL, [6]University of Pennsylvania, Philadelphia, PA*

5:42 p.m. **(283)** ***Major Adverse Kidney Events is a Predictor of Reduced Survival in Patients Supported with Ventricular Assist Devices***; S. Barua[1], S. Conte[1], C. Cherrett[1], D. Robson[2], C. Bragg[1], P. MacDonald[1], K. Muthiah[2], C. Hayward[1]. *[1]St Vincent's Hospital Sydney, Darlinghurst, Australia, [2]St. Vincent's Hospital Sydney, Darlinghurst, Australia*

5:48 p.m. **(284)** ***Progression of Valvular Insufficiency with the Heartmate 3 Left Ventricular Assist Left Ventricular Assist Device: An Institutional Experience***; M. F. Kilcoyne, K. Bhandari, A. Ghannam, J. H. Kwon, W. McDonald, B. Welch, K. Shorbajji, A. Kilic. *Department of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC*

5:54 p.m. **(285)** ***Associations Between Pre-Implant Cancer and Left Ventricular Assist Device Outcomes: An Intermacs Registry Analysis***; R. Steinberg[1], A. Nayak[2], J. Wang[1], A. Okoh[3], A. Morris[4], J. Cowger[5], A. Nohria[6]. *[1]Emory University School of Medicine, Atlanta, GA, [2]Emory Univ, Jersey City, NJ, [3]RWJ Barnabas Health, Woodbridge, NJ, [4]Emory Univ, Atlanta, GA, [5]Henry Ford Hospitals, Detroit, MI, [6]Brigham & Women's Hospital, Boston, MA*

6:00 p.m. **(286)** ***Validation of the Heartmate 3 Risk Score in a Real World Patient Cohort***; J. Grewal[1], B. Bortner[1], M. Gregoski[1], D. Cook[1], A. Britt[1], J. Hajj[2], M. Rofael[1], M. Sheidu[3], M. Montovano[4], M. Mehta[5], A. Hajduczok[6], I. Rajapreyar[7], Y. Brailovski[8], M. Genuardi[5], M. Kanwar[9], P. Atluri[10], M. Lander[11], P. Shah[12], S. Hsu[13], A. Kilic[2], B. Houston[2], R. Tedford[14]. *[1]MUSC, Charleston, SC, [2]Inova, Falls Church, VA, [3]Johns Hopkins, Baltimore, MD, [4]Univ of Pennsylvania, Philadelphia, PA, [5]Thomas Jefferson, Philadelphia, PA, [6]Allegheny Gen Hosp, Pittsburgh, PA*

6:06 p.m. **(287)** ***Acute Right Ventricular Dimensional Change Predicts Outcomes in Patients with Heartmate 3***; H. Hayashi[1], M. Krischner[1], A. Vinogradsky[1], Y. Ning[2], P. Kuransky[1], Y. Kaku[1], Y. Naka[1], M. Yuzefpolskaya[3], P. C. Colombo[3], G. Sayer[3], N. Uriel[3], K. Takeda[1]. *[1]Cardiothoracic Surgery, Columbia University, New York, NY, [2]Center of Inovation and Outcome Research, Columbia University, New York, NY, [3]Cardiology, Columbia University, New York, NY*

6:12 p.m. **(288)** ***Preoperative Left Ventricular Diastolic Dimension Index Predicts Outcomes after Heartmate 3 Implantation***; H. Hayashi[1], M. Krischner[1], A. Vinogradsky[1], Y. Ning[2], P. Kuransky[1], Y. Kaku[1], Y. Naka[1], M. Yuzefpolskaya[3], P. C. Colombo[3], G. Sayer[3], N. Uriel[3], K. Takeda[1]. *[1]Cardiothoracic surgery, Columbia University, New York, NY, [2]Center of inovation and outcome research, Columbia University, New York, NY, [3]Cardiology, Columbia University, New York, NY*

6:18 p.m. **(289)** ***Does Lateral Approach Preserve Better Right Ventricular Function after Left Ventricular Assist Device Insertion?***; H. Hayashi[1], M. Krischner[1], A. Vinogradsky[1], Y. Ning[2], P. Kuransky[1], Y. Kaku[1], Y. Naka[1], M. Yuzefpolskaya[3], P. C. Colombo[3], G. Sayer[3], N. Uriel[3], K. Takeda[1]. *[1]Cardiothoracic Surgery, Columbia University, New York, NY, [2]Columbia University, New York, NY, [3]Cardiology, Columbia University, New York, NY*

6:24 p.m. **(290)** ***Comparison of Patient Characteristics and Outcomes of Left Ventricular Assist Devices before and after the Heart Transplant Allocation Change***; K. Fetten[1], J. van Zyl[2], J. Felius[3], S. Hall[4], M. Medina[4], D. Meyer[5]. *[1]Baylor Scott and White, Dallas, TX, [2]Baylor Scott & White Health, Dallas, TX, [3]Baylor Univ Med Ctr, Dallas, TX, [4]Baylor University Medical Center, Dallas, TX, [5]Baylor Scott and White Health, Health Texas Provider Network, Cardiac and Thoracic Surgery at Baylor, Dallas, TX*

WEDNESDAY, 19 APRIL, 2023

5:30 – 6:30 p.m.

MINI ORAL 06: THE EMPIRE STRIKES BACK: PROGRESS IN CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD)

Location: Rooms 201-203

Core Therapies: LUNG
Practice Areas: Pulmonology, Cardiothoracic Surgery, Infectious Diseases, Pharmacy, Research and Immunology

Session Summary: This session highlights new information on translational studies in CLAD pathogenesis and outcomes.

Co-Chairs: Anil Trindade, MD, Vanderbilt University Medical Center, Nashville, TN USA
Gregory Snell, MBBS, FRACP, MD, Alfred Hospital, Melbourne, VIC Australia

5:30 p.m. **(291)** ***Bronchoalveolar Lavage Lipopolysaccharide is Associated with Aspiration, Acute Rejection, and Chronic Lung Allograft Dysfunction in Lung Transplant Recipients***; R. Ramendra[1], J. Havlin[2], L. Levy[3], K. Zhang[4], M. Ahmed[5], L. Singer[6], J. Todd[7], S. Weigt[8], J. Yeung[4], A. Sage[9], S. Keshavjee[10], T. Martinu[11]. *[1]Ajmera Transplant, Univ Health Network, Toronto, ON, Canada, [2]Univ Hosp Motol, Praha 8, Czech Republic, [3]Sheba MC, Gealya, Israel, [4]Univ of Toronto, Toronto, ON, Canada, [5]Winnipeg, MB, Canada, [6]Univ Health Network, Toronto, ON, Canada, [7]Duke Univ Medical Center, Durham, NC, [8]UCLA, Los Angeles, CA, [9]Toronto General Hosp, Toronto, ON, Canada, [10]UHN, Toronto, ON, Canada, [11]Toronto General Hosp/UHN, Toronto, ON, Canada*

5:36 p.m. **(292)** ***Association of Peripheral Blood Absolute Lymphocyte Count with Chronic Lung Allograft Dysfunction and Survival after Lung Transplantation: A Retrospective Single-Center Cohort Study***; T. Ishiwata[1], S. Wang[2], E. Huszti[2], M. Aversa[1], L. G. Singer[1], T. Martinu[1]. *[1]Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, [2]Biostatistics Research Unit, University Health Network, Toronto, ON, Canada*

5:42 p.m. **(293)** ***Altered Pigr/Iga Mucosal Immunity in Bronchiolitis Obliterans Syndrome***; F. M. Carlier[1], M. Pretolani[2], B. Detry[3], T. Planté-Bordeneuve[3], E. Longchampt[4], L. Falque[5], M. Reynaud-Gobert[6], S. Hirschi[7], X. Demant[8], J. Mornex[9], A. Tissot[10], J. Le Pavec[11], V. Bunel-Gourdy[12], A. Foureau[13], A. Vallée[14], C. Pilette[3], O. Brugière[15]. *[1]Pulmonology and Lung Transplant Centre, CHU UCL Namur, Yvoir, Belgium, [2]Unité de recherche 1152, Inserm, Paris, France, [3]IREC/PNEU, Université Catholique de Louvain, Brussels, Belgium, [4]Pathology, Foch Hospital, Suresnes, France, [5]Pulmonology and Lung Transplantation, CHU Grenoble, Grenoble, France, [6]Pulmonology and Lung Transplantation, CHU Marseille, Marseille, France, [7]Pulmonology and Lung Transplantation, CHU Strasbourg, Strasbourg, France, [8]Pulmonology and Lung Transplantation, CHU Bordeaux, Bordeaux, France, [9]Pulmonology and Lung Transplantation, CHU Lyon, Lyon, France, [10]Pulmonology and Lung Transplantation, CHU Nantes, Nantes, France, [11]Pulmonology and Lung Transplantation, Centre Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France, [12]Pulmonology and Lung Transplantation, Hôpital Bichat-Claude-Bernard, Paris, France, [13]CHU Nantes, Nantes, France, [14]Biostatistic Unit, Foch Hospital, Suresnes, France, [15]Pulmonology and Lung Transplantation, Foch Hospital, Suresnes, France*

5:48 p.m. **(294)** ***Baseline Lung Allograft Dysfunction Provides Risk Stratification for Patients with Chronic Lung Allograft Dysfunction***; R. Mohsin, M. Malouf, M. Plit, G. Gazibarich, D. Smith, D. Darley. *Lung Transplant, St Vincent's Hospital, Sydney, Australia*

5:54 p.m. **(295)** ***Utility of First Year Surveillance Lung Allograft HRCT Scan for Predicting of Early CLAD***; S. M. Lari, F. Abtin, D. M. Sayah, A. DerHovanessian, R. Saggar, M. Y. Shino, A. L. Ramsey, G. A. Turner, O. O. Amubieya, J. P. Lynch, A. Ardehali, J. Zhou, S. S. Weigt, J. A. Belperio. *UCLA, Los Angeles, CA*

6:00 p.m. **(296)** ***Sex and Sex Hormones Matter in Lung Transplant Outcomes***; A. Guzman-Gomez[1], E. Skala[2], A. Dani[1], N. Sharma[3], A. Ziady[2], D. Hayes[4]. *[1]Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, [2]Cancer and Blood Disease Institute, Cincinnati Children's Hospital, Cincinnati, OH, [3]Brigham & Women's Hospital, Boston, MA, [4]Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*

6:06 p.m. **(297)** ***Oscillometry Resistance Parameters Elucidate Obstructive Physiology in Chronic Lung Allograft Dysfunction Phenotypes: Results from a Multi-Centre Cross-Sectional Study***; D. R. Darley[1], K. Nilsen[2], J. Vazirani[2], B. Borg[2], B. Levvey[3], G. Snell[4], M. Plit[5], K. Tonga[6]. *[1]Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia, [2]The Alfred Hospital, Melbourne, Australia, [3]The Alfred Hospital, Melbourne, Australia, Melbourne, Australia, [4]Alfred Hospital, Melbourne, Australia, [5]St. Vincent 's Hospital, Rose Bay, Australia, [6]Thoracic Medicine, St Vincent's Hospital, Sydney, Australia*

6:12 p.m. **(298)** ***Role of Donor-Derived Cell-Free DNA in Chronic Lung Allograft Dysfunction, a Longitudinal Study***; M. Arjona Peris[1], B. Saez Gimenez[2], C. Berastegui Garcia[1], V. Ruiz[3], M. Boada Pérez[3], M. Zapata[1], E. Revilla[1], M. Lopez Meseguer[1], V. Monforte[1], C. Bravo Masgoret[1], S. Gomez[4], J. Riera Del Brio[5], A. Roman[1]. *[1]Pulmonology Service, Lung Transplant Program, Hospital Universitari Vall D'Hebron, Barcelona, Spain, [2]Pulmonology Service, Lung Transplant Program, Hospital Universitari Vall D'Hebrón. Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Barcelona, Spain., Barcelona, Spain, [3]Vall d'Hebron Research Institute, Barcelona, Spain, [4]Department of Pulmonology, Vall d'Hebron Research Institute, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain, [5]ICU, Vall d'Hebron University Hospital, SODIR, VHIR, CIBERES, ISCIII, Barcelona, Spain*

6:18 p.m. **(299)** ***A Multicenter Experience with Extracorporeal Photopheresis as Treatment of Clad***; A. Benazzo[1], S. Auner[2], P. Boehm[3], S. Schwarz[4], C. Bagnera[5], F. Ius[6], K. Hoetzenecker[7], F. Meloni[8], P. Jaksch[9], M. Greer[6]. *[1]Medical University of Vienna, Wien, Austria, [234]Medical University of Vienna, [5]IRCCS Policlinico San Matteo, Pavia, Italy, [6]Hannover Medical School, Hannover, Germany, [7]Medical University of Vienna, Wien, 9, Austria, [8]Policlinico San Matteo di Pavia, Pavia, PV, Italy, [9]Medical University Vienna, Austria, Wien, Austria*

6:24 p.m. **(1230)** ***Quantitative CT Identifies Phenotypes of Chronic Lung Allograft Dysfunction (CLAD) in Single Lung Transplants (LTx) with Greater Allograft Injury Compared to Double LTx***; M. C. McInnis[1], S. Wang[2], C. Houbois[3], G. R. Karur[1], G. Berra[4], L. Levy[4], C. Chow[4], L. G. Singer[4], E. Huszti[4], T. Martinu[4]. *[1]Department of Medical Imaging, University Health Network, Toronto, ON, Canada, [2]Biostatistics Research Unit, University Health Network, Toronto, ON, Canada, [3]Department of Medical Imaging, University of Toronto, Toronto, ON, Canada, [4]Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada*

WEDNESDAY, 19 APRIL, 2023

6:30 – 7:30 p.m.

POSTER SESSION 01: CARDIOLOGY

Location: Mile High Ballroom

Core Therapies: HEART
Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Cardiology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Sophia Airhart, MD, Saint Alphonsus Medical Center, Boise, ID USA
Mohammad Al-Ani, MD, University of Florida, Gainesville, FL USA
Nael Aldweib, MD, Oregon Health Science University, Portland, OR USA
Tamas Alexy, MD, PhD, University of Minnesota, North Oaks, MN USA
Rami Alharethi, MD, FACC, Intermountain Medical Center, Murray, UT USA
Yevgeniy Brailovsky, DO, New York, NY USA
Kelly Bryce, PhD, Henry Ford Hospital, Detroit, MI USA
Andres Carmona Rubio, MD, Cleveland Clinic, Cleveland, OH USA
Francesco Castagna, MD, Montefiore Medical Center, New York, NY USA
Leway Chen, MD, MPH, University of Rochester Medical Center, Rochester, NY USA
Erin Coglianese, MD, Massachusetts General Hospital, Boston, MA USA
Monica Colvin, MD, MS, FAHA, University of Michigan Health System, Ann Arbor, MI USA
Adrian daSilva-deAbreu, MD, MSc, PhD(c), Mayo Clinic-Rochester, Rochester, MN USA
Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN USA
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain
Claudia Gidea, MD, Newark Beth Israel Medical Center, New York, NY USA
José González-Costello, MD, PhD, Bellvitge Hospital, Barcelona, Spain
Oscar Gonzalez Fernandez, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Jennifer Hajj, MHDS, BSN, Medical University of South Carolina, Charleston, SC USA
Eman Hamad, MD, MHA, Temple University, Philadelphia, PA USA
Karlee Hoffman, DO, Cleveland Clinic, Cleveland, OH USA
Brian Houston, MD, Medical University of South Carolina, Charleston, SC USA
Gregory Jackson, MD, Mount Pleasant, SC USA
Maryl Johnson, MD, University of Wisconsin, Madison, WI USA
Mandisa-Maia Jones, MD, Weill Cornell NY Presbyterian, New York, NY USA
Tomoko Kato, MD, PhD, International University of Health and Welfare, Tokyo, Japan
Jamie Kennedy, MD, Inova Heart and Vascular Institute, Falls Church, VA USA
In-Cheol Kim, Keimyung University Dongsan Hospital, Dalseo-Gu, South Korea
Liviu Klein, MD, MS, University of California San Francisco, San Francisco, CA USA
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Beverly Hills, CA USA
Benjamin Kopecky, MD, PhD, Washington University in St. Louis, St. Louis, MO USA
Jill Krisl, PharmD, Houston Methodist Hospital, Houston, TX USA
Shivank Madan, MD, Montefiore Medical Center, New York, NY USA
Claudius Mahr, DO, University of Washington, Seattle, WA USA
Yosef Manla, MD, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Mrudula Munagala, MD, University of Miami, Miami, FL USA
Kavitha Muthiah, MBChB, PhD, St. Vincent's Hospital, Sydney, NSW Australia
Lazaros Nikolaidis, MD, Baylor Scott & White Medical Center, Temple, TX USA

Marish Oerlemans, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands
Carlos Ortiz-Bautista, MD, PhD, Hospital Universitario Gregorio Marañón, Madrid, Spain
Pujan Patel, MD, AdventHealth, Raleigh, NC USA
Yael Peled, MD, Sheba Medical Center, Ramat Gan, Israel
Michael Petty, PhD, RN, APRN, CNS, CCNS, University of Minnesota MC, Minneapolis, MN USA
Gregor Poglajen, MD, PhD, Advanced Heart Failure and Transplantation Center, Ljubljana, Slovenia
Jayant Raikhelkar, MD, Columbia University, New York, NY USA
Amresh Raina, MD, Allegheny General Hospital, Pittsburgh, PA USA
Roopa Rao, MBBS, Indiana University, Carmel, IN USA
Ravikumar Ratnagiri, MD, PhD, MGM Hospital, Chennai, India
Ashwin Ravichandran, MD, MPH, St. Vincent Heart Center of Indiana, Indianapolis, IN USA
María Renedo, MD, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina
Victor Rossel, MD, Instituto Nacional del Torax, Las Condes, Chile
Sia Saatee, MD, Northwestern Medicine, Chicago, IL USA
Marc Simon, MD, MS, University of California San Francisco, San Francisco, CA USA
Melissa Smallfield, MD, Virginia Commonwealth University, Richmond, VA USA
Pallavi Solanki, MD, FACC, Rutgers-NJMS, Montville, NJ USA
Tae Song, MD, University of Chicago, Chicago, IL USA
Swethika Sundaravel, MD, University of Pennsylvania, Philadelphia, PA USA
Jose Tallaj, MD, Univ of Alabama at Birmingham, Birmingham, AL USA
Sarumathi Thangavel, MD, Chennai, India
Adrian Van Bakel, MD, PhD, Medical University of South Carolina, Charleston, SC USA
Melana Yuzefpolskaya, MD, Columbia University Medical Center, New York, NY USA

(421) ***Endomyocardial Biopsy Utilization and Outcomes Among Patients with Myocarditis;*** M. Mohamad Alahmad[1], T. Dalia[1], A. Goyal[1], P. Bhyan[1], Z. Shah[2]. *[1]The University of Kansas Health System; Kansas University Medical Center, Kansas City, KS, [2]Cardiology, The University of Kansas Health System; Kansas University Medical Center, Kansas City, KS*

(422) ***Changes in Pulse Pressure after 24 Hours of Initiation of Inotrope Therapy in Cardiogenic Shock is Associated with Adverse Outcomes;*** J. Han[1], J. Grinstein[1], P. Di Santo[2], B. Hibbert[2], M. Belkin[1]. *[1]University of Chicago Medical Center, Chicago, IL, [2]University of Ottawa Heart Institute, Ottawa, ON, Canada*

(423) ***Decoupling of Hemodynamics and Congestive Symptoms in Obese Heart Failure Patients;*** C. Keck[1], M. Gregoski[1], S. Liwtin[1], B. Borlaug[2], M. Fudim[3], R. Tedford[4], B. Houston[1]. *[1]Medical University of South Carolina, Charleston, SC, [2]Mayo Clinic, Rochester, MN, [3]Duke, Durham, NC, [4]Medical University of South Carolina, Mt Pleasant, SC*

(424) ***Impact of Intra-Aortic Balloon Pumps on Cardiogenic Shock Survival Pre-Transplant: A Propensity Score Stratified Analysis;*** J. S. Dickey, M. Anderson, M. A. Chavez, C. Selzman, E. Tseliou, C. Kapelios, J. Fang, S. Drakos, J. Stehlik, T. Hanff. *University of Utah, Salt Lake City, UT*

(425) ***Myocardial Metabolic Positron Emission Tomography for Viability Assessment During Impella Support;*** L. Baldetti, G. Barone, M. Gramegna, V. Pazzanese, S. Sacchi, F. Calvo, S. Ajello, E. Busnardo, M. Scandroglio. *IRCCS "San Raffaele" Hospital, Milano, Italy*

(426) ***Response in Kidney Function in Heart Failure after Milrinone Loading;*** M. Siddiki, J. Han, M. Belkin, A. Plana, N. Gupta, S. Pinney, S. Kalantari, J. Grinstein. *University of Chicago Medical Center, Chicago, IL*

(427) ***Gender Disparities in LVAD Utilization: A NIS Database Analysis 2009-2020;*** M. Faisaluddin[1], A. Zaky Ahmed[1], H. Patel[2], S. Thakkar[3], S. S. Dani[4], R. Alweis[1], S. Feitell[1]. *[1]Rochester General Hospital, Rochester, NY, [2]Southern Illinois University, Springfield, IL, [3]Houston Methodist Hospital, Houston, TX, [4]Lahey Hospital & Medical Center, Burlington, MA*

(428) ***A Case of Acute Mitoxantrone Mediated Myocarditis in Refractory Acute Myeloid Leukemia (AML);*** S. Fleming[1], S. Sennhauser[1], L. May[1], N. Simone[1], A. Beuningen[1], K. Bhatt[2]. *[1]Heart Failure/Cardiac Imaging, Emory University School of Medicine, Atlanta, GA, [2]Emory University, Atlanta, GA*

(429) ***Rescue of Cardiogenic Shock with Multiple Staged Interventions Each Bridging to the Next;*** M. A. Peterzan[1], S. Price[2], R. Trimlett[2], N. Lees[1], E. Khoshbin[1], J. Hill[2], E. Heng[1], R. Smith[1], A. Barron[1], O. Dar[1], F. Riesgo Gil[1], A. Morley-Smith[1], J. Dunning[1]. *[1]Cardiothoracic Transplantation. Harefield Hospital. Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, [2]Royal Brompton Hospital. Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom*

(430) ***Paraganglioma as a Cause of Acute Heart Failure Causing Cardiogenic Shock;*** M. Konicoff[1], J. Dunning[2], F. Riesgo Gil[2], O. Dar[2], A. Morley-Smith[2]. *[1]Cardiothoracic Transplantation, Harefield Hospital. Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom, [2]Cardiothoracic Transplantation, Harefield Hospital. Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom*

(431) ***A Masquerading Tick Bite Associated Acute Myocarditis;*** V. Jayachandiran[1], L. Pi[2], S. Smith[3], R. Davey[4], S. De[5]. *[1]Department of Medicine, Western University, London, ON, Canada, [2]Western University, Richmond Hill, ON, Canada, [3]LHSC-University Hosp, London, ON, Canada, [4]Western University, London, ON, Canada, [5]London, ON, Canada*

(432) ***The Heart On Fire: A Case of Fulminant Eosinophilic Myocarditis;*** E. Rashed[1], M. Norris[2], E. Peyster[3], J. Wald[4], T. Wang[1]. *[1]University of Pennsylvania, Philadelphia, PA, [2]Hospital of the University of Pennsylvania, Philadelphia, PA, [3]Cardioloy, University of Pennsylvania, Philadelphia, NJ, [4]University of Pennsylvania Hospital, Philadelphia, PA*

(433) ***Cardiogenic Shock in Eosinophilic Myocarditis;*** S. Desai, J. Ruiz, S. Paghdar, S. Malkani, J. Nativi, L. Juan, D. Yip, P. Patel, M. Lyle, R. Goswami. *Transplant, Mayo Clinic, Jacksonville, FL*

(434) ***An Alarming Surprise;*** N. Shahandeh[1], S. David[1], M. King[2], J. Smith[2], M. Fishbein[1], R. Biniwale[1], A. Nsair[1], M. Kamath[1]. *[1]University of California, Los Angeles, Los Angeles, CA, [2]UCLA Heart & Lung Transplant Program, Los Angeles, CA*

(435) ***Dobutamine Induced Hypersensitivity Eosinophilic Myocarditis;*** M. Alarfaj[1], T. Dalia[1], H. Farhoud[1], T. Fields[2], Z. Shah[1], A. Vidic[1]. *[1]Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, KS, [2]Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS*

(436) ***Consequences of Chemo: A Case of Cyclophosphamide Induced Cardiotoxicity;*** M. Pelter, D. Cork, J. Heywood. *Scripps Health, La Jolla, CA*

(437) ***Extreme HLA Homozygosity Contributing to Extreme HLA Sensitization;*** P. Srivastava[1], X. Zhang[2], J. Moriguchi[1], D. Chang[1], L. Czer[1], R. Cole[1], M. Kittleson[1], E. Kransdorf[1], J. Kobashigawa[1], J. Patel[1]. *[1]Cedars-Sinai Heart Institute, Los Angeles, CA, [2]Cedars Sinai Medical Center, Los Angeles, CA*

(438) ***Absence of Ventricular Arrhythmias in a Patient with Giant Cell Myocarditis;*** M. Oberoi, S. Lundgren. *University of Nebraska Medical Center, Omaha, NE*

(439) ***Severe Biventricular Dysfunction Following Pericardiectomy in a Pediatric Patient;*** J. Schauer, B. Hong, M. Files, M. McMullan. *Seattle Children's Hospital, Seattle, WA*

(440) ***Cardiomyopathy Associated with Systemic Disease: The Case of a 31-Year-Old Female with Left Ventricular Thickening;*** R. Solomon[1], A. Michaels[2], J. Cowger[3]. *[1]Henry Ford Hospital, Detroit, MI, [2]Detroit, MI, [3]Henry Ford Hospitals, Detroit, MI*

(441) ***Cardiac Allograft Vasculopathy Trajectory Score Helpful to Avoid Annual Angiograms in Heart-Kidney Transplant Recipients;*** M. Kittleson, J. Patel, B. Azarbal, S. Kim, T. Singer-Englar, R. Trajano, A. Velleca, D. Geft, D. Megna, L. Czer, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(442) ***High HDL Levels are Associated with Survival Benefit after Heart Transplantation;*** J. Patel, M. Kittleson, N. Patel, T. Singer-Englar, S. Kim, S. Thein, K. Norland, A. Hage, L. Czer, D. Emerson, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(443) ***Validation of the Cardiac Allograft Vasculopathy (CAV) Trajectory Score after Heart Transplantation;*** N. Patel, M. Kittleson, D. Chang, J. Patel, B. Azarbal, T. Singer-Englar, D. Geft, L. Czer, F. Esmailian, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(444) ***In-Stent Re-Stenosis for Cardiac Allograft Vasculopathy in the Current Era for Heart Transplantation;*** M. Kittleson, J. Patel, B. Azarbal, N. Patel, T. Singer-Englar, T. Yeomans, G. Esmailian, A. Nikolova, A. Hage, D. Emerson, L. Czer, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(445) ***Outcomes of Heart Transplant Recipients That Had a Percutaneous Coronary Intervention;*** W. Rzechorzek, A. Malik, D. Bandyopadhyay, A. Goel, E. Levine, C. Aggarwal Gupta, G. Lanier, A. Gass, S. Pan. *Westchester Medical Center, Valhalla, NY*

(446) ***Serum Biomarker Detection of Early Cardiac Allograft Vasculopathy: ECAV Sub-Study;*** N. Aleksova[1], L. Zhang[2], A. Chong[2], V. Džavík[1], D. Y. So[2], G. A. Wells[2], J. Bernick[2], C. B. Overgaard[1], L. M. Mielniczuk[2], E. Stadnick[2], R. S. Beanlands[2], P. Liu[2], H. J. Ross[1], S. Chih[2]. *[1]Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre, Toronto, ON, Canada, [2]University of Ottawa Heart Institute, Ottawa, ON, Canada*

(447) ***Impact of Systolic Blood Pressure on Risk of Cardiac Allograft Vasculopathy;*** A. J. Feinberg, C. Yarber, M. U. Farooq, S. Vukelic, O. Saeed, S. Madan, J. J. Shin, S. Murthy, P. Chavez, D. B. Sims, U. P. Jorde, S. R. Patel, Y. M. Rochlani. *Division of Cardiology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY*

(448) ***Coronary Allograft Vasculopathy is Associated with Decreased Cd34⁺ Peripheral Cell Count and Increased Vegf Serum Levels;*** L. Poljancic[1], G. Poglajen[2], N. Žorž[2], S. Frljak[2], A. Cerar[2], G. Zemljic[2], R. Okrajsek[2], M. Sebestjen[2], B. Vrtovec[2]. *[1]Institute of Radiology, UMC Ljubljana, Ljubljana, Slovenia, [2]Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia*

(449) ***An Overlooked Contributor to CAV;*** A. B. Cochrane[1], M. Nable[1], A. G. Barber[2], P. Shah[3], J. Kennedy[3], I. Isseh[4], A. Rollins[1], A. Thatcher[1], K. Bussa[1], K. Mauro[1], M. Maydosz[5], S. Sinha[6], S. Desai[7], M. Psotka[3]. *[1]Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA, [2]Butler University, Indianapolis, IN, [3]Inova Heart and Vascular Institute, Falls Church, VA, [4]Inova, Arlington, VA, [5]Inova Heart and Vascular instititute, Alexandria, VA, [6]Inova Fairfax Medical Campus, Arlington, VA, [7]Inova Health System, McLean, VA*

(450) ***Tolerability and Effectiveness of Intensified Statin after Heart Transplantation;*** E. Hirsch[1], D. Nnani[1], S. Patel[2], Y. Rochlani[3], S. Vukelic[4], J. Shin[1], P. Chavez[1], S. Madan[5], D. Sims[6], U. Jorde[1], O. Saeed[7]. *[1]Montefiore Medical Center, Bronx, NY, [2]Montefiore-Einstein, Bronx, NY, [3]Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, [4]Albert Einstein College of Medicine, Montefiore MC, Bronx, NY, [5]Montefiore Medical Center, New York, NY, [6]Montefiore Medical Center NY, New York, NY, [7]Montefiore Medical Ctr, New York, NY*

(451) ***Donor-Derived Cell-Free DNA in Heart Transplant Recipients with Coronary Allograft Vasculopathy;*** C. M. Moeller[1], D. Oren[1], E. M. DeFilippis[1], D. Lotan[1], G. Rubinstein[1], Y. Mehlman[1], A. Raja[1], S. Slomovich[1], J. Fried[1], J. Raikhelkar[1], E. Lin[1], K. Oh[1], S. Lee[1], V. Topkara[1], D. Majure[2], F. Latif[1], G. Sayer[3], N. Uriel[1], K. Clerkin[1]. *[1]Columbia University Irving Medical Center, New York, NY, [2]Weill Cornell Medical College, New York, NY, [3]Columbia University Irving Medical Center, Hartsdale, NY*

(452) ***Recurrent Enteroviral Myocarditis in Transplanted Heart from Induced Immune Deficiency;*** A. Azmeen[1], R. P. Garvin[2], A. P. Basheer[2], R. Zolty[1]. *[1]University of Nebraska Medical Center, Omaha, NE, [2]University of Nebraska Medical Center - - Omaha, NE, Omaha, NE*

(453) ***Human Papilloma Virus Associated Malignancies in Heart Transplant Recipients;*** E. Brown[1], W. Whiteley[2], P. Kale[3]. *[1]Baylor Scott and White Health, Arlington, TX, [2]Baylor University Medical Center, Dallas, TX, [3]Baylor U Med Ctr, Dallas, TX*

(454) ***Disseminated Coccidioidomycosis from Orthotopic Heart Transplant Donor Allograft;*** E. S. Lee[1], L. Sanborn[1], E. C. DePasquale[2], K. A. Pandya[2]. *[1]Internal Medicine, University of Southern California, Los Angeles, CA, [2]Cardiology, University of Southern California, Los Angeles, CA*

(455) ***Acute Liver Injury as a Complication of Heart Transplant from a Hepatitis C+ Donor;*** A. Plana[1], M. Belkin[2], J. Grinstein[3]. *[1]Internal Medicine, University of Chicago Hospitals, Chicago, IL, [2]University of Chicago, Chicago, IL, [3]University of Chicago Medicine, Chicago, IL*

(456) ***Early Recurrence of Cardiac Sarcoidosis after Orthotopic Heart Transplantation;*** S. P. Khan[1], M. Seplowe[2], L. Vemulakonda[3], F. Shakil[3], C. Aggarwal-Gupta[1], G. Lanier[4], E. Levine[4], S. Ohira[5], D. Spielvogel[6], A. Gass[4], M. Kai[7], S. Pan[7]. *[1]Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, [2]Internal Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, [3]Pathology, Westchester Medical Center, Valhalla, NY, [4]Cardiology, Westchester Medical Center, Valhalla, NY, [5]Cardiothoracic Surgery, Westchester Medical Center, New York Medical College, Valhalla, NY, [6]Cardiothoracic Surgery, Westchester Medical Center, Valhalla, NY, [7]Westchester Medical Center, Valhalla, NY*

(457) ***Disseminated Toxoplasmosis in a Cardiac Transplant Patient: When Prophylaxis Isn't Enough;*** E. Rashed[1], K. Whitaker[2], M. Ambrose[3], E. Feldbaum[3], R. McLean[4]. *[1]Advanced Heart Failure and Transplant, University of Pennsylvania, Philadelphia, PA, [2]Penn Medicine, Philadelphia, PA, [3]Cardiology, University of Pennsylvania, Philadelphia, PA, [4]Philadelphia, PA*

(458) ***'Un-Break My Heart' - Successful Heart Transplantation From A Donor with Reverse Takotsubo Syndrome;*** A. Fardman[1], E. Nachum[2], A. Morgan[3], J. Lavee[4], T. Fink[5], R. Kuperstein[3], Y. Shapira[5], J. Patel[6], Y. Peled[7]. *[1]Chaim Sheba Medical Center, Ramat-Gan, Israel, [2]Sheba Medical Center, Kiryat Ono, Israel, [3]Sheba Medical Center, Ramat-Gan, Israel, [4]Sheba Medical Center, Ramat Gan, Israel, [5]Rabin Medical Center, Petah Tikva, Israel, [6]Cedars-Sinai Smidt Heart Institute, Calabasas, CA, [7]Sheba Medical Center, Ramat Gan, M, Israel*

(459) ***Severe Myocardial Necrosis and Acute Allograft Failure from Fulminant Clostridium Perfringens Sepsis;*** H. Rosenblum[1], C. Lee[1], E. M. DeFilippis[1], F. Latif[1], J. Fried[1], D. Lotan[1], K. Clerkin[1], J. Aaron[1], K. Takeda[1], Y. Kaku[1], D. Santoriello[1], G. Sayer[1], N. Uriel[2], J. Raikhelkar[1]. *[1]Columbia University College of Physicians & Surgeons, New York, NY, [2]New York Presbyterian, New York, NY*

(460) ***Calcinosis Cutis in the Setting of Rapamycin Use: Balancing Infection and Vasculopathy;*** E. Rashed[1], M. Molina[2], L. Goldberg[1], P. Mather[3]. *[1]University of Pennsylvania, Philadelphia, PA, [2]Hospital of the University of Pennsylvania, Philadelphia, PA, [3]Univ of Pennsylvania, Ambler, PA*

(461) ***Coinciding Sinus Node Dysfunction and High Degree Av Block in a Heart Transplant Patient;*** R. Crespo, K. Hryniewicz, C. Gornick, P. Eckman. *Minneapolis Heart Institute, Minneapolis, MN*

(462) ***'Tri'Ing to Clip the Gap: Percutaneous Tricuspid Intervention in a Heart Transplant;*** N. Gorrie, N. Bart, D. Muller. *St Vincent's Hospital, Sydney, Australia*

(463) ***One-year Outcome in a Patient Who Underwent Three Organ Transplant Using Thoracoabdominal Normothermic Regional Perfusion (ta-nrp) for Al- Amyloidosis;*** A. S. Birs[1], M. Urey[2]. *[1]University of California San Diego, La Jolla, CA, [2]UC San Diego Health, San Diego, CA*

(464) ***Outcomes of Heart Transplantation in Pediatric Patients with Noonan Syndrome: An Institutional Case Series;*** J. M. Andreola[1], L. D'Addese[1], S. Shugh[1], F. Fricker[2], R. Winchester[1], M. Chrisant[1]. *[1]Heart Institute, Joe DiMaggio Children's Hospital, Hollywood, FL, [2]Congenital Heart Center, UF Health, Gainesville, FL*

(465) ***Extensive Cardiac Allograft Vasculitis and Concurrent Constrictive Pericarditis 23 Years after Heart Transplantation;*** T. Teszak[1], A. Assabiny[1], A. Kiraly[1], Z. Tarjanyi[1], N. Parazs[1], Z. Szakal-Toth[1], S. Kugler[1], Z. Szabolcs[1], A. Fintha[2], G. Muzes[3], H. Vago[1], A. Jermendy[1], I. Edes[1], B. Merkely[1], B. Sax[1]. *[1]Semmelweis University Heart and Vascular Centre, Budapest, Hungary, [2]Semmelweis University Department of Pathology and Experimental Cancer Research, Budapest, Hungary, [3]Semmelweis University Department of Internal Medicine and Hematology, Budapest, Hungary*

(466) ***Clinical Utility of Near-Infrared Spectroscopy Intravascular Ultrasound in the Assessment of Rapidly Progressive Cardiac Allograft Vasculopathy;*** S. Takenaka[1], T. Sato[1], S. Kazui[1], Y. Yasui[1], K. Saiin[1], S. Naito[1], Y. Takahashi[1], Y. Mizuguchi[1], A. Tada[1], Y. Kobayashi[1], K. Omote[1], T. Konishi[1], K. Kamiya[1], T. Ooka[2], T. Nagai[1], S. Wakasa[2], T. Anzai[1]. *[1]Department of Cardiovascular Medicine, Hokkaido University, Sapporo, Japan, [2]Department of Cardiovascular Surgery, Hokkaido University, Sapporo, Japan*

(467) ***Shone's Complex: Not So 'Simple' after All;*** L. Labrada[1], J. Mazurek[2], C. Haeffele[3], A. Weingarten[4], T. Gupta[5], J. Menachem[6]. *[1]Advanced Heart Failure and Transplant, Vanderbilt University Medical Center, Nashville, TN, [2]University of Pennsylvania, Merion Station, PA, [3]Stanford University, Palo Alto, CA, [4]Vanderbilt, Nashville, TN, [5]Vanderbilt University Medical Center, Nashville, TN, [6]Vanderbilt University, Nashville, TN*

(468) ***The Intra-Operative "Gross Pathology": An Approach to Determining Heart-Only Versus Heart-Liver Transplantation in Fontan Patients;*** D. M. Torpoco Rivera[1], E. Martin[2], M. Ma[3], S. Hollander[4], R. Bensen[5], N. Ebel[5], K. Zhang[5], A. Bonham[6], A. Gallo[6], C. O. Esquivel[6], M. Navaratnam[7], D. Rosenthal[8], S. Chen[9]. *[1]Pediatric Cardiology - Heart Transplant, Lucile Packard Children's Hospital at Stanford University, Palo Alto, CA, [2]Cardiothoracic Surgery, Lucile Packard Children's Hospital at Stanford University, Palo Alto, CA, [3]Stanford University, Stanford, CA, [4]San Carlos, CA, [5]Gastroenterology, Lucile Packard Children's Hospital at Stanford University, Palo Alto, CA, [6]Surgery, Lucile Packard Children's Hospital at Stanford University, Palo Alto, CA, [7]Lucile Packard Children's Hospital at Stanford University, Palo Alto, CA, [8]Pediatric Cardiology, Stanford, Palo ALto, CA, [9]Stanford University, Palo Alto, CA*

(469) ***Urgent Heart Transplantation: Mechanical Circulatory Ssupport on Ischemic Cardiogenic Shock;*** M. Louro-Freire[1], M. Solla-Buceta[1], R. Estévez-Loureiro[2], M. García-Vieites[1], D. Couto-Mallon[1], A. Aller-Fernández[1], L. Fernández-Arias[1], A. Ceniceros-Barros[1], G. Barge-Caballero[1], J. López-Canoa[1], J. Vázquez-Rodríguez[1], M. Crespo-Leiro[1]. *[1]Hospital Universitario A Coruña, A Coruña, Spain, [2]Hospital Universitario Vigo, Vigo, Spain*

(470) ***Successful Heart Transplantation in Severe Pulmonary Hypertension with Reversibility;*** M. A. Peterzan, A. Danskine, P. Brookes, B. Olwell, E. Khoshbin, J. Dunning, F. Riesgo Gil, O. Dar, A. Morley-Smith. *Cardiothoracic Transplantation. Harefield Hospital. Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom*

(471) ***Biventricular Heartmate 3s as a Bridge-To-Candidacy;*** P. Marogil, M. Dela Cruz, G. Macaluso, S. Pauwaa, J. Monaco, V. Chau, J. Pillarella, M. T. Kabbany, C. Sciamanna, A. Joshi, W. Cotts, A. Tatooles, P. Pappas, N. Narang. *Advocate Christ Medical Center, Oak Lawn, IL*

(472) ***Giant Cell Myocarditis with LVAD Presenting with Acute Severe AI Managed with Valve-In-Valve TAVI;*** Y. Rochlani[1], S. Madan[1], S. Vukelic[1], O. Saeed[1], S. Murthy[1], J. Shin[1], S. Patel[1], M. Latib[2], D. Goldstein[1], U. Jorde[1], D. Sims[1]. *[1]Montefiore Medical Center, New York, NY, [2]Cardiology, Montefiore Medical Center, New York, NY*

(473) ***Incorporating Palliative Care Services in the Advanced Heart Failure Clinic;*** E. Brown[1], W. Whiteley[2], P. Kale[2]. *[1]Baylor Scott and White Health, Baylor Scott and White Dallas, TX, [2]Baylor University Medical Center, Dallas, TX*

(474) ***Not All That Flares is Gout: Calcineurin-Inhibitor Induced Pain Syndrome (CIPS) Post Heart Transplant;*** A. A. Kelkar[1], B. Rasmussen[1], R. Thapa[2]. *[1]Cardiovascular Medicine, Atrium Health/Wake Forest Baptist, Winston Salem, NC, [2]Department of Rheumatology, Atrium Health/Wake Forest Baptist, Winston Salem, NC*

(475) ***Post Heart Transplant Immunosuppression During Pregnancy;*** R. Lief, D. Wolfe, C. Gjelaj, D. Sims, P. Chavez. *Montefiore Medical Center, Bronx, NY*

(476) ***From Vpra of 100% to Transplantation, Journey of the First Ocs-dbd Case in Switzerland;*** B. Schnegg[1], C. Muster[2], M. Wieser[2], M. Pavlicek-Bahlo[2], S. Wiedermann[2], S. Dobner[2], J. Bruno[2], L. Capek[2], P. Potratz[3], H. Jenni[3], D. Sidler[4], I. Chanias[5], M. Daskalakis[5], J. Consiglio[3], F. Schwitz[6], C. Thomet[6], M. Schwerzmann[6], F. Immer[7], S. Longnus[8], M. Martinelli[2], L. Hunziker[2], M. Siepe[3], D. Reineke[3]. *[1]Centre for Advanced Heart Failure, Inselspital, University Hospital Bern, CH, Wabern, Switzerland, [2]Centre for Advanced Heart Failure, Inselspital, University Hospital Bern, Bern, Switzerland, [3]Department of Cardiac Surgery, Inselspital, University Hospital Bern, Bern, Switzerland, [4]Department of Nephrology and Hypertension, Inselspital, University Hospital Bern, Bern, Switzerland, [5]Department of Haematology and Central Hematology Laboratory, Inselspital, University Hospital Bern, Bern, Switzerland, [6]Center for Congenital Heart Defects, Inselspital, University Hospital Bern, Bern, Switzerland, [7]Swisstransplant, Bern, Switzerland, [8]Department of Cardiac Surgery, Inselspital, University Hospital Bern, Berne, Switzerland*

(477) ***In the Thick of It: A Mysterious Case of Biventricular Hypertrophy;*** E. R. Cedarbaum, J. Ra, T. A. Ports, K. Soni, J. D. Davis, M. A. Aras, L. Klein. *University of California, San Francisco, San Francisco, CA*

(478) ***Heart-lung Transplantation for Restrictive Cardiomyopathy and Pulmonary Hypertension Due to Emery-Dreifuss Muscular Dystrophy;*** C. Thomas[1], K. Klein[2], J. Kennedy[3], M. Psotka[3], I. Isseh[4], D. Tang[5], S. Aryal[6], V. Khangoora[7], A. Nyquist[8], A. Singhal[9], O. Cantres-Fonseca[10], O. Shlobin[7], S. Nathan[11], C. King[12]. *[1]Inova Fairfax, Washington, DC, [2]Virginia Commonwealth University, Fairfax, VA, [3]Inova Heart and Vascular Institute, Falls Church, VA, [4]Inova, Arlington, VA, [5]Inova, McLean, VA, [6]Inova, Falls Church, VA, [7]Inova Fairfax Hospital, Fairfax, VA, [8]Inova Fairfax Hospital, Falls Church, VA, [9]Arlington, VA, [10]VA Caribbean Health System, Fairfax, VA, [11]Inova Fairfax Hospital, Vienna, VA, [12]Inova Fairfax Hospital, Reston, VA*

(480) ***Cardiac Contractility Modulation Use in Decompensated Heart Failure Requiring Inotropic Support;*** P. Doshi[1], S. Zhou[2], D. Valdivia[3], M. Yanamandra[4], P. Abarca[5], A. Iyer[6], D. Skoll[7], K. Kharidia[8], A. Zadeh[1], M. Fong[9]. *[1]Division of Cardiology, Keck School of Medicine of USC, Los Angeles, CA, [23]USC Keck School of Medicine Hospital, Los Angeles, CA, [4]USC, Pasadena, CA, [5]LAC+USC Medical Center, Los Angeles, CA, [6]Keck School of Medicine of USC, Pasadena, CA, [7]Keck School of Medicine of USC, [8]USC Keck School of Medicine, Santa Clara, CA, [9]University of Southern California, West Hollywood, CA*

(481) ***Mimicry;*** S. Sennhauser[1], L. May[1], S. Sakaleshpura Mallikarjunappa[2], K. Bhatt[3], A. Van Beuningen[1]. *[1]Cardiology, Emory University, Atlanta, GA, [2]Surgical Pathology, Emory University, Atlanta, GA, [3]Emory University, Decatur, GA*

(482) ***Transcatheter Edge to Edge Repair of the Mitral Valve as a Bridge for Refractory Acute End Stage Hfref, Case Reoprt;*** R. Sadraldin[1], A. Alsayed[2], M. Aloatiby[3], T. Al Garni[4], N. Al Harbi[3]. *[1]Adult cardiology, Prince Sultan Cardiac Center, Riyad, Saudi Arabia, [2]prince sultan cadiac centrr, riyadh, Saudi Arabia, [3]Prince sultan cardiac center, Riyadh, 1, Saudi Arabia, [4]Prince Sultan Cardiac Center, Riyadh, Saudi Arabia*

(483) ***The Effect of Temperature Control Versus Icebox Preservation on Post Heart Transplant Outcome;*** F. Latif[1], G. Sayer[1], D. Lotan[1], J. Mendoza[1], M. Regan[1], D. Tsapepas[1], A. Ramakrishnan[1], E. M. DeFilippis[1], M. Yuzefpolskaya[1], P. Colombo[1], P. Kennel[1], J. Raikhelkar[1], K. Clerkin[1], J. Fried[1], E. Lin[1], S. Lee[1], Y. Naka[2], K. Takeda[2], N. Uriel[1]. *[1]Division of Cardiology -Center for Advanced Cardiac Care, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY, [2]Division of Cardiothoracic Surgery, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY*

(484) ***Donor Characteristic Between Donor Circulatory Death and Donor Brain Death;*** J. Silva Enciso[1], A. Duran[2], H. Tran[3], M. Urey[4], E. Adler[5], R. White[6], M. Kearns[4], V. Pretorius[1]. *[1]UCSD, La Jolla, CA, [2]University of California San Diego, San Diego, CA, [3]University of California, San Diego, San Diego, CA, [4]UC San Diego Health, San Diego, CA, [5]Univ of California, SD, Apple Valley, CA, [6]UCSD, San Diego, CA*

(485) ***Determination of Incidence and Mortality of Cancer in Cardiac Transplant Patients-A Unos Database Analysis;*** N. Nair[1], A. Harish[2], D. Du[3]. *[1]Medicine/Cardiology, Texas Tech University Health Sciences, Wolfforth, TX, [2]Medicine/Cardiology, TTUHSC, Lubbock, TX, [3]Industrial and Structural Engineering, TTU, Lubbock, TX*

(486) ***Electronic Nose for Detecting Impaired Glucose Metabolism in Heart Transplant Recipients;*** N. Wijbenga[1], M. J. van Kekem[1], M. M. Goedendorp - Sluimer[2], S. Roest[2], J. J. Brugts[2], K. Caliskan[2], A. A. Constantinescu[2], D. Bos[3], M. E. Hellemons[4], O. C. Manintveld[2]. *[1]Department of Respiratory Medicine, Department of Cardiology, and Erasmus MC Transplant Institute, Erasmus MC University Medical Center, Rotterdam, Netherlands, [2]Department of Cardiology and Erasmus MC Transplant Institute, Erasmus MC University Medical Center, Rotterdam, Netherlands, [3]Department of Radiology & Nuclear Medicine and Epidemiology, Erasmus MC University Medical Center, Rotterdam, Netherlands, [4]Department of Respiratory Medicine and Erasmus MC Transplant Institute, Erasmus MC University Medical Center, Rotterdam, Netherlands*

(487) ***Use of Leadless Cardiac Pacemakers in Heart Transplant Recipients: A Case Series;*** M. Satish[1], P. Ting[1], L. Mitrani[1], M. A. Miller[1], M. Barghash[2], N. Moss[3], A. Lala[3], A. Anyanwu[4], D. Mancini[5]. *[1]Icahn School of Medicine at Mount Sinai, New York, NY, [2]The Mount Sinai Hospital, New York, NY, [3]Mount Sinai Hospital, New York, NY, [4]Mount Sinai Med Ctr, New York, NY, [5]Mount Sinai, New York, NY*

(488) ***Impaired Liver Function is Associated with Hypotension and Elevated Right Atrial Pressure but Not Depressed Cardiac Index in Chronic Heart Failure;*** C. Kapelios[1], E. Tseliou[1], R. Alharethi[2], K. Shah[3], T. Hanff[3], C. Kyriakopoulos[4], K. Sideris[1], I. Taleb[3], J. Stehlik[3], S. Carter[1], A. Kfoury[5], W. Caine[6], C. Selzman[3], J. Fang[7], O. Wever-Pinzon[3], S. Drakos[3]. *[1]University of Utah Hospital, Salt Lake City, UT, [2]Intermountain Medical Center, Murray, UT, [3]University of Utah, Salt Lake City, UT, [4]University of Utah School of Medicine, Salt Lake City, UT, [5]Intermountain Med Ctr, Murray, UT, [6]Intermountain Medical Ctr, Salt Lake City, UT, [7]Univ of Utah Health Sciences Center, Salt Lake City, UT*

(489) ***Does Echocardiography-Guided Endomyocardial Biopsy Reduce the Incidence of Tricuspid Regurgitation after Heart Transplantation;*** M. Nable[1], S. Kumar[2], J. Goldberg[3], A. Cochrane[1], M. Psotka[1], D. Tang[1], I. Isseh[1], S. Desai[1], A. Rollins[1], K. Klein[1], K. Bussa[1], K. Mauro[1], M. Maydosz[1], A. Thatcher[1], J. Kennedy[1], P. Shah[1]. *[1]Inova Heart and Vascular Institute, Falls Church, VA, [2]MedStar Health, Washington, DC, [3]Inova L.J. Murphy Children's Hospital, Fall Church, VA*

(490) ***Calcineurin Inhibitor-Induced Atypical Hemolytic Uremic Syndrome after Heart Transplantation;*** J. Patel[1], I. Mahana[1], P. H. Lam[1], M. Hofmeyer[1], S. Rao[1], A. Kadakkal[1], N. Afari-Armah[1], M. Krishnan[1], E. Molina[1], S. Najjar[2], F. Sheikh[1], M. Rodrigo[1], R. Gupta[1]. *[1]MedStar Washington Hospital Center, Washington, DC, [2]MedStar Health, Baltimore, MD*

(491) ***Atrial Thrombosis in Heart Transplantation: An Old Problem Revisited;*** A. Maestro Benedicto[1], D. García-Cosculluela[1], C. González-Freixa[1], M. de Antonio[2], I. Zegrí[1], R. Leta[1], T. Koller[1], A. Ginel[1], L. López López[1], M. Campreciós[1], S. Mirabet Perez[3]. *[1]Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain, [2]Hospital de la Santa Creu i Sant Pau, Barcelona, B, Spain, [3]Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, CIBERCV, Barcelona, Spain*

(492) ***Impact of Indeterminate Donor Derived Cell Free DNA Results on Clinical Events in the First Year after Heart Transplantation;*** P. Gosain[1], K. Khush[2], M. Fei[3], Y. Fu[3], S. Hall[4]. *[1]Memorial Cardiac and Vascular Institute, Fort Lauderdale, FL, [2]Stanford University, Stanford, CA, [3]Biostatistics and Data Sciences, CareDx, Brisbane, CA, [4]Baylor University Medical Center, Dallas, TX*

(493) ***Unique Immunological Profiles in Stable African American, Caribbean, Latinx, and Caucasian Heart Transplant Patients;*** V. Ravichandran[1], R. Burke[1], T. Bueno[2], E. Ladich[2], I. Dumitru[3]. *[1]CareDx Inc., Brisbane, CA, [2]Memorial Regional Hospital, Hollywood, FL, [3]Tampa General Hospital, Tampa, FL*

(494) ***The Utility and Characteristics of Cardiovascular Magnetic Resonance Imaging in Suspected Chronic Allograft Rejection;*** D. Lotan[1], R. Park[2], G. Rubinstein[1], C. Moeller[1], E. M. DeFilippis[1], K. Oh[1], S. Slomovich[1], D. Oren[1], E. Lin[1], K. Clerkin[1], F. Latif[1], P. Colombo[1], M. Yuzefpolskaya[1], V. Topkara[1], J. Kim[2], D. Majure[3], G. Sayer[1], W. Jonathan[2], N. Uriel[1]. *[1]Division of Cardiology - Center for Advanced Cardiac Care, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY, [2]Greenberg Cardiology Division - Department of Medicine, Weill Cornell Medicine/New York Presbyterian, New York, NY, [3]Division of Cardiology -Center for Advanced Cardiac Care, Weill Cornell Medical College, New York, NY*

(495) ***End-Expiratory versus Averaged PAWP Measurements for the Diagnosis of Exercise-Induced HFpEF;*** O. Mithoefer[1], J. Read[1], C. Keck[1], J. E. Epps[1], S. Fu[2], J. Grewal[1], M. Rofael[1], M. Gregoski[1], B. Houston[1], R. Tedford[1]. *[1]Medical University of South Carolina, Charleston, SC, [2]University of Louisville, Louisville, KY*

(496) ***Effects of Sedation on Right Heart Catheterization Hemodynamic Measurements in Advanced Heart Failure Patients;*** J. Lattell[1], J. Han[2], A. Kanelidis[2], S. Kalantari[2], M. Belkin[2], J. Grinstein[2]. *[1]Department of Cardiology, University of Chicago Medical Center, Chicago, IL, [2]University of Chicago Medical Center, Chicago, IL*

(497) ***Surveillance Imaging and Management of Cardiac Sarcoidosis after Advanced Heart Failure Therapies;*** R. Gupta[1], F. Bermudez[2], T. Vora[1], A. Kadakkal[1], N. Afari-Armah[1], S. Rao[1], P. H. Lam[1], M. E. Rodrigo[1], M. Hofmeyer[1], M. Krishnan[1], J. Fajardo[1], S. S. Najjar[3], F. H. Sheikh[1]. *[1]MedStar Washington Hospital Center, Washington, DC, DC, [2]Georgetown University School of Medicine, Washington, DC, DC, [3]MedStar Health, Baltimore, MD*

(498) ***Diagnostic Performance of Molecular Microscope Diagnostic System in Addition to Cell Free DNA in Heart Transplant Rejection;*** F. Ishaq, N. Fida, D. T. Nguyen, G. A. Edward, A. Guha. *Houston Methodist Hospital, Houston, TX*

(499) ***Transverse and Longitudinal Right Ventricular Fractional Parameters Derived from Four-Chamber Cine Mri are Associated with Right Ventricular Dysfunction Etiology;*** T. S. Kato[1], M. Sato[2], C. Takamura[2], J. Ito[2], M. Ito[2], Y. Watanabe[3], M. Terashima[2]. *[1]Department of Cardiology, International University of Health and Welfare, Tokyo, Japan, [2]Cardiovascular Imaging Clinic Iidabashi, Tokyo, Japan, [3]Cardiovascular Imaging Clinic Iidabashi, Cardiovascular Imaging Clinic Iidabashi, Japan*

(500) ***Initial Experience with Local Laboratory Run Assay to Detect Donor-Derived Cell Free Dna for Non-Invasive Diagnosis of Acute Myocardial Rejection;*** L. Potena[1], G. Spitaleri[1], M. Masetti[1], L. Borgese[1], L. Giovannini[1], A. Orsini[2], B. De Nicolò[2], M. Scuppa[2], S. Manno[2], C. Baldovini[1], O. Leone[1], E. Bonora[2]. *[1]IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, [2]University of Bologna, Bologna, Italy*

(501) ***Ex-Vivo Heart Perfusion for Cardiac Transplantation: An Initial Experience in the United States;*** A. Isath[1], S. Ohira[2], E. Levine[3], S. Pan[4], G. Lanier[5], C. Gupta[6], K. Wolfe[1], D. Spielvogel[4], A. Gass[4], M. Kai[4]. *[1]Westchester Medical Center and New York Medical College, Valhalla, NY, [2]Westchester Medical Center, New York Medical College, Valhalla, NY, [3]Westchester Medical Center, Teaneck, NJ, [4]Westchester Medical Center, Valhalla, NY, [5]Westchester Medical Center, New York, NY, [6]Westchester Medical Center, Pleasantville, NY*

(502) ***Obese Donors in Heart Transplantation: Hemodynamic Assessment and Survival;*** N. Rajagopalan, D. Dennis, J. Akhtarekhavari, A. Kolodziej, M. Sekela. *University of Kentucky, Lexington, KY*

(503) ***Donor-Related Clinical Factors Influencing One-Year Outcomes in Adult Patients after Orthotopic Heart Transplantation - A Single-Center Polish Experience;*** A. A. Kuczaj[1], S. Warwas[2], B. Król[3], T. Hrapkowicz[1], J. Śliwka[1], S. Pawlak[1], P. Przybyłowski[1]. *[1]Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze. Medical University of Silesia, Zabrze, Poland, [2]Students' Scientific Association Affiliated with the Department of Cardiac, Vascular and Endovascula, Students' Scientific Association Affiliated with the Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Zabrze, Poland, [3]Transplant Coordination Office, Silesian Center for Heart Diseases in Zabrze, Zabrze, Poland*

(504) ***Correlation of Donor Electrocardiogram Abnormalities with Donor Echocardiograms and Angiograms: The Donor Heart Study;*** N. Tapaskar[1], B. Wayda[2], H. Luikart[3], D. Malinoski[4], T. Groat[5], J. Nguyen[6], J. Nieto[7], R. P. Wood[7], N. Neidlinger[8], A. Salehi[9], P. Geraghty[10], B. Nicely[11], M. Jendrisak[12], J. Belcher[13], T. Pearson[14], J. Zaroff[15], K. Khush[1]. *[1]Stanford University, Stanford, CA, [2]Stanford University School of Medicine, San Mateo, CA, [3]Stanford Hospital, Ca, CA, [4]Surgery, Oregon Health and Science University, Portland, OR, [5]Oregon Health and Science University, Portland, OR, [6]University of California San Francisco, San Francisco, CA, [7]LifeGift, Houston, TX, [8]University of Wisconsin, Madison, WI, [9]Donor Network West, San Ramon, CA, [10]Donor Network of Arizona, Tempe, AZ, [11]Gift of Life Michigan, Ann Arbora, MI, [12]Gift of Hope, Itasca, IL, [13]New England Donor Service, Waltham, MA, [14]Emory University Hospital, Atlanta, GA, [15]Kaiser Permanente, San Francisco, CA*

(505) ***Outcomes Comparison of Commonly Used Heart Transplant Preservation Solutions During the Covid-19 Pandemic;*** S. N. Paluri[1], U. Siddiqi[2], D. Rodgers[2], S. C. Uppalapati[2], S. Bangaru[3], K. Ram[4], J. Kumar[3], K. Sorensen[5], K. Sudheendra[6], A. Madhushankar[7], K. Johnson[8], D. Hynes[9], S. Jain[2], V. Jeevanandam[2], D. Onsager[2]. *[1]Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL, [2]Section of Cardiac Surgery, University of Chicago, Chicago, IL, [3]Illinois Mathematics and Science Academy, Chicago, IL, [4]University of Michigan, Ann Arbor, MI, [5]Dominican University, River Forest, IL, [6]Hinsdale Central High School, Hinsdale, IL, [7]Adlai E. Stevenson High School, Lincolnshire, IL, [8]Illinois Mathematics and Science Academy, Aurora, IL, [9]Hamilton College, Clinton, NY*

(506) ***Characterization of Donor-Derived Cell-Free DNA Results in Cardiac Donation after Brain Death vs. Donation after Cardiac Death;*** L. J. Rupert[1], J. Campain[1], D. D'Alessandro[2], G. Lewis[2]. *[1]Cardiology, Massachusetts General Hospital, Boston, MA, [2]Massachusetts General Hospital, Boston, MA*

(507) ***Leukotriene B4 Mediates Development of Cardiac Allograft Vasculopathy after Heart Transplantation;*** K. Khush[1], D. Wang[2], H. Luikart[3], D. Kim[1], S. Schrepfer[4]. *[1]Cardiovascular Medicine, Stanford University, Stanford, CA, [2]TSI-Laboratory University Heart Center Hamburg, San Francisco, CA, [3]Stanford Hospital, Ca, CA, [4]UCSF Medical Center, San Francisco, CA*

(508) ***Outcome of the Kidney in Heart-Kidney Transplant - Does It Take an Immune Hit;*** D. Chang[1], M. Kittleson[1], J. Patel[1], T. Singer-Englar[1], S. Kim[1], P. Hage[1], K. Norland[1], L. Czer[1], F. Esmailian[1], S. Jordan[2], J. Kobashigawa[1]. *[1]Cedars-Sinai Heart Institute, Los Angeles, CA, [2]Cedars-Sinai Medical Center, Los Angeles, CA*

(509) ***What Should the GFR Threshold Be for Redo Heart Transplant Patients to Qualify for Combined Heart-Kidney Transplantation;*** M. Kittleson, J. Patel, A. Nikolova, N. Patel, T. Singer-Englar, J. Hu, F. De Leon, M. Hamilton, L. Czer, F. Esmailian, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(510) ***Are Redo Heart Transplant Patients Appropriately Listed as Status 4 on the Waitlist;*** M. Kittleson, J. Patel, T. Singer-Englar, S. Kim, N. Patel, Z. Wakefield, M. Welton, L. Czer, F. Esmailian, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(511) ***Fast Metabolism of Tacrolimus and Impact of Dosing in Heart Transplant Patients;*** S. Jafri[1], L. Schenkelberg[2], M. Guglin[3], R. P. Kreutz[4], T. C. Skaar[4], K. Saleem[5], O. Ilonze[6], K. Ballut[3], R. Rao[5]. *[1]Advanced Heart Failure and Transplant Cardiology, Indiana University, Indianapolis, IN, [2]Carmel, IN, [3]Indiana University, Indianapolis, IN, [4]Indiana university, Indianapolis, IN, [5]Indiana University, Carmel, IN, [6]Indiana University, Houston, TX*

(512) ***Donor-Derived Cell-Free DNA in Heart Multiorgan Transplantation;*** S. Kumar[1], D. T. Nguyen[2], E. A. Graviss[2], S. Patil[3], J. H. Kim[1], E. E. Suarez[1], I. Hussain[1], R. Yousefzai[1], S. A. Ahsan[1], J. Gorthi[4], M. Kassi[1], A. Bhimaraj[1], C. M. Martin[1], A. Guha[1]. *[1]Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, [2]Department of Pathology and Genomic Medicine, Institute for Academic Medicine, Houston Methodist Hospital, Houston, TX, [3]Department of Medicine, RajaRajeswari Medical College & Hospital, Bangalore, India, [4]Cardiolgoy, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX*

(513) ***Renal Function Stabilization in Patients with Advanced Heart Failure and Chronic Kidney Disease Supported with Impella 5.5 as a Bridge to Transplantation;*** S. Desai, T. Jarmi, J. Ruiz, S. Paghdar, P. Patel, S. Malkani, J. Nativi, D. Yip, M. Lyle, J. Leoni, R. Goswami. *Transplant, Mayo Clinic, Jacksonville, FL*

(514) ***Clinical Utility of Donor Derived Cell-Free DNA in the Multiorgan Transplantation;*** C. Moeller[1], D. Oren[1], G. Rubinstein[1], D. Lotan[1], S. Slomovich[1], K. Clerkin[1], J. Fried[1], J. Raikhelkar[1], Y. Mehlman[1], E. Lin[1], S. Lee[1], A. Kleet[1], K. Oh[1], V. Topkara[1], E. M. DeFilippis[1], D. Majure[2], F. Latif[1], N. Uriel[1], G. Sayer[1]. *[1]Division of Cardiology, Center for Advanced Cardiac Care, Columbia University Irving Medical Center, New York, NY, [2]Weill Cornell Medical College, New York, NY*

(515) ***Burden of Arrythmias and Hospital Outcomes Among Patients with Heart Transplant: A Nis Database Analysis from 2015-2020;*** M. Faisaluddin[1], A. Ismail Zaky Ahmed[1], H. Patel[2], S. Thakkar[3], S. S. Dani[4], R. Alweis[1], S. Feitell[1]. *[1]Rochester General Hospital, Rochester, NY, [2]Southern Illinois University, Springfield, IL, [3]Houston Methodist Hospital, Houston, TX, [4]Lahey Hospital & Medical Center, Burlington, MA*

(516) ***A Multicenter Experience in the Use of Allomap and Allosure Surveillance Strategies in Multiorgan Heart-Kidney and Heart-Liver Transplantation;*** J. Nattiv[1], K. Pandya[2], M. Fong[3], D. Vucicevic[4], J. Hsu[5], R. Lee[6], A. Wolfson[7], M. Deng[8], A. Vaidya[9], E. DePasquale[10], M. Kamath[4]. *[1]University of Southern California - Keck Hospital of USC, Los Angeles, CA, [2]University of California Davis, Sacramento, CA, [3]University of Southern California, West Hollywood, CA, [4]UCLA, Los Angeles, CA, [5]University of California at Los Angeles (UCLA), Los Angeles, CA, [6]University of Southern CA Keck School of Medicine, Los Angeles, CA, [7]University of Arizona - Tucson, Los Angeles, CA, [8]David-Geffen Sch Med, Venice, CA, [9]Keck Medical Center of USC, La Canada Flintridge, CA, [10]University of Southern California, Valley Village, CA*

(517) ***Actual-to-Expected Advanced Heart Failure Therapy Utilization in the United States by Race/Ethnicity;*** D. Concha[1], A. Chung[2], H. Lumish[3], J. Batra[4], G. Sayer[5], K. Clerkin[6], J. Raikhelkar[7], P. Colombo[7], Y. Naka[8], F. Latif[9], K. Takeda[7], J. Fried[10], M. Yuzefpolskaya[10], Y. Kaku[7], N. Uriel[11]. *[1]Internal Medicine, Columbia University Medical Center, New York, NY, [2]Columbia University Irving Medical Center, New York, NY, [3]New York Presbyterian Hospital - Columbia, New York, NY, [4]Cardiology, Columbia University Medical Center, New York, NY, [5]Cardiology, Columbia University Irving Medical Center, New York, NY, [6]Columbia University Irving Medical Center, New york, NY, [7]Columbia University, New York, NY, [8]New York Presbyterian Hospital, New York, NY, [9]NY Presbyterian Hospital, New York, NY, [10]Columbia University Medical Center, New York, NY, [11]New York Presbyterian, New York, NY*

(518) ***Impact of the 2018 French Allocation Scheme on the Profile of Heart Transplantation Candidates and Recipients: Insights from a High-Volume Center;*** G. Coutance[1], E. Desiré[2], M. Lescroart[2], G. Lebreton[3], A. Combes[2], A. Bouglé[2], S. Varnous[4], P. Leprince[5]. *[1]Pitié-Salpetrière Hospital, Paris, France, [2]Pitié-Salpêtrière Hospital, Paris, France, [3]Hosp La Pitie, La Pitie, France, [4]Hosp Pitie Salpetriere, Paris, 75, France, [5]Hopital de La Pitie Salpetriere, Sorbonne University, Paris, 75, France*

(519) ***Oversized Donors for Patients with Pulmonary Hypertension Awaiting Heart Transplant: Busting the Myth of Using Female Donors;*** M. Kittleson, J. Patel, A. Hage, D. Geft, T. Singer-Englar, S. Kim, A. Velleca, M. Hamilton, L. Czer, F. Esmailian, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(520) ***Limitations of Cardiac Size Matching Based on Predicted Heart Mass in the 2018 Heart Allocation System;*** M. Yadollahikhales[1], K. Clerkin[2], V. Topkara[3]. *[1]College of Medicine, State University of New York Downstate Health Sciences University, Brooklyn, NY, [2]Columbia University Irving Medical Center, Ridgewood, NJ, [3]Columbia University New York Presbyterian Hospital, New York, NY*

(521) ***Derivation and Validation of a Risk Prediction Model for Waitlist Mortality in Left Ventricular Assist Device Patients;*** A. Tibrewala[1], M. Hu[1], L. C. Petito[1], J. Rich[1], D. Pham[1], T. De By[2], F. Gustafsson[3], K. Veen[4], M. Vanderheyden[5], D. Lloyd-Jones[1], S. Shah[1]. *[1]Northwestern University, Chicago, IL, [2]Euromacs, S-Gravenhage, ZH, Netherlands, [3]Rigshospitalet, Copenhagen, Denmark, [4]Erasmus MC, Rotterdam, Netherlands, [5]OLV Hospital, Antwerpen, Belgium*

(522) ***Impact of Blood Group on Status 2 vs Status 3 Heart Transplant Listing in the U.S;*** M. A. Chavez[1], M. Anderson[2], J. Dickey[3], C. Selzman[3], S. Drakos[3], J. Stehlik[3], T. Hanff[3]. *[1]Cardiovascular Disease, University of Utah, Salt Lake City, UT, [23]University of Utah, Salt Lake City, UT*

(523) ***Impact of the Donor Organ Allocation Change on Heart Transplant of Patients with Small Body Surface Area;*** S. Riaz[1], I. Konstantinidis[2], W. Baker[3], A. Jaiswal[4]. *[1]Cardiology, Hartford Hospital/University of Connecticut, Hartford, CT, [2]Internal Medicine, Hartford Hospital/University of Connecticut, Hartford, CT, [3]Hartford Hospital, Hartford, CT, [4]Cardiology, Hartford Hospital, Hartford, CT*

(524) ***Impact of the Donor Organ Allocation Change on Heart Transplant of Latinos;*** S. Riaz[1], I. Konstantinidis[2], W. Baker[3], A. Jaiswal[4]. *[1]Cardiology, Hartford Hospital/University of Connecticut, Hartford, CT, [2]Internal Medicine, Hartford Hospital/University of Connecticut, Hartford, CT, [3]Hartford Hospital, Hartford, CT, [4]Cardiology, Hartford Hospital, Hartford, CT*

(526) ***Effect of the 2018 Unos Adult Heart Allocation Policy Change on Post-Transplant Complication Rates;*** E. S. Lee[1], A. S. Vaidya[2], E. S. Kawaguchi[3], E. C. DePasquale[2], A. M. Wolfson[2]. *[1]Internal Medicine, Keck School of Medicine at USC, Los Angeles, CA, [2]Keck School of Medicine at USC, Los Angeles, CA, [3]Preventive Prevention, Keck School of Medicine at USC, Los Angeles, CA*

(527) ***Transplantation Trends in End Stage Hypertrophic Cardiomyopathy Over 35 Years: A UNOS Registry Analysis;*** D. J. Miklin[1], E. DePasquale[2]. *[1]Northwell Health, Manhasset, NY, [2]University of Southern California, Los Angeles, CA*

(528) ***How Low Can You Go? Equivalent Outcomes with the Select Use of Size Mismatched Hearts;*** D. T. Kim[1], A. Guevara-Castro[1], B. Wayda[1], E. Henricksen[2], H. Luikart[1], Y. Moayedi[3], R. Lee[2], J. Han[4], B. M. Zhang[5], B. Guenthart[6], K. Khush[1], J. Teuteberg[1], S. Hsiao[1]. *[1]Cardiology, Stanford University, Stanford, CA, [2]Transplant, Stanford Health Care, Stanford, CA, [3]Cardiology, University Health Network, Toronto, ON, Canada, [4]University of Chicago Medical Center, Chicago, IL, [5]Pathology, Stanford University, Stanford, CA, [6]Cardiothoracic Surgery, Stanford University, Stanford, CA*

(529) ***Transthyretin Amyloid May Have a Protective Effect for Rejection after Heart Transplantation;*** A. Shen, J. Patel, M. Kittleson, D. Chang, G. Esmailian, T. Singer-Englar, F. De Leon, M. Hamilton, D. Geft, L. Czer, D. Megna, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(530) ***Late Graft Dysfunction after Heart Transplantation: A Single Centre Experience;*** L. Barrios[1], W. Droogne[1], J. Stassen[2], L. Van Aelst[1], V. Gabor[1], J. Van Cleemput[1]. *[1]Cardiology, University Hospitals Leuven, Leuven, Belgium, [2]Cardiology, Jessa Hospital, Hasselt, Belgium*

(531) ***Differences in Pressure-Volume Relationship Between Obese and Non-Obese Patients with Advanced Heart Failure;*** V. Kittipibul[1], M. Fudim[1], J. Molinger[1], M. Silver[2], D. Yaranov[3]. *[1]Duke University Medical Center, Durham, NC, [2]Rosalind Franklin University of Medicine and Science, Chicago, IL, [3]Baptist Memorial Hospital, Memphis, TN*

(532) ***Relationship Between Blood Volume Measures and Cardiopulmonary Exercise Testing Performance in Advanced Heart Failure;*** V. Kittipibul[1], M. Fudim[1], J. Molinger[1], M. Silver[2], D. Yaranov[3]. *[1]Duke University Medical Center, Durham, NC, [2]Rosalind Franklin University/Chicago Medical School, Chicago, IL, [3]Baptist Memorial Hospital, Memphis, TN*

(533) ***Association of Strain with Clinical Outcomes in Lmna Cardiomyopathy;*** Q. Bui[1], M. Kraushaar[2], L. Hanko[2], M. Reed[2], A. Kumar[2], H. Vu[2], B. Greenberg[3], M. Urey[4], E. Adler[5], K. Hong[6]. *[1]UC San Diego, San Diego, CA, [2]UC San Diego, La Jolla, CA, [3]University of California, San Diego, San Diego, CA, [4]UC San Diego Health, San Diego, CA, [5]Univ of California, SD, Apple Valley, CA, [6]University of California, San Diego, La Jolla, CA*

(534) ***The H_2FPEF Score is Predictive of Exercise Capacity Amongst Minorities with Heart Failure with Preserved Ejection Fraction, from the Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations Study;*** H. Rosenblum[1], E. Driggin[1], C. Rodriguez[1], B. Jaya[1], D. Fine[2], S. Helmke[1], M. Winburn[2], N. Sabogal[2], S. Teruya[1], F. L. Ruberg[2], M. Maurer[1]. *[1]Columbia University College of Physicians & Surgeons, New York, NY, [2]Boston University Chobanian & Avedisian School of Medicine, Boston University Medical Center, Boston, MA*

(535) ***Evaluating Mismatch in Adult Heart Transplantation: Risk Factors for Patients with and without Relevant Predicted Heart Mass Ratio Mismatch;*** M. B. Immohr[1], D. Scheiber[2], D. Sigetti[1], F. S. Jenkins[1], N. Kalampokas[1], F. Bönner[2], H. Aubin[1], P. Akhyari[1], A. Lichtenberg[1], U. Boeken[1]. *[1]Dept. of Cardiac Surgery, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, [2]Dept. of Cardiology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany*

(536) ***Outcomes After Renal Transplantation in Patients with Reduced Left Ventricular Ejection Fraction;*** A. D. Kelkar[1], M. Desta[1], D. McDonald[2], D. Majure[2], G. Stryjniak[3], M. Aull[3], D. Dadhania[4], M. Karas[2]. *[1]Internal Medicine, New York Presbyterian / Weill Cornell, New York, NY, [2]Cardiology, New York Presbyterian / Weill Cornell, New York, NY, [34]Nephrology, New York Presbyterian / Weill Cornell, New York, NY*

(537) ***Differences in Cardiopulmonary Exercise Performance Between True Anemia and Hemodilution in Patients with Advanced Heart Failure;*** V. Kittipibul[1], M. Fudim[1], J. Molinger[1], M. Silver[2], D. Yaranov[3]. *[1]Duke University Medical Center, Durham, NC, [2]Rosalind Franklin University/Chicago Medical School, Chicago, IL, [3]Baptist Memorial Hospital, Memphis, TN*

(538) ***Echocardiographic Findings in Patients with Methamphetamine Cardiomyopathy;*** I. Mizrahi[1], P. Shah[1], R. Huang[2], T. Nagamine[2], M. Gozun[1], D. Lee[3], L. Shimabuku[4], Z. Khan[1], C. Lum[5], M. Brodsky[1]. *[1]University of Hawaii, Honolulu, HI, [2]University of Hawaii Internal Medicine Residency Program, Honolulu, HI, [3]Queens Heart Institute, Kaneohe, HI, [4]Queens Heart Institute, Honolulu, HI, [5]Queen's Heart Physicians Practice, Honolulu, HI*

(539) ***Decreased Peripheral Cd34$^+$ Cell Count is Associated with Worse Left Ventricular Function in Patients with Takotsubo Cardiomyopathy;*** G. Poglajen[1], M. Jovanovic[2], N. Žorž[1], S. Frljak[1], B. Vrtovec[1]. *[1]Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, [2]Dept. of Internal Medicine, UMC Ljubljana, Ljubljana, Slovenia*

(540) ***Multi-Organ Transplantation in Hiv-Positive Recipients – Patient Characteristics and Outcomes***; J. Batra[1], V. Topkara[2], K. Clerkin[3], F. Latif[4], J. Fried[1], J. Raikhelkar[5], D. Lotan[5], E. Donald[6], H. Lumish[7], K. Oh[8], M. Yuzefpolskaya[1], P. Colombo[5], E. Lin[9], G. Sayer[10], N. Uriel[11]. *[1]Columbia University Medical Center, New York, NY, [2]Columbia University New York Presbyterian Hospital, New York, NY, [3]Columbia University Irving Medical Center, Ridgewood, NJ, [4]NY Presbyterian Hospital, New York, NY, [5]Columbia University, New York, NY, [6]New York Presbyterian, Columbia University Medical Center, New York, NY, [7]New York Presbyterian Hospital – Columbia, New York, NY, [8]Columbia University Irving Medical Center, Bronx, NY, [9]Columbia Univ Med Ctr, New York, NY, [10]Columbia University Irving Medical Center, Hartsdale, NY, [11]New York Presbyterian, New York, NY*

(541) ***A Probable Winner in the Race for the Best Cardiac Preservation Solution: A Single-Center's Experience***; S. N. Paluri[1], U. Siddiqi[2], D. Rodgers[2], S. C. Uppalapati[2], S. Bangaru[3], K. Ram[4], K. Sorensen[5], K. Sudheendra[6], A. Madhushankar[7], K. Johnson[3], D. Hynes[8], S. Jain[2], V. Jeevanandam[2]. *[1]Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL, [2]Section of Cardiac Surgery, University of Chicago, Chicago, IL, [3]Illinois Mathematics and Science Academy, Aurora, IL, [4]University of Michigan, Ann Arbor, MI, [5]Dominican University, River Forest, IL, [6]Hinsdale Central High School, Hinsdale, IL, [7]Adlai E. Stevenson High School, Lincolnshire, IL, [8]Hamilton College, Clinton, NY*

(542) ***Path to Eliminating Surveillance Endomyocardial Biopsies in Heart Transplant: Early Use of Donor Derived Cell-Free DNA – One Year Follow Up***; D. Miklin[1], K. Ravi[2], T. Wolf-Doty[3], G. Shekhtman[3], J. Kobulnik[3], A. Salimbangon[3], R. Cartus[2], A. Cochran[2], A. Berg[2], M. Ackerman[2], A. Wolfson[2], A. Vaidya[2], J. Nattiv[2], E. DePasquale[2]. *[1]Northwell Health, Manhasset, NY, [2]University of Southern California, Los Angeles, CA, [3]CareDx, Brisbane, CA*

(543) ***Novel Use of Cardiac Contractility Modulator Implantable Device in Patients with Advanced Heart Failure***; K. P. Mody, S. Jamal. *Cardiology, Hackensack University Medical Center, Hackensack, NJ*

(544) ***Patient-Reported Outcomes in Short-Time Follow-Up after Discharge of Patients with Advanced Heart Failure***; T. Wagner, L. Zhou, C. Magnussen, A. Bernhardt, H. Reichenspurner, P. Kirchhof, H. Grahn. *University Heart and Vascular Center, Hamburg, Germany*

(545) ***Outcomes of Heart Transplantation (HT) for Chagas Cardiomyopathy (CM) in US***; S. Madan[1], J. Teitelbaum[2], O. Saeed[3], D. Sims[4], S. Forest[5], D. Goldstein[6], S. Patel[7], U. Jorde[5]. *[1]Montefiore Medical Center, New York, NY, [2]Albert Einstein College of Medicine, Bronx, NY, [3]Montefiore Medical Ctr, New York, NY, [4]Montefiore Medical Center NY, New York, NY, [5]Montefiore Medical Center, Bronx, NY, [6]Montefiore, Bronx, NY, [7]Montefiore-Einstein, Bronx, NY*

(546) ***Higher Utilization of Non-Invasive Rejection Surveillance in Year Two after Heart Transplant is Associated with Higher Rates of Detection Of Rejection, Graft Dysfunction, and Vasculopathy***; B. Lowes[1], E. DePasquale[2], S. Pinney[3], M. Hsueh[4], Y. Fu[4], L. Shen[4], D. Baran[5], J. Kobashigawa[6], J. Teuteberg[7], N. Raval[8]. *[1]U. Nebraksa Med Ctr, Omaha, NE, [2]University of Southern California, Valley Village, CA, [3]University of Chicago, Chicago, IL, [4]Biostatistics and Data Sciences, CareDx, Brisbane, CA, [5]Cleveland Clinic Heart, Vascular and Thoracic Institute, Parkland, FL, [6]Cedars-Sinai Heart Institute, Los Angeles, CA, [7]Stanford University School of Medicine, Stanford, CA, [8]AdventHealth Transplant Institute, Orlando, FL*

(547) ***Cost-Effectiveness of a Prehabilitation Program in Patients Listed for Heart Transplantation***; M. A. Castel[1], M. Lopez-Baamonde[2], M. J. Arguis[2], A. Burniol[3], E. Gimeno-Santos[4], B. Romano[5], R. Navarro-Ripoll[2], M. Farrero Torres[6], M. Sanz-de la Garza[7], E. Sole[1], E. Sandoval[8], A. García-Alvárez[7], G. Martinez-Palli[2]. *[1]Heart Failure and Heart Transplantation Unit, Cardiology Department, Hospital Clinic Barcelona, Barcelona, Spain, [2]Anaesthesiology Department, Hospital Clinic Barcelona, Barcelona, Spain, [3]Economics and Business Department-Centre for Research in Health and Economics (CRES-UPF), Pompeu Fabra University, Barcelona, Spain, [4]Respiratory Clinic Institute, Hospital Clinic Barcelona, Barcelona, Spain, [5]Nutrition and Clinical Dietetics, Hospital Clinic Barcelona, Barcelona, Spain, [6]Heart Failure and Heart Transplantation Unit, Cardiology Department, Hospital Clinic de Barcelona, Barcelona, Spain, [7]Cardiology Department, Hospital Clinic Barcelona, Barcelona, Spain, [8]Cardiovascular Surgery Department, Hospital Clinic Barcelona, Barcelona, Spain*

(548) ***Bridge to Transplant and Transplant Outcomes in Cardiac Amyloidosis: A Systematic Review***; N. Raftopulos[1], N. Gorrie[2], N. Bart[3]. *[1St] Vincent's Hospital, Sydney, Darlinghurst, Australia, [2]St Vincent's Hospital Sydney, Darlinghurst, Australia, [3]St Vincent's Hospital, Sydney, Australia*

(550) ***A Retrospective Study on Gender, LAA Morphology and Stroke Risk***; K. Sorensen[1], D. Rodgers[1], S. Chandra Uppalapati[1], U. Siddiqi[2], S. Jain[1], S. Paluri[3], A. Madhushanka[1], K. Sudheendra[1], K. Johnson[1], S. Bangaru[1], K. Ram[1], D. Hynes[1], C. Ozcan[1], L. Lee[1], G. Kim[1], V. Jeevanandam[4]. *[1]University of Chicago, Chicago, IL, [2]University of Chicago Medicine, Elmhurst, IL, [34]University of Chicago Medical Center, Chicago, IL*

(551) ***Post-Transplant Outcomes in LVAD-BTT Patients: Differences Based on Order of Acceptance of Donor Organs***; E. Purohit[1], D. Fermin[2], M. Jani[2], M. Dickinson[2], M. Gonzalez[3], S. Lee[2], R. Grayburn[2], M. Leacche[2], P. Tremblay[2], N. Manandhar-Shrestha[2]. *[1]Cardiovascular Disease, Spectrum Health/Michigan State University, Grand Rapids, MI, [2]Spectrum Health, Grand Rapids, MI, [3]Cardiovascular Disease, Spectrum Health, Grand Rapids, MI*

(552) ***As Comfortable as a Pillow: The Superiority of the Sternasafe® Device Over the Standard of Care***; E. Ochoa[1], S. Jain[2], D. Rodgers[2], S. Norton de Matos[2], S. C. Uppalapati[2], S. Bangaru[3], K. Johnson[3], K. Sudheendra[4], K. Ram[5], D. Hynes[6], K. Sorensen[7], S. N. Paluri[8], A. Madhushankar[9], V. Jeevanandam[10]. *[1]Washington University in St. Louis School of Medicine, St. Louis, MO, [2]University of Chicago, Chicago, IL, [3]Illinois Mathematics and Science Academy, Aurora, IL, [4]Hinsdale Central High School, Hinsdale, IL, [5]University of Michigan, Ann Arbor, MI, [6]Hamilton College, Clinton, NY, [7]Dominican University, River Forest, IL, [8]Chicago College of Osteopathic Medicine, Midwestern University, Chicago, IL, [9]Adlai E. Stevenson High School, Lincolnshire, Lincolnshire, IL, [10]University of Chicago Medical Center, Chicago, IL*

(553) ***Cardiac Allograft Rejection Surveillance with Donor Derived Cell Free Dna is a Reliable Non-Invasive Alternative to Endomyocardial Biopsy***; S. Roberts[1], B. Lowes[2], T. Washington[1], L. Snell Kinen[3], M. Hyden[4]. *[1]UNMC, Omaha, NE, [2]U. Nebraksa Med Ctr, Omaha, NE, [3]Nebraska Medicine, Gretna, NE, [4]Univ of Nebraska Med Ctr, Omaha, NE*

(554) ***Revascularization of Donor Transmitted Coronary Artery Disease After Heart Transplantation: Impact on Survival and Cardiovascular Events. Insights from the DONOR-CAD Study***; D. Couto-Mallon[1], L. Almenar Bonet[2], E. Barge-Caballero[1], S. Lozano-Jiménez[3], J. López-Azor García[4], T. Domingo Gardeta[5], M. A. Castel[6], S. Mirabet Perez[7], I. Garrido Bravo[8], C. Diez-Lopez[9], A. López Granados[10], R. Manrique Anton[11], J. Muñiz[12], M. G. Crespo-Leiro[1]. *[1]Cardiology, Hospital Universitario A Coruña. Instituto de Investigación Biomédica de A Coruña (INIBIC). CIBERCV., A Coruña, Spain, [2]Hospital Universitario y Politécnico La Fe, Valencia, Spain, [3]Hospital Universitario Puerta de Hierro, Majadahonda, Spain, [4]Hospital Universitario 12 de Octubre, Madrid, Spain, [5]Hospital General Universitario Gregorio Marañón, Madrid, Spain, [6]Hospital Clínic, Barcelona, Spain, [7]Hospital Sant Pau. IIB SANT PAU. CIBERCV, Barcelona, Spain, [8]H Virgen de la Arrixaca, Murcia, Spain, [9]Bellvitge University Hospital, Barcelona, Spain, [10]Hospital Universitario Reina Sofía, Córdoba, Spain, [11]Clinica Universidad Navarra, PAMPLONA/IRUÑA, NA, Spain, [12]Universidade de A Coruña. Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain*

(555) ***Permanent Pacemaker Placement Following Donation after Circulatory Death Heart Transplantation***; M. Begur[1], A. Lin[2], L. Keyt[3], Q. Bui[4], A. Duran[4], M. Urey[4], E. Adler[4], V. Pretorius[5], J. Cruz Rodriguez[4]. *[1]Internal Medicine, UC San Diego, La Jolla, CA, [2]Cardiology, UC San Diego, San Diego, CA, [3]Internal Medicine, UC San Diego, San Diego, CA, [4]Cardiology, Advanced Heart Failure, UC San Diego, San Diego, CA, [5]Cardiothoracic Surgery, UC San Diego, San Diego, CA*

(556) ***Severity of Donor Transmitted Coronary Artery Disease and Survival after Heart Transplantation. Results from the Donor Coronary Artery Disease (DONOR-CAD) Study***; D. Couto-Mallon[1], R. López-Vilella[2], E. Barge-Caballero[1], F. Hernández-Pérez[3], J. López-Azor García[4], T. Domingo Gardeta[5], M. A. Castel[6], M. de Antonio[7], I. Garrido Bravo[8], C. Diez-Lopez[9], R. Manrique Anton[10], A. López Granados[11], J. Muñiz[12], M. G. Crespo-Leiro[1]. *[1]Hospital Universitario A Coruña. Instituto de Investigación Biomédica de A Coruña (INIBIC). CIBERCV., A Coruña, Spain, [2]Hospital Universitario y Politécnico La Fe, Valencia, Spain, [3]Hospital Universitario Puerta de Hierro, Majadahonda, Spain, [4]Hospital Universitario 12 de Octubre, Madrid, Spain, [5]Hospital General Universitario Gregorio Marañón, Madrid, Spain, [6]Hospital Clínic, Barcelona, Spain, [7]Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, [8]H Virgen de la Arrixaca, Murcia, Spain, [9]Bellvitge University Hospital, Barcelona, Spain, [10]Clinica Universidad Navarra, Pamplona/Iruña, Spain, [11]Hospital Universitario Reina Sofía, Córdoba, Spain, [12]Universidade de A Coruña. Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain*

(557) ***Effect of Pre-Transplant Sensitization on Gene Expression Profiling and Donor Derived Cell Free DNA Results***; J. Han[1], A. Nguyen[2], W. Tian[3], A. Nguyen[4], J. Zeng[3], L. Shen[3], E. DePasquale[5], S. Patel[6]. *[1]University of Chicago Medical Center, Chicago, IL, [2]University of Chicago Medicine, Chicago, IL, [3]Biostatistics and Data Sciences, CareDx, Brisbane, CA, [4]CareDx, Brisbane, CA, [5]University of Southern California, Valley Village, CA, [6]Montefiore-Einstein, Bronx, NY*

(558) ***Impact of Rejection Surveillance Practices on Outcomes after Heart Transplantation;*** M. Kanwar[1], N. Uriel[2], U. Jorde[3], W. Tian[4], K. Pinney[4], L. Shen[4], P. Shah[5]. *[1]Allegheny General Hospital, Pittsburgh, PA, [2]New York Presbyterian, New York, NY, [3]Montefiore Medical Center, Bronx, NY, [4]Biostatistics and Data Sciences, CareDx, Brisbane, CA, [5]Inova Heart and Vascular Institute, Falls Church, VA*

(559) ***Heart Transplantation Using Super Aged Donors at 65 Years and Over;*** T. Hada[1], O. Seguchi[1], S. Komeyama[1], H. Mochizuki[1], T. Watanabe[1], S. Fukushima[2], T. Fujita[2], Y. Tsukamoto[1]. *[1]Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan, [2]Department of Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan*

(560) ***Influence of Chronic Kidney Disease and Other Risk Factors Pre-Heart Transplantation on Malignancy Incidence Post-Heart Transplantation;*** S. Roest[1], M. T. Gürgöze[1], W. S. Cherikh[2], J. Stehlik[3], E. H. Boersma[1], F. Zijlstra[1], O. C. Manintveld[4]. *[1]Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, [2]United Network for Organ Sharing, Richmond, VA, [3]University of Utah, Salt Lake City, UT, [4]Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands*

(561) ***Phase Angle Assessment and Its Correlation with Biochemical Parameters and Body Composition after Heart or Lung Transplantation;*** A. Radtke-Lysek[1], M. Bohdan[1], M. Nowak[1], A. Borzyszkowska[2], W. Raczyńska[1], M. Ręcka[1], A. Frankiewicz[1], S. Żegleń[3], P. Siondalski[4], M. Gruchala[1]. *[1]First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland, [2]Department of Cardiac & Vascular Surgery, Medical University of Gdansk, Gdansk, Poland, [3]Department of Pulmonology and Allergology, Medical University of Gdansk, Gdansk, Poland, [4]Department of Cardiac and Vascular Surgery, Medical University of Gdansk, Gdansk, Poland*

(562) ***Donor-Derived Cell-Free DNA in Heart Transplant Recipients Bridged with Left Ventricular Assist Device;*** G. Rubinstein[1], D. Lotan[1], C. Moeller[1], S. Slomovich[1], D. Oren[1], Y. Mehlman[1], E. M. DeFilippis[1], E. Lin[1], J. Raikhelkar[1], K. Clerkin[1], E. Donald[1], K. Oh[1], A. Kleet[1], D. Majure[2], S. Lee[1], V. Topkara[1], P. Colombo[1], F. Latif[1], M. Yuzefpolskaya[1], G. Sayer[1], N. Uriel[1]. *[1]Division of Cardiology, Center for Advanced Cardiac Care, Columbia University Irving Medical Center, New York, NY, [2]Weill Cornell Medical College, New York, NY*

(563) ***Persistently Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients;*** D. Lotan, C. M. Moeller, G. Rubinstein, D. Oren, Y. Mehlman, S. Slomovich, R. Aishwarya, E. M. DeFilippis, J. Fried, K. Clerkin, J. Raikhelkar, K. Oh, E. Lin, S. Lee, P. Colombo, A. Kleet, M. Yuzefpolskaya, V. Topkara, F. Latif, G. Sayer, N. Uriel. *Division of Cardiology -Center for Advanced Cardiac Care, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY*

(564) ***The Effect of Persistently Elevated Dd-Cfdna with De-Novo Donor Specific Antibody on Heart Transplant Recipients Outcomes;*** D. Lotan, G. Rubinstein, C. Moeller, D. Oren, S. Slomovich, Y. Mehlman, E. M. DeFilippis, H. Rosenblum, J. Raikhelkar, K. Clerkin, J. Fried, K. Oh, E. Lin, S. Lee, V. Topkara, F. Latif, P. C. Colombo, M. Yuzefpolskaya, G. Sayer, N. Uriel. *Division of Cardiology -Center for Advanced Cardiac Care, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY*

(565) ***Donor-Derived Cell-Free DNA in Cancer Survivors Following Heart Transplantation;*** S. Slomovich[1], G. Rubinstein[1], C. M. Moeller[1], D. Lotan[1], Y. Mehlman[1], E. Donald[1], J. Batra[1], D. Oren[1], K. Oh[1], K. Clerkin[1], J. Fried[1], E. DeFilippis[1], V. Topkara[1], A. Kleet[1], P. C. Colombo[1], M. Yuzefpolskaya[1], E. F. Lin[1], S. Lee[1], D. Majure[2], F. Latif[1], G. T. Sayer[1], N. Uriel[1], J. K. Raikhelkar[1]. *[1]Division of Cardiology, Columbia University, New York, NY, [2]Division of Cardiology, Weill Cornell Medicine, New York, NY*

(566) ***Cardiogenic Shock with Fulminant Myocarditis Following Covid-19 Infection Tends to Have Slightly Worse Outcome Than That From Covid-19 Vaccinations;*** A. Etuk[1], O. Ilonze[2], M. Guglin[2]. *[1]Internal Medicine, Thomas Hospital, Infirmary Health, Fairhope, AL, [2]Indiana University, Indianapolis, IN*

(568) ***Impact of Dcd Donor Hearts on Transplant Outcomes: A Propensity-Matched Analysis;*** A. Y. Lin[1], Q. Bui[1], A. Duran[1], Y. Gernhofer[2], R. White[1], K. Sharaf[1], D. Cookish[1], H. Tran[1], K. Hong[1], E. Adler[1], N. Wettersten[1], J. Silva Enciso[1], M. Urey[1], M. Kearns[1], V. Pretorius[1]. *[1]University of California San Diego, La Jolla, CA, [2]University of the Incarnate Word School of Osteopathic Medicine, San Antonio, TX*

(569) ***Postoperative Outcomes of Patient with Sarcoidosis Undergoing Heart Transplantation;*** M. A. Martillo[1], B. Ebner[2], M. Munagala[1]. *[1]University of Miami/Jackson Memorial Hospital, Miami, FL, [2]University of Miami/Jackson Memorial, Miami, FL*

(570) ***Postoperative Outcomes of Patients with Chagas Cardiomyopathy Undergoing Heart Transplantation;*** M. Martillo[1], B. Ebner[2], M. Munagala[1]. *[1]University of Miami/Jackson Memorial Hospital, Miami, FL, [2]Miami, University of Miami/Jackson Memorial, Miami, FL*

(571) ***Low Pulmonary Artery Pulsatility Index (PAPi) Early Post Heart Transplant is Associated with Short Term Outcomes;*** R. Barriola Rubarth, A. Duran, K. Sung, Q. Bui, M. McLenon, J. Cruz Rodriguez, M. Urey, E. Adler, N. Wettersten, M. Kearns, V. Pretorius, J. Silva Enciso, H. Tran. *UC San Diego Health, San Diego, CA*

(572) ***Safety of Ventricular Endomyocardial Biopsy in Heart Transplant Patients;*** K. Bermpeis, G. Esposito, D. Bertolone, E. Gallinoro, S. Verstreken, E. Bogaerts, D. Munhoz, W. Heggermont, R. Dierckx, J. Bartunek, M. Vanderheyden. *Cardiovascular Center Aalst, Aalst, Belgium*

(573) ***Outcomes of Hepatitis B Virus-Infected Donors in Heart Transplantation;*** E. Habib[1], O. Baqal[1], B. Aqel[1], M. Klanderman[1], L. LeMond[2]. *[1]Mayo Clinic, Phoenix, AZ, [2]Mayo Clinic, Scottsdale, AZ*

(574) ***Comparison of Chart-Based and Physical Frailty Assessment in Heart Transplant Candidates to Predict Clinical Outcomes;*** Y. Lee[1], B. Chy[2], M. Shukman[3], M. Kamath[4], A. Nsair[4], A. Ardehali[4], R. Biniwale[4], B. Seligman[5], J. Schaenman[4]. *[1]UCLA David Geffen School of Medicine, Fremont, CA, [2]University of Arizona, Tucson, AZ, [3]UCLA Medical Center, Los Angeles, CA, [4]David Geffen School of Medicine at UCLA, Los Angeles, CA, [5]David School of Medicine at UCLA, Los Angeles, CA*

(575) ***The Outcome of Heart Transplant Patients with Severe Rejection Requiring ECMO Support: Is it Futile;*** J. Kobashigawa, M. Kittleson, S. Kim, T. Singer-Englar, G. Esmailian, C. Runyan, R. Cole, J. Moriguchi, D. Megna, L. Czer, J. Patel. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(576) ***Analysis of the Impact of Holding Angiotensin Inhibiting Medications at Various Time Points Prior to Heart Transplant and Primary Graft Dysfunction;*** E. Henricksen[1], M. Lam[1], Z. Tulu[1], D. T. Kim[2], A. Guevara-Castro[2], H. Luikart[2], K. Khush[2], Y. Moayedi[3], R. Lee[1], T. Le[1], U. Wang[1], J. Han[4], B. Wayda[2], J. Njoroge[2], S. Hsiao[5], B. M. Zhang[2], J. MacArthur[2], J. Teuteberg[2]. *[1]Transplant, Stanford Medicine, Stanford, CA, [2]Stanford University, Stanford, CA, [3]UHN, Toronto, ON, Canada, [4]University of Chicago Medical Center, Chicago, IL, [5]Stanford Medicine, Stanford, CA*

(577) ***Parvovirus B19 Myocarditis in a Covid19 MIS-C Syndrome: Cause or Causality?;*** E. Bellettini, E. Mencarelli, M. Rebonato, P. Francalanci, N. Cantarutti, S. Alfieri, L. Galletti, R. Kirk, A. Amodeo, R. Adorisio. *Bambino Gesù Children's Hospital, IRCCS, Rome, Italy*

(578) ***Severe Covid-19 Infection Causing Severe Vasculopathy Resulting in Death in a Heart Transplant Recipient;*** M. MacKay[1], W. Khalife[2], P. Boor[3], K. Kislingbury[4], S. Lick[5]. *[1]University of Texas Medical Branch, Galveston, TX, [2]University of Texas Medical Center, Friendswood, TX, [3]Pathology, University of Texas Medical Branch, UTMB Galveston, TX, [4]Univ Texas Med Branch, Galveston, TX, [5]UTMB, Galveston, TX*

(579) ***Is Heart Transplantation from Mycobacterium Tuberculosis Positive Donor Safe?;*** A. Fardman[1], E. Nachum[2], A. Wieder[3], A. Morgan[3], J. Lavee[4], T. Ashkenazi[5], J. Patel[6], Y. Peled[7]. *[1]Chaim Sheba Medical Center, Ramat-Gan, Israel, [2]Sheba Medical Center, Kiryat Ono, Israel, [3]Sheba Medical Center, Ramat-Gan, Israel, [4]Sheba Medical Center, Ramat Gan, Israel, [5]State of Israel Ministry of Health, Tel-Aviv, Israel, [6]Cedars-Sinai Smidt Heart Institute, Calabasas, CA, [7]Sheba Medical Center, Ramat Gan, M, Israel*

(580) ***Disseminated Yersinia Enterocolitica after Orthotopic Heart Transplant;*** Y. Paulenka, L. Gilstrap, M. Yazdi, R. A. Zuckerman, A. Ortengren. *Dartmouth-Hitchcock Medical Center, Lebanon, NH*

(581) ***Chagas Disease Masquerading as Cardiac Sarcoidosis;*** A. Rahman[1], A. Hasani[2], A. Decconda[3], M. Esposito[4], R. Mitra[5], F. Wallach[6], S. Shah[7]. *[1]Northwell Health, Jamaica, NY, [2]Northwell Health, Manhasset, NY, [3]Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, [4]Department of Pathology, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, [5]Department of Cardiology, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, [6]Scarsdale, NY, [7]Long Island City, NY*

(582) ***Proposed Algorithm Aids Assessment of COVID Positive Donors in Thoracic Organ Transplant;*** A. Velleca[1], P. Zakowski[2], H. Berliner[1], T. Kao[1], B. May[1], J. Kobashigawa[1], R. Rampolla[3], F. Esmailian[1], D. Megna[1]. *[1]Cedars-Sinai Heart Institute, Los Angeles, CA, [2]Cedars Sinai Medical Group, Los Angeles, CA, [3]Cedars-Sinai Medical Center, Los Angeles, CA*

(583) ***Sotrovimab in Heart Transplant Recipients with Covid-19 in the Omicron Era: A National Transplant Center Experience;*** C. N. Perez Garcia[1], K. Hewitt[1], S. Aslam[1], B. Parlon[1], T. Baby[1], B. Lynch[2], M. Hannan[2], P. Ging[3], G. Giblin[1], K. Murphy[1], E. Joyce[1]. *[1]Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland, [2]Microbiology, Mater Misericordiae University Hospital, Dublin, Ireland, [3]Pharmacy, Mater Misericordiae University Hospital, Dublin, Ireland*

(584) ***Safety of Immunosuppression Maintenance in Heart Transplant Recipients with Covid-19: A Single Center Experience;*** J. Amione Guerra[1], R. Guajardo[2], C. Kunavarapu[2], M. Kwan[2]. *[1]UT Health Science Center San Antonio, San Antonio, TX, [2]Methodist Hospital, San Antonio, TX*

(585) ***Impact of the SarsCov2 Booster Dose on Clinical Events in Heart Transplant Patients in Galicia. INMU TC Study;*** D. Enriquez[1], E. Barge Caballero[1], P. Blanco Canosa[1], Z. Grille Cancela[1], G. Bou Arévalo[1], P. Rodríguez Vázquez[1], C. Riveiro Rodríguez[1], D. Couto Mallon[1], G. Barge Caballero[1], M. Paniagua[1], J. Muñiz[2], V. José Manuel[1], M. Crespo-Leiro[1]. *[1]Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain, [2]Universidade de A Coruña, A Coruña, Spain*

(586) ***Trying to Protect HT Patients Poor Vaccine Responders: Reducing MMF or Trust Tixagevimab/Cilgavimab? Insights from CONTRAST Study;*** M. Masetti[1], M. Scuppa[1], L. Giovannini[1], L. Borgese[1], A. Aloisio[1], G. Spitaleri[1], M. Giannella[2], L. Potena[1]. *[1]Heart Failure and Transplant Unit IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, [2]Infectious Diseases Unit, Department of Integrated Management of Infectious Risk, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy*

(587) ***Elevation of Donor Derived Cell Free Dna Levels Due to Hiv Infection in Heart Transplant Patient;*** R. Rao[1], A. Darroca[2], L. Jenkins[3]. *[1]Indiana University, Carmel, IN, [2]Indiana University, Indianapolis, IN, [3]CareDx, GreatLakes, IN*

(588) ***Proteomic Discovery of Molecular Pathways in Patients with Biopsy-Proven Myocarditis;*** E. Kim[1], S. Lee[2], D. Jang[3], Y. Kyoung[3], J. Kim[3], I. Kim[2], J. Kim[3], J. Youn[4]. *[1]Korea Advanced Institute of Science and Technology, Daejeon, South Korea, [2]Keimyung University Dongsan Hospital, Daegu, South Korea, [3]Seoul National University, Seoul, South Korea, [4]Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea*

WEDNESDAY, 19 APRIL, 2023

6:30 – 7:30 p.m.

POSTER SESSION 01: CARDIOTHORACIC SURGERY

Location: Mile High Ballroom

Core Therapies: HEART, LUNG, MCS
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Infectious Diseases, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Cardiothoracic Surgery. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Nathan Airhart, MD, Saint Alphonsus Medical Center, Boise, ID USA
Kamal Ayyat, MD, PhD, Cleveland Clinic, Cleveland, OH USA
Yaron Barac, MD, PhD, Rabin Medical Center, Petah Tiqva, Israel
Markus Barten, MD, PhD, University Heart and Vascular Center Hamburg, Hamburg, Germany
Stacey Brann, MD, MSc, FRCS(Ed), TransMedics, Inc., Andover, MA USA
William (Bill) Baumgartner, MD, Johns Hopkins Medicine, Sanibel, FL USA
Gustavo Calado Ribeiro, Clinic Cardio Cirurgica Campinas, Campinas, Brazil
Jose Luis Campo-Cañaveral de la Cruz, Hosp Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
Philip Carrott, MD, University of Virginia, Charlottesville, VA USA
Alfred Casillan, MD, PhD, Johns Hopkins University, Baltimore, MD USA
Lin-Chiang Philip Chou, MD, Houston Methodist Hospital, Houston, TX USA
Jenalee Coster, MD, UPMC, Pittsburgh, PA USA
Rob Dowling, MD, The Christ Hospital and Lindner Research and Education Center, Cincinnati, OH USA
Sahar Saddoughi, MD, PhD, Mayo Clinic, Rochester, MN USA
Thomas Egan, MD, MSC, UNC at Chapel Hill, Chapel Hill, NC USA
Sam Emmanuel, MBBS, BHSc (Hons), St Vincent's Hospital Sydney, Sydney, NSW Australia
Fabian Emrich, MD, University of Frankfurt, Frankfurt, Germany
Alexander Fardman, MD, Chaim Sheba Medical Center, Ramat-Gan, Israel
Stephen Forest, MD, Montefiore Medical Center, Bronx, NY USA
Meg Fregoso, MSN, NP-BC CCTC, Inova Fairfax Hospital, Fairfax, VA USA
Miriam Freundt, MD, Hershey, PA USA
Emily Granger, MBBS, St Vincent's Hospital Sydney, Sydney, NSW Australia
Eric Griffiths, MD, University of Utah, Salt Lake City, UT USA
Matthew Goodwin MD, MS, University of Utah, Salt Lake City, UT USA
Christian Heim, MD, MHBA, University of Erlangen, Möhrendorf, Germany
David Hormuth, MD, MBA, StarTeamsLLC, Jupiter, FL USA
Peter Ivak, MD, PhD, IKEM, Prague, Czech Republic
Suresh Keshavamurthy, MD, FACS, FRCS, University of Kentucky, Lexington, KY USA
Ahmet Kilic, MD, The Johns Hopkins University, Baltimore, MD USA
Kevin Koomalsingh, MD, Providence St Vincent Medical Center, Portland, OR USA
Kewal Krishan, MD, Temple University Hospital, Philadelphia, PA USA
Sandra Lindstedt, MD, PhD, Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden
Lucian Lozonschi, MD, University of South Florida, Tampa General Hospital, Tampa, FL USA
Aurelie Merlo, MD, University of North Carolina, Chapel Hill, NC USA
Ezequiel Molina, MD, Piedmont Heart Institute - Samsky Advanced Heart Failure Center, Atlanta, GA USA
Kentaro Noda, PhD, University of Pittsburgh, Pittsburgh, PA USA
Isabelle Opitz, MD, Universitätsspital Zürich, Zurich, Switzerland
Siddharth Pahwa, MD, Univ of Louisville Physicians Cardiovascular and Thoracic Surgery, Louisville, KY USA

Alessandro Palleschi, MD, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico of Milan, Milano, Italy
Anthony Panos, MD, MSc, FRCSC, FACS, University of Iowa Hospital and Clinics, Iowa City, IA USA
Yazhini Ravi, MD, Scott & White, Temple, TX USA
Pedro Reck dos Santos, MD, MSc, PhD, Mayo Clinic, Arizona, Phoenix, AZ USA
Sahar Saddoughi, MD, PhD, Mayo Clinic, Rochester, MN USA
Chris Salerno, MD, University of Chicago, Chicago, IN USA
Elena Sandoval, MD, FEBCTS, Barcelona, Spain
Stephan Schueler, MD, PhD, FRCS, Newcastle upon Tyne Hospitals, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Fawwaz Shaw, MD, Emory University/Children's Health Care of Atlanta, Atlanta, GA USA
Yasuhiro Shudo, MD, PhD, Stanford University, Palo Alto, CA USA
Dirk Van Raemdonck, MD, PhD, University Hospitals Leuven, Leuven, Belgium
Barbara Wilkey, BSN, MPAS, MD, University of Colorado, Denver, CO USA
Yoshito Yamada, MD, PhD, Kyoto University Hospital, Kyoto City, Japan

(589) ***Hyperammonemic Encephalopathy with Normal Liver Enzymes and Function in a Heart Transplant Patient;*** E. L. Poe, M. C. Smith. *Providence Sacred Heart Medical Center, Spokane, WA*

(590) ***Sars_Cov2 Experience in the West Australian Heart Transplant Population;*** C. House[1], F. Lee[2], A. Clothier[1], C. Fazackerley[2], M. Kelly[2], P. Boan[3], A. Geldenhuys[1], K. Lam[2]. *[1]Fiona Stanley Hospital, Perth, Australia, [2]Cardiology, Fiona Stanley Hospital, Perth, Australia, [3]Infectious Disease, Fiona Stanley Hospital, Perth, Australia*

(591) ***Prolonged V.v.-Ecmo for Covid-19 Ards with Lung Recovery;*** A. Beckett, L. Michalik, A. Tatooles. *Rush University Medical Center, Chicago, IL*

(592) ***The Long-Term Impact of Cmv in Adult Primary Lung Transplant Recipients- 16-Year Single-Center Study;*** R. A. Lehikoinen[1], A. Nykanen[2], J. Tikkanen[2], E. Heliovaara[2], S. Syrjala[2], K. Lemstrom[2]. *[1]Transplantation Laboratory, University of Helsinki, Helsinki, Finland, [2]Helsinki University Hospital, Helsinki, Finland*

(593) ***Utilization of Lung Transplantation in Patients with Covid-19;*** A. Kashem[1], M. Villavicencio[2], D. Van Raemdonck[3], G. Loor[4], M. Hartwig[5], K. Ghadimi[6], F. Ius[7], N. Langer[8], A. Osho[9], S. Chandrashekaran[10], T. Machuca[11], P. Sanchez[12], K. Subramaniam[13], M. Warnick[14], A. Neyrinck[15], S. Huddleston[16], A. Shaffer[17], E. D'Silva[4], J. Salman[7], H. Zhao[14], A. Leon Pena[4], A. Emtiazjoo[18], Y. Toyoda[19]. *[1]Temple University School of Med, Philadelphia, PA, [2]Mayo Clinic, Rochester, Rochester, MN, [3]University Hospitals Leuven, Leuven, Belgium, [4]Baylor College of Medicine, Houston, TX, [5]Duke University Medical Center, Durham, NC, [6]Duke Unversity, Raleigh, NC, [7]Hannover Medical School, Hannover, Germany, [8]Massachusetts General Hospital, Wellesley, MA, [9]Duke University Medical Center, Boston, MA, [10]Emory University Hospital, Gainesville, FL, [11]University of Miami, Gainesville, FL, [12]University of Pittsburgh Medical Center, Pittsburgh, PA, [13]Univ of Pittsburgh Med Ctr Presbyterian Hospital, Sewickley, PA, [14]Temple University School of Medicine, Philadelphia, PA, [15]Leuven University Hospitals, Leuven, Belgium, [16]University of Minnesota, Minneapolis, MN, [17]Univ of Minnesota, Minneapolis, MN, [18]University of Florida, Gainesville, FL, [19]Temple Univ Sch of Med, Philadelphia, PA*

(594) ***Disseminated Aspergillosis with Possible CNS Involvement after Durable Left Ventricular Assist Device Placement;*** O. De La Cruz[1], S. Kadir[2]. *[1]Pulmonary and Critical Care Medicine, University of Miami-Miami Transplant Institute-Jackson Memorial Hospital, Miami, FL, [2]Jackson Health System, Miami, FL*

(595) ***When Lack of Resources Necessitates Implantation of Old Big Hearts Into Little Children - 4:1 Donor/Recipient Weight Mismatch;*** T. F. Pasley[1], J. Brink[2], P. Ruygrok[1]. *[1]Auckland City Hospital, Auckland, New Zealand, [2]Auckland District Health Board, Auckland, New Zealand*

(596) ***Trapped: Cardiac Herniation Requiring Transplant;*** F. Haregu[1], M. Roeser[1], J. J. Gangemi[1], M. McCulloch[1], S. White[1], T. Alderson[2], P. Smith[3], A. Ellis[2], E. Tucker[2], L. Mamikonian[2], E. Downs[3]. *[1]University of Virginia, Charlottesville, VA, [2]Children's Hospital of the King's Daughters, Norfolk, VA, [3]Virginia Congenital Cardiac Collaborative, Charlottesville, VA*

(597) ***Cardiac Transplantation in the Failing Fontan: Impact of a Prior Norwood***; R. G. McQueen[1], N. M. Singh[2], R. K. Woods[2]. *[1]Medical College of Wisconsin, Milwaukee, WI, [2]Children's Wisconsin, Milwaukee, WI*

(598) ***Outcomes in Children and Young Adults with Congenital Heart Disease Undergoing Transplant: A Subgroup Analysis of the Guardian Heart Registry***; U. Boston[1], A. Zuckermann[2], Y. Stukov[3], J. Schroder[4], Y. Shudo[5], J. Bustamante-Munguira[6], M. Leacche[7], S. Silvestry[8], M. Kawabori[9], K. Takeda[10], J. P. Jacobs[3]. *[1]Le Bonheur Children's Hosp, Memphis, TN, [2]Medical University of Vienna, Wien, Austria, [3]University of Florida, Gainesville, FL, [4]Duke University Medical Center, Durham, NC, [5]Stanford University, Menlo Park, CA, [6]Hospital Clinico Universitario de Valladolid, Valladolid, Spain, [7]Corewell Health, Grand Rapids, MI, [8]AdventHealth Transplant Institute, Orlando, FL, [9]Tufts Medical Center, Brookline, MA, [10]Columbia University, New York, NY*

(599) ***Neonatal Heart Transplantation in the United States: Trends and Outcomes***; M. John, T. Zinyandu, J. Rosenblum, S. Shashidharan, P. Chai, F. Shaw. *Children's Healthcare of Atlanta/ Emory University, Atlanta, GA*

(600) ***In-Hospital Opioid Requirements Predict Poor Survival in Pediatric Heart Transplant***; K. Kulshrestha[1], J. Greenberg[1], J. Kennedy[2], S. Hogue[1], A. Guzman-Gomez[1], D. S. Cooper[1], F. Zafar[1], D. Morales[1]. *[1]Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [2]University of Cincinnati Medical Center, Cincinnati, OH*

(601) ***Outcomes of Heart Transplantation in Children with Familial Dilated Cardiomyopathy***; H. F. Ahmed[1], K. Kulshrestha[1], A. Guzman-Gomez[2], J. W. Greenberg[3], S. Hogue[3], E. Kantemneni[1], C. Chin[4], D. Morales[5], F. Zafar[2]. *[1]Cardiothoracic Surgery, Cincinnati Children' Hospital Medical Center, Cincinnati, OH, [2]Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, [3]Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [4]Pediatrics, Division of Cardiology, Cincinnati Children's Hospital, Cincinnati, OH, [5]Cardiothoracic Surgery, Cincinnati Children's Hosp, Cincinnati, OH*

(602) ***Allograft Discard Risk Index for Pediatric Heart Transplantation***; J. Lynn[1], T. Malik[2], C. Keller[1], A. Lang[1], A. Rana[3]. *[1]Baylor College of Medicine, Houston, TX, [2]Department of Internal Medicine, New York University, New York, NY, [3]Department of Surgery, Baylor College of Medicine, Houston, TX*

(603) ***Selecting Undersized Organs for Obese Pediatric Heart Transplant Recipients Predicts Worsened Survival***; K. Kulshrestha, P. Chin, J. Greenberg, S. Hogue, A. Guzman-Gomez, D. Morales, F. Zafar. *Cincinnati Children's Hospital Medical Center, Cincinnati, OH*

(604) ***A Potential Underutilized Donor Pool Exists for Infant Heart Transplant Candidates***; J. W. Greenberg[1], A. Sood[1], A. Guzman-Gomez[1], K. Kulshrestha[1], J. T. Kennedy[2], D. S. Winlaw[1], D. L. Morales[1], F. Zafar[1]. *[1]The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [2]University of Cincinnati Medical Center, Cincinnati, OH*

(605) ***Heartmate 3 Implantation in Small Pediatric Patients Using Computed Tomography Virtual Simulation***; A. Furuta, T. Shinkawa, Y. Ichihara, H. Niinami. *Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan*

(606) ***Intracorporeal Durable Lvad Support in Children Using Hvad or Hm 3 - Euromacs Analysis***; M. Schweiger. *Children's Hospital Zurich, Zürich, Switzerland*

(607) ***Successful Explantation of Children from the Berlin Heart Excor Ventricular Assist Device: A Systematic Review***; M. F. Mikulski[1], S. Iyer[1], A. Well[1], S. Subramanian[1], C. M. Mery[1], W. F. Owens[1], L. D. Glass[2], C. D. Castleberry[2], C. D. Fraser[1]. *[1]Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin, Austin, TX, [2]Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX*

(608) ***Could the Full Maglev Technology be the Next Option for Pediatric Patients?***; U. Kervan[1], S. Kocabeyoglu[2], D. Sert[3], M. Karahan[3], A. Yilmaz[4], V. Kavur[4], &. Ece[4], M. A. Turkcu[4], Z. Catav[5]. *[1]Heart Failure, University of Health Sciences, Ankara City Hospital, Yuksek Ihtisas Hospital, Çankaya, Turkey, [2]Ankara City Hosp, Altindag, 6, Turkey, [3]Yuksek Ihtisas Hospital, Ankara, Turkey, [4]Ankara City Hospital, Ankara, Turkey, [5]Ankara Yuksek Ihtisas Hospital, Altindag, 6, Turkey*

(609) ***Small Patient or Small Left Ventricular Cavity associated with Left Ventricular End-Systolic Dimension and Mortality after Implantation of a Third-Generation Continuous Flow Centrifugal Pumps in Pediatric Patients;*** U. Kervan[1], S. Kocabeyoglu[2], D. Sert[3], M. Karahan[4], A. Yilmaz[5], V. Kavurt[5], D. Bagrul[5], Z. Catav[6], M. Ozatik[7]. *[1]Heart Failure, University of Health Sciences, Ankara City Hospital, Yuksek Ihtisas Hospital, Çankaya, Turkey, [2]Ankara City Hosp, Altindag, 6, Turkey, [34]Yuksek Ihtisas Hospital Yuksek Ihtisas Hospital, Ankara, 6, Turkey, [5]Ankara City Hospital, Ankara, Turkey, [6]Ankara Yuksek Ihtisas Hospital, Altindag, 6, Turkey, [7]Çankaya, 6, Turkey*

(610) ***A Single Institutional Experience with 36 Children Smaller Than 5 Kilograms Supported with Pulsatile Ventricular Assist Device;*** M. S. Bleiweis, J. Philip, Y. Stukov, G. J. Peek, J. C. Fudge, H. V. Vyas, K. J. Sullivan, A. D. Pitkin, J. F. Hernandez-Rivera, A. J. Brock, S. S. Suguna Narasimhulu, S. C. Beltran, O. M. Sharaf, J. P. Jacobs. *Congenital Heart Center, University of Florida, Gainesville, FL*

(612) ***Using the SCAI Classification for Early Identification and Real-Time Monitoring of Cardiogenic Shock Patients;*** J. J. Kooij[1], E. De Troy[2], D. Vlasselaers[2], D. Dauwe[2], S. Janssens[3], C. Vandenbriele[3], T. Adriaenssens[3], P. Dewolf[4], S. Jacobs[1], B. Meyns[1]. *[1]Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium, [2]Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium, [3]Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium, [4]Emergency Medicine, University Hospitals Leuven, Leuven, Belgium*

(613) ***Single Coronary Ostium in a Donor Heart: Case Report of Successful Heart Transplantation;*** L. Stastny[1], F. Sommerauer[1], G. Poelzl[2], N. Bonaros[1], M. Grimm[1], J. Dumfarth[1]. *[1]Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria, [2]Department of Cardiology, Medical University of Innsbruck, Innsbruck, Austria*

(614) ***Protecting the Heart Prior to Onset of Thoraco-Abdominal Normothermic Regional Perfusion (TA-NRP);*** K. Vandendriessche[1], J. Brouckaert[1], K. Degezelle[2], L. Ceulemans[3], I. Jochmans[4], D. Monbaliu[4], S. Rex[5], B. Meyns[6], J. Van Cleemput[7], A. Neyrinck[8], F. Rega[3]. *[1]Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium, [2]Perfusionist, University Hospitals Leuven, Leuven, Belgium, [3]University Hospitals Leuven, Leuven, Belgium, [4]Abdominal Transplant Surgery, University Hospitals Leuven, Leuven, Belgium, [5]Anesthesiology, University Hospitals Leuven, Leuven, Belgium, [6]UZ Leuven, Leuven, Belgium, [7]UZ Leuven, 3000 Leuven, Belgium, [8]Leuven University Hospitals, Leuven, Belgium*

(615) ***Late Complication of Graft Versus Host Disease after Cardiac Transplantation;*** E. M. Schumer[1], A. Pawale[2], M. Masood[3], C. Lin[4], J. Moreno[5], K. Kotkar[6]. *[1]Washington University, St. Louis, MO, [2]Washington University, Saint Louis, MO, [3]Washington Univ Sch of Med, Saint Louis, MO, [4]Washington University in St. Louis, St. Louis, MO, [5]Washington Univ in St. Louis Barnes Jewish Hospital, Saint Louis, MO, [6]Washington University at St. Louis, Saint Louis, MO*

(616) ***Mechanical Circulatory Support and Heart Transplantation for Acute on Chronic Heart Failure in Untreated Hypothyroidism;*** D. I. Aronowitz[1], L. Bougioukas[1], J. Newman[2], M. Avila[3], Z. Kon[1], C. Saikus[4]. *[1]Northwell Health, Manhasset, NY, [2]Northwell Health, East Northport, NY, [3]Northwell Health, West Islip, NY, [4]Northwell Health, Great Neck, NY*

(617) ***Fontan Failure with Arch Aneurysm and Cirrhosis Managed with Orthotopic Heart Transplantation and Arch Replacement Alone;*** Y. Tan[1], J. Murala[1], C. Heid[1], A. Amin[2], M. Farr[2], M. Drazner[2], M. Peltz[1]. *[1]Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, [2]Internal Medicine - Cardiology, University of Texas Southwestern Medical Center, Dallas, TX*

(618) ***Successful Aortic Arch Cannulation and Perfusion of a Heart Donated after Circulatory Death;*** M. Vervoorn[1], P. Van Kaam[2], M. Mokhles[1], N. van der Kaaij[1], M. Gianoli[1]. *[1]UMC Utrecht, Utrecht, Netherlands, [2]Heartbeat Dutch Perfusion Services, Eemnes, Netherlands*

(619) ***Custodiol-N versus Custodiol: Results from a Prospective Randomised Single Blind, Multicenter Phase Iii Trial in Patients Undergoing Heart Transplantation;*** A. Aliabadi-Zuckermann[1], E. Osorio-Jaramillo[2], C. Knosalla[3], J. Gummert[4], G. Szabo[5], F. Wittmann[6], R. Yeter[7], R. Schramm[8], J. Goekler[9], F. Hennig[3], M. Morshuis[8], A. Zuckermann[10]. *[1]Cardiac Surgery, Medical University of Vienna, Vienna, Austria, [2]Medical University of Vienna, Vienna, Austria, [3]Deutsches Herzzentrum Berlin, Berlin, Germany, [4]Herz und Diabeteszentrum NRW, Bad Oeynhausen, Germany, [5]Universitätsklinikum Halle, Halle, Germany, [6]Medical Univ of Vienna AKH Vienna, Wien, 9, Austria, [7]German Heart Institute, Berlin, BE, Germany, [8]Heart Center NRW, Bad Oeynhausen, Germany, [9]Med Univ Vienna, Wien, Austria, [10]Medical University of Vienna, Wien, Austria*

(620) ***First Report of the Transmedics Organ Care System Heart Perfusion Registry. A Multi-Institutional Outcomes Analysis;*** J. Stehlik[1], J. Schroder[2], S. Pinney[3], C. Patel[2], D. D'Alessandro[4], D. Goldstein[5], U. Jorde[5], S. Patel[5], D. Mani[6], F. Esmailian[7], J. Kobashigawa[7], K. Takeda[8], N. Uriel[8], S. Pham[9], P. Patel[9], M. Kai[10], B. Sun[11], A. Shah[12], M. Ono[13], G. Couper[14], D. DeNofrio[14], A. Vest[14], D. Joyce[15], A. DeVore[2], H. Mallidi[16], A. Itoh[16], M. R. Mehra[16], M. Givertz[16], C. Milano[2], M. Farr[17]. *[1]University of Utah, Salt Lake City, UT, [2]Duke University Medical Center, Durham, NC, [3]University of Chicago, Chicago, IL, [4]MGH, Weston, MA, [5]Montefiore Medical Center, Bronx, NY, [6]Emory University, Atlanta, GA, [7]Cedars-Sinai Heart Institute, Los Angeles, CA, [8]New York Presbyterian, New York, NY, [9]Mayo Clinic Florida, Jacksonville, FL, [10]Westchester Medical Center, Valhalla, NY, [11]Minneapolis Heart Institute, Minneapolis, MN, [12]Vanderbilt University Medical Center, Mount Juliet, TN, [13]Methodist Hospital, San Antonio, TX, [14]Tufts Medical Center, Boston, MA, [15]Froedtert & the Med College of Wisconsin, Milwaukee, WI, [16]Brigham and Women's Hospital, Boston, MA, [17]UT Southwestern Medical Center, Dallas, TX*

(621) ***How Long Can We Go? Redefining the Upper Limit of Ischemic Times for Hypothermic Donor Heart Preservation;*** K. Takeda[1], S. Silvestry[2], J. Schroder[3], D. D'Alessandro[4], M. Leacche[5], C. Sciortino[6], S. M. Pham[7], A. Vidic[8], D. Meyer[9], M. Kawabori[10], Y. Shudo[11]. *[1]Columbia University, New York, NY, [2]AdventHealth Transplant Institute, Orlando, FL, [3]Duke University Medical Center, Durham, NC, [4]MGH, Weston, MA, [5]Corewell Health, Grand Rapids, MI, [6]Sentara, Norfolk, VA, [7]Mayo, Jacksonville, FL, [8]University of Kansas Health System, Kansas City, KS, [9]Baylor Scott and White Health, Health Texas Provider Network, Cardiac and Thoracic Surgery at Baylor, Dallas, TX, [10]Tufts Medical Center, Brookline, MA, [11]Stanford University, Menlo Park, CA*

(622) ***First Report on the Performance of the National OCS Program (NOP) in U.S. Heart and Lung Transplants;*** W. Hassanein[1], L. Kane[1], P. Lezberg[1], A. Hassanein[1], N. Dang[2], S. LaFrancesca[3], A. Kaw[4], S. Brann[5], M. Omara[6], S. Reddy[7], K. Ihnken[8], M. Al Salihi[9], F. Zafar[10], T. Khayal[1]. *[1]TransMedics, Inc., Andover, MA, [2]TransMedics, Inc., Honolulu, HI, [3]TransMedics. Inc., Los Angeles, CA, [4]TransMedics, Inc., Chicago, IL, [5]TransMedics, Inc., Elkins Park, PA, [6]TransMedics, Inc., Cleveland, OH, [7]TransMedics, Inc., Durham, NC, [8]TransMedics, Inc., San Francisco, CA, [9]TransMedics, Inc., Riverview, FL, [10]TransMedics, Inc., Cincinnati, OH*

(623) ***Uncontrolled Cardiac Arrest of Donor Heart Before Donation Does Not Affect Heart Transplant Recipient Outcomes: Proof of Concept for DCD Long-Term Outcomes;*** N. Pradegan[1], G. Evangelista[1], C. Tessari[1], G. Guerra[1], G. Ciccarelli[1], M. Gallo[2], G. Toscano[1], G. Feltrin[3], V. Tarzia[1], G. Gerosa[1]. *[1]University of Padova, Padova, Italy, [2]UofL Health, Louisville, KY, [3]Regional Centre For Transplant Coordinat, Padova, PD, Italy*

(624) ***Utilization of an Independent Procurement Team for Direct Procurement and Machine Perfusion of Cardiac Allografts Following Donation after Cardiac Death;*** S. Ragnarsson[1], A. Morrison[1], A. Acuna Higaki[1], C. Mullan[1], S. Sen[2], T. Ahmad[2], M. Anwer[1], A. Geirsson[1], C. Maulion[2], R. Davis[1]. *[1]Department of Surgery, Division of Cardiac Surgery, Yale University School of Medicine, New Haven, CT, [2]Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT*

(625) ***Positive Correlative Volume-Outcome Relationship for Multiorgan Heart Transplantation;*** C. Song[1], N. Weingarten[2], D. Rekhtman[1], A. Iyengar[2], M. Patel[2], D. A. Herbst[2], M. Helmers[2], M. Cevasco[2], P. Atluri[2]. *[1]Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, [2]Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA*

(626) ***Bariatric Surgery is Safe and Effective in Thoracic Organ Transplant Recipients;*** M. Hussain[1], J. Yazji[2], P. Garg[2], I. Wadiwala[3], E. Alamouti-fard[2], M. E. Alomari[2], S. Jacob[4], M. A. Edwards[1], S. Pham[5]. *[1]Department of Surgery, Division of Advanced GI and Bariatric Surgery, Mayo Clinic Florida Jacksonvil, Mayo Clinic, Jacksonville, FL, [2]Department of Cardio-thoracic Surgery, Mayo Clinic Florida, Jacksonville, FL, USA, Mayo Clinic, Jacksonville, FL, [3]Mayo Clinic Florida, Jacksonville, FL, [4]Mayo Clinic, Jacksonville, FL, [5]Jacksonville, FL*

(627) ***Failed Fontan Physiology with Associated Liver Disease in Adults- Are Two Organs Better Than One;*** A. Weisberg, J. Murala, C. Heid, A. Amin, M. Drazner, M. Farr, M. Wait, M. Jessen, L. Huffman, A. Hackmann, M. Peltz. *UT Southwestern Medical Center, Dallas, TX*

(628) ***Expanding BMI Criteria for Heart Transplant Eligibility;*** A. Firoz[1], A. Kashem[1], Y. Toyoda[2], E. Hamad[2]. *[1]Lewis Katz School of Medicine at Temple University, Philadelphia, PA, [2]Temple University Hospital, Philadelphia, PA*

(629) ***Outcomes of Status 4 Heart Transplant Candidates: A Nationwide Analysis;*** C. M. Jarrett, O. Mahmoud, Y. Abu-Omar, Y. Elgudin, O. Hussian, M. Pelletier, J. F. Sabik, C. ElAmm. *University Hospitals Cleveland, Cleveland, OH*

(630) ***The Fate of Status 6 Heart Transplant Candidates: A Nationwide Analysis;*** C. M. Jarrett, O. Mahmoud, Y. Elgudin, O. Hussian, M. Pelletier, J. F. Sabik, C. ElAmm, Y. Abu-Omar. *University Hospitals Cleveland, Cleveland, OH*

(631) ***Abandonment of Non-Primary Thoracic Organs at Donor Sites;*** H. A. Tetteh[1], P. Brandenhoff[2], J. Tessier[3], R. S. Higgins[4]. *[1]Uniformed Services University of the Health Sciences, Bethesda, MD, [2]Thoracic Transplant Consultants Inc, San Francisco, CA, [3]STAR Teams, Springfield, VA, [4]Mass General Brigham, Boston, MA*

(632) ***Effect of UNOS 2018 Heart Transplant Policy Change on LVAD Patients Undergoing Heart Transplantation in an Academic Medical Center;*** T. Neal, K. Drezek, A. Ramsay, D. D'Alessandro, G. Lewis, E. Coglianese. *Massachusetts General Hospital, Boston, MA*

(633) ***"Extension" of Status in the New Heart Transplant Allocation System;*** J. Trivedi[1], S. Pahwa[2], M. Gallo[3], M. Slaughter[4]. *[1]University of Louisville, Louisville, KY, [2]University of Louisville Physicians Cardiovascular and Thoracic Surgery, Louisville, KY, [3]University of Padua, Lugano, Switzerland, [4]University of Louisville School of Medicine, Louisville, KY*

(634) ***Is Off-Pump Coronary Bypass Surgery the Savior of Low EF Coronary Artery Disease Patients?;*** A. Malhotra, M. A. Islam, G. Tavilla, D. L. Beckles, R. C. Reddy. *Department of Cardiothoracic Surgery, Baylor Scott & White Medical Center, Temple, TX*

(635) ***24 Hour Outcomes of 689 Hearts and Lungs Recovered by a Specialized Thoracic Organ Recovery Team;*** H. A. Tetteh[1], J. Tessier[2], P. Brandenhoff[3], R. S. Higgins[4]. *[1]Uniformed Services University of the Health Sciences, Bethesda, MD, [2]STAR Teams, Springfield, VA, [3]Thoracic Transplant Consultants Inc, San Francisco, CA, [4]Mass General Brigham, Boston, MA*

(636) ***The Timing and Coordination of Heart Procurement from Incision to Hospital Departure;*** H. A. Tetteh[1], P. Brandenhoff[2], J. Tessier[3], R. S. Higgins[4]. *[1]Uniformed Services University of the Health Sciences, Bethesda, MD, [2]Thoracic Transplant Consultants Inc, San Francisco, CA, [3]STAR Teams, Springfield, VA, [4]Mass General Brigham, Boston, MA*

(637) ***Type a Aortic Dissection in Heart Transplant Recipients: Patient Characteristics and Outcomes from a National United States Database;*** Y. Wang[1], J. Mohnot[1], K. Yin[2], N. Dobrilovic[3], N. M. Edwards[1], M. Kawabori[4], Y. Zhan[4]. *[1]Division of Cardiothoracic Surgery, Boston Medical Center, Boston, MA, [2]Department of Surgery, Washington University School of Medicine, St. Louis, MO, [3]Division of Cardiac Surgery, NorthShore University HealthSystem, Chicago, IL, [4]Division of Cardiac Surgery, CardioVascular Center, Tufts Medical Center, Boston, MA*

(638) ***Transfusion-Free Fontan Heart Transplants are Achievable: Initial Experience;*** H. Ahmed[1], C. L. Greene[2], D. Mauchley[2], J. Friedland-Little[2], D. McMullan[2], L. Bohuta[2]. *[1]Seattle Children's Hospital, Seattle, WA, [2]Seattle Children's Hospital, Seattle, WA*

(639) ***Incidence and Impact of Post-Transplant Stroke on Outcomes Following Orthotopic Heart Transplantation Under the 2018 United States Heart Allocation System: A UNOS Registry Analysis;*** Y. Hong[1], L. V. Huckaby[2], N. R. Hess[3], L. A. Ziegler[3], G. W. Hickey[4], J. H. Huston[4], M. A. Mathier[4], D. M. McNamara[4], M. E. Keebler[4], D. J. Kaczorowski[3]. *[1]Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, [2]Surgery, Emory University Hospital, Atlanta, GA, [3]Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, [4]Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA*

(640) ***Is Recipient Survival Following Transplantation of Hearts from Substance Abuse Donors Impacted by Regional Variations?;*** C. Lemoine[1], L. Copeland[2], J. Silverman[1], M. Dean[3], C. Zoni[4], F. Valle Diaz[5], T. Raines[6], C. Sai-Sudhakar[4], Y. Ravi[4]. *[1]University of Connecticut Health, Farmington, CT, [2]Population and Quantitative Health Sciences, University of Massachusetts Medical School, Leeds, MA, [3]Virginia Commonwealth University Health, Richmond, VA, [4]Cardiac Surgery, University of Connecticut Health, Farmington, CT, [5]University of Puerto Rio School of Medicine, San Juan, PR, [6]University of Tennessee Health Science Center, Memphis, TN*

(641) ***Impact of Bridge-to-Transplant Left Ventricular Assist Device Support Duration on Candidate Characteristics and Post-Heart Transplant Complications;*** C. Siems[1], R. John[1], S. Jackson[2], T. Alexy[3]. *[1]University of Minnesota, Minneapolis, MN, [2]MHealth Fairview, Minneapolis, MN, [3]University of Minnesota, North Oaks, MN*

(642) ***Characteristics and Outcomes of Cardiac Amyloidosis after Heart Transplantation: A Systematic Review and Meta-Analysis;*** V. Yan, D. Ahmad, M. Im, Y. Brailovsky, I. Rajapreyar, E. Storozynsky, J. Rame, K. Rajagopal, J. W. Entwistle, H. Massey, V. Tchantchaleishvili. *Thomas Jefferson University, Philadelphia, PA*

(643) ***The New Heart Allocation System Change and DCD Heart Availability: Effects on Durable VAD Patients;*** K. Drezek, A. Ramsay, T. Neal, G. Lewis, D. D'Alessandro, E. Coglianese. *Massachusetts General Hospital, Boston, MA*

(644) ***Improved Outcomes in Older Recipients Undergoing Transplant Using the Sherpapak System: A Subgroup Analysis of the Guardian Heart Registry;*** H. Copeland[1], M. Leacche[2], D. D'Alessandro[3], C. Sciortino[4], J. Schroder[5], S. M. Pham[6], M. Rodrigo[7], S. Silvestry[8], M. Kawabori[9], Y. Shudo[10], D. Meyer[11]. *[1]Lutheran Medical Group, Fort Wayne, IN, [2]Corewell Health, Grand Rapids, MI, [3]MGH, Weston, MA, [4]Sentara, Norfolk, VA, [5]Duke University Medical Center, Durham, NC, [6]Mayo, Jacksonville, FL, [7]Medstar Washington Hospital Center, Potomac, MD, [8]AdventHealth Transplant Institute, Orlando, FL, [9]Tufts Medical Center, Brookline, MA, [10]Stanford University, Menlo Park, CA, [11]Baylor Scott and White Health, Health Texas Provider Network, Cardiac and Thoracic Surgery at Baylor, Dallas, TX*

(645) ***Outcomes Related to Hospital Characteristics of Heart Transplant Centers: A NRD Analysis;*** F. Amirkhosravi[1], R. Secchi Del Rio[1], D. T. Nguyen[1], N. Fida[2], E. Suarez[3], A. Guha[4], E. Graviss[1], A. Bhimaraj[2]. *[1]Houston Methodist, Houston, TX, [2]Houston Methodist Hospital, Houston, TX, [3]Houston, TX, [4]Houston Methodist Hosp, Houston, TX*

(646) ***Can Comparative Outcomes Following Solid Organ Transplantation Serve as a Launchpad for Value-Based Research Funding?;*** J. W. Greenberg, M. V. Desai, K. Kulshrestha, A. Guzman-Gomez, S. Hogue, A. Arif, H. F. Ahmed, D. L. Morales, F. Zafar. *The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*

(647) ***Utilization of Hepatitis C Virus Infected Donor in Heart Transplant Recipients with Elevated Meld-Xi Score;*** S. Ohira[1], K. Okumura[1], A. Isath[2], D. Abhay[3], G. M. Lanier[2], E. Levine[2], S. Pan[2], C. Aggarwal Gupta[2], A. Gass[2], D. Spielvogel[1], M. Kai[1]. *[1]Cardiothoracic Surgery, Westchester Medical Center, New York Medical College, Valhalla, NY, [2]Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, [3]Transplant Infectious Disease, Westchester Medical Center, New York Medical College, Valhalla, NY*

WEDNESDAY, 19 APRIL, 2023

6:30 – 7:30 p.m.

POSTER SESSION 01: INFECTIOUS DISEASES

Location: Mile High Ballroom

Core Therapies: HEART, LUNG
Practice Areas: Infectious Diseases, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Infectious Diseases. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Rayid Abdulqawi, MD, PhD, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Saima Aslam, MD, MS, University of California San Diego, San Diego, CA USA
Udo Boeken, MD, PhD, University Hospital, Düsseldorf, Germany
Silvia Campos, PhD, Heart Institute of Sao Paulo Medical School HCFMUSP, São Paulo, Brazil
Karen Doucette, MD, MSc, University of Alberta, Edmonton, AB Canada
Christine Falk, PhD, Hannover Medical School, MHH, Hannover, Germany
Brad Gardiner, MBBS, FRACP, MS, PhD, Alfred Health/Monash University, Melbourne, VIC Australia
Megan Greene, PharmD, BCPPS, Children's Hospital Colorado, Aurora, CO USA
Paolo Antonio Grossi, MD, PhD, University of Insubria, Varese, Italy
Jonathan Hand, MD, Ochsner Medical Center, New Orleans, LA USA
Livia Goldraich, MD, MSc, Hospital de Clínicas Porto Alegre, Porto Alegre, Brazil
Shahid Husain, MD, MS, University Health Network, Toronto, ON Canada
Nandan Kumar Mondal, MSc, MPhil, PhD, Baylor College of Medicine, Houston, TX USA
Orla Morrissey, MD, PhD, Alfred Health, Melbourne, VIC Australia
Miriam Aguilar Perez, MD, Univ Puerta de Hierro Majadahonda Hospital, Madrid, Spain
Stephanie Pouch, MD, MS, Emory University, Atlanta, GA USA
Macé Matthew Schuurmans, MD, University Hospital Zurich, Zurich, Switzerland
Roh Yanagida, MD, PhD, Temple University Hospital, Philadelphia, PA USA
Lorenzo Zaffiri, MD, PhD, Cedars-Sinai, Los Angeles, CA USA

(648) ***Successful Management of Massive Brain Nocardiosis in a Heart Transplant Recipient;*** E. Italiano[1], N. Pradegan[1], C. Tessari[2], G. Toscano[1], S. Marinello[3], G. Gerosa[1]. *[1]University of Padova, Padova, Italy, [2]Univ of Padova, Padova, PD, Italy, [3]Padova, PD, Italy*

(649) ***Use of Hepatitis C Positive Donor in HIV Positive Heart Transplant Recipient;*** A. Ganapathi[1], S. Sarwar[2], A. Hasan[3], B. Lampert[4], M. C. Henn[5], N. Mokadam[6], S. Emani[3], N. Marschalk[7], B. Whitson[3]. *[1]Ohio State University Wexner Medical Center, Columbus, OH, [2]The Ohio State Wexner Medical Center, Columbus, OH, [3]Ohio State University, Columbus, OH, [4]Ohio State University Wexner Medical Center, Bexley, OH, [5]Ohio State Univeristy Wexner Medical Center, Columbus, OH, [6]The Ohio State Univ Wexner Med Ctr, Columbus, OH, [7]The Ohio State University Wexner Medical Center, Columbus, OH*

(650) ***Impact of SARS-CoV-2 Infection on Reactivation of Herpesviridae after Heart and Heart and Kidney Transplantation;*** M. B. Immohr[1], D. Oehler[2], C. Ballázs[1], V. H. Hettlich[1], F. Voß[2], H. Dalyanoglu[1], H. Aubin[1], P. Akhyari[1], A. Lichtenberg[1], U. Boeken[1]. *[1]Dept. of Cardiac Surgery, Heinrich-Heine-Univ, Düsseldorf, Germany, [2]Dept. of Cardiology, Heinrich-Heine-Univ, Düsseldorf, Germany*

(651) ***Long-Term Safety and Efficacy of Mrna Sars-Cov2 Vaccination in Heart Transplant Recipients;*** G. Poglajen[1], N. Žorž[1], A. Ihan[2], S. Frljak[1], A. Cerar[1], G. Zemljic[1], R. Okrajsek[1], M. Sebestjen[1], B. Vrtovec[1]. *[1]Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, [2]Institute of Microbiology and Immunology, Faculty of Medicine at Univ ofLjubljana, Ljubljana, Slovenia*

(652) ***Effect of Seroconversion after SARS-CoV-2 Vaccination on the Severity of COVID-19 Disease in Heart Transplant Recipients;*** S. Kugler[1], D. Vári[2], D. Veres[3], Á. Király[4], T. Teszák[4], N. Parázs[4], Z. Tarjányi[4], Z. Drobni[4], Z. Szakál-Tóth[4], G. Prinz[4], P. Miheller[5], B. Merkely[2], B. Sax[4]. *[1]Semmelweis University, Heart and Vascular Center, Budapest, Hungary, [2]Semmelweis University, Budapest, Hungary, [3]Dept of Biophysics and Radiation Biology, Semmelweis Univ, Budapest, Hungary, [4]Heart and Vascular Center, Semmelweis Univ, Budapest, Hungary, [5]Dept of Surgery, Transplantation and Gastroenterology, Semmelweis University, Budapest, Hungary*

(653) ***Tixagevimab and Cilgavimab Reduced the Likelihood of Covid after Heart Transplant in the Age of Omicron;*** R. Lee[1], E. J. Henricksen[1], D. T. Kim[2], H. Luikart[2], Y. Moayedi[3], B. Wayda[2], B. Guenthart[2], J. Teuteberg[4], K. Khush[2], A. Subramanian[2]. *[1]Stanford Health Care, Stanford, CA, [2]Stanford Univ, Stanford, CA, [3]UHN, Toronto, ON, Canada, [4]Stanford Univ SoM, Stanford, CA*

(654) ***Personalizing Cytomegalovirus Prophylaxis in the First Year after Pediatric Heart Transplantation: Impact of a CMV Cell Mediated Immunity-Based Approach;*** L. J. Radel[1], P. K. Sue[2], T. Ellimuttil[3], G. Kalkan[4], N. Baez Hernandez[5], R. Butts[6], M. Bano[7]. *[1]Department of Pediatric Cardiology, Children's Medical Center/UTSW, Dallas, TX, [2]Division of Pediatric Infectious Diseases, UTSW, Dallas, TX, [3]Department of Pharmacy, Children's Medical Center, Dallas, TX, [4]Department of Pediatrics, UTSW, Dallas, TX, [5]Children's Medical Center, Dallas TX, Dallas, TX, [6]Children's Medical Center of Dallas/UTSW, Dallas, TX, [7]UTSW Medical Center, Dallas, TX*

(655) ***Outcomes of Immunosuppression Reduction During Covid-19 Infection in Heart Transplant Patients;*** E. Sauers, J. Clark, C. Kotton, G. Lewis, M. Doucette, G. Waldman[5]. *[1]Massachusetts General Hospital, Boston, MA*

(656) ***Assessment of Risk Factors for Cytomegalovirus DNAemia after Termination of Regular Prophylaxes after Heart Transplantation;*** M. Immohr[1], D. Oehler[2], F. S. Jenkins[1], N. Kalampokas[1], F. Voß[2], H. Dalyanoglu[1], H. Aubin[1], P. Akhyari[1], A. Lichtenberg[1], U. Boeken[1]. *[1]Dept. of Cardiac Surgery, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, [2]Dept. of Cardiology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany*

(657) ***Fighting a Losing Battle From The Start? Disseminated Rhizopus Infection in a Lung Transplant Recipient;*** S. Biswas Roy[1], H. Mohamed[2], R. Walia[2], A. Arjuna[2]. *[1]Pulmonary and Critical Care Medicine, Mayo Clinic, Phoenix, AZ, [2]St. Joseph's Hospital and Medical Center Norton Thoracic Institute, Phoenix, AZ*

(658) ***Amoebic Encephalitis: A Rare Cause of Encephalopathy in a Lung Transplant Patient;*** K. Calhoun, A. Gray, M. Steele, J. Smith. *University of Colorado, Denver, CO*

(659) ***Post COVID Pulmonary Necrosis and Polymicrobial Empyema Managed with Bilateral Lung Transplantation and Post-Transplant Local and Parenteral Antibiotics;*** N. Marschalk, C. Nichols, P. Burcham, J. Rosenheck, V. Ramsammy, S. Kirkby, D. Nunley, M. Henn, A. Ganapathi, N. Mokadam, B. Whitson, S. Sarwar. *The Ohio State University Wexner Medical Center, Columbus, OH*

(660) ***Successful Use of Glecapravir/pibrentasvir in the Setting of Extracorporeal Membrane Oxygenation in a Lung Transplant Recipient: A Case Report;*** S. Farghaly[1], S. Alsunaid[2], K. Stryker[2], J. Joseph[2], S. Forest[3], J. Borgi[3], A. Mansour[2]. *[1]Pharmacy, Montefiore Medical Center, Bronx, NY, [2]Pulmonary Failure and Lung Transplantation, Montefiore Medical Center, Bronx, NY, [3]Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY*

(661) ***Acrophialophora Anastomotic Site Infection in a Re-Do Lung Transplant Recipient with Cystic Fibrosis;*** P. N. Persaud[1], J. A. Morillas[2], M. Budev[1], S. Mukhopadhyay[1], S. Sethi[1], F. Almeida[1], J. Lum[1]. *[1]Cleveland Clinic, Cleveland, OH, [2]Infectious Disease, Spectrum Health, Grand Rapids, MI*

(662) ***Heart and Lung Transplant Unit - Western Australia Covid-19 Experience;*** C. House[1], F. Lee[2], M. Daniels[1], A. Clothier[1], S. Lawrence[3], C. Fazackerley[2], M. Kelly[2], M. Rawlins[1], P. Boan[4], A. Geldenhuys[1], K. Lam[2], M. Musk[3]. *[1]Fiona Stanley Hospital, Perth, Australia, [2]Advanced Heart Failure Unit, Fiona Stanley Hospital, Perth, Australia, [3]Advanced Lung Disease Unit, Fiona Stanley Hospital, Perth, Australia, [4]Infectious Diseases, Fiona Stanley Hospital, Perth, Australia*

(663) ***Eravacycline Utilization in Lung Transplant Recipients at a Single Center;*** P. N. Persaud, X. Xhemali, K. Neuhaus, M. Budev, J. Lum. *Cleveland Clinic, Cleveland, OH*

(664) ***Compliance with CMV Prophylaxis Guidelines in Lung Transplantation: Do We Need New Recommendations?;*** S. García-Masedo, R. Laporta Hernandez, M. Aguilar Perez, C. García Fadul, J. Anel Pedroche, M. Cabrera Pineda, A. Royuela Vicente, I. Sánchez Romero, P. Ussetti. *Puerta de Hierro University Hospital, Majadahonda (Madrid), Spain*

WEDNESDAY, 19 APRIL, 2023

6:30 – 7:30 p.m.

POSTER SESSION 01: PEDIATRICS

Location: Mile High Ballroom

Core Therapies: HEART, LUNG
Practice Areas: Pediatrics, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Pediatrics. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Shahnawaz Amdani, MD, Cleveland Clinic, Cleveland, OH USA
Nicholas Avdimiretz, MD, FRCPC, University of Alberta, Edmonton, AB Canada
Estela Azeka, MD, University of Sao Paulo, São Paulo, Brazil
Maria Bano, MD, UT Southwestern Medical Center, Dallas, TX USA
Neha Bansal, MD, Children's Hospital at Montefiore, New York, NY USA
Christian Benden, MD, MBA, FCCP, University of Zürich, Zürich, Switzerland
Charles Canter, MD, St Louis Children's Hosp, Saint Louis, MO USA
Michael Carboni, MD, Duke Children's Hospital, Durham, NC USA
Anne Dipchand, MD, The Hospital for Sick Children, Toronto, ON Canada
Jeffrey Gossett, MD, Northwell Health, New York, NY USA
Dipankar Gupta, MBBS, Temple University, Philadelphia, PA USA
Kyle Hope, MD, MS, Texas Children's Hospital, Baylor College of Medicine, Houston, TX USA
Jonathan Johnson, MD, Mayo Clinic, Rochester, MN USA
Steven Kindel, MD, Children's Hospital of Wisconsin, Milwaukee, WI USA
Amy Kiskaddon, PharmD, MBA, Johns Hopkins All Children's Hospital, St. Petersburg, FL USA
Ken Knecht, MD, Arkansas Children's Hospital, Little Rock, AR USA
Jacqueline Lamour, MD, Mount Sinai Medical Center, New York, NY USA
Heang Lim, MD, C.S. Mott Children's Hospital, Ann Arbor, MI USA
Aine Lynch, MBBCh, BAO, MSc, The Hospital for Sick Children, Toronto, ON Canada
David Moreno McNeill, MD, Texas Children's Hospital, Houston, TX USA
Kristen Nelson McMillan, MD, Advocate Children's Heart Institute, Univ of Chicago, Chicago, IL USA
Matthew O'Connor, MD, Children's Hospital of Philadelphia, Philadelphia, PA USA
Michelle Ploutz, MD, MPH, University of Utah, Salt Lake City, UT USA
Adam Putschoegl, Minneapolis, MN USA
Joseph Rossano, MD, The Children's Hospital, Philadelphia, PA USA
Marc Schecter, MD, University of Florida, Gainesville, FL USA
David L. Sutcliffe, MD, Children's Mercy Hospital, Kansas City, MO USA
Madeleine Townsend, MD, Cleveland Clinic Children's, Cleveland, OH USA
Sebastian Tume, MD, Texas Children's Hospital, Houston, TX USA
Simon Urschel, MD, University of Alberta, Edmonton, AB Canada
Carol Wittlieb-Weber, MD, Media, PA USA
David Youssef, FRACP, MBBS, BPharm, The Children's Hospital Westmead, Sydney, NSW Australia

(665) ***Covid-19 Infection and Subsequent Development of Antibody-Mediated Rejection in an Infant Post-Lung Transplant;*** D. Parrish[1], E. Melicoff-Portillo[2], C. Gazzaneo[2], E. Moulton[3], S. Nicholas[4]. *[1]Pediatric Pulmonology, Texas Children's Hospital, Houston, TX, [2]Pediatric Pulmonology, Baylor College of Medicine, Houston, TX, [3]Pediatric Infectious Disease, Baylor College of Medicine, Houston, TX, [4]Pediatric Allergy and Immunology, Baylor College of Medicine, Houston, TX*

(666) ***A Case Report of Cytomegalovirus Treatment and Dd-Cfdna in a Pediatric Lung Transplant Recipient;*** S. Leftin Dobkin[1], J. Gross[1], M. Krady[1], S. Sheikh[1], L. Mita[1], P. Joshi[2], M. Josephson[1]. *[1]Children's Hospital of Philadelphia, Philadelphia, PA, [2]CareDx, South San Francisco, MA*

(667) ***Antibody Response to Sars-Cov-2 Vaccination in Adolescents Following Solid Organ Transplantation;*** R. Brugha[1], E. Davis[1], N. Low[1], E. O'Connor[2], S. Marks[2], A. Mai[3], M. Johnson[4], K. Gilmour[3], J. Simmonds[5], L. Grandjean[6], H. Spencer[1], D. Goldblatt[7]. *[1]Cardiothoracic Transplantation, Great Ormond St. Hosp, London, UK, [2]Dept of Nephrology, Great Ormond St. Hosp, London, UK, [3]Dept of Laboratory Med, Great Ormond St. Hosp, London, UK, [4]Great Ormond St. Inst of Child Health Biomedical Research Ctr, Univ College London, London, UK, [5]Great Ormond St. Hosp for Children, London, UK, [6]Dept of Immunology, Great Ormond St. Hosp, London, UK, [7]Infection, Immunity & Inflammation, Great Ormond St. Inst of Child Health Biomedical Research Centre, London, UK*

(668) ***Stem-Cell Based Tissue-Engineered Tracheal Transplant in Pediatric Patients: A Single-Centre Experience;*** M. Ramaswamy[1], C. Butler[1], D. McIntyre[1], N. McIntosh[1], E. Mann[1], R. Hewitt[1], P. De Coppi[1], M. Elliott[1], N. Muthialu[2]. *[1]Great Ormond Street Hospital, London, United Kingdom, [2]Great Ormond Street Hospital London, St. Albans, United Kingdom*

(669) ***Innovative Clinical Model in Managing Children with Refractory Lung Failure;*** W. Koh[1], A. Benscoter[1], M. Chlebowski[1], D. Cooper[1], D. Lehenbauer[2], D. Winlaw[3], D. Morales[4], D. Hayes[3]. *[1]Cincinnati Children's Hospital MC, Cincinnati, OH, [2]Cincinnati Children's Hospital, Cincinnati, OH, [3]Cincinnati Children's Hospital MC, Cincinnati, OH, [4]Cincinnati Children's Hosp, Cincinnati, OH*

(670) ***Pediatric Lung Transplantation (pltx): 15 Years Experience in a Low Donation Rate Country;*** P. F. Undurraga[1], D. Lazo[2], J. Melo[2], J. Dreyse[3], H. Rodriguez[2], B. Gaete[2], R. Jorge[2], E. Perez[2], P. Gaete[2], D. Invernizzi[2], J. Mora[4], G. Perez[2], C. Morales Melgarejo[5], L. Calabran[2], P. Alarcon[6], F. Silva[2], J. Lecaros[2], C. Valverde[7]. *[1]Clinica Las Condes, Providencia, Chile, [2]Lung Transplant, Clinica Las Condes, Santiago, Chile, [3]Pulmonology / Lung Transplant, Clinica Las Condes, Santiago, Chile, [4]Clinica Las Condes, Santiago, Chile, [5]Hospital Luis Calvo Mackenna, Quilicura, RM, Chile, [67]Pediatric ICU, Clinica Las Condes, Santiago, Chile*

(671) ***Pediatric Lobar Lung Transplantation (plltx): Increasing Utilization of Lung in a Low Donation Rate Country;*** P. Undurraga[1], J. Dreyse[2], J. Melo[2], D. Lazo[2], H. Rodriguez[2], P. Gaete[2], E. Perez[2], J. Mora[2], C. Morales Melgarejo[3], C. Muñoz[2], A. Gatica[2], N. Seguel[2], L. Calabran[2], P. Alarcon[2], C. Valverde[2]. *[1]Clinica Las Condes, Santiago, Chile, [2]Lung Transplant, Clinica Las Condes, Santiago, Chile, [3]Hospital Luis Calvo Mackenna, Quilicura, RM, Chile*

(672) ***Donor Derived Cell-Free DNA as a Marker of Allograft Dysfunction in Pediatric Lung Transplant Recipients;*** S. Kirkby[1], K. Nicholson[1], D. Boyer[1], S. Cohen[1], P. Baker[2], M. Galantowicz[3], P. McConnell[3]. *[1]Pediatric Pulmonary Medicine, Nationwide Children's Hospital, Columbus, OH, [2]Pathology, Nationwide Children's Hospital, Columbus, OH, [3]Cardiothoracic Surgery, Nationwide Children's Hospital, Columbus, OH*

(673) ***Mechanical Circulatory Support, Heart Transplantation and Death in a Large-Scale Population of the Multicenter Registry for Suspected Pediatric Myocarditis - "MYKKE";*** N. Rolfs[1], F. Seidel[1], B. Opgen-Rhein[2], M. Böhne[3], B. Wannenmacher[4], T. Hecht[5], J. Mannert[6], K. Reineker[7], A. Rentzsch[8], M. Grafmann[9], G. Wiegand[10], D. Kiski[11], M. Fischer[12], B. Ruf[13], K. Papakostas[14], R. Hellwig[15], R. Foth[16], M. Kaestner[17], J. Kramp[18], I. Voges[19], A. Blank[20], G. Tarusinov[21], U. Schweigmann[22], S. Oezcan[23], I. Graumann[24], W. Knirsch[25], T. Pickardt[26], E. Schwarzkopf[1], K. Klingel[10], D. Messroghli[1], S. Schubert[27]. *[1]German Heart Center, Berlin, Germany, [2]Charité Univ, Berlin, Germany, [3]Hannover Med Sch, Hannover, Germany, [4]Heart Centre Univ of Leipzig, Germany, [5]Heart- and Diabetescenter NRW & Univ Clinic of Ruhr-Univ Bochum, Bad Oeynhausen, Germany, [6]Univ Hosp, Erlangen, Germany, [7]Univ Heart Center Freiburg-Bad Krozingen, Freiburg, Germany, [8]Saarland Univ Hosp, Homburg, Germany, [9]Univ Heart Center, Hamburg, HH, Germany, [10]Univ Hosp, Tübingen, Germany, [11]Univ Hosp, Münster, Germany, [12]Ludwig Maximilians Univ of Munich, Germany, [13]German Heart Centre, Munich, Germany, [14]Hosp Bremen-Mitte, Bremen, Germany, [15]Univ Hosp, Heidelberg, Germany, [16]Univ Göttingen, Göttingen, Germany, [17]Univ Hosp, Homburg, Germany, [18]Univ Hosp, Cologne, Germany, [19]Univ Hosp Schleswig-Holstein, Kiel, Germany, [20]Univ Hosp, Giessen, Germany, [21]Heart Center, Diusburg, Germany, [22]Olga Hosp, Stuttgart, Germany, [23]Univ Hosp RWTH, Aachen, Germany, [24]Univ Hosp, Halle, Germany, [25]Paediatric Heart Center, Zurich, Switzerland, [26]Competence Network for Congenital Heart Defects, Berlin, Germany, [27]Herz- und Diabeteszentrum NRW and German Heart Center Berlin, Bad Oeynhausen, Germany*

(674) ***Enriching Single Ventricle Assist Device Understanding via Granular Database;*** B. Kulp[1], M. N. Khan[2], A. S. Said[2], E. J. Rabinowitz[2]. *[1]St Louis Children's Hospital, St Louis, MO, [2]Pediatrics, Washington University in St Louis, St Louis, MO*

(675) ***"We're Not Really By Ourselves Anymore": Implementation and Effectiveness Evaluation of a Mindfulness-Based Retreat for Mothers of Pediatric Heart Transplant Recipients;*** I. Siqueira[1], J. Lin[1], T. Robertson[1], J. Mitchell[2], S. Ahola Kohut[1], A. Jamyang Donma[1], M. Seifert-Hansen[1], H. Telfer[1], S. J. Anthony[1]. *[1]The Hospital for Sick Children, Toronto, ON, Canada, [2]Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada*

WEDNESDAY, 19 APRIL, 2023

6:30 – 7:30 p.m.

POSTER SESSION 01: PULMONOLOGY

Location: Mile High Ballroom

Core Therapies: LUNG
Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Pathology, Pharmacy, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Pulmonology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Ambalavanan Arunachalam, MD, Northwestern Memorial Hospital, Chicago, IL USA
Hakim Azfar Ali, MD, Duke University Hospital, Durham, NC USA
David Bennett, MD, PhD, University Hospital of Siena, Italy, Siena, Italy
Heidi Brink, PharmD, BCPS, Nebraska Medical Center, Omaha, NE USA
Marie Budev, DO, MPH, Cleveland Clinic, Cleveland, OH USA
Daniel Calabrese, MD, University of California, San Francisco, CA USA
Fiorella Calabrese, MD, University of Padova, Padova, Italy
Kevin Chan, MD, Michigan Medicine, Ann Arbor, MI USA
Prangthip Charoenpong, MD, MPH, Louisiana State University Health Sciences Center, Shreveport, LA USA
Andrew Courtwright, MD, PhD, Hospital of the University of Pennsylvania, Philadelphia, PA USA
Daniel Dilling, MD, Loyola University Chicago, Stritch School of Medicine, Maywood, IL USA
Patrick Evrard, MD, CHU UCL Namur site Godinne, Yvoir, Belgium
Vicky Gerovasili, MD, PhD, Royal Brompton and Harefield Hospitals UK, Harefield, United Kingdom
Laurent Godinas, MD, PhD, UZ Leuven, Leuven, Belgium
Renea Jablonski, MD, The University of Chicago, Chicago, IL USA
Anthony Joudi, MD, Northwestern Memorial Hospital, Chicago, IL USA,
Vaidehi Kaza, MD, MPH, UT Southwestern Medical Center, Dallas, TX USA
Angela Koutsokera, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland
Brian Keller, MD, PhD, Massachusetts General Hospital, Boston, MA USA
Erin Lowery, MD, MS, University of Wisconsin-Madison, Madison, WI USA
Archer Martin, MD, Mayo Clinic, Jacksonville, FL USA
Sravanthi Nandavaram, MD, FCCP, University of Kentucky, Lexington, KY USA
Luca Paoletti, MD, Medical University of South Carolina, Mount Pleasant, SC USA
Michael Perch, MD, Rigshospitalet, Copenhagen, Denmark
Anja Roden, MD, Mayo Clinic Rochester, Rochester, MN USA
Justin Rosenheck, PharmD, Janssen Pharmaceuticals, Powell, OH USA
Ashish Sharma, MD, Brigham & Women's Hospital, Boston, MA USA
Laurie Snyder, MD, MHS, Duke University, Durham, NC USA
Mark Snyder, MD, University of Pittsburgh, Pittsburgh, PA USA,
Grant Turner, MD, MHA, UCLA, Los Angeles, CA USA
Rajat Walia, MD, St. Joseph's Hospital and Medical Center Norton Thoracic Institute, Phoenix, AZ USA
Chad Witt, MD, Washington University School Med, Saint Louis, MO USA

(676) ***Prevalence, Risk Factors and Outcomes for Scedosporium and Lomentospora spp. Following Lung Transplantation at a Single Australian Centre;*** A. Abbott[1], P. Karas[1], F. Mirdad[2], D. Marriott[3], M. Malouf[4], M. Plit[5], D. Darley[1]. *[1]Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia, [2]Infectious Diseases, St Vincent's Hospital, Sydney, Australia, [3]Infectious Diseases, St. Vincent's Hospital, Sydney, Australia, [4]Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia, [5]Lung Transplant Unit, St. Vincent 's Hospital, Sydney, Australia*

(677) ***Serum and BAL Fluid Aspergillus Galactomannan Titers in Lung Transplant Recipients;*** M. Park[1], S. Yong[1], H. Paik[2], J. Lee[2], S. Kim[1], H. Kim[2], A. Woo[1], E. Kim[1]. *[1]Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea, [2]Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea*

(678) ***Impact of Hygiene Measures on the Incidence of CARV in LTR Before and During the First Year of Covid-19;*** R. Hage[1], I. Baumann[2], G. Ortmanns[1], J. Aubert[3], P. Gasche-Soccal[4], M. Schuurmans[5]. *[1]Pulmonology, University Hospital Zurich, Zurich, Switzerland, [2]Medical Faculty, University of Zurich, Zurich, Switzerland, [3]Lausanne, Switzerland, [4]Hopital Cantonal University de Geneve, Geneva, GE, Switzerland, [5]University Hospital Zurich, Zurich, Switzerland*

(679) ***Cytomegalovirus Serologic Mismatch Impact Long-Term Outcomes after Lung Transplantation;*** T. Toyoda[1], J. Lysne[2], B. L. Thomae[1], V. Kandula[1], A. J. Manerikar[1], T. Kaiho[1], Y. Yagi[1], E. Cerier[1], R. Tomic[2], G. Budinger[2], A. Bharat[1], C. Kurihara[1]. *[1]Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, [2]Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL*

(680) ***Effect of Combined Cytomegalovirus Prophylaxis on the Incidence of Cmv Infections, Clad and Survival after Lung Transplantation: Single-Center Experience of 1100 Patients;*** Z. Kovacs[1], P. Jaksch[2], K. Hoetzenecker[3]. *[1]Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria, [2]Medical University Vienna, Austria, Wien, Austria, [3]Medical University of Vienna, Wien, 9, Austria*

(681) ***Return of the Dark Side: A Case Of ECMO Support in Advanced HIV/AIDS for Severe ARDS from SARS-CoV2, Pneumocystis Jirovecii(PJP) and CMV Pneumonitis;*** O. De La Cruz[1], S. Kadir[2], A. Pelaez[3], T. Machuca[4], J. Salgado[5]. *[1]Pulmonary and Critical Care, University of Miami-Miami Transplant Institute-Jackson Memorial Hospital, Miami, FL, [2]Jackson Health System, Miami, FL, [3]Pulmonary and Critical Care Medicine, University of Miami-Miami Transplant Institute-Jackson Memorial Hospital, Miami, FL, [4]University of Miami, Gainesville, FL, [5]University of Miami, Miami, FL*

(682) ***Herpetic Inclusion Bodies in Bronchoalveolar Lavage in a Recent Lung Transplant Recipient with Odynophagia;*** D. Sindu, H. Mohamed, H. Abdelrazek, R. Walia, A. Arjuna. *Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(683) ***Successful Treatment of Endobronchial Mucormycosis with Antifungal Therapy Only;*** J. Jacob[1], H. Mohamed[2], A. Arjuna[2]. *[1]Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ, [2]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(684) ***Thoracic Capnocytophaga Infection in a Lung Transplant Recipient;*** D. Sindu, S. Tokman, K. Mcanally, R. Walia, H. Mohamed, H. Abdelrazek, A. Omar, B. Buddhdev, A. Arjuna. *Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(685) ***Adenovirus Infection in Lung Transplant Recipients: Treatment & Outcomes;*** S. Verga[1], H. Underwood[2], R. Evans[3], S. Nandavaram[1]. *[1]University of Kentucky, Lexington, KY, [2]UK HealthCare, Lexington, KY, [3]University of Kentucky Healthcare, Lexington, KY*

(686) ***West Nile Virus Meningoencephalitis in a Bilateral Lung Transplant Recipient;*** D. Sindu, S. Tokman, K. Mcanally, B. Buddhdev, R. Walia, H. Mohamed, H. Abdelrazek, M. A. Smith, A. Omar, A. Arjuna. *Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(687) ***Treatment Refractory CMV Viremia in a Lung Transplant Recipient;*** D. Sindu, S. Tokman, A. Arjuna, K. Mcanally, R. Walia, H. Mohamed, H. Abdelrazek, A. Omar, B. Buddhdev. *Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(688) ***Alternaria in Lung Transplant: An Unusual Pathogen;*** S. Verga[1], R. Evans[2], H. Underwood[3], S. Nandavaram[1]. *[1]University of Kentucky, Lexington, KY, [2]University of Kentucky Healthcare, Lexington, KY, [3]UK HealthCare, Lexington, KY*

(689) ***Rhodococcus Equi Infection in Lung Transplant: Two Cases;*** B. M. Menachem[1], J. Schneider[2], H. Ali[1]. *[1]Pulmonary and Critical Care, Duke University Hospital, Durham, NC, [2]Duke University Hospital, Durham, NC*

(690) ***Lung Transplant for Severe Covid-19-Related Acute Lung Injury: Promise or Over-Enthusiasm? Clinical Characteristics and Outcomes of Patients Bridged on Extracorporeal Membrane Oxygenation;*** O. Deri[1], L. Levy[1], E. Huszti[2], E. Nachum[3], S. Ladot[3], N. Shimoni[4], M. Saute[5], L. Sternik[3], R. Kremer[5], Y. Kasif[3], N. Zeitlin[5], J. Frogel[4], I. Lembrikov[4], I. Matskovsky[4], S. Chatterji[6], L. Seluk[6], N. Furie[6], I. Shafran[6], R. Mass[6], A. Onn[6], E. Raanani[3], A. Grinberg[7], Y. Levy[7], A. Afek[7], Y. Kreiss[7], A. Kogan[3]. *[1]The Sheba Lung Transplant Program, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, [2]University Health Network, Toronto, ON, Canada, [3]Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, [4]Department of Anesthesiology, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, [5]Department of Thoracic Surgery, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, [6]Institute of Pulmonary Medicine, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, [7]General Management, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel*

(691) ***Right Heart Recovery after Lung Transplantation in Patients with COVID-19-Associated Acute Respiratory Distress Syndrome: A Cohort Study;*** T. Toyoda[1], T. Nayak[2], A. Arunachalam[3], B. L. Thomae[2], V. Kandula[2], A. J. Manerikar[2], M. Jankowski[3], T. Kaiho[1], Y. Yagi[1], E. Cerier[1], K. Maganti[3], R. Tomic[3], G. Budinger[3], A. Bharat[1], C. Kurihara[1]. *[1]Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, [2]Northwestern University Feinberg School of Medicine, Chicago, IL, [3]Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL*

(692) ***Safety and Immunogenicity of the AntiCOVID19 Vaccines in a Cohort of Lung Transplant Recipients;*** L. Morlacchi[1], V. Rossetti[1], S. Uceda Renteria[2], I. Righi[3], F. Ceriotti[2], L. Rosso[3], F. Blasi[1]. *[1]Respiratory Unit and Adult Cystic Fibrosis Center, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, [2]Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, [3]Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy*

(693) ***Infection with Covid Variants of Concern in a Lung Transplant Population;*** J. P. Rosenheck[1], V. Ramsammy[2], S. Kirkby[3], A. Ganapathi[4], N. Mokadam[5], M. Henn[2], S. Sarwar[6], C. Nichols[7], N. Marschalk[8], T. Fallah[4], P. Burcham[8], C. Sawyer[9], J. Mohr[10], S. Hoover[2], K. Nicholson[11], B. McLaughlin[12], R. Brown[13], S. Carter[8], K. Maas[14], J. Bennett[2], C. Shafner[2], M. Reilly[2], B. Whitson[2], D. Nunley[15]. *[1]Internal Medicine, Ohio State University, Columbus, OH, [2]Ohio State University, Columbus, OH, [3]Nationwide Children's Hospital, Columbus, OH, [4]Ohio State University Wexner Medical Center, Columbus, OH, [5]The Ohio State Univ Wexner Med Ctr, Columbus, OH, [6]The Ohio State Wexner Medical Center, Columbus, OH, [7]Columbus, OH, [8]The Ohio State University Wexner Medical Center, Columbus, OH, [9]Ohio State University Wexner Medical Center, Granville, [10]Ohio State Wexner Medical Center, Dublin, OH, [11]Nationwide Children's Hospital, Pickerington, OH, [12]The Ohio State University, Columbus, OH, [13]OSU Wexner Medical Center, Reynoldsburg, OH, [14]The Ohio State University Wexner Medical Center, Delaware, OH, [15]Wexford, PA*

(694) ***Preservation of Lung Function Despite Covid-19 Infection in a Cohort of Lung Transplant Recipients;*** S. L. Ennis[1], B. Levvey[1], H. Shingles[1], L. Holsworth[1], G. Snell[1], B. Gardiner[2]. *[1]Lung Transplantation Service, Alfred Hospital, Melbourne, Australia, [2]Alfred Health/Monash University, Melbourne, Australia*

(695) ***Predictors of Omicron Covid-19 Severity in a Large Lung Transplant Cohort;*** B. Levvey[1], S. Ennis[1], H. Shingles[2], B. Gardiner[3], G. Snell[1]. *[1]Lung Transplant Service, Respiratory Medicine, The Alfred Hospital & Monash University, Melbourne, Australia, [2]Lung Transplant Service, Respiratory Medicine, The Alfred Hospital, Melbourne, Australia, [3]Infectious Diseases Department, Alfred Health & Monash University, Melbourne, Australia*

(696) ***Low Covid-19 Related Mortality Among Lung Transplant Recipients at a Single Center***; R. F. Gomez[1], A. Kafi[1], G. Yung[1], S. Aslam[2], T. Pollema[3], E. Golts[3], C. Lin[1], K. Afshar[1]. *[1]Division of Pulmonary and Critical Care Medicine, University of California, San Diego Medical Center, La Jolla, CA, [2]Division of Infectious Disease and Global Public Health, University of California, San Diego Medical Center, La Jolla, CA, [3]Department of Cardiothoracic Surgery, University of California, San Diego Medical Center, La Jolla, CA*

(697) ***Donor Derived Cell Free DNA in Lung Transplant Recipients with COVID Based on Hospitalization***; S. Jyothula[1], R. Hussain[1], M. Patel[1], J. Patel[1], C. Pham[2], D. Levine[3]. *[1]Memorial Hermann Hospital / University of Texas at Houston, Houston, TX, [2]Medical Affairs, CareDx, Brisbane, CA, [3]Stanford University, Palo Alto, CA*

(698) ***Covid-19 is Less Severe with the Omicron Variant Compared to Prior Variants and the Original Sars-Cov-2 Strain in Lung Transplant Recipients***; D. Sindu[1], D. Razia[2], K. Grief[1], J. Padiyar[1], L. Schaheen[1], A. Omar[1], R. Walia[1], M. A. Smith[1], R. M. Bremner[1], S. Tokman[3]. *[1]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, [2]Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ, [3]Norton Thoracic Institute, Phoenix, AZ*

(699) ***No Association Between BNT162B2 Vaccine and Graft Rejection Among Lung Transplant Recipients***; Y. Shostak[1], M. Kramer[2], I. Bakal[3], O. Edni[4], A. Gluzman[4], N. Shafran[4], D. Rosengarten[5], D. Shitenberg[6], M. Heching[7], S. Amor[8], H. Ben Zvi[9], B. Pertzov[8], M. Israeli[10], Y. Peysakhovich[11], Y. Barac[6], O. Shtraichman[12]. *[1]Petah Tiqva, Israel, [2]Rabin Med Ctr Belinson, Petah Tiqva, Israel, [3]Rabin Medical Center, Shoham, Israel, [4]Department of Medicine D, Rabin Medical Center, Petach Tikva, Israel, [5]Rabin Med Ctr, Petah Tiqva, Israel, [6]Rabin Medical Center, Petah Tiqva, Israel, [7]Pulmonary Institute, Rabin Medical Center, Petach Tikva, Israel, [8]Rabin Medical Center, Petach Tikva, Israel, [9]Microbiology Laboratory, Rabin Medical Center, Petach Tikva, Israel, [10]HLA Laboratory, Rabin Medical Center, Petach Tikva, Israel, [11]Petah Tikva, Israel, [12]Pulmonary Institute, Rabin Medical Center, Petah Tiqva, Israel*

(700) ***Vaccination with >2 Doses of Mrna Vaccines is Needed to Reduce Mortality Among Lung Transplant Recipients with Covid-19***; D. Sindu[1], D. Razia[2], K. Grief[1], L. Schaheen[1], J. Padiyar[1], M. A. Smith[1], R. M. Bremner[1], A. Omar[1], R. Walia[1], S. Tokman[1]. *[1]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, [2]Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ*

(701) ***Use of Tixagevimab and Cilgavimab (Evusheld) and Subsequent Outcomes of SARS-CoV-2 Infections in Lung Transplant Recipients***; A. Grillini, P. Stracener, D. Scarola, J. Lyons, D. Dilling. *Loyola University Medical Center, Maywood, IL*

(702) ***WITHDRAWN***

(703) ***WITHDRAWN***

(704) ***Risk Factors for Persistent FEV$_1$Decline Following COVID-19 Infection in Lung Transplant Recipients; a Single Australian Transplant Centre Experience***; C. Thomson[1], P. Karas[2], A. Abbott[3], M. Malouf[4], M. Plit[5], D. Darley[6]. *[1]Thoracic Medicine and Lung Transplantation, St Vincent's Hospital, Darlinghurst, Australia, [2]St Vincents Hospital, [3]St Vincent's Hospital, Camperdown, Australia, [4]St. Vincent's Hospital, Darlinghurst, Australia, [5]St. Vincent 's Hospital, Rose Bay, Australia, [6]St Vincent's Hospital Darlinghurst, Surry Hills, Australia*

(705) ***Risk Factors for Death and Hospitalisation in COVID-19 Infection in Lung Transplant Recipients; a Single Australian Centre Experience***; C. Thomson[1], P. Karas[2], A. Abbott[3], M. Malouf[4], M. Plit[5], D. Darley[6]. *[1]Thoracic Medicine and Lung Transplantation, St Vincent's Hospital, Darlinghurst, Australia, [2]St Vincents Hospital, [3]St Vincent's Hospital, Camperdown, Australia, [4]St. Vincent's Hospital, Darlinghurst, Australia, [5]St. Vincent 's Hospital, Rose Bay, Australia, [6]St Vincent's Hospital Darlinghurst, Surry Hills, Australia*

(706) ***Prevalence and Risk Factors for Rejection Following COVID-19 in a Single Centre Australian Lung Transplant Cohort***; P. Karas[1], D. Darley[2], A. Abbott[3], M. Malouf[4], M. Plit[5], C. Thomson[6]. *[1]Thoracic Medicine and Lung Transplantation, St Vincents Hospital, Darlinghurst, Australia, [2]St Vincent's Hospital Darlinghurst, Surry Hills, Australia, [3]St Vincent's Hospital, Camperdown, Australia, [4]St. Vincent's Hospital, Darlinghurst, Australia, [5]St. Vincent 's Hospital, Rose Bay, Australia, [6]Thoracic Medicine and Lung Transplantation, St Vincent's Hospital, Darlinghurst, Australia*

7:00 – 7:45 a.m.

SPECIAL SESSION: THE WONDERFUL WORLD OF EARLY CAREER: HOW TO GET THAT GRANT

Location: Rooms 205-207

Core Therapies: ALL
Practice Areas: ALL

Session Summary: This "lightning style" session will cover two 20-minute topics. Co-chairs will lead a brief Q&A segment with speakers after each topic with questions from the audience.

CME is not offered for this session.

Co-Chairs: Brittany Koons, PhD, Villanova University M. Louise Fitzpatrick College of Nursing, Villanova, PA USA
Ashley Fritz, DO, Mayo Clinic, Jacksonville, FL USA

7:00 a.m. ***Topic 1: Off to See the Wizard: Tips and Tricks to Get That Grant - Junior Researcher Perspective***
Sahar Saddoughi, MD, PhD, Mayo Clinic, Rochester, MN USA

Junior and senior researchers discuss how, when, and where to begin a grant proposal. Speakers will share tips and strategies for grant writing success!

7:05 a.m. ***Topic 1: Off to See the Wizard: Tips and Tricks to Get That Grant - Senior Researcher Perspective***
Howard Eisen, MD, Penn State Milton S. Hershey Medical Center, Hershey, PA USA

Junior and senior researchers discuss how, when, and where to begin a grant proposal. Speakers will share tips and strategies for grant writing success!

7:10 a.m. ***Topic 1 Q&A***

7:20 a.m. ***Topic 2: Follow the ISHLT Road: How to Get Involved - Early Career Perspective***
Tara Veasey, PharmD, BCTXP, Allegheny General Hospital, Pittsburgh, PA USA

Mentee and mentor teams discuss the ISHLT organization through the lens of junior and senior faculty. Speakers will discuss avenues to get involved with ISHLT from the professional communities to directors at large. Speakers will also discuss other avenues to engage ISHLT through abstract submission, volunteering, and utilization of other resources available (i.e. Expertlink) to further career progression.

7:25 a.m. ***Topic 2: Follow the ISHLT Road: How to Get Involved - Senior Faculty Perspective***
Michael Shullo, PharmD, West Virginia University Hospitals, Morgantown, WV USA

Mentee and mentor teams discuss the ISHLT organization through the lens of junior and senior faculty. Speakers will discuss avenues to get involved with ISHLT from the professional communities to directors at large. Speakers will also discuss other avenues to engage ISHLT through abstract submission, volunteering, and utilization of other resources available (i.e. Expertlink) to further career progression.

7:30 a.m. ***Topic 2 Q&A***

7:00 – 7:45 a.m.

SPECIAL SESSION: THE WONDERFUL WORLD OF EARLY CAREER: JUMPSTART YOUR FUTURE

Location: Rooms 201-203

Core Therapies: ALL
Practice Areas: ALL

Session Summary: This "lightning style" session will cover two 20-minute topics. Co-chairs will lead a brief Q&A segment with speakers after each topic with questions from the audience.

CME is not offered for this session.

Co-Chairs: Kyle Hope, MD, MS, Texas Children's Hospital, Baylor College of Medicine, Houston, TX USA
Francesca Lunardi, MD, ScD, PhD, University of Padova, Padova, Italy

7:00 a.m. ***Topic 1: Follow the ISHLT Road: How to Get Involved - Early Career Perspective***
Rebecca Klingbeil, MSN, DNP, Mayo Clinic, Jacksonville, FL USA

Mentee and mentor teams discuss the ISHLT organization through the lens of junior and senior faculty. Speakers will discuss avenues to get involved with ISHLT through abstract submission, volunteering, and resources available (i.e. Expertlink) to further career progression.

7:05 a.m. ***Topic 1: Follow the ISHLT Road: How to Get Involved - Senior Faculty Perspective***
Archer Martin, MD, Mayo Clinic, Jacksonville, FL USA

Mentee and mentor teams discuss the ISHLT organization through the lens of junior and senior faculty. Speakers will discuss avenues to get involved with ISHLT through abstract submission, volunteering, and resources available (i.e. Expertlink) to further career progression.

7:10 a.m. ***Topic 1 Q&A***

7:20 a.m. ***Topic 2: If I Only Had a Job — Advice for Starting Your Career - Early Career Perspective***
Caroline Patterson, BMBS, BMedSci, MD, Royal Papworth Hospital, Cambridge, United Kingdom

Speakers from North America and Europe discuss opportunities and suggestions for looking for that perfect job whether you are just starting out in your career or are considering changing positions later in your career.

7:25 a.m. ***Topic 2: If I Only Had a Job — Advice for Starting Your Career - Senior Faculty Perspective***
Hakim Azfar Ali, MD, Duke University Hospital, Durham, NC USA

Speakers from North America and Europe discuss opportunities and suggestions for looking for that perfect job whether you are just starting out in your career or are considering changing positions later in your career.

7:30 a.m. ***Topic 2 Q&A***

THURSDAY, 20 APRIL, 2023

8:30 – 9:30 a.m.

GENERAL SESSION (PLENARY) II

Location: Four Seasons Ballroom

Core Therapies: ALL
Practice Areas: ALL

Co-Chairs: John Wallwork, FRCS, FmedSci, Royal Papworth Hospital, Cambridge, United Kingdom
Sharon Hunt, MD, Stanford University Medical Center, Stanford, CA USA

8:00 a.m. ***International Thoracic Organ Transplant Registry Report***
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN USA

ISHLT International Thoracic Organ Transplant Registry Medical Director will give an overview of the registry's activities.

8:10 a.m. ***Norman Shumway Centenary Recognition***
John Wallwork, FRCS, FMedSci, Royal Papworth Hospital, Cambridge, United Kingdom

8:20 a.m. ***Health Equity and Advanced Heart and Lung Disease***
Ala Stanford, MD, FACS, FAAP, U.S. Dept. of Health and Human Services, Philadelphia, PA USA

The speaker will address issues of health equity and access to care including access to advanced therapies for end-stage heart and lung disease.

8:40 a.m. ***United Kingdom Perspective on Health Equity***
Caroline Patterson, BMBS, BMedSci, MD, Royal Papworth Hospital, Cambridge, United Kingdom

8:50 a.m. ***FEATURED PRESENTATION:*** **(3)** ***Heart Transplantation Outcomes in Patients from Socioeconomically Distressed Communities***; Q. Chen, J. Malas, D. Emerson, D. Megna, P. Catarino, F. Esmailian, J. Chikwe, M. E. Bowdish. *Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA*

9:00 a.m. ***Q&A with Interactive Discussant***
Alanna Morris, MD, MSc, Emory University, Atlanta, GA USA

9:05 a.m. ***Introduction to Lifetime Achievement Award Recipient***
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

9:10 a.m. ***2023 Lifetime Achievement Award Recipient Lecture***
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Beverly Hills, CA USA

10:00 – 11:00 a.m.

SESSION 29: THE RIGHT MCS DEVICES FOR THE RIGHT PATIENTS

Location: Rooms 603-605

Core Therapies: MCS, HEART
Practice Areas: Cardiothoracic Surgery, Cardiology, Pediatrics

Session Summary: HF-CS represent a growing CS subpopulation for which there are few evidence-based therapies. It is a continuum where dynamic and accurate risk stratification is needed, and a systematic re-profiling allows clinical decision making. The selection of the best MCS device for a given patient depends on baseline patient characteristics, CS severity, the goal of temporary MCS and institutional expertise. Also, acute RV failure and its clinical presentation need to be addressed with all the different aspects of RV failure and the ways to overcome it. RV failure in CS patients demands fast decision making and adequate selection of temporary MCS.

Co-Chairs: Maria Renedo, MD, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina
Adrian daSilva-deAbreu, MD, MSc, PhD(c), Mayo Clinic, Rochester, MN USA

10:00 a.m. ***In the Pool of Diversity: Individualized Temporary MCS Transitions Beyond Etiologies and Phenotypes***
Ivan Netuka, MD, PhD, IKEM, Prague, Czech Republic

This talk will review the different aspects we should evaluate regarding gender, body mass index, social environment, and comorbidities during decision-making and tMCS deployment, and how to reach an individualized therapeutic approach in this complex patient population.

10:10 a.m. ***When Appearances are Deceptive: Phenotyping Specific Diagnoses to Target Therapy and Myocardial Recovery***
Linda Van Laake, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands

This talk will explain the importance of etiology assessment to identify the possibility of myocardial recovery and its usefulness in the decision-making comprehensive approach. Considerations about how to wean tMCS and when to think about transition to durable VAD. This talk will also focus on clinical parameters and risk factors for successful durable VAD implantation.

10:20 a.m. ***When Smaller Bodies Turn into Bigger Problems: What's New in MCS in the Pediatric Population?***
Martin Schweiger, Prof., MBA, FABS, FEBS, Children's Hospital Zurich, Zürich, Switzerland

This presentation will address the current state of the art regarding HF-CS management in the pediatric population. The available devices and their selection process will also be reviewed. The talk will also present data on possible pediatric durable VAD implantation after tMCS and what to physiological aspects to focus on when implanting durable pediatric VADs.

10:30 a.m. ***To Pulsate or Not to Pulsate: Pulsatile vs. Continuous Right Ventricle Support***
Yaron Barac, MD, PhD, Rabin Medical Center, Petah Tiqva, Israel

This talk will focus on survival and weaning results by pulsatile vs continuous RVAD. Right ventricular support in cardiogenic shock also needs to be addressed in this talk. How to best treat patient in acute biventricular failure and subsequent RV failure after tMCS.

10:40 a.m. ***Panel Discussion***

10:00 – 11:00 a.m.

SESSION 30: EXPLORING THE LIMITS IN HEART TRANSPLANTATION IN CHILDREN AND ADULTS

Location: Rooms 401-404

Core Therapies: HEART
Practice Areas: Pediatrics, Cardiology, Cardiothoracic Surgery, Nursing & Allied Health

Session Summary: This session, in Pecha Kucha format, focuses on strategies aimed at successful transplantation of children and adults who are often deemed 'un-transplantable', 'highly unlikely', or 'too high risk'. Talks will focus on patient selection, peri- and post-op management, and outcomes.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: Challenges in heart transplant selection and management

Co-Chairs: Kelly Schlendorf, MD, Vanderbilt University Medical Center, Nashville, TN USA
Manuela Camino Lopez, MD, Hospital Gregorio Marañon, Madrid, Spain

10:00 a.m. ***Warrior and Not Just a Survivor! Transplanting Patients With History of Cancer***
Neha Bansal, MD, Children's Hospital at Montefiore, Bronx, NY USA

Whether heart transplantation will be appropriate for all cancer survivors and patients with cancer-therapy-related cardiotoxicity will require demonstrating similarly good outcomes to ensure proper organ allocation. This talk will discuss the trend, complications, and overall survival of heart transplantation for survivors of cancer and define selection criteria and diagnostic approach for candidates across the age-spectrum.

10:08 a.m. ***A Heavy Problem: Weight Loss for the Obese Candidate***
Jong-Chan Youn, MD, PhD, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

Because obesity is associated with inferior post-transplant outcomes, BMI>35 kg/m2 is considered a relative or absolute contraindication to heart transplant at most centers. This talk will present data for weight loss techniques in children and adults, including bariatric surgery in LVAD or heart failure patients that may allow for subsequent transplantation.

10:16 a.m. ***HLA Antibodies Do Not Bind Me: Transplanting the Highly Sensitized***
Kevin Daly, MD, Boston Children's Hospital, Boston, MA USA

This talk will present methodologies for transplanting patients with an elevated cPRA, including prospective or virtual crossmatch, methods and timing of desensitization, intra-operative plasma exchange, post-operative induction and immunosuppression management. Short- and long-term outcomes for both children and adults will be presented.

10:24 a.m. ***When the First Transplant Fails: Heart Retransplantation in the Young Adult***
Amanda Vest, MBBS, MPH, Tufts Medical Center, Boston, MA USA

The talk will focus on heart retransplant in the young adult who has recently transitioned to the adult center capturing important clinical co-morbidities resulting from the first heart transplant, difficulties with transition to an adult care team, and psychosocial challenges associated with this population.

10:32 a.m. ***Blood Group is Just a Speed Bump: Pushing the Limits in ABOi Transplants***
Simon Urschel, MD, University of Alberta, Edmonton, AB Canada

This talk will discuss the current practice of ABO-incompatible cardiac transplantation, its effect on waiting list mortality and time to transplant, and the clinical and immunologic outcomes after ABO-incompatible transplantation. Special attention will be focused on the whether this technique can be applied to older candidates and/or retransplant candidates with prior ABOi transplant.

10:40 a.m. ***Panel Discussion and Audience Vote***

10:00 – 11:00 a.m.

SESSION 31: WINTER SOLDIER: MERGING BASIC AND CLINICAL SCIENCE TO OVERCOME PERIOPERATIVE CHALLENGES

Location: Four Seasons Ballroom

Core Therapies: LUNG, HEART, PVD
Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery

Session Summary: This session will use a pro/con debate format to discuss two peri-operative topics critical for success of lung transplantation. The first debate will discuss lung preservation and the second debate will discuss best practices for bridging highly critical patients.

Co-Chairs: Wiebke Sommer, MD, University of Heidelberg, Heidelberg, Germany
Asvin Ganapathi, MD, Ohio State University Wexner Medical Center, Columbus, OH USA
Alberto Benazzo, MD, PhD, Medical University of Vienna, Vienna, Austria

10:00 a.m. ***DEBATE: How Would You Like Your Lung Cooked? Rare or Well Done? Rare: Lung Preservation at 4°C***
Shaf Keshavjee, MD, MSc, FRCSC, FACS, University Health Network, Toronto, ON Canada

In this Pro/Con Debate, an argument for lung preservation at 4°C will be made.

10:08 a.m. ***DEBATE: How Would You Like Your Lung Cooked? Rare or Well Done? Well Done: Lung Preservation at 10°C***
Marcelo Cypel, MD, University Health Network, Toronto, ON Canada

In this Pro/Con Debate, an argument for lung preservation at 10°C will be made.

10:16 a.m. ***Rebuttals/Q&A***

10:30 a.m. ***DEBATE: ECMO on the Edge: Bridging the High Risk Recipient is Necessary (PRO)***
Jasleen Kukreja, MD, MPH, University of California San Francisco, San Francisco, CA USA

This speaker will argue for ECMO as a bridge to transplant for high risk candidates.

10:38 a.m. ***DEBATE: ECMO on the Edge: Bridging the High Risk Recipient is Necessary (CON)***
Anne Olland, MD, PhD, University Hospital Strasbourg, Strasbourg, France

This speaker will argue against ECMO as a bridge to transplant for high risk candidates.

10:46 a.m. ***Rebuttals/Q&A***

10:00 – 11:00 a.m.

SESSION 32: MEDICAL MANAGEMENT OF PH: SOMETHING OLD, SOMETHING NEW, SOMETHING BORROWED, SOMETHING BLUE

Location: Rooms 501-504

Core Therapies: PVD, LUNG, HEART
Practice Areas: Pharmacy and Pharmacology, Cardiology, Nursing & Allied Health, Pediatrics, Pulmonology

Session Summary: There are a number of new agents being launched for PAH, there are also new strategies for PH - how do we put it all together to maximise benefit for diverse populations? This session, in Pecha Kucha format, will emphasize where these new treatments fit in and what it all means for the traditional triple therapy - what about the patient?

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: Update in treatment strategies in PH / PAH with new agents

Co-Chairs: Sara Strout, PharmD, Johns Hopkins Hospital, Baltimore, MD USA
Jordan Whitson, MD, Duke University Medical Center, Durham, NC USA

10:00 a.m. ***Something Old: Novel Regenerative Therapies for the Failing RV***
Olaf Mercier, MD, PhD, Marie Lannelongue Hospital, Le Plessis Robinson, France

Stem cell therapy possesses revolutionary potential in treatment of patients with failing systemic RV. This discussion will address up-to-date clinical trials utilizing stem cell therapy to prevent RV failure, the ability to improve angiogenesis and mitigate oxidative stress in pressure overload.

10:08 a.m. ***Something New: Sotatercept and Novel Small Molecules***
James Coons, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA USA

New pathways are being targeted for PH - this talk will focus on Sotatercept but will also mention new small molecule treatments in pipeline and how these may fit among current treatments.

10:16 a.m. ***Something Borrowed: Treating PH in ILD***
Tanya McWilliams, MD, PhD, Auckland City Hospital, Auckland, New Zealand

In 4/2021, inhaled prostacyclin became the first FDA-approved therapy for pulmonary hypertension with interstitial lung disease (PH-ILD), including in patients with underlying connective tissue disease (CTD). A common clinical scenario confronting providers is the patient with precapillary PH in the context of ILD and CTD, where the precise etiology of PH (due to ILD or underlying CTD) is unclear, and considerable equipoise exists regarding the optimal therapeutic and management strategy. This talk fulfills the needs of PH specialists in exploring the options for targeted therapy in CTD with PH-ILD, exploring the evidence for and against inhaled prostacyclin therapy versus traditional PH combination targeted therapy in these patients. Speaker will also discuss use of Sildenafil for this indication

10:24 a.m. ***Happily Ever After: Best Combos, Best Outcomes***
Amy Kiskaddon, PharmD, Johns Hopkins All Children's Hospital, St. Petersburg, FL USA

Speaker will discuss best evidence for treatment combinations of the available targeted therapies

10:32 a.m. ***Something Blue: Why Can't We Get Along Together?***
Rachel Crackett, MSc, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Will discuss various factors including the treatment burden of PH which prevents many patients being on gold standard treatments e.g. IV Prostacyclin

10:40 a.m. ***Panel Discussion and Audience Vote***

10:00 – 11:00 a.m.

SESSION 33: THE TEMPEST: INFECTIONS IN HEART TRANSPLANT DONORS AND RECIPIENTS

Location: Rooms 205-207

Core Therapies: HEART
Practice Areas: Infectious Diseases, Cardiology, Cardiothoracic Surgery, Research and Immunology

Session Summary: A potpurri of infectious topics will be presented in this session including outcomes from infected donors (COVID-19 or Hepatitis C Virus), impact on DSA by COVID-19, and the deveopment of cellular immunity to COVID-19.

Co-Chairs: Valentina Stosor, MD, Northwestern University Feinberg School of Medicine, Chicago, IL USA
Farooq Sheikh, MD, MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Washington, DC USA

10:00 a.m. **(59)** ***Mid-Term Outcomes of Heart Transplants from HCV NAT+ Donors***; Y. Xia[1], S. T. Kim[2], J. Hermsen[3], R. Dhingra[3], M. Johnson[3], A. Ardehali[4]. *[1]Surgery, University of WIsconsin, Madison, WI, [2]UCLA, Los Angeles, CA, [3]University of Wisconsin, Madison, WI, [4]UCLA School of Medicine, Los Angeles, CA*

10:15 a.m. **(60)** ***Impact of Donor Specific Antibodies in Cardiac Transplant Recipients after Acute Covid-19***; J. A. Martissa[1], M. J. Gregoski[1], B. Houston[1], A. Kilic[1], A. Celia[1], S. Shore[2], A. Tamas[3], V. Maharaj[3], A. C. Agdamag[3], E. Vorovich[4], L. A. Farina[4], H. Vidula[5], R. Sampath[5], S. Hsiao[6], K. Alexander[6], A. Jamil[7], E. Birati[7], S. Chaudhry[8], A. Patel[8], R. J. Tedford[1], M. V. Genuardi[7]. *[1]Medical University of South Carolina, Charleston, SC, [2]University of Michigan, Ann Arbor, MI, [3]University of Minnesota, Minneapolis, MN, [4]Northwestern University, Chicago, IL, [5]University of Rochester School of Medicine and Dentistry, Rochester, NY, [6]Stanford University Medical Center, Stanford, CA, [7]University of Pennsylvania, Philadelphia, PA, [8]St Vincent Heart Center, Indianapolis, IN*

10:30 a.m. **(61)** ***Prevalence and Determinants of Cellular Immunity Against Sars-Cov-2 in Heart Transplant Recipients: A Cross-Sectional Study***; H. Flament[1], M. Ben Ahmed[2], C. Kfoury[2], V. Ferré[3], M. Para[4], V. Da Silva Melo[5], C. Charpentier[3], N. Houhou-Fidouh[6], E. Vicaut[7], D. Descamps[3], R. Dorent[5]. *[1]AP-HP, Bichat-Claude Bernard University Hospital, Immunology Department; INSERM, Center for Research on Inflammation, UMR1149, Paris Cité University, Paris, France, [2]AP-HP, Bichat-Claude Bernard University Hospital, Immunology Department, Paris, France, [3]AP-HP, Bichat-Claude Bernard University Hospital, Virology Department; INSERM, IAME, UMR1137, Paris Cité University, Paris, France, [4]AP-HP, Bichat-Claude Bernard University Hospital, Cardiac Surgery Department; INSERM, UMR1148, Paris Cité University, Paris, France, [5]AP-HP, Bichat-Claude Bernard University Hospital, Cardiac Surgery Department, Paris, France, [6]AP-HP, Bichat-Claude Bernard University Hospital, Virology Department, Paris, France, [7]AP-HP, Clinical Research Unit Lariboisière - Saint-Louis; Paris Cité University, Paris, France*

10:45 a.m. **(62)** ***Heart Transplantation (ht) from Active and Recently Active Covid19 Donors***; S. Madan[1], M. G. Chan[2], O. Saeed[1], D. B. Sims[1], V. S. Hemmige[1], S. Forest[1], D. J. Goldstein[1], S. R. Patel[1], U. P. Jorde[1]. *[1]Montefiore Medical Center, Bronx, NY, [2]Montefiore New Rochelle, New Rochelle, NY*

10:00 – 11:00 a.m.

SESSION 34: BALANCING THE SCALES: HEALTHCARE DISPARITIES IN HEART TRANSPLANTATION

Location: Rooms 405-407

Core Therapies: HEART
Practice Areas: Cardiothoracic Surgery, Cardiology, Pediatrics

Session Summary: Racial disparities and social determinants of health have a multifactoral affect on patient outcomes. This session highlights ongoing issues of access to care and disparity in heart transplantation.

Co-Chairs: Larry Allen, MD, MHS, University of Colorado, Aurora, CO USA
Johanna Contreras, MD, MSC, Mount Sinai Hospital, New York, NY USA

10:00 a.m. **(63)** ***Racial Disparities in Pediatric Heart Transplantation: A National Registry Analysis***; E. Chan[1], N. Jacobs[1], J. Lee[1], S. Kidambi[2], R. Zawadzki[3], E. Kim[1], J. Dykes[4], D. Rosenthal[5], M. Ma[1]. *[1]Stanford University, Stanford, CA, [2]Stanford University Medical Center, Palo Alto, CA, [3]University of California, Irvine, Irvine, CA, [4]Lucile Packard Children's Hosp, Redwood City, CA, [5]Stanford, Portland, OR*

10:15 a.m. **(64)** ***Emerging Racial Differences in Heart Transplant Waitlist Outcomes for Patients on Temporary Mechanical Circulatory Support***; D. Rekhtman[1], A. Iyengar[2], C. Song[1], N. Weingarten[2], M. Shin[1], M. Patel[2], D. Herbst[2], M. Helmers[2], M. Cevasco[2], P. Atluri[2]. *[1]Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, [2]Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA*

10:30 a.m. **(65)** ***Assessment of Heart Transplantation Allocation Policy Change by Zip Code and Median Household Income: An OPTN Database Analysis***; C. E. Kelty[1], M. Dickinson[1], M. Leacche[1], M. Jani[1], N. K. Shrestha[1], S. Lee[1], D. Acharya[2], I. Rajapreyar[3], E. R. McNeely[1], R. C. Sadler[4], R. Loyaga-Rendon[1]. *[1]Spectrum Health, Grand Rapids, MI, [2]University of Arizona, Tucson, AZ, [3]Thomas Jefferson University Hospital, Philadelphia, PA, [4]Michigan State University, Flint, MI*

10:45 a.m. **(66)** ***Lower Neighborhood Opportunity is Associated with Worse Outcomes after Listing in Pediatric Heart Transplantation***; H. Kim, M. Iqbal, R. Butts. *University of Texas Southwestern Medical Center, Dallas, TX*

10:00 – 11:00 a.m.

SESSION 35: AN UNEXPECTED JOURNEY: PERFUSION SCIENCE IN LUNG TRANSPLANTATION

Location: Rooms 201-203

Core Therapies: LUNG
Practice Areas: Cardiothoracic Surgery, Pulmonology

Session Summary: This session will give providers an in depth view into the current data regarding machine perfusion including EVLP, preservation strategies and normothermic regional perfusion. Following the session, providers will have a better understanding of the impact of machine perfusion strategies on lung transplantation outcomes.

Co-Chairs: Dirk Van Raemdonck, MD, PhD, University Hospitals Leuven, Leuven, Belgium
Matthew Hartwig, MD, Duke University Medical Center, Durham, NC USA

10:00 a.m. **(67)** ***Screening for Donor Lung Pulmonary Emboli During Ex-Vivo Lung Perfusion***; K. S. Ayyat, T. Okamoto, A. Tantawi, I. Sakanoue, H. Elgharably, U. Ahmad, S. Unai, J. Yun, M. Budev, K. McCurry. *Cleveland Clinic, Cleveland, OH*

10:15 a.m. **(68)** ***Not Too Warm, Not Too Cold: Real-World Multi-Center Outcomes with Elevated Hypothermic Preservation of Donor Lungs***; J. Haney[1], M. Hartwig[2], N. Langer[3], P. Sanchez[4], E. Bush[5]. *[1]Duke University, Durham, NC, [2]Duke University Medical Center, Durham, NC, [3]Massachusetts General Hospital, Wellesley, MA, [4]University of Pittsburgh Medical Center, Pittsburgh, PA, [5]Johns Hopkins, Baltimore, MD*

10:30 a.m. **(69)** ***Thoracoabdominal Normothermic Regional Perfusion Does Not Adversely Impact Early Outcomes in Donation after Circulatory Death Lung Transplantation***; J. Malas, Q. Chen, D. Emerson, M. Bowdish, J. Chikwe, D. Megna, P. Catarino. *Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA*

10:45 a.m. **(70)** ***Normothermic Regional Perfusion in Donation after Circulatory Death Heart Donors May Not Have a Detrimental Effect on Lung Transplant Outcomes***; Y. Xia[1], S. T. Kim[2], E. Lowery[3], J. Maloney[4], M. DeCamp[4], D. McCarthy[5], A. Ardehali[2]. *[1]University of WIsconsin, Madison, WI, [2]UCLA School of Medicine, Los Angeles, CA, [3]University of Wisconsin School of Medicine and Public Health, Madison, WI, [4]University of Wisconsin, Madison, WI, [5]University of Wisconsin, Middleton, WI*

1:00 – 2:30 p.m.

SESSION 36: THE ACHILLES HEEL: FRAILTY IN HEART TRANSPLANT AND LVAD CANDIDATES

Location: Four Seasons Ballroom

Core Therapies: HEART, MCS
Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing & Allied Health, Pediatrics

Session Summary: Frailty is an independent predictor of one-year all-cause mortality. Frailty assessment and depression and cognitive impairment evaluation in heart transplant (HTx) and LVAD candidates are mandatory. Pre-habilitation is associated to morbidity and mortality reduction in this patient population. This session will review the current approaches for frailty, depression, and cognitive impairment assessment in HTx and LVAD candidates and how to reduce their impact in this high-risk population.

Co-Chairs: Fabiana Marcondes-Braga, MD, PhD, Heart Institute (InCor), Hospital das Clinicas, Universidade de Sao Paulo, São Paulo, Brazil
Brittany Koons, PhD, Villanova University M. Louise Fitzpatrick College of Nursing, Villanova, PA USA

1:00 p.m. ***The Eyeball Test or The End of The Bed Assessment: How Can We Best Identify Patients Who May Benefit from a Prehabilitation Programme?***
Quin Denfeld, PhD, RN, Oregon Health and Science University, Portland, OR USA

In this talk we will review the main characteristics of patients with HF and frailty considering there are different phenotypes (including HTx and LVAD candidates), the presence of cardiovascular and non-cardiovascular frailty and the possibility of reversibility of this dynamic condition.

1:15 p.m. ***When Frailty Doesn't Come Alone: How to Manage Depression and Cognitive Impairment***
Patrick Smith, PhD, MPH, University of North Carolina, Chapel Hill, NC USA

Clinical practice real-world data and registries have reported the high prevalence of depression and cognitive impairment in HF patients and their connection with frailty. This talk will review how to assess both conditions in frail HF patients.

1:30 p.m. ***Less is More: Talking Frailty in Pediatric Heart Failure***
Kurt Schumacher, MD, MS, CS Mott Children's Hospital, Ann Arbor, MI USA

This talk will discuss how to assess and manage frailty in pediatric and adult congenital heart disease (e.g Fontans) and the unique challenges associated with it.

1:45 p.m. ***Rehabilitation in The New Era: Ways to Adapt the Best Routine to The Right Patient***
Sarah Wright, DPT, Massachusetts General Hospital, Boston, MA USA

This talk will discuss the current approaches in the management of frail HF patients by incorporating different strategies. How to choose and tailor the intensity of each session regarding the different phenotypes and when to prefer individual or group sessions will also be discussed. Will discuss strategies for mobilizing the critical care patient with attention to ambulating temporary MCS patients.

2:00 p.m. ***When "One Suit Fits All" Doesn't Work: Looking for a Multidimensional Tool for Frailty Dynamic Assessment***
Geetha Bhat, MD, The Christ Hospital, Cincinnati, OH USA

In this talk we will review the different scores used in the clinical practice to assess frailty. It is time to develop a new frailty score with prospective validation in a younger population including different phenotypes regarding frail HF population.

2:15 p.m. ***Panel Discussion***

1:00 – 2:30 p.m.

SESSION 37: I SPY WITH MY LITTLE EYE: MULTIMODAL IMAGING IN DURABLE MECHANICAL CIRCULATORY SUPPORT

Location: Rooms 603-605

Core Therapies: MCS, HEART
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Infectious Diseases, Nursing & Allied Health, Pediatrics, Research and Immunology

Session Summary: Left ventricular assist devices (LVADs) are an established treatment option for patients with end stage heart failure. However, the increased survival benefit and improved quality of life are still limited by adverse events. This session will describe the full spectrum of multimodality imaging for durable MCS, from preoperative implantation planning and postoperative management of complications to myocardial recovery and optimization of unloading strategies and thus clinical outcomes.

Co-Chairs: Linda Van Laake, MD, PhD, UMC Utrecht, Utrecht, Netherlands
Palak Shah, MD, MS, Inova Heart and Vascular Institute, Falls Church, VA USA

1:00 p.m. ***Three-Dimensional Virtual Anatomical Fitting of Implantable VADs for Improved Clinical Outcomes***
David Morales, MD, Cincinnati Children's Hospital, Cincinnati, OH USA

This talk will discuss 3D computed tomography (CT) reconstruction and virtual fit testing to assist MCS clinicians in selecting the best choice and fit for implanting VADs in adult and pediatric patients and to explore the lower limits of patient size for improved clinical outcomes.

1:15 p.m. ***Utility of Intra- and Post-operative Mapping Systems and Ablation of Ventricular Arrhythmia in LVAD Patients***
Simon Pecha, MD, University Heart and Vascular Center Hamburg, Hamburg, Germany

LVAD-associated complications have unique pathophysiology. This talk will discuss common adverse events such as pump thrombosis, outflow graft obstruction, driveline infection, and the associated CT and FDG PET/CT imaging features and the role of imaging in their early detection and management.

1:30 p.m. ***Role of Computed Tomography Imaging in Diagnosis and Management of LVAD Complications***
Gloria Faerber, MD, PhD, Uniklinikum Jena, Jena, Germany

LVAD-associated complications have unique pathophysiology. This talk will discuss common adverse events such as pump thrombosis, outflow graft obstruction, driveline infection, and the associated CT and FDG PET/CT imaging features and the role of imaging in their early detection and management.

1:45 p.m. ***Anatomic Landmarks and LVAD Malposition Using Chest X-rays and Implications for Adverse Events***
Thomas Schloeglhofer, MSc, Medical University of Vienna, Vienna, Austria

This presentation will review methods for evaluating preoperative anatomic landmarks and postoperative pump position from chest X-rays of LVAD patients in correlation to hemocompatibility related adverse events.

2:00 p.m. ***Echocardiographic Parameters for Device Optimization: A Path to Better MCS Outcomes and Recovery?***
Jerry Estep, MD, Cleveland Clinic, Cleveland, OH USA

This lecture will discuss how echocardiography-guided MCS optimization is associated with more favorable event-free survival and improved myocardial recovery. Novel aspects of 3D echocardiographic assessment of LV and RV volume, shape, and unloading will be presented.

2:15 p.m. ***Panel Discussion***

1:00 – 2:30 p.m.

SESSION 38: THE UNUSUAL SUSPECTS: IMMUNE AND TISSUE DRIVERS OF LUNG ALLOGRAFT PATHOLOGIES

Location: Rooms 401-404

Core Therapies: LUNG, HEART
Practice Areas: Research and Immunology, Cardiothoracic Surgery, Pediatrics, Pulmonology

Session Summary: Lung allograft injury occurs through a diverse array of mechanisms. This session will discuss atypical contributors to the cascade of injury that occurs during the lifetime of an allograft. These presentations and discussion will review recent insights into metabolic and airway changes linked to poor transplant outcomes and advances in strategies to promote solid organ survival.

Co-Chairs: Benjamin Renaud-Picard, MD, Nouvel Hopital Civil, Strasbourg, France
Christine Falk, PhD, Hannover Medical School, Hannover, Germany

1:00 p.m. ***Myeloid Cell Metabolism in Lung Transplantation***
Andrew Gelman, PhD, Washington University School of Medicine, St. Louis, MO USA

This talk will review the latest discoveries into the metabolic regulation of neutrophil effector responses and antigen presenting cell activation that promote ischemia reperfusion injury and alloimmune responses.

1:12 p.m. ***Q&A***

1:18 p.m. ***Innate Lymphoid Cells: Nice Neighbors or Unruly Residents After Lung Transplant?***
Daniel R. Calabrese, MD, University of California, San Francisco, San Francisco, CA USA

This talk will review the immunobiology of NK cells and innate lymphoid cells in the lung and their role in propagating tissue injury or inducing tolerance. This talk will include discussion about the impact of these cells in both PGD and AMR.

1:30 p.m. ***Q&A***

1:36 p.m. ***Lymphocytes and Lymphatics: Implications for Tolerance***
Wayne Hancock, MD, PhD, Children's Hospital of Pennsylvania, Philadelphia, PA USA

This talk will review present knowledge on the metabolic requirements for lymphatic development and regulatory CD4+ T cell-mediated immunosuppression with its implications for promoting transplant tolerance.

1:48 p.m. ***Q&A***

1:54 p.m. ***Endothelium and Barrier Dysfunction in Lung Allograft Injury***
Ciara Shaver, MD, PhD, Vanderbilt University Medical Center, Nashville, TN USA

This talk will review present knowledge on endothelial dysfunction in the lung allograft and how this promotes allograft pathology.

2:06 p.m. ***Q&A***

2:12 p.m. ***Epithelial Cell Reprogramming: How Lung Transplant Injury Impacts Epithelial Cells***
John Greenland, MD, PhD, University of California, San Francisco, San Francisco, CA USA

Primary graft dysfunction, acute cellular and humoral rejection, and chronic lung allograft dysfunction directly impact the epithelium, driving pathology through changes in epigenetics, cell metabolism, and cell phenotype.

2:24 p.m. ***Q&A***

THURSDAY, 20 APRIL, 2023

1:00 – 2:30 p.m.

SESSION 39: RIGHTING A WRONGED VENTRICLE

Location: Rooms 501-504

Core Therapies: PVD, HEART, LUNG, MCS
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing & Allied Health, Pulmonology

Session Summary: This session will focus on the diagnosis and management of acute RV failure in the ICU under various clinical settings.

Co-Chairs: Marc Simon, MD, MS, University of California San Francisco, San Francisco, CA USA
Alessandra Verzelloni Sef, MD, Harefield Hospital, Royal Brompton and Harefield Hospitals, London, United Kingdom

1:00 p.m. ***Pathophysiology of Acute RV Failure: Impact on End Organs?***
Christopher Barnett, MD, MPH, University of California, San Francisco, San Francisco, CA USA

This talk will review the mechanisms of acute RV failure in the ICU, with focus on the impact of acute RV failure on other organs (liver, kidneys, etc.).

1:15 p.m. ***Q&A***

1:18 p.m. ***Acute RV Failure in PAH: Diagnosis and Management Pearls***
John Granton, MD, University of Toronto, Toronto, ON Canada

This talk will focus on the hemodynamics, treatment including therapeutic targets and advanced therapies in PAH.

1:33 p.m. ***Q&A***

1:36 p.m. ***RV Failure Management in Hypoxic Lung Failure/Bridge to Lung Transplantation***
Michael Perch, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

This talk will address the management of PH and RV failure and hypoxemia caused by ILD in a critically ill patient.

1:51 p.m. ***Q&A***

1:54 p.m. ***Right Heart Failure in Left Heart Failure/Cardiogenic Shock***
Filio Billia, MD, PhD, University Health Network, Toronto, ON Canada

This talk will address the management of RV failure/biventricular failure in patients presenting with LV failure related cardiogenic shock.

2:09 p.m. ***Q&A***

2:12 p.m. ***Toolbox for Acute RV Failure***
Anna Meyer, MD, University Hospital Heidelberg, Heidelberg, Germany

This talk will focus on temporary mechanical circulatory support therapies in acute RV failure.

2:27 p.m. ***Q&A***

THURSDAY, 20 APRIL, 2023

1:00 – 2:30 p.m.

SESSION 40: EARLY CAREER AND TRAINEES CLINICAL CASE DILEMMAS: THE BEST OF THE BEST AWARD SESSION

Location: Rooms 205-207

Core Therapies: ALL
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pediatrics, Pulmonology, Research and Immunology

Session Summary: This award recognizes excellence by early career and trainees from top abstracts submitted in the Early Career Clinical Case Reports category. Four early career clinical case report finalists will present their work in this session. Expert senior clinicians will discuss the intricacies of these cases, applying clinical insights and wisdom to expand the learning experience for the viewing audience. At the conclusion of the session, the best case presentation will be selected by a panel of judges and the winner will be recognized during the Awards Presentations in the General Session (Plenary) on Saturday, 22 April.

Co-Chairs: Kevin Chan, MD, Michigan Medicine, Ann Arbor, MI USA
Lori West, MD, DPhil, University of Alberta, Edmonton, AB Canada

1:00 p.m. **(71)** ***CD 38 Antibody Daratumumab in Allosensitized Recipients for Cardiac Transplantation - A Case Series***; C. Atteneder[1], R. Moayedifar[1], D. Koren[2], G. Fischer[2], M. Nackenhorst[3], G. Böhmig[4], G. Laufer[1], A. Zuckermann[1]. *[1]Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, [2]Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria, [3]Department of Pathology, Medical University of Vienna, Vienna, Austria, [4]Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria*

1:07 p.m. ***Expert Discussant in Advanced Heart Failure and Transplantation***
Kevin Daly, MD, Boston Children's Hospital, Boston, MA USA

1:14 p.m. ***Discussion***

1:22 p.m. **(72)** ***A Case of Type A Aortic Dissection in a Patient with Heartmate 3***; A. Lloji[1], I. Zepeda[1], D. Y. Lu[1], N. Wan[1], R. Bhatt[1], M. Karas[1], E. Horn[2], Y. Naka[1], I. Sobol[3]. *[1]Weill Cornell Medical Center, New York, NY, [2]Weill Cornell Medical Ctr, New York, NY, [3]Weill Cornell Medicine-New York Presbyterian, New York, NY*

1:29 p.m. ***Expert Discussant in Mechanical Circulatory Support***
Gloria Faerber, MD, PhD, Uniklinikum Jena, Jena, Thuringen, Germany

1:36 p.m. ***Discussion***

1:44 p.m. **(73)** ***Successful Use of Right Ventricular Assist Device after Pulmonary Endarterectomy***; S. Burki[1], C. Lee[2], H. Kassis-George[1], A. Hadi[3], M. Kanwar[1]. *[1]Allegheny General Hospital, Pittsburgh, PA, [2].Allegheny General Hospital, Pittsburgh, PA, [3]Pittsburgh, PA*

1:51 p.m. ***Expert Discussant in Pulmonary Vascular Disease***
Isabelle Opitz, MD, Universitätsspital Zürich, Zurich, Switzerland

1:58 p.m. ***Discussion***

2:06 p.m. **(74)** ***Cytotoxic T-Lymphocyte Therapy for Post-transplant Lymphoproliferative Disease in an Adolescent Following Lung Transplantation***; R. Brugha[1], A. Menon[1], M. Sunther[1], J. Silva[2], P. Amrolia[2], P. Aurora[1], H. Spencer[1]. *[1]Cardiothoracic Transplantation, Great Ormond Street Hospital, London, United Kingdom, [2]Department of Bone Marrow Transplantation, Great Ormond Street Hospital, London, United Kingdom*

2:13 p.m. ***Expert Discussant in Advanced Lung Failure and Transplantation***
Sarah Nicholas, MD, Texas Children's Hospital, Houston, TX USA

2:20 p.m. ***Discussion***

THURSDAY, 20 APRIL, 2023

1:00 – 2:30 p.m.

SESSION 41: AS GOOD AS IT GETS: PATIENT CENTERED OUTCOMES IN LUNG TRANSPLANT

Location: Rooms 405-407

Core Therapies: LUNG
Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pediatrics, Pharmacy, Research and Immunology

Session Summary: This session focuses on a broad evaluation of important patient-oriented outcomes in lung transplant recipients.

Co-Chairs: Daniel Dilling, MD, Loyola University Chicago, Stritch School of Medicine, Maywood, IL USA
Meg Fregoso, MSN, NP-BC, Inova Fairfax Hospital, Falls Church, VA USA

1:00 p.m. **(75)** ***Pregnancy Outcomes in 42 Female Lung Transplant Recipients***; F. G. Lee[1], L. Coscia[2], S. Constantinescu[3], M. J. Moritz[4]. *[1]General Surgery, Mayo Clinic, Rochester, MN, [2]Transplant Pregnancy Registry International, Philadelphia, PA, [3]Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, [4]Surgery, Lehigh Valley Health Network, Allentown, PA*

1:15 p.m. **(76)** ***A Scandinavian Controlled Randomized Open-Label and Multi-Center Study Evaluating if Once-Daily Tacrolimus versus Twice-Daily Cyclosporine De Novo, Reduces the 3-Year Incidence of Chronic Lung Allograft Dysfunction after Lung Transplantation***; G. Dellgren[1], T. Lund[2], P. Raivio[3], I. Leuckfeld[4], J. Svahn[5], P. Olsen[6], R. Halme[7], A. Fiane[8], S. Lindstedt[9], G. Riise[10], J. Magnusson[10]. *[1]Cardiothoracic Surgery and Transplant Institute, Sahlgrenska University Hospital, Göteborg, Sweden, [2]Copenhagen, 84, Denmark, [3]Helsinki University Hospital, Helsinki, Finland, [4]Oslo Univ Hosp, Oslo, 3, Norway, [5]Skåne University Hospital, Genarp, M, Sweden, [6]Rigshospitalet, København Ø, 84, Denmark, [7]Helsinki U Central Hosp, Helsinki, 18, Finland, [8]Rikshospitalet, Oslo, 3, Norway, [9]Wallenberg Centre for Molecular Medicine, Lund University, Lund, M, Sweden, [10]Sahlgrenska University Hospital, Gothenburg, Sweden*

1:30 p.m. **(77)** ***Defining the Temporal Relationship Between Peak Lung Function and Quality of Life Trajectories after Lung Transplantation in a Large Multi-Center Cohort***; W. M. Tsuang[1], M. L. Neely[2], S. M. Palmer[2], L. G. Singer[3], M. Budev[1], P. Shah[4], J. A. Belperio[5], J. M. Reynolds[2], L. D. Snyder[2]. *[1]Cleveland Clinic, Cleveland, OH, [2]Duke University, Durham, NC, [3]University of Toronto, Toronto, ON, Canada, [4]Johns Hopkins University, Baltimore, MD, [5]UCLA Pulmonary & C C Med, Los Angeles, CA*

1:45 p.m. **(78)** ***Indication and Long-Term Outcome of Pediatric Lung Transplantation in Japan; A Multicenter, Retrospective Study***; Y. Morimura[1], S. Tanaka[1], K. Matsubara[2], S. Tanaka[2], T. Kanou[3], Y. Yamada[1], Y. Yutaka[1], A. Ohsumi[1], D. Nakajima[1], M. Hamaji[1], Y. Shintani[3], S. Sugimoto[2], S. Toyooka[2], H. Date[1]. *[1]Thoracic Surgery, Kyoto University, Kyoto, Japan, [2]Thoracic Surgery, Okayama University, Okayama, Japan, [3]Thoracic Surgery, Osaka University, Suita, Japan*

2:00 p.m. **(79)** ***Towards a Patient-Centered Definition of Baseline Lung Allograft Dysfunction: A Multicenter Cohort Study***; L. G. Singer[1], M. Neely[2], W. Tsuang[3], M. Budev[4], P. Shah[5], J. Belperio[6], J. Reynolds[7], S. Palmer[2], L. Snyder[2]. *[1]University Health Network, Toronto, ON, Canada, [2]Duke University, Durham, NC, [3]Cleveland Cinic, Beachwood, OH, [4]Cleveland Clinic, Pepper Pike, OH, [5]Johns Hopkins University, Rockville, MD, [6]UCLA Pulmonary & C C Med, Los Angeles, CA, [7]Duke University, Chapel Hill, NC*

2:15 p.m. **(80)** ***Lung Transplantation Outcomes in Patients from Socioeconomically Distressed Communities***; J. Malas, Q. Chen, D. Emerson, J. Chikwe, P. Catarino, D. Megna, M. Bowdish. *Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA*

1:00 – 2:30 p.m.

SESSION 42: CURRENT CHALLENGES IN PEDIATRIC HEART TRANSPLANT SELECTION AND OUTCOMES

Location: Rooms 201-203

Core Therapies: HEART
Practice Areas: Pediatrics, Cardiology, Cardiothoracic Surgery, Research and Immunology

Session Summary: This session will review state-of-the-art science regarding selection of candidates for pediatric heart transplant and heart-kidney transplant. Studies will examine risk factors relating to VAD, congenital heart disease, obesity, and anti-HLA sensitization.

Co-Chairs: Estela Azeka, MD, University of Sao Paulo, São Paulo, SP, Brazil
Simon Urschel, MD, University of Alberta, Edmonton, AB Canada

1:00 p.m. **(81)** ***Obesity Should No Longer Be a Contraindication to Pediatric Heart Transplantation***; J. T. Kennedy[1], J. W. Greenberg[2], C. J. Glenn[3], K. Kulshrestha[2], A. Guzman-Gomez[2], C. Chin[2], F. Zafar[2], D. L. Morales[2]. *[1]Division of Cardiothoracic Surgery, University of Cincinnati Medical Center, Cincinnati, OH, [2]Cincinnati Children's Hospital MC, Cincinnati, OH, [3]University of Cincinnati College of Medicine, Cincinnati, OH*

1:15 p.m. **(82)** ***Outcomes of Heart Transplantation in Children with Previously Palliated Hypoplastic Left Heart Syndrome***; B. Alsoufi[1], J. Sizemore[1], S. Wilkens[2], J. Furlong-Dillard[1], D. Kozik[3], A. Lambert[4], J. Trivedi[5]. *[1]University of Louisville and Norton Children's Hospital, Louisville, KY, [2]University of Louisville, Norton Children's Hospital, Louisville, KY, [3]Univ of Louisville, Louisville, KY, [4]tbd, Nashville, TN, [5]Univ of Louisville, Louisville, KY*

1:30 p.m. **(83)** ***Donor Heart Preservation Strategy Using a Cold Storage System for Pediatric Heart Transplantation***; C. Buyukgoz[1], M. Absi[2], H. R. Martinez[3], T. Street[4], R. Siddique[5], U. Boston[4]. *[1]Pediatric Cardiology, University of Tennessee Health Science Center, Memphis, TN, [2]University of Tennessee Health Science Center, Germantown, TN, [3]University of Tennessee Health Science Center, Memphis, TN, [4]Le Bonheur Children's Hosp, Memphis, TN, [5]Le Bonheur Children's Hospital, Memphis, TN*

1:45 p.m. **(84)** ***Combined Heart Kidney Transplant: Risk Factors and Outcomes***; S. Choudhry[1], H. Tunuguntla[2], K. Puri[3], Y. Wang[2], K. Hope[4], J. Spinner[3], S. Denfield[3], J. Price[2], W. Dreyer[5]. *[1]Texas Children's Hospital, Baylor College of Medicine, Houston, TX, [2]Texas Children's Hospital, Houston, TX, [3]Baylor College of Medicine, Houston, TX, [4]Texas Children's Hospital, Baylor College of Medicine, Houston, TX, [5]Baylor College of Med, Houston, TX*

2:00 p.m. **(85)** ***DQ Matching in Pediatric Heart Transplantation***; L. K. Wright[1], R. Gajarski[2], E. Hayes[3], J. Yester[1], D. Nandi[1]. *[1]Nationwide Children's Hospital, Columbus, OH, [2]Nationwide Children 's Hospital, Columbus, OH, [3]Nationwide Children's Hospital, Bexley, OH*

2:15 p.m. **(86)** ***Impact of Anti-HLA Antibody Desensitization Strategies in Pediatric Heart Transplant Recipients: A PHTS-PHIS Linkage Analysis***; D. Nandi[1], R. Gajarski[1], H. Zhao[2], K. Tully[1], R. Cantor[2], B. Birnbaum[3], S. Zangwill[4], R. Khan[5], J. Godown[6], J. Kirklin[7], J. Friedland-Little[8]. *[1]Nationwide Children's Hospital, Columbus, OH, [2]University of Alabama at Birmingham (UAB), Birmingham, AL, [3]Children 's Mercy Hospital, Kansas City, MO, [4]Phoenix Children's Hospital, Phoenix, AZ, [5]University of Iowa Stead Family Children's Hospital, Iowa City, IA, [6]Vanderbilt University, Brentwood, [7]University of Alabama Birmingham, Birmingham, AL, [8]Seattle Children's Hospital, Seattle, WA*

THURSDAY, 20 APRIL, 2023

3:00 – 4:00 p.m.

SESSION 43: WOULD YOU RATHER: CHOICES AT THE END OF THE SHOCK ROAD

Location: Rooms 603-605

Core Therapies: MCS, HEART
Practice Areas: Cardiology, Cardiothoracic Surgery

Session Summary: This session will demonstrate a cardiogenic shock case that highlights the decision-making required in these critically sick patients - from accurate prognostication to promotion of cardiac recovery promotion versus urgent need for heart transplant or left ventricular assist device.

Game Show Format: This symposium will begin with one of the Co-Chairs presenting Case Scenarios of a potential recipient and a potential donor. Then four 'contestants' (speakers) will each have 8 minutes to explain their position on whether or not the donor (or Case Scenario) is acceptable. A 20-minute audience Q&A segment led by the Co-Chairs will conclude with an audience vote for the winning speaker.

Donor Case Scenario: Donor is a 48 year old male donor who died of a cocaine overdose and a brief cardiac arrest. Virtual crossmatch is compatible. Angio unobtainable.

Recipient Case Scenario: A previously healthy woman presents with cardiogenic shock and biventricular failure after her 5th pregnancy. She improves with temp MCS but is unable to be weaned.

Co-Chairs:
Matthew Lander, MD, Allegheny Health Network, Pittsburgh, PA USA
David McGiffin, MBBS, FRACS, Alfred Health, Melbourne, VIC Australia
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX USA

3:00 p.m. ***Introductory Case Presentation***
David McGiffin, MBBS, FRACS, Alfred Health, Melbourne, VIC Australia

3:05 p.m. ***Transplant Her!***
Christopher Hayward, MD, St. Vincent's Hospital, Sydney, NSW Australia

This contestant will discuss how transplanting her is the best path forward.

3:13 p.m. ***Durable LVAD and Temporary RVAD Wean!***
Anna Meyer, MD, University of Heidelberg, Heidelberg, Germany

This contestant will discuss how placing a durable LVAD and weaning a temporary RVAD is the best path forward.

3:21 p.m. ***Keep the Heart and Put Bivads Now!***
Christopher Salerno, MD, University of Chicago, Chicago, IL USA

This contestant will discuss how keeping the heart and adding biventricular support is the best path forward.

3:29 p.m. ***Remove the Heart and Move On Mechanically!***
Francisco Arabia, MD, MBA, Banner University Medical Center, Phoenix, AZ USA

This contestant will discuss how removing the heart and adding biventricular support is the best path forward.

3:37 p.m. ***Panel Discussion and Audience Vote***

3:00 – 4:00 p.m.

SESSION 44: MOUNTAIN FOR EVERY MIRACLE! FIELD OF CARDIO-ONCOLOGY: THE HIGH-YIELD TIPS

Location: Four Seasons Ballroom

Core Therapies: HEART, MCS
Practice Areas: Cardiology, Nursing & Allied Health, Pathology, Pharmacy and Pharmacology, Research and Immunology

Session Summary: In recent years, cardio-oncology has emerged as a highly relevant topic in the HF community. With rising cancer survival rates, the use of durable LVADs and HTx are now considered for increasing numbers of cancer survivors. This session will provide high yield cardio-oncology tips to HF providers, focusing on key considerations for patients with advanced HF and a history of cancer, surveillance and management of cancer or PTLD after HTx, and the emerging role of immunotherapy after heart transplantation.

Co-Chairs: Maria Generosa Crespo-Leiro, MD, Hospital Universitario A Coruña, La Coruña, Spain
Richard Cheng, MD, MSc, University of Washington Medical Center, Seattle, WA USA

3:00 p.m. ***Broken Hearts – LVAD or Heart Transplant in Patients With Recent Cancer: Who and When?***
Bhavadharini Ramu, MD, Medical University of South Carolina, Charleston, SC USA

Discuss considerations for patients with prior or active cancer before AHFT. (1) Review the epidemiology of advanced HF in patients with prior or active cancer. (2) For which patients with history of cancer is LVAD an option? (3) Managing risks of bleeding, thrombosis and infection (4) Review of the data on HTx in patients with history of cancer.

3:15 p.m. ***Double Jeopardy: Managing Risk in Heart Transplant and MCS Patients With a History of Malignancy***
Yael Peled, MD, Sheba Medical Center, Tel Aviv, Israel

There are two major considerations for this talk: (1) Management of the patient with a history of cancer after HTx or LVAD and (2) Risk for de novo cancer in a heart transplant patient on chronic immunosuppression and reduced immunosurveillance.

3:25 p.m. ***DEBATE: New Kids on the Block! Immunotherapy Can Be Employed in Heart Transplant Recipients With Cancer (PRO)***
Daniel Zlotoff, MD, PhD, Massachusetts General Hospital, Boston, MA USA

Pro perspective for using immunotherapies in HTx recipients; the oncologic benefits exceed the cardiac risks. If using immunotherapy, how do we balance risk for rejection with treating the cancer? Also, is there a role for increased surveillance (e.g. echo or cfDNA)?

3:35 p.m. ***DEBATE: New Kids on the Block! Immunotherapy Can Be Employed in Heart Transplant Recipients With Cancer (CON)***
Maria Generosa Crespo-Leiro, MD, Hospital Universitario A Coruña, La Coruña, Spain

Con perspective arguing against immunotherapy use in HTx patients; cardiac risks outweigh potential oncologic benefits. Even with monitoring, identification of acute rejection may be too late. Too little is known about ICI use in HTx and their use in this group should be limited to clinical trials.

3:45 p.m. ***Panel Discussion***

3:00 – 4:00 p.m.

SESSION 45: PTLD AFTER THORACIC ORGAN TRANSPLANTATION: NEW CONSIDERATIONS AND NOVEL THERAPIES

Location: Rooms 401-404

Core Therapies: LUNG, HEART
Practice Areas: Pulmonology, Cardiology, Pathology, Pharmacy and Pharmacology

Session Summary: As survival after thoracic transplantation has improved, transplant recipients are more frequently developing malignancies, including post-transplant lymphoproliferative disorder (PTLD). During the session, we will review how immunosuppression changes immune surveillance for malignancy and provide updated knowledge of PTLD incidence, risk factors, pathogenesis, pathological classification, and diagnostic biomarkers, and novel therapeutic approaches for management of PTLD.

Co-Chairs: Nandini Nair, MD, PhD, Texas Tech University Health Sciences, Lubbock, TX USA
Heather Strah, MD, University of Nebraska Medical Center, Omaha, NE USA

3:00 p.m. ***Impaired Immunosurveillance in Post-Transplant Malignancies***
Lorenzo Zaffiri, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA USA

This talk will summarize the mechanisms contributing to failure of immune surveillance and development of post-transplant malignancies.

3:15 p.m. ***Q&A***

3:20 p.m. ***Pathological Classification of PTLD and Risk Factors for Disease***
Francesca Lunardi, MD, ScD, PhD, University of Padova, Padova, Italy

This talk will discuss the pathogenesis, pathology, and emerging biomarkers of PTLD as well as risk factors for PTLD in both adult and pediatric lung transplant recipients.

3:35 p.m. ***Q&A***

3:40 p.m. ***Novel Therapeutic Strategies for Management of PTLD***
Carlo Iasella, PharmD, MPH, University of Pittsburgh, Pittsburgh, PA USA

This talk will review the current therapeutic approaches for the management of PTLD as well as discuss the use of novel off-the-shelf virus-specific T cells for PTLD.

3:55 p.m. ***Q&A***

3:00 – 4:00 p.m.

SESSION 46: SUSPICIOUS MINDS: IMMUNIZATIONS IN THE PRE- AND POST-TRANSPLANT PERIOD

Location: Rooms 501-504

Core Therapies: HEART, LUNG
Practice Areas: Pediatrics, Infectious Diseases, Pharmacy and Pharmacology

Session Summary: This session will discuss the controversy/science surrounding immunizations in pediatric patients pre- and post-transplant. Specific topics include: COVID-19 immunization/booster requirements for pediatric patients/caregivers, live-attenuated immunizations, mitigating negative press/social media, and the ethics of refusing to list patients who refuse vaccines.

Co-Chairs: Amy Kiskaddon, PharmD, Johns Hopkins All Children's Hospital, St. Petersburg, FL USA
Karen Doucette, MD, MSc, University of Alberta, Edmonton, AB Canada

3:00 p.m. ***Bridge Over Troubled Water: Challenges and Ethics of Immunizations in Pediatric Patients***
Olivia Kates, MD, MA, Johns Hopkins University, Baltimore, MD USA

Accurately conveying scientific evidence about vaccine adverse events concerns raised by patients/caregivers, ethics of refusing to list patients who refuse vaccines, how to mitigate/manage negative news press/social media regarding immunization requirements for transplant patients.

3:15 p.m. ***If I Can Dream: Live-Attenuated Immunizations?***
Anne Dipchand, MD, The Hospital for Sick Children, Toronto, ON Canada

Discussion regarding live-attenuated immunizations in pediatric heart and lung transplant recipients. While historically, such vaccines have been avoided in solid organ transplant recipients, there is interest whether the benefits of certain live-attenuated immunization outweigh risks.

3:30 p.m. ***A COVID-19 Immunization Trilogy: Requirements for Pediatric Transplant Recipients and Caregivers***
Joseph Spinner, MD, Baylor College of Medicine, Houston, TX USA

Discussion of most up-to-date evidence for COVID-19 immunization/booster requirements in patients/caregivers of heart/lung pediatric transplant recipients, knowing as facts change, the degree of benefit gained and infringement on access to transplant/caregiver choice that is tolerated will change

3:45 p.m. ***Panel Discussion***

THURSDAY, 20 APRIL, 2023

3:00 – 4:00 p.m.

SESSION 47: PREDICTING THE FUTURE: IMPACT OF VARIOUS FACTORS ON OUTCOMES AFTER HEART TRANSPLANTATION

Location: Rooms 205-207

Core Therapies: HEART
Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing and Allied Health

Session Summary: This session will include research related to various pre-transplant factors and impact on outcomes after heart transplant.

Co-Chairs: Kari Mohney, BSN, RN, Allegheny Health Network, Pittsburgh, PA USA
Keziban Uyanik-Uenal, MD, Medical University of Vienna, Vienna, Austria

3:00 p.m. **(87)** ***A Less Restrictive Approach to Procuring Organs is Not an Indicator of Prognostic Survival in Heart Transplantation: A Retrospective Analysis of 118 Adult Heart Transplant Centers from 2020 to 2022***; S. Bangaru[1], S. Uppalapati[2], S. Palluri[3], K. Ram[4], K. Sudheendra[5], S. Jain[6], K. Johnson[1], D. Hynes[7], A. Madhushankar[8], J. Grinstein[9], S. Pinney[10], D. Onsager[11], D. Rodgers[10], V. Jeevanandam[12]. *[1]Illinois Mathematics and Science Academy, Aurora, IL, [23]Chicago College of Osteopathic Medicine, Midwestern University, Chicago, IL, [4]University of Michigan, Ann Arbor, MI, [5]Hinsdale Central High School, Hinsdale, IL, [6]Univeristy of Chicago, Chicago, IL, [7]Hamilton College, Clinton, NY, [8]Adlai E. Stevenson High School, Lincolnshire, IL, [9]MedStar Heart and Vascular Institute, Chicago, IL, [10]University of Chicago, Chicago, IL, [11]University of Chicago, Libertyville, IL, [12]University of Chicago Medical Center, Chicago, IL*

3:15 p.m. **(88)** ***A Comparison of Quality-Adjusted Life Years in Older Adults after Heart Transplantation Versus Long-Term Mechanical Support: Findings from SUSTAIN-IT***; K. L. Grady[1], T. Wu[1], A. Kao[2], J. Spertus[3], E. Hsich[4], M. Dew[5], C. Yancy[6], D. Pham[1], J. Hartupee[7], M. Petty[8], W. Cotts[9], S. V. Pamboukian[10], F. Pagani[11], B. Lampert[12], M. Johnson[13], M. Murray[14], M. Yuzefpolskaya[15], K. Takeda[16], S. Silvestry[17], J. Kirklin[10], A. Andrei[1]. *[1]Northwestern University, Chicago, IL, [2]St. Luke's Cardiovascular Consultants, Inc., Kansas City, MO, [3]University of Missouri - Kansas City, Kansas City, MO, [4]Cleveland Clinic Foundation, Cleveland, OH, [5]University of Pittsburgh School of Medicine, Pittsburgh, PA, [6]Northwestern University Feinberg School of Medicine, Chicago, IL, [7]Washington University, St. Louis, MO, [8]M Health Fairview, University of Minnesota Medical Center, Richfield, MN, [9]Advocate Christ Medical Center, Oak Lawn, IL, [10]University of Alabama Birmingham, Birmingham, AL, [11]University of Michigan, Ann Arbor, MI, [12]Ohio State University Wexner Medical Center, Columbus, OH, [13]University of Wisconsin, Madison, WI, [14]University of Wisconsin Hospital and Clinics, Madison, WI, [15]Columbia University Medical Center, New York, NY, [16]Columbia University, New York, NY, [17]AdventHealth Transplant Institute, Orlando, FL*

3:30 p.m. **(89)** ***Heart Transplant Outcomes in Restrictive Cardiomyopathy: UNOS Registry Analysis***; D. J. Miklin[1], E. DePasquale[2]. *[1]Northwell Health, Manhasset, NY, [2]University of Southern California, Los Angeles, CA*

3:45 p.m. **(90)** ***Outcomes of Heart Transplant for Valve Disease***; E. L. Larson[1], J. Ruck[2], A. Zhou[1], B. Shou[3], A. Kilic[4]. *[1]Johns Hopkins University School of Medicine, Baltimore, MD, [2]Johns Hopkins Hospital, Baltimore, MD, [3]Johns Hopkins University School of Medicine, Houston, TX, [4]The Johns Hopkins University, Baltimore, MD*

3:00 – 4:00 p.m.

SESSION 48: SEX, RACE AND SOCIAL DETERMINANTS OF HEALTH IN MCS CARE

Location: Rooms 405-407

Core Therapies: MCS
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pediatrics

Session Summary: This session will feature important research examining the associations of sex, race, and social determinants of health on adult and pediatric MCS outcomes and care.

Co-Chairs: Shahnawaz Amdani, MD, Cleveland Clinic, Cleveland, OH USA
Sarah Schettle, PA-C, MS, MBA, Mayo Clinic, Rochester, MN USA

3:00 p.m. **(91)** ***Sex Disparities in the Use of Temporary Mechanical Circulatory Support for Nonischemic-Cardiogenic Shock***; A. Bhardwaj[1], I. Rajapreyar[2], S. Kumar[3], A. Nair[4], Y. Brailovsky[5], P. Pirlamarla[6], D. Baran[7]. *[1]Advanced Heart Failure, University of Texas/McGovern Medical School, Houston, Texas, Houston, TX, [2]Thomas Jefferson University Hospital, Philadelphia, PA, [3]University of Texas Health Science Center, Houston, TX, [4]Houston, TX, [5]Lafayette Hill, PA, [6]Mount Sinai, Philadelphia, PA, [7]Cleveland Clinic Heart, Vascular and Thoracic Institute, Parkland, FL*

3:15 p.m. **(92)** ***Greater Burden of Biventricular Dysfunction in Female Recipients of Continuous-Flow Left Ventricular Devices***; H. Lamba[1], R. Kherallah[2], M. Kassi[3], R. Delgado[2], A. Mattar[2], A. Nair[4], S. Chatterjee[2], A. Shafii[5], G. Loor[5], J. Rogers[6], A. Civitello[7], K. Liao[5]. *[1]Baylor College of Med, Houston, TX, [2]BCM, Houston, TX, [3]Houston Methodist Hospital, Houston, TX, [4]Houston, TX, [5]Baylor College of Medicine, Houston, TX, [6]Texas Heart Institute, Durham, NC, [7]Texas Heart Institute, Houston, TX*

3:30 p.m. **(93)** ***Race and Incidence of Right Heart Failure after Left Ventricular Assist Device Implantation***; A. Bahl, B. Qureshi, C. Bravo, C. Mahr, S. Li. *University of Washington, Seattle, WA*

3:45 p.m. **(94)** ***Social Determinants of Heath and Outcomes after Pediatric Ventricular Assist Device Implantation***; C. West[1], H. Zhao[2], R. Cantor[2], V. Sood[1], A. Lal[3], C. Beaty[4], J. Kirklin[2], D. Peng[1]. *[1]University of Michigan, Ann Arbor, MI, [2]University of Alabama at Birmingham, Birmingham, AL, [3]University of Utah, Salt Lake City, UT, [4]Nemours Children's Health, Baltimore, MD*

THURSDAY, 20 APRIL, 2023

3:00 – 4:00 p.m.

SESSION 49: DAYS OF OUR LIVES: LUNG DONOR-RECIPIENT ALLOCATION AND OUTCOMES

Location: Rooms 201-203

Core Therapies: LUNG
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Nursing and Allied Health, Pulmonology

Session Summary: This session will provide an update on diverse topics within donor-recipient allocation science and related outcomes.

Co-Chairs: John Dark, MB, FRCS, Newcastle University, Newcastle upon Tyne, United Kingdom
Sofya Tokman, MD, Norton Thoracic Institute, Phoenix, AZ USA

3:00 p.m. **(95)** ***Lung Transplantation from HCV NAT+ Donors: Reassuring Mid-Term Outcomes***; S. T. Kim[1], Y. Xia[1], J. K. Ho[1], E. Lowery[2], M. DeCamp[2], D. McCarthy[2], A. Ardehali[1]. *[1]University of California, Los Angeles, Los Angeles, CA, [2]University of Wisconsin - Madison, Madison, WI*

3:15 p.m. **(96)** ***Impact of Donor Age on Survival of Lung Transplant Recipients According to Their Primary Diagnosis***; A. A. Tantawi, Y. Itoda, K. Ayyat, T. Okamoto, L. Thuita, I. Sakanoue, H. Elgharably, J. Yun, K. McCurry. *Cleveland Clinic, Cleveland, OH*

3:30 p.m. **(97)** ***International Multicenter Extracorporeal Life Support in Lung Transplantation Registry. Impact of Cold Ischemic Time on Primary Graft Dysfunction and One-Year Mortality***; M. Villavicencio[1], A. Kashem[2], G. Loor[3], E. D'Silva[3], M. Hartwig[4], K. Ghadimi[5], F. Ius[6], S. Jawad[6], N. Langer[7], A. Osho[7], S. Chandrashekaran[8], T. Machuca[9], P. Sanchez[10], K. Subramaniam[11], D. Van Raemdonck[12], A. Neyrinck[13], S. Huddleston[14], A. Shaffer[15], B. Lahr[16], Y. Toyoda[17]. *[1]Cardiovascular Surgery, Mayo Clinic, Rochester, MN, [2]Temple University School of Med, Philadelphia, PA, [3]Baylor College of Medicine, Houston, TX, [4]Duke University Medical Center, Durham, NC, [5]Duke Unversity, Raleigh, NC, [6]Hannover Medical School, Hannover, Germany, [7]Massachusetts General Hospital, Boston, MA, [8]Emory University Hospital, Atlanta, GA, [9]University of Miami, Miami, FL, [10]University of Pittsburgh Medical Center, Pittsburgh, PA, [11]Univ of Pittsburgh Med Ctr Presbyterian Hospital, Sewickley, PA, [12]University Hospitals Leuven, Leuven, Belgium, [13]Leuven University Hospitals, Leuven, Belgium, [14]University of Minnesota, Minneapolis, MN, [15]Univ of Minnesota, Minneapolis, MN, [16]Mayo Clinic, Rochester, MN, [17]Temple Univ Sch of Med, Philadelphia, PA*

3:45 p.m. **(98)** ***The UK Lung Risk Index (UKLRI); An Objective Prognostic Score Based on Donor and Recipient Factors to Aid Decision Making in Lung Utilisation***; G. Hardman[1], S. Rushton[1], R. Hogg[1], K. Booth[2], J. H. Dark[3], A. J. Fisher[3]. *[1]NHS Blood and Transplant, Bristol, United Kingdom, [2]Freeman Hospital, Newcastle Upon Tyne, United Kingdom, [3]Newcastle University, Newcastle Upon Tyne, United Kingdom*

4:15 – 5:15 p.m.

MINI ORAL 07: WASTE NOT WANT NOT: PUSHING THE BOUNDARIES IN DONOR HEART SELECTION!

Location: Rooms 603-605

Core Therapies: HEART
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Pathology, Research and Immunology

Session Summary: What is the optimal heart for transplant and how can achieve the best outcome for cardiac transplant recipients? This rapid fire session will cover the broad spectrum of donor hearts, from histopathological analysis of preservation technique, to donor myocardial hypertrophy, age mismatching, primary graft dysfunction and post-transplant survival. This session brings it all together: the centerpiece, of course, is the donor heart.

Co-Chairs: Pascal Leprince, MD, PhD, Hopital de La Pitie Salpetriere, Sorbonne University, Paris, France
Kavitha Muthiah, MBChB, PhD, St. Vincent's Hospital, Paddington, NSW Australia

4:15 p.m. **(301)** ***Donor Cardiopulmonary Resuscitation (CPR) and Donation after Circulatory Death Heart Transplantations (HT)***; S. Madan[1], S. Patel[2], O. Saeed[3], D. Sims[4], Y. Rochlani[5], S. Vukelic[6], S. Forest[7], J. Shin[7], D. Goldstein[8], U. Jorde[7]. *[1]Montefiore Medical Center, NYC, NY, [2]Montefiore-Einstein, Bronx, NY, [3]Montefiore Medical Ctr, New York, NY, [4]Montefiore Medical Center NY, New York, NY, [5]Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, [6]Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, [7]Montefiore Medical Center, Bronx, NY, [8]Montefiore, Bronx, NY*

4:21 p.m. **(302)** ***Left Ventricular Hypertrophy and Reduced Ejection Fraction in Donor Hearts - Contraindications to Transplantation***; M. R. Dean[1], F. Del Valle Díaz[2], C. Lemoine[3], L. Copeland[4], J. Silverman[5], T. Raines[6], C. Sai-Sudhakar[7], Y. Ravi[7], R. Zoni[7]. *[1]Internal Medicine Residency, Virginia Commonwealth University Health System, Richmond, VA, [2]University of Puerto Rico School of Medicine, San Juan, Puerto Rico, [34]Department of Population Health and Quantitative Health, University of Massachusetts Medical School, Worcester, MA, [5]University of Connecticut School of Medicine, Farmington, CT, [6]University of Tennessee Health Science Center, Memphis, TN, [7]Department of Cardiothoracic Surgery, University of Connecticut Health Center, Farmington, CT*

4:27 p.m. **(303)** ***In-Situ Recovery of the Dcd Donor Heart Shows Equivalent Survival to Conventional Donor Hearts***; J. O. Louca[1], M. Öchsner[1], A. Shah[2], J. Hoffman[3], G. Vilchez-F[4], I. Garrido[5], M. Royo-Villanova[5], B. Domínguez-Gil[6], D. Smith[7], L. James[8], N. Moazami[9], F. Rega[10], J. Brouckaert[10], J. Van Cleemput[11], V. Tchana-Sato[12], M. Urban[13], A. Manara[14], M. Berman[1], S. Messer[15], S. Large[16], W. Group[17]. *[1]Royal Papworth Hospital, Cambridge, UK, [2]Vanderbilt Univ MC, Nashville, TN, [3]Univ of Colorado School of Medicine, Denver, CO, [4]Spanish Registry on Heart Transplantation, Madrid, Spain, [5]Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, [6]Organización Nacional de Trasplantes, Madrid, Spain, [7]NYU Langone Health, Bronxville, NY, [8]NYU, Langone Health, New York CIty, NY, [9]NYU Langone Health, New York, NY, [10]University Hospitals Leuven, Leuven, Belgium, [11]UZ Leuven, 3000 Leuven, Belgium, [12]Dept of Cardiovascular Surgery, CHU Liege, Liege, Belgium, [13]UNMC, Omaha, NE, [14]The Intensive Care Unit, Southmead Hospital, Bristol, UK, [15]Golden Jubilee Hospital Agamermnon Street, Glasgow, UK, [16]Papworth Hospital, Cambridge, UK, [17]Various, UK*

4:33 p.m. **(304)** ***Graft Preservation in Heart Transplantation: Clinical and Histological Results Using Three Different Techniques***; A. Lechiancole[1], S. Sponga[1], I. Vendramin[1], V. Ferrara[2], G. Benedetti[1], G. Guzzi[1], C. Nalli[1], C. Di Nora[1], R. M. Calandruccio[1], Y. Brindicci[1], M. Bressan[1], U. Livi[1]. *[1]Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy, [2]University of Udine, Udine, UD, Italy*

4:39 p.m. **(305)** ***Characteristics and Outcomes Among Recipients of Dcd Versus Dbd Heart Transplantation - The Vanderbilt Experience***; H. Siddiqi, A. DeBose-Scarlett, J. Trahanas, C. Pasrija, K. Amancherla, D. Brinkley, J. Lindenfeld, J. Menachem, H. Ooi, D. Pedrotty, L. Punnoose, A. Rali, S. Sacks, M. Wigger, S. Zalawadiya, W. McMaster, A. Shah, K. Schlendorf. *Vanderbilt University Medical Center, Nashville, TN*

4:45 p.m. **(306)** ***Regardless of Donor Cardiac Function, When Other Organs are Not Utilized, Decreased Post-Heart Transplant Survival Can Be Expected***; J. W. Greenberg[1], K. Kulshrestha[1], J. T. Kennedy[2], M. V. Desai[1], D. S. Winlaw[1], D. G. Lehenbauer[1], T. D. Ryan[1], F. Zafar[1], D. L. Morales[1]. *[1]The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [2]University of Cincinnati Medical Center, Cincinnati, OH*

4:51 p.m. **(307)** ***Preserved Post-Transplant Survival in Patients Receiving Hard to Place Organs (HTPO): A Unos Database Analysis***; E. Purohit[1], M. Jani[2], M. Dickinson[2], M. Gonzalez[2], D. Fermin[2], R. Grayburn[2], R. Loyaga-Rendon[2], M. Leacche[3], P. Tremblay[3], S. Lee[2], N. Manandhar-Shrestha[2]. *[1]Cardiovascular Disease, Spectrum Health/Michigan State University, Grand Rapids, MI, [2]Spectrum Health, Grand Rapids, MI, [3]Cardiothoracic Surgery, Spectrum Health, Grand Rapids, MI*

4:57 p.m. **(308)** ***A Very 37-Year Heart Transplantation Single-Center Experience: The Impact of Donor-Recipient Age Mismatch on Long-Term Outcomes***; N. Pradegan[1], G. Evangelista[1], C. Tessari[1], A. Fabozzo[1], G. Guerra[1], G. Ciccarelli[1], M. Gallo[2], G. Toscano[1], A. Angelini[3], G. Gerosa[1]. *[1]University of Padova, Padova, Italy, [2]UofL Health, Louisville, KY, [3]University of Padua, Padova, Italy*

5:03 p.m. **(309)** ***Risk Factors for Primary Graft Dysfunction after Heart Transplantation - A Systematic Review and Meta-Analysis***; M. Vervoorn, S. Kaffka Genaamd Dengler, J. Kernkamp, E. Ballan, M. Mishra, N. van der Kaaij. *UMC Utrecht, Utrecht, Netherlands*

5:09 p.m. **(310)** ***Impact of Professional Organ Procurement Organizations and Statewide Collaboration on Expanding Organ Donor Registry and Organ Transplantation in California***; K. Gianaris, L. Czer, P. Catarino, F. Esmailian, D. Megna, D. Emerson, W. Cheng, J. Kobashigawa, A. Trento. *Cedars-Sinai Heart Institute, Los Angeles, CA*

4:15 – 5:15 p.m.

MINI ORAL 08: A NEW HOPE: LUNG TRANSPLANT CANDIDATE SELECTION

Location: Rooms 401-404

Core Therapies: LUNG
Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Pathology, Research and Immunology

Session Summary: This rapid fire session provides insight into clinical, biological, and radiographic risk factors for adverse outcomes in lung transplant recipients.

Co-Chairs: Bronwyn Levvey, RN, BEd Stu, Grad Dip Clin Epi, The Alfred Hospital, Melbourne, VIC Australia
Julia Maheshwari, MD, University of California, San Francisco, CA USA

4:15 p.m. **(311)** ***Lung Transplant in Patients with Suspicious Lung Nodules: A Single-Center Retrospective Data Analysis***; M. Begic[1], S. Schwarz[1], P. Boehm[1], A. Benazzo[1], Z. Kovac[1], G. Murakoezy[1], P. Jaksch[2], K. Hoetzenecker[1]. *[1]Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria, [2]Department of Thoracic Surgery, Medical University Vienna, Austria, Vienna, Austria*

4:21 p.m. **(312)** ***Risk Stratifying by DQA and Risk Epitope Mismatches in Lung Transplantation***; A. Valverde Zuñiga[1], J. Kiernan[2], T. Martinu[3], L. Singer[4], R. Ghany[2], J. Yeung[2], M. Cypel[4], S. Keshavjee[5], K. Tinckam[4], M. Aversa[2]. *[1]CCSS, Toronto, Costa Rica, [2]University of Toronto, Toronto, ON, Canada, [3]Toronto General Hospital/UHN, Toronto, ON, Canada, [4]University Health Network, Toronto, ON, Canada, [5]UHN, Toronto, ON, Canada*

4:27 p.m. **(313)** ***Evaluating Inter-Rater Agreement of Radiographic Features and Diagnoses Across Lung Transplant Centers***; M. P. Combs[1], M. McInnis[2], S. Simpson[3], E. Kazerooni[4], B. Alexander[4], T. Martinu[5], J. Diamond[3], C. J. Galbán[4], V. Lama[4]. *[1]Pulmonary & Critical Care, University of Michigan, Ann Arbor, MI, [2]University Health Network, Toronto, ON, Canada, [3]University of Pennsylvania, Philadelphia, PA, [4]University of Michigan, Ann Arbor, MI, [5]Toronto General Hospital/UHN, Toronto, ON, Canada*

4:33 p.m. **(314)** ***Lung Transplantation for Patients with a High-Risk Profile***; P. M. Boehm, A. E. Frick, S. Schwarz, S. Auner, A. Benazzo, Z. Kovacs, G. Murakoezy, P. Jaksch, K. Hoetzenecker. *Med Univ of Vienna, Vienna, Austria*

4:39 p.m. **(315)** ***Transplanting Candidates with Stacked Risks Negatively Affects Outcomes***; D. Jin[1], M. Mccurry[1], J. Friskey[1], J. Lisowski[1], J. Diamond[2], M. Anderson[2], M. Crespo[2], A. Courtwright[2], M. Cevasco[1], C. Bermudez[1], R. Gallop[3], Y. J. Hsu[4], J. Christie[2], D. Schaubel[4], E. Cantu[1]. *[1]Div of Cardiovascular Surgery, Perelman SoM at the Univ of Pennsylvania, Philadelphia, PA, [2]Perelman SoM at the Univ of Pennsylvania, Philadelphia, PA, [3]Dept of Mathematics, West Chester Univ, West Chester, PA, [4]Div of Biostatistics, Dept of Biostatistics, Epidemiology and Informatics, Perelman SoM at the Univ of Pennsylvania, Philadelphia, PA*

4:45 p.m. **(316)** ***Predictors of Early Mortality after Lung Transplantation for Primary Pulmonary Hypertension: A UNOS Analysis***; R. Girgis[1], N. Shrestha[2], S. Krishnan[3], R. Loyaga-Rendon[4]. *[1]Spectrum Health, Michigan State University, Grand Rapids, MI, [2]Grand Rapids, MI, [3]Rockford, MI, [4]Spectrum Health, Grand Rapids, MI*

4:51 p.m. **(317)** ***Hospital Free Days in the First Year after Lung Transplantation as a Predictor of Survival***; A. Frisch[1], C. K. Lawson[2], L. LeQuia[1], B. Kowalske[1], R. Girgis[3]. *[1]Michigan State University College of Human Medicine, Grand Rapids, MI, [2]Spectrum Health, Grand Rapids, MI, [3]Spectrum Health, Michigan State Univ, Grand Rapids, MI*

4:57 p.m. **(318)** ***Peripheral Blood Cytokines Predict Primary Graft Dysfunction after Lung Transplantation***; J. Schaenman[1], S. Weigt[1], M. Pan[2], X. Zhou[2], D. Elashoff[2], M. Shino[1], J. Reynolds[3], M. Budev[4], P. Shah[5], L. Singer[6], L. Snyder[7], S. Palmer[7], J. Belperio[1]. *[1]UCLA, Los Angeles, CA, [2]David Geffen School of Medicine at UCLA, Los Angeles, CA, [3]Duke University, Chapel Hill, NC, [4]Cleveland Clinic, Pepper Pike, OH, [5]Johns Hopkins University, Rockville, MD, [6]University Health Network, Toronto, ON, Canada, [7]Duke University, Durham, NC*

5:03 p.m. **(319)** ***Preoperative Plasma SuPAR Levels are Associated with AKI after Lung Transplantation***; K. Manrique[1], K. Raphael[1], S. Griffiths[1], T. Miano[2], L. Kalman[1], M. Oyster[1], D. Xie[2], E. Clausen[1], P. Shah[3], V. Lama[4], G. Dhillon[5], L. Snyder[6], E. Cantu[7], J. Diamond[1], J. Christie[1], M. Shashaty[1]. *[1]Pulmonary, Allergy, and Critical Care Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, [2]Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, [3]Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, [4]Pulmonary Diseases, Critical Care Medicine, University of Michigan Health System, Ann Arbor, MI, [5]Pulmonary and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, [6]Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, NC, [7]Division of Cardiovascular Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA*

5:09 p.m. **(320)** ***Predicting Long-Term Functional Status after Lung Retransplantation***; R. L. Deitz[1], S. Clifford[1], J. P. Ryan[2], E. Chan[1], J. Coster[2], M. Furukawa[2], C. Hage[3], P. Sanchez[2]. *[1]Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, [2]Department of Cardiothoracic Surgery, Division of Lung Transplant and Lung Failure, University of Pittsburgh Medical Center, Pittsburgh, PA, [3]Department of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA*

4:15 – 5:15 p.m.

MINI ORAL 09: A QUICK TRIP THROUGH THE PEDIATRIC HEART FUNCTION AND TRANSPLANT JOURNEY

Location: Rooms 501-504

Core Therapies: HEART
Practice Areas: Pediatrics, Cardiology, Cardiothoracic Surgery, Pediatrics, Pharmacy

Session Summary: This rapid fire session will explore a potpourri of topics in pediatric heart function, heart transplant donor selection, and post-heart transplant outcomes.

Co-Chairs: Anna Joong, MD, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL USA
Joseph Rossano, MD, The Children's Hospital, Philadelphia, PA USA

4:15 p.m. **(321)** ***Endomyocardial Biopsy in Myocarditis Identifies Factors That Predict Outcome in Children***; R. Adorisio[1], G. Ingrasciotta[1], A. Ionata[2], N. Cantarutti[1], E. Bellettini[1], E. Mencarelli[1], M. Pilati[1], R. Kirk[1], A. Amodeo[1]. *[1]Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, [2]University of Rome "Tor Vergata", Rome, Italy*

4:21 p.m. **(322)** ***A Pediatric Heart Failure Registry is Needed: A Time for ACTION***; J. Spinner[1], N. D'Souza[2], T. Duganiero[2], S. Stark[2], A. Lorts[2], C. Almond[3], K. Simpson[4], L. Wright[5], D. Nandi[5], S. Wilkens[6], N. Bansal[7], J. Conway[8], K. Broda[8], A. Lal[9], I. Lytrivi[10], T. Hunter[11], N. Gralia[12], J. Parent[13], R. Butts[14]. *[1]Baylor CoM, Houston, TX, [2]Cincinnati Children's Hospital MC, Cincinnati, OH, [3]Stanford University, Palo Alto, CA, [4]University of Colorado Denver, Denver, CO, [5]Nationwide Children's Hospital, Columbus, OH, [6]University of Louisville, Norton Children's Hospital, Louisville, KY, [7]Children's Hospital at Montefiore, Cliffside Park, NJ, [8]Stollery Children's Hospital, Edmonton, AB, Canada, [9]University of Utah, Salt Lake City, UT, [10]Columbia Presbyterian Hospital, New York, New York, NY, [11]C.S. Mott Children's Hospital, Ann Arbor, MI, [12]Riley Hospital For Children, Carmel, IN, [13]Indiana Univ SoM, Indianapolis, IN, [14]Children's Medical Center of Dallas/UT Southwestern, Dallas, TX*

4:27 p.m. **(323)** ***Suboptimal Titration of Heart Failure Medications in Pediatric Patients: Baseline Data from the ACTION Network***; D. Nandi[1], L. Wright[1], J. Sublett-Smith[2], A. Brax[1], C. Almond[3], N. Bansal[4], E. Azeka[5], R. Butts[6], J. Conway[7], C. Chen[8], C. Cunningham[7], L. A. Fisher[1], E. Hall[9], T. Hunter[10], R. Kobayashi[11], D. Patterson[12], D. Peng[10], K. Simpson[12], T. Ryan[2], J. Spinner[13], B. Wisotzkey[14], S. Zangwill[14], R. Gajarski[1], M. O'Connor[15]. *[1]Nationwide Children's Hosp, Columbus, OH, [2]Cincinnati Children's Hosp MC, Cincinnati, OH, [3]Stanford Univ, Palo Alto, CA, [4]Children's Hosp at Montefiore, Bronx, NY, [5]Univ of Sao Paulo, São Paulo, SP, Brazil, [6]Children's MC of Dallas/UT Southwestern, Dallas, TX, [7]Stollery Children's Hosp, Edmonton, AB, Canada, [8]Palo Alto, CA, [9]New Haven, CT, [10]Univ of Michigan, Ann Arbor, MI, [11]Boston Children's Hosp, Boston, MA, [12]Univ of Colorado, Denver, CO, [13]Baylor CoM, Houston, TX, [14]Phoenix Children's Hosp, Phoenix, AZ, [15]CHOP, Philadelphia, PA*

4:33 p.m. **(324)** ***Stanford Pediatric Psychosocial Optimization Tool for Transplant***; L. Schneider[1], M. Sunnquist[1], J. Ruiz[1], K. Dahl[1], N. Mishra[2], H. Motlagh[2], C. Almond[2], R. J. Shaw[1]. *[1]Stanford University School of Medicine, Stanford, CA, [2]Stanford University, Palo Alto, CA*

4:39 p.m. **(325)** ***Impact of Donor Hypernatremia on Outcomes after Heart Transplantation in Adult and Pediatric Patients***; A. Alvarez[1], M. Killian[2], B. Pietra[3], M. Ahmed[4], G. J. Peek[4], J. P. Jacobs[5], M. Bleiweis[3], F. Fricker[3], D. Gupta[6]. *[1]n/a, [2]Florida State Univ, Tallahassee, FL, [3]UF Congenital Heart Ctr, Gainesville, FL, [4]Univ of Florida, Gainesville, FL, [5]UF Congenital Heart Ctr, Univ of Florida, Gainesville, FL, [6]UF CoM, Gainesville, FL*

4:45 p.m. **(326)** ***When Can one Expect Normalization of Hemodynamics for Fontan Patients Post-Heart Transplantation?***; S. J. Hogue[1], A. Guzman-Gomez[1], K. Kulshrestha[1], K. Boucek[2], J. W. Greenberg[1], H. F. Ahmed[1], C. Villa[2], A. M. Lubert[2], C. Chin[2], A. Lorts[2], F. Zafar[1], D. G. Lehenbauer[1], D. S. Winlaw[1], D. L. Morales[1]. *[1]Cardiothoracic Surgery, Cincinnati Children's Hosp MC, Cincinnati, OH, [2]Cardiology, Cincinnati Children's Hosp MC, Cincinnati, OH*

4:51 p.m. **(327)** ***Sensitized Pediatric Heart Transplant Recipients in a Ten-Year Single Center Study***; E. M. Kalb, C. Laternser, M. Monge, P. Thrush. *Ann & Robert H. Lurie Children's Hospital, Chicago, IL*

4:57 p.m. **(328)** ***Impact of Donor Specific Antibodies on Donor-Derived Cell-Free DNA Levels in Pediatric Heart Transplant Recipients***; M. L. Staron-Ehlinger[1], R. S. Khan[2], T. Hardin[2], J. Baker[2], G. S. Beasley[2]. *[1]Pediatric Cardiology, University of Iowa Stead Family Children's Hospital, Iowa City, IA, [2]University of Iowa Stead Family Children's Hospital, Iowa City, IA*

5:03 p.m. **(329)** ***Mycophenolic Acid Therapeutic Drug Monitoring Using Area Under the Curve in Pediatric Heart Transplant Recipients***; D. M. Newland[1], J. L. Pak[1], R. Ali[1], T. L. Nemeth[1], W. Tressel[2], R. Kronmal[2], E. L. Albers[3], J. M. Friedland-Little[3], H. Ahmed[3], M. S. Kemna[3], B. J. Hong[3], K. L. Spencer[3], Y. M. Law[3]. *[1]Pharmacy, Seattle Children's Hospital, Seattle, WA, [2]Department of Biostatistics, University of Washington, Seattle, WA, [3]Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA*

5:09 p.m. **(330)** ***Prevalence of Iron Deficiency and Anemia in Pediatric Heart Transplant Recipients***; D. M. Newland[1], K. L. Spencer[2], L. D. Do[1], M. M. Palmer[1], H. Ahmed[2], E. L. Albers[2], J. M. Friedland-Little[2], B. J. Hong[2], M. S. Kemna[2], L. R. Knorr[1], D. Mark[1], J. S. Schauer[2], Y. M. Law[2]. *[1]Pharmacy, Seattle Children's Hospital, Seattle, WA, [2]Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA*

4:15 – 5:15 p.m.

MINI ORAL 10: MECHANICAL CIRCULATORY SUPPORT: WE LIKE TO MOVE IT, MOVE IT!

Location: Rooms 205-207

Core Therapies: MCS
Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health

Session Summary: This rapid fire session will focus on the impact of cardiac rehabilitation in patients with mechanical assist devices and its impact on survival, quality of life, and more!

Co-Chairs: Joyce Wald, DO, University of Pennsylvania, Philadelphia, PA USA
Donna Mancini, MD, Mount Sinai, New York, NY USA

4:15 p.m. **(331)** ***New Ventricular Assist Device-Specific Self-Report Measures are Important for Understanding Health-Related Quality of Life: Findings from the MCS A-QOL Study***; K. Grady[1], J. Burns[1], J. Teuteberg[2], L. Allen[3], D. Beiser[4], J. Lindenfeld[5], C. Yancy[6], D. Cella[1], J. Kirklin[7], Q. Denfeld[8], B. Ruo[9], C. McIlvennan[3], M. Walsh[10], E. Adler[11], L. Klein[12], C. Murks[13], D. Pham[14], J. Rich[1], J. Stehlik[15], M. Kiernan[16], E. Hahn[1]. *[1]Northwestern University, Chicago, IL, [2]Stanford University School of Medicine, Stanford, CA, [3]University of Colorado, Aurora, CO, [4]University of Chicago, Chicago, IL, IL, [5]Vanderbilt University, Nashville, TN, [6]Northwestern University Feinberg School of Medicine, Chicago, IL, [7]University of Alabama Birmingham, Birmingham, AL, [8]Oregon Hlth & Sci Univ, Hillsboro, OR, [9]University of California, San Diego, San Diego, CA, [10]St. Vincent Hospital, Indianapolis, IN, [11]Univ of California, SD, Apple Valley, CA, [12]University of California San Francisco, San Rafael, CA, [13]University of Chicago, Chicago, IL, [14]NW Memorial Hospital, Chicago, IL, [15]University of Utah, Salt Lake City, UT, [16]Tufts Medical Center, Wellesley, MA*

4:21 p.m. **(332)** ***Left Ventricular Functional Improvement is Associated with Lower Rates of Device Thrombosis in Patients on Durable Mechanical Circulatory Support***; C. P. Kyriakopoulos, B. Horne, K. Sideris, I. Taleb, R. Griffin, E. Sheffield, R. Alharethi, T. Hanff, J. Stehlik, C. Selzman, S. G. Drakos. *Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program (University of Utah Health and School of Medicine, Intermountain Medical Center, George E. Wahlen Department of Veterans Affairs Medical Center), Salt Lake City, UT*

4:27 p.m. **(333)** ***Transitioning Vad Care: Outcomes of Virtual Vad Follow Up Visits***; K. Meehan, A. Chinco, C. LaBuhn, D. Rodgers, O. Justin, K. Chickerillo, S. Creighton, V. Kagan, K. Ohalloran, V. Jeevanandam. *University of Chicago Medical Center, Chicago, IL*

4:33 p.m. **(334)** ***Outcomes and Quality of Life in Patients Receiving Durable Ventricular Assist Device Therapy with Bivad Support***; A. Iyengar[1], N. Weingarten[2], C. Song[1], D. Rekhtman[1], M. Helmers[1], D. Herbst[1], M. Patel[1], J. Dominic[1], S. Guevara-Plunkett[1], P. Atluri[3]. *[1]University of Pennsylvania, Philadelphia, PA, [2]Cleveland Clinic, Philadelphia, PA, [3]Univ of Pennsylvania, Penn Valley, PA*

4:39 p.m. **(335)** ***Left Ventricular Assist Device Therapy in "Cold and Dry" Patients***; A. Balgobind[1], S. Patel[1], D. Varrias[2], I. Safiriyu[2], M. Alvarez Villela[1]. *[1]Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, [2]Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY*

4:45 p.m. **(336)** ***Optimizing Ventricular Assist Device Outcomes: A Multidisciplinary Protocol***; S. Baudart, A. Strehlow, Y. Wu, L. Curiel, N. Iris, A. Jannesen, A. Abad, G. Wieselthaler, L. Klein. *Advanced Heart Failure Comprehensive Care Center, UCSF, San Francisco, CA*

4:51 p.m. **(337)** ***Evaluating Quality of Life and Satisfaction with Virtual Visits for Ventricular Assist Device Patients***; K. Meehan, A. Chinco, C. LaBuhn, C. Krystina, J. Okray, D. Rodgers, V. Kagan, S. Crieghton, K. Ohalloran, K. Moore, V. Jeevanandam. *University of Chicago Medical Center, Chicago, IL*

4:57 p.m. **(338)** ***Complications and Health-Related Quality of Life after Heartmate 3 Implantation***; N. Weingarten, A. Iyengar, D. Rekhtman, C. Song, D. Herbst, S. Guevara-Plunkett, M. Patel, M. Helmers, J. Dominic, P. Atluri. *University of Pennsylvania, Philadelphia, PA*

5:03 p.m. **(339)** ***VADs on the Move: Safety of Travelling with an LVAD Internationally***; A. Folch Sandoval[1], S. Bonenfant[1], T. Sparaco[1], J. Roldan[1], M. Cagliostro[2], J. Contreras[1], D. Mancini[3], A. Anyanwu[4], N. Moss[1]. *[1]Mount Sinai Hospital, New York, NY, [2]Icahn School of Medicine at Mount Sinai, New York, NY, [3]Mount Sinai, New York, NY, [4]Mount Sinai Med Ctr, New York, NY*

5:09 p.m. **(340)** ***Prognostic Value of Repeated Peak Oxygen Uptake Measurements in LVAD Patients - Follow Up on PRO-VAD Study***; M. K. Szymanski[1], K. Mirza[2], N. De Jonge[1], T. Schmidt[3], D. Brahmbhatt[4], F. Billia[4], S. Hsu[5], G. MacGowan[6], D. G. Jakovljevic[6], P. Agostoni[7], F. Trombara[7], U. Jorde[8], Y. Rochlani[8], K. Vandersmissen[9], N. Reiss[3], S. Russell[10], B. Meyns[9], F. Gustafsson[2]. *[1]Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands, [2]Rigshospitalet, Copenhagen, Denmark, [3]Schuechtermann-Klinik, Bad Rothenfelde, Germany, [4]University Health Network, University of Toronto, Toronto, ON, Canada, [5]Johns Hopkins University School of Medicine, Baltimore, MD, [6]Freeman Hospital, Newcastle Upon Tyne, United Kingdom, [7]Centro Cardiologico Monzino, Milan, Italy, [8]Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, [9]UZ Leuven, Leuven, Belgium, [10]Duke University School of Medicine, Raleigh, NC*

4:15 – 5:15 p.m.

MINI ORAL 11: ATTACK OF THE CLONES: INFECTIOUS THREATS AFTER LUNG TRANSPLANT

Location: Rooms 405-407

Core Therapies: LUNG
Practice Areas: Infectious Diseases, Anesthesiology and Critical Care, Cardiothoracic Surgery, Pharmacy, Pulmonology, Research and Immunology

Session Summary: This rapid fire session will discuss new data in viral, fungal, and mycobacterial infections, including new approaches to assess treatment responses.

Co-Chairs: C. Orla Morrissey, MD, PhD, Alfred Health, Melbourne, VIC Australia
Selim Arcasoy, MD, MPH, Columbia University, New York, NY USA

4:15 p.m. **(341)** ***Effect of Statin Use for Aspergillosis Post Lung Transplant (LT) - A Multicenter Study***; L. N. Walti[1], C. G. Crone[2], M. Helleberg[3], M. Perch[4], A. Perez Cortes Villalobos[5], W. Clement[6], T. Martinu[7], S. Keshavjee[8], S. Husain[9]. *[1]University Health Network, Toronto, ON, Canada, [2]Rigshospitalet - University of Copenhagen, Copenhagen, Denmark, [3]Department of Infectious Diseases, Rigshospitalet - University of Copenhagen, Denmark, Denmark, [4]Rigshospitalet, Gentofte, Denmark, [5]University of Manitoba, Winnipeg, MB, Canada, [6]Ottawa Hospital Research Institute, Ottawa, ON, Canada, [7]Toronto General Hospital/UHN, Toronto, ON, Canada, [8]UHN, Toronto, ON, Canada, [9]University Health Network, Toronto, ON, Canada*

4:21 p.m. **(342)** ***Mycobacterium Abscessus Complex Infections Among Lung Transplant Recipients: A National Retrospective Cohort Study***; R. Bitterman[1], H. Soualhine[2], C. Poirier[3], P. Ferraro[3], D. Kabbani[4], A. Hirji[4], G. Tyrrell[5], C. Bergeron[6], R. Levy[6], A. Wright[6], V. Leung[7], L. G. Singer[1], C. Chaparro[1], S. Keshavjee[1], M. Richard-Greenblatt[8], S. Husain[1], M. Luong[3]. *[1]University Health Network, Toronto, ON, Canada, [2]National Microbiology Laboratory, Winnipeg, MB, Canada, [3]Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada, [4]University of Alberta, Edmonton, AB, Canada, [5]Mackenzie Health Sciences Centre, Edmonton, AB, Canada, [6]Vancouver General Hospital, Vancouver, BC, Canada, [7]Providence Health Care, Vancouver, BC, Canada, [8]Public Health Ontario, Toronto, ON, Canada*

4:27 p.m. **(343)** ***Hyperammonemia Syndrome (HS) in Lung Transplant (LT) Recipients - A Survey on Current Clinical Practice***; L. N. Walti[1], L. Del Sorbo[2], S. Husain[1]. *[1]University Health Network, Toronto, ON, Canada, [2]Toronto General Hospital, Toronto, ON, Canada*

4:33 p.m. **(344)** ***Cytomegalovirus (CMV)-Specific Humoral Immune Responses Pre-Transplantation are Associated with Risk of Post-Transplant CMV DNAemia***; M. J. Harnois[1], R. Barfield[1], S. Palmer[1], L. Snyder[1], C. Chan[1], A. M. Jackson[1], S. R. Permar[2]. *[1]Duke University, Durham, NC, [2]Weill Cornell Medicine, New York, NY*

4:39 p.m. **(345)** ***Immune Markers Predictive of CMV Infection in Seropositive Lung Transplant Recipients***; B. J. Gardiner, S. J. Lee, A. N. Robertson, G. I. Snell, A. Y. Peleg, G. P. Westall. *Alfred Health/Monash University, Melbourne, Australia*

4:45 p.m. **(346)** ***Donor Urease Producing Bacteria (DU) Detection and Serum Ammonium Screening for Hyperammonemia Syndrome (HS) Post-Lung Transplant: A Prospective Observational Study***; L. N. Walti[1], S. Arora[1], L. Donahoe[2], S. Almansour[1], L. Del Sorbo[3], T. Mazzulli[4], A. Sidhu[5], T. Martinu[6], S. Keshavjee[7], C. Chaparro[8], S. Husain[1]. *[1]University Health Network, Toronto, ON, Canada, [2]University of Toronto, Mississauga, ON, Canada, [3]Toronto General Hospital, Toronto, ON, Canada, [4]University Health Network/Mount Sinai Hospital, Toronto, ON, Canada, [5]Toronto, ON, Canada, [6]Toronto General Hospital/UHN, Toronto, ON, Canada, [7]UHN, Toronto, ON, Canada, [8]University of Toronto, Toronto, ON, Canada*

4:51 p.m. **(347)** ***Augmented Humoral Response to a Third And Fourth Dose of Mrna Sars-Cov-2 Vaccines in Lung Transplant Recipients***; S. Kawana[1], S. Sugimoto[2], K. Matsubara[3], S. Tanaka[4], K. Miyoshi[5], H. Choshi[2], H. Ujike[6], Y. Kubo[7], D. Shimizu[8], K. Hashimoto[9], K. Shien[10], K. Suzawa[10], H. Yamamoto[10], M. Okazaki[11], S. Toyooka[10]. *[1]Okayama University, Okayama-Shi, Japan, [2]Okayama University Hospital, Okayama, 33, Japan, [3]Okayama University Hospital, Okayamashi Kitaku, 33, Japan, [4]Okayama University Hospital, Okayama-Shi, Japan, [5]Okayama University, Okayama-Shi, 33, Japan, [6]Okayama University Hospital, ???, 33, Japan, [7]Okayama University Hospital, Okayama-Shi Kita-Ku, 33, Japan, [8]Okayama University, Kita-Ku, 13, Japan, [9]Okayama University Hospital, Kita-Ku, 13, Japan, [10]Okayama University Hospital, Okayama, Japan, [11]Okayama University Okayama University, Okayama-Shi, 33, Japan*

4:57 p.m. **(348)** ***Longitudinal Dynamics of SARS-CoV-2 Spike-Specific Antibody Responses in Patients on Waiting List and after Lung Transplantation***; M. Hübner[1], J. Sauer[1], L. Ruhl[1], J. Kühne[1], K. Beushausen[1], J. Keil[1], M. Schael[2], F. Ius[3], T. Welte[4], A. Haverich[5], J. Gottlieb[4], M. Greer[4], C. Falk[1]. *[1]Institute of Transplant Immunology, Hannover Medical School, Hannover, German Center for Lung Research (DZL/BREATH), Hannover, German Center for Infection Research (DZIF), Braunschweig, Hannover, Germany, [2]Department of Pneumology, Hannover Medical School, Hannover, Germany, [3]Department for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, German Center for Lung Research (DZL/BREATH), Hannover, Germany, [4]Department of Pneumology, Hannover Medical School, Hannover, German Center for Lung Research (DZL/BREATH), Hannover, Germany, [5]Department for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany*

5:03 p.m. **(349)** ***Molnupiravir vs Remdesivir for Treatment of Covid-19 in Lung Transplant Recipients***; D. Razia[1], D. Sindu[2], K. Grief[2], L. Cherrier[2], A. Omar[2], R. Walia[2], S. Tokman[2]. *[1]Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ, [2]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

5:09 p.m. **(350)** ***Evaluation of Immunosuppressant Drug Tolerability and Infections in Lung Transplant Recipients with Short Telomere Syndrome***; A. T. Logan[1], E. Heiman[1], M. Qureshi[2], K. Patel[2]. *[1]Pharmacy, Tampa General Hospital, Tampa, FL, [2]USF Morsani College of Medicine, Tampa, FL*

4:15 – 5:15 p.m.

MINI ORAL 12: A NEW FRONTIER: EMERGING APPROACHES FOR DIAGNOSIS AND IMMUNE MODULATION IN HEART TRANSPLANTATION

Location: Rooms 201-203

Core Therapies: HEART
Practice Areas: Research and Immunology, Cardiology, Cardiothoracic Surgery, Pathology

Session Summary: In this rapid fire session, you will learn new experimental and clinical approaches in biomarkers and immunomodulation in heart transplantation.

Co-Chairs: Jose Gonzalez-Costello, MD, PhD, Bellvitge Hospital, Barcelona, Spain
Charles Marboe, MD, Columbia University Vagelos College of Physicians & Surgeons, New York, NY USA

4:15 p.m. **(351)** ***Utility of Intraoperative Cytokine Hemoadsorption Therapy During Cardiac Transplantation***; N. A. Kamat[1], A. Gaur[2], A. Phadke[3], N. Waje[3], R. Bunage[3], T. Meeran[3], S. Sinha[3], A. Chavan[3], J. Haji[4], A. Rathod[5], A. Mulay[6]. *[1]Advanced Cardiac Surgery and Heart/Lung Transplant, Sir HN Reliance Foundation Hospital & Research Center, Mumbai, India, Mumbai, India, [2]Advanced Cardiac Surgery and Heart/Lung Transplant, Sir HN Reliance Foundation Hospital and Research Center, Mumbai, India, [3]Advanced Cardiac Surgery & Heart/Lung Transplant, Sir HN Reliance Foundation Hospital and Research Center, Mumbai, India, [4]Advanced Cardiac Surgery & Heart/Lung Transplant, Sir HN Reliance Foundation Hospital and Reesearch Center, Mumbai, India, [5]Advanced Cardiac Surgery & Heart/Lung Transplant, Sir HN Relaince Foundation Hospital and Research Center, Mumbai, India, [6]Advanced Cardiac Surgery & Heart/Lung Transplant, Sir HN Reliance Foundation hospital and Research Center, Mumbal, India*

4:21 p.m. **(352)** ***Cytokine Adsorption During Ex-Vivo Blood Perfusion Improves Contractility and Modifies the Transcriptomic Profile of Donation after Circulatory Death Hearts***; L. Saemann[1], F. Hoorn[2], K. Wächter[1], S. Pohl[1], S. Korkmaz-Icöz[2], F. Wenzel[3], M. Karck[2], A. Simm[1], G. Szabó[1]. *[1]Department of Cardiac Surgery, University Hospital Halle, Halle (Saale), Germany, [2]Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany, [3]Faculty Medical and Life Sciences, Furtwangen University of Applied Sciences, Villingen-Schwenningen, Germany*

4:27 p.m. **(353)** ***Pre-Transplant Sensitization is Associated with Lower Levels of Immunomodulatory Metabolite Concentrations after Heart Transplantation***; J. Han[1], M. Dela Cruz[2], H. Lin[3], E. Adler[3], M. Khalid[3], J. Cantoral[3], A. Moran[3], A. Sundararajan[4], A. Sidebottom[3], M. Alegre[5], E. Pamer[3], A. Nguyen[1]. *[1]Section of Cardiology, University of Chicago Medical Center, Chicago, IL, [2]Advocate Christ Medical Center, Chicago, IL, [3]Duchossois Family Institute, University of Chicago, Chicago, IL, [4]University of Chicago, Chicago, IL, [5]Department of Immunology, University of Chicago, Chicago, IL*

4:33 p.m. **(354)** ***De Novo Donor Specific Antibodies and Late Graft Dysfunction: Another Reason to Treat Before the Damage is Done?***; I. Marco[1], J. López Azor[2], M. Garcia Cosio[3], E. Mancebo[4], A. Rodriguez Chaverri[5], P. Caravaca[3], J. De Juan[3], L. Moran[5], J. Nuche[1], J. Delgado Jiménez[1]. *[1]Heart Failure and Heart Transplantation, Hospital Universitario 12 de Octubre, Madrid, Spain, [2]Heart Failure and Heart Transplantation, Hospital Universitario 12 de Octubre, CIBER CV, Madrid, Spain, [3]Heart Failure and Heart Transplantation, Hospital Universitario 12 de Octubre, CIBERCV, Madrid, Spain, [4]Inmunology, Hospital Universitario 12 de Octubre, Madrid, Spain, [5]Heart Failure and Heart Transplantation, Hospital Universitario La Paz, Madrid, Spain*

4:39 p.m. **(355)** ***Use of Complement-Fixing Assays to Expand the Donor Pool for Highly Sensitized Heart Transplant Recipients - The Role of C1q Testing***; A. Loethen[1], R. Lavelle[2], M. Sadzak[3], J. Bucio[2], N. Sarswat[4], B. Chung[5], B. Smith[6], S. Kalantari[7], J. Grinstein[8], A. Nguyen[3], M. Belkin[9], C. Murks[9], T. Riley[9], J. Powers[3], A. Jones[9], G. Kim[9], S. Pinney[9]. *[1]Pharmacy, Univ of Chicago Med, Chicago, IL, [23]Univ of Chicago Med, Chicago, IL, [4]Univ of Chicago Hospital, Glencoe, IL, [5]Univ of Chicago, Chicago, IL, [6]Univ of Chicago MC, Chicago, IL, [7]Univ of Chicago, Chicago, IL, [8]MedStar Heart and Vascular Inst, Chicago, IL, [9]Univ of Chicago, Chicago, IL*

4:45 p.m. **(356)** ***A Novel Multiplex Digital PCR Assay for Same-Day Detection of Donor-Derived Cell-Free DNA in Pediatric Heart Transplant Recipients***; R. L. Edwards[1], J. E. Takach[2], M. J. McAndrew[2], J. Menteer[3], R. M. Lestz[4], D. Whitman[2], L. Baxter-Lowe[1]. *[1]Department of Pathology & Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, [2]Luminex Corporation, A DiaSorin Company, Austin, TX, [3]Division of Cardiology, Children's Hospital Los Angeles, Los Angeles, CA, [4]Division of Nephrology, Children's Hospital Los Angeles, Los Angeles, CA*

4:51 p.m. **(357)** ***Higher Frequency of Host Cd8+ Memory T Cells Correlates with Failure to Achieve Heart Allograft Tolerance via Mixed Chimerism and Il-6 Blockade in Multiparous Female Non-Human Primates***; C. L. Miller[1], J. M. O[1], A. Dehnadi[1], J. T. Nawalaniec[1], S. M. Landino[1], M. Momodu[1], D. Muldoon[1], J. M. Muoio[1], I. M. Hanekamp[1], J. S. Allan[1], G. Benichou[1], J. C. Madsen[2]. *[1]Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, [2]2Division of Cardiac Surgery and Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA*

4:57 p.m. **(358)** ***Banff Human Organ Transplant Consensus Gene Panel for Detecting Antibody Mediated Rejection in Heart Allograft Biopsies***; A. Giarraputo[1], G. Coutance[2], D. Zielinski[3], O. Aubert[3], M. Fedrigo[4], F. Mezine[3], M. Mengel[5], J. Duong-Van-Huyen[6], P. Bruneval[7], A. Angelini[8], A. Loupy[9]. *[1]Cardiovascular Pathology and Pathological Anatomy, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy, University of Padua, Italy, [2]Pitié-Salpetrière Hospital, Paris, France, Paris, France, [3]Université de Paris Cité, INSERM, PARCC, Paris Translational Research Centre for Organ Transplantation, F-75015 Paris, France, Paris, France, [4]Cardiovascular Pathology and Pathological Anatomy, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy, Padua, Italy, [5]AlbertaTx App Genomics Ctr University of Alberta, Edmonton, AB, Canada, [6]Hospital Necker, Paris, France, [7]Hosp Europ Geo Pompidou, Paris, France, [8]Cardiovascular Pathology and Pathological Anatomy, Department of Cardiac, Thoracic, Vascular Science, Cardiovascular Pathology and Pathological Anatomy, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy, Padova, Italy, [9]Université de Paris Cité, INSERM, PARCC, Paris Translational Research Centre for Organ Transplantation, F-75015 Paris, France/Necker Hospital, Paris, France*

5:03 p.m. **(359)** ***Single Cell Transcriptomic Analysis of Acute Heart Rejection in a Rat Model***; O. Ainasoja[1], G. Bishwa[2], J. Lahtela[2], S. Syrjälä[3], K. Lemström[4], M. Hurskainen[5]. *[1]Transplantation Laboratory, University of Helsinki, Helsinki, Finland, [2]Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland, [3]Department of Cardiothoracic Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, [4]Department of Cardiothoracic Surgery, University of Helsinki and Helsinki University Hospita, Helsinki, Finland, [5]Department of Pediatric Cardiology, New Children's hospital and Pediatric Research Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland*

5:09 p.m. **(360)** ***Use of Anti-Il-6 or Anti-IL-6r Therapy in a Mixed Chimerism Protocol to Achieve Heart Allograft Tolerance in Non-Human Primates***; C. L. Miller[1], J. M. O[1], A. Dehnadi[1], S. M. Landino[1], J. T. Nawalaniec[1], M. Momodu[1], D. Muldoon[1], J. M. Muoio[1], H. Lee[1], I. M. Hanekamp[1], J. S. Allan[1], G. Benichou[1], J. C. Madsen[2]. *[1]Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, [2]Division of Cardiac Surgery and Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA*

4:15 – 5:15 p.m.

POSTER SESSION 02: ANESTHESIOLOGY AND CRITICAL CARE

Location: Mile High Ballroom

Core Therapies: HEART, LUNG, MCS
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pediatrics, Pharmacy, Pulmonology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Anesthesiology and Critical Care. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Patrick Evrard, MD, CHU UCL Namur site Godinne, Yvoir, Belgium
Julien Fessler, MD, Foch Lung Transplant Group, Paris, France
Ashley Fritz, DO, Mayo Clinic, Jacksonville, FL USA
Claudia Gidea, MD, Newark Beth Israel Medical Center, New York, NY USA
Matthew Goodwin, MD, MS, University of Utah, Salt Lake City, UT USA
John Granton, MD, University of Toronto, Toronto, ON Canada
Sean Kiley, MD, Mayo Clinic Florida, Jacksonville, FL USA
Rebecca Klingbeil, MSN, DNP, Mayo Clinic, Jacksonville, FL USA
Archer Martin, MD, Mayo Clinic, Jacksonville, FL USA
Dave Nagpal, MD, FRCSC, London Health Sciences Centre, London, ON Canada
Kristen Nelson McMillan, MD, Advocate Children's Heart Institute, Univ of Chicago, Chicago, IL USA
Sia Saatee, MD, Northwestern Medicine, Chicago, IL USA
Sebastian Tume, MD, Texas Children's Hospital, Sugar Land, TX USA
Barbara Wilkey, BSN, MPAS, MD, University of Colorado, Denver, CO USA

(707) ***A Novel Strategy for Transplant Eligible Patients Presenting in Cardiogenic Shock Results in Excellent Outcome Pre- and Post-Heart Transplantation;*** M. Freundt[1], R. Devich[2], B. Mahesh[3], B. Soleimani[3], H. Eisen[4], R. Dowling[3]. *[1]Heart and Vascular Institute, Critical Care Unit, Penn State Health, Milton S. Hershey Medical Center, Hershey, PA, [2]Penn State College of Medicine, Hershey, PA, [3]Heart and Vascular Institute, Cardiac Surgery, Penn State Health, Milton S. Hershey Medical Center, Hershey, PA, [4]Heart and Vascular Institute, Advanced Heart Failure, Penn State Health, Milton S. Hershey Medical Center, Hershey, PA*

(708) ***Donor Anemia Before Organ Recovery Does Not Impair the Outcome after Heart Transplantation;*** M. B. Immohr[1], C. Ballázs[1], V. H. Hettlich[1], D. Scheiber[2], D. Sigetti[1], F. Bönner[2], H. Aubin[1], A. Lichtenberg[1], U. Boeken[1], P. Akhyari[1]. *[1]Dept. of Cardiac Surgery, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, [2]Dept. of Cardiology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany*

(709) ***The IMPACT Score: Does Sex Matter;*** M. Jones[1], V. Tangel[2], R. S. White[1], L. Rong[1]. *[1]Anesthesiology, Weill Cornell NY Presbyterian, New York, NY, [2]Anesthesiology, Weill Cornell, New York, NY*

(710) ***Bolus Dosage of Heparin According to ACT Versus Continuous Dosage of Heparin According to ROTEM for ECMO Anticoagulation in Lung Transplantation - Effect on Perioperative Blood Loss;*** J. Vajter[1], M. Garaj[2], R. Lischke[3], M. Durila[4]. *[1]Department of Anesthesiology and Intensive Care Medicine, Motol University Hospital, Second Faculty of Medicine, Charles University, Prague, Czech Republic, [2]Department of Anesthesiology and Intensive Care Medicine, Motol University Hospital and Second Faculty of Medicine, Charles University, Prague, Czech Republic, [3]3rd Department of Surgery, 1st Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic, [4]University Hospital Motol, Charles University, Prague, Czech Republic*

(711) ***Capillary Leak Syndrome Induced by Tacrolimus in Post-Lung Transplant Recipient;*** S. Verga[1], S. Nandavaram[1], R. Evans[2], H. Underwood[3], M. I. Anstead[1], A. P. Maskey[1], S. Keshavamurthy[4]. *[1]University of Kentucky, Lexington, KY, [2]University of Kentucky Healthcare, Lexington, KY, [3]UK HealthCare, Lexington, KY, [4]University Of Kentucky, Lexington, Lexington, KY*

(712) ***Looking for Zebras: Non-Human Leukocyte Antigen Antibody Mediated Rejection Leading to Hyperacute Rejection;*** C. Harberg[1], E. Lowery[2], D. McCarthy[3], G. Demiralp[1]. *[1]Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, [2]Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, [3]Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI*

(713) ***Pneumatosis Intestinalis after Lung Transplantation: A Single Institution Case Series;*** B. Hernandez, C. Cassara, J. Tawil, E. Lowery, D. McCarthy, G. Demiralp. *University of Wisconsin Madison, Madison, WI*

(714) ***Pulmonary Stress Index During Ex Vivo Lung Perfusion is Associated with Evlp and Lung Transplant Recipient Outcomes;*** O. Hough[1], X. Zhou[1], M. Di Nardo[1], A. Ali[2], E. Brambate[1], R. Ribeiro[2], B. Gomes[1], M. Cypel[1], A. Slutsky[3], A. Sage[2], S. Keshavjee[4], L. Del Sorbo[2]. *[1]University Health Network, Toronto, ON, Canada, [2]Toronto General Hospital, Toronto, ON, Canada, [3]St. Michael's Hospital, Toronto, ON, Canada, [4]UHN, Toronto, ON, Canada*

(715) ***Diaphragm Dysfunction from Covid-19 Phrenic Neuropathy: Utilization of Diaphragm Pacing for Recovery;*** R. Onders[1], M. Elmo[1], N. Carl[1], R. Hejal[2], R. Schilz[3]. *[1]University Hospitals Cleveland Medical Center, Cleveland, OH, [2]University Hospitals Cleveland Medical Center, Cleveland, OH, [3]Case Western Reserve University, Cleveland, OH*

(716) ***Can Pediatric Lung Transplantation be Safely Performed in an Adult Hospital - The ICU Experience;*** S. Varkey[1], G. Westall[1], G. Snell[1], P. Nixon[1], J. Sheldrake[1], T. Rozen[2], B. Bourne[2], J. Harrison[2], M. Buckland[1], S. Marasco[1], V. Nanjayya[1]. *[1]Alfred Hospital, Melbourne, Australia, [2]Royal Children's Hospital, Melbourne, Australia*

(717) ***Prognostic Significance of Serial Troponin Measurement after Lung Transplantation;*** E. Rodenas-Alesina[1], A. Luk[2], J. Gajasan[3], A. Alhussaini[1], C. Overgaard[4], G. Martel[5], c. serrick[5], K. McRae[6], M. Cypel[7], L. Singer[7], J. Tikkanen[8], S. Keshavjee[9], L. Del Sorbo[10]. *[1]Peter Munk Cardiac Centre, Toronto, ON, Canada, [2]University of Toronto, North York, ON, Canada, [3]University of Toronto, Toronto, ON, Canada, [4]Southlake Regional Healthcare Centre, Newmarket, ON, Canada, [5]Departments of Perfusion and Anesthesia and Pain Management, University Health Network, Toronto, ON, Canada, [6]Toronto Gen Hospital, Toronto, ON, Canada, [7]University Health Network, Toronto, ON, Canada, [8]Helsinki University Central Hospital, Kauniainen, 18, Finland, [9]UHN, Toronto, ON, Canada, [10]Toronto General Hospital, Toronto, ON, Canada*

(718) ***Multiorgan Donor Bronchoalveolar Lavage Positivity: Incidence, Risk Factors, and Lung Transplant Recipients' Outcome;*** J. Fumagalli[1], L. Rosso[2], M. Cattaneo[2], G. Romeo[1], V. Scaravilli[1], I. Righi[2], F. Damarco[2], D. Mangioni[3], F. Gori[1], A. Bandera[3], V. Rossetti[4], L. Morlacchi[4], M. Nosotti[2], A. Zanella[1], G. Grasselli[1]. *[1]Anesthesia, Critical Care and Pain Medicine, Fondazione IRCCS Ca' Granda Policlinico, Milan, Italy, [2]Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Policlinico, Milan, Italy, [3]Infectious Disease, Fondazione IRCCS Ca' Granda Policlinico, Milan, Italy, [4]Pulmonary Division, Fondazione IRCCS Ca' Granda Policlinico, Milan, Italy*

(719) ***Outcomes of Extremely Prolonged (> 50 Days) Venovenous Extracorporeal Membrane Oxygenation Support: A Single Center Experience;*** J. Malas[1], Q. Chen[1], C. Premananthan[1], A. Krishnan[1], T. Shen[1], D. Emerson[1], T. Gunn[1], D. Megna[1], P. Catarino[1], M. Nurok[1], M. Bowdish[1], J. Chikwe[1], S. Cheng[2], J. Ebinger[2], A. Kumaresan[1]. *[1]Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, [2]Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA*

(720) ***Extracorporeal Membrane Oxygenation Utilization in Pregnant and Post-Partum Patients During the Covid-19 Pandemic;*** D. Miller[1], C. Pellecchia[1], C. Couch[1], O. Hernandez[2], S. Biggers[1]. *[1]Medical City Plano, Plano, TX, [2]*

(721) ***Thoracic Epidural Anaesthesia Improves Outcomes Following Lung Transplant - A Single Centre Long Term Follow Up Study;*** J. Vazirani[1], B. Levvey[2], S. Okahara[3], G. Westall[4], G. Snell[5]. *[1]The Alfred Hospital, Melbourne, Australia, [2]The Alfred Hospital, Melbourne, Australia, Melbourne, Australia, [3]Monash University & Alfred Hospital, Melbourne, Australia, [4]Alfred Hospital, Prahran, Australia, [5]Alfred Hospital, Melbourne, Australia*

(722) ***Angiotensin II Use in Cardiogenic Shock Patients Supported by Temporary Mechanical Circulatory Support;*** M. Tamae-Kakazu, J. Parent, S. Orey, N. Manandhar, C. Michaud, R. Loyaga-Rendon, B. Trethowan. *Spectrum Health/Michigan State University, Grand Rapids, MI*

(723) ***Impact of an Institutional Allocation Protocol to Short Term Mechanical Circulatory Support to Improve Survival in Cardiogenic Shock - A Propensity Score Matched Analysis;*** S. Ott[1], G. Nersesian[2], D. Lewin[2], I. Just[3], C. T. Starck[4], B. O'Brien[5], F. Schoenrath[2], V. Falk[6], E. Potapov[2], P. Lanmueller[2]. *[1]Cardiac Anaesthesiology and Intensive Care Medicine, German Heart Center Berlin, Berlin, Germany, [2]Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany, [3]DZHK (German Centre for Cardiovascular Research), Berlin, Germany, [4]Institute (STI) of Cardiovascular Perfusion, Steinbeis University Berlin, Berlin, Germany, [5]Department of Cardiac Anesthesiology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany, [6]Department of Cardiothoracic Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany*

(724) ***Determinants of LV Filling Pressure During ECPR with VA-ECMO: A Mock Circulatory Loop Study;*** J. Jiang[1], P. Jain[2], A. Adji[3], S. Barua[4], C. Hayward[4]. *[1]University of New South Wales, Darlinghurst, Australia, [2]Royal Prince Alfred Hospital, Sydney, Australia, [3]Victor Chang Cardiac Research Institute, Sydney, Australia, [4]St Vincent's Hospital, Darlinghurst, Australia*

(725) ***Open Chest Central ECMO Cannulation Air Transport of a Patient With Post-Cardiotomy Shock & Biventricular Failure;*** J. Lee[1], O. O. Hernandez[2], O. Espinoza[2], B. Lima[2]. *[1]Medical City Fort Worth, Fort Worth, TX, [2]Medical City Heart Hospital, Dallas, TX*

(726) ***Safety and Efficacy of Intensivist Led Ecmo Retrievals;*** M. R. Mihu[1], M. O. Maybauer[2], K. Cain[1], L. V. Swant[1], M. Harper[3], R. S. Schoaps[1], A. Sharif[1], C. Benson[1], J. M. Brewer[1], A. ElBanayosy[1], A. El Banayosy[1]. *[1]Integris Baptist Medical Center, Oklahoma City, OK, [2]Anesthesiology, The University of Florida, Gainesville, FL, [3]MedStar Washington Hospital Center, Oklahoma City, OK*

(727) ***Obesity is Associated with Improved Outcome of Extracorporeal Membrane Oxygenation for Severe Covid-19 Pneumonia;*** N. Prasad[1], K. Elkholey[1], E. Junqueira[2], E. Cohen[3], S. Whitmore[3]. *[1]Internal Medicine, TriStar Centennial Medical Center, Nashville, TN, [2]TriStar Centennial Medical Center, Nashville, TN, [3]Critical Care Medicine, TriStar Centennial Medical Center, Nashville, TN*

THURSDAY, 20 APRIL, 2023

4:15 – 5:15 p.m.

POSTER SESSION 02: CARDIOLOGY

Location: Mile High Ballroom

Core Therapies: MCS, HEART, PVD
Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Cardiology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Mustafa Ahmed, MD, University of Florida, Gainesville, FL USA
Sophia Airhart, MD, Saint Alphonsus Medical Center, Boise, ID USA
Tamas Alexy, MD, PhD, University of Minnesota, Minneapolis, MN USA
Shahnawaz Amdani, MD, Cleveland Clinic, Cleveland, OH USA
Allen Anderson, MD, FACC, FAHA, FHFSA, University of Texas Health, San Antonio, San Antonio, TX USA
Charles Canter, MD, St Louis Children's Hospital, Saint Louis, MO USA
Maria Castel, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain
Leway Chen, MD, MPH, University of Rochester Medical Center, Rochester, NY USA
Erin Coglianese, MD, Massachusetts General Hospital, Boston, MA USA
Monica Colvin, MD, MS, FAHA, University of Michigan Health System, Ann Arbor, MI USA
Bala Cynwyd, PA USA, Kiran Khush, MD, MAS, Stanford University, Stanford, CA USA
Adrian daSilva-deAbreu, MD, MSc, PhD(c), Mayo Clinic-Rochester, Rochester, MN USA
Eugene DePasquale, MD, University of Southern California, Los Angeles, CA USA
Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis Heart Institute, Minneapolis, MN USA
Alexander Fardman, MD, Chaim Sheba Medical Center, Ramat-Gan, Israel
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain
Megan Greene, PharmD, BCPPS, Children's Hospital Colorado, Aurora, CO USA
Dipankar Gupta, MBBS, Temple University, Philadelphia, PA USA
Jennifer Hajj, MHDS, BSN, Medical University of South Carolina, Charleston, SC USA
Eman Hamad, MD, MHA, Temple University, Philadelphia, PA USA
Thomas Hanff, MD, MSCE, MPH, University of Utah, Salt Lake City, UT USA
Karlee Hoffman, DO, Cleveland Clinic, Cleveland, OH USA
Brian Houston, MD, Medical University of South Carolina, Charleston, SC USA
Eileen Hsich, MD, Cleveland Clinic Foundation, Cleveland, OH USA
Gregory Jackson, MD, Mount Pleasant, SC USA
George Javorsky, MBBS, FRACP, The Prince Charles Hospital, Chermside, QLD Australia
Tomoko Kato, MD, PhD, International University of Health and Welfare, Narita, Japan
Jamie Kennedy, MD, Inova Heart and Vascular Institute, Falls Church, VA USA
In-Cheol Kim, Keimyung University Dongsan Hospital, Dalseo-Gu, South Korea
Steven Kindel, MD, Children's Hospital of Wisconsin, Milwaukee, WI USA
Aine Lynch, MBBCh, BAO, MSc, The Hospital for Sick Children, Toronto, ON Canada
Shivank Madan, MD, Montefiore Medical Center, New York, NY USA
Claudius Mahr, DO, University of Washington, Seattle, WA USA
Yosef Manla, MD, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Marco Masetti, MD, PhD, IRCCS S. Orsola Malpighi, University of Bologna, Bologna, Italy
Assi Milwidsky, MD, Tel-Aviv Medical Center, Herzliya, Israel
Sonia Mirabet, MD, PhD, Hospital Sant Pau, Barcelona, Spain
Paul Mohacsi, MD, MBA, Cardiovascular Center Zürich, Klinik im Park Hirlsandenklinik, Zürich, Switzerland

Mrudula Munagala, MD, University of Miami, Miami, FL USA
Kavitha Muthiah, MBChB, PhD, St. Vincent's Hospital, Sydney, NSW Australia
Emil Najjar, MD, PhD, Karolinska University Hospital, Stockholm, Sweden
Lazaros Nikolaidis, MD, Baylor Scott & White Medical Center, Temple, TX USA
Marish Oerlemans, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands
Juan Ortega-Legaspi, MD, PhD, University of Pennsylvania, Philadelphia, PA USA
Carlos Ortiz-Bautista, MD, PhD, Hospital Universitario Gregorio Marañón, Madrid, Spain
Pujan Patel, MD, AdventHealth, Raleigh, NC USA
Yael Peled, MD, Sheba Medical Center, Ramat Gan, Israel
Gregor Poglajen, MD, PhD, Advanced Heart Failure and Transplantation Center, Ljubljana, Slovenia
Adam Putschoegl, Minneapolis, MN USA
Amresh Raina, MD, Allegheny General Hospital, Pittsburgh, PA USA
Navin Rajagopalan, MD, University of Kentucky, Lexington, KY USA
Jayant Raikhelkar, MD, Columbia University, New York, NY USA
Bhavadharini Ramu, MD, Medical University of South Carolina, Charleston, SC USA
Roopa Rao, MBBS, Indiana University, Carmel, IN USA
Ashwin Ravichandran, MD, MPH, St. Vincent Heart Center of Indiana, Indianapolis, IN USA
María Renedo, MD, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina
Joseph Rossano, MD, The Children's Hospital, Philadelphia, PA USA
Victor Rossel, MD, Instituto Nacional del Torax, Las Condes, Chile
Marc Simon, MD, MS, University of California San Francisco, San Francisco, CA USA
Melissa Smallfield, MD, Virginia Commonwealth University, Richmond, VA USA
Pallavi Solanki, MD, FACC, Rutgers-NJMS, Montville, NJ USA
Kristin Stawiarski, MD, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, West Haven, CT USA
Swethika Sundaravel, MD, University of Pennsylvania, Philadelphia, PA USA
Jose Tallaj, MD, Univ of Alabama at Birmingham, Birmingham, AL USA
Madeleine Townsend, MD, Cleveland Clinic Children's, Cleveland, OH USA
Sarumathi Thangavel, MD, Chennai, India
Carol Wittlieb-Weber, MD, Media, PA USA
Melana Yuzefpolskaya, MD, Columbia University Medical Center, New York, NY USA

(525) ***Impact of the Donor Organ Allocation Change on Heart Transplant of Patients ›65 Years of Age;*** I. Konstantinidis[1], S. Riaz[2], W. L. Baker[2], A. Jaiswal[2]. *[1]Internal Medicine, University of Connecticut, Farmington, CT, [2]Hartford Hospital, Hartford, CT*

(549) ***Belatacept-Based Immunosuppression in Heart Transplant Recipients: National Trends with Outcomes from a Single Center;*** W. Magua[1], A. K. Okoh[1], P. Pranav[1], J. Wang[1], G. Karadkhele[1], R. Cole[1], M. Daneshmand[2], D. Gupta[3], C. Larsen[4], A. Morris[1]. *[1]Emory University, Atlanta, GA, [2]Emory University, Durham, NC, [3]Emory Univ School of Med, Atlanta, GA, [4]The Emory Clinic Chief, Transplant Services, Atlanta, GA*

(567) ***Symptomatic Peripheral Vascular Disease Increases Long Term Mortality after Heart Transplantation;*** I. Konstantinidis[1], S. Riaz[2], W. L. Baker[2], A. Jaiswal[2]. *[1]Internal Medicine, University of Connecticut, Farmington, CT, [2]Hartford Hospital, Hartford, CT*

(729) ***Clinical Impact of a Cardiac Intensivist in an Adult Cardiac Care Unit from the Rescue Registry;*** D. Bae. *Chungbuk National University Hospital, Cheongju, South Korea*

(730) ***Continuous Temperature Measurements in Donor Hearts During Cold Organ Procurement;*** S. Bangaru[1], S. C. Uppalapati[2], S. N. Palluri[3], K. Ram[4], A. Madhushankar[5], K. Johnson[6], D. Hynes[7], S. Jain[2], K. Sudheendra[8], D. Rodgers[2], V. Jeevanandam[9], D. Onsager[10]. *[1]Illinois Mathematics and Science Academy, Springfield, IL, [2]Univeristy of Chicago, Chicago, IL, [3]Chicago College of Osteopathic Medicine, Midwestern University, Chicago, IL, [4]University of Michigan, Ann Arbor, IL, [5]Adlai E. Stevenson High School, Lincolnshire, IL, [6]Illinois Mathematics and Science Academy, Aurora, IL, [7]Hamilton College, Clinton, NY, [8]Hinsdale Central High School, Hinsdale, IL, [9]University of Chicago Medical Center, Chicago, IL, [10]University of Chicago, Libertyville, IL*

(731) ***Enzymatic Removal of A-Antigen in a Mouse Model of ABO-Incompatible (ABOi) Transplantation;*** T. Erickson[1], B. Motyka[1], L. Xu[1], K. Tao[1], J. Pearcey[1], M. Cypel[2], J. N. Kizhakkedathu[3], P. Rahfeld[4], P. J. Cowan[5], S. G. Withers[4], L. J. West[1]. *[1]Pediatrics, University of Alberta, Edmonton, AB, Canada, [2]Department of Surgery, University of Toronto, Toronto, ON, Canada, [3]Pathology and Lab Medicine, University of British Columbia, Vancouver, BC, Canada, [4]Chemistry, University of British Columbia, Vancouver, BC, Canada, [5]Immunology Research Centre, St Vincent's Hospital Melbourne, Melbourne, Australia*

(732) ***Enhanced Release of Endothelin-1 and Angiopoietin-2 During Experimentally-Induced Peripheral Venous Congestion is Associated with Heart Failure-Related Clinical Events;*** F. Castagna[1], D. Onat[2], K. Wong[3], A. Harxhi[3], Y. Hayashi[3], A. Pinsino[4], A. Mebazaa[5], M. Arrigo[6], T. H. LeJemtel[7], H. Sabbah[8], A. Schmidt[9], M. Yuzefpolskaya[2], R. Demmer[10], P. C. Colombo[2]. *[1]Montefiore Medical Center, New York, NY, [2]Columbia University Medical Center, New York, NY, [3]Columbia University Medical Center, New York City, NY, [4]Columbia University Medical Center, Bronx, NY, [5]AP-HP Saint Louis and Lariboisière University Hospitals, Paris, France, [6]Stadtspital Zurich Triemli, Zurich, Switzerland, [7]Tulane University School of Medicine, New Orleans, LA, [8]Henry Ford Health, Detroit, MI, [9]New York University, New York, NY, [10]University of Minnesota, Minneapolis, MN*

(733) ***Peripheral Indicators of Dysbiosis in Heart Transplant Recipients (PoD-HTR);*** Y. Moayedi[1], F. Billia[2], K. Runeckles[3], S. Fan[4], E. Ruguera Nunez[5], N. Yee[5], K. Tsang[6], J. Duero Posada[7], M. McDonald[8], H. Ross[8], K. Kain[5], B. Coburn[7]. *[1]UHN, Toronto, ON, Canada, [2]Ted Rogers Centre for Heart Research, Toronto, ON, Canada, [3]Ted Rogers Computational Program, Toronto, ON, Canada, [4]Ted Rogers Computational Program, UHN, Toronto, ON, Canada, [5]Division of Infectious Diseases, UHN, Toronto, ON, Canada, [6]Division of Cardiology, UHN, Toronto, ON, Canada, [7]University Health Network, Toronto, ON, Canada, [8]Toronto General Hospital, Toronto, ON, Canada*

(734) ***Post-Mortem Genetic Testing of Sudden Cardiac Death Cases in Young Individuals: Value of Next-Generation Sequencing in Molecular Autopsy;*** A. Akilzhanova[1], M. Zhalbinova[1], A. Chamoieva[1], D. Samatkyzy[1], S. Rakhimova[1], U. Kozhamkulov[1], G. Akilzhanova[2], U. Kairov[3], K. Akilzhanov[2], T. Polyakova[4], T. Zhakupova[4], M. Bekbossynova[5], D. Sarbassov[6]. *[1]Laboratory of Genomic and Personalized Medicine, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, [2]Semey Medical University, Pavlodar Branch, Semey Medical University, Pavlodar, Kazakhstan, [3]Laboratory of Bioinformatics and Computational Systems Biology, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, [4]Center for Forensic Medicine, Medical University Astana, Astana, Kazakhstan, [5]National Research Center for Cardiac Surgery, Astana, Kazakhstan, [6]School of Sciences and Humanities, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan*

(735) ***Impact of Asynchronous Rotational Speed Modulation of Continuous Flow Left Ventricular Assist Device on Cardiac Condition;*** S. Tanaka[1], T. Nishinaka[1], A. Umeki[1], S. Imaoka[1], T. Murakami[1], T. Mizuno[1], T. Tsukiya[1], M. Ono[2]. *[1]Department of Artificial Organs, National Cerebral and Cardiovascular Center, Osaka, Japan, [2]The University of Tokyo Hospital, Bunkyo-Ku, 13, Japan*

(736) ***The Application of Plasma Oncostatin M (OSM) to Quantify the Inflammatory Burden and to Predict the Outcome of V-A ECMO Therapy;*** H. Setiadi[1], A. M. El-Banayosy[1], D. W. Schmidtke[2], M. R. Mihu[1], J. W. Long[1], A. El Banayosy[1]. *[1]Advanced Cardiac Care, INTEGRIS Baptist Medical Center, Oklahoma City, OK, [2]University of Texas at Dallas, Richardson, TX*

(737) ***Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Finland Between 2008 and 2020 (FINPAH) - A Descriptive Real-World Cohort Study;*** M. O. Pentikäinen[1], P. Simonen[1], H. Tuunanen[2], P. Leskelä[3], T. Harju[4], P. Jääskeläinen[5], E. Soini[6], C. Asseburg[6], P. Mankinen[6], C. Wennerström[7], A. Puhakka[8]. *[1]Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland, [2]Turku University Hospital, Turku, Finland, [3]Tampere University Hospital, Tampere, Finland, [4]Department of Internal Medicine, Oulu University Hospital, Oulu, Finland, [5]Kuopio University Hospital, Kuopio, Finland, [6]Esior Oy, Kuopio, Finland, [7]Janssen-Cilag AB, Solna, Sweden, [8]Janssen-Cilag Oy, Espoo, Finland*

(738) ***The Effect of Acute Alterations in Left Atrial Pressure on Rc Time in the Pulmonary Circulation;*** K. Kearney[1], P. Jain[2], A. Adji[3], K. Muthiah[4], D. Robson[5], D. Chemla[6], E. Kotlyar[7], A. Jabbour[8], C. Hayward[9], E. M. Lau[10]. *[1]St Vincent's Hospital, Darlinghurst, Australia, [2]St Vincent's Hospital, Waverley, Australia, [3]Victor Chang Cardiac Research Institute, Sydney, Australia, [4]St. Vincent's Hospital, Paddington, Australia, [5]St. Vincent's Hospital, Darlinghurst, Australia, [6]Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, Paris, France, [7]St Vincent's Hospital, Sydney, Darlinghurst, Australia, [8]Victor Chang Cardiac Research Institute St Vincent's Hospital, Darlinghurst, Australia, [9]St. Vincent's Hospital, Longueville, Australia, [10]Royal Prince Alfred Hospital, Camperdown, Australia*

(739) ***Malnutrition Severity is Associated with Worse Outcomes in Advanced Heart Failure Recipients;*** M. Mohamad Alahmad. *The University of Kansas Health System; Kansas University Medical Center, Kansas City, KS*

(740) ***Malnutrition is Associated with Worse Outcomes in Advanced Heart Failure Recipients;*** M. Mohamad Alahmad. *The University of Kansas Health System; Kansas University Medical Center, Kansas City, KS*

(741) ***Impact of Frailty on Mortality, Length of Stay, and Resource Utilization after Advanced Heart Failure Therapy;*** M. Mohamad Alahmad. *The University of Kansas Health System; Kansas University Medical Center, Kansas City, KS*

(742) ***Prognostic Value of Donor Specific Human Leukocyte Antibodies in Pre-Sensitized Heart Transplant Patients;*** H. Lee[1], G. Oh[2], H. Cho[3]. *[1]Seoul Nat'l Univ Hospital Seoul National University Hospital, Seoul, South Korea, [2]Seoul National University Hospital, Gangnan0Gu, [3]Seoul National University Hospital Seoul National University Hospital, Jongrogu*

(743) ***Heart Transplantation Characteristics and Outcomes in Recipients of Diabetic Donor Hearts;*** J. L. Gavin, A. M. Ganapathi, N. A. Mokadam, B. A. Whitson, M. C. Henn, G. J. Haas, A. K. Hasan, V. Franco, A. Vallakati, S. Emani, B. A. Foreman, V. N. Patel, I. Bole, B. C. Lampert. *The Ohio State University Wexner Medical Center, Columbus, OH*

(744) ***Comparison of Heart Transplantation Outcomes in Recipients of Insulin-Dependent Diabetic Donor Hearts Based Upon Duration of Insulin Use;*** J. L. Gavin, B. C. Lampert, A. K. Hasan, G. J. Haas, N. A. Mokadam, B. A. Whitson, M. C. Henn, V. Franco, A. Vallakati, S. Emani, B. A. Foreman, V. N. Patel, I. Bole, A. M. Ganapathi. *The Ohio State University Wexner Medical Center, Columbus, OH*

(745) ***Outcomes and Characteristics of Heart Transplant Recipients Requiring Oral Vasopressor Agents;*** K. Elkholey, K. Schlendorf, I. Biaggioni, K. Amancherla, D. Brinkley, J. Lindenfeld, J. Menachem, H. Ooi, D. Pedrotty, L. Punnoose, A. Rali, S. B. Sacks, M. Wigger, S. Zalawadiya, H. Siddiqi. *Vanderbilt University Medical Center, Nashville, TN*

(746) ***Impact of Recipient Age and Ecmo or Rrt Support on Post-Heart Transplant Outcomes: An Analysis of the Korean Organ Transplant Registry;*** J. Hyun[1], J. Youn[2], J. Kim[2], H. Cho[3], H. Lee[3], S. Kang[4], J. Kim[1], E. Jeon[5], J. Choi[5]. *[1]Asan Medical Center, Seoul, South Korea, [2]Seoul St. Mary's Hospital, Seoul, South Korea, [3]Seoul National University Hospital, Seoul, South Korea, [4]Severance Cardiovascular Hospital, Seoul, South Korea, [5]Samsung Medical Center, Seoul, South Korea*

(747) ***Incidence, Predictors and Outcomes of Acute Cardiac Conduction Abnormalities after Orthotopic Heart Transplant;*** L. K. Keyt[1], A. Lin[2], M. Begur[3], Q. Bui[4], A. Duran[5], M. Urey[6], E. Adler[7], V. Pretorius[8], J. B. Cruz Rodriguez[5]. *[1]University of California San Diego, San Diego, CA, [2]UCSD, San Diego, CA, [3]UC San Diego, La Jolla, CA, [4]UC San Diego, San Diego, CA, [5]Department of Medicine, Heart Failure/Cardiac Transplantation Program, University of California, San Diego, San Diego, CA, [6]UC San Diego Health, San Diego, CA, [7]Univ of California, SD, Apple Valley, CA, [8]UCSD, La Jolla, CA*

(748) ***Development and Validation of Specific Post-Transplant Risk Scores According to the Transplant Era: A Unos Cohort Analysis;*** M. Lescroart[1], E. Kransdorf[2], E. Desiré[1], J. Patel[3], G. Coutance[4]. *[1]Pitié-Salpêtrière Hospital, Paris, France, [2]Cedars-Sinai, Beverly Hills, CA, [3]Cedars-Sinai Smidt Heart Institute, Calabasas, CA, [4]Pitié-Salpetrière Hospital, Paris, France*

(749) ***Pulmonary Elastance (PEa) Has Greater Impact on RV Function Than PVR and Ratio of Pulmonary to Systemic Elastance (SEa) Predicts Survival after Heart Transplantation: A Clinical Study with Physiological Correlation from a Mathematical Model of the Cardiovascular System;*** K. R. Balakrishnan[1], K. G. Sureshrao[1], G. Rajagopalan[2], R. Krishnakumar[2], R. Ratnagiri[3]. *[1]Heart and Lung Transplantation, MGM Healthcare, Chennai, India, [2]Department of Engineering Design, Indian Institute of Technology (IIT) Madras, Chennai, India, [3]MGM Healthcare, Chennai, India*

(750) ***Determinants of Successful Bridging to Heart Transplantation on Temporary Percutaneous Left Ventricular Support - An Insight Using Artificial Intelligence;*** M. A. Al-Ani[1], C. Bai[2], B. Shickel[3], M. Bledsoe[4], M. M. Ahmed[1], J. Vilaro[1], A. Parker[5], J. Aranda[1], E. Jeng[5], M. Bleiweis[6], J. P. Jacobs[6], A. Bihorac[3], M. T. Mardini[2]. *[1]Cardiovascular medicine, University of Florida, Gainesville, FL, [2]Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, FL, [3]Medicine, University of Florida, Gainesville, FL, [4]UF Health Shands Hospital, Gainesville, FL, [5]University of Florida, Gainesville, FL, [6]UF Health Congenital Heart Center, Gainesville, FL*

(751) ***Estimation of Arrhythmia Risk in Patients with Fabry Disease Using a Machine Learning Model;*** J. Jefferies[1], P. Aguiar[2], G. Biondetti[3], D. Warnock[4], S. Kallish[5], M. Nelson[6], J. Giuliano[6], J. Zabinksi[3], C. Boussios[3], G. Curhan[3], J. Bandaria[3], R. Gliklich[3]. *[1]University of Tennessee Methodist Le Bonheur Healthcare, Memphis, TN, [2]Centro Hospitalar Lisboa Norte, Lisbon, Portugal, [3]OM1, Boston, MA, [4]UAB, Birmingham, AL, [5]University of Pennsylvania, Philadelphia, PA, [6]Amicus, Cranbury, NJ*

(752) ***Does Age Modify Racial Disparities in Mortality Among Patients with Heart Failure;*** M. Suliman[1], E. Rahman[2], K. Mansoor[1], M. Tashani[1], K. Zaheer[3], C. Rueda[4]. *[1]Cardiology, Marshall university, Huntington, WV, [2]Internal Medicine, St Marys Medical Center, Huntington, WV, [3]Internal Medicine, Marshall university, Huntington, WV, [4]Proctorville, OH*

(753) ***Estimation of Stroke Risk in Patients with Fabry Disease Using a Machine Learning Model;*** J. Jefferies[1], S. Kallish[2], G. Biondetti[3], P. Aguiar[4], M. Nelson[5], J. Giuliano[5], J. Zabinksi[3], C. Boussios[3], G. Curhan[3], J. Bandaria[3], R. Gliklich[3], D. Warnock[6]. *[1]University of Tennessee Methodist Le Bonheur Healthcare, Memphis, TN, [2]University of Pennsylvania, Philadelphia, PA, [3]OM1, Boston, MA, [4]Centro Hospitalar Lisboa Norte, Lisbon, Portugal, [5]Amicus, Cranbury, NJ, [6]UAB, Birmingham, AL*

(754) ***Hemodynamic Consequences of Right Ventricular (RV) Dysfunction in Left Heart Failure : Insights from a Mathematical Model with Clinical Correlation from Patients Awaiting a Heart Transplant;*** K. Balakrishnan[1], K. G. Sureshrao[2], R. Krishnakumar[3], G. Rajgopalan[4], R. Ratnagiri[5]. *[1]MGM Healthcare, Chennai, TN, India, [2]Heart and Lung Transplantation, MGM Healthcare, Chennai, India, [3]DEPARTMENT OF ENGINEERING DESIGN, Indian Institute of Technology (IIT) Madras, Chennai, India, [4]Department of Engineering Design, Indian Institute of Technology (IIT) Madras, Chennai, India, [5]MGM Hospital Chennai India, Chennai, India*

(755) ***Prescription of Aceis and Arbs on an Individualized Basis for Patients with Acute Myocardial Infarction;*** K. Kim. *Incheon Sejong Hospital, Incheon, South Korea*

(756) ***Immunogenicity of COVID-19 Vaccination in Cardiac Transplant Recipients: 5 Months Follow-Up after the 3rd Dose;*** A. Rahman[1], D. Golombeck[1], K. Malhame[2], D. Rossi[2], F. Wallach[3], M. Avila[1], S. Maybaum[1]. *[1]Department of Cardiology, Northwell Health, Manhasset, NY, [2]Department of Cardiothoracic Surgery, Northwell Health, Manhasset, NY, [3]Department of Medicine, Northwell Health, Manhasset, NY*

(757) ***Prolonged-Release Tacrolimus-Based Immunosuppression in Heart Transplant Recipients: 5-Year Follow-Up;*** G. Poglajen, S. Frljak, G. Zemljic, A. Cerar, M. Sebestjen, R. Okrajsek, N. Žorž, B. Vrtovec. *Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia*

(758) ***Evaluation of Donor Derived Cell-Free DNA in ABO Mismatched Heart Transplant Patients;*** D. Oren[1], C. M. Moeller[1], G. Rubinstein[1], D. Lotan[1], E. M. DeFilippis[1], Y. Mehlman[1], A. Raja[1], S. Slomovich[1], K. Clerkin[1], J. Fried[1], J. Raikhelkar[1], E. Lin[1], K. Oh[1], S. Lee[1], V. Topkara[1], F. Latif[1], D. Majure[2], G. Sayer[1], N. Uriel[1]. *[1]Columbia University Irving Medical Center, New York, NY, [2]Weill Cornell Medical College, New York, NY*

(759) ***Stroke and Survival Outcomes in Left Ventricular Device Patients;*** N. Berg[1], C. Shah[2], M. Guglin[3], H. Ferguson[4]. *[1]Cardiology, Indiana University School of Medicine, Indianapolis, IN, [2]Internal Medicine, Indiana University School of Medicine, Indianapolis, IN, [3]Indiana University, Indianapolis, IN, [4]Indiana Univeristy School of Medicine, Zionsville, IN*

(760) ***Is Chronic Kidney Disease Truly a Contraindication for Total Artificial Heart Candidacy and Subsequent Heart Transplantation;*** M. Kittleson, J. Patel, D. Chang, N. Patel, G. Esmailian, T. Singer-Englar, C. Runyan, J. Moriguchi, L. Czer, F. Esmailian, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(761) ***Does Donor Age Impact Outcomes for MCS Patients Undergoing Heart Transplantation;*** J. Patel, M. Kittleson, D. Chang, S. Kim, T. Singer-Englar, V. Dixon, B. Azarbal, L. Czer, A. Hage, F. Esmailian, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(762) ***Does Psychosocial Support Affect Survival in Patients with Left Ventricular Assist Devices?;*** I. Konstantinidis[1], R. Kompella[1], A. Jaiswal[2], K. McNamara-Diorio[2], J. Gluck[2], A. Maxfield[2]. *[1]Internal Medicine, University of Connecticut, Farmington, CT, [2]Hartford Hospital, Hartford, CT*

(763) ***The Interaction of Nutritional Status and Body Mass Index on Outcomes after LVAD Implantation;*** H. Fahey[1], F. H. Sheikh[1], N. Afari-Armah[1], P. H. Lam[1], M. Hofmeyer[1], A. Kadakkal[1], R. Gupta[1], S. S. Najjar[2], M. Krishnan[1], M. E. Rodrigo[1], M. Cellamare[1], C. Zhang[1], T. Elliott[1], S. Glocker[1], J. Rice[1], K. Balsara[1], A. Alassar[1], S. D. Rao[1]. *[1]MedStar Washington Hospital Center, Washington, DC, [2]MedStar Health, Baltimore, MD*

(764) ***Left Ventricular Assist Device Implantation Outcomes: Single-Center Experience in a Latin American Advanced Heart Failure Reference Program;*** L. Salazar[1], C. Rozo[2], A. Hurtado[3], S. A. Gomez-Ochoa[4], L. Echeverria[5]. *[1]ECMO and VAD program, Fundación Cardiovascular de Colombia, Floridablanca, Colombia, [2]Fundación Cardiovascular de Colombia, Bucaramanga, Colombia, [3]Epidemiology Unit, Fundación Cardiovascular de Colombia, Bucaramanga, Colombia, [4]Epidemiology, Fundación Cardiovascular de Colombia, Bucaramanga, Colombia, [5]Fundacion Cardiovascular de Colombia, Floridablanca, Colombia*

(765) ***Impact of Perioperative Sarcopenia and Dysphagia on LVAD Related Complications;*** M. Nishikawa[1], M. R. Carey[1], A. Ladanyi[1], G. M. Mondellini[1], A. Pinsino[1], K. Antler[2], E. Goldberg[2], J. Hastie[1], K. Clerkin[1], G. T. Sayer[1], N. Uriel[2], K. Takeda[1], P. C. Colombo[1], M. Yuzefpolskaya[1]. *[1]Columbia University Irving Medical Center, New York, NY, [2]New York Presbyterian Hospital, New York, NY*

(766) ***Improvement in Peak Oxygen Uptake During First Year of Mechanical Circulatory Support in End-Stage Heart Failure Patients - Follow Up on PRO-VAD Study;*** M. Szymanski[1], K. Mirza[2], N. De Jonge[1], T. Schmidt[3], D. Brahmbhatt[4], F. Billia[4], S. Hsu[5], G. MacGowan[6], D. G. Jakovljevic[6], P. Agostoni[7], F. Trombara[7], U. Jorde[8], Y. Rochlani[8], K. Vandersmissen[9], N. Reiss[3], S. Russell[10], B. Meyns[9], F. Gustafsson[2]. *[1]Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands, [2]Rigshospitalet, Copenhagen, Denmark, [3]Schuechtermann-Klinik, Bad Rothenfelde, Germany, [4]University Health Network, University of Toronto, Toronto, ON, Canada, [5]Johns Hopkins University School of Medicine, Baltimore, MD, [6]Freeman Hospital, Newcastle Upon Tyne, United Kingdom, [7]Centro Cardiologico Monzino, Milan, Italy, [8]Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, [9]UZ Leuven, Leuven, Belgium, [10]Duke University School of Medicine, Raleigh, NC*

(767) ***Impella 5.5 as Bridge to Heart Transplant Improves Mobility and Length of Stay after Transplant;*** J. Yet Kwong Horman[1], P. Mohan[1], S. Patel[2], M. Freundt[1], R. Dowling[3], H. Eisen[4], B. Mahesh[5]. *[1]Penn State Health, Hershey, PA, [2]Rutgers University School of Engineering, New Brunswick, NJ, [3]Hershey, PA, [4]Penn State Milton S. Hershey Medical Center, Hershey, PA, [5]Penn State Hershey Medical Center, Hummelstown, PA*

(768) ***Hospital Readmissions in Patients Supported with Durable Centrifugal-Flow Left Ventricular Assist Devices;*** C. P. Kyriakopoulos[1], T. Giannouchos[2], R. Mylavarapu[1], E. Krauspe[1], E. Sheffield[1], K. Sideris[1], A. Elmer[1], N. Vance[1], S. Carter[1], T. Hanff[1], O. Wever-Pinzon[1], J. Stehlik[1], C. Selzman[1], S. G. Drakos[1], M. Goodwin[1]. *[1]University of Utah Health and School of Medicine & George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, [2]Arnold School of Public Health, University of South Carolina, Columbia, SC*

(769) ***Patient Survival and Prevalence of Substance Use at the Time of Left Ventricular Assist Device Implantation and at One Year Post Implant;*** A. Merlo[1], P. Tasoudis[2], M. Byku[3], C. Chien[4], J. Ikonomidis[5], P. Tessmann[1], T. Caranasos[2]. *[1]University of North Carolina, Chapel Hill, NC, [2]Surgery, University of North Carolina, Chapel Hill, NC, [3]University of North Carolina in Chapel Hill, Saint Louis, MO, [4]University of North Carolina, Raleigh, NC, [5]Univ of North Carolina at Chapel Hill, Chapel Hill, NC*

(770) ***Chronic Renal Replacement Therapy in Patients with Durable Left Ventricular Assist Devices;*** A. S. Madgula[1], J. Brocious[1], M. Lander[2], A. Raina[1], M. Kanwar[1]. *[1]Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, [2]Allegheny Health Network, Pittsburgh, PA*

(771) ***Post-Implant Outcomes in Diabetic vs. Non-Diabetic Durable LVAD Patients;*** S. Verma, A. Ramsay, K. Drezek, A. Pico, O. Chubrikova, J. Barnes, J. R. Guiry, T. Winship, D. A. D'Alessandro, V. Ton, E. Coglianese. *Massachusetts General Hospital, Boston, MA*

(772) ***Fully Magnetically Levitated Continuous Flow Left Ventricular Assist Device: Are We There Yet?;*** T. Frahm, A. G. Kfoury, W. T. Caine, R. Ehlert, V. Hebl, B. Reid, K. House, R. A. Butschek, D. Mohebali, R. Alharethi. *Cardiovascular Medicine, Intermountain Medical Center, Murray, UT*

(773) ***Rethinking Early Clinical Trials: Design of the CorWave LVAD Feasibility Trial;*** J. A. Cowger[1], W. Cornwell[2], C. Hayward[3], P. Jansz[4], M. Strueber[5], D. Zimpfer[6], Y. Pya[7], M. Kanwar[8], A. El Banayosy[9], P. Leprince[10], F. Gustafsson[11], S. Tsui[12], T. A. Snyder[13]. *[1]Henry Ford Hospitals, Detroit, MI, [2]University of Colorado, Parker, CO, [3]St. Vincent's Hospital, Longueville, Australia, [4]St Vincent's Hospital, Darlinghurst, Australia, [5]Baptist Medical Group, Ada, MI, [6]Medical University Vienna, Vienna, Austria, [7]National Res Center for Cardiac Surgery, Astana, Kazakhstan, [8]Allegheny General Hospital, Pittsburgh, PA, [9]Nazih Zuhdi Transplant Institute, Edmond, OK, [10]Hopital de La Pitie Salpetriere, Sorbonne University, Paris, 75, France, [11]Rigshospitalet, Copenhagen, Denmark, [12]Royal Papworth Hospital, Cambridge, United Kingdom, [13]CorWave, Clichy, France*

(774) ***Gender Disparities in the Heart Transplant Implantation: A Nationwide Study from 2009-2020;*** M. Faisaluddin[1], A. Zaky Ahmed[1], H. Patel[2], S. Thakkar[3], S. S. Dani[4], R. Alweis[1], S. Feitell[1]. *[1]Rochester General Hospital, Rochester, NY, [2]Southern Illinois University, Springfield, IL, [3]Houston Methodist Hospital, Houston, TX, [4]Lahey Hospital & Medical Center, Burlington, MA*

(775) ***Racial and Regional Disparities in Lvad Utilization: A Nis Database Analysis 2009-2020;*** M. Faisaluddin[1], A. Zaky Ahmed[1], H. Patel[2], S. Thakkar[3], S. S. Dani[4], R. Alweis[1], S. Feitell[1]. *[1]Rochester General Hospital, Rochester, NY, [2]Southern Illinois University, Springfield, IL, [3]Houston Methodist Hospital, Houston, TX, [4]Lahey Hospital & Medical Center, Burlington, MA*

(776) ***Burden of Arrythmias and Hospital Outcomes Among Patients with Left Ventricular Assisted Device Patients: A Nis Database Analysis from 2015-2020;*** M. Faisaluddin[1], A. Zaky Ahmed[1], H. Patel[2], S. Thakkar[3], S. S. Dani[4], R. Alweis[1], S. Feitell[1]. *[1]Rochester General Hospital, Rochester, NY, [2]Southern Illinois University, Springfield, IL, [3]Houston Methodist Hospital, Houston, TX, [4]Lahey Hospital & Medical Center, Burlington, MA*

(777) ***Successful Bridge From Va-Ecmo to Heart Transplant in an Adult after Mechanical Thrombectomy for Acute Ischemic Stroke;*** S. Riaz[1], M. Hakim[2], T. V. Mehta[3], A. Jaiswal[4], A. Scatola[4]. *[1]Cardiology, Hartford Hospital/University of Connecticut, Hartford, CT, [2]Radiology, Hartford Hospital, Hartford, CT, [3]Neurology, Hartford Hospital, Hartford, CT, [4]Cardiology, Hartford Hospital, Hartford, CT*

(779) ***Persistent Cardiogenic Shock after Valve in Valve TAVR Rescued with Durable LVAD;*** S. Sundaravel[1], J. Wald[2], R. Senker[3], M. Cevasco[4], J. H. Giri[1], N. Desai[5], J. Ortega-Legaspi[6], J. Pieretti[7], A. Owens[1], M. Genuardi[8], L. Holzhauser[1]. *[1]University of Pennsylvania, Philadelphia, PA, [2]University of Pennsylvania Hospital, Philadelphia, PA, [3]Hospital of the University of Pennsylvania, Philadelphia, PA, [4]Hospital of the University of Pennsylvania, Villanova, PA, [5]University of Pennsylvania, University of Pennsylvania, Philadelphia, PA, [6]University of Pennsylvania, Bala Cynwyd, PA, [7]Hospital of the University of Pennsylvania, Wayne, PA, [8]*

(780) ***Transcatheter Aortic Valve-In-Valve Implantation in Patients with Left Ventricular Assisted Device;*** R. Harada[1], O. Al-Abboud[2], A. Kazem[1], T. George[3], S. Potluri[1], M. Szerlip[1], J. I. Ejiofor[4], K. B. Harrington[4], J. Schaffer[4], N. Kabra[5], D. Rawitscher[6], A. Afzal[7]. *[1]Division of Cardiology, Baylor Scott and White the Heart Hospital Plano, Plano, TX, [2]Baylor Scott and White, Plano, TX, [3]The Heart Hospital Baylor Plano, Dallas, TX, [4]Division of Cardiothoracic Surgery, Baylor Scott and White the Heart Hospital Plano, Plano, TX, [5]La Jolla, CA, [6]The Heart Hospital Baylor Plano, Plano, TX, [7]Baylor University Medical Center, Dallas, TX*

(781) ***Sanguine Success: Bloodless Implantation of a LVAD in a Jehovah's Witness;*** R. Umrani[1], R. Judge[2], V. Singh[3], M. Moshiyakhov[4], K. Barn[5], R. E. Ross[2]. *[1]Rowan University School of Osteopathic Medicine, Stratford, NJ, [2]Deborah Heart and Lung Center, Browns Mills, NJ, [3]Ocala, FL, [4]Cardiology, Deborah Heart and Lung Center, Browns Mills, NJ, [5]Deborah Heart and Lung Center, Robbinsville, NJ*

(782) ***Use of Extracorporeal Membrane Oxygenation in Ranolazine Overdose;*** J. McLeod[1], H. Rosenblum[1], P. Kennel[1], D. Lotan[1], G. Rubinstein[1], C. Moeller[1], K. Theodoropoulos[1], J. Raikhelkar[1], K. Clerkin[1], G. Sayer[1], Y. Kaku[1], K. Takeda[2], N. Uriel[1], J. Fried[1]. *[1]Division of Cardiology -Center for Advanced Cardiac Care, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY, [2]Division of Cardiothoracic Surgery, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY*

(783) ***LVAD as a Bridge to Candidacy in a Patient with Left Ventricular Noncompaction Cardiomyopathy Complicated by RHF;*** L. Aguilar[1], A. Delgado[1], E. Grandin[1], P. Quintero[1], L. Fleming[1], S. Motiwala[1], R. Sriwattanakomen[1], J. Ho[1], C. Lee[1], A. Malinn[1], S. Frias[1], B. Nicole[1], L. Chu[2], A. Garan[1], M. Sabe[1]. *[1]Advanced Heart Failure, Beth Israel Deaconess Medical Center, Boston, MA, [2]Thoracic and Cardiac Surgery, Beth Israel Deaconess Medical Center, Boston, MA*

(784) ***Impella 5.5 Use as a Bridge to Transplant in Hereditary Transthyretin Amyloidosis;*** N. Maliakkal[1], H. Shakoor[1], S. McKean[2], C. Harrison[3], J. van Zyl[4], R. Patel[5], M. Sherwood[5], S. Hall[5], A. Alam[5]. *[1]Baylor Scott and White Research Institute, Dallas, TX, [2]Baylor University Medical Center, Murphy, TX, [34]Baylor Scott & White Health, Dallas, TX, [5]Baylor University Medical Center, Dallas, TX*

(785) ***Successful Ventricular Tachycardia Ablation in a Patient with Biventricular Support Post Heartmate 3 Implantation;*** O. A. Al-Abboud[1], R. Harada[2], M. Alom[3], G. Bhattal[4], N. Kabra[5], D. Rawitscher[6], A. Afzal[7], A. Yousif[8], T. George[9]. *[1]Advanced Heart Failure, Baylor Scott and White, Plano, TX, [2]Cardiology, Baylor Scott and White, Plano, TX, [3]Baylor University Medical Center/The Heart Hospital Plano, Plano, TX, [4]The Heart Hospital Baylor Scott and White Plano, Plano, TX, [5]La Jolla, CA, [6]The Heart Hospital Baylor Plano, Plano, TX, [7]Baylor University Medical Center, Dallas, TX, [8]Electrophysiology, Baylor Scott and White, Plano, TX, [9]The Heart Hospital Baylor Plano, Dallas, TX*

(786) ***Bridge to Resection: Impella 5.5 Support for High-Risk Neurosurgery;*** M. Tagliafierro[1], M. Alsaloum[2], F. Vargas[2], T. Mawson[2], M. Hassanein[2], B. Gill[2], J. Raikhelkar[2], J. Fried[2], Y. Kaku[2], M. Yuzefpolskaya[2], S. Ravalli[2], H. Rosenblum[2]. *[1]Sapienza University of Rome, Rome, Italy, [2]Columbia University College of Physicians & Surgeons, New York, NY*

(787) ***Escalation of Mechanical Circulatory Support in a Patient with an Acute Myocardial Infarction, Cardiogenic Shock and Refractory Ventricular Tachycardia;*** A. Isath[1], S. Ohira[2], E. Hoch[3], D. Frenkel[3], J. Jacobson[3], G. Lanier[4], M. Kai[3], A. Gass[3], E. Levine[5]. *[1]Department of Cardiology, Westchester Medical Center,New York Medical College, Valhalla, NY, [2]Westchester Medical Center, New York Medical College, Valhalla, NY, [3]Westchester Medical Center, Valhalla, NY, [4]Westchester Medical Center, New York, NY, [5]Westchester Medical Center, Teaneck, NJ*

(788) ***A Mock Circulatory Loop Analysis of the Procyrion Aortix Pump;*** S. Barua[1], P. Lo[1], M. Stephens[2], G. Vazquez[2], S. Diab[3], J. Krisher[3], J. Heuring[3], K. Muthiah[1], C. Hayward[1]. *[1]St Vincent's Hospital Sydney, Darlinghurst, Australia, [2]University of New South Wales, Kensington, Australia, [3]Procyrion, Houston, TX*

(789) ***The Patients' Point of View: Eye Tracking Based Human Factors Analysis of Simulated Everyday and Emergency Scenarios with HeartMate 3 LVAD Peripherals;*** G. Widhalm[1], T. Abart[1], M. Noeske[1], L. Kumer[2], L. Rössler[2], C. Atteneder[1], A. Berger[2], G. Laufer[1], D. Wiedemann[1], D. Zimpfer[1], H. Schima[3], M. Wagner[2], T. Schloeglhofer[1]. *[1]Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, [2]Divison of Neonatology, Department of Pediatrics, Medical University of Vienna, Vienna, Austria, [3]Center for Medical Physics and Biomedical Engineering, Medical University Vienna Austria, Vienna, Austria*

(790) ***Safety and Utility of Low-Flow Controller in Heartmate 3 LVAD Patients;*** M. A. Cagliostro[1], J. Roldan[2], A. Young[2], A. Folch Sandoval[1], M. Barghash[2], N. Moss[2]. *[1]Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, [2]Cardiology, The Mount Sinai Hospital, New York, NY*

(791) ***Clinical Implications of Hemodynamic Assessment in Small Body Surface Area Patients with Left Ventricular Assist Device;*** T. Sato[1], S. Takenaka[1], S. Kazui[1], Y. Yasui[1], K. Saiin[1], S. Naito[1], Y. Takahashi[1], Y. Mizuguchi[1], A. Tada[1], Y. Kobayashi[1], K. Omote[1], T. Konishi[1], K. Kamiya[1], T. Ooka[2], T. Nagai[1], S. Wakasa[2], T. Anzai[1]. *[1]Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan, [2]Department of Cardiovascular and Thoracic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan*

(792) ***Does Right Ventricular Support with Mechanical Assist Devices Compromise Outcome for Heart Transplantation?;*** J. Patel, M. Kittleson, J. Moriguchi, T. Singer-Englar, S. Kim, F. De Leon, C. Runyan, L. Czer, D. Emerson, D. Megna, F. Esmailian, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(793) ***Validation of the Heartmate 3 Survival Risk Score in a Large Left Ventricular Assist Device Center;*** C. M. Moeller[1], G. Rubinstein[1], D. Lotan[1], D. Oren[1], K. Clerkin[1], J. Raikhelkar[1], P. Colombo[1], N. Leahy[1], J. Fried[1], K. Takeda[2], Y. Naka[2], V. Topkara[1], M. Yuzefpolskaya[1], G. Sayer[1], N. Uriel[1]. *[1]Division of Cardiology, Center of Advanced Cardiac Care, Columbia University Irving Medical Center, New York, NY, [2]Department of Cardiothoracic Surgery, Columbia University Irving Medical Center, New York, NY*

(794) ***Achieving Equity in Minority Populations by Using the "Hub-And-Spoke" Model for Durable Left Ventricular Assist Devices;*** K. Mahmood, J. Contreras, A. Omar, A. Fox, Y. Balboul, M. Lorente Ros, M. Riasat, J. Roldan, A. Correa, P. Pirlamarla, A. Parikh, N. Moss, A. Anyanwu, C. Gidea. *Icahn School of Medicine at Mount Sinai, New York, NY*

(795) ***Associations Between Obesity and Outcomes After Left Ventricular Assist Device Implantation;*** R. Chia[1], P. Kazemian[2], L. Chec[3], B. Bhikadiya[3], M. Sobieraj[1], A. Balatsky[3], M. Moshiyakhov[4], P. Burns[5], K. Barn[6]. *[1]Cardiology, Thomas Jefferson University / Deborah Heart and Lung Center, Browns Mills, NJ, [2]Electrophysiology, Deborah Heart and Lung Center, Browns Mills, NJ, [3]Deborah Heart and Lung Center, Browns Mills, NJ, [4]Cardiology, Deborah Heart and Lung Center, Browns Mills, NJ, [5]Cardiothoracic Surgery, Deborah Heart and Lung Center, Browns Mills, NJ, [6]Advanced Heart Failure, Deborah Heart and Lung Center, Browns Mills, NJ*

(796) ***Should Psychosocial Standards for DT LVAD be Different Than for Transplant? Interim Results from a Delphi Panel;*** C. Knoepke[1], A. Latimer[2], K. Malaer[3], G. E. Yoder[4], B. Siry-Bove[5], C. Mayton[6], J. E. Portz[4], P. Khazanie[7]. *[1]Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, [2]University of Kentucky School of Nursing, Lexington, KY, [3]Memorial Hermann, Houston, TX, [4]University of Colorado School of Medicine, Aurora, CO, [5]University of Albany, Albany, NY, [6]Virginia Commonwealth University, Richmond, VA, [7]Univ of Colorado, Aurora, CO*

(797) ***Implantation from Short Term MCS to Durable VAD: Single Center Experience;*** S. Stewart[1], K. P. Mody[2], P. Walters[3], C. Silva[4], B. Kim[5], D. Silber[1], K. Satya[6], R. Berkowitz[1], E. Elmann[7], M. Anderson[1], G. Batsides[1]. *[1]Hackensack University Medical Center, Hackensack, NJ, [2]Cardiology, Hackensack University Medical Center, Hackensack, NJ, [3]Hackensack University Medical Center, Secaucus, NJ, [4]Hackensack Meridian Health, Metuchen, NJ, [5]Hackensack Univ Med Ctr, Hackensack, NJ, [6]Hackensack UMC, Hackensack, NJ, [7]Hackensack UMC Heart Vascular, Hackensack, NJ*

(798) ***Safety of Levosimendan Infusion Before LVAD Implantation. A Retrospective Study;*** R. Godinho[1], A. Nowacka[2], S. Aur[1], J. Regamey[1], Z. Ltaief[3], M. Rusca[3], R. Hullin[1], L. Liaudet[3], M. Kirsch[4], P. Yerly[4]. *[1]Department of Heart-Vessels, Division of Cardiology, Lausanne University Hospital, Lausanne, Switzerland, [2]Department of Heart-Vessels, Division of Cardiac Surgery, Lausanne University Hospital, Lausanne, Switzerland, [3]Service of Adult Intensive Care Medicine, Lausanne University Hospital, Lausanne, Switzerland, [4]Lausanne University Hospital, Lausanne, Switzerland*

(799) ***Impact of Lv Venting During Va-Ecmo Support on Survival Outcomes: A Contemporary 5-Year Analysis of a Single Center Experience;*** K. Ginder[1], C. Riddle[2], J. Cox[3], A. Amin[2], P. Mammen[4], F. Araj[5]. *[1]Cardiology, Advanced Heart Failure, UT Southwestern Medical Center, Dallas, TX, [2]UT Southwestern, Dallas, TX, [3]Parkland Memorial Hospital and Health System, Dallas, TX, [4]UT Southwestern Medical Center, Plano, TX, [5]UT Southwestern Medical Center, Dallas, Texas, Dallas, TX*

(800) ***Systemic Effects of Impella 5.5 Purge Solution in Patients with Heart Failure Cardiogenic Shock;*** S. Desai[1], M. Soto-Arenall[2], J. Ruiz[1], A. Postell[2], S. Paghdar[1], S. Malkani[1], J. Nativi[1], P. Patel[1], D. Yip[1], M. Lyle[1], J. Leoni[1], R. Goswami[1]. *[1]Transplant, Mayo Clinic, Jacksonville, FL, [2]Pharmacy, Mayo Clinic, Jacksonville, FL*

(801) ***An Analysis of the Effect of an Advanced Heart Failure Program on ECMO Outcomes at a Tertiary Care Center in Hawaii;*** J. Zhang[1], T. Nagamine[1], K. Vu[1], M. Ali[1], N. Limpruttidham[1], J. Pino Moreno[1], D. Banerjee[2]. *[1]University of Hawaii, Honolulu, HI, [2]University of Hawai'i, Honolulu, HI*

(802) ***Determinants of Cardiac Index Improvement after Intra-Aortic Balloon Pump Insertion;*** F. Castagna[1], G. Chalhoub[1], P. Ippolito[1], O. Saeed[2], D. Sims[3], U. Jorde[4]. *[1]Montefiore Medical Center, New York, NY, [2]Montefiore Medical Ctr, New York, NY, [3]Montefiore Medical Center NY, New York, NY, [4]Montefiore Medical Center, Bronx, NY*

(803) ***Early Adverse Events Post-Iabp Discontinuation are Reduced with a Rapid Daily Structured Iabp Assessment;*** F. Castagna[1], P. Ippolito[1], G. Chalhoub[1], O. Saeed[2], D. Sims[3], U. Jorde[4]. *[1]Montefiore Medical Center, New York, NY, [2]Montefiore Medical Ctr, New York, NY, [3]Montefiore Medical Center NY, New York, NY, [4]Montefiore Medical Center, Bronx, NY*

(804) ***Predictors of Poor Early Hemodyamic Response to Intra-Aortic Balloon Pump;*** F. Castagna[1], G. Chalhoub[1], P. Ippolito[1], O. Saeed[2], D. Sims[3], U. Jorde[4]. *[1]Montefiore Medical Center, New York, NY, [2]Montefiore Medical Ctr, New York, NY, [3]Montefiore Medical Center NY, New York, NY, [4]Montefiore Medical Center, Bronx, NY*

(805) ***Novel Left Ventricular Unloading Strategies in Patients on Peripheral Venoarterial Extracorporeal Membrane Oxygenation;*** S. Inglis[1], A. Rosenbaum[1], C. Cassianni[1], J. Anderson[1], S. Yalamuri[1], P. Spencer[1], M. Villavicencio[2], A. Behfar[1]. *[1]Mayo Clinic, Rochester, MN, [2]Mayo Clinic, Rochester, Rochester, MN*

(806) ***Ethnic and Geographic Distribution of Patients Undergoing ECMO at aTertiary Referral Center in the State of Hawaii;*** J. Zhang[1], T. Nagamine[1], K. Vu[1], M. Ali[1], N. Limpruttidham[1], J. Pino Moreno[1], D. Banerjee[2]. *[1]University of Hawaii, Honolulu, HI, [2]University of Hawai'i, Honolulu, HI*

(807) ***The Impact of Axillary Mechanical Circulatory Support in Patients Awaiting Heart Transplantation with Pulmonary Hypertension;*** J. Ruiz, S. Desai, S. Paghdar, S. Malkani, J. Nativi, D. Yip, P. Patel, J. Leoni, M. Lyle, R. Goswami. *Transplant, Mayo Clinic, Jacksonville, FL*

(808) ***Hemodynamic Response after Intra-Aortic Balloon Counter-Pulsation in Cardiac Amyloidosis and Cardiogenic Shock;*** J. Longinow, Z. Il'Giovine, P. Martens, A. Higgins, E. G. Soltesz, M. Z. Tong, J. D. Estep, R. C. Starling, W. Tang, M. Hanna, R. Lee. *Heart Vascular and Thoracic Institute, Department of Heart Failure and Transplantation, Cleveland Clinic Foundation, Cleveland, OH*

(809) ***Outcomes of Refractory Cardiogenic Shock (CS) Patients Supported by Impella 5.5 as a Bridge to Recovery or Advanced HF Therapies;*** A. M. El Banayosy, D. Vanhooser, M. Bell, D. Horstmanshof, L. Cunningham, M. Corder, M. Maybauer, J. Long, A. El Banayosy. *Integris Baptist Medical Center, Oklahoma City, OK*

(810) ***Nationwide Utilization, Cost, and Outcome of Temporary Mechanical Circulatory Support in Takotsubo Cardiomyopathy;*** N. Thalia[1], K. Patel[2], N. Patel[3]. *[1]University of California, Los Angeles, CA, [2]Cardiology, Nazareth Hospital, Philadelphia, PA, [3]Cardiology, University of California, Los Angeles, CA*

(811) ***Incidence of Right Ventricular Dysfunction in Lvad Patients Bridged with High Dose Inotropes;*** K. P. Mody[1], P. Walters[2], S. Stewart[3], C. Silva[4], Y. Dudiy[2], E. Elmann[2], A. Ng[2], D. Landers[1], G. P. Batsides[2], M. B. Anderson[2]. *[1]Cardiology, Hackensack University Medical Center, Hackensack, NJ, [2]Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, NJ, [3]Hackensack University Medical Center, Hackensack, NJ, [4]Hackensack Meridian Health, Metuchen, NJ*

(812) ***A Misty Case of Left Ventricular Thrombus Demystified by Cardiopulmonary Bypass;*** S. Miyashita[1], J. Ortoleva[2], A. Vest[1], G. Couper[1], M. Kawabori[1]. *[1]CardioVascular Center, Tufts Medical Center, Boston, MA, [2]Anesthesia, Tufts Medical Center, Boston, MA*

(813) ***Prolonged Cardiopulmonary Resuscitation with Lucas Device in a Patient with Left Ventricular Assist Device;*** C. Theeuwes[1], M. Frost[1], J. Vierecke[2]. *[1]Internal Medicine Residency Program, University of Cincinnati, Cincinnati, OH, [2]Division of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, OH*

(814) ***Successful Surgical and Percutaneous Ventricular Tachycardia Ablation for Heartmate-3 LVAD Management: A Case Series;*** G. Bhattal[1], M. Alom[2], D. Rawitscher[3], N. Kabra[4], A. K. Yousif[5], T. George[6], A. Afzal[7]. *[1]The Heart Hospital Baylor Scott and White Plano, Plano, TX, [2]Baylor University Medical Center/The Heart Hospital Plano, Plano, TX, [3]The Heart Hospital Baylor Plano, Plano, TX, [4]La Jolla, CA, [5]Electrophysiology, The Heart Hospital Baylor Scott and White Plano, Plano, TX, [6]The Heart Hospital Baylor Plano, Dallas, TX, [7]Baylor University Medical Center, Dallas, TX*

(815) ***Endovascular Management of Extrinsic Lvad Outflow Tract Obstructions- A Case Series;*** K. Kochar[1], N. Ruggiero[2], A. Vishnevsky[2], H. Massey[3], J. Rame[2], R. Alvarez[2], I. Rajapreyar[2], Y. Brailovsky[2]. *[1]Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, [2]Cardiology, Thomas Jefferson University Hospital, Philadelphia, PA, [3]Cardiac Surgery, Thomas Jefferson University Hospital, Philadelphia, PA*

(816) ***Mechanical Circulatory Support as a Bridge to Recovery in Acute Fulminant Myocarditis with Cardiogenic Shock;*** S. Mahabir[1], A. Madgula[1], G. S. Samra[1], C. Link[1], M. Lander[2], M. Kanwar[1]. *[1]Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, [2]Allegheny Health Network, Pittsburgh, PA*

(817) ***Lvad-Stem Cell Combination Therapy in Non-Ischemic Dilated Cardiomyopathy Patient: Case Report;*** G. Poglajen[1], S. Frljak[1], G. Zemljic[1], A. Cerar[1], R. Okrajsek[1], M. Sebestjen[1], N. Žorž[1], I. Knezevic[2], B. Vrtovec[1]. *[1]Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, [2]Department of Surgery, UMC Ljubljana, Ljubljana, Slovenia*

(818) ***Hemodynamic Optimization in Patients With a Durable Leftventricular Assisted Device with CardioMEMS;*** R. Harada[1], B. Daniel[1], T. George[2], G. Bhattal[3], M. Alom[4], N. Kabra[5], D. Rawitscher[6], A. Afzal[7]. *[1]Division of Cardiology, Baylor Scott and White the Heart Hospital Plano, Plano, TX, [2]The Heart Hospital Baylor Plano, Dallas, TX, [3]The Heart Hospital Baylor Scott and White Plano, Plano, TX, [4]Baylor University Medical Center/The Heart Hospital Plano, Plano, TX, [5]La Jolla, CA, [6]The Heart Hospital Baylor Plano, Plano, TX, [7]Baylor University Medical Center, Dallas, TX*

(819) ***Pulmonary Artery Banding to Optimize Ventricular Interaction after Lvad Explant Following Myocardial Recovery;*** B. Langanecha[1], A. Jeewa[2], M. Mazwi[2], O. Zaulan[2], E. Jean-St-Michel[3], C. Haller[2], O. Honjo[2], A. Lynch[2], K. George[4], L. Fazari[2], A. Maurich[2]. *[1]Pediatric Cardiology, The Hospital for Sick Children, Toronto, ON, Canada, [2]The Hospital for Sick Children, Toronto, ON, Canada, [3]Hospital for Sick Children, Toronto, ON, Canada, [4]Sick Kids, Toronto, ON, Canada*

(820) ***Percutaneous Removal of Pulmonary Emboli in a Patient with Right Ventricular Failure after LVAD Implantation;*** M. K. Szymanski[1], E. E. van Aarnhem[2], O. L. Cremer[3], M. G. van der Meer[1], N. P. van der Kaaij[2], A. O. Kraaijeveld[1]. *[1]Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands, [2]Cardiothoracic Surgery, University Medical Centre Utrecht, Utrecht, Netherlands, [3]Intensive Care, University Medical Centre Utrecht, Utrecht, Netherlands*

(821) ***Biopsy-Proven Fulminant Myocarditis Requiring Mechanical Circulatory Support Following Third Dose of COVID-19 MRNA Vaccination;*** T. Hamaya[1], T. Sato[1], Y. Kobayashi[1], Y. Mori[1], K. Kamiya[1], N. Otsuka[2], T. Nagai[1], T. Anzai[1]. *[1]Department of Cardiovascular Medicine, Hokkaido University, Sapporo, Japan, [2]Department of Surgical Pathology, Hokkaido University, Sapporo, Japan*

(822) ***Recurrent Pyogenic Granulomas Complicating a Driveline Site;*** I. A. Zepeda[1], A. Lloji[1], J. Kim[1], Y. Naka[2], M. Karas[1], E. Horn[1], I. Sobol[1]. *[1]Weill Cornell Medicine-New York Presbyterian, New York, NY, [2]New York Presbyterian Hospital, New York, NY*

(823) ***Survival of the Unfittest: The Longest Living LVAD-Supported Patient with DMD-Associated Cardiomyopathy;*** S. Godfrey[1], F. Araj[2], N. Hendren[3], A. Amin[4], E. Hardin[5], S. Garg[1], J. Grodin[4], R. Morlend[6], J. Thibodeau[1], M. Peltz[1], M. Drazner[1], M. Farr[7], P. Mammen[8]. *[1]UT Southwestern Medical Center, Dallas, TX, [2]UT Southwestern Medical Center, Dallas, Texas, Dallas, TX, [34]UT Southwestern, Dallas, TX, [5]UT Southwestern Medical Center UT Southwestern, Dallas, TX, [6]UT Southwestern Medical Center, Dallas, [7]Columbia University, Dallas, TX, [8]UT Southwestern Medical Center, Plano, TX*

(824) ***Stereotactic Arrhythmia Radioablation (STAR) as Treatment for Recurrent Ventricular Tachycardia (VT) in Two Patients with Left Ventricle Assist Devices (LVAD);*** G. S. Samra[1], S. Mahabir[1], A. Madgula[1], M. Kanwar[2], M. G. Trombetta[3], O. Seungjong[3], T. Cherian[4], J. Silverstein[4], W. Belden[4], M. Friehling[4], E. Liu[4], A. Thosani[4], G. Shaw[4]. *[1]Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, [2]Division of Advanced Heart Failure and Transplant, Allegheny General Hospital, Pittsburgh, PA, [3]Radiation Oncology, Allegheny Health Network, Pittsburgh, PA, [4]Division of Electrophysiology, Allegheny Health Network, Pittsburgh, PA*

(825) ***Heartmate 3 and Home Hemodialysis as a Bridge to Heart-Kidney Transplantation;*** N. Ibarra Marquez[1], E. Sole[1], M. Castel[1], J. Broseta[2], E. Sandoval[3], P. Caravaca[1], A. Sa[1], P. Cordoba[1], I. Forado[1], J. Rodriguez[1], J. Casal[1], E. Torrecilla[1], L. Izquierdo[1], C. Simon[1], E. Quintana[4], M. Farrero Torres[5]. *[1]Advanced Heart Failure and Heart Transplant, Hospital Clinic de Barcelona, Barcelona, Spain, [2]Nephrology, Hospital Clinic de Barcelona, Barcelona, Spain, [3]Barcelona, B, Spain, [4]Cardiothoracic Surgery, Hospital Clinic de Barcelona, Barcelona, Spain, [5]Hospital Clinic de Barcelona, Barcelona, Spain*

(826) ***Dual VADs to Dual Organs: Successful Bridge to Heart and Kidney Transplantation with 2 HeartMate 3 LVADs in Biventricular Failure;*** L. Njoroge[1], R. Malyala[1], L. Meece[2], E. Jeng[2], M. Ahmed[2], E. Birks[1]. *[1]University of Kentucky, Lexington, KY, [2]University of Florida, Gainesville, FL*

(827) ***Hemi-Diaphragmatic Plication in LVAD Patients with Post-Implantation Diaphragm Paralysis;*** M. Alom[1], G. Bhattal[2], O. Al-Abboud[3], M. Alex[1], M. Salih[4], A. Kazem[5], N. Kabra[6], D. Rawitscher[7], T. George[8], A. Afzal[9]. *[1]Baylor University Medical Center/The Heart Hospital Plano, Plano, TX, [2]The Heart Hospital Baylor Scott and White Plano, Plano, TX, [3]Baylor Scott and White, Plano, TX, [4]Baylor University Medical Center/ The Heart Hospital Plano, Plano, TX, [5]Baylor Scott & White The Heart Hospital - Plano, Plano, TX, [6]La Jolla, CA, [7]The Heart Hospital Baylor Plano, Plano, TX, [8]The Heart Hospital Baylor Plano, Dallas, TX, [9]Baylor University Medical Center, Dallas, TX*

(828) ***Apixaban Anticoagulation in Children and Young Adults Supported with the Heartmate 3™ Ventricular Assist Device;*** R. L. Kobayashi, P. Esteso, M. Cetatoiu, C. Ventresco, B. Hawkins, K. Daly, F. Fynn-Thompson, C. Vander Pluym. *Boston Children's Hospital, Boston, MA*

(829) ***Self-Management if Anticoagulation in Patients with Lvad, is There a Cost to Anticoagulation on Target?;*** B. Schnegg[1], D. Jenni[1], M. Fürholz[1], C. Muster[1], L. Capek[1], P. Lombardo[2], L. Kopfstein[3], S. Chavali[4], C. Hayward[4], M. Martinelli[1], L. Hunziker[1]. *[1]Centre for Advanced Heart Failure, Inselspital, University Hospital Bern, Bern, Switzerland, [2]Cabinet Medical du Chauderon, Chexbres, Switzerland, [3]Stiftung Coagulation Care, Lucern, Switzerland, [4]Heart Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia*

(830) ***Are You Happy Now? Satisfaction of Patients on LVAD Switched from Warfarin to Direct Oral Anticoagulation (DOAC). First Result of the Apixivad Study;*** B. Schnegg[1], S. Chavali[2], C. Hayward[2]. *[1]Centre for Advanced Heart Failure, Inselspital, University Hospital Bern, CH, Bern, Switzerland, [2]Heart Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia*

(831) ***The Post-Operative Course of Von Willebrand Factor in Patients with Heartmate 3: A Longitudinal Study;*** P. Jahangiri[1], K. Veen[2], J. Bunge[3], F. Leebeek[4], K. Caliskan[1]. *[1]Cardiology, Erasmus MC University Medical Centre, Rotterdam, Netherlands, [2]Cardiothoracic Surgery, Erasmus MC University Medical Centre, Rotterdam, Netherlands, [3]Intensive Care, Erasmus MC University Medical Centre, Rotterdam, Netherlands, [4]Hematology, Erasmus MC University Medical Centre, Rotterdam, Netherlands*

(832) ***Understanding Successful Implementation of a Patient Decision Aid for Left Ventricular Assist Device: Qualitative Analysis of I-DECIDE-LVAD;*** J. S. Thompson[1], D. D. Matlock[1], C. McIlvennan[2], L. Allen[3], M. K. Wynia[1], C. Tietbohl[1]. *[1]University of Colorado School of Medicine, Aurora, CO, [2]University of Colorado, Denver, CO, [3]University of Colorado, Aurora, CO*

(833) ***Changes in Echocardiographic Parameters after Transcatheter Aortic Valve Replacement in Patients with a Left Ventricular Assist Device: A Case Series;*** S. C. Uppalapati[1], D. Rodgers[1], S. N. Paluri[2], K. Ram[3], S. Jain[1], K. Sorensen[4], S. Bangaru[5], A. Madhushankar[6], K. Sudheendra[7], K. Johnson[5], D. Hynes[8], J. Grinstein[9], R. Kalathiya[9], V. Jeevanandam[1]. *[1]Cardiac Surgery, University of Chicago Medical Center, Chicago, IL, [2]Chicago College of Osteopathic Medicine, Midwestern University, Chicago, IL, [3]Undergaduate, University of Michigan, Ann Arbor, MI, [4]Postbaccalaureate, Dominican University, River Forest, IL, [5]Illinois Mathematics and Science Academy, Aurora, IL, [6]Adlai E. Stevenson High School, Lincolnshire, IL, [7]Hinsdale Central High School, Hinsdale, IL, [8]Undergraduate, Hamilton College, Clinton, NY, [9]Cardiology, University of Chicago Medical Center, Chicago, IL*

(834) ***Soluble Suppression of Tumorigenicity-2 (sst2) Predicts Mortality and Right Heart Failure in Lvad Patients;*** L. Numan[1], E. Aarts[2], F. Ramjankhan[3], M. G. Van Der Meer[1], M. Oerlemans[4], N. De Jonge[1], A. Oppelaar[3], H. Kemperman[5], F. Asselbergs[4], L. W. Van Laake[1]. *[1]Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands, [2]Methodology & Statistics, University of Utrecht, Utrecht, Netherlands, [3]Cardiothoracic surgery, University Medical Centre Utrecht, Utrecht, Netherlands, [4]Cardiology, University Medical Center Utrecht, Utrecht, Netherlands, [5]Central Diagnostic Laboratory, University Medical Centre Utrecht, Utrecht, Netherlands*

(835) ***Preoperative Levosimendan to Reduce Risk of Right Ventricular Failure after LVAD Surgery;*** R. Godinho[1], A. Nowacka[2], S. Aur[1], J. Regamey[1], Z. Ltaief[3], M. Rusca[3], R. Hullin[1], L. Liaudet[3], M. Kirsch[2], P. Yerly[1]. *[1]Department of Heart-Vessels, Division of Cardiology, Lausanne University Hospital, Lausanne, Switzerland, [2]Dept of Heart-Vessels, Division of Cardiac Surgery, Lausanne Univ HosP, Lausanne, Switzerland, [3]Service of Adult Intensive Care Medicine, Lausanne Univ Hosp, Lausanne, Switzerland*

(836) ***Is There a Relationship Between Cannula Position and Right Ventricular Failure Outcome in Patients with Centrifugal Flow Left Ventricular Assist Devices?;*** S. Zook[1], S. Ingram[2], A. Guha[3], A. Bhimaraj[4], N. Fida[4], J. Kim[4], R. Yousefzai[5], S. Ahsan[4], S. Legha[6], C. Martin[7], I. Hussain[1], J. Gorthi[8], E. Graviss[4], D. Nguyen[4], M. Moreno[2], E. Suarez[9], P. Chou[4], M. Kassi[4]. *[1]Cardiology, Houston Methodist Debakey Heart and Vascular Center, Houston, TX, [2]Texas A&M University, Houston, TX, [3]Houston Methodist Hosp, Houston, TX, [4]Houston Methodist Hospital, Houston, TX, [5]Houston Methodist Hospital, Bellaire, TX, [6]Houston Methodist, Shenandoah, TX, [7]Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX, [8]Cardiology, Houston Methodist Hospital, Houston, TX, [9]Houston, TX*

(837) ***The Achilles' Heel of Heartmate 3?: Development and Hemodynamic Impacts of Aortic Insufficiency;*** M. Liotta, M. Ruge, C. Zurlo, K. Kochar, M. Gamero, A. Hajduczok, W. Ullah, Y. Brailovsky, J. Rame, R. Alvarez, H. Massey, I. Rajapreyar. *Thomas Jefferson University Hospital, Philadelphia, PA*

(838) ***Proactive Right Ventricular Assist Device Placement in Patients Undergoing Left Ventricular Assist Device Implantation Leads to Improved Short and Long Term Survival;*** R. Crespo[1], N. A. Khan[2], K. Mudy[1], A. Bae[3], M. Samara[1], P. Eckman[1], B. Sun[1], K. Hryniewicz[1]. *[1]Minneapolis Heart Inst, Minneapolis, MN, [2]Southern Illinois Univ, Springfield, IL, [3]Brown University, Edina, MN*

(839) ***Assessment of the Optimal Echocardiographic Profile on Left Ventricular Assist Device Support: Consider the Right Parameters;*** F. Riesgo Gil[1], G. Gallone[1], A. Morley-Smith[1], O. Dar[1], J. Ibero Valencia[2], M. Monteagudo Vela[1], F. Fiorelli[1], M. Konicoff[1], G. Edwards[1], B. Raj[1], M. Shanmuganathan[1], S. Frea[3], G. De Ferrari[3], V. Panoulas[1], U. Stock[1], C. Bowles[1], J. Dunning[1]. *[1]Cardiothoracic Transplantation., Harefield Hospital. Guy's and St Thomas' NHS Foundation Trust, London, UK, [2]Hosp San Pedro, Logrono, Spain, [3]Div of Cardiology, Cardiovascular and Thoracic Dept., "Citta della Salute e della Scienza" Hosp, Turin, Italy*

(840) ***Comparison of Heart Failure Therapy Implementation in Patients with and without Temporary Right Ventricular Assist Device Following HeartMate 3 LVAD Implantation: A 6-Month Post-Implant Comparison;*** R. Wolsky, L. Coyle, C. Gallagher, P. Marogil, M. Dela Cruz, M. Kabbany, J. Monaco, V. Chau, J. Pillarella, A. Joshi, C. Sciamanna, M. Dia, S. Pauwaa, G. Macaluso, P. Pappas, A. Tatooles, W. Cotts, N. Narang. *Advocate Christ Medical Center, Oak Lawn, IL*

(841) ***Interventricular Interactions in LVAD Recipients: Insights from PV Loop Analysis;*** M. Brener[1], M. Kanwar[2], M. Lander[3], N. Hamid[4], A. Raina[5], S. S. Sethi[6], M. T. Finn[6], J. Fried[6], J. Raikhelkar[7], A. Masoumi[7], G. Sayer[8], D. Burkhoff[9], N. Uriel[10]. *[1]Columbia University Medical Center, New Rochelle, NY, [2]Allegheny General Hospital, Pittsburgh, PA, [3]Allegheny Health Network, Pittsburgh, PA, [4]Minneapolis Heart Institute, Minneapolis, MN, [5]Allegheny General Hospital, Wexford, PA, [6]Columbia University Medical Center, New York, NY, [7]Columbia University, New York, NY, [8]Columbia University Irving Medical Center, Hartsdale, NY, [9]CircuLite, Inc., Saddle Brook, NJ, [10]New York Presbyterian, New York, NY*

(842) ***Imaging Attributes of Right Ventricular Systolic and Diastolic Function in Patients with Continuous-Flow LVADs: A Contrast Computed Tomography Study;*** R. Barsoom[1], B. Cathey[1], D. T. Nguyen[2], E. A. Graviss[2], E. E. Suarez[3], A. Guha[3]. *[1]School of Engineering Medicine, Texas A&M University, Houston, TX, [2]Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, [3]DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX*

(843) ***Change in NT-ProBNP to Predict Development of Right, Left, and Biventricular Heart Failure in Heartmate 3 LVAD Patients;*** M. T. Gamero[1], M. Liotta[2], S. Marek-Iannucci[1], P. Uber[3], A. Hajduczok[4], Y. Brailovsky[5], R. Alvarez[6], J. Rame[1], G. Gibson[7], E. Storozynsky[8], V. Tchantchaleishvili[9], I. Rajapreyar[1]. *[1]Thomas Jefferson University Hospital, Philadelphia, PA, [23]Penn Highlands, Haverford, PA, [4]Thomas Jefferson University, Philadelphia, PA, [5]Lafayette Hill, PA, [6]Thomas Jefferson University, Cherry Hill, NJ, [7]Northwell, West Deptford, NJ, [8]Strong Memorial Hospital, Rochester, NY, [9]Thomas Jefferson Univ, Philadelphia, PA*

(844) ***Utilization of the Temporary MCS for LV Unloading and RV Optimization Prior to Durable LVAD Implantation;*** K. P. Mody[1], P. Walters[2], S. Stewart[3], C. Silva[4], Y. Dudiy[5], G. Batsides[5], M. B. Anderson[5]. *[1]Hackensack University Medical Center, Allendale, NJ, [2]Hackensack University Medical Center, Secaucus, NJ, [3]Hackensack University Medical Center, Hillsdale, NJ, [4]Hackensack Meridian Health, Metuchen, NJ, [5]Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, NJ*

(845) ***The Mysterious Enemy: Beyond A Few Episodes of Sudden Death Events;*** A. Valverde Zuñiga[1], M. Aversa[2]. *[1]UHN - CCSS, Toronto - San Jose, Costa Rica, [2]University of Toronto, Toronto, ON, Canada*

(846) ***Remote Pulmonary Artery Pressure Monitoring in a Patient with Severe Pulmonary Arterial Hypertension - Is It Underutilized?;*** A. S. Madgula[1], S. Mahabir[2], G. Samra[2], M. Lander[1]. *[1]Allegheny Health Network, Pittsburgh, PA, [2]Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA*

(847) ***Turning Back The Clock; A Unique Case of Reversible Pulmonary Hypertension;*** N. Gorrie[1], G. Kaur[2], N. Bart[1], L. Girgis[1], E. Kotlyar[1]. *[1]St Vincent's Hospital, Sydney, Australia, [2]University of New South Wales, Sydney, Australia*

(848) ***Unique Approach to Evaluate Exercise Induced Pulmonary Hypertension Using Invasive Exercise Testing: Case Study;*** C. Altherr[1], K. Ballut[2], T. Sullivan[3], Z. Fulkerson[4], O. Ilonze[2]. *[1]Indiana Center Musculoskeletal Health – Clinical Research Center, Indiana University, Indianapolis, IN, [2]Krannert Cardiovascular Research Center, Indiana University, Indianapolis, IN, [3]Pulmonology and Sleep Medicine, IU Health Methodist Hospital, Indianapolis, IN, [4]Pulmonary, Critical Care, and Sleep Medicine, IU Health West Hospital, Avon, IN*

(849) ***The Utility of Mechanical Circulatory Support in the Management of Massive Pulmonary Embolism with Right Ventricular Failure;*** S. Mahabir, G. S. Samra, A. Madgula, C. Link, A. Khalif, K. Ranganathan, M. Kanwar. *Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA*

(850) ***Percutaneous Transluminal Pulmonary Angioplasty for Takayasu Arteritis-Associated Pulmonary Hypertension: A Systemic Review and Single-Arm Meta-Analysis;*** M. Sun[1], Z. Yong-Jian[2], Y. Zhou[3], X. Zhu[3], Y. Yang[3], C. Cheng[3], K. Mei[3], X. Li[3], C. Liu[3], X. Xu[3], K. Sun[3], Z. Jing[3]. *[1]Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, China, [2]The First Affiliated Hospital of Zhengzhou University, Henan Province, China, [3]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China*

(851) ***ARTISAN: A Novel Study of Mean Pulmonary Artery Pressure-Targeted Approach with Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Pulmonary Arterial Hypertension;*** R. Benza[1], I. Lang[2], H. Matsubara[3], R. Naeije[4], C. Vizza[5], A. Waxman[6], P. Adamson[7], Y. Liu[8], G. Golden[9]. *[1]Ohio State University, Columbus, OH, [2]General Hospital Vienna, Wien, 9, Austria, [3]Nat'l Hosp Org Okayama Med Ctr, Okayama-Shi, 33, Japan, [4]Erasme Univ Hospital, Beersel, Belgium, [5]U of Rome Policlinico Umb, Roma, Italy, [6]Brigham & Women 's Hosp, Boston, MA, [7]Abbott, Cedar Park, TX, [8]United Therapeutics Corporation, Research Triangle Park, NC, [9]United Therapeutics Corporation, Durham, NC*

(852) ***Invasive Hemodynamic Indices That Are Associated with Mortality at One Year in Patients with Pulmonary Hypertension Per Newly Proposed Criteria;*** S. C. Johnson[1], S. A. Ali[1], C. D. Shah[1], H. E. Arman[1], R. Nabrzyski[2], H. I. Elsemesmani[1], R. Gandy[3], D. Wong[4], M. Al Gibbawi[1], H. R. Omar[5], B. Siddegowda Bangalore[6], M. Duncan[7], M. Guglin[1]. *[1]Indiana University, Indianapolis, IN, [2]University of Colorado, Aurora, CO, [3]Henry Ford Hospital, Detroit, MI, [4]Loyola University, Chicago, IL, [5]Internal Medicine, Swedish American Hospital, Rockford, IL, [6]Methodist IU, Fishers, IN, [7]Dallas, TX*

(853) ***The Combination of the Ratio of Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Arterial Pressure and Reveal Lite 2.0 in Early Prediction of Disease Progression of Pulmonary Arterial Hypertension;*** H. Ali[1], J. Bhatt[2], E. Graviss[3], D. Nguyen[3], S. Nagueh[3], A. Guha[4], S. Sahay[3]. *[1]Cardiology, Houston Methodist Hospital, Houston, TX, [2]Houston, TX, [3]Houston Methodist Hospital, Houston, TX, [4]Houston Methodist Hosp, Houston, TX*

(854) ***Effect of Dobutamine on Rv Contractility and Rv-Pa Coupling in the Normal Rv;*** S. H. Friedman[1], A. Varga-Szemes[2], U. Schoepf[2], A. Johnson[3], J. Johnson[4], R. Baxley[5], B. Houston[4], S. E. Litwin[4], J. Atkins[4], R. Tedford[4]. *[1]Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston, SC, [2]Radiology & Radiological Sciences, Medical University of South Carolina, Charleston, SC, [3]Internal Medicine, Medical University of South Carolina, Charleston, SC, [4]Cardiology, Medical University of South Carolina, Charleston, SC, [5]Medical University of South Carolina, Charleston, SC*

(855) ***Coronary Artery and Microvascular Physiology in Heart Transplant Recipients from Hepatitis C Viremic Donors;*** A. S. Birs[1], G. Ma[2], S. Aslam[3], K. Hong[4], L. Ang[5], E. Adler[5]. *[1]University of California San Diego, La Jolla, CA, [2]UC San Diego Health, San Diego, CA, [3]University of California San Diego, San Diego, CA, [4]University of California, San Diego, La Jolla, CA, [5]University of California San Diego Health, San Diego, CA*

THURSDAY, 20 APRIL, 2023

4:15 – 5:15 p.m.

POSTER SESSION 02: CARDIOTHORACIC SURGERY

Location: Mile High Ballroom

Core Therapies: HEART, LUNG, MCS
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Cardiothoracic Surgery. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Nathan Airhart, MD, Saint Alphonsus Medical Center, Boise, ID USA
Yaron Barac, MD, PhD, Rabin Medical Center, Petah Tiqva, Israel
Markus Barten, MD, PhD, University Heart and Vascular Center Hamburg, Hamburg, Germany
Udo Boeken, MD, PhD, University Hospital, Düsseldorf, Germany
Stacey Brann, MD, MSc, FRCS(Ed), TransMedics, Inc., Andover, MA USA
Nicolas Brozzi, MD, Cleveland Clinic, Weston, FL USA
Kelly Bryce, PhD, Henry Ford Hospital, Royal Oak, MI USA
Holger Buchholz, MD, Univ of Alberta Hosp, Edmonton, AB Canada
Gustavo Calado Ribeiro, Clinic Cardio Cirurgica Campinas, Campinas, Brazil
Philip Carrott, MD, University of Virginia, Charlottesville, VA USA
Robert Chen, MD, MPH, Stanford University School of Medicine, Palo Alto, CA USA
Lin-Chiang Philip Chou, MD, Houston Methodist Hospital, Houston, TX USA
Oliver Dewald, MD, University Hospital Erlangen, Erlangen, Germany
Rob Dowling, MD, The Christ Hospital and Lindner Research and Education Center, Cincinnati, OH USA
Thomas Egan, MD, MSC UNC at Chapel Hill, Chapel Hill, NC USA
Sam Emmanuel, MBBS, BHSc (Hons), St Vincent's Hospital Sydney, Surry Hills, NSW Australia
Fabian Emrich, MD, University of Frankfurt, Frankfurt, Germany
Stephen Forest, MD, Montefiore Medical Center, Bronx, NY USA
Miriam Freundt, MD, Hershey, PA USA
Kathleen Grady, PhD, RN, MS, FAAN, Northwestern University, Chicago, IL USA
Emily Granger, MBBS, St Vincent's Hospital Sydney, Sydney, NSW Australia
Eric Griffiths, MD, University of Utah, Salt Lake City, UT USA
David Hormuth, MD, MBA, StarTeamsLLC, Jupiter, FL USA
Peter Ivak, MD, PhD, IKEM, Prague, Czech Republic
Jonathan Johnson, MD, Mayo Clinic, Rochester, MN USA
Umit Kervan, MD, Çankaya, Turkey
Suresh Keshavamurthy, MD, FACS, FRCS, University of Kentucky, Lexington, KY USA
Ahmet Kilic, MD, The Johns Hopkins University, Baltimore, MD USA
Kevin Koomalsingh, MD, Providence St Vincent Medical Center, Portland, OR USA
Kewal Krishan, MD, Temple University Hospital, Philadelphia, PA USA
Lucian Lozonschi, MD, University of South Florida, Tampa General Hospital, Tampa, FL USA
Jorge Mallea, MD, Mayo Clinic Florida, Jacksonville, FL USA
Ezequiel Molina, MD, Piedmont Heart Institute - Samsky Advanced Heart Failure Center, Atlanta, GA USA
Minoru Ono, MD, PhD, The University of Tokyo Hospital, Bunkyo-Ku, Japan
Siddharth Pahwa, MD, University of Louisville Physicians, Louisville, KY USA
Anthony Panos, MD, MSc, FRCSC, FACS, University of Iowa Hospital and Clinics, Iowa City, IA USA
Chetan Pasrija, University of Maryland, Baltimore, MD USA
Michael Petty, PhD, RN, APRN, CNS, CCNS, University of Minnesota Medical Center, Minneapolis, MN USA

Chetan Pasrija, University of Maryland, Baltimore, MD USA
Yazhini Ravi, MD, Scott & White, Temple, TX USA
Pedro Reck dos Santos, MD, MSc, PhD, Mayo Clinic, Arizona Phoenix, AZ USA
Sahar Saddoughi, MD, PhD, Mayo Clinic, Rochester, MN USA
Diyar Saeed, MD, PhD, Heart Center Niederrhein, Leipzig, Germany
Andrew Sage, PhD, MSc, Toronto General Hospital, Toronto, ON Canada
Elena Sandoval, MD, FEBCTS, Barcelona, Spain
Stephan Schueler, MD, PhD, FRCS, Newcastle upon Tyne Hospitals, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Fawwaz Shaw, MD, Emory University/Children's Health Care of Atlanta, Atlanta, GA USA
Tae Song, MD, University of Chicago, Chicago, IL USA
Cumara Sivathasan, MBBS, FRCS, National Heart Center, Singapore
Daniel Tang, MD, Inova, Falls Church, VA USA
Roh Yanagida, MD, PhD, Temple University Hospital, Livingston, NJ USA

(856) ***Extracorporeal Cytokine Hemoadsorption During Orthotopic Heart Transplantation: A Comparative Study;*** C. Volgmann[1], A. Gebauer[1], S. Leonie[2], M. Barten[1], H. Reichenspurner[1], A. Bernhardt[1]. *[1]University Heart and Vascular Center Hamburg, Hamburg, Germany, [2]University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

(857) ***Bilateral Lung Transplant with Recognition of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) of rhe Donor Lungs in the Immediate Postoperative Period;*** B. Bromberger[1], F. McLafferty[2], J. Smith[1], B. Elicker[1], K. Jones[3], C. Mulvey[1], A. Urisman[1], A. Venado[1], S. Hays[4], J. Kukreja[1], B. Trinh[5]. *[1]University of California San Francisco, San Francisco, CA, [2]University of California, San Francisco, CA, [3]University of Calif San Francisco, San Francisco, CA, [4]UCSF Medical Center, San Francisco, CA, [5]Univ Cardiovascular Center, Fresno, CA*

(858) ***Donation after Circulatory Death Using Mobile Normothermic Regional Perfusion;*** P. J. Spencer[1], S. Saddoughi[2], K. Choi[3], T. Dickinson[1], A. Richman[1], C. Blau[1], F. A. Reynolds[1], C. Colby[1], M. Villavicencio[3]. *[1]Cardiovascular Surgery, Mayo Clinic, Rochester, MN, [2]Mayo Clinic, Rochester, MN, [3]Mayo Clinic, Rochester, Rochester, MN*

(859) ***Concurrent Tracheobronchoplasty and Bilateral Lung Transplant for Obstructive Lung Disease;*** S. H. Chang[1], T. Geraci[1], M. El Zaeedi[1], J. Chan[1], L. Angel[2]. *[1]Cardiothoracic Surgery, NYU Langone Health, New York, NY, [2]NYU Langone Medical Center, New York, NY*

(860) ***Nebulised Gas Persufflation to Preserve Hearts Donated after Circulatory Death;*** W. A. Pavey[1], N. Dixon[2], R. Hahn[1], A. Hannaway[1], V. Vincent[3], N. Grainger[4], S. Chitmis[3], J. Saxton[1], H. Ludewick[1], K. Ho[4], L. Hool[2]. *[1]Heart and Lung Research Institute WA, Perth, Australia, [2]University of Western Australia, Perth, Australia, [3]Fiona Stanley Hospital, Perth, Australia, [4]Royal Perth Hospital, Perth, Australia*

(861) ***Hypoxic Reperfusion of the Ischemic Pig Heart is Safe and Effective;*** A. Page[1], J. Louca[1], M. Öchsner[1], P. White[2], S. Large[3]. *[1]Royal Papworth Hospital, Cambridge, United Kingdom, [2]Cambridge Univ Hosp, Cambridge, United Kingdom, [3]Papworth Hospital, Cambridge, United Kingdom*

(862) ***Coronary Angiography During Ex Situ Heart Perfusion: Feasibility and Toxicity in a Porcine Model;*** A. Akamkam[1], G. Fadel[1], T. Legrand[2], V. Furlan[2], C. Bastos Dias[1], S. Dang Van[3], M. Gaillard[1], A. Vallee[1], J. Andarelli[1], V. Palermo[1], J. Guihaire[4]. *[1]Marie Lannelongue Hospital, Le Plessis Robinson, France, [2]Kremlin Bicetre University Hospital, Kremlin Bicetre, France, [3]University Hospital of Angers, Angers, France, [4]Marie Lannelongue Hospital, University of Paris Saclay, Le Plessis-Robinson, France*

(863) ***Biomarkers for Cardiac Hypothermic Machine Perfusion: A Multitargeted Approach;*** E. Ballan, M. Vervoorn, S. Kaffka Genaamd Dengler, J. Marsman, M. Mishra, S. de Jager, J. Sluijter, P. Doevendans, F. Asselbergs, M. Mokry, N. van der Kaaij. *University Medical Center Utrecht, Utrecht, Netherlands*

(865) ***Improving Asystolic Warm Ischemic Time Tolerance in Donation after Circulatory Death Donor Hearts;*** Y. Joshi[1], J. Villanueva[2], L. Gao[2], B. Hwang[3], K. Wang[3], A. Kasavaraj[3], A. Doyle[2], J. Wu[2], N. Palpant[4], G. King[4], A. Iyer[1], P. Jansz[1], P. MacDonald[1]. *[1]St Vincent's Hospital, Sydney, Australia, [2]Victor Chang Cardiac Research Institute, Darlinghurst, Australia, [3]UNSW, Strathfield, Australia, [4]University of Queensland, Brisbane, Australia*

(866) ***Subnormothermic Machine Perfusion of Neonatal and Small Pediatric Sized Hearts;*** G. Mainardi[1], S. Hatami[1], M. Wagner[1], M. Khan[1], X. Wang[1], T. Pidborochynski[1], J. Nagendran[1], J. Conway[2], D. Freed[2]. *[1]University of Alberta, Edmonton, AB, Canada, [2]Stollery Children's Hospital, Edmonton, AB, Canada*

(867) ***Functional Assessment During Unloaded, Ex-Vivo Perfusion Could Help Predict Recovery in Cardiac Dcd Grafts: Studies in a Porcine Model;*** M. U. Egle[1], S. Graf[1], A. Segiser[1], M. Sanz[1], A. Clavier[1], M. Arnold[1], A. Kadner[1], T. Carrel[2], M. Siepe[1], S. Longnus[1]. *[1]Department of Cardiac Surgery, Inselspital, Bern, Switzerland, [2]Department of Cardiac Surgery, University Hospital of Zurich, Zurich, Switzerland*

(868) ***Ex-Situ Electrical Mapping of Machine Perfused Hearts Donated after Circulatory Death;*** J. H. Amesz, M. F. Bierhuizen, S. J. Langmuur, P. Knops, D. Dumay, O. C. Manintveld, N. M. de Groot, Y. J. Taverne. *Erasmus University Medical Center, Rotterdam, Netherlands*

(869) ***Ex-situ Normothermic ECMO Technology with Continuous Perfusate Hemofiltration for Organ Management;*** T. Lesbekov, R. Kaliyev, Z. Nurmykhametova, L. Faizov, A. Medressova, M. Aripov, N. Tanaliyev, E. Zuparov, A. Iskakova, Y. Pya. *National Research Cardiac Surgery Center, Astana, Kazakhstan*

(870) ***Metabolic Indicators in Donor Hearts Following Conventional and Temperature Controlled Storage;*** G. Sharma[1], R. Vela[1], L. Powell[1], M. Mizerska[2], S. Deja[2], S. Burgess[2], C. R. Malloy[3], M. E. Jessen[1], M. Peltz[1]. *[1]Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX, [2]Biochemistry, Center for Human Nutrition, UT Southwestern Medical Center, Dallas, TX, [3]Internal Medicine, Division of Cardiology and Radiology, UT Southwestern Medical Center, Dallas, TX*

(871) ***Cytokine Profiles During Thoraco-Abdominal Normothermic Regional Perfusion (TA-NRP) in a Porcine Model;*** K. Vandendriessche[1], J. Brouckaert[2], V. van Suylen[3], D. Dauwe[4], M. Erasmus[5], S. Rex[4], A. Neyrinck[6], B. Meyns[4], F. Rega[7]. *[1]KU Leuven UZ Leuven, Leuven, Belgium, [2]Snellegem, Belgium, [3]University Medical Centre Groningen, Groningen, Netherlands, [4]UZ Leuven, Leuven, Belgium, [5]University Medical Center Groningen, Groningen, Netherlands, [6]Leuven University Hospitals, Leuven, Belgium, [7]University Hospitals Leuven, Leuven, Belgium*

(872) ***Preclinical Evaluation of the VP.S ENCORE™ Cardiac Preservation Device;*** R. Veraza[1], K. Andrijauskaite[1], R. Lopez[1], I. Cano[1], E. Cisneros[1], I. Jessop[1], M. Watt[1], M. Morales Garza[2], A. Elgalad[2], L. Bunegin[1]. *[1]Vascular Perfusion Solutions, Inc., San Antonio, TX, [2]Texas Heart Institute, Houston, TX*

(873) ***Batch Replacement of Cellular Perfusate Does Not Improve Outcomes in a Model of 24-Hour Negative Pressure Ventilation Ex-Situ Lung Perfusion with Transplantation;*** K. A. Forgie[1], A. Watkins[2], K. Du[2], A. Ribano[2], D. Freed[3], J. Nagendran[2]. *[1]Cardiac Surgery, University of Alberta, Edmonton, AB, Canada, [2]University of Alberta, Edmonton, AB, Canada, [3]Stollery Children's Hospital, Edmonton, AB, Canada*

(874) ***Mild Permissive Alkalosis Improves Outcomes in Porcine Negative Pressure Ventilation Ex-Situ Lung Perfusion;*** K. A. Forgie[1], K. Du[2], A. Ribano[2], A. Watkins[2], D. Freed[3], J. Nagendran[2]. *[1]Cardiac Surgery, University of Alberta, Edmonton, AB, Canada, [2]University of Alberta, Edmonton, AB, Canada, [3]Stollery Children's Hospital, Edmonton, AB, Canada*

(875) ***A Novel Strategy In Vivo Lung Recovery for Prompt Recovery from Primary Graft Dysfunction after Lung Transplantation;*** K. Matsubara[1], K. Miyoshi[2], K. Takeshi[3], S. Kawana[1], Y. Kubo[1], D. Shimizu[1], K. Hashimoto[2], S. Tanaka[2], M. Okazaki[2], S. Sugimoto[2], S. Toyooka[2]. *[1]Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama-Shi, Japan, [2]Okayama University Hospital, Okayama-Shi, Japan, [3]Okayama Rosai Hospital, Okayama-Shi, Japan*

(876) ***Preoperative Recipient CRP/Albumin Ratio Predicts Survival and Outcome after Heart Transplantation;*** D. Oehler[1], M. B. Immohr[2], C. Böttger[3], R. R. Bruno[1], D. Sigetti[2], J. Haschemi[1], D. Scheiber[1], H. Aubin[2], P. Horn[1], I. Tudorache[2], R. Westenfeld[1], F. Bönner[1], P. Akhyari[2], M. Kelm[1], A. Lichtenberg[2], U. Boeken[2]. *[1]Department of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, [2]Department of Cardiac Surgery, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, [3]Department of Diagnostic and Interventional Radiology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany*

(877) ***Postoperative Neurological Events are Associated with Worse Outcome and Fatal Midterm Survival after Heart Transplantation;*** D. Oehler[1], M. B. Immohr[2], C. Böttger[3], R. R. Bruno[1], D. Sigetti[2], J. Haschemi[1], H. Oehler[4], H. Aubin[2], P. Horn[1], I. Tudorache[2], R. Westenfeld[1], P. Akhyari[2], M. Kelm[1], A. Lichtenberg[2], U. Boeken[2]. *[1]Department of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, [2]Department of Cardiac Surgery, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, [3]Department of Diagnostic and Interventional Radiology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, [4]Department of Neurology, Heidelberg University, Medical Faculty, Heidelberg University, Heidelberg, Germany*

(878) ***How Old is Too Old for Heart Transplantation;*** A. Firoz[1], A. Kashem[1], Y. Toyoda[2], E. Hamad[2]. *[1]Lewis Katz School of Medicine at Temple University, Philadelphia, PA, [2]Temple University Hospital, Philadelphia, PA*

(879) ***Heart Transplant Outcomes in Patients ›65 Years Old with Previous Non-Transplant Cardiac Surgery;*** A. Y. Lee[1], E. L. Larson[2], H. Rando[3], A. Kilic[3]. *[1]University of Hawaii John A. Burns School of Medicine, Honolulu, HI, [2]Johns Hopkins University School of Medicine, Baltimore, MD, [3]Johns Hopkins Hospital, Baltimore, MD*

(880) ***Individual Association of Predicted Left and Right Ventricular Mass Ratios with Survival after Heart Transplantation: A UNOS Database Analysis;*** A. Jain[1], D. Ahmad[2], C. Pritting[1], G. T. Gibson[3], I. Rajapreyar[4], J. Rame[4], R. Alvarez[4], K. Rajagopal[2], J. Entwistle[2], H. T. Massey[2], V. Tchantchaleishvili[2]. *[1]Sidney Kimmel Medical College, Philadelphia, PA, [2]Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, PA, [3]Cardiology, Division of Cardiology, Thomas Jefferson University, Philadelphia, PA, [4]Division of Cardiology, Thomas Jefferson University, Philadelphia, PA*

(881) ***Evaluating the Impact of Donor-Recipient Race Mismatch on Graft Survival in Infant Heart Transplantation;*** B. J. So[1], J. Lee[2], S. Kidambi[3], J. Dykes[4], D. Rosenthal[5], M. Ma[6]. *[1]Stanford University School Medicine, Palo Alto, CA, [2]Stanford University, Palo Alto, CA, [3]Stanford University Medical Center, Palo Alto, CA, [4]Lucile Packard Children's Hosp, Redwood City, CA, [5]Stanford, Portland, OR, [6]Stanford University, Stanford, CA*

(882) ***Nine-Year Results of an IgA-And IgM-Enriched Human Immunoglobulin-Based Therapy for Early Detectable Anti-HLA Donor Specific Antibodies after Lung Transplantation;*** K. Aburahma[1], M. Franz[1], P. Yablonski[1], N. D. de Manna[1], A. Saipbaev[1], M. Avsar[1], N. Schwerk[1], W. Sommer[2], M. Greer[3], C. Falk[4], T. Welte[3], A. Haverich[1], C. Kuehn[1], G. Warnecke[2], J. Salman[1], F. Ius[1]. *[1]Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, [2]Department of Cardiac surgery, University of Heidelberg, Heidelberg, Germany, [3]Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, [4]Institute of Transplant Immunology, Hannover Medical School, MHH, Hannover, Germany*

(883) ***Selective Distal Perfusion and Small Arterial Cannula Use Can Minimize Limb Ischemia Requiring Surgery in Patients in Femoral Veno-Arterial Extracorporeal Life Support;*** A. Vinogradsky, P. Kurlansky, Y. Ning, J. Beck, D. Brodie, D. Spragan, M. Hassanein, Y. Kaku, J. Fried, K. Takeda. *Columbia University Irving Medical Center, New York City, NY*

(884) ***One Hundred Consecutive Heartmate 3 Left Ventricular Assist Device Implants at a Destination Therapy Center;*** T. J. George[1], A. Kluis[2], J. DiMaio[3], D. Rawitscher[4], N. Kabra[5], A. Afzal[6]. *[1]Cardiac Surgery, Baylor Scott and White, The Heart Hospital, Plano, Plano, TX, [2]Baylor Scott and White, The Heart Hospital, Plano, Plano, TX, [3]Baylor Scott & White Health, Dallas, TX, [4]Plano, TX, [5]La Jolla, CA, [6]Baylor University Medical Center, Dallas, TX*

(885) ***Concomitant Tricuspid Valve Repair During the Implant of Left Ventricular Assist Device: Propensity-Score Matched Analysis;*** S. Yoshida[1], H. Kim[2], C. Mehta[3], A. Churyla[3], T. Wu[4], R. Harap[4], E. Vorovich[5], J. Rich[5], J. Wilcox[5], D. Pham[3]. *[1]Division of Cardiac Surgery, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Chicago, IL, [2]Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, [3]Division of Cardiac Surgery, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital, Chicago, IL, [4]Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital, Chicago, IL, [5]Division of Cardiology, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital, Chicago, IL*

(886) ***Impact of Left Ventricular Unloading on Venoarterial Extracorporeal Membrane Oxygenation Support Prior to Left Ventricular Assist Device Implantation;*** O. D. Bhadra, J. Mersmann, J. Pausch, M. Barten, Y. Alassar, H. Reichenspurner, A. Bernhardt. *Department for Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Hamburg, Germany*

(887) ***Sternal Sparing Left Ventricular Assist Devices in Patients with who Class 2 or Greater Obesity;*** C. A. Heid[1], A. Hackmann[1], N. S. Hendren[2], L. C. Huffman[1], M. Farr[2], A. Amin[2], M. Drazner[2], J. Grodin[2], S. Yeganeh[1], W. Ring[1], M. Peltz[1]. *[1]Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, [2]Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX*

(888) ***Initiating an ECMO Program at a Safety Net Hospital During a Global Pandemic;*** J. Ehab[1], C. A. Heid[2], M. Leveno[3], M. Peltz[4], J. Cox[5], M. Wait[6], L. Huffman[4], A. Hackmann[7]. *[1]Surgery, University of Texas Southwestern Medical Center, Dallas, TX, [2]Cardiovascular and Thoracic Surgery, University of Texas Southwestern, Dallas, TX, [3]Intermal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, [4]UT Southwestern Medical Center, Dallas, TX, [5]Parkland Health and Hospital System, Dallas, TX, [6]University of Texas Southwestern Medical Center, Dallas, Cedar Hill, TX, [7]UT Southwestern, Dallas, TX*

(889) ***Off-Pump Less Invasive HeartMate3 LVAD Implantation is Safe and Feasible Compared to the On-Pump Technique;*** A. Goodman[1], M. Fryer[1], A. Jones[1], K. Wood[2], M. Bjelic[3], F. Paic[1], E. Thomas[1], M. Hack[4], H. Vidula[5], J. Alexis[6], C. Cheyne[7], K. Chase[2], W. Bernstein[8], D. Lindenmuth[1], J. Wyrobek[1], I. Gosev[9]. *[1]University of Rochester, Rochester, NY, [2]University of Rochester Medical Center, Rochester, NY, [3]Rochester, NY, [4]Oregon Health and Sciences, Portland, OR, [5]University of Rochester, Naperville, IL, [6]Univ Rochester Med Ctr, Pittsford, NY, [7]URMC, Rochester, NY, [8]University of Rochester Medical Center, Brooklandville, MD, [9]University of Rochester Medical Center, Pittsford, NY*

(890) ***Lung Transplantation for Chronic Beryllium Disease;*** M. Olson[1], R. Walia[2], A. Arjuna[2]. *[1]University of Arizona, School of Medicine, Phoenix, AZ, [2]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(891) ***Bilateral Lung Transplantation from Living Donors in a 67-Year-Old Patient;*** H. Ujike, S. Tanaka, H. Choshi, S. Kawana, Y. Kubo, D. Shimizu, K. Matsubara, K. Hashimoto, K. Shien, K. Suzawa, K. Miyoshi, H. Yamamoto, M. Okazaki, S. Sugimoto, S. Toyooka. *Okayama University Hospital, Okayama, Japan*

(892) ***Lung Transplantation in a Patient with End-Stage Lung Disease and Suspected Early-Stage Lung Cancer: A Case Report;*** Y. Yagi[1], E. Cerier[2], T. Toyoda[3], B. Dhaliwal[4], R. Tomic[3], A. Bharat[3], C. Kurihara[5]. *[1]Northwestern Medicine, Chicago, IL, [2]Northwestern Memorial Hospital, Chicago, IL, [3]Northwestern University, Chicago, IL, [4]Northwestern University Feinberg School of Medicine, Chicago, IL, [5]Northwestern Univ, Chicago, IL*

(893) ***Chemoembolization for Hepatocellular Carcinoma as a Bridge to Lung Transplant in a Patient with Advanced Lung Disease;*** M. Olson[1], R. Walia[2], A. Arjuna[2]. *[1]University of Arizona, School of Medicine, Phoenix, AZ, [2]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(894) ***Case Report: 10-Year Survival after Combined Heart+Lung Transplant in a 13-Month-Old Child;*** Y. Stukov, J. P. Jacobs, G. J. Peek, M. S. Bleiweis. *UF Health Congenital Heart Center, Gainesville, FL*

(895) ***Airway Stenting for Tracheal Anastomotic Dehiscence after a Combined Heart-Lung Transplant;*** O. Tisekar, m. Lalani, V. Rahulan, S. Arora, M. M, P. Dutta, S. Attawar. *Institute of Heart and Lung Transplant, KIMS Hospital, Hyderabad, India*

(896) ***Severe Hypoxia Caused by Hepatopulmonary Syndrome after Lung Transplantation;*** G. Singh[1], D. Laskey[1], J. Mudd[2], S. Scheinin[3], H. Seethamraju[4]. *[1]Thoracic Surgery, Mount Sinai Hospital, New York, NY, [2]Pulmonary and Critical Care Medicine, Mount Sinai Hospital, New York, NY, [3]Mount Sinai, New York, NY, [4]Ridgewood, NJ*

(897) ***Pulmonary Vein Gas Analysis Predicts Diminished Function after Transplant Not Clinically Manifested in Donor;*** D. Laskey[1], G. Singh[1], H. Seethamraju[2], S. Scheinin[3]. *[1]Thoracic Surgery, Mount Sinai Hospital, New York, NY, [2]Ridgewood, NJ, [3]Mount Sinai, New York, NY*

(898) ***Diagnosis of Thrombotic Microangiopathy Following Lung Transplant via Skin Biopsy;*** A. Wang[1], G. Singh[2], D. Laskey[2], S. Scheinin[3], H. Seethamraju[4]. *[1]Pulmonary and Critical Care Medicine, Mount Sinai Hospital, New York, NY, [2]Thoracic Surgery, Mount Sinai Hospital, New York, NY, [3]Mount Sinai, New York, NY, [4]Ridgewood, NJ*

(899) ***Early Azithromycin Initiation is Associated with Improved Outcome in Lung Transplant Recipients Who Develop Clad;*** R. A. Lehikoinen[1], A. Nykanen[2], J. Tikkanen[2], S. Syrjala[2], E. Heliovaara[2], K. Lemstrom[2]. *[1]University of Helsinki, Helsinki, Finland, [2]Helsinki University Hospital, Helsinki, Finland*

(900) ***Impact of National OCS Lung Procurement & Management Program on Post-Transplant Survival - Real World Data from the Thoracic Organ Perfusion (TOP) Post-Approval Registry;*** S. Huddleston[1], M. Hertz[1], G. Loor[2], P. Garcha[2], M. Hartwig[3], L. Snyder[4], A. Siddique[5], H. Strah[5], J. Kukreja[6], T. Song[7], R. Jablonski[8], M. Smith[9], R. Walia[10], A. Arjuna[11], L. Lozonschi[12], K. Patel[13], G. Katlaps[14], H. Nemeh[15], E. Suarez[16], H. Huang[17], N. Langer[18], J. Madsen[19], A. Lee[20], G. Dhillon[21], J. MacArthur[22], S. Keshavamurthy[23], S. Nandavaram[24], M. Daneshmand[25], D. Neujahr[26], E. Bush[27], D. Joyce[28], A. Ardehali[29], M. Budev[30], K. McCurry[31]. *[1]University of Minnesota, Minneapolis, MN, [2]Baylor College of Medicine, Houston, TX, [3]Duke University Medical Center, Durham, NC, [4]Duke University, Durham, NC, [5]University of Nebraska Medical Center, Omaha, NE, [6]University of California San Francisco, San Francisco, CA, [7]University of Chicago, Chicago, IL, [8]The University of Chicago, Chicago, IL, [9]St. Joseph's Hosp & Med Center Norton Thoracic Institute, Phoenix, AZ, [10]St. Joseph's Hospital and Medical Center Norton Thoracic Institute, Phoenix, AZ, [11]St. Joseph's Hospital & Medical Center Norton Thoracic Institute, Phoenix, AZ, [12]University of South Florida, Tampa General Hospital, Tampa, FL, [13]USF Morsani College of Medicine, Tampa, FL, [14]University of South Florida, Tampa General Hospital, St Pete Beach, FL, [15]Henry Ford Hospital, Troy, MI, [16]Houston, TX, [17]Houston Methodist J.C. Walter Jr. Transplant Center, Houston, TX, [18]Massachusetts General Hospital, Wellesley, MA, [19]Massachusetts General Hospital, Charlestown, MA, [2021]Stanford University, Stanford, CA, [22]Stanford University, Palo Alto, CA, [23]University Of Kentucky, Lexington, Lexington, KY, [24]University of Kentucky, Lexington, KY, [25]Emory University, Durham, NC, [26]Emory Univesity, Atlanta, GA, [27]Johns Hopkins, Baltimore, MD, [28]Froedtert & the Med College of Wisconsin, Milwaukee, WI, [29]UCLA School of Medicine, Los Angeles, CA, [30]Cleveland Clinic, Pepper Pike, OH, [31]Cleveland Clinic, Solon, OH*

(901) ***Back-Table Evaluation Prior to Ex-Vivo Lung Perfusion: An Approach for Improving Utilization Rates;*** K. S. Ayyat, T. Okamoto, A. Tantawi, I. Sakanoue, H. Elgharably, U. Ahmad, S. Unai, J. Yun, M. Budev, K. McCurry. *Cleveland Clinic, Cleveland, OH*

(902) ***Impact of OCS Lung Warm Perfusion Times on Post-Transplant Survival - "Real-World" Experience from Thoracic Organ Perfusion (TOP) Registry;*** G. Loor[1], P. Garcha[2], S. Huddleston[3], M. Hertz[3], M. Hartwig[4], L. Snyder[5], A. Siddique[6], H. Strah[6], J. Kukreja[7], T. Song[8], R. Jablonski[9], M. Smith[10], R. Walia[11], A. Arjuna[12], L. Lozonschi[13], K. Patel[14], G. Katlaps[15], H. Nemeh[16], E. Suarez[17], H. Huang[18], N. Langer[19], J. Madsen[20], A. Lee[21], G. Dhillon[22], J. MacArthur[23], S. Keshavamurthy[24], S. Nandavaram[25], M. Daneshmand[26], D. Neujahr[27], E. Bush[28], D. Joyce[29], A. Ardehali[30], M. Budev[31], K. McCurry[32]. *[1]Cardiothoracic Surgery, Baylor St. Luke's Medical Center, Houston, TX, [2]Baylor College of Medicine, Houston, TX, [3]University of Minnesota, Minneapolis, MN, [4]Duke University Medical Center, Durham, NC, [5]Duke University, Durham, NC, [6]University of Nebraska Medical Center, Omaha, NE, [7]University of California San Francisco, San Francisco, CA, [8]University of Chicago, Chicago, IL, [9]The University of Chicago, Chicago, IL, [10]St. Joseph's Hosp & Med Center Norton Thoracic Institute, Phoenix, AZ, [11]St. Joseph's Hospital and Medical Center Norton Thoracic Institute, Phoenix, AZ, [12]Pulmonology, St. Joseph's Hospital and Medical Center Norton Thoracic Institute, Phoenix, AZ, [13]University of South Florida, Tampa General Hospital, Tampa, FL, [14]USF Morsani College of Medicine, Tampa, FL, [15]University of South Florida, Tampa General Hospital, St Pete Beach, FL, [16]Henry Ford Hospital, Troy, MI, [17]Houston, TX, [18]Houston Methodist J.C. Walter Jr. Transplant Center, Houston, TX, [19]Massachusetts General Hospital, Wellesley, MA, [20]Massachusetts General Hospital, Charlestown, MA, [2122]Stanford University, Stanford, CA, [23]Stanford University, Palo Alto, CA, [24]University of Kentucky, Lexington, Lexington, KY, [25]University of Kentucky, Lexington, KY, [26]Emory University, Durham, NC, [27]Emory Univesity, Atlanta, GA, [28]Johns Hopkins, Baltimore, MD, [29]Froedtert & the Med College of Wisconsin, Milwaukee, WI, [30]UCLA School of Medicine, Los Angeles, CA, [31]Cleveland Clinic, Pepper Pike, OH, [32]Cleveland Clinic, Solon, OH*

(903) ***Impact of Ex Vivo Lung Perfusion on a Lung Transplant Program: A Single Center Experience;*** T. Okamoto[1], K. Ayyat[2], I. Sakanoue[3], A. Tantawi[2], S. Unai[1], U. Ahmad[1], H. Elgharably[4], J. Yun[1], M. Budev[5], K. McCurry[6]. *[1]Cleveland Clinic, Cleveland, OH, [2]Cleveland Clinic, Westlake, OH, [3]Cleveland Clinic, Beachwood, OH, [4]Beachwood, OH, [5]Cleveland Clinic, Pepper Pike, OH, [6]Cleveland Clinic, Solon, OH*

(904) ***Early Weight Gain During Ex Vivo Lung Perfusion Can Predict Transplant Suitability and Post-Transplant Outcomes;*** I. Sakanoue, T. Okamoto, K. S. Ayyat, A. Tantawi, J. J. Yun, H. Niikawa, K. R. McCurry. *Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH*

(905) ***Can We Safely Use Donors after Cardiocirculatory Death for Lung Transplantation;*** A. Firoz[1], A. Kashem[1], N. Shigemura[2], Y. Toyoda[2]. *[1]Lewis Katz School of Medicine, Philadelphia, PA, [2]Temple University Hospital, Philadelphia, PA*

(906) ***Impact of Donor Quality on Recipient Outcomes in Lung Transplantation: 12-Year Single-Center Experience Using the Eurotransplant Lung Donor Score;*** K. Floethmann[1], K. Aburahma[1], N. D. de Manna[1], M. Franz[1], P. Yablonski[1], A. Saipbaev[1], M. Greer[2], M. Avsar[1], D. Bobylev[1], N. Schwerk[3], W. Sommer[4], G. Warnecke[4], T. Welte[2], A. Haverich[1], C. Kuehn[1], J. Salman[1], F. Ius[1]. *[1]Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, [2]Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, [3]Department of Paediatrics, Hannover Medical School, Hannover, Germany, [4]Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany*

(907) ***Lung Transplantation from Uncontrolled Donation after Circulatory Death Donors with Prolonged Ischemic Times. Favourable Outcomes with a Simple Ventilation-Based Preservation Strategy;*** A. Palleschi[1], V. Musso[2], D. Tosi[1], A. Zanella[3], L. Morlacchi[4], V. Vaira[2], V. Rossetti[4], L. Rosso[1], I. Righi[1], P. Mendogni[1], M. Nosotti[1]. *[1]Thoracic Surgery and Lung Transplantation Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico of Milan, Milano, Italy, [2]University of Milan, Milano, Italy, [3]Anaesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico of Milan, Milano, Italy, [4]Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico of Milan, Milano, Italy*

(908) ***Does Donor-Recipient Sex Mismatch Have an Influence on Long Term Outcomes after Lung Transplantation? An Experience of a High Volume Center;*** M. Franz[1], K. Aburahma[1], M. Avsar[1], D. Bobylev[1], W. Sommer[2], M. Greer[3], I. Tudorache[4], T. Welte[3], A. Haverich[1], G. Warnecke[2], C. Kuehn[1], F. Ius[1], J. Salman[1]. *[1]Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, [2]Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany, [3]Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, [4]University Hospital Duesseldorf, Duesseldorf, Germany*

(909) ***The Reality of Using DCD Donors in Pediatric Thoracic Transplantation;*** H. F. Ahmed[1], A. Guzman-Gomez[2], J. W. Greenberg[3], K. Kulshrestha[4], S. Hogue[5], E. Kantemneni[4], F. Zafar[2], D. Morales[6]. *[1]Department of Cardiothoracic Surgery, Cincinnati Children' Hospital Medical Center, Cincinnati, OH, [2]Cincinnati Children's Hospital, Cincinnati, OH, [3]Department of Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [4]Cincinnati Children' Hospital Medical Center, Cincinnati, OH, [5]Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [6]Cincinnati Children's Hosp, Cincinnati, OH*

(910) ***Identifying Characteristics of Expediated Warm Ischemia Times in Donation after Circulatory Death Lung Donors;*** J. N. Coster[1], J. P. Ryan[2], M. Furukawa[3], P. Sanchez[4]. *[1]Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, [2]Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, [3]University of Pittsburgh, Pittsburgh, PA, [4]University of Pittsburgh Medical Center, Pittsburgh, PA*

(911) ***Older Donors in Lung Transplantation: The Portuguese Experience;*** Z. Cruz[1], C. Figueiredo[1], C. Moita[1], J. E. Reis[1], J. S. Silva[1], J. M. Barbosa[1], P. Calvinho[1], L. Semedo[2]. *[1]Unidade Funcional de Cirurgia Torácica, Hospital de Santa Marta - Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal, [2]Serviço de Pneumologia, Hospital de Santa Marta - Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal*

(912) ***Impact of Donor Lung Quality on Outcomes of Lung Transplantation: Clinical Reality of Extended Criteria Donors;*** H. Kim[1], Y. Yang[1], W. Ara[2], S. Kim[2], M. Park[2], J. Lee[1]. *[1]Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, South Korea, [2]Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea*

(913) ***Randomized Trial Evaluating Routine Versus On-Demand Intraoperative Extracorporeal Membrane Oxygenation in Lung Transplantation;*** B. S. Nasir, P. Ferraro, M. Liberman, C. Overbeek, A. Moore. *Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada*

(914) ***Renal Failure after Lung Transplantation: A Bump in the Road or a Grave Complication?;*** S. T. Kim, Y. Xia, J. K. Ho, A. Ardehali. *University of California, Los Angeles, Los Angeles, CA*

(915) ***Lung Transplantation Utilizing Donor after Circulatory Death with Normothermic Regional Perfusion;*** S. H. Chang, G. Piper, J. Chan, T. C. Geraci, T. Hsiung, L. James, J. Ngai, J. Natalini, D. Rudym, M. Lesko, S. Hussain, A. Reyentovich, N. Moazami, D. Smith, L. Angel. *NYU Langone Health, New York, NY*

(916) ***Lung Transplant Outcomes in Young Adults with Pulmonary Hypertension Bridged with ECMO;*** A. M. Guzman-Gomez[1], H. F. Ahmed[1], D. Lehenbauer[1], D. Morales[1], P. Critser[2], R. Hirsch[2], F. Zafar[1], D. Hayes[3]. *[1]Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, [2]Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [3]Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*

(917) ***Outcomes Following Lung Transplants in Patients ›65 Years Old with Previous Cardiothoracic Surgery;*** A. Y. Lee[1], E. L. Larson[2], J. M. Ruck[3], C. Merlo[3], J. S. Ha[3], E. L. Bush[3]. *[1]University of Hawaii John A. Burns School of Medicine, Honolulu, HI, [2]Johns Hopkins University School of Medicine, Baltimore, MD, [3]Johns Hopkins Hospital, Baltimore, MD*

(918) ***Outcomes of Heart-Lung Transplant Compared to Lung Transplant in Patients with Secondary Pulmonary Hypertension;*** E. L. Larson[1], K. Jiang[1], J. Ruck[2], B. Shou[3], A. Zhou[1], A. Kilic[4]. *[1]Johns Hopkins University School of Medicine, Baltimore, MD, [2]Johns Hopkins Hospital, Baltimore, MD, [3]Johns Hopkins University School of Medicine, Houston, TX, [4]The Johns Hopkins University, Baltimore, MD*

(919) ***Reoperative CABG in a Patient with Prior Concomitant Lung Transplantation and Two-Vessel CABG;*** E. L. Larson[1], A. Y. Lee[2], H. Aziz[3]. *[1]Johns Hopkins University School of Medicine, Baltimore, MD, [2]University of Hawaii John A. Burns School of Medicine, Honolulu, HI, [3]Johns Hopkins Hospital, Baltimore, MD*

(920) ***Elective Cardiopulmonary Bypass for Lung Transplantation: Is It Safer Than We Think;*** W. Blanding[1], M. Hill[1], Z. Hashmi[2], T. Whelan[3], L. Paoletti[2], K. Engelhardt[1], B. Gibney[1]. *[1]Surgery, Medical University of South Carolina, Charleston, SC, [2]Medical University of South Carolina, Charleston, SC, [3]Charleston Afb, SC*

(921) ***Effect of Surgical Exposure on Short-Term Outcomes after Bilateral Lung Transplantation;*** N. D. de Manna[1], D. Van Raemdonck[2], M. Hartwig[3], B. Bottiger[4], G. Loor[5], A. Leon[5], M. Villavicencio[6], N. Langer[7], A. Emtiazjoo[8], S. Chandrashekaran[9], A. Neyrinck[2], Y. Toyoda[10], A. Kashem[10], S. Huddleston[11], P. Sanchez[12], K. Subramaniam[13], G. Warnecke[14], F. Ius[1]. *[1]Hannover Medical School, Hannover, Germany, [2]University Hospitals Leuven, Leuven, Belgium, [3]Duke University Medical Center, Durham, NC, [4]Duke University Hospital, Hillsborough, NC, [5]Baylor College of Medicine, Houston, TX, [6]Mayo Clinic, Rochester, Rochester, MN, [7]Massachusetts General Hospital, Wellesley, MA, [8]University of Florida, Gainesville, FL, [9]Emory University Hospital, Gainesville, FL, [10]Temple University School of Medicine, Philadelphia, PA, [11]University of Minnesota, Minneapolis, MN, [12]University of Pittsburgh Medical Center, Pittsburgh, PA, [13]University of Pittsburgh Medical Center, Sewickley, PA, [14]University of Heidelberg, Heidelberg, Germany*

(922) ***Impact of Simultaneous Abdominal Normothermic Regional Perfusion in Lung Transplantation from Controlled Donation after Circulatory Death;*** J. Campo-Cañaveral de la Cruz, M. Barturen, A. Romero Román, L. Hoyos Mejia, S. Crowley, J. Naranjo Gomez, M. Cordoba Pelaez, R. Laporta Hernandez, A. Romero Berrocal, M. Pérez Redondo, P. Cordero Iglesias, F. Alayza Avendaño, D. Gómez De Antonio. *Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain*

(923) ***The Effect of Donor-Recipient Sex Matches on Lung Transplant Survival Rates: A Single Center Analysis;*** E. Profozich, S. Jafar, A. Kashem, H. Zhao, K. Cheng, R. Yanagida, E. Leotta, H. Kehara, N. Shigemura, Y. Toyoda. *Lewis Katz School of Medicine at Temple University, Philadelphia, PA*

(924) ***The Use of Intraoperative Ecmo in Lung Transplantation: A Retrospective Analysis from the Largest Lung Transplant Center in Brazil;*** S. dos Santos[1], M. Razuk Filho[2], F. Pola[3], L. G. Abdalla[4], L. M. Fernandes[5], P. Pego-Fernandes[2]. *[1]Instituto do Coração HCFMSUP, São Paulo, Brazil, [23]Heart Institute, São Paulo, Brazil, [4]Heart Institue - HCFMUSP, São Paulo, Brazil, [5]Heart Institute - HCMFUSP, São Paulo, Brazil*

(925) ***Combined Lung-Kidney Transplantation Yields Better Survival Than Isolated Lung Transplantation in Recipients with Underlying Renal Failure;*** A. Casillan[1], E. Larson[2], J. Ruck[1], A. Zhou[3], J. Ha[1], P. Shah[4], C. Merlo[3], E. Bush[5]. *[1]Johns Hopkins Hospital, Baltimore, MD, [2]Johns Hopkins School of Medicine, Baltimore, MD, [3]Johns Hopkins University School of Medicine, Baltimore, MD, [4]Johns Hopkins University, Rockville, MD, [5]Johns Hopkins, Baltimore, MD*

(926) ***Lung Transplantation Following Prior Cardiac Surgery;*** S. S. Scott[1], J. Rosenheck[2], M. Henn[3], N. Mokadam[4], B. Whitson[5], V. Ramsammy[5], D. Nunley[6], S. Smith[7], A. Ganapathi[8]. *[1]Division of Cardiac Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, [2]Powell, OH, [3]The Ohio State University Wexner Medical Center, Columbus, OH, [4]The Ohio State Univ Wexner Med Ctr, Columbus, OH, [5]Ohio State University, Columbus, OH, [6]Wexford, PA, [7]Ohio State University, New Albany, OH, [8]Ohio State University Wexner Medical Center, Columbus, OH*

(927) ***Types of Lung Transplantation Survival Outcomes at a Single Center: Donor and Recipient Age in Interstitial Lung Disease;*** K. Hanna[1], A. Kashem[2], H. Kehara[3], E. Leotta[4], R. Yanagida[4], N. Shigemura[5], Y. Toyoda[4]. *[1]Lewis Katz School of Medicine at Temple University, Philadelphia, PA, [2]Temple University School of Med, Philadelphia, PA, [3]Temple University, Philadelphia, PA, [4]Temple University Hospital, Philadelphia, PA, [5]Temple University Health System and Lewis Katz School of Medicine, Philadelphia, PA*

(928) ***Impact of Donor Vaping or Electronic Cigarette Use on Early Outcomes after Lung Transplantation- A Single Center's Experience;*** B. Seal[1], A. Sharma[1], M. Thronton[1], C. Liu[2], E. Hauptmann[1], M. Ali[1], V. Kaza[3], C. Heid[4], M. Peltz[4], M. Wait[5], W. Ring[4], J. Murala[6]. *[1]University of Texas Southwestern Medical Center, Dallas, TX, [2]UT Southwestern Medical Center, Katy, TX, [3]UT Southwestern Medical Center, Coppell, TX, [4]UT Southwestern Medical Center, Dallas, TX, [5]University of Texas Southwestern Medical Center, Dallas, Cedar Hill, TX, [6]UT Southwestern, Dallas, TX*

(929) ***Long-Term Survival Among Single Lung Transplant Recipients is Shorter Than That of Matched Bilateral Lung Transplant Recipients;*** J. L. Jacob[1], D. Razia[1], A. Omar[2], R. Walia[2], M. A. Smith[2], R. M. Bremner[2], S. Tokman[2]. *[1]Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ, [2]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(930) ***Comparing Lung Donation after Circulatory Death to Donation after Brain Death in a Single Australian Centre;*** S. Emmanuel[1], C. Thomson[2], D. Darley[3], M. Malouf[4], A. Havryk[5], M. Benzimra[6], A. Abbott[7], R. Pearson[5], M. Plit[8], M. Connellan[9], E. Granger[10], A. Iyer[11], A. Watson[12], P. Jansz[3]. *[1]Cardiothoracic Surgery, St Vincent's Hospital Sydney, Darlinghurst, Australia, [2]St Vincent's Hospital Sydney, Darlinghurst, Australia, [3]St Vincent's Hospital, Darlinghurst, Australia, [4]St. Vincent's Hospital, Darlinghurst, Australia, [5]Darlinghurst, Australia, [6]St Vincent's Hospital, Zetland, Australia, [7]St Vincent's Hospital, Camperdown, Australia, [8]St. Vincent 's Hospital, Rose Bay, Australia, [9]St. Vincent 's Hospital, Cremorne Point, Australia, [10]St Vincent's Hospital Sydney, Sydney, Australia, [11]St Vincent 's Hospital, Darlinghurst, Australia, [12]St Vincent's Hospital, Sydney, Australia*

(931) ***Indication for CABG Preceding Lung Transplant;*** J. Zywiciel[1], A. Thomas[1], R. Verm[2], J. Schwartz[3], C. Mangukia[3]. *[1]Loyola Stritch School of Medicine, Maywood, IL, [2]Loyola University Medical Center, Westmont, IL, [3]Loyola University Medical Center, Maywood, IL*

(932) ***VA-ECLS for Cardiogenic Shock in Adult Congenital Heart Disease;*** J. D. Garry, R. A. Dieter, K. H. Schlendorf, M. D. Bacchetta, S. K. Zalawadiya, K. Mishra, J. Trahanas, B. P. Frischhertz, J. Lindenfeld, J. N. Menachem, A. S. Rali. *Vanderbilt University Medical Center, Nashville, TN*

(933) ***Mechanical Circulatory Support as a Weaning Platform from Extracorporeal Membrane Oxygenation;*** T. J. George[1], J. Sheasby[2], J. DiMaio[3], N. Kabra[4], D. Rawitscher[5], A. Afzal[6]. *[1]The Heart Hospital Baylor Plano, Dallas, TX, [2]Baylor Scott and White, The Heart Hospital, Plano, Plano, TX, [3]Baylor Scott & White Health, Dallas, TX, [4]La Jolla, CA, [5]The Heart Hospital Baylor Plano, Plano, TX, [6]Baylor University Medical Center, Dallas, TX*

(934) ***Short-Term Mechanical Support with the Impella 5.x for Mitral Valve Surgery in Advanced Heart Failure;*** A. Osswald, M. El Gabry, S. Shehada, A. Zubarevich, M. Thielmann, A. Weymann, A. Ruhparwar, B. Schmack. *Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany*

(935) ***Va Ecmo Decannulation at Bedside with Manta Closure Device;*** V. Kagan[1], R. Rose[2], A. Alund[1], T. Song[1]. *[1]Cardiac Surgery, University of Chicago Medicine, Chicago, IL, [2]University of Chicgo Medicine, Chicago, IL*

(936) ***Outcome after ECMO with Axillary Cannulation: The Frankfurt Experience;*** S. Riess[1], M. Radwan[2], K. Baghdadi[1], A. Winter[1], P. Kaiser[1], M. Hermann[1], T. Walther[1], F. Emrich[1]. *[1]University Hospital Frankfurt, Heartcenter, Frankfurt, Germany, [2]University Hospital Tuebingen, Tuebingen, Germany*

(937) ***Temporary Mechanical Circulatory Support: Central versus Peripheral Cannulation;*** J. Kremer, H. Philipps, W. Sommer, G. Warnecke, M. Karck, A. Meyer. *Department of Cardiac Surgery, Heidelberg, Germany*

(938) ***Extended Impella 5.0 and 5.5 Microaxillary Left Ventricular Mechanical Circulatory Support for Cardiogenic Shock;*** H. Lamba[1], H. Ali[2], M. E. Delgado[2], C. Walther[2], K. Nordick[2], A. Shafii[2], S. Chatterjee[2], A. Nair[2], L. Simpson[3], K. Liao[4], A. Civitello[3]. *[1]Surgery, Baylor College of Med, Houston, TX, [2]BCM, Houston, TX, [3]Texas Heart Institute, Houston, TX, [4]Baylor College of Medicine, Houston, TX*

(939) ***Mechanical Circulatory Support Using Impella 5.5 for Patients Presented with Ischemic Heart Disease and Severely Impaired Left Ventricular Function Undergoing Coronary Artery Bypass Surgery: A Three-Year Single Centre Experience;*** S. Shehada[1], M. Jasarevic[1], S. Jarkas[1], A. Haddad[2], F. Al-Rashid[3], M. Thielmann[1], A. Koch[1], N. Pizanis[1], M. Kamler[1], A. Ruhparwar[1], B. Schmack[1]. *[1]Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany, [2]Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, Essen, Germany, [3]Department of Cardiology and Angiology, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany*

(940) ***Impact of Impella 5.0 and 5.5 Microaxillary Left Ventricular Mechanical Circulatory Support on Right Ventricular Hemodynamics;*** H. Lamba[1], H. Ali[2], M. E. Delgado[2], A. Shafii[3], s. chatterjee[2], C. Walther[2], A. Nair[4], L. Simpson[5], K. Liao[6], A. Civitello[5]. *[1]Baylor College of Med, Houston, TX, [2]BCM, Houston, TX, [3]BCM, houston, TX, [4]Houston, TX, [5]Texas Heart Institute, Houston, TX, [6]Baylor College of Medicine, Houston, TX*

(941) ***Intra-Aortic Balloon Pump Optimization Before Left Ventricular Assist Device Implantation;*** O. M. Sharaf[1], M. Falasa[2], H. Liu[2], M. Ahmed[3], J. Vilaro[4], A. Parker[3], M. Al-Ani[5], J. Aranda[3], D. Demos[2], D. Neal[6], T. M. Beaver[3], E. Jeng[3]. *[1]University of Florida College of Medicine, Gainesville, FL, [2]University of Florida Health, Department of Surgery, Division of Cardiovascular Surgery, Gainesville, FL, [3]University of Florida, Gainesville, FL, [4]UF Hlth Shands Hospital, Gainesville, FL, [5]Gainesville, FL, [6]University of Florida Health, Gainesville, FL*

(943) ***Hemodynamic Effects of Intra-Aortic Balloon Pump as a Bridge to Durable Left Ventricular Assist Device;*** M. Brown[1], A. Lekan[2], M. Hofmeyer[3], M. Rodrigo[4], A. Kadakkal[5], P. H. Lam[5], M. Krishnan[6], N. Afari-Armah[7], S. Rao[8], R. Gupta[9], A. Alassar[5], E. Molina[10], F. Sheikh[11]. *[1]Cardiac Surgery, University of Pennsylvania, Philadelphia, PA, [2]Georgetown University School of Medicine, Washington, DC, [3]MedStar Heart and Vascular Institute, Bethesda, MD, [4]Medstar Washington Hospital Center, Potomac, MD, [5]Cardiology, Medstar Heart and Vascular Institute, Washington, DC, [6]MedStar Washington Hospital Center, Laurel, MD, [7]Silver Spring, MD, [8]Medstar Washington Hospital Center, Washington, DC, [9]Columbia, MD, [10]Piedmont Heart Institute - Samsky Advanced Heart Failure Center, Chevy Chase, MD, [11]MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Clarksville, MD*

(944) ***Native Heart Recovery after Left Ventricular Unloading with the Impella 5.5 in Patients with Cardiogenic Shock;*** K. P. Mody[1], G. Batsides[2], S. Stewart[3], P. Walters[4], C. Silva[5], Y. Dudiy[2], E. Elmann[2], A. Ng[2], D. Landers[3], P. P. Vaidya[3], M. Lim[3], M. B. Anderson[2]. *[1]Cardiology, Hackensack University Medical Center, Allendale, NJ, [2]Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, NJ, [3]Cardiology, Hackensack University Medical Center, Hackensack, NJ, [4]Hackensack University Medical Center, Secaucus, NJ, [5]Hackensack Meridian Health, Metuchen, NJ*

(945) ***Early Upgrade to Impella 5.5 Improves Survival in Acute Coronary Syndrome Complicated by Cardiogenic Shock;*** P. Walters[1], K. P. Mody[2], S. Stewart[3], C. Silva[4], M. Lim[2], D. Landers[2], Y. Dudiy[5], E. Elmann[6], A. Ng[5], G. P. Batsides[5], M. B. Anderson[5]. *[1]Hackensack University Medical Center, Secaucus, NJ, [2]Cardiology, Hackensack University Medical Center, Hackensack, NJ, [3]Hackensack University Medical Center, Hillsdale, NJ, [4]Hackensack Meridian Health, Metuchen, NJ, [5]Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, NJ, [6]Hackensack UMC Heart Vascular, Hackensack, NJ*

(946) ***Axillary Artery Impella 5.5 Single Center Experience;*** G. P. Batsides[1], K. P. Mody[2], P. Walters[3], S. Stewart[4], C. Silva[5], D. Landers[2], E. Elmann[1], A. Ng[1], Y. Dudiy[1], M. B. Anderson[1]. *[1]Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, NJ, [2]Cardiology, Hackensack University Medical Center, Hackensack, NJ, [3]Hackensack University Medical Center, Secaucus, NJ, [4]Hackensack University Medical Center, Hackensack, NJ, [5]Hackensack Meridian Health, Metuchen, NJ*

(947) ***Retrograde Washout of a Pre-Pump HVAD Thrombosis;*** M. Elbayomi, R. Tandler, M. Weyand, K. Steger, C. Heim. *University of Erlangen-Nurnberg, Erlangen, Germany*

(948) ***Anterolateral Thoracotomy and Rib Resection for LVAD Inflow Repositioning and Thrombectomy;*** S. Allam, E. Sorensen, L. Dees, M. Ananthram, B. Griffith. *University of Maryland, Baltimore, MD*

(949) ***Fetal Viability via Maternal Acute Mechanical Circulatory Support as a Bridge to Durable Lvad;*** Z. W. Sollie[1], I. A. Haque[2], Z. Hashmi[1], K. Bhandari[1], A. Carnicelli[3], A. Kilic[3], L. Witer[1]. *[1]Department of Surgery, Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC, [2]Harvard University, Cambridge, MA, [3]Medical University of South Carolina, Charleston, SC*

(950) ***Pathological Examination of Explanted Native Heart after Impella 5.5 Support: A First-In-Human Study;*** E. S. Choi[1], R. Dowling[2], R. Devich[1], M. Freundt[3], B. Mahesh[4], B. Soleimani[5], F. Ruggiero[6]. *[1]PennState College of Medicine, Hershey, PA, [2]Heart and Vascular Institute Cardiac Surgery, PennState Health Milton S. Hershey Medical Center, Hershey, PA, [3]Heart and Vascular Institute Critical Care Unit, PennState Health Milton S. Hershey Medical Center, Hershey, PA, [4]Heart and Vascular Institute Cardiac Surgery, Penn State Hershey Medical Center, Hershey, PA, [5]Heart and Vascular Institute Cardiac Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, [6]Pathology, PennState Health Milton S. Hershey Medical Center, Hershey, PA*

(951) ***The Role of Impella 5.5 to Reduce Pulmonary Artery Pressures in Patients with Cardiac Amyloidosis with Small Ventricular Cavity as a Bridge to Heart Transplant;*** I. J. Wadiwala[1], P. Garg[1], J. Nativi[2], M. Lyle[2], J. Leoni[2], D. S. Yip[2], R. Goswami[2], P. C. Patel[2], B. Sareyyupoglu[1], E. A. MM[1], S. Jacob[1], K. Landolfo[1], S. M. Pham[1]. *[1]Department of Cardiothoracic Surgery, Mayo Clinic Florida, Jacksonville, Florida, Mayo Clinic Florida, Jacksonville, FL, [2]Department of Transplantation, Mayo Clinic Florida, Jacksonville, Florida, Mayo Clinic Florida, Jacksonville, FL*

(952) ***Hospital-To-Hospital Sharing of Patients with Cardiogenic Shock Bridged with Ecmella;*** K. Kosiorowska[1], M. Bochenek[1], G. Bielicki[1], M. Zakliczyński[1], T. Hrapkowicz[2], W. Kuliczkowski[3], R. Przybylski[1]. *[1]Department of Cardiac Surgery, Wroclaw Medical University, Wroclaw, Poland, [2]Department of Cardiac Surgery, Silesian Centre for Heart Diseases, Zabrze, Poland, [3]Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland*

(953) ***Successful Repair of Acute Severe Mitral Regurgitation with Mitraclip® on Impella®5.5 Support Following Initial ECPELLA for Decompensated Heart Failure;*** T. Wombacher, A. Alaiti, K. Telukuntla, T. Dewey, J. MacHannaford, K. Hoang, S. Vasireddy, O. Hernandez, O. Espinoza, B. Lima. *Medical City Heart Hospital, Dallas, TX*

(954) ***Escalation from Impella 5.5 to Ecpella Support as a Bridge to Mitral Valve Surgery in a Patient with Non-Ischemic Cardiomyopathy with Degenerative Mitral Regurgitation***; V. Gregory[1], M. Grunfeld[1], A. Kanwal[2], A. D. Bali[3], A. Isath[2], S. Pan[2], D. Spielvogel[4], M. Kai[4], S. Ohira[4]. *[1]New York Medical College, Valhalla, NY, [2]Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, [3]Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, [4]Cardiothoracic Surgery, Westchester Medical Center, New York Medical College, Valhalla, NY*

(955) ***A New Implantable Direct Cardiac Compression Device Improves Cardiac Performance in a Chronic Ovine Heart Failure Model***; G. V. Letsou[1], B. Leschinsky[2], W. Altman[2], C. Bolch[2], E. Hord[2], J. C. Criscione[3]. *[1]St Joseph's Medical Center, Houston, TX, [2]CorInnova, Inc, Houston, TX, [3]Texas A&M Medical School, Houston, TX*

(956) ***Chronic in Vivo Animal Data on a Wireless Systolic Synchronized Mini-Cardiac Pump***; K. Nubret Le Coniat[1], L. Barandon[1], S. Garrigue[2]. *[1]Medical University of Bordeaux, Pessac, France, [2]Cardiac University Hospital Institute, Pessac, France*

(957) ***Implantable Direct Cardiac Compression Devices Do Not Cause Cardiac Injury or Induce Thrombus Formation***; G. Letsou[1], B. Leschinsky[2], W. Altman[2], C. Bolch[2], E. Hord[2], J. C. Criscione[3]. *[1]St Joseph's Hospital, Houston, TX, [2]CorInnova, Inc, Houston, TX, [3]Texas A&M Engineering & Medical School, Houston, TX*

(958) ***Impact of a Novel Left Ventricular Assist Device Adapter with Transvalvular Aortic Outflow on the Device Flow Rate In Vitro***; D. Eichelkraut, F. Meissner, M. Wetzel, M. Schimmel, M. Czerny, W. Bothe. *Department of Cardiovascular Surgery, University Medical Center Freiburg, Freiburg, Germany*

(959) ***Results with the Protekduo® Cannula in Temporary Right Ventricular Support***; A. Holler[1], W. Sommer[2], G. Warnecke[3], M. Karck[4], A. Meyer[5], J. Kremer[6]. *[1]Department of Cardiac Surgery, Heidelberg University Hospital, Heidelberg, Germany, [2]University of Heidelberg, Hannover, Germany, [3]University of Heidelberg, Heidelberg, BW, Germany, [4]Hannover Medical School, Hannover, Germany, [5]Universitätsklinikum Heidelberg, Heidelberg, Germany, [6]University Hospital, Heidelberg, Germany*

(960) ***The Future of Biventricular Mechanical Circulatory Support***; S. Emmanuel[1], P. Jansz[2], A. Iyer[3], A. Watson[4], M. Connellan[5], E. Granger[6], D. Robson[7], P. MacDonald[8], D. Timms[9], F. Nestler[9], P. Ayre[10]. *[1]St Vincent's Hospital Sydney, Darlinghurst, Australia, [2]St Vincent's Hospital, Darlinghurst, Australia, [3]St Vincent 's Hospital, Darlinghurst, Australia, [4]Victor Chang Cardiac Research Institute, Vancouver, BC, Canada, [5]St. Vincent 's Hospital, Cremorne Point, Australia, [6]St Vincent's Hospital Sydney, Sydney, Australia, [7]St. Vincent's Hospital, Darlinghurst, Australia, [8]St. Vincent 's Hospital, Darlinghurst, Australia, [9]BiVACOR, Houston, TX, [10]CardioBionic, Sydney, Australia*

(961) ***Assessment of Hemodynamics in the Axial B-Impeller with a Focus on Wall Shear Stress***; M. A. Siddiqi[1], P. Bonde[2]. *[1]Bonde Artificial Heart Lab, Yale School of Medicine, New Haven, CT, [2]Yale School of Medicine, New Haven, CT*

(962) ***Redesign and Improvement of Hemodynamics in a Centrifugal Left Ventricular Assist Device Using Heuristic Aerodynamic Techniques on the Bladed Flow Domain***; M. A. Siddiqi. *Islamic Foundation School, Villa Park, IL*

(963) ***Temporary Mechanical Circulatory Support for High Risk Cardiac Surgery***; E. M. Schumer[1], M. Kamalia[2], A. Pawale[3], M. Masood[4], K. Kotkar[5]. *[1]Washington University, St Louis, MO, [2]Medical College of Wisconsin, Milwaukee, WI, [3]Washington University, Saint Louis, MO, [4]Washington Univ Sch of Med, Saint Louis, MO, [5]Washington University at St. Louis, Saint Louis, MO*

(964) ***Preliminary Experience of Extracorporeal Cytokine Hemoadsorption During Lvad Implantation in Cardiogenic Shock Patients***; J. Pausch[1], O. Bhadra[2], M. Barten[1], L. Schulte-Uentrop[3], H. Reichenspurner[4], A. Bernhardt[2]. *[1]University Heart and Vascular Center Hamburg, Hamburg, Germany, [2]University Heart and Vascular Center Hamburg, Hamburg, HH, Germany, [3]Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, [4]University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

(965) ***Preoperative Pulmonary Function is Associated with Left Ventricular Assist Device Outcomes***; A. Kluis, A. Afzal, J. DiMaio, N. Kabra, D. Rawitscher, T. George. *The Heart Hospital Baylor Plano, Plano, TX*

(966) ***Computational Fluid Dynamics as a Surgical Tool to Optimise the Positioning of the LVAD Outflow Graft for Reducing Aortic Regurgitation;*** G. B. Lopez-Santana[1], A. De Rosis[1], S. W. Grant[2], R. Venkateswaran[2], A. Keshmiri[1]. *[1]Department of Mechanical, Aerospace and Civil Engineering, The University of Manchester, Manchester, United Kingdom, [2]Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom*

(967) ***Use of the SherpaPak Cardiac Transport System Improves Freedom from Requirement for Mechanical Circulatory Support, Reduced Early Acute Cellular Rejection and Preserves Early Lv Function When Compared to Conventional Cold Storage;*** B. Krishnamoorthy[1], W. Critchley[2], N. Nwaejike[3], V. Mehta[4], P. Callan[5], S. Shaw[6], J. Barnard[7], R. Venkateswaran[8]. *[1]Cardiothoracic Surgery, University of Salford/ Manchester Foundation Trust, Manchester, United Kingdom, [2]Endothelial Biology, University of Leeds, Leeds, United Kingdom, [3]Manchester Foundation Trust, Manchester, United Kingdom, [4]Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom, [5]Manchester Foundation Trust, Altrincham, United Kingdom, [6]Transplant Centre Wythenshawe Hospital, Manchester, United Kingdom, [7]Manchester University Foundation Hospitals NHS Trust, Altrincham, United Kingdom, [8]Wythenshawe Hospital, Manchester, United Kingdom*

(968) ***Outcomes of Thoracotomy vs Median Sternotomy Approach in Patients Undergoing Heartmate 3 Implant: A Single-Center Experience;*** M. Alarfaj[1], T. Dalia[1], P. Bhyan[1], C. Xi[2], H. Jinxiang[2], A. Medley[1], T. Zorn[3], P. Downey[3], H. Shah[1], A. Vidic[1], Z. Shah[1], M. Danter[3]. *[1]Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, KS, [2]Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, [3]Department of Cardiothoracic Surgery, University of Kansas Medical Center, Kansas City, KS*

(969) ***Do Concomitant Procedures Worsen LVAD Outcomes in Long-Term?;*** M. Karahan, U. Kervan, S. S. Kocabeyoglu, D. E. Sert, A. Yilmaz, S. Kucuker, E. Sener, Z. Catav. *Cardiovascular Surgery, Ankara City Hospital, Ankara, Turkey*

(970) ***Comparison of Different Temporary RVAD Systems in Patients Undergoing LVAD Implantation;*** D. Opacic, C. Klüß, T. Becker, M. Rudloff, V. Lauenroth, M. Deutsch, A. Costard-Jäckle, H. Fox, R. Schramm, M. Morshuis, J. Gummert, S. V. Rojas. *Clinic for Thoracic- and Cardiovascular Surgery, Heart and Diabetes Centre North Rhine Westphalia, Bad Oeynhausen, Germany*

(971) ***Pulmonary Endarterectomy for Chronic Thromboembolic Changes in a Patient after Lung Transplantation - A Case Report;*** J. Mengers, L. Hoyos Mejia, H. Martina, C. Caviezel, M. Schuurmans, S. Ulrich, I. Opitz. *University Hospital Zurich, Zurich, Switzerland*

(972) ***Modified Body Mass Index But Not Conventional Body Mass Index Predicts Mortality after Pulmonary Thromboendarterectomy;*** G. Dardik[1], Y. Ning[1], P. Kurlansky[1], S. Sethi[2], E. Berman[3], K. Takeda[1]. *[1]Department of Surgery, Columbia University Medical Center, New York, NY, [2]Department of Medicine, Columbia University Medical Center, New York, NY, [3]Department of Pediatrics, Columbia University Medical Center, New York, NY*

(973) ***Mapping Chronic Pulmonary Embolism by Computed Tomography: Interobserver Agreement Across the Pulmonary Vasculature;*** G. K. Grafham[1], M. Bambrick[2], C. Houbois[2], S. Mafeld[2], L. Donahoe[3], M. De Perrot[3], M. McInnis[2]. *[1]Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada, [2]Joint Department of Medical Imaging, University Health Network, Toronto, ON, Canada, [3]Division of Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada*

(974) ***Impact of a Multidisciplinary Team on Surgical Management of Chronic Thromboembolic Pulmonary Hypertension;*** A. L. Zaki[1], B. Yang[1], N. Oh[1], J. Umana-Pizano[1], G. Heresi[2], I. Haddadin[3], A. Goyanes[2], N. Smedira[1], H. Elgharably[1], M. Z. Tong[1]. *[1]Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, [2]Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, [3]Department of Interventional Radiology, Cleveland Clinic, Cleveland, OH*

(1282) ***Effect of Patient and Donor Age in Single vs. Double Lung Transplantation;*** M. Warnick[1], M. A. Kashem[1], H. Kehara[2], E. Leotta[3], R. Yanagida[4], N. Shigemura[5], Y. Toyoda[1]. *[1]Temple University School of Medicine, Philadelphia, PA, [2]Temple University, Philadelphia, PA, [3]Chicago, IL, [4]Temple University Hospital, Livingston, NJ, [5]Temple University Health System and Lewis Katz School of Medicine, Philadelphia, PA*

4:15 – 5:15 p.m.

POSTER SESSION 02: PULMONOLOGY

Location: Mile High Ballroom

Core Therapies: PVD, LUNG
Practice Areas: Pulmonology, Cardiology, Cardiothoracic Surgery

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Pulmonology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Miriam Aguilar Perez, MD, University Puerta de Hierro Majadahonda Hospital, las Rozas de Madrid, Spain
Ambalavanan Arunachalam, MD, Northwestern Memorial Hospital, Chicago, IL USA
Shambhu Aryal, MD, Inova, Falls Church, VA USA
Nicholas Avdimiretz, MD, FRCPC, University of Alberta, Edmonton, AB Canada
Hakim Azfar Ali, MD, Duke University Hospital, Durham, NC USA
Christian Benden, MD, MBA, FCCP, University of Zürich, Zürich, Switzerland
David Bennett, MD, PhD, University Hospital of Siena, Italy, Siena, Italy
Heidi Brink, PharmD, BCPS, Nebraska Medical Center, Omaha, NE USA
Marie Budev, DO, MPH, Cleveland Clinic, Cleveland, OH USA
Silvia Campos, PhD, Heart Institute of Sao Paulo Medical School HCFMUSP, São Paulo, Brazil
Kevin Chan, MD, Michigan Medicine, Ann Arbor, MI USA
Prangthip Charoenpong, MD, MPH, Louisiana State University Health Sciences Center, Shreveport, LA USA
Letizia Corinna Morlacchi, MD, Milano, Italy
Andrew Courtwright, MD, PhD, Hospital of the University of Pennsylvania, Philadelphia, PA USA
Maria M. Crespo, MD, Hospital of the University of Pennsylvania, Philadelphia, PA USA
Karen Doucette, MD, MSc, University of Alberta, Edmonton, AB Canada
Meg Fregoso, MSN, NP-BC CCTC, Inova Fairfax Hospital, Fairfax, VA USA
Puneet Garcha, MD, Baylor College of Medicine, Houston, TX USA
Allan Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, NSW Australia
Laurent Godinas, MD, PhD, UZ Leuven, Leuven, Belgium
Vicky Gerovasili, MD, PhD, Royal Brompton and Harefield Hospitals UK, Harefield, United Kingdom
Peter Hopkins, FRACP, The Prince Charles Hospital, Chermside, QLD Australia
Renea Jablonski, MD, The University of Chicago, Chicago, IL USA
Arun Jose, MD, MS, University of Cincinnati, Cincinnati, OH USA
Vaidehi Kaza, MD, MPH, UT Southwestern Medical Center, Dallas, TX USA
Angela Koutsokera, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland
Erin Lowery, MD, MS, University of Wisconsin-Madison, Madison, WI USA
Dennis Lyu, MD, University of Michigan, Ann Arbor, MI USA
Julia Maheshwari, MD, University of California, San Francisco, CA USA
Tanya McWilliams, MD, PhD, Auckland City Hospital, Auckland, New Zealand
David Moreno McNeill, MD, Texas Children's Hospital, Houston, TX USA
Sravanthi Nandavaram, MD, FCCP, University of Kentucky, Lexington, KY USA
Luca Paoletti, MD, Medical University of South Carolina, Charleston, SC USA
Joanna Pepke-Zaba, PhD, FRCP, Royal Papworth Hospital NHS Trust, Cambridge, United Kingdom
Justin Rosenheck, PharmD, Janssen Pharmaceuticals, Powell, OH USA
Macé Matthew Schuurmans, MD, University Hospital Zurich, Zurich, Switzerland
Laurie Snyder, MD, MHS, Duke University, Durham, NC USA
Mark Snyder, MD, University of Pittsburgh, Pittsburgh, PA USA
Grant Turner, MD, MHA, UCLA, Los Angeles, CA USA
Rajat Walia, MD, St. Joseph's Hospital and Medical Center Norton Thoracic Institute, Phoenix, AZ USA
Chad Witt, MD, Washington Univ Sch Med, Saint Louis, MO USA

(975) ***A Case of Diffuse Distal Congenital Pulmonary Artery Hypoplasia Successfully Treated with Pulmonary Artery Stenting;*** S. Wiltshire[1], S. Conte[1], D. Tardo[1], E. Kotlyar[2], K. Kearney[3], E. Lau[4], P. MacDonald[5], D. Boshell[1], R. Cordina[4]. *[1]St. Vincent's Hospital, Sydney, Australia, [2]St Vincent's Hospital, Sydney, Darlinghurst, Australia, [3]St Vincent's Hospital, Darlinghurst, Australia, [4]Royal Prince Alfred Hospital, Sydney, Australia, [5]St. Vincent 's Hospital, Darlinghurst, Australia*

(976) ***Assessment of Clinical Practices and Unmet Needs in Chronic Thromboembolic Pulmonary Hypertension (CTEPH) - A Global Cross-Sectional Scientific Survey (CLARITY);*** G. Heresi[1], K. Abe[2], P. Forfia[3], M. Jevnikar[4], O. Moiseeva[5], G. Kopeć[6], K. Sheares[7], N. Skoro-Sajer[8], M. Terra-Filho[9], H. Whitford[10], A. Beaudet[11], V. Gressin[12], C. Meijer[13], Z. Zhai[14]. *[1]Cleveland Clinic, Cleveland, OH, [2]Kyushu University Hospital, Fukuoka, Japan, [3]Temple University Hospital, Philadelphia, PA, [4]Hôpital de Bicêtre, Le Kremlin-Bicêtre, France, [5]Almazov National Medical Research Centre, St. Petersburg, Russian Federation, [6]Pulmonary Circulation Centre Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland, [7]Royal Papworth Hospital, Cambridge, United Kingdom, [8]Medical University of Vienna, Vienna, Austria, [9]Pulmonary Division- Heart Institute (Incor), University of Sao Paulo, Sao Paulo, Brazil, [10]The Alfred Hospital, Melbourne, Australia, [11]Global Market Access, Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, Allschwil, Switzerland, [12]Global Medical Affairs, Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, Allschwil, Switzerland, [13]Monitor Deloitte, Zaventem, Belgium, [14]National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China*

(977) ***Post-Operative Use of Direct Oral Anticoagulants is Associated with Increased Risk of Recurrent Pulmonary Embolism Following Pulmonary Thromboendarterectomy;*** D. C. Paneitz, V. Nguyen, D. Giao, A. K. Wong, A. S. Witkin, J. M. Rodriguez-Lopez, C. D. Wright, N. B. Langer. *Massachusetts General Hospital, Boston, MA*

(978) ***Prospective Study to Determine the Impact of Pulmonary Endarterectomy on Quality of Life in Chronic Thromboembolic Pulmonary Hypertension;*** N. Shokri[1], F. B. Zaeimi[1], S. Karim[1], L. Donahoe[2], M. De Perrot[1]. *[1]Toronto General Hospital, Toronto, ON, Canada, [2]University of Toronto, Mississauga, ON, Canada*

(979) ***Advanced Pulmonary Hypertension - Cross Sectional Study;*** E. Wainstein[1], G. Svetliza[2], E. Beveraggi[3], A. Dietrich[4], A. Da Lozzo[5], M. L. Orazi[1], M. Raices[6], I. Bluro[7]. *[1]Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, [2]Hospital Italiano de Buenos Aires, CABA, B, Argentina, [3]Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, [4]Surgery Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, [5]Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, B, Argentina, [6]Hospital Italiano de Buenos Aires, Buenos AIres, Argentina, [7]Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina*

(980) ***Short Term Outcomes of Combined Heart-Lung Transplant Patients from India;*** M. lalani, O. Tisekar, V. Rahulan, S. Arora, P. Dutta, M. Menander, A. Mohandas, S. Attawar. *Krishna Institute of Medical Sciences, Hyderabad, India*

(981) ***Impact of VV ECMO Use as Bridge to Lung Transplant in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome;*** T. Toyoda[1], B. L. Thomae[1], V. Kandula[1], A. J. Manerikar[1], T. Kaiho[1], Y. Yagi[1], E. Cerier[1], R. Tomic[2], G. Budinger[2], A. Bharat[1], C. Kurihara[1]. *[1]Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, [2]Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL*

(982) ***Feasibility of Veno-Venous Extracorporeal Membrane Oxygenation Using ProtekDuo™ Cannula Ina Patients with COVID-19-Associated Acute Respiratory Distress Syndrome with Severe Right Heart Dysfunction Before Lung Transplantation;*** T. Toyoda[1], T. Nayak[2], A. Arunachalam[3], B. L. Thomae[2], V. Kandula[2], A. J. Manerikar[2], M. Jankowski[3], T. Kaiho[1], Y. Yagi[1], E. Cerier[1], K. Maganti[3], R. Tomic[3], G. Budinger[3], A. Bharat[1], C. Kurihara[1]. *[1]Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, [2]Northwestern University Feinberg School of Medicine, Chicago, IL, [3]Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL*

(983) ***Lung Transplant Outcomes in Hiv-Infected Patients: A Single Center Case Series;*** D. F. Martin, D. Barnes, L. Marte, J. Rhoades, R. Rampolla, L. Zaffiri. *Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA*

4:15 – 5:15 p.m.

POSTER SESSION 02: RESEARCH AND IMMUNOLOGY

Location: Mile High Ballroom

Core Therapies: HEART
Practice Areas: Research and Immunology, Cardiology, Cardiothoracic Surgery, Pathology, Pediatrics, Pharmacy

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Research and Immunology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Rayid Abdulqawi, MD, PhD, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Mohammad Al-Ani, MD, University of Florida, Gainesville, FL USA
Nael Aldweib, MD, Oregon Health Science University, Portland, OR USA
Yevgeniy Brailovsky, DO, New York, NY USA
Daniel Calabrese, MD, University of California, San Francisco, CA USA
Christine Falk, PhD, Hannover Medical School, Hannover, Germany
Martin Goddard, FRCS, FRCPath, Papworth Hospital, Cambridge, United Kingdom
Anthony Joudi, MD, Northwestern Memorial Hospital, Chicago, IL USA
Stephen Juvet, MD, PhD, University Health Network, Toronto, ON Canada
Benjamin Kopecky, MD, PhD, Washington University in St. Louis, St. Louis, MO USA
Nandan Kumar Mondal, MSc, MPhil, PhD, Baylor College of Medicine, Houston, TX USA
Kentaro Noda, PhD, University of Pittsburgh, Pittsburgh, PA USA
Michael Perch, MD, Rigshospitalet, Copenhagen, Denmark
Anja Roden, MD, Mayo Clinic Rochester, Rochester, MN USA
Ashish Sharma, MD, Brigham & Women's Hospital, Boston, MA USA
Akira Shimamoto, MD, PhD, Mie University Graduate School of Medicine, Tsu, Japan
Simon Urschel, MD, University of Alberta, Edmonton, AB Canada
Yoshito Yamada, MD, PhD, Kyoto University Hospital, Kyoto City, Japan
Lorenzo Zaffiri, MD, PhD, West Hollywood, CA USA

(984) ***Donor CD11c Cell Depletion Increases Chimerism in Neonatal Mice Tolerized with an Allogeneic Spleen/Bone Marrow Protocol Involving Peripheral CD8 T Cell Depletion and CD154 Co-Stimulation Blockade;*** R. A. Bascom, K. Tao, L. J. West. *University of Alberta, Edmonton, AB, Canada*

(985) ***Circulating Factors, Measured Both in the Donor and During Ex-Vivo Heart Perfusion, Correlate with Subsequent Heart Recovery in a Pig Model of Dcd;*** S. Graf[1], M. Egle[2], M. Sanz[1], A. Segiser[1], M. Arnold[1], A. Kadner[1], M. Siepe[1], S. Longnus[1]. *[1]Department of Cardiac Surgery, Inselspital, Bern University Hospital, Bern, Switzerland, [2]Inselspital, Bern, BE, Switzerland*

(986) ***Hyper Personalized Educational Social Network Intervention to Improve Health Equity in Transplantation;*** P. De Alcantara Rocha[1], D. Pinheiro[2], M. Nuño[3], M. Cadeiras[1]. *[1]Internal Medicine, University of California, Davis, Sacramento, CA, [2]Catholic University of Pernambuco, Recife, Brazil, [3]Public Health, University of California, Davis, Davis, CA*

(987) ***A Porcine Model of Acute Rejection for Cardiac Transplantation;*** M. Mendiola Pla[1], Y. Chiang[2], C. Glass[1], D. Wendell[1], D. Swain Lenz[1], L. Kang[1], A. Vekstein[1], M. Bishawi[1], A. Evans[1], F. H. Lee[1], M. F. Smith[1], A. Roki[1], K. Mitra[1], R. T. Gross[1], K. Dewan[1], C. Wang[1], L. E. Gault[3], S. Ho[3], M. Fudim[1], D. Bonadonna[1], P. M. Lezberg[4], C. A. Milano[1], D. E. Bowles[1]. *[1]Duke University, Durham, NC, [2]Columbia University, New York, NY, [3]Gift of Hope Organ and Tissue Donor Network, Itasca, IL, [4]TransMedics, Inc., Andover, MA*

(988) ***Coincidence of Early Graft Rejection and Replication of Human Herpesvirus 6 in the Donor Heart Associated with a CD38+ Lineage of Negative T Cells***; D. Oehler[1], A. Lang[1], R. R. Bruno[1], H. Aubin[2], I. Tudorache[2], R. Westenfeld[1], M. Kelm[1], A. Lichtenberg[2], N. Gerdes[1], C. Falk[3], U. Boeken[2]. *[1]Department of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, [2]Department of Cardiac Surgery, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, [3]Institute of Transplant Immunology, Hannover Medical School, MHH, Hannover, Germany*

(989) ***Does Pre-Sensitization with HLA-DP Impact the Outcome in a Heart Transplant Recipient***; A. Agrawal[1], J. L. Cox[2], C. Gebhart[3]. *[1]Cardiology, University of South Florida, Tampa, FL, [2]University of Nebraska Medical Center, Omaha, NE, [3]Immunology, LifeLink Transplantation Immunology Lab, Tampa, FL*

(990) ***Monitored Covid-19 Vaccine Humoral Response in Immunocompromised Solid Organ Transplant Recipients***; A. Chemmalakuzhy[1], S. Khan[2], M. Lerman[2], J. Hunt[2], A. Nikaein[3]. *[1]Transplant Immunology, Texas Medical Specialty, Inc., Dallas, TX, [2]Transplant, Medical City Dallas, Dallas, TX, [3]Texas Medical Specialty, Inc., Dallas, TX*

(991) ***Belatacept as Primary Maintenance Immunosuppression in Heart Transplant Recipients: A Single Center Experience***; E. P. Bilgili[1], A. L. Rumore[1], B. D. Mackie[2], L. H. Arroyo[2]. *[1]Pharmacy, Tampa General Hospital, Tampa, FL, [2]Tampa General Hospital, Tampa, FL*

(992) ***Platelet Transcriptome as a Liquid Biopsy for Acute Cellular Rejection After Heart Transplantation***; R. Krebs[1], K. Dhaygude[1], E. Holmstrom[1], M. Kankainen[2], S. Syrjala[1], P. Mattila[2], A. Nykanen[1], K. Lemstrom[1]. *[1]Transplantation Laboratory, University of Helsinki, Helsinki, Finland, [2]Institute for Molecular Medicine Finland, Helsinki, Finland*

8:00 – 9:00 a.m.

SESSION 50: ASSESSMENT OF COVID-19 POSITIVE DONOR FOR HEART TRANSPLANT

Location: Four Seasons Ballroom

Core Therapies: HEART
Practice Areas: Cardiology, Cardiothoracic Surgery, Infectious Diseases, Pediatrics

Session Summary: This symposium will ask speakers to argue "for" or "against" specific aspects of accepting a COVID-19 positive donor for heart transplant, providing the audience a brief review of the available (albeit limited) primary literature on this topic and provide clinicians a systematic approach to evaluating a COVID-19 positive donor, the recipient for such a donor, and controversies around prophylaxis and treatment of the recipient after transplant.

Game Show Format: This symposium will begin with one of the Co-Chairs presenting Case Scenarios of a potential recipient and a potential donor. Then three 'contestants' (speakers) will each have 12 minutes to explain their position on whether or not the donor (or Case Scenario) is acceptable. A 20-minute audience Q&A segment led by the Co-Chairs will conclude with an audience vote for the winning speaker.

Donor Case Scenario: 28 female COVID-vaccinated, died of opioid overdose with no symptoms of COVID-19. Nasopharyngeal swab was COVID-19 positive (cycle threshold 26); chest x-ray shows right middle lobe (RML) infiltrate.

Recipient Case Scenario: 52 female COVID-vaccinated, Blood type A, BMI 26 with stage D NICM listed status 6 for transplant with INTERMACS 5 exertion intolerant profile.

Co-Chairs: Christopher Link, MD, Allegheny Health Network, Pittsburgh, PA USA
Kiran Khush, MD, MAS, Stanford University, Stanford, CA USA

8:04 a.m. ***Approach to Donor Evaluation***
Yael Peled, MD, Sheba Medical Center, Ramat Gan, Israel

This "contestant" will discuss how to evaluate a COVID-19 positive donor, including interpretation of test results and the significance of the site sampled.

8:16 a.m. ***Approach to Recipient Evaluation and Consent***
Rebecca N. Kumar, MD, Georgetown University Hospital Center, Washington, DC USA

This "contestant" will discuss how to evaluate and consent a recipient who is offered an organ from a COVID-19 positive donor, as well as management of recipients not fully up to date on vaccines.

8:28 a.m. ***Therapies for the Recipients of COVID-19 Positive Donors***
Paolo Grossi, MD, PhD, University of Insubria, Varese, Italy

This "contestant" will discuss the role of prophylaxis as well as therapeutics including monoclonal antibodies, remdesivir.

8:40 a.m. ***Panel Discussion and Audience Vote***

8:00 – 9:00 a.m.

SESSION 51: HIGH YIELD TIPS FOR LVAD OR HEART TRANSPLANT IN CAUSE-SPECIFIC CARDIOMYOPATHIES

Location: Rooms 603-605

Core Therapies: HEART, MCS
Practice Areas: Cardiology, Pathology, Pharmacy and Pharmacology, Research and Immunology

Session Summary: This session, in Pecha Kucha format, will explore nuances of selecting advanced heart failure therapies in systemic diseases with extra-cardiac manifestations and cause-specific cardiomyopathies in which clear triggers for advanced treatment are not easily identified.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: In certain types of cardiomyopathy and systemic diseases that lead to advanced heart failure, there is clinical equipoise about (1) appropriate timing for advanced therapies such as heart transplantation (2) appropriate patient selection in the setting of extra-cardiac disease. This session will explore different scenarios that highlight such challenges.

Co-Chairs: Ana Roussoulieres, MD, PhD, Cliniques Universitaires de Bruxelles, Brussels, Belgium
Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, UT USA

8:00 a.m. ***AHFT in Hypertrophic Cardiomyopathy: Balancing Risk-Benefit and When to Pull the Trigger***
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain

The speaker will discuss how to decide timing for transplantation in hypertrophic cardiomyopathy?assessing concerns regarding pulmonary hypertension, functional status and role of cardiac output/index. The talk will also explore decision making for advanced therapies in the setting of concurrent renal or hepatic insufficiency.

8:08 a.m. ***AHFT in Sarcoidosis: Considering Appropriate Strategies for Advanced Heart Failure***
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

This talk will examine (1) approach to biventricular dysfunction and arrhythmias when considering LVAD (2) strategies for immunosuppression and surveillance after transplant (3) considerations for how to manage extra-cardiac involvement (hepatic or renal involvement).

8:16 a.m. ***AHFT in Amyloidosis: When Can a Systemic Disease Have a Cardiac Solution?***
Michelle Kittleson, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA USA

This talk will examine patient selection and post-transplant considerations in patients with AL or ATTR cardiac amyloidosis and extra-cardiac disease.

8:24 a.m. ***AHFT in ARVC: What Do We Do When the Right Heart Fails?***
Mrudula Munagala, MD, University of Miami, Miami, FL USA

This talk will explore (1) how to characterize RV failure in this population (2) appropriate timing for advanced therapies in patients with ARVC with respect to arrhythmias, worsening right heart failure and (3) circulatory support strategies to bridge to transplant.

8:32 a.m. ***It's Not Only a Broken Heart: Muscular Dystrophy***

Pradeep Mammen, MD, FACC, FAHA, FHFSA, UT Southwestern Medical Center, Dallas, TX USA

Patients with muscular dystrophy can have associated myocardial involvement leading to advance heart failure needing heart transplantation. When should we propose heart transplantation for those patients? The speaker will examine also how concerns regarding skeletal muscle and pulmonary involvement affect patient selection.

8:40 a.m. ***Panel Discussion and Audience Vote***

8:00 – 9:00 a.m.

SESSION 52: IMMUNE CHECKPOINTS IN THORACIC TRANSPLANTATION: LESSONS LEARNED FROM CANCER

Location: Rooms 401-404

Core Therapies: LUNG, HEART
Practice Areas: Cardiology, Research and Immunology, Cardiothoracic Surgery, Pathology, Pharmacy and Pharmacology, Pulmonology

Session Summary: This session, in Pecha Kucha format, will discuss immune checkpoint inhibitors and how they may be used as new immunomodulatory tools for thoracic organ transplant recipients. Each speaker will focus on a different aspect of immune checkpoint biology, ranging from basic mechanisms of action to detection and quantification of checkpoint activation to use of these medications in transplant recipients.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: A state-of-the-art analysis of immune checkpoints: from the knowledge accumulated in oncology to their likely role in tolerance/lack thereof, focusing on possible innovative therapeutic protocols.

Co-Chairs: Ravi Kumar Ratnagiri, MD, PhD, MGM Hospital Chennai India, Chennai, India
Lorenzo Rosso, MD, PhD, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

8:00 a.m. ***Review of the Immune Checkpoint System in Thoracic Transplant and Malignancy***
Eric Morrell, MD, University of Washington, Seattle, WA USA

This talk will give a brief review of immune checkpoint pathways and what has been learned from thoracic oncology to apply to thoracic transplantation.

8:08 a.m. ***Is Thoracic Allograft Rejection Caused By Checkpoint Receptors? Lessons Learned From Oncology***
Letizia Corinna Morlacchi, MD, University of Milan, Milano, Italy

This talk will discuss what is known about immune checkpoint inhibitors triggering T-cell immune responses that may contribute to rejection.

8:16 a.m. ***Ice and Fire: Treating Malignancy With Checkpoint Inhibition After Thoracic Transplantation***
Michael Shullo, PharmD, West Virginia University Hospitals, Morgantown, WV USA

This talk will review the risks and benefits of immune checkpoint inhibitor use during treatment for malignancy in thoracic transplant recipients.

8:24 a.m. ***Present and Future Applications: Engineering the Immune Checkpoint System to Promote Tolerance***
Daniel Kreisel, MD, PhD, Washington University SoM, St. Louis, MO USA

This talk will discuss how interruption of immune checkpoint pathways may be manipulated as a novel form of immunosuppression by inducing tolerance of organ allografts.

8:32 a.m. ***Panel Discussion and Audience Vote***

8:00 – 9:00 a.m.

SESSION 53: IT TAKES A VILLAGE: THE MULTI-DISCIPLINARY APPROACH TO DURABLE LVAD CANDIDACY

Location: Rooms 501-504

Core Therapies: MCS, HEART
Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing & Allied Health, Pediatrics

Session Summary: This session will discuss LVAD candidacy based on multi-disciplinary discussions (surgeon v cardiologist v anaesthesiologist) with special focus on the importance of special psychosocial aspects.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: LVAD candidacy

Co-Chairs: Sarah Schroeder, ACNP-BC, MSN, RN, Bryan Heart, Lincoln, NE USA
Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Hari Tunuguntla, MD, Texas Children's Hospital, Houston, TX USA

8:00 a.m. ***The CT Surgeon's Perspective for LVAD Candidacy***
Diyar Saeed, MD, PhD, Leipzig Heart Center, Leipzig, Germany.

The speaker will discuss their approach with focus on the cardiothoracic surgeons' point of view. For instance: impact of patient's cachexia, biological age, frailty (determined during a 10 min meeting with the patient), history of thoracic surgeries, need for concomitant surgeries etc.

8:08 a.m. ***The Cardiologist's Perspective for LVAD Candidacy***
Paolo Colombo, MD, Columbia University Medical Center, New York, NY USA

The speaker will discuss their approach with focus on a cardiologist's take on LVAD candidacy. Factors to be included age, lung function, BMI(?), functional capacity, pharmaceutical changes, etc.

8:16 a.m. ***The Anesthesiologist's Perspective on LVAD Candidacy***
Eric de Waal, MD, PhD, University Medical Centre, Utrecht, Netherlands

The speaker will discuss their approach with focus on the anaesthesiologists' perspective on LVAD candidacy, including a discussion of factors such as age, BMI, medical history, blood loss, and functional capacity etc. Other factors of importance for the anaesthesiologists perspective on candidacy may be included.

8:24 a.m. ***The Adult Psychosocial Perspective on LVAD Candidacy***
Heike Spaderna, PhD, Trier University, Trier, Germany

The speaker will outline the importance of psychosocial factors that should be considered before accepting a complex case to receive an LVAD.

8:32 a.m. ***The Pediatric Psychosocial Perspective on LVAD Candidacy***
Melissa Cousino, PhD, University of Michigan, Ann Arbor, MI USA

The speaker will outline pediatrics approach to evaluate candidacy for MCS.

8:40 a.m. ***Panel Discussion and Audience Vote***

8:00 - 9:00 a.m.
SESSION 54: Hiding in Plain Sight: Science of Lung Antibody-Mediated Rejection
Location: Rooms 205-207

Core Therapies: LUNG
Practice Areas: Pathology, Cardiothoracic Surgery, Pulmonology, Research and Immunology

Session Summary: This session will review advances in the clinical and translational science of antibody-mediated rejection.

Co-Chairs: Elizabeth Pavlisko, MD, Duke University Medical Center, Durham, NC USA
Nirmal Sharma, MD, Brigham & Women's Hospital, Boston, MA USA

8:00 a.m. **(99)** ***Mapping a DSA-Negative ABMR-Like State in Lung Transplants That is Highly Associated with NK Cells***; P. T. Gauthier[1], M. Mackova[1], K. Halloran[2], P. F. Halloran[2], .. INTERLUNG Collaborators[3]. *[1]Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, [2]University of Alberta, Edmonton, AB, Canada, [3]AB, Canada*

8:15 a.m. **(100)** ***Phosphorylated S6 Ribosomal Protein as an Additional Marker of Antibody-Mediated Rejection in Lung Allografts: A Multicentre Study***; F. Lunardi[1], L. Vedovelli[1], F. Pezzuto[1], J. Le Pavec[2], P. Dorfmuller[2], M. Ivanovic[3], T. Pena[3], K. Wassilew[4], M. Perch[5], S. Hirschi[6], M. Chenard[6], D. Neil[7], M. Montero-Fernandez[8], A. Rice[4], E. Cozzi[1], F. Rea[1], D. J. Levine[9], A. Roux[10], M. Goddard[11], G. A. Fishbein[12], F. Calabrese[1]. *[1]University of Padova, Padova, Italy, [2]Hôpital Marie-Lannelongue, Le Plessis-Robinson, France, [3]University of Iowa, Iowa City, IA, [4]Royal Brompton & Harefield NHS, London, United Kingdom, [5]Rigshospitalet, Gentofte, Denmark, [6]University Hospital of Strasbourg, Strasbourg, France, [7]QEHB, Birmingham, United Kingdom, [8]NHS, Manchester, United Kingdom, [9]Stanford University, Stanford, CA, [10]Foch Hospital, Suresnes, France, [11]Papworth Hospital, Cambridge, United Kingdom, [12]David Geffen School of Medicine at UCLA, Los Angeles, CA*

8:30 a.m. **(101)** ***Nine-Year Experience with Treatment of Early Detectable Donor Specific Anti-HLA Antibodies in Pediatric Lung Transplant Recipients***; M. Franz[1], K. Aburahma[1], P. Yablonski[1], J. Carlens[2], A. Saipbaev[1], C. Mueller[2], W. Sommer[3], C. Kuehn[1], A. Haverich[1], G. Warnecke[3], M. Avsar[1], N. Schwerk[2], J. Salman[1], D. Bobylev[1], F. Ius[1]. *[1]Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, [2]Department of Paediatrics, Hannover Medical School, Hannover, Germany, [3]Department of Cardiac surgery, University of Heidelberg, Heidelberg, Germany*

8:45 a.m. **(300)** ***The Significant Impact of HLA Homozygosity on Sensitization, Chronic Lung Allograft Dysfunction and Overall Survival***; S. Hiho[1], S. L. Ennis[2], L. Sullivan[3], G. Westall[2], G. Snell[2], B. Levvey[2]. *[1]Australian Red Cross LifeBlood, Victorian Transplantation and Immunogenetics, Melbourne, Australia, [2]Alfred Hospital, Melbourne, Australia, [3]Australian Red Cross LifeBlood, South Australian Transplantation and Immunogenetics, Adelaide, Australia*

FRIDAY, 21 APRIL, 2023

8:00 – 9:00 a.m.

SESSION 55: THE TAMING OF THE SHREW: ALL ABOUT ANTIBODIES: DESENSITIZATION, AMR, AND MORE IN HEART TRANSPLANT

Location: Rooms 405-407

Core Therapies: HEART
Practice Areas: Cardiology, Cardiothoracic Surgery, Research and Immunology

Session Summary: The session will highlight research relating to assessment, management, and impact of antibodies before and after heart transplantation.

Co-Chairs: Douglas Jennings, PharmD, NY Presbyterian Hospital / Columbia University, New York, NY USA
Teresa De Marco, MD, FACC, University of California, San Francisco, CA USA

8:00 a.m. **(103)** ***Homozygosity at Multiple HLA Loci Increases the Risk of Sensitization but Decreases the Risk of Rejection***; G. Coutance[1], R. Jain[2], X. Zhang[3], L. Gragert[4], N. Patel[2], J. Patel[2], E. Kransdorf[2], J. Rushakoff[2], J. Kobashigawa[2]. *[1]Pitié-Salpetrière Hospital, Paris, France, [2]Cedars-Sinai Heart Institute, Los Angeles, CA, [3]Cedars Sinai Medical Center, Los Angeles, CA, [4]Tulane University Medical School, Tulane, LA*

8:15 a.m. **(104)** ***Relation Between Individual Blood Gene Expression Profile (GEP) and Tissue GEP in Antibody-Mediated Rejection in Heart Transplant***; D. Lee[1], A. Usmani[1], R. Wu[1], T. Wicks[2], J. Fernandez[1], J. Huang[1], L. Arroyo[2], D. Rinde-Hoffman[2], S. Kumar[2], J. Feliberti[2], G. Oliveira[1], P. Berman[2], B. Mackie[2]. *[1]University of South Florida, Tampa, FL, [2]Tampa General Hospital, Tampa, FL*

8:30 a.m. **(105)** ***Clinical Outcomes of Heart Transplantation in Desensitized Durable Mechanical Circulatory Support Patients***; D. Kim[1], J. Youn[2], J. Kim[3], I. Kim[4], J. Choi[1], E. Kransdorf[5], D. Chang[6], M. Kittleson[7], J. Patel[8], R. Cole[6], J. Moriguchi[9], F. Esmailian[10], J. Kobashigawa[7]. *[1]Samsung Medical Center, Seoul, South Korea, [2]The Catholic University of Korea, Seoul, South Korea, [3]Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea, [4]Keimyung University Dongsan Hospital, Daegu, South Korea, [5]Cedars-Sinai, Beverly Hills, CA, [6]Cedars-Sinai Medical Center, Los Angeles, CA, [7]Cedars-Sinai Heart Institute, Beverly Hills, CA, [8]Cedars-Sinai Smidt Heart Institute, Calabasas, CA, [9]Cedar Sinai, Beverly Hills, CA, [10]Cedars-Sinai Heart Institute, Los Angeles, CA*

8:45 a.m. **(106)** ***Does Bortezomib Have an Effect on Pre-Transplant Desensitization Therapy or Benefit Post-Heart Transplant Outcomes for Highly Sensitized Patients***; M. Dhillon[1], J. Kobashigawa[1], N. Patel[1], M. Kittleson[1], X. Zhang[2], J. Patel[1]. *[1]Cedars-Sinai Heart Institute, Los Angeles, CA, [2]Cedars Sinai Medical Center, Los Angeles, CA*

FRIDAY, 21 APRIL, 2023

8:00 – 9:00 a.m.

SESSION 56: THE CURIOUS CASE OF CLAD PHENOTYPES

Location: Rooms 201-203

Core Therapies: LUNG
Practice Areas: Pulmonology, Cardiothoracic Surgery, Pathology, Research and Immunology

Session Summary: This session will discuss new information on differences in biology and outcomes of restrictive and obstructive CLAD patterns.

Co-Chairs: Fiorella Calabrese, MD, University of Padova, Padova, Italy
Robin Vos, MD, PhD, UZ Leuven, Leuven, Belgium

8:00 a.m. **(107)** ***Differences in the Transcriptional Landscape of Human End-Stage CLAD Phenotypes***; H. Beeckmans[1], P. Kerckhof[1], J. McDonough[2], L. De Sadeleer[1], J. Kaes[1], A. Sacreas[1], C. Aelbrecht[1], A. Vanstapel[3], K. Maes[1], H. Schoemans[1], E. Wauters[1], A. Neyrinck[3], G. Verleden[3], L. Dupont[3], L. Godinas[3], D. Van Raemdonck[3], B. Vanaudenaerde[1], R. Vos[3]. *[1]KULeuven, Leuven, Belgium, [2]Yale, New Haven, CT, [3]University Hospitals Leuven, Leuven, Belgium*

8:15 a.m. **(108)** ***Morphometric Airway Changes in Explanted Human Lungs with Chronic Lung Allograft Dysfunction***; P. Kerckhof[1], G. P. Ambrosio[2], H. Beeckmans[3], J. Kaes[4], V. Geudens[5], J. Slambrouck[6], S. Bos[7], M. Vermant[5], C. Aelbrecht[5], W. Lynn[5], V. Astrid[5], L. Aversa[5], Y. Mohamady[5], X. Jin[5], D. Charlotte[5], T. Goos[5], G. Iwein[5], A. Vanstapel[8], M. Orlitova[9], M. Boone[10], W. Janssens[5], I. Josipovic[10], V. Varghese[11], L. Dupont[12], L. Godinas[13], G. Verleden[14], D. Van Raemdonck[6], L. Ceulemans[6], A. Neyrinck[15], J. McDonough[16], G. Gayan-Ramirez[5], B. Vanaudenaerde[4], R. Vos[17]. *[1]CHROMETA, KULeuven, Leuven, Belgium, [2]University of the Philippines, Manilla, Philippines, [3]., Leuven, Belgium, [4]KU Leuven, Leuven, Belgium, [5]KULeuven, Leuven, Belgium, [6]University Hospitals Leuven, Leuven, Belgium, [7]Newcastle University and Freeman Hospital, Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom, [8]Leuven, Belgium, [9]UZ Leuven, 3000 Leuven, Belgium, [10]UGent, Ghent, Belgium, [11]Naruvi Hospitals Vellore, Vellore, India, [12]University Hospital Gasthuisberg, Leuven, Belgium, [13]UZ Leuven, Woluwe-Saint-Lambert, Belgium, [14]University Hospital Leuven, Leuven, Belgium, [15]Leuven University Hospitals, Leuven, Belgium, [16]Yale University, New Haven, NY, [17]UZ Leuven, Leuven, Belgium*

8:30 a.m. **(109)** ***Insights Into the Lung Microenvironment During Chronic Allograft Rejection: The Role of Bal-Evs in Rewiring Respiratory Cells Inflammatory Response***; V. Vaira[1], A. Storaci[2], S. Franzi[3], M. Pitasi[3], F. Gentile[3], V. Musso[3], L. Morlacchi[4], V. Rossetti[5], F. Blasi[6], M. Nosotti[7], S. Ferrero[2], A. Palleschi[8]. *[1]University of Milan and Fondazione IRCCS Ca Granda, Milano, Italy, [2]University of Milan, Milan, Italy, [3]Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [4]Milano, MI, Italy, [5]Fond IRCCS Ca Granda, Milano, Italy, [6]University of Milan, Milano, Italy, [7]Milan, Italy, [8]Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico of Milan, Milano, Italy*

8:45 a.m. **(110)** ***Effect of Clad Phenotypes on the Outcome after Lung Retransplantation - A Retrospective Single Center Data Analysis***; S. Auner, P. M. Boehm, S. Schwarz, T. Schweiger, A. E. Frick, G. Murakoezy, Z. Kovacs, G. Lang, S. Taghavi, P. Jaksch, K. Hoetzenecker, A. Benazzo. *Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria*

9:30 – 11:00 a.m.

SESSION 57: NOVEL DESENSITIZATION APPROACHES TO FACILITATE TRANSPLANTATION FOR HIGHLY SENSITIZED CANDIDATES

Location: Four Seasons Ballroom

Core Therapies: HEART, LUNG
Practice Areas: Cardiology, Cardiothoracic Surgery, Pathology, Pharmacy and Pharmacology, Pulmonology, Pediatrics, Research and Immunology

Session Summary: Desensitization regimens must consider temporal changes in thoracic transplant candidates. A rising incidence is anticipated due to the expanding indications for heart and lung transplantation, particularly in medically complex patients. Novel strategies to desensitize patients that target multiple steps of donor-specific antibody (DSA) production will be considered and anticipated. Discussion will include novel approaches for desensitizing highly sensitized patients awaiting transplant and thereby facilitate their transplantation, identifying clinically irrelevant HLA antibodies, the importance of CPRA points and virtual crossmatch to facilitate transplant under the revised heart & lung allocation policies, and novel approaches to enable the desensitization of highly sensitized patients and facilitate transplantation.

Co-Chairs: Rajalingam Raja, University of California San Francisco, San Francisco, CA USA
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Beverly Hills, CA USA

9:30 a.m. ***Acceptable HLA Antibodies in Heart and Lung Transplantation***
Fabio Ius, MD, Hannover Medical School, Hannover, Germany

Discuss the identification of clinically acceptable HLA Ab in heart and lung transplantation. This will highlight how less injurious HLA Ab like HLA-C or DP DSAs may not cause rejection or how transfusion-induced HLA Ab are unstable and do not rebound post-H/L Tx. The talk will also address how de novo DSA may be more problematic for development of chronic rejection.

9:45 a.m. ***Value of CPRA and Virtual Crossmatch in New Heart and Lung Allocation Algorithms in Transplanting Sensitized Patients***
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX USA

Discuss the revised heart and lung allocation policy proposals that eliminate the Donation Service Area and Region as distribution units. Discuss the importance of CPRA points and virtual crossmatch in facilitating the transplantation of highly sensitized patients.

10:00 a.m. ***Plasma Cell Targeted Desensitization Strategies***
Marlena Habal, MD, NYU Grossman School of Medicine, New York, NY USA

Synergism between plasma cell targeted approaches to desensitization, including daratumumab and belatacept facilitating heart and lung transplantation; Dr. Habal will discuss her ongoing research on the role of belatacept as an approach to desensitize HS-Pt as well as future plans to investigate this.

10:15 a.m. ***IL-6 Inhibitor Based Desensitization Strategies***
Joren Madsen, MD, DPhil, Massachusetts General Hospital, Boston, MA USA

Discuss pipeline of IL-6 and IL-6R inhibitors in both heart and lung transplantation, including the future of these agents in thoracic transplantation and their ongoing investigation.

10:30 a.m. ***Autologous Chimeric Antigen Receptor Engineered T cell (CARS-T) Immunotherapy for Desensitization of Patients Awaiting Transplantation***
Ali Naji, MD, PhD, University of Pennsylvania, Philadelphia, PA USA

Dr. Naji will discuss how CARS-T can be applied to highly sensitized candidates for thoracic organ transplantation, informed by randomized clinical trial data regarding use of CARS-T in highly sensitized renal transplant candidates.

10:45 a.m. ***Panel Discussion***

9:30 – 11:00 a.m.

SESSION 58: FOR ALL AGES: MCS SUPPORT IN CONGENITAL HEART DISEASE IN CHILDREN AND ADULTS

Location: Rooms 603-605

Core Therapies: MCS, HEART
Practice Areas: Pediatrics, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing & Allied Health

Session Summary: MCS in congenital heart disease (CHD) is ever evolving and guidelines are limited. Updated best practices for device selection, strategies, and management for heart failure for children and adults with CHD will be presented and discussed.

Co-Chairs: David Morales, MD, Cincinnati Children's Hospital, Cincinnati, OH USA
Nathalie Roy, MD, Boston Children's Hospital, Boston, MA USA

9:30 a.m. ***Use of ECMO for Acute Decompensated Heart Failure in CHD***
Antonio Amodeo, MD, Ospedale Pediatrico Bambino Gesù, Roma, Italy
How is ECMO best utilized in supporting acute decompensated heart failure in children and adults with CHD? Optimal ECMO utilization, cannulation, and management practices for the complex CHD patient will be shared.

9:45 a.m. ***Q&A***

9:48 a.m. ***Use of Temporary Circulatory Support for Acute Decompensated Heart Failure in CHD***
Sebastian Tume, MD, Texas Children's Hospital, Houston, TX USA
Novel uses of Impella and other (non-ECMO) TCS for older children and adults with CHD heart failure will be presented. Indications, patient selection, device strategy, implantation, management will be explored.

10:03 a.m. ***Q&A***

10:06 a.m. ***Longer-Term Ventricular Assist Device Selection for CHD: From Neonates to Adults***
Jennifer Conway, MD, University of Alberta, Edmonton, AB Canada
The complex decision-making and updated best practices in longer-term device selection for CHD patients will be presented. Updated strategies for supporting small neonates/infants with CHD will be highlighted.

10:21 a.m. ***Q&A***

10:24 a.m. ***What's the Difference? Pre-VAD Implant Evaluation and Considerations for the Patient with Fontan Circulation***
David Peng, MD, University of Michigan, Ann Arbor, MI USA
Durable VAD indications, patient selection, and careful pre-operative evaluation (including imaging, catheterization/intervention, extracardiac status) unique to the patient with Fontan circulation will be discussed.

10:39 a.m. ***Q&A***

10:42 a.m. ***What's the Difference? Post-Operative VAD Management and Complications in the Patient with Fontan Circulation***
Peta Alexander, MBBS, Boston Children's Hospital, Boston, MA USA
Patient and device management and optimization after VAD implant in the patient with Fontan circulation will be presented. Strategies for unique Fontan-associated complications will be shared.

10:57 a.m. ***Q&A***

9:30 – 11:00 a.m.

SESSION 59: DIE HARD: PREVENTING AND MANAGING HARD-TO-TREAT FUNGAL AND BACTERIAL INFECTIONS IN THE PERIOPERATIVE SETTING

Location: Rooms 401-404

Core Therapies: LUNG, HEART
Practice Areas: Anesthesiology and Critical Care, Cardiology, Infectious Diseases, Pharmacy, Pulmonology

Session Summary: This session will focus on novel aspects to manage perioperative infections. A range of topics from recipient colonization, emerging fungal agents and anti-infective considerations (inhaled and ECMO) will be discussed by a range of experts in their field.

Co-Chairs: Paulo M. Pego-Fernandes, MD, PhD, Universidade de Sao Paulo, São Paulo, Brazil
Georgina Waldman, PharmD, BCTXP, Massachusetts General Hospital, Boston, MA USA

9:30 a.m. ***Brace Yourself - Infections are Coming: Bacterial Colonization Management***
Fernanda Silveira, MD, MS, University of Pittsburgh Medical Center, Pittsburgh, PA USA

This talk will focus on management of pre-transplant colonization of complicated infections: Burkholderia cenocepacia, multi-drug resistant organisms (carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter, and Clostridioides difficile.

9:43 a.m. ***Q&A***

9:48 a.m. ***Every Breath You Take: Inhaled Anti-Infective Delivery Options***
Catherine Orla Morrissey, MD, PhD, Alfred Health, Melbourne, VIC Australia

This talk will focus on inhaled anti-infective for pre-transplant colonization of complicated bacterial and fungal infections with relevance to anastomosis management. Systemic absorption, pharmacokinetics, and side effect profiles of inhaled agents will also be discussed.

10:01 a.m. ***Q&A***

10:06 a.m. ***Fungus is Among Us: Emerging Life-Threatening Fungal Infections in Thoracic Transplant***
Me-Linh Luong, MD, Centre Hospitalier de l'Université de Montréal, Montreal, QC Canada

This talk will focus on the management of Lomentospora prolificans and Scedosporium apiospermun infection before and after thoracic transplantation.

10:19 a.m. ***Q&A***

10:24 a.m. ***Sequestered: Anti-Microbial Loss in the ECMO Circuit***
Haifa Lyster, MSc, FRPharmS, FFRPS, Royal Brompton & Harefield Clinical Group, Harefield, United Kingdom

This talk will focus on pharmacokinetic changes of anti-microbial agents in ECMO patients. Recommendations for dose adjustments will be discussed for agents most commonly used in the perioperative settings.

10:37 a.m. ***Q&A***

10:42 a.m. ***Not So Small At All: Perioperative Bacterial and Fungal Infections in Pediatric Thoracic Transplant***
Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital Medical Center, Cincinnati, OH USA

This talk will focus on risk factors and outcomes of hard-to-treat fungal infection and MDR bacteria after pediatric thoracic transplantation.

10:55 a.m. ***Q&A***

9:30 – 11:00 a.m.

SESSION 60: WHAT'S NEW WITH THE ESC/ERS GUIDELINES 2022 FOR PULMONARY HYPERTENSION

Location: Rooms 501-504

Core Therapies: PVD, HEART, LUNG
Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing & Allied Health, Pulmonology

Session Summary: The updated guidelines for PH were published in August 2022 with significant changes to the definition, diagnostic and therapeutic approach to PH. This session will review key changes and discuss the clinical implications of the change on our daily practices.

Co-Chairs:	Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA USA Colin Church, BSC(Hons), PhD, FRCP, Golden Jubilee National Hospital, Glasgow, United Kingdom
9:30 a.m.	***Hemodynamic Definition of PH: An Update*** Ryan Tedford, MD, Medical University of South Carolina, Charleston, SC USA *Focus on the updated definition and classification of pulmonary hypertension, with focus on PAH.*
9:45 a.m.	***Q&A***
9:48 a.m.	***Initial Treatment Approach and Sequential Escalation of Therapies in PAH*** Jean-Luc Vachiery, MD, CUB Hôpital Erasme, Brussels, Belgium *Focus on the updated approach to initial therapy and escalation of therapy in PAH.*
10:03 a.m.	***Q&A***
10:06 a.m.	***Treatment Goals in PAH*** Mardi Gomberg-Maitland, MD, MSc, George Washington University, Washington, DC USA *Review the updated approach to clinical management in PAH with focus on treatment goals*
10:21 a.m.	***Q&A***
10:24 a.m.	***Management of WHO Group 2 PH (Left Heart Disease)*** Marco Guazzi, MD, PhD, University of Milano School of Medicine, Milan, Italy *Focus on the updated approach to diagnosis and management of Group 2 PH (due to left heart disease) per the ERS/ESC guidelines*
10:39 a.m.	***Q&A***
10:42 a.m.	***Management of WHO Group 3 PH (Lung Disease)*** Ioana Preston, MD, Tufts Medical Center, Boston, MA USA *Focus on the updated approach to diagnosis and management of Group 3 PH (due to lung disease)*
10:57 a.m.	***Q&A***

FRIDAY, 21 APRIL, 2023

9:30 – 11:00 a.m.

SESSION 61: PHILIP K. CAVES AWARD CANDIDATE PRESENTATIONS

Location: Rooms 205-207

Core Therapies: ALL
Practice Areas: Cardiology, Cardiothoracic Surgery, Pulmonology, Research and Immunology

Session Summary: Established in 1982, the Philip K. Caves Award encourages and rewards original high-quality research performed by residents, fellows, trainees, and graduate students. Six candidates have been selected to present their high-scoring research in this session. At the conclusion of the session, the best research presentation will be selected by a panel of judges and the winner will be recognized during the Awards Presentations in the General Session (Plenary) on Saturday, 22 April.

Co-Chairs: Andrew Fisher, FRCP, PhD, Newcastle University, Newcastle Upon Tyne, United Kingdom
Simon Pecha, MD, University Heart and Vascular Center Hamburg, Hamburg, Germany

9:30 a.m. **(111)** ***Pushing The Boundaries of Donation After Circulatory Death Heart Transplantation - The Australian Experience***; Y. Joshi[1], S. Scheuer[2], C. Soto[1], H. Chew[3], B. Hwang[4], A. Iyer[1], M. Connellan[1], A. Watson[1], E. Granger[1], P. Jansz[1], P. MacDonald[1]. *[1]St Vincent's Hospital, Sydney, Australia, [2]Royal Melbourne Hospital, Carlton, Australia, [3]Victor Chang Cardiac Res Inst, Kingsgrove, Australia, [4]UNSW, Strathfield, Australia*

9:45 a.m. **(112)** ***Prediction of Donor Heart Acceptance for Transplant: Results From the Donor Heart Study***; B. Wayda[1], Y. Weng[1], S. Zhang[1], H. Luikart[1], T. Pearson[2], R. Wood[3], J. Nieto[3], B. Nicely[4], P. Geraghty[5], J. Belcher[6], J. Nguyen[7], J. Zaroff[8], K. Khush[1]. *[1]Stanford Univ SoM, Stanford, CA, [2]Emory Univ Hospital, Atlanta, GA, [3]LifeGift, Houston, TX, [4]Lifenet, Virginia Beach, VA, [5]Donor Network of Arizona, Tempe, AZ, [6]New England Donor Services, Waltham, MA, [7]California TX Donor Network, Oakland, CA, [8]Kaiser Permanente, San Francisco, CA*

10:00 a.m. **(113)** ***Improved ex Vivo Lung Perfusion (EVLP) with Dialysis and Nutrition to Achieve Successful 36h EVLP and Lung Transplantation***; O. Hough[1], A. Mariscal[1], H. Yamamoto[1], H. Mangat[1], D. Taniguchi[1], H. Gokhale[1], M. Chen[1], H. Shan[1], D. Bojic[1], T. Aulja[1], A. Ali[1], K. Main[1], N. Yoshiyasu[1], C. Chan[2], M. Cypel[1], S. Keshavjee[1], M. Liu[1]. *[1]Latner Thoracic Research Laboratories, Toronto General Hospital, University Health Network, Toronto, ON, Canada, [2]Dept of Nephrology, Toronto General Hospital, University Health Network, Toronto, ON, Canada*

10:15 a.m. **(114)** ***Prophylactic Use of Extracorporeal Photopheresis (ecp) - A Prospective Randomized Single Center Trial***; A. Benazzo[1], P. Jaksch[1], A. Cho[2], T. Wekerle[1], N. Worel[3], K. Hoetzenecker[1], G. Muraközy[4], R. Knobler[1]. *[1]Medical University of Vienna, Vienna, Austria, [2]Department of Dermatology, Medical University of Vienna, Vienna, Austria, [3]Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria, [4]Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria*

10:30 a.m. **(115)** ***Female Sex is Associated with Worse Functional Impairment and Health-Related Quality of Life In Pulmonary Arterial Hypertension: Baseline Results from the Pulmonary Hypertension Association Registry (PHAR)***; J. T. DesJardin[1], N. Kolaitis[1], N. Kime[2], R. Kronmal[2], M. Lammi[3], S. Mathai[4], J. Ryan[5], C. Ventetuolo[6], T. De Marco[1]. *[1]University of California, San Francisco, San Francisco, CA, [2]University of Washington, Seattle, WA, [3]Louisiana State University, New Orleans, LA, [4]Johns Hopkins, Baltimore, MD, [5]University of Utah, Salt Lake City, UT, [6]Brown University, Providence, RI*

10:45 a.m. **(116)** ***The Magentum 2 Study: Long-Term Analysis of Complete Withdrawal of Anticoagulation Therapy with the Heartmate 3 LVAD***; Z. Tucanova[1], P. Ivak[2], S. Gregor[3], M. Hegarová[4], Z. Dorazilova[5], T. Marek[6], V. Melenovsky[7], H. Riha[8], D. Crandall[9], J. Connors[10], M. Mehra[11], I. Netuka[8]. *[1]Dept of Cardiovascular Surgery, Inst for Clinical and Experimental Med, Prague, Czech Republic, [2]IKEM, Prague, Czech Republic, [3]Agentura Columbus s.r.o. IKEM, Praha, Czech Republic, [4]Dept of Cardiology, Inst for Clinical and Experimental Med, Prague, Czech Republic, [5]Klinika kardiologie IKEM IKEM, Praha, Czech Republic, [6]Dept of Cardiothoracic Surgery, Inst for Clinical and Experimental Med, Prague, Czech Republic, [7]IKEM Dept. of Cardiology, Praha, Czech Republic, [8]Inst for Clinical & Exp. Med, Praha, Czech Republic, [9]Abbott, Wakefield, MA, [10]BWH/Harvard Med Sch, Winchester, MA, [11]Harvard Medical School, Boston, MA*

FRIDAY, 21 APRIL, 2023

9:30 – 11:00 a.m.

SESSION 62: DEUS EX MACHINA: TRANSFORMATION OF HEART TRANSPLANTATION BY MACHINE PERFUSION

Location: Rooms 405-407

Core Therapies: HEART
Practice Areas: Cardiothoracic Surgery, Cardiology, Nursing and Allied Health, Research and Immunology

Session Summary: Has technology arrived to save the day? Do we now have devices capable of solving the challenges of heart preservation? This session will present the perfusion machines making a difference in organ procurement, protection and transport. Is the era of intercontinental retrieval, elective daytime heart transplantation upon us? What are the results? Which hearts should be perfused in these systems? Where to next? Is this the new way, a neat solution for a happy ending?

Co-Chairs: Claudia Gidea, MD, NYU Langone Medical Center, New York, NY USA
Maryl Johnson, MD, University of Wisconsin, Madison, WI USA

9:30 a.m. **(117)** ***Initial Australian Experience with the Xvivo Non-Ischaemic Hypothermic Perfusion Device for Heart Preservation***; S. Emmanuel[1], P. MacDonald[2], C. Hayward[3], A. Watson[4], A. Iyer[5], M. Connellan[6], E. Granger[7], C. Herrera[8], C. Kure[9], J. Fraser[10], D. Kaye[11], D. McGiffin[12], P. Jansz[13]. *[1]St Vincent's Hospital Sydney, Surry Hills, Australia, [2]St. Vincent 's Hospital, Darlinghurst, Australia, [3]St. Vincent's Hospital, Longueville, Australia, [4]Victor Chang Cardiac Research Institute, Vancouver, BC, Canada, [5]St Vincent 's Hospital, Darlinghurst, Australia, [6]St. Vincent 's Hospital, Cremorne Point, Australia, [7]St Vincent's Hospital Sydney, Sydney, Australia, [8]St VIncent's Hospital (Sydney), Darlinghurst, Australia, [9]The Alfred Hospital, Melbourne, Australia, [10]The Prince Charles Hospital, Chermside, Australia, [11]Alfred Hospital, Melbourne, Australia, [12]Alfred Health, Melbourne, Australia, [13]St Vincent's Hospital, Darlinghurst, Australia*

9:45 a.m. **(118)** ***Heart Donation and Transplantation of Circulatory Death Donors: The Dutch Experience***; N. P. van der Kaaij[1], O. C. Manintveld[2], Y. J. Taverne[3], K. Damman[4], L. W. Van Laake[5], M. E. Erasmus[6]. *[1]Cardiothoracic Surgery, UMC Utrecht, Utrecht, Netherlands, [2]Cardiology, Erasmus MC, Rotterdam, Netherlands, [3]Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands, [4]Cardiology, University Medical Center Groningen, Groningen, Netherlands, [5]Cardiology, UMC Utrecht, Utrecht, Netherlands, [6]Cardiothoracic Surgery, University Medical Center Groningen, Groningen, Netherlands*

10:00 a.m. **(119)** ***Demographics and Outcomes of Clinical Trial vs Initial Post-Approval Use of Transmedics Organ Care System Heart***; C. Milano[1], J. Schroder[1], M. Farr[2], A. DeVore[1], D. D'Alessandro[3], D. Goldstein[4], U. Jorde[4], S. Patel[4], M. Daneshmand[5], S. Pinney[6], F. Esmailian[7], J. Kobashigawa[7], K. Takeda[8], N. Uriel[8], S. Pham[9], P. Patel[9], M. Kai[10], B. Sun[11], A. Shah[12], M. Ono[13], G. Couper[14], D. DeNofrio[14], A. Vest[14], D. Joyce[15], H. Mallidi[16], A. Itoh[16], M. R. Mehra[16], M. Givertz[16], C. Patel[1], J. Stehlik[17]. *[1]Duke University Medical Center, Durham, NC, [2]UT Southwestern Medical Center, Dallas, TX, [3]MGH, Weston, MA, [4]Montefiore Medical Center, Bronx, NY, [5]Emory University, Atlanta, GA, [6]University of Chicago, Chicago, IL, [7]Cedars-Sinai Heart Institute, Los Angeles, CA, [8]New York Presbyterian, New York, NY, [9]Mayo Clinic Florida, Jacksonville, FL, [10]Westchester Medical Center, Valhalla, NY, [11]Minneapolis Heart Institute, Minneapolis, MN, [12]Vanderbilt University Medical Center, Mount Juliet, TN, [13]Methodist Hospital, San Antonio, TX, [14]Tufts Medical Center, Boston, MA, [15]Froedtert & the Med College of Wisconsin, Milwaukee, WI, [16]Brigham and Women's Hospital, Boston, MA, [17]Univ of Utah, Salt Lake City, UT*

10:15 a.m. **(120)** ***Heart Preservation with the Organ Care System in Extended Criteria Donor Hearts: A Single Center Experience***; M. Franz[1], P. Yablonski[1], M. Arar[1], A. Haverich[1], G. Warnecke[2], A. Niehaus[1], M. Avsar[1], J. Salman[1], F. Ius[1]. *[1]Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, [2]Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany*

10:30 a.m. **(121)** ***Results from over 800 Transplant Recipients Enrolled in the Guardian Heart Registry***, D. D'Alessandro[1], Y. Shudo[2], D. Meyer[3], S. Silvestry[4], M. Leacche[5], C. Sciortino[6], M. Rodrigo[7], S. M. Pham[8], J. P. Jacobs[9], K. Takeda[10], H. Copeland[11], A. Vidic[12], M. Kawabori[13], J. Schroder[14]. *[1]MGH, Weston, MA, [2]Stanford University, Menlo Park, CA, [3]Baylor Scott and White Health, Health Texas Provider Network, Cardiac and Thoracic Surgery at Baylor, Dallas, TX, [4]AdventHealth Transplant Institute, Orlando, FL, [5]Corewell Health, Grand Rapids, MI, [6]Sentara, Norfolk, VA, [7]Medstar Washington Hospital Center, Potomac, MD, [8]Mayo, Jacksonville, FL, [9]University of Florida, Gainesville, FL, [10]Columbia University, New York, NY, [11]Lutheran Medical Group, Fort Wayne, IN, [12]University of Kansas Health System, Kansas City, KS, [13]Tufts Medical Center, Brookline, MA, [14]Duke University Medical Center, Durham, NC*

10:45 a.m. **(122)** ***Influence of Hypothermic Machine Perfusion (HMP) on Donor Heart Function Following an Ischemic Time of 6-8 Hours***; D. Kaye[1], J. Fraser[2], P. Jansz[3], P. MacDonald[4], S. Marasco[5], A. Doi[6], C. Merry[1], S. Emmanuel[7], A. Leet[8], J. Hare[9], C. Cheshire[10], R. Larbalestier[11], A. Shah[12], C. Wasywich[13], J. Mathew[14], A. Sibal[15], C. Kure[1], D. McGiffin[16]. *[1]Alfred Hospital, Melbourne, Australia, [2]The Prince Charles Hospital, Chermside, Australia, [3]St Vincent's Hospital, Darlinghurst, Australia, [4]St. Vincent 's Hospital, Darlinghurst, Australia, [5]Alfred Health, South Yarra, Australia, [6]Melbourne, Australia, [7]St Vincent's Hospital Sydney, Surry Hills, Australia, [8]Heart Centre, Alfred Hospital, Melbourne, Australia, [9]The Alfred Hospital, Melbourne, Australia, [10]Alfred Hospital, Caulfield, Australia, [11]Fiona Stanley Hospital, Perth, Australia, [12]Fiona Stanley Hospital, Churchlands, WA, Australia, [13]Auckland City Hospital, Auckland, New Zealand, [14]Royal Children's Hospital, Parkville, Australia, [15]Green Lane Cardiothoracic Surgical Unit, Auckland City Hospital, NZ, Auckland, New Zealand, [16]Alfred Health, Melbourne, Australia*

FRIDAY, 21 APRIL, 2023

9:30 – 11:00 a.m.

SESSION 63: HOW LONG IS MY BRIDGE? ECMO AND DURABLE VAD OUTCOMES

Location: Rooms 201-203

Core Therapies: MCS
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Nursing and Allied Health, Pulmonology

Session Summary: This session will give insight into topics including ECMO teams, investigational biventricular assist devices as well as convention MCS devices and the bridge to transplant.

Co-Chairs: David Baran, MD, Cleveland Clinic Heart, Vascular and Thoracic Institute, Parkland, FL USA
Jennifer Cook, MD, University of Cincinnati, Cincinnati, OH USA

9:30 a.m. **(123)** ***Rapid ECMO Deployment Team: Outcomes Associated with an Emerging Inter-Facility Transport Program***; O. Espinoza[1], O. Hernandez[1], L. Plucinski[2], T. Wombacher[3], J. Piecik[4], C. Pellecchia[5], S. VanPoppel[6], J. MacHannaford[7], B. Lima[8]. *[1]ECMO, Medical City Heart Hospital, Dallas, TX, [2]ECMO, Medical City Ft. Worth, Ft.Worth, TX, [3]Medical City Healthcare, Dallas, TX, [4]Critical Care Flite Team, PHi Air Medical, McKinney, TX, [5]ECMO, Medical City Plano, Plano, TX, [6]Pulmonary Critical Care, Medical City Plano, Plano, TX, [7]Cardiothoracic Surgery, Medical City Heart Hospital, Dallas, TX, [8]Medical City Heart Hospital, Dallas, TX*

9:45 a.m. **(124)** ***The Impact of Small Left Ventricular Dimension on Outcomes after HeartMate 3 LVAD Implantation***; E. J. Molina[1], M. M. Ahmed[2], F. H. Sheikh[3], J. C. Cleveland[4], D. J. Goldstein[5], N. Y. Uriel[6], A. Wang[7], J. J. Revis[7], M. R. Mehra[8]. *[1]Piedmont Heart Institute, Atlanta, GA, [2]University of Florida, Gainesville, FL, [3]MedStar Washington Hospital Center, Georgetown University School of Medicine, Washington, DC, [4]University of Colorado School of Medicine, Aurora, CO, [5]Montefiore Einstein Center for Heart and Vascular Care, New York, NY, [6]Columbia University College of Physician and Surgeons and New York-Presbyterian Hospital, New York, NY, [7]Abbott Incorporation, Abbott Park, IL, [8]Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA*

10:00 a.m. **(125)** ***Influence of the Outflow Graft Position on Thromboembolic and Bleeding Complications in Patients with a Left Ventricular Assist Device***; J. J. Peek[1], C. Zijderhand[1], J. Sjatskig[1], C. van der Heiden[2], A. A. Constantinescu[2], J. J. Brugts[2], O. C. Manintveld[2], O. Birim[1], J. Bekkers[1], E. A. Mahtab[1], A. J. Bogers[1], K. Caliskan[2]. *[1]Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands, [2]Cardiology, Erasmus MC, Rotterdam, Netherlands*

10:15 a.m. **(126)** ***Heart Transplantation from Donors after Circulatory Death in Patients Supported by Left Ventricular Assist Devices***; S. Lee[1], M. H. Gonzalez[1], N. K. Shrestha[1], M. Jani[1], M. Dickinson[1], D. Fermin[1], R. Grayburn[1], M. Leacche[1], P. Tremblay[1], D. Acharya[2], I. Rajapreyar[3], R. Y. Loyaga-Rendon[1]. *[1]Spectrum Health, Grand Rapids, MI, [2]University of Arizona, Tucson, AZ, [3]Thomas Jefferson University Hospital, Philadelphia, PA*

10:30 a.m. **(127)** ***Preclinical Evaluation of the Bivacor Total Artificial Heart***; D. L. Timms[1], N. Greatrex[1], F. Nestler[1], E. Wu[1], M. Kleinheyer[1], W. Cohn[2], O. Frazier[2]. *[1]BiVACOR Inc, Houston, TX, [2]Texas Heart Institute, Houston, TX*

10:45 a.m. **(128)** ***Does Extracorporeal Membrane Oxygenation Duration as a Bridge to Total Artificial Heart Affect Outcomes***; J. Malas[1], Q. Chen[1], A. Akhmerov[1], P. Tremblay[1], N. Egorova[2], J. Moriguchi[3], J. Kobashigawa[3], L. Czer[3], R. Cole[3], D. Emerson[1], J. Chikwe[1], F. Arabia[4], F. Esmailian[1]. *[1]Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, [2]Icahn School of Medicine at Mount Sinai, New York, NY, [3]Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, [4]Banner University Medical Center - Phoenix, Phoenix, AZ*

1:00 – 2:00 p.m.

SESSION 64: AT THE LIMITS OF CARE: SAILING THE ROUGH SEAS WITH AWAKE PATIENTS ON PUMPS

Location: Four Seasons Ballroom

Core Therapies: MCS, HEART, LUNG
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing & Allied Health, Pediatrics

Session Summary: This session will focus on adult and pediatric patients with heart or lung failure supported with mechanical pumps (e.g., VA or VV-ECMO, short term VADs, durable LVADs) where the patient is conscious but escalation or continuation of care is not feasible or appropriate. Making and communicating decisions can be challenging for the team, and the process of stopping life-sustaining supports in this setting can be practically and psychologically difficult. This session explores these real-life challenges faced by multidisciplinary care teams. This session will conclude with a moderated panel discussion.

Co-Chairs: Andrew Morley-Smith, MRCP PhD, Harefield Hospital, Harefield, United Kingdom
Christiane Kugler, PhD, Albert-Ludwigs University Freiburg, Freiburg, Germany
Sharon McCartney, MD, Duke University, Durham, NC USA

1:00 p.m. ***Choppy Waters: The Ethics of Risk and Decision Making***
Colleen McIlvennan, PhD, DNP, ANP, University of Colorado, Denver, CO USA

MCS and transplant teams make decisions about risk daily. This talk will explore the concept and ethics of risk (to the individual and risks to good organ utilization), and explore the process of team decision making and how clinical leaders can support the wider care team in this process.

1:12 p.m. ***Discontinuing MCS Therapy in Awake Adults on Short Term and Durable Devices***
Kavitha Muthiah, MBChB, PhD, St. Vincent's Hospital, Sydney, NSW Australia

This talk will take a practical approach to ceasing MCS in adults with heart or lung failure, reviewing situations where this might arise, how to manage communication with patient/family, the process of reducing pump-based support, managing symptoms during device discontinuation, and organ donation in this context. An international perspective will be presented, considering BTT and DT settings, legal aspects, and practical approaches.

1:24 p.m. ***Discontinuing MCS Therapy in Children on Short-Term and Durable Devices***
Seth Hollander, MD, Stanford University, Palo Alto, CA USA

This talk will focus on the unique challenges of discontinuing pump therapy in critically ill children on forms of short and long-term mechanical circulatory support for heart or lung failure. MCS deactivation checklists will be reviewed and recent palliative and end of life care guidelines specific to pediatrics will be expounded upon.

1:36 p.m. ***Amidst the Wind and the Waves: Supporting Family and Professional Caregivers***
Melissa Sanchez, BSc Hons, PGDip, DClinPsy, MSc, Central and North West London NHS Foundation Trust, London, United Kingdom

This talk recognises the psychological challenges the caregiver team will experience during the end of life phase, particularly for awake or pediatric patients on MCS device therapy. The talk will consider how to encourage open recognition of the challenges, programs to support staff members, and how to provide effective supportive care for the bereaved family.

1:48 p.m. ***Panel Discussion***

1:00 – 2:00 p.m.

SESSION 65: CARDIAC ALLOGRAFT VASCULOPATHY – WHAT DOES THE FUTURE HOLD?

Location: Rooms 603-605

Core Therapies: HEART
Practice Areas: Cardiology, Research and Immunology

Session Summary: This session, in Pecha Kucha format, will enable attendees to learn about novel methods of screening and management, along with emerging technologies that may shape CAV prevention and treatment in the future.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: This session will focus on the latest understanding of CAV and emerging clinical and translational research that may shape the way it is screened for and managed in the coming years.

Co-Chairs: Stephan Ensminger, MD, Dphil, University of Lubeck, Lübeck, Germany
Sharon Chih, MBBS, University of Ottawa Heart Institute, Ottawa, ON Canada

1:00 p.m. ***Computational Analysis of Routine Endomyocardial Biopsies for Prediction of Cardiac Allograft Vasculopathy***
Guillaume Coutance, MD, PhD, Pitié-Salpetrière Hospital, Paris, France

Discuss the role/performance/potential of morphological biomarkers extracted from EMBs for predicting future cardiac allograft vasculopathy development and impact on clinical practice (individualized approach, cost, minimizing complications, etc.)

1:08 p.m. ***Ex Vivo Perfusion and Gene Therapy for Cardiac Allograft Vasculopathy***
Jun-Neng Roan, MD, PhD, National Cheng Kung University Hospital, Tainan, Taiwan

The procedure for cardiac transplantation offers a unique opportunity for gene delivery that does not exist for other indications for therapeutic gene intervention for heart disease. Discuss gene delivery to a whole cardiac graft utilizing ex vivo perfusion methods and future directions.

1:16 p.m. ***Biomarkers to Detect or Predict CAV***
Kevin Clerkin, MD, MSc, Columbia University Irving Medical Center, New York, NY USA

Discuss the most recent findings linking clonal hematopoiesis and CAV; microRNAs; immune mediators and Donor-reactive CD4 T-cell immunity; Utilization as a potential biomarker for CAV detection, risk classification, and mortality

1:24 p.m. ***Vascular Remodeling and Rapidly Progressive Intimal Thickening in the Contemporary Era***
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA USA

Discuss mechanisms for vascular remodeling; Related novel methodologies to detect CAV, and therapies aiming to regulate intimal thickening, the pathological hallmark of CAV, and explore future directions.

1:32 p.m. ***Systems Biology Approaches to Early Detection and Prevention of Cardiac Allograft Vasculopathy***
Kaushik Amancherla, MD, Vanderbilt University Medical Center, Nashville, TN USA
Technological development led to an increased interest in systems biological approaches to characterize disease mechanisms and candidate genes relevant to specific diseases. A systems biology approach hypothesizes that the response against the transplanted graft results from a constellation of events mediated by various cellular pathways. Discuss how molecular biology techniques and omics science could be integrated for cardiac allograft monitoring and impact clinical practice.

1:40 p.m. ***Panel Discussion and Audience Vote***

1:00 – 2:00 p.m.

SESSION 66: CATCH ME IF YOU CAN: SUCCESSFUL PATIENT TRANSITIONS FROM PEDIATRIC INTO ADULT THORACIC TRANSPLANT PROGRAMS - A CENTER-BASED APPROACH

Location: Rooms 401-404

Core Therapies: HEART, LUNG
Practice Areas: Nursing & Allied Health, Cardiology, Pediatrics, Pharmacy and Pharmacology, Pulmonology

Session Summary: Moving patient care from a pediatric to adult transplant center is complex and happens as a vulnerable time for young adult patients. This session, in Pecha Kucha format, will present real-world experience with successful transitions of care and will highlight patient-centered practices and teamwork between adult and pediatric specialists.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: Thoughtful planning and a multifaceted approach to pediatric care provides the best prospect for a successful transfer to adult care.

Co-Chairs:
Marc Schecter, MD, University of Florida, Gainesville, FL USA
Joshua Diamond, MD, University of Pennsylvania, Philadelphia, PA USA
Melissa Cousino, PhD, University of Michigan, Ann Arbor, MI USA

1:00 p.m. ***A Standardized Approach to Transitions of Care: Learning From CF***
Brandi Mahar, BSN, MSN, Cincinnati Children's Hospital Medical Center, Cincinnati, OH USA

This talk will describe the importance of developing center protocols for how patients transition from pediatric to adult hospitals and will discuss the challenges of implementing such protocols in both pediatric and adult spaces.

1:08 p.m. ***Patient-Centered Benefits of Moving to an Adult Hospital or Center***
Angela Velleca, MHDS, BSN, RN, CCTC, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA USA

This talk will review the pros and cons of moving from a pediatric center to an adult transplant center. The speaker will also discuss how to prepare the young adult patient for inherent changes in care delivery that come with moving to a larger adult center that may be closer to home.

1:16 p.m. ***What's This For? Medication Adherence and Autonomy Through the Teenage Years***
Steven Ivulich, BPharm, Alfred Hospital, Melbourne, VIC Australia

This talk will review the importance of medication adherence, including independently requesting refills and actively participating in medication approvals and discussions, as part of the successful transition from pediatric to adult care

1:24 p.m. ***Beyond Adherence! Factors Impacting Rejection in Young Adults***
Donna Guadiz, BSN, Children's Hospital Los Angeles, Los Angeles, CA USA

This talk will discuss common pitfalls in transitions of care that leave patients vulnerable to rejection episodes or other complications.

1:32 p.m. ***Don't Talk to Me That Way: Communication During Times of Transition***
Jo Wray, PhD, DHP (NC), Great Ormond Street Hospital for Children, London, United Kingdom

This talk will cover communication between adult and pediatric transplant centers and between teenagers, parents, and physicians to promote engagement in the transition of care, as well as challenges with special patient populations including those who rely on adult caregivers because of neurodevelopmental needs.

1:40 p.m. ***Panel Discussion and Audience Vote***

1:00 – 2:00 p.m.

SESSION 67: CHALLENGES OF PH MANAGEMENT IN SPECIAL POPULATIONS

Location: Rooms 501-504

Core Therapies: PVD, LUNG
Practice Areas: Cardiology, Infectious Diseases, Pediatrics, Pulmonology

Session Summary: This session will cover the unique challenges in management of patients with pulmonary hypertension.

Co-Chairs: Teresa De Marco, MD, FACC, University of California San Francisco, San Francisco, CA USA
Shahid Husain, MD, MS, University Health Network, Toronto, ON Canada

1:00 p.m. ***Hello Hello: Hearing from a Patient Living with Pulmonary Hypertension***
Kristen Allyson Ramones, MD, Rainbow Babies Hospital, Case Western University, Cleveland, OH USA

Talk from a patient living with pulmonary hypertension to discuss and share the disease state, therapy related, and social challenges that come with pulmonary hypertension, and opportunities for continued improvement to care for patients and ensure optimal quality of life.

1:12 p.m. ***Growing Up with Pulmonary Hypertension***
Karin Tran-Lundmark, MD, PhD, Skane University Hospital, Lund, Sweden

This talk will discuss how to transition care from pediatrics to adulthood while living with PH.

1:24 p.m. ***Pulmonary Hypertension From Methamphetamine Use***
Nicholas Kolaitis, MD, University of California San Francisco, San Francisco, CA USA

Diagnosis and management of the unique population of patients with pulmonary hypertension related to methamphetamine use.

1:36 p.m. ***Should We Screen for PH in Sarcoid and How to Proceed?***
Helen Whitford, MBBS, FRACP, The Alfred Hospital, Melbourne, VIC Australia

This talk will describe the importance of looking for this in sarcoid and examining the flaws of screening, then discuss best modalities to investigate fully.

1:48 p.m. ***Panel Discussion***

1:00 – 2:00 p.m.

SESSION 68: HOW IT STARTED...HOW IT'S GOING: OMICS AND AI IN HEART TRANSPLANT BIOPSIES AND REJECTION SURVEILLANCE

Location: Rooms 205-207

Core Therapies: HEART
Practice Areas: Pathology, Cardiology, Cardiothoracic Surgery, Pediatrics, Research and Immunology

Session Summary: Novel means of rejection surveillance including serum proteomic and biopsy-based transcriptomic approaches as well as a machine learning algorithm applied to biopsy histology are the focus of this session.

Co-Chairs: Chieh-Yu Lin, MD, PhD, Washington University in St. Louis, St. Louis, MO USA
Carmela Tan, MD, Cleveland Clinic, Cleveland, OH USA

1:00 p.m. **(129)** ***Detecting Rejection Infiltrates with Deep-Learning Algorithm from HE-Stained Clinical Endomyocardial Biopsies***; A. J. Lahtiharju[1], M. Mäyränpää[1], S. Syrjala[2], K. Lemstrom[3]. *[1]University of Helsinki, Helsinki, Finland, [2]Helsinki University Hospital, Helsinki, Finland, [3]University of Helsinki, Helsinki, 18, Finland*

1:15 p.m. **(130)** ***Dysregulated Circulating Proteins in Cellular and Antibody-Mediated Rejection, on Behalf of the Graft Investigators***; J. F. Goldberg[1], C. R. deFilippi[1], C. Lockhart[2], E. R. McNair[1], S. Sinha[1], H. Kong[3], S. S. Najjar[4], B. J. Lohmar[1], I. Tchoukina[5], K. Shah[5], E. Feller[6], S. Hsu[7], M. E. Rodrigo[8], M. Jang[3], C. Marboe[9], G. J. Berry[10], H. A. Valantine[10], S. Agbor-Enoh[3], P. Shah[1]. *[1]Inova Heart and Vascular Institute, Falls Church, VA, [2]Bioinformatics, George Mason University, Fairfax, VA, [3]National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, [4]MedStar Health, Baltimore, MD, [5]Virginia Commonwealth University, Richmond, VA, [6]University of Maryland School of Medicine, Baltimore, MD, [7]John Hopkins Medical Institute, Baltimore, MD, [8]Medstar Washington Hospital Center, Potomac, MD, [9]Columbia University Vagelos College of Physicians & Surgeons, New York, NY, [10]Stanford University School of Medicine, Palo Alto, CA*

1:30 p.m. **(131)** ***Diagnostic Performance of MMDx in Real World Heart Transplant Population: A Single Center Experience***; N. Fida, F. Ishaq, D. Nguyen, E. A. Graviss, A. Guha. *Houston Methodist Hospital, Houston, TX*

1:45 p.m. **(132)** ***Molecular Diagnostic Classification of Heart Allograft Rejection Based on the Targeted Banff Human Organ Transplant Gene Expression Panel***; A. Giarraputo[1], G. Coutance[2], M. Fedrigo[1], O. Aubert[3], J. Dagobert[4], B. Robin[4], I. Barison[5], F. Mezine[4], C. Castellani[6], P. Rouvier[7], P. Bruneval[8], J. Patel[9], J. Duong-Van-Huyen[10], A. Angelini[5], A. Loupy[11]. *[1]Cardiovascular Pathology and Pathological Anatomy, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy, University of Padua, Italy, Padua, Italy, [2]Pitié-Salpetrière Hospital, Paris, France, [3]Université de Paris Cité, INSERM, PARCC, Paris Translational Research Centre for Organ Transplantation, F-75015 Paris, France, Université de Paris Cité, INSERM, PARCC, France, Paris, France, [4]Université de Paris Cité, INSERM, PARCC, Paris Translational Research Centre for Organ Transplantation, F-75015 Paris, France, Paris, France, [5]Cardiovascular Pathology and Pathological Anatomy, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy, Padua, Italy, [6]Cardiovascular Pathology and Pathological Anatomy, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy, Padova, Italy, [7]Pitié-Salpetrière Hospital, Paris, France, Paris, France, [8]Hosp Europ Geo Pompidou, Paris, 75, France, [9]Cedars-Sinai Smidt Heart Institute, Calabasas, CA, [10]Hospital Necker, Paris, France, [11]Université de Paris Cité, INSERM, PARCC, Paris Translational Research Centre for Organ Transplantation, F-75015 Paris, France/Necker Hospital, Paris, France, Paris, France*

1:00 – 2:00 p.m.

SESSION 69: MCS: BLEEDING AND CLOTTING - WE JUST CAN'T WIN!

Location: Rooms 405-407

Core Therapies: MCS
Practice Areas: Pharmacy and Pharmacology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Research and Immunology

Session Summary: This session will describe the clinical conundrum of bleeding and thrombosis within mechanical circulatory devices. The session features novel strategies for addressing bleeding and clotting.

Co-Chairs: Lilibeth Carlos, B.Pharm (Hons), St Vincent's Hospital Sydney, Darlinghurst, NSW Australia
Pia Lanmueller, German Heart Center Berlin, Berlin, Germany

1:00 p.m. **(133)** ***Clinical Effects of Hemoadsorption in Patients Undergoing Left Ventricular Assist Device Implantation***; Z. Haidari[1], M. Thielmann[1], P. Lüdike[2], M. El Gabry[1], N. Pizanis[1], M. Biewer[1], M. Kamler[1], T. Rassaf[2], A. Ruhparwar[1], B. Schmack[1]. *[1]Thoracic and Cardiovascular Surgery, University Hospital Essen, Essen, Germany, [2]Cardiology, University Hospital Essen, Essen, Germany*

1:15 p.m. **(134)** ***Lysis Therapy vs. Pump Exchange for Intra-Pump Thrombosis of Left Ventricular Assist Devices***; C. Hoermandinger[1], F. Kaufmann[2], J. Mulzer[3], M. Mueller[4], V. Falk[1], E. Potapov[3], F. Schoenrath[5], I. A. Just[1]. *[1]German Heart Center Berlin, Berlin, Germany, [2]Berlin German Hrt Inst, Berlin, BE, Germany, [3]German Heart Institute, Berlin, BE, Germany, [4]German Heart center, Berlin, BE, Germany, [5]Deutsches Herzzentrum Berlin, Berlin, Germany*

1:30 p.m. **(135)** ***Glycoprotein (GP)Ibα Protein Expression is Reduced in HeartMate 3 Patients with Non-Surgical Bleeding Complications Within the First 3 Months***; K. Klaeske, A. Brade, S. Eifert, K. Jawad, D. Saeed, J. Haunschild, M. Borger, M. Dieterlen. *Heart Center Leipzig, Leipzig, Germany*

1:45 p.m. **(136)** ***Platelet Function and Sildenafil Use During Left Ventricular Assist Device Support***; O. Saeed, M. Farooq, T. Chinnadurai, J. Ramos, S. Patel, P. Chavez, Y. Rochlani, S. Murthy, J. Shin, S. Vukelic, D. Sims, D. Goldstein, U. Jorde. *Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY*

FRIDAY, 21 APRIL, 2023

1:00 – 2:00 p.m.

SESSION 70: LOST IN TRANSLATION: MOLECULAR TOOLS IN LUNG TRANSPLANTATION

Location: Rooms 201-203

Core Therapies: LUNG
Practice Areas: Pulmonology, Infectious Diseases, Pharmacy, Research and Immunology

Session Summary: This session highlights application of molecular technologies in a range of lung transplant-related areas, including Baseline Lung Allograft Dysfunction (BLAD), phage therapy in Burkholderia cepacia complex infections, post-transplant neutropenia, and UIP/IPF-related cancers.

Co-Chairs: Karl Lemstrom, MD, PhD, University of Helsinki, Helsinki, Finland
Justin Rosenheck, DO, Ohio State University Hospital, Columbus, OH USA

1:00 p.m. **(137)** ***Molecular Features Associated with Baseline Lung Allograft Dysfunction***; M. Mackova[1], P. Gauthier[1], J. Chang[1], G. Snell[2], G. Westall[3], S. Juvet[4], J. Havlin[5], P. Halloran[1], K. Halloran[1]. *[1]University of Alberta, Edmonton, AB, Canada, [2]Alfred Hospital, Melbourne, Australia, [3]Alfred Hospital, Prahran, Australia, [4]University Health Network, Toronto, ON, Canada, [5]University Hospital Motol, Praha 8, Czech Republic*

1:15 p.m. **(138)** ***Development of Burkholderia Cepacia Complex Targeted Clinical Registry and Phage Library***; S. Aslam[1], O. Yerushalmy[2], A. Courtwright[3], C. Koval[4], M. Luong[5], K. Demir[6], S. Pouch[7], H. Onallah[2], R. Browunshtine[2], C. Rakov[2], D. Gelman[2], S. Coppenhagen-Glazer[2], J. Pilewski[8], J. Lipuma[9], R. Nir-Paz[10], R. Hazan[2]. *[1]University of California San Diego, San Diego, CA, [2]Hebrew University of Jerusalem, Jerusalem, Israel, [3]Hospital of the University of Pennsylvania, Philadelphia, PA, [4]Cleveland Clinic Foundation, Shaker Heights, [5]Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, [6]Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada, [7]Emory University, Decatur, GA, [8]University of Pittsburgh Medical Center, Pittsburgh, PA, [9]University of Michigan Medical School, Ann Arbor, MI, [10]Hadassah Medical Center, Jerusalem, Israel*

1:30 p.m. **(139)** ***Polymorphism T300a in Atg16l1 is Associated with Post-Transplant Neutropenia in Lung Transplant Recipients***; L. Tague[1], H. K. Anthony[2], A. Khallaf[2], D. Kreisel[3], A. Gelman[4]. *[1]Washington Univ in St. Louis, Saint Louis, MO, [2]Pulmonary & Critical Care Medicine, Washington University, Saint Louis, MO, [3]Washington Univ Sch Med, Saint Louis, MO, [4]Washington University School of Medicine, Saint Louis, MO*

1:45 p.m. **(140)** ***Morphological and Molecular Analysis of Incidental Neoplasia in Explanted Lungs with UIP/IPF: A Single Centre Experience***; F. Lunardi[1], V. Verzeletti[1], F. Pezzuto[1], C. De Chellis[1], V. Tauro[1], F. Fortarezza[2], A. Kilitci[3], M. Schiavon[1], E. Faccioli[1], M. Loy[2], F. Rea[1], F. Calabrese[1]. *[1]University of Padova, Padova, Italy, [2]Padova University Hospital, Padova, Italy, [3]Duzce University, Duzce, Turkey*

2:15 – 3:15 p.m.

SESSION 71: AROUND THE WORLD IN 60 MINUTES: APPROACHES TO INFECTED DONORS - HEART AND LUNG TRANSPLANT CONSIDERATIONS

Location: Four Seasons Ballroom

Core Therapies: HEART, LUNG
Practice Areas: Cardiology, Cardiothoracic Surgery, Infectious Diseases, Pharmacy and Pharmacology, Nursing & Allied Health, Pediatrics, Pulmonology

Session Summary: This symposium, in Pecha Kucha format, will address considerations for organ acceptance, both heart and lung, from donors at risk for latent tuberculosis, Chagas disease, Strongyloides, hepatitis infection, and COVID-19 and will address how to minimize the risk of disease transmission and ensure organ safety while minimizing inappropriate organ discard.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: Considerations for heart and lung transplantation from donors with endemic infections, including latent tuberculosis, Chagas disease, Strongyloides, hepatitis, and COVID-19.

Co-Chairs: Erika D. Lease, MD, University of Washington, Seattle, WA USA
Paolo Grossi, MD, PhD, University of Insubria, Varese, Italy

2:15 p.m. ***TB or Not-TB? Donor with Latent TB: Considerations for Heart and Lung Transplant***
Margaret Hannan, MD, Mater Hospital, Dublin, Ireland

This talk will focus on the risks of latent TB donor to a heart recipient and a lung recipient – accept or not? Considerations on prophylaxis will be discussed to safely use this kind of donor.

2:23 p.m. ***Donor from Chagas Endemic Area: Considerations for Heart and Lung Transplant***
Silvia Campos, PhD, Heart Institute of Sao Paulo Medical School, São Paulo, Brazil

This talk will focus on considerations for organ acceptance, both HEART and LUNG, from donors at risk for, Chagas disease and address how to minimize the risk of disease transmission and ensure organ safety while minimizing inappropriate organ discard.

2:31 p.m. ***Thoracic Transplantation from a Strongyloides-Seropositive Donor***
Bradley Gardiner, MBBS, FRACP, MS, PhD, Alfred Health/Monash University, Melbourne, VIC Australia

This talk will focus on considerations for organ acceptance, both HEART and LUNG, from donors at risk for Strongyloides disease and address how to minimize the risk of disease transmission and ensure organ safety while minimizing inappropriate organ discard.

2:39 p.m. ***Thoracic Transplantation from Viral Hepatitis Donors***
Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

This talk will focus on the use of heart and lung donors infected with Hepatitis B virus (HBV) and also donor in a region with a hepatitis E outbreak. Prevalence, morbidity, and therapy of hepatitis B and E virus infection will be discussed to safely use this kind of donor.

2:47 p.m. ***The Final Frontier: SARS-CoV-2 Positive Donors - Considerations for Heart and Lung Transplant***
Cameron Wolfe, MD, Duke University Medical Center, Durham, NC USA

This talk will focus on the use of donors with recent SARS-CoV-2 infection or discordant testing (i.e. positive nasopharyngeal testing and negative lower respiratory tract testing) is not well described. Considerations include transmission to the recipient, infection of the surgical teams, and overall graft outcomes will be included. This talk will also discuss how to consider donor utilization in future pandemics.

2:55 p.m. ***Panel Discussion and Audience Vote***

2:15 – 3:15 p.m.

SESSION 72: NOW IS NOT THE TIME TO RELAX: VASOPLEGIA AFTER HEART TRANSPLANT

Location: Rooms 603-605

Core Therapies: ALL
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pharmacy

Session Summary: This session, in Pecha Kucha format, seeks to solicit contemporary perspectives on the definition of, risk factors for and treatment of peri-operative vasoplegia in heart transplant recipients.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: To understand contemporary perspectives on risk factors and associated practice patterns around perioperative vasoplegia during heart transplantation.

Co-Chairs: Yasbanoo Moayedi, MD, University Health Network, Toronto, ON Canada
Hermann Reichenspurner, MD, PhD, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Tara Veasey, PharmD, BCTXP, Allegheny General Hospital, Pittsburgh, PA USA

2:15 p.m. ***Past, Present and Future of Vasoplegia***
Fernando Bacal, MD, University of Sao Paulo, São Paulo, Brazil

This presentation should address the pathophysiology and definition of vasoplegia, including the new insights of the PGD consortium.

2:23 p.m. ***How Do I Know If My Patient Is At Risk For Vasoplegia Prior To Transplant***
Alessandra Verzelloni Sef, MD, Harefield Hospital, Royal Brompton and Harefield Hospitals, London, United Kingdom

This presentation should address the complexity of risk factors to assess the patient prior to transplantation. Not exclusively focused on drug/VADs.

2:31 p.m. ***VADs and Vasoplegia - A Recipe for Disaster***
Robert Miller, MD, FRCPC, FACC, University of Calgary, Calgary, AB Canada

This presentation will focus on patients on VADs as bridge to transplant with relation to the onset and management of vasoplegia.

2:39 p.m. ***Are Meds to Blame for Vasoplegia: Stopping ARNIs/SGLT2i Prior to Transplant Listing***
Kimberly Harrison, PharmD, Vanderbilt University Medical Center, Nashville, TN USA

This presentation will focus on the drug related effects resulting in vasoplegia, how to anticipate and manage prior to transplantation.

2:47 p.m. ***Early Management for Vasoplegia***
Archer Martin, MD, Mayo Clinic Florida, Jacksonville, FL USA

This presentation should address the perioperative and early postoperative measures to treat vasoplegia during/after heart transplantation.

2:55 p.m. ***Panel Discussion and Audience Vote***

2:15 – 3:15 p.m.

SESSION 73: REJECTING THE OLD WAYS: THE FUTURE OF CLAD MONITORING FROM INFANCY TO ADULTHOOD

Location: Rooms 401-404

Core Therapies: LUNG
Practice Areas: Pediatrics, Pulmonology

Session Summary: This case-based session will discuss novel methods of CLAD monitoring - including multiple breath washout, lung magnetic resonance imaging, and cell-free DNA - for pediatric and adult lung transplant recipients who may be unable to perform conventional monitoring techniques. The use, feasibility, limitations, and evidence for CLAD monitoring with these techniques will be discussed.

Co-Chairs: Christian Benden, MD, MBA, FCCP, University of Zürich, Zurich, Switzerland
Stuart Sweet, MD, PhD, Washington University in St. Louis, St. Louis, MO USA

2:15 p.m. ***Case Presentation: A 4-year-old with ABCA3 Surfactant Deficiency Undergoes Lung Transplantation and Develops CLAD After AMR***
Xin Si, MD, Stanford University, Palo Alto, CA USA

This presentation will be a short clinical case presentation to set the stage for 3 talks in this session.

2:20 p.m. ***Multiple Breath Washout (MBW) in Pediatric Patients After Lung Transplantation: Ready for Routine Clinical Practice?***
Rossa Brugha, BMBCh MA(Oxon), MRCPCH, PhD, Great Ormond Street Hospital, London, United Kingdom

This presentation describes the arguments for and against the use of MBW in pediatric patients after lung transplantation. A focus will also be on the practical issues associated with MBW and how it can be applied in daily clinical practice.

2:32 p.m. ***Why MRI? Feasibility and Clinical Use of Advanced Lung Imaging in Pediatric Lung Transplant***
Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany

This presentation describes the current evidence and preliminary findings from lung MRI data in children for CLAD detection following lung transplantation. This will also describe lung MRI work in adult lung transplant patients, and some of its practical issues and limitations.

2:44 p.m. ***If the Shoe Fits: Challenges of Applying Adult Biomarkers to Pediatric Lung Transplant***
Stuart Sweet, MD, PhD, Washington University in St. Louis, St. Louis, MO USA

This presentation describes the novel biomarkers being studied for CLAD monitoring, with special focus on cell-free DNA. This will also touch on biomarkers from bronchoalveolar lavage, and how results may translate to the pediatric population.

2:56 p.m. ***Panel Discussion***

2:15 – 3:15 p.m.

SESSION 74: CONNECTING THE CLOTS: JOURNEY OF AN ACUTE TO CHRONIC PULMONARY EMBOLISM

Location: Rooms 501-504

Core Therapies: PVD, HEART, LUNG
Practice Areas: Pulmonology, Cardiology, Cardiothoracic Surgery, Nursing & Allied Health, Pharmacy and Pharmacology

Session Summary: Chronic thromboembolic pulmonary disease (CTEPD) is characterized by the presence of chronic thromboembolic disease without pulmonary hypertension at rest. CTEPD patients represent a small proportion of the patients referred to expert centers, with symptoms and quality of life that may be as poor as those of patients with chronic thromboembolic pulmonary hypertension (CTEPH). It is still unknown why some patients with acute PE develop CTEPD.

Co-Chairs: Olaf Mercier, MD, PhD, Marie Lannelongue Hospital, Le Plessis Robinson, France
Micheal McInnis, MD, University Health Network, Toronto, ON Canada

2:15 p.m. ***Just Getting Started: Post-PE Syndrome in the COVID-19 Era***
Jason Weatherald, MD, MSc, University of Alberta, Edmonton, AB Canada

A significant proportion of patients will report long term functional limitations after pulmonary embolism (PE) yet only a small fraction will be ultimately diagnosed with CTEPH. The purpose of this talk is to describe the post-pulmonary embolism syndrome and how to evaluate the post-PE patient during the COVID era.

2:30 p.m. ***Are We There Yet? The Diagnosis and Management of CTEPD***
Scott Visovatti, MD, Davis Heart and Lung Research Institute, Columbus, OH USA

Following acute pulmonary embolism, around one quarter of patients will have imaging evidence of chronic thromboembolic disease at follow-up. The purpose of this talk is to describe the approach to a symptomatic patient with chronic thromboembolic disease, in the setting of normal resting pulmonary artery pressures, and to discuss when intervention may be warranted.

2:45 p.m. ***Is This a Roadmap? Imaging in Chronic Thromboembolic Disease***
Micheal McInnis, MD, University Health Network, Toronto, ON Canada

There may be a role for pulmonary endarterectomy and balloon pulmonary angioplasty in carefully selected symptomatic CTEPD patients. This presentation will review the role of imaging in the diagnosis of CTEPD and how it may assist in planning multidisciplinary management.

3:00 p.m. ***Panel Discussion***

2:15 – 3:15 p.m.

SESSION 75: THE COMEDY OF ERRORS: NEW ALLOCATION POLICY, DCD DONORS...WHAT ABOUT PRIMARY GRAFT DYSFUNCTION?

Location: Rooms 205-207

Core Therapies: HEART
Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery

Session Summary: The session includes data on the impact on primary graft dysfunction in different scenarios.

Co-Chairs: Maxime Tremblay-Gravel, MD, MSc, Montreal Heart Institute, Montréal, QC Canada
Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY USA

2:15 p.m. **(141)** ***Normothermic Regional Perfusion Versus Direct Procurement and Preservation: Is There a Difference for DCD Heart Recipients?***; J. Trahanas, A. DeBose-Scarlett, H. K. Siddiqi, K. Amancherla, D. M. Brinkley, J. Lindenfeld, J. Menachem, H. Ooi, D. Pedrotty, L. Punnoose, A. Rali, S. Sacks, M. Wigger, S. Zalawadiya, J. Hoffman, W. McMaster, A. S. Shah, K. Schlendorf, C. Pasrija. *Vanderbilt Univ Medical Center, Nashville, TN*

2:30 p.m. **(142)** ***Validating the 2014 Consensus Primary Graft Definition: An Analysis on the 1,056 Patients from the Multi-Center Guardian Registry***; A. Zuckermann[1], J. P. Jacobs[2], Y. Shudo[3], D. Meyer[4], S. Silvestry[5], M. Leacche[6], C. Sciortino[7], M. Rodrigo[8], S. Pham[9], K. Takeda[10], H. Copeland[11], A. Vidic[12], M. Kawabori[13], U. Boston[14], J. Bustamante-Munguira[15], A. Eixeres Esteve[16], R. Venkateswaran[17], J. Schroder[18], D. D'Alessandro[19]. *[1]Medical University of Vienna, Wien, Austria, [2]University of Florida, Gainesville, FL, [3]Stanford University, Menlo Park, CA, [4]Baylor Scott and White Health, Health Texas Provider Network, Cardiac and Thoracic Surgery at Baylor, Dallas, TX, [5]AdventHealth Transplant Institute, Orlando, FL, [6]Corewell Health, Grand Rapids, MI, [7]Sentara, Norfolk, VA, [8]Medstar Washington Hospital Center, Potomac, MD, [9]Jacksonville, FL, [10]Columbia University, New York, NY, [11]Lutheran Medical Group, Fort Wayne, IN, [12]University of Kansas Health System, Kansas City, KS, [13]Tufts Medical Center, Brookline, MA, [14]Le Bonheur Children's Hosp, Memphis, TN, [15]Hospital Clinico Universitario de Valladolid, Valladolid, Spain, [16]12 de Octubre, Madrid, Spain, [17]University Hospital of South Manchester, Manchester, United Kingdom, [18]Duke University Medical Center, Durham, NC, [19]MGH, Weston, MA*

2:45 p.m. **(143)** ***Impact of the 2018 Adult Heart Allocation Policy Change on the Incidence of Primary Graft Dysfunction after Heart Transplantation***; C. S. Premananthan[1], Q. Chen[1], J. Malas[1], D. Emerson[1], D. Megna[1], P. Catarino[1], J. Kobashigawa[2], M. Kittleson[2], J. Patel[2], J. Chikwe[1], M. Bowdish[1], F. Esmailian[1]. *[1]Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, [2]Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA*

3:00 p.m. **(144)** ***Cold Static Storage of Donation after Circulatory Death (DCD) Hearts Procured via Normothermic Region Perfusion (NRP): Effect of Ischemic Time on Outcomes***; K. Sharaf[1], D. Cookish[1], R. White[1], B. Jackson[1], A. Brann[1], A. Lin[1], Q. Bui[1], A. Duran[1], Y. Gernhofer[2], M. Urey[1], M. Kearns[1], V. Pretorius[1]. *[1]UC San Diego Health, San Diego, CA, [2]University of the Incarnate Word School of Osteopathic Medicine, San Antonio, TX*

2:15 – 3:15 p.m.

SESSION 76: SPOTLIGHT ON NURSING AND ALLIED HEALTH MCS INTERVENTION SCIENCE

Location: Rooms 405-407

Core Therapies: MCS
Practice Areas: Nursing & Allied Health, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pharmacy, Pulmonology, Research and Immunology

Session Summary: This session will feature nursing and allied health led MSC intervention science, including interventions specific to MCS shared decision making, MCS social work assessments, caregiver strain, and survival to discharge following VV ECMO.

Co-Chairs: Edward Horn, PharmD, University of Pittsburgh, Pittsburgh, PA USA
Desiree Robson, RN, BSc (Hons), St. Vincent's Hospital, Darlinghurst, NSW Australia

2:15 p.m. **(145)** ***Patients' Experiences Around Shared Decision Making for Left Ventricular Assist Devices: Results from I-DECIDE-LVAD***; D. D. Matlock[1], J. S. Thompson[1], C. McIlvennan[2], M. K. Wynia[1], C. Tietbohl[1], B. Mosley[1], L. Allen[3]. *[1]University of Colorado School of Medicine, Aurora, CO, [2]University of Colorado, Denver, CO, [3]University of Colorado, Aurora, CO*

2:30 p.m. **(146)** ***Impact of a Novel Social Worker Psychosocial Assessment (6D-SW) on Prospective Outcomes in HeartMate 3 (HM3) Patients***; A. Ladanyi[1], S. Deluty[2], M. R. Carey[1], C. Shahidi[3], G. M. Mondellini[1], E. S. Harris[1], V. R. Feldman[2], C. Maguire[2], P. A. Kurlansky[1], Y. Kaku[1], K. Clerkin[1], G. Sayer[1], N. Uriel[2], K. Takeda[1], M. Pavol[1], M. Yuzefpolskaya[1], P. C. Colombo[1]. *[1]Columbia University Irving Medical Center, New York, NY, [2]New York Presbyterian Hospital, New York, NY, [3]Columbia University, New York, NY*

2:45 p.m. **(147)** ***Improving Veno-Veno Extracorporeal Membrane Oxygenation (VV ECMO) Survival to Discharge by Implementing a Goal-Oriented Expected Progression Patient Management Guideline***; O. O. Hernandez[1], O. Espinoza[1], D. Miller[1], B. Lima[2], C. Couch[3], C. Pellecchia[3]. *[1]ECMO Department, Medical City Plano, Plano, TX, [2]Cardiothoracic Surgery, Medical City Heart Hospital, Dallas, TX, [3]Pulmonary Critical Care, Medical City Plano, Plano, TX*

3:00 p.m. **(148)** ***The Effect of the ENABLE-LVAD Program on Caregiver Strain and Sleep Quality in Ventricular Assist Device Caregivers***; J. Nowaczyk[1], K. McFarland[2], A. Smith[2], L. Puglisi[1], F. Ber[2]. *[1]Scripps Health, San Diego, CA, [2]Scripps Memorial Hospital La Jolla, La Jolla, CA*

2:15 – 3:15 p.m.

SESSION 77: NEW FRONTIERS IN BIOMARKER DEVELOPMENT: ANTIBODIES, OMICS, AND GRAFT INJURY

Location: Rooms 201-203

Core Therapies: HEART
Practice Areas: Research and Immunology, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy

Session Summary: Don't miss this session where anti-HLA antibodies are explored in interesting scenarios and new omics approaches in heart transplantation.

Co-Chairs: Indranee Rajapreyar, MD, Thomas Jefferson University Hospital, Philadelphia, PA USA
Lourdes Chacon, Texas Heart Institute, Houston, TX USA

2:15 p.m. **(149)** ***Detection of Donor-Specific Antibodies May Be Impacted by Race and Ethnicity***; J. C. Quon[1], J. Menteer[2], R. Lestz[2], M. Weisert[2], L. A. Baxter-Lowe[2]. *[1]Keck School of Medicine of USC, Los Angeles, CA, [2]Children's Hospital Los Angeles, Los Angeles, CA*

2:30 p.m. **(150)** ***Trends in HeartCare Values Following the Development of De Novo Donor Specific Antibodies***; M. Kamath[1], P. Shah[2], Y. Fu[3], K. Qu[3], J. Kobashigawa[4]. *[1]UCLA, Los Angeles, CA, [2]Inova Heart and Vascular Institute, Falls Church, VA, [3]Biostatistics and Data Sciences, CareDx, Brisbane, CA, [4]Cedars-Sinai Heart Institute, Los Angeles, CA*

2:45 p.m. **(151)** ***Plasma Proteomic Signature of Human Heart Transplant Recipients After Restoration of Blood Circulation and Its Relationship to Graft Outcome***; A. Salin[1], K. Dhaygude[1], R. Krebs[1], S. Joenväärä[2], E. Holmstrom[1], J. Lukac[1], R. Renkonen[2], A. Nykanen[3], K. Lemstrom[3]. *[1]Translational Immunology Research Program and Transplantation Laboratory, University of Helsinki, Helsinki, Finland, [2]HUSLAB, Helsinki University Hospital, Helsinki, Finland, [3]Department of Cardiothoracic Surgery, Helsinki University Hospital, Helsinki, Finland*

3:00 p.m. **(152)** ***Metabolomic Profiling During Ex-Vivo Normothermic Perfusion Prior to Heart Transplantation Defines Patterns of Substrate Utilization and Correlates with Markers of Allograft Injury***; L. K. Truby[1], D. Bowles[2], S. Casalinova[3], L. C. Kwee[4], O. Ilkayeva[4], M. Muehlbauer[4], J. Huebner[4], C. Holley[5], A. D. DeVore[6], C. Patel[6], L. Kang[6], M. Mendiola Pla[7], R. Gross[6], R. W. McGarrah[4], J. Schroder[6], C. Milano[8], S. H. Shah[4]. *[1]University of Texas Southwestern Medical Center, Dallas, TX, [2]Duke, Durham, NC, [3]Duke University Hospital, Durham, NC, [4]Duke Molecular Physiology Institute, Durham, NC, [5]Duke University, Chapel Hill, NC, [6]Duke University Medical Center, Durham, NC, [78]Duke University Med Ctrr, Durham, NC*

3:45 – 4:45 p.m.

SESSION 78: ACUTE MECHANICAL CIRCULATORY SUPPORT: GUIDELINES, CONSENSUS AND PRACTICAL ISSUES

Location: Four Seasons Ballroom

Core Therapies: MCS, HEART
Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Diseases, Nursing & Allied Health, Pharmacy and Pharmacology, Research and Immunology

Session Summary: Selection of the acute MCS can vary from country to country, region to region, and among the providers within the same institution. The field lacks prospective randomized trials. The acute mechanical circulatory support devices have changed, our knowledge has grown. We have safely been able to expand their use, to recover patients, bridge patients to durable support/tx. This session will highlight the major points of the ISHLT Donor Acute Mechanical Circulatory Support Guidelines Paper.

Co-Chairs: Hannah Copeland, MD, Lutheran Medical Group, Fort Wayne, IN USA
David Baran, MD, Cleveland Clinic Heart, Vascular and Thoracic Institute, Weston, FL USA

3:45 p.m. ***30,000 Feet: The ISHLT/HFSA Acute MCS Guidelines***
Alexander Bernhardt, MD, University Heart and Vascular Center, Hamburg, Germany

This talk will focus on specific considerations of the basics of acute mechanical circulatory options, timing to implement the device and device selection. Considerations for VA ECMO, Impella, IABP, for timing, and duration, for sicker patients on VA ECMO, Impella vs IABP

3:57 p.m. ***Cardiogenic Shock: ISHLT Consensus Conference on HF-Shock***
David Baran, MD, Cleveland Clinic Heart, Vascular and Thoracic Institute, Weston, FL USA

The ISHLT held an expert consensus conference recently on the topic of HF CS, ie CS not due to an acute ischemic insult. Conclusions from the conference are summarized

4:09 p.m. ***Post Implant Management: Thin the Blood, Kill the Bugs***
Ian Hollis, PharmD, BCPS-AQ. University of North Carolina Medical Center, Chapel Hill, NC USA

The presentation will review the post-implant management of anti-coagulation. The presentation will also discuss anti-biotic prophylaxis. Will review anticoagulation in VA ECMO, VV ECMO, Impella and IABP, review heparin vs bivalirudin, and review anti-biotic prophylaxis.

4:21 p.m. ***Blazing a Trail: Helping Guide Patient and Family Following Temporary Support Implantation***
Paola Morejon Barragan, MD, Clinica Guayaquil, Guayaquil, Ecuador

The presentation will review the need for social worker, and palliative care after acute mechanical circulatory support. 1) What does the patient want? 2) Making decisions when the family, significant others and next of kin are not available. 3) How to help families and loved ones through the process.

4:33 p.m. ***Panel Discussion***

3:45 – 4:45 p.m.

SESSION 79: UNRAVELLING DEATHS IN HEART TRANSPLANTATION: TURNING TRAGEDY INTO TRIUMPH

Location: Rooms 603-605

Core Therapies: HEART, MCS
Practice Areas: Pathology, Cardiology, Cardiothoracic Surgery, Pediatrics

Session Summary: This session, in Pecha Kucha format, addresses the current knowledge on modes of deaths in heart transplant recipients and how lessons learned from transplant deaths can help living transplant recipients.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: Giovanni Morgagni (18th century Italian Anatomist) described his work as turning the tragedy of death to the service and benefit of the living. That is the theme of this session: turning the lessons gleaned from studying post-heart transplant deaths (including from epidemiologic, autopsy, and device investigations) to aid and improve clinical decision-making for surviving patients and stimulate further research in the field.

Co-Chairs: Douglas Greig, MD, P. Universidad Catolica de Chile, Santiago, Chile
Gregory Fishbein, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA USA

3:45 p.m. ***Living on the Edge: Contemporary Epidemiology, Risk Factors and Modes of Death Following Heart Transplant***
Livia Goldraich, MD, MSc. Hospital de Clínicas Porto Alegre, Porto Alegre, Brazil

This talk will briefly review recent data regarding mortality following heart transplantation, highlighting modes, mechanisms and risk factors for death, particularly in the long-term follow-up.

3:53 p.m. ***The Supporting Role of Autopsy in Understanding Allograft-Related Deaths***
Chieh-Yu Lin, MD, PhD, Washington University in St. Louis, St. Louis, MO USA

This talk will review the spectrum of pathologic findings encountered at autopsy in heart transplant recipients, with examples of how autopsy findings have impacted clinical management of heart transplant recipients.

4:01 p.m. ***What's CAV Got To Do With It?***
Carmela Tan, MD, Cleveland Clinic, Cleveland, OH USA

This talk will summarize the current understanding of CAV derived from autopsy and explant heart pathology and highlight clinical strategies for preventing CAV that came about as a result of this knowledge.

4:09 p.m. ***Are Post-Transplant Sudden Deaths Predictable and Preventable?***
Ana Alba, MD, PhD, Toronto General Hospital, Toronto, ON Canada

This talk will provide a critical review of the evidence for predictive and preventive strategies to decrease sudden cardiac deaths, focusing on the use of implantable cardioverter defibrillators among heart transplant recipients.

4:17 p.m. ***Failing Forward: Pathologic Examination of MCS Devices Removed for Complications and After Recovery***

Dylan Miller, MD, Intermountain Central Lab, Murray, UT USA

This talk will review the contribution of autopsy and explant-based pathology of device complications to refinements in mechanical support device technology and lessons learned about successful recovery patients from examining their devices.

4:25 p.m. ***Panel Discussion and Audience Vote***

3:45 – 4:45 p.m.

SESSION 80: ROCKY MOUNTAIN HIGH: SCALING NEW HEIGHTS IN CMV

Location: Rooms 401-404

Core Therapies: LUNG, HEART
Practice Areas: Infectious Diseases, Pediatrics, Pharmacy and Pharmacology, Pulmonology

Session Summary: CMV remains a significant challenge to success in lung transplantation with end organ disease, impact on allograft function, and toxicity related to treatment. The past two years have been notable for new approaches for prophylaxis and treatment, and greater understanding of the antigen-specific immune response.

Pecha Kucha Format: the Japanese term for the sound of conversation ("chit chat"), this style symposium is designed to keep presentations concise and fast-paced. The session will begin with a brief description of the Unifying Theme, followed by five speakers who will each have 8 minutes to discuss the theme, using 20 slides total and only spending 20 seconds per slide. The last 20 minutes will be audience Q&A and a vote for the winning speaker.

Unifying Theme: New approaches for CMV prophylaxis and treatment in lung transplantation

Co-Chairs: Jennifer Chow, MD, MS, Tufts Medical Center, Boston, MA USA
Michael Perch, MD, Rigshospitalet, Copenhagen, Denmark

3:45 p.m. ***New Strategies for CMV Prophylaxis Including Letermovir***
Miranda So, PharmD, MPH, BScPhm, University Health Network, Toronto, ON Canada

This talk will discuss new agents for CMV prophylaxis, including discussion of relative efficacy and side effects of each agent.

3:53 p.m. ***New Antivirals for CMV Treatment Including Maribavir***
Emily Blumberg, MD, University of Pennsylvania, Philadelphia, PA USA

This talk will discuss new antivirals for treatment of CMV reactivation and will discuss when to select these agents over more traditional antivirals.

4:01 p.m. ***CMV-Specific T-Cell Response and Control of Primary Infection and Reactivation***
Laurie Snyder, MD, MHS, Duke University, Durham, NC USA

This talk will discuss how to use CMV-specific T cell responses to guide prevention and management of CMV infection in thoracic transplant recipients.

4:09 p.m. ***Clinical Applications of CMV Immune Monitoring in Lung Transplantation***
Glen Westall, FRACP, PhD, Alfred Hospital, Melbourne, VIC Australia

This talk will discuss how CMV-specific immune monitoring can be used to monitor degree of immunosuppression and risk of infection and rejection after lung transplantation.

4:17 p.m. ***Adoptive T-Cell Therapy for Refractory Cases in Adults and Children***
Peter Hopkins, FRACP, The Prince Charles Hospital, Brisbane, QLD Australia

This talk will provide new insight and recent data regarding development and use of T cell therapy for refractory CMV.

4:25 p.m. ***Panel Discussion and Audience Vote***

3:45 – 4:45 p.m.

SESSION 81: NOVEL IMAGING MODALITIES: TOOLS TO ASSESS LONG TERM PROGNOSIS AFTER HEART TRANSPLANT

Location: Rooms 501-504

Core Therapies: HEART
Practice Areas: Cardiology, Cardiothoracic Surgery, Pathology, Research and Immunology

Session Summary: This session will present opportunities with PET-CT and optical coherence tomography to assess cardiac allograft vasculopathy and prognosis after transplant.

Co-Chairs: Jeffrey Teuteberg, MD, Stanford University School of Medicine, Stanford, CA USA
Dmitry Abramov, MD, Loma Linda University, Claremont, CA USA

3:45 p.m. **(153)** ***Visually Estimated Coronary Artery Calcium is an Independent Prognostic Marker Following Heart Transplantation***; L. R. Sewanan[1], E. Harris[2], V. Topkara[3], J. Fried[4], J. Raikhelkar[1], P. Colombo[1], G. Sayer[5], M. R. Castillo[1], E. R. Lam[1], M. R. Chernovolenko[1], M. Yuzefpolskaya[4], E. DeFilippis[6], F. Latif[7], K. Takeda[1], L. R. Johnson[1], N. Uriel[8], A. Einstein[1], K. Clerkin[9]. *[1]Columbia University, New York, NY, [23]Columbia University New York Presbyterian Hospital, New York, NY, [4]Columbia University Medical Center, New York, NY, [5]Columbia University Irving Medical Center, Hartsdale, NY, [6]Columbia University Irving Medical Center, Short Hills, NJ, [7]NY Presbyterian Hospital, New York, NY, [8]New York Presbyterian, New York, NY, [9]Columbia University Irving Medical Center, Ridgewood, NJ*

4:00 p.m. **(154)** ***Optical Coherence Tomography Evaluation of Donor Transmitted Coronary Atherosclerosis and Risk of Cardiac Allograft Vasculopathy***; T. Takahashi[1], Y. Kobayashi[2], O. Saeed[3], S. Vukelic[4], U. Jorde[5], J. Shin[5], S. Patel[6]. *[1]Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, [2]New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, [3]Montefiore Medical Ctr, New York, NY, [4]Albert Einstein College of Medicine, Montefiore MC, Bronx, NY, [5]Montefiore Medical Center, Bronx, NY, [6]Montefiore-Einstein, Bronx, NY*

4:15 p.m. **(155)** ***Coronary Flow Reserve is an Independent Predictor of Major Adverse Cardiovascular Events in Long Term Heart Transplantation Survivors***; J. M. Ortega-Legaspi[1], M. Molina[1], J. Leon[2], A. Cunningham[2], M. Guerraty[1], E. Peyster[1], H. Julien[1], R. McLean[1], L. Goldberg[1], P. Bravo[1]. *[1]Department of Medicine. Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, [2]Department of Radiology. Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA*

4:30 p.m. **(156)** ***PET-CT Defined Micro-Vascular Dysfunction and Cardiac Allograft Vasculopathy Risk Factors in Heart Transplant Recipients***; A. Milwidsky[1], M. A. Chan[2], M. Travin[3], C. Gjelaj[4], O. Saeed[5], S. Vukelic[6], Y. Rochlani[7], S. Madan[8], J. J. Shin[9], D. Sims[10], S. Murthy[11], P. Chavez[12], U. Jorde[12], S. Patel[13]. *[1]Tel-Aviv Medical Center, Tel-Aviv, Israel, [2]Medicine, Montefiore New Rochelle, New Rochelle, NY, [3]Radiology, Montefiore Medical Center, New York, NY, [4]Cardithoracic Surgery, Montefiore Medical Center, New York, NY, [5]Montefiore Medical Ctr, New York, NY, [6]Albert Einstein College of Medicine, Montefiore MC, Bronx, NY, [7]Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, [8]Montefiore Medical Center, New York, NY, [9]Cardiology, Montefiore medical Center, New York, NY, [10]Montefiore Medical Center NY, New York, NY, [11]Montefiore Medical Center, Nyack, NY, [12]Montefiore Medical Center, Bronx, NY, [13]Montefiore-Einstein, Bronx, NY*

3:45 – 4:45 p.m.

SESSION 82: MORE THAN A NUMBER: NAVIGATING THE COMPLEXITIES OF PSYCHOSOCIAL SUPPORT IN HEART TRANSPLANTATION

Location: Rooms 205-207

Core Therapies: HEART
Practice Areas: Nursing & Allied Health, Cardiology, Cardiothoracic Surgery, Pediatrics, Pulmonology

Session Summary: This session reviews the use of psychosocial assessment tools with associated outcomes in both adult and pediatric populations as well as innovative psychosocial support programs.

Co-Chairs: Lisa Guertin, DNP, University of Washington Medical Center, Seattle, WA USA
Lauren Schneider, PsyD, Stanford University, Stanford, CA USA

3:45 p.m. **(157)** ***Utility of Stanford Integrated Psychosocial Assessment for Transplantation (Sipat) as a Predictor of Outcomes after Orthotopic Heart Transplantation: A Single Center Experience***; L. K. Keyt[1], Q. Bui[2], A. Duran[3], M. McLenon[3], M. Urey[4], E. Adler[5], J. B. Cruz Rodriguez[3]. *[1]University of California San Diego, San Diego, CA, [2]UC San Diego, San Diego, CA, [3]Department of Medicine, Heart Failure/Cardiac Transplantation Program, University of California, San Diego, San Diego, CA, [4]UC San Diego Health, San Diego, CA, [5]Univ of California, SD, Apple Valley, CA*

4:00 p.m. **(158)** ***Association of SIPAT Score with Long-Term Psychosocial and Clinical Outcomes in Orthotopic Heart Transplant Recipients***; R. Kosaraju, E. Vandenbogaart, E. Core, J. Creaser, N. Livingston, M. Moore, M. Kamath, M. Deng. *Department of Medicine, Division of Cardiology, University of California Los Angeles, Los Angeles, CA*

4:15 p.m. **(159)** ***"It Felt Really Nice to Have Someone Who Understands": The Experiences of Adolescent Thoracic Transplant Patients Participating in the iPeer2Peer Online Mentorship Program***; M. Liang[1], J. Lin[1], I. Siqueira[1], S. Ahola Kohut[1], J. Stinson[1], A. Gold[1], S. Urschel[2], S. Soto[2], M. Seifert-Hansen[1], M. McCoy[2], S. Boucher[1], S. J. Anthony[1]. *[1]The Hospital for Sick Children, Toronto, ON, Canada, [2]Stollery Children's Hospital, Edmonton, AB, Canada*

4:30 p.m. **(160)** ***Pediatric Psychosocial Assessment Tool: An Initial Risk Assessment Tool for Pediatric Heart Transplant Candidates***; L. McLendon[1], E. M. Kaufmann[1], M. Killian[2], S. R. Beckwith[1], J. Coppola[1], E. Martin[3], J. Rackley[4], L. A. Coleman[1], H. H. Blanchette[1], R. Shih[5], B. Pietra[6], F. Fricker[7], D. Gupta[8]. *[1]University of Florida, Gainesville, FL, [2]Florida State University, Tallahassee, FL, [3]UF Health, Gainesville, FL, [4]UF Hlth/Shands TX Ctr, Gainesville, FL, [5]UF Health Congenital Heart Center, Gainesville, FL, [6]U FL Congenital Hrt Ctr, Gainesville, FL, [7]Congenital Hrt Ctr @ UF Hlth, Gainesville, FL, [8]UF Congenital Heart Center, UF College of Medicine, Gainesville, FL*

3:45 – 4:45 p.m.

SESSION 83: WHAT'S DRUGS GOT TO DO WITH IT: MEDICATION HIGHLIGHTS IN HEART TRANSPLANTATION

Location: Rooms 405-407

Core Therapies: HEART
Practice Areas: Pharmacy and Pharmacology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Research and Immunology

Session Summary: This session will highlight research describing various medications in the management of heart transplant recipients.

Co-Chairs: Jennifer Day, PharmD, Little Rock, AR USA
Eric Epailly, MD, University Hospital Strasbourg France, Strasbourg, France

3:45 p.m. **(161)** ***Risk of Acute Rejection in Heart Transplant Patients Treated with M-TOR Inhibitors***; T. Alexy[1], S. Patel[2], Y. Rochlani[3], O. Saeed[4], C. Gjelaj[5], S. Madan[6], J. Shin[7], V. Maharaj[8], D. Goldstein[9], U. Jorde[7], S. Vukelic[10]. *[1]University of Minnesota, North Oaks, MN, [2]Montefiore-Einstein, Bronx, NY, [3]Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, [4]Montefiore Medical Ctr, New York, NY, [5]Montefiore Medical Center, Yorktown Heights, NY, [6]Montefiore Medical Center, New York, NY, [7]Montefiore Medical Center, Bronx, NY, [8]University of Minnesota, Edina, MN, [9]Montefiore, Bronx, NY, [10]Cardiology, Albert Einstein College of Medicine, Montefiore MC, Bronx, NY*

4:00 p.m. **(162)** ***A Multicenter Randomized Placebo-Controlled Trial of Intravenous Thyroxine for Heart-Eligible Brain-Dead Organ Donors***; R. Dhar[1], D. Lebovitz[2], A. Lele[3], P. Lange[4], C. Kensinger[5], W. D. Klinkenberg[6], G. Marklin[6]. *[1]Washington University School of Medicine, Saint Louis, MO, [2]Lifebanc, Cleveland, OH, [3]LifeCenter Northwest, Bellevue, WA, [4]Donor Alliance, Denver, CO, [5]Lifelink of Georgia, Augusta, GA, [6]Mid-America Transplant, St. Louis, MO*

4:15 p.m. **(163)** ***Efficacy and Tolerability of Belatacept in Heart Transplant Recipients***; A. Loethen[1], R. Lavelle[2], N. Sarswat[3], B. Chung[4], B. Smith[5], S. Kalantari[6], J. Grinstein[7], A. Nguyen[8], M. Belkin[9], C. Murks[9], T. Riley[10], J. Powers[8], A. Jones[11], G. Kim[9], S. Pinney[9]. *[1]Pharmacy, University of Chicago Medicine, Chicago, IL, [23]Univ of Chicago Hospital, Glencoe, IL, [4]Univ of Chicago, Chicago, IL, [5]University of Chicago Medical Center, Chicago, IL, [6]University of Chicago University of Chicago, Chicago, IL, [7]MedStar Heart and Vascular Institute, Chicago, IL, [8]University of Chicago Medicine, Chicago, IL, [9]University of Chicago, Chicago, IL, [10]University of Chicago Medical Center, Matteson, IL, [11]Univ of Chicago Med, Willow Springs, IL*

4:30 p.m. **(164)** ***Real-World Eligibility and Cost-Effectiveness Analysis for Empagliflozin in Patients with Heart Failure***; E. Kim[1], K. Kim[2], S. Park[3], J. Youn[4]. *[1]Korea Advanced Institute of Science and Technology, Daejeon, South Korea, [2]Seoul St. Mary's Hospital, Seoul, South Korea, [3]The Catholic University of Korea, Bucheon, South Korea, [4]Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea*

3:45 – 4:45 p.m.

SESSION 84: ONE FOR THE MONEY: WHO GROUP 1/PULMONARY ARTERIAL HYPERTENSION

Location: Rooms 201-203

Core Therapies: PVD
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: This session will highlight research abstracts for Group 1 Pulmonary Arterial Hypertension (PAH).

Co-Chairs: Sophia Airhart, MD, Saint Alphonsus Medical Center, Boise, ID USA
Helen Whitford, MBBS, FRACP, The Alfred Hospital, Melbourne, VIC Australia

3:45 p.m. **(165)** ***Effective Transition from Continuous Parenteral Treprostinil to Oral Prostacyclin Pathway-Based Therapies in Pulmonary Arterial Hypertension***; A. Guglielmi, N. Hristakos, C. Ndiaye, V. LaRoy, N. Victor, P. Shah, S. Pauwaa, M. Sunbuli, G. Macaluso, M. Dia. *Advocate Christ Medical Center, Oak Lawn, IL*

4:00 p.m. **(166)** ***Treatment Patterns in Congenital Heart Disease Associated Pulmonary Arterial Hypertension: Results from a Real-World PAH-CHD Study in the United States***; J. D. Awerbach[1], C. Paoli[2], M. Scott[3], G. Doad[4], J. Harley[3], D. Graham[3], M. Small[3], S. Panjabi[2], L. Reardon[5]. *[1]Center for Heart Care, Phoenix Children's, Phoenix, AZ, [2]Janssen Scientific Affairs, Titusville, FL, [3]Adelphi Real World, Bolington, United Kingdom, [4]Actelion, Philadelphia, PA, [5]UCLA, Los Angeles, CA*

4:15 p.m. **(167)** ***Pulmonary Vascular Dysfunction in Systemic Sclerosis***; M. J. Andersen[1], T. Clemmensen[2], S. Mellemkjaer[2]. *[1]Cardiology, Aarhus University, Aarhus N, Denmark, [2]Aarhus University Hospital, Aarhus N, 82, Denmark*

4:30 p.m. **(168)** ***Nitric Oxide Administered in Oxygenator During Ecmo Improves Ventricular-Arterial Coupling and Decreases Inflammation and Oxidative Stress in an Experimental Model of Pulmonary Arterial Hypertension***; S. Dolci, S. Martinazzi, D. Linardi, R. Mani, V. Di Nicola, S. Di Sarcina, I. Decimo, G. Luciani, A. Rungatscher. *University of Verona, Verona, Italy*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

MINI ORAL 13: ANALYZING THE PRESENT AND IMPROVING THE FUTURE IN HEART TRANSPLANTATION

Location: Rooms 603-605

Core Therapies: HEART
Practice Areas: Cardiology, Cardiothoracic Surgery, Pathology, Pediatrics, Research and Immunology

Session Summary: This rapid fire session combines abstracts focused on the impact of certain scenarios on the waiting list and abstracts focused on heart failure, cardiomyopathies and congenital heart disease.

Co-Chairs: Martin Goddard, FRCS, FRCPath, Papworth Hospital, Cambridge, United Kingdom
Scott Silvestry, MD, AdventHealth Transplant Institute, Orlando, FL USA

5:00 p.m. **(361)** ***New System, Familiar Problem: Increased Wait Time for High Priority Heart Transplant Candidates***; E. S. Harris, L. Sewanan, V. Topkara, J. Fried, J. Raikhelkar, P. Colombo, M. Yuzefpolskaya, E. DeFilippis, F. Latif, K. Takeda, M. Hassanein, S. Singh, G. Sayer, N. Uriel, K. Clerkin. *Columbia Univ Irving MC, New York, NY*

5:06 p.m. **(362)** ***The Impact of Donation after Circulatory Death Heart Transplants on Waitlist Time: A UNOS Analysis***; K. Patel[1], D. T. Nguyen[2], E. A. Graviss[2], A. Bhimaraj[1], M. Kassi[1], J. H. Kim[1], A. Guha[1]. *[1]Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, [2]Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX*

5:12 p.m. **(363)** ***Proceeding with Heart Transplant in Flow Positive Cyto-Negative Prospective Donor-Specific Crossmatch in Highly Sensitized Patients: Saving Lives***; L. Stern, J. Patel, M. Kittleson, D. Chang, N. Patel, T. Singer-Englar, A. Velleca, K. Norland, M. Hamilton, L. Czer, F. Esmailian, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

5:18 p.m. **(364)** ***Pre-Transplant Waitlist Mortality Not Associated with Severity of Shock Hemodynamics***; M. Anderson[1], M. Chavez[2], J. Dickey[2], C. Selzman[2], J. Fang[3], S. Drakos[2], J. Stehlik[2], T. Hanff[2]. *[1]Cardiovascular Disease, University of Utah, Salt Lake City, UT, [2]University of Utah, Salt Lake City, UT, [3]Univ of Utah Health Sciences Center, Salt Lake City, UT*

5:24 p.m. **(365)** ***Diminishing Effect of Blood Type on Waitlist and Heart Transplantation Outcomes in the Contemporary UNOS Allocation System***; D. Chauhan[1], S. Patel[2], S. Cohen[3], S. Madan[2], D. Goldstein[2], U. Jorde[2], Y. Rochlani[2], S. Vukelic[2], J. Shin[2], S. Murthy[4], D. Sims[2], S. Forest[2], O. Saeed[2]. *[1]Children's Mercy Hospital, Kansas City, MO, [2]Montefiore Medical Center, Bronx, NY, [3]Mount Sinai Hospital, Jamaica, NY, [4]Montefiore Medical Center, Bronx, NY*

5:30 p.m. **(366)** ***Right Atrial Pressure and Rv-Pa Uncoupling May Improve Risk Stratification of Patients with Advanced Hf and Secondary Mitral Regurgitation***; L. Ong[1], M. Burrage[2], W. Watson[3], M. Garbi[2], S. Pettit[2], S. Bhagra[4]. *[1]Ruislip, United Kingdom, [2]Royal Papworth Hospital, Cambridge, United Kingdom, [3]Department of Transplantation, Royal Papworth Hospital, Cambridge, United Kingdom, [4]Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom*

5:36 p.m. **(367)** ***Initial Experience with a Decision Tree to Assess the Need for Concurrent Liver Transplantat in Fontan Patients Undergoing Heart Transplant***; H. Ahmed[1], M. Files[2], K. Saarela[3], B. Morray[2], G. Shivaram[2], C. Greene[2], C. Choi[2], D. Mauchley[2], D. McMullan[2], L. Bohuta[2], B. Hong[2], E. Albers[4], M. Kemna[5], A. Rubio[2], Y. Law[6], R. C. Reed[7], J. Friedland-Little[2], M. Pacheco[2], E. K. Hsu[2]. *[1]Seattle Children's Hospital, Seattle, WA, [2]Seattle Children's Hospital, Seattle, WA, [3]Hepatology, Seattle Children's Hospital, Seattle, WA, [4]Seattle Children's Hospital, Seattle, [5]Seattle Children's Hospital, River Ridge, LA, [6]Seattle Children 's Hospital, Seattle, WA, [7]Pathology, Seattle Children's Hospital, Seattle, WA*

5:42 p.m. **(368)** ***Predictive Validity of the Kansas City Cardiomyopathy Questionnaire in Adults with Congenital Heart Disease***; R. D. Byrne, S. J. Dolgner, A. Nair, C. Broda. *Baylor College of Medicine, Houston, TX*

5:48 p.m. **(369)** ***Acellular Human Amniotic Fluid Prevents the Development of Ischemic Heart Failure***; H. Javan, G. Mitchell, J. Pierce, C. Selzman. *University of Utah, Salt Lake City, UT*

5:54 p.m. **(370)** ***Genetic Signature of Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study***; M. Hofmeyer[1], G. Haas[2], E. Kransdorf[3], G. Ewald[4], A. Morris[5], A. Owens[6], B. Lowes[7], D. Stoller[7], W. Tang[8], S. Garg[9], B. Trachtenberg[10], P. Shah[11], S. Pamboukian[12], N. Sweitzer[4], M. Wheeler[13], J. Wilcox[14], S. Katz[15], S. Pan[16], J. Jimenez[17], F. Smart[18], J. Wang[19], S. Gottlieb[20], D. Judge[21], C. Moore[22], G. Huggins[23], E. Jordan[2], D. Kinnamon[2], H. Ni[2], R. E. Hershberger[2]. *[1]Medstar/Washington Hospital Center, Washington, DC, [2]The Ohio State University, Columbus, OH, [3]Cedars-Sinai Medical Center, Los Angeles, CA, [4]Washington University, St. Louis, MO, [5]Emory University, Atlanta, GA, [6]University of Pennsylvania, Philadelphia, PA, [7]University of Nebraska Medical Center, Omaha, NE, [8]Cleveland Clinic, Cleveland, OH, [9]University of Texas Southwestern, Dallas, TX, [10]Methodist Hospital, Houston, TX, [11]Inova Heart & Vascular Institute, Falls Church, VA, [12]University of Washington, Seattle, WA, [13]Stanford University, Palo Alto, CA, [14]Northwestern University, Evanston, IL, [15]Langone Medical Center, New York, NY, [16]Westchester Medical Center, New York Medical College, Valhalla, NY, [17]South Miami Hospital, Miami, FL, [18]Louisiana State University, New Orleans, LA, [19]University of California, Los Angeles, Los Angeles, CA, [20]University of Maryland, Baltimore, MD, [21]Medical University of South Carolina, Charleston, SC, [22]University of Mississippi, Jackson, MS, [23]Tufts University, Boston, MA*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

MINI ORAL 14: THE PHANTOM MENACE: BASIC SCIENCE MECHANISMS OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD)

Location: Rooms 401-404

Core Therapies: LUNG
Practice Areas: Research and Immunology, Cardiothoracic Surgery, Pathology, Pulmonology

Session Summary: This rapid fire session will explore new discoveries in the molecular pathogenesis of chronic lung allograft dysfunction.

Co-Chairs: Stephen Juvet, MD, PhD, University Health Network, Toronto, ON Canada
Ciara Shaver, MD, PhD, Vanderbilt University Medical Center, Nashville, TN USA

5:00 p.m. **(371)** ***An Ex Vivo Model of Acute Rejection Using Precision Cut Lung Slices***; A. Niroomand[1], G. Hirdman[1], M. Mittendorfer[1], D. Bolukbas[2], F. Olm[1], S. Lindstedt[3]. *[1]Lund University, Lund, Sweden, [2]Astra Zeneca, Gothenburg, Sweden, [3]Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden*

5:06 p.m. **(373)** ***Proteomic Analysis of Eosinophilia in Transbronchial Biopsies Identifies Distinct Inflammatory Pathways***; T. M. Cree[1], A. Ravipati[2], A. M. Philp[3], C. Thomson[1], M. Raftery[2], M. Plit[1], S. T. Grey[4], D. Darley[1]. *[1]St Vincent's Hospital, Darlinghurst, Australia, [2]Bioanalytical Mass Spectrometry Facility, UNSW, Darlinghurst, Australia, [3]St Vincent's Clinical School, UNSW Medicine, Darlinghurst, Australia, [4]Transplantation Immunology, Garvan Institute of Medical Research, Darlinghurst, Australia*

5:12 p.m. **(374)** ***Bronchoalveolar Lavage Cytokine Profile at Two Weeks Post-Transplant is Associated with Chronic Lung Allograft Dysfunction***; E. Reilly[1], L. Sullivan[2], G. Snell[1], L. Holsworth[1], B. Levvey[1], G. Westall[1], S. Stankovic[1]. *[1]Alfred Hospital, Melbourne, Australia, [2]South Australian Transplantation and Immunogenetics Service, Australian Red Cross Lifeblood, Women's and Children's Hospital, Adelaide, Australia*

5:18 p.m. **(375)** ***Endothelial Derived IL-33 Induces Fibrogenesis and is Associated with CLAD***; M. Banday[1], M. Qureshi[2], K. Patel[3], N. Movval[2], N. Sharma[2]. *[1]Brigham and Women's Hospital, Boston, MA, [2]University of South Florida / Tampa General Hospital, Wesley Chapel, FL, [3]USF Morsani College of Medicine, Tampa, FL*

5:24 p.m. **(376)** ***AAV9 PD-L1 Mediated Immunodulation of Donor Graft in Rat Lung Allotransplantation***; R. Kahan[1], Q. Gao[1], M. Zhang[1], N. Abraham[1], T. Gonzalez[2], M. Song[1], J. Carney[3], I. Alderete[1], A. Asokan[2], A. Barbas[1], M. Hartwig[4]. *[1]Department of Surgery, Duke University, Durham, NC, [2]Department of Molecular Genetics & Microbiology, Duke University, Durham, NC, [3]Department of Pathology, Duke University, Durham, NC, [4]Division of Cardiovascular and Thoracic Surgery, Duke University, Durham, NC*

5:30 p.m. **(377)** ***Airway Adiporon Reduces Edema in a Rat Model of Prolonged Cold Ischemia and Normothermic Ex Situ Lung Perfusion***; S. Himmat[1], I. J. Ma[1], X. Wang[1], K. Forgie[2], S. Hatami[1], G. Mainardi Aguiar da Silva[1], J. P. Acker[3], J. R. Dyck[4], D. Freed[5], J. Nagendran[2]. *[1]Surgery, University of Alberta, Edmonton, AB, Canada, [2]Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada, [3]Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada, [4]Pediatrics, University of Alberta, Edmonton, AB, Canada, [5]Stollery Children's Hospital, Edmonton, AB, Canada*

5:36 p.m. **(378)** ***Donorexosomebiomarkers for Primary Graft Dysfunction in Transplants Using Ex-Vivo Lung Perfusion***; R. Kanchi[1], L. Chacon[2], E. D'Silva[1], M. Salan-Gomez[1], A. Leon-Pena[1], M. Castillo[3], P. Gunaratne[3], C. Hochman Mendez[2], C. Coarfa[1], G. Loor[1]. *[1]Baylor College of Medicine, Houston, TX, [2]Texas Heart Institute, Houston, TX, [3]University of Houston, Houston, TX*

5:42 p.m. **(379)** ***Aspiration of Lipopolysaccharide is Associated with Markers of Type 1 and Type 3 Immunity as Well as Epithelial-Mesenchymal Transition in Lung Transplant Recipients***; R. Ramendra[1], K. Zhang[2], S. Moshkelgosha[3], A. Sage[4], J. Yeung[2], S. Keshavjee[5], S. Juvet[6], T. Martinu[7]. *[1]Ajmera Transplant, University Health Network, Toronto, ON, Canada, [2]University of Toronto, Toronto, ON, Canada, [3]Toronto, ON, Canada, [4]Toronto General Hospital, Toronto, ON, Canada, [5]UHN, Toronto, ON, Canada, [6]University Health Network, Toronto, ON, Canada, [7]Toronto General Hospital/UHN, Toronto, ON, Canada*

5:48 p.m. **(380)** ***Club Cell Secretory Protein (CCSP) Treatment in a Mouse Model of Chronic Lung Allograft Dysfunction (CLAD)***; W. Zhong[1], J. Oliver[2], O. Mekhael[1], Z. Carter[1], S. Keshavjee[3], A. L. Pilon[4], A. Gelman[5], S. Juvet[1], T. Martinu[6]. *[1]University Health Network, Toronto, ON, Canada, [2]Toronto General Hospital Research Institute, Toronto, ON, Canada, [3]UHN, Toronto, ON, Canada, [4]APCBio Innovations, Rockville, MD, [5]Washington University School of Medicine, Saint Louis, MO, [6]Toronto General Hospital/UHN, Toronto, ON, Canada*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

MINI ORAL 15: THE FULL SPECTRUM OF INNOVATION IN MCS

Location: Rooms 501-504

Core Therapies: MCS
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pediatrics, Pulmonology, Research and Immunology

Session Summary: This rapid fire session will highlight innovative new devices, technology, techniques, and practices in adult and pediatric MCS.

Co-Chairs: Kathleen Simpson, MD, University of Colorado Denver, Denver, CO USA
Alexander Bernhardt, MD, University Heart and Vascular Center Hamburg, Hamburg, Germany

5:00 p.m. **(381)** ***Left Ventricular Contractile Reserve is Associated with Optimal Exercise Hemodynamics in Cf-lvad Patients: A Pressure-Volume Loop Analysis***; R. C. Campos Deveza e Silva[1], P. Jain[2], A. Adji[2], S. Shehab[2], K. Muthiah[2], D. Robson[2], F. Koppe[2], M. Granegger[3], P. Jansz[2], P. MacDonald[2], C. Hayward[2]. *[1]Cardiology, St Vincent's Hospital, Darlinghurst, Australia, [2]St Vincent's Hospital, Darlinghurst, Australia, [3]Medical University of Vienna, Vienna, Austria*

5:06 p.m. **(382)** ***Pre-Clinical Development & Testing of the CorWave Membrane LVAD***; W. K. Cornwell[1], C. Hayward[2], P. Jansz[3], M. Strueber[4], D. Zimpfer[5], J. Cowger[6], M. Kanwar[7], A. El Banayosy[8], P. Leprince[9], F. Gustafsson[10], S. Tsui[11], Y. Pya[12], T. A. Snyder[13]. *[1]University of Colorado, Parker, CO, [2]St. Vincent's Hospital, Longueville, Australia, [3]St Vincent's Hospital, Darlinghurst, Australia, [4]Baptist Medical Group, Ada, MI, [5]Medical University Vienna, Vienna, Austria, [6]Henry Ford Hospitals, Detroit, MI, [7]Allegheny General Hospital, Pittsburgh, PA, [8]Nazih Zuhdi Transplant Institute, Edmond, OK, [9]Hopital de La Pitie Salpetriere, Sorbonne University, Paris, 75, France, [10]Rigshospitalet, Copenhagen, Denmark, [11]Royal Papworth Hospital, Cambridge, United Kingdom, [12]National Res Center for Cardiac Surgery, Astana, Kazakhstan, [13]CorWave, Clichy, France*

5:12 p.m. **(383)** ***Five-Day Respiratory Support with Novel Ambulatory Pulmonary Assist System in an Awake Ovine Model***; Y. Hong[1], S. Shin[1], U. Nasim[1], K. G. Roberts[1], A. S. Potchernikov[1], B. E. Woolley[1], D. J. Skoog[2], M. D. Bacchetta[3], K. E. Cook[1]. *[1]Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, [2]Advanced Respiratory Technologies, Pittsburgh, PA, [3]Vanderbilt University Medical Center, Nashville, TN*

5:18 p.m. **(384)** ***Urine Exosomes for Kidney Health Assessment in Mechanical Circulatory Support***; N. K. Mondal[1], S. Li[1], K. V. Nordick[1], C. P. Walther[2], I. Murrieta-Alvarez[1], Z. Gray[1], C. Hochman-Mendez[3], A. E. Shafii[1], K. K. Liao[1]. *[1]Department of Surgery, Baylor College of Medicine, Houston, TX, [2]Department of Medicine, Baylor College of Medicine, Houston, TX, [3]Regenerative Medicine Research, Texas Heart Institute, Houston, TX*

5:24 p.m. **(385)** ***Association of Sarcopenia and Gut Microbiome in HF, LVAD and Heart Transplant***; M. Yuzefpolskaya[1], B. Bohn[2], A. Ladanyi[1], G. M. Mondellini[1], A. Pinsino[1], K. Antler[3], K. Clerkin[1], F. Latif[3], P. A. Kurlansky[1], G. T. Sayer[1], N. Uriel[4], K. Takeda[1], A. Uhlemann[1], P. C. Colombo[1], R. T. Demmer[2]. *[1]Columbia University Irving Medical Center, New York, NY, [2]University of Minnesota, Minneapolis, MN, [3]New York Presbyterian Hospital, New York, NY, [4]New York Presbyterian, New York, NY*

5:30 p.m. **(386)** ***A Novel Wireless Power Transmission System for Left Ventricular Assist Devices***; D. McEneaney[1], O. Escalona[2], A. Bosnjak[2], M. Karim[2], P. Crawford[3], J. McLaughlin[4]. *[1]Cardiovascular Research Unit, Craigavon Area Hospital, Portadown, United Kingdom, [2]Nanotechnology and Integrated Bioengineering Centre (NIBEC), Ulster University, Belfast, United Kingdom, [3]PC Veterinary Services, Larne, United Kingdom, [4]School of Engineering, Ulster University, Belfast, United Kingdom*

5:36 p.m. **(387)** ***Incidence, Predictors and Outcome of Vasoplegia after Left Ventricular Assist Device Implantation***; Z. Haidari[1], M. Thielmann[1], P. Lüdike[2], M. El Gabry[1], N. Pizanis[1], M. Biewer[1], M. Kamler[1], T. Rassaf[2], A. Ruhparwar[1], B. Schmack[1]. *[1]Thoracic and Cardiovascular Surgery, University Hospital Essen, Essen, Germany, [2]Cardiology, University Hospital Essen, Essen, Germany*

5:42 p.m. **(388)** ***Early in vivo Acute Experience with Pediatric Continuous-Flow Total Artificial Heart with Rotor Axial Position Tracking***; C. Miyagi, T. Kuroda, B. D. Kuban, C. R. Flick, A. R. Polakowski, J. H. Karimov, K. Fukamachi. *Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland, OH*

5:48 p.m. **(389)** ***Impact of Heartware Vad Discontinuation on the Pediatric Population-An Advanced Heart Failure Improving Outcomes (ACTION) Registry Analysis***; R. Niebler[1], A. Lorts[2], M. O'Connor[3], M. Shezad[4], D. Rosenthal[5]. *[1]Pediatrics, Medical College of Wisconsin, Milwaukee, WI, [2]Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [3]Children's Hospital of Philadelphia, Wynnewood, PA, [4]Cincinnati Children's Hospital, Cincinnati, OH, [5]Stanford, Portland, OR*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

MINI ORAL 16: THE WINTER'S TALE: HYPOTHERMIC MACHINE PRESERVATION OF DONOR HEARTS

Location: Rooms 205-207

Core Therapies: HEART
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Pediatrics, Research and Immunology

Session Summary: Is ex vivo hypothermic machine perfusion of donor hearts going to transform organ retrieval? What is the science behind these cold boxes with engines to rival a formula one car? From metabolic analysis to renal outcomes and graft function, this rapid fire session will chill you to the bone. That's the key, right?

Co-Chairs: Roxana Moayedifar, MD, Medical University of Vienna, Vienna, Austria
Jennifer Conway, MD, Stollery Children's Hospital, Edmonton, AB Canada

5:00 p.m. **(391)** ***Leveraging Advanced Hypothermic Preservation to Achieve Transplant Program Goals***; J. Schroder[1], M. Leacche[2], C. Sciortino[3], Y. Shudo[4], M. Rodrigo[5], D. Meyer[6], M. Kawabori[7], D. D'Alessandro[8]. *[1]Duke University Medical Center, Durham, NC, [2]Corewell Health, Grand Rapids, MI, [3]Sentara, Norfolk, VA, [4]Stanford University, Menlo Park, CA, [5]Medstar Washington Hospital Center, Potomac, MD, [6]Baylor Scott and White Health, Health Texas Provider Network, Cardiac and Thoracic Surgery at Baylor, Dallas, TX, [7]Tufts Medical Center, Brookline, MA, [8]MGH, Weston, MA*

5:06 p.m. **(392)** ***Metabolic Analysis of Human Hearts Preserved with a Novel Hypothermic Perfusion System***; G. Sharma[1], R. Vela[1], L. Powell[1], C. R. Malloy[2], M. E. Jessen[1], M. Peltz[1]. *[1]Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX, [2]Internal Medicine, Division of Cardiology and Radiology, UT Southwestern Medical Center, Dallas, TX*

5:12 p.m. **(393)** ***Prediction of Graft Function from Hypothermic Machine Perfusion Parameters in Heart Transplantation from Donation after Circulatory Death***; N. Moeslund[1], I. A. Ertugrul[2], F. F. Dalsgaard[3], M. A. Hu[2], P. K. Ryhammer[4], L. Ilkjaer[5], M. Pedersen[3], M. Erasmus[2], H. Eiskjaer[6]. *[1]Cardiology Research, Depertment of Clinical Medicine, Aarhus University, Aarhus N, Denmark, [2]Cardiothoracic surgery, University Medical Center Groningen, Groningen, Netherlands, [3]Comparative Medicine Lab, Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark, [4]Anesthesiology, Region Hospital Silkeborg, Silkeborg, Denmark, [5]Cardiothoracic surgery, Aarhus University Hospital, Aarhus, Denmark, [6]Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark*

5:18 p.m. **(394)** ***Evaluating Heart Transplant Outcomes Utilizing the Sherpapak Heart Storage System***; S. Finkbiner, J. Mancuso, T. Dalia, J. Baer, H. Farhoud, M. Danter, T. Zorn, J. Hu, J. Baker, H. Shah, Z. Shah, P. Downey, A. Vidic. *University of Kansas Medical Center, Kansas City, KS*

5:24 p.m. **(395)** ***Role of Sherpapak in Donors with Drug Overdose and Long Ischemic Times***; J. Mancuso[1], T. Dalia[1], A. Malhotra[1], J. Baer[1], T. Zorn[1], P. Downey[1], D. D'Alessandro[2], D. Meyer[3], H. Farhoud[4], K. Munshi[1], Z. Shah[1], M. Danter[1], S. Silvestry[5], A. Vidic[1]. *[1]University of Kansas Medical Center, Kansas City, KS, [2]Massachusetts General Hospital, Boston, MA, [3]Baylor University Medical Center, Dallas, TX, [4]University of Kansas Medical Center, Wichita, KS, [5]AdventHealth Transplant Institute, Orlando, FL*

5:30 p.m. **(396)** ***Sherpapak Reduces Mcs Use Post Heart Transplant in Long Donor Down and Ischemic Times***; J. Baer[1], A. Malhotra[1], T. Dalia[1], J. Mancuso[1], T. Zorn[1], P. Downey[1], D. D'Alessandro[2], D. Meyer[3], S. Greer[1], H. Shah[1], Z. Shah[1], M. Danter[1], S. Silvestry[4], A. Vidic[1]. *[1]University of Kansas Medical Center, Kansas City, KS, [2]Massachusetts General Hospital, Boston, MA, [3]Baylor Scott and White Health, Dallas, TX, [4]AdventHealth Transplant Institute, Orlando, FL*

5:36 p.m. **(397)** ***Use of the SherpaPak Cardiac Transport System for Infant and Pediatric Donor Hearts: An Initial Experience***; E. L. Profita[1], E. Lee[2], M. Ma[1], E. Martin[1], S. Hollander[1], D. Rosenthal[1], C. Almond[1], T. Nasirov[1]. *[1]Stanford University, Palo Alto, CA, [2]Lucile Packard Children's Hospital Stanford, Palo Alto, CA*

5:42 p.m. **(398)** ***Favorable Impact of Hypothermic Machine Perfusion (HMP) on Early Renal Outcomes in Patients Undergoing Heart Transplantation Using Prolonged (6-8 Hour) Donor Hearts***; D. Kaye[1], J. Fraser[2], P. Jansz[3], P. MacDonald[4], S. Marasco[5], A. Doi[6], C. Merry[1], S. Emmanuel[7], R. Larbalestier[8], A. Shah[8], A. Geldenhuys[8], A. Sibal[9], C. Wasywich[10], C. Kure[1], D. McGiffin[11]. *[1]Alfred Hospital, Melbourne, Australia, [2]The Prince Charles Hospital, Chermside, Australia, [3]St Vincent's Hospital, Darlinghurst, Australia, [4]St. Vincent 's Hospital, Darlinghurst, Australia, [5]Alfred Health, South Yarra, Australia, [6]Melbourne, Australia, [7]St Vincent's Hospital Sydney, Surry Hills, Australia, [8]Fiona Stanley Hospital, Perth, Australia, [9]Green Lane Cardiothoracic Surgical Unit, Auckland City Hospital, NZ, Auckland, New Zealand, [10]Auckland City Hospital, Auckland, New Zealand, [11]Alfred Health, Melbourne, Australia*

5:48 p.m. **(399)** ***Novel Portable Hypothermic Perfusion Preservation Device Enhances Cardiac Output of Donated Human Hearts***; K. Andrijauskaite[1], R. J. Veraza[1], R. P. Lopez[1], Z. Maxwell[1], I. Cano[1], M. D. Watt[1], E. C. Cisneros[1], I. J. Jessop[1], J. Nespral[2], L. Bunegin[1]. *[1]Vascular Perfusion Solutions, Inc., San Antonio, TX, [2]Texas Organ Sharing Alliance, San Antonio, TX*

5:54 p.m. **(400)** ***Can Controlled Hypothermic Preservation Provide Clinical Benefits in the Setting of Shorter Ischemic Times Prior to Heart Transplant***; D. Meyer[1], Y. Shudo[2], J. Schroder[3], D. D'Alessandro[4], S. Silvestry[5], C. Sciortino[6], S. M. Pham[7], M. Rodrigo[8], J. P. Jacobs[9], M. Kawabori[10], K. Takeda[11], M. Leacche[12]. *[1]Baylor Scott and White Health, Health Texas Provider Network, Cardiac and Thoracic Surgery at Baylor, Dallas, TX, [2]Stanford University, Menlo Park, CA, [3]Duke University Medical Center, Durham, NC, [4]MGH, Weston, MA, [5]AdventHealth Transplant Institute, Orlando, FL, [6]Sentara, Norfolk, VA, [7]Mayo, Jacksonville, FL, [8]Medstar Washington Hospital Center, Potomac, MD, [9]University of Florida, Gainesville, FL, [10]Tufts Medical Center, Brookline, MA, [11]Columbia university, New York, NY, [12]Corewell Health, Grand Rapids, MI*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

MINI ORAL 17: THE CLONE WARS: OR AND PERI-OPERATIVE IMPROVEMENTS IN LUNG TRANSPLANTATION

Location: Rooms 405-407

Core Therapies: LUNG
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Pediatrics, Pulmonology, Research and Immunology

Session Summary: This rapid fire session examines diverse peri-operative approaches to improve lung transplantation outcomes, as well as pre-transplant predictors of peri-operative transplant outcomes.

Co-Chairs: Pedro Undurraga, MD, Clinica Las Condes, Providencia, Chile
Barbara Wilkey, BSN, MPAS, MD, University of Colorado, Denver, CO USA

5:00 p.m. **(401)** ***Outcomes of ECMO as Bridge to Lung Transplant in Children with Pulmonary Hypertension***; A. M. Guzman-Gomez[1], H. F. Ahmed[1], D. Lehenbauer[1], D. Morales[1], P. Critser[2], R. Hirsch[2], F. Zafar[1], D. Hayes[3]. *[1]Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, [2]Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [3]Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*

5:06 p.m. **(402)** ***12-Year Experience with Postoperatively Extended Intraoperative Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Severe Pulmonary Arterial Hypertension***; M. Franz[1], K. Aburahma[1], M. Avsar[1], D. Bobylev[1], W. Sommer[2], M. Greer[3], I. Tudorache[4], T. Welte[3], A. Haverich[1], G. Warnecke[2], C. Kuehn[1], F. Ius[1], J. Salman[1]. *[1]Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, [2]Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany, [3]Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, [4]University Hospital Duesseldorf, Duesseldorf, Germany*

5:12 p.m. **(403)** ***Pre-Transplantation Recipient Blood Transfusions Increase the Risk of Primary Graft Dysfunction Following Lung Transplantation***; Y. Yagi[1], E. Cerier[2], T. Toyoda[3], A. Manerikar[1], B. Thomae[1], V. Kandula[1], A. Bharat[3], C. Kurihara[4]. *[1]Northwestern University Feinberg School of Medicine, Chicago, IL, [2]Northwestern Memorial Hospital, Chicago, IL, [3]Northwestern University, Chicago, IL, [4]Northwestern Univ, Chicago, IL*

5:18 p.m. **(404)** ***Impact of Intraoperative Therapeutic Plasma Exchange on Bleeding in Lung Transplantation***; S. Saddoughi[1], T. Martinu[2], L. Singer[3], X. Ge[4], R. Ghany[4], E. Huszti[3], C. Patriquin[4], D. Barth[4], K. McRae[5], S. Keshavjee[6], M. Cypel[3], M. Aversa[4]. *[1]Mayo Clinic, Rochester, MN, [2]Toronto General Hospital/UHN, Toronto, ON, Canada, [3]University Health Network, Toronto, ON, Canada, [4]University of Toronto, Toronto, ON, Canada, [5]Toronto Gen Hospital, Toronto, ON, Canada, [6]UHN, Toronto, ON, Canada*

5:24 p.m. **(405)** ***Predictors and Outcomes of Post-Operative Extracorporeal Membrane Oxygenation at 72 Hours Following Lung Transplantation***; S. T. Kim[1], Y. Xia[1], J. K. Ho[2], D. Sayah[1], A. Ardehali[1]. *[1]University of California, Los Angeles, Los Angeles, CA, [2]University of California Los Angeles, Los Angeles, CA*

5:30 p.m. **(406)** ***Concomitant Heart and Lung Surgery During Lung Transplantation***; A. Firoz[1], A. Kashem[1], M. Brown[1], R. Yanagida[2], N. Shigemura[2], Y. Toyoda[2]. *[1]Lewis Katz School of Medicine, Philadelphia, PA, [2]Temple University Hospital, Philadelphia, PA*

5:36 p.m. **(407)** ***Combined Lung Transplantation and Coronary Artery Bypass Grafting: To Graft or Not to Graft?*** ; J. Padiyar[1], S. Tokman[1], D. Sindu[1], B. Buddhdev[1], A. Omar[1], K. Brady[2], K. Ashton[2], S. Hashimi[1], J. Huang[1], M. A. Smith[1], R. Walia[1], R. M. Bremner[1], L. Schaheen[1]. *[1]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, [2]St. Joseph's Hospital and Medical Center, Phoenix, AZ*

5:42 p.m. **(408)** ***Comparison of Multimodal Pain Control Following Bilateral Lung Transplantation***; J. A. Treffalls, V. K. Hart, C. McDonald, A. Warren, L. Hastings, N. Das, E. Sako. *University of Texas Health San Antonio, San Antonio, TX*

5:48 p.m. **(409)** ***Epidural Analgesia Reduces Total In-Hospital Opioid Use by 57% in the Paediatric Lung Transplant Population***; S. Azzopardi[1], R. Glick[1], S. Karna[2], A. Konstantatos[1], K. Mclaughlin[1]. *[1]Alfred Health, Melbourne, Australia, [2]Monash Health, Melbourne, Australia*

5:54 p.m. **(410)** ***Perioperative Desensitization Changes the Plasma Cytokine Milieu in Lung Transplant Patients with Preformed Donor Specific Antibodies***; E. Heise[1], E. Chichelnitskiy[1], M. Franz[2], K. Aburahma[1], P. Iablonski[1], D. Bobylev[1], A. Saipbaev[1], N. Schwerk[3], W. Sommer[4], M. Greer[1], M. Avsar[5], B. Wiegmann[1], A. Knöfel[1], J. Kühne[1], G. Warnecke[6], A. Haverich[1], C. Kühn[1], J. Salman[1], C. Falk[7], F. Ius[1]. *[1]Hannover Medical School, Hannover, Germany, [2]Hannover Medical School, Hannover, NI, Germany, [3]Hannover Med School, Hannover, Germany, [4]University of Heidelberg, Hannover, Germany, [5]Med Hochschule Hannover, Hannover, Germany, [6]University of Heidelberg, Heidelberg, BW, Germany, [7]Hannover Medical School, MHH, Hannover, Germany*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

MINI ORAL 18: THE COVID-19 BEAT: COVID-19 AND HEART TRANSPLANTATION

Location: Rooms 201-203

Core Therapies: HEART
Practice Areas: Infectious Diseases, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pediatrics, Pharmacy, Research and Immunology

Session Summary: Mini but mighty, this rapid fire session explores the continum of COVID-19's effects on heart transplantation.

Co-Chairs: Emily Eichenberger, MD, MHS, Emory University School of Medicine, Atlanta, GA USA
Spencer Liu, MD, Tufts Medical Center, Boston, MA USA

5:00 p.m. **(411)** ***Safety and Efficacy of Monoclonal Antibodies Against Sars-Cov-2 in a Heart Transplant Population***; H. Brink[1], D. Stoller[2], B. Lowes[3], S. Lundgren[2]. *[1]Nebraska Medical Center, Omaha, NE, [2]University of Nebraska Medical Center, Omaha, NE, [3]U. Nebraksa Med Ctr, Omaha, NE*

5:06 p.m. **(412)** ***Persistent Risk of Severe Covid-19 in Heart Transplant Recipients: A National Cohort Study***; C. Legeai[1], N. Abdoul[1], C. Jasseron[1], P. Battistella[2], K. Nubret[3], F. Kerbaul[1], R. Dorent[1]. *[1]Agence de la Biomédecine, Saint-Denis, France, [2]Hosp Arnaud De Villeneuve, Montpellier, France, [3]Hospital De Haut Leveque, Bordeaux, France*

5:12 p.m. **(413)** ***Triple Positive Effect? Impact of Vaccination, Early Remdesivir Treatment and Omicron Expansion on the Evolution of Covid-19 Infection in Heart Transplant Recipients***; J. López-Azor[1], I. Marco[1], M. Flores[2], P. Caravaca[3], J. De Juan[1], F. López-Medrano[4], J. Delgado Jimenez[1], M. Cosio[1]. *[1]Heart Failure and Heart Transplantation, Hospital Universitario 12 de Octubre. CIBER de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain, [2]Departamento de Cardiología, Hospital General Universitario de Toledo, Toledo, Spain, [3]Heart Failure and Heart Transplantation, Hospital Clinic, Barcelona, Spain, [4]Infectious Disease Unit, Hospital Universitario 12 de Octubre. Fundación de Investigación Biomédica 12 de Octubre, Departamento de Medicina, Facultad de Medicina, Universidad Complutense, Madrid, Spain*

5:18 p.m. **(414)** ***Low Incidence of Long COVID in Heart Transplant Recipients***; J. Feinman, A. Parikh, J. Behar, K. Ashley, M. Barghash, N. Moss, A. Lala-Trindade, A. Anyanwu, B. Natelson, D. Mancini. *Mount Sinai Hosp, New York, NY*

5:24 p.m. **(415)** ***Evaluating a Routine Immunity Score (RIS2020) to Predict Development of Severe Infection in Solid Organ Recipients***; M. Jimenez[1], E. Sarmiento[1], K. Limay[1], E. Zatarain[2], M. Salcedo[3], M. Rodriguez-Ferrero[4], P. Padilla[5], A. Cerron[5], J. Chaman[5], J. Carbone[1]. *[1]Clinical Immunology, Hosp Gen Univ Gregorio Marañon, Madrid, Spain, [2]Cardiology, Hosp Gen Univ Gregorio Marañon, Madrid, Spain, [3]Gastroenterology, Hosp Gen Univ Gregorio Marañon, Madrid, Spain, [4]Nephrology, Hosp Gen Univ Gregorio Marañon, Madrid, Spain, [5]Departamento de Trasplantes, Hospital Nivel IV Guillermo Almenara Irigoyen, Lima, Peru*

5:30 p.m. **(416)** ***Heart Transplantation with Covid 19 Positive Donor Hearts***; S. B. Wolfe[1], R. Singh[1], D. C. Paneitz[1], R. Asija[2], S. Rabi[3], E. Michel[3], D. D'Alessandro[4], A. Ganapathi[5], A. Osho[1]. *[1]Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, [2]Columbia University, New York, NY, [3]Massachusetts General Hospital, Boston, MA, [4]MGH, Weston, MA, [5]Ohio State University Wexner Medical Center, Columbus, OH*

5:36 p.m. **(417)** ***Subclinical Myocardial Leukocyte Infiltration after Covid-19-Vaccination in Heart-Transplant Recipients***; F. Voss[1], D. Oehler[1], D. Scheiber[1], H. Schultheiss[2], M. Kelm[1], A. Lichtenberg[3], U. Boeken[3], R. Westenfeld[1]. *[1]Department of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, [2]Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany, [3]Department of Cardiac Surgery, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany*

5:42 p.m. **(418)** ***Long-Term Impact of Covid-19 Infection Among Solid Organ Transplant Recipients***; M. MacKay[1], W. Khalife[2], R. Washerlesky[3], M. Clewis[3]. *[1]University of Texas Medical Branch, Galveston, TX, [2]University of Texas Medical Center, Friendswood, TX, [3]UTMB, Galveston, TX*

5:48 p.m. **(419)** ***Serological Evaluation for Sars-cov-2 in Pediatric Heart Transplant Recipients and Patients on Pediatric Heart Transplant Waiting List in a Quaternary Hospital***; C. A. Villari[1], A. Siqueira[2], C. Strunz[2], C. Moscan[2], M. Jatene[2], N. Miura[2], E. Azeka[2]. *[1]University of São Paulo, São Paulo, Brazil, [2]Heart Institute - Hospital das Clinicas FMUSP, São Paulo, Brazil*

5:54 p.m. **(420)** ***Covid-19 after Heart Transplantation: Treatment and Outcome in a German Transplant Centre***; D. Oehler[1], M. B. Immohr[2], R. R. Bruno[1], D. Sigetti[2], J. Haschemi[1], H. Aubin[2], I. Tudorache[2], R. Westenfeld[1], F. Bönner[1], M. Kelm[1], A. Lichtenberg[2], U. Boeken[2]. *[1]Department of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, [2]Department of Cardiac Surgery, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

POSTER SESSION 03: CARDIOLOGY

Location: Mile High Ballroom

Core Therapies: HEART, MCS
Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Cardiology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Mohammad Al-Ani, MD, University of Florida, Gainesville, FL USA
Ana Alba, MD, PhD, Toronto General Hospital, Toronto, ON Canada
Tamas Alexy, MD, PhD, University of Minnesota, Minneapolis, MN USA
Allen Anderson, MD, FACC, FAHA, FHFSA, University of Texas Health, San Antonio, TX USA
Udo Boeken, MD, PhD, University Hospital, Düsseldorf, Germany
Yevgeniy Brailovsky, DO, New York, NY USA
Maria Castel, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain
Leway Chen, MD, MPH, University of Rochester Medical Center, Rochester, NY USA
Monica Colvin, MD, MS, FAHA, University of Michigan Health System, Ann Arbor, MI USA
Erin Coglianese, MD, Massachusetts General Hospital, Boston, MA USA
Eugene DePasquale, MD, University of Southern California, Los Angeles, CA USA
Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis Heart Institute, Minneapolis, MN USA
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain
Eileen Hsich, MD, Cleveland Clinic Foundation, Cleveland, OH USA
Gregory Jackson, MD, Mount Pleasant, SC USA
George Javorsky, MBBS, FRACP, The Prince Charles Hospital, Chermside, QLD Australia
Tomoko Kato, MD, PhD, International University of Health and Welfare, Narita, Japan
Jamie Kennedy, MD, Inova Heart and Vascular Institute, Falls Church, VA USA
Kiran Khush, MD, MAS, Stanford University, Stanford, CA USA
Matthew Lander, MD, Allegheny Health Network, Pittsburgh, PA USA
Shivank Madan, MD, Montefiore Medical Center, New York, NY USA
Sonia Mirabet, MD, PhD, Hospital Sant Pau, Barcelona, Spain
Yosef Manla, MD, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Mrudula Munagala, MD, University of Miami, Miami, FL USA
Marco Masetti, MD, PhD, IRCCS S. Orsola Malpighi, University of Bologna, Bologna, Italy
Paul Mohacsi, MD, MBA, Cardiovascular Center Zürich, Klinik im Park Hirlsandenklinik, Zürich, Switzerland
Kavitha Muthiah, MBChB, PhD, St. Vincent's Hospital, Sydney, NSW Australia
Lazaros Nikolaidis, MD, Baylor Scott & White Medical Center, Temple, TX USA
Juan Ortega-Legaspi, MD, PhD, University of Pennsylvania, Philadelphia, PA USA
Carlos Ortiz-Bautista, MD, PhD, Hospital Universitario Gregorio Marañón, Madrid, Spain
Pujan Patel, MD, AdventHealth, Raleigh, NC USA
Yael Peled, MD, Sheba Medical Center, Ramat Gan, Israel
Stephen Pettit, MBBS, PhD, Royal Papworth Hospital, Cambridge, United Kingdom
Bhavadharini Ramu, MD, Medical University of South Carolina, Charleston, SC USA
Navin Rajagopalan, MD, University of Kentucky, Lexington, KY USA
Jayant Raikhelkar, MD, Columbia University, New York, NY USA
Roopa Rao, MBBS, Indiana University, Carmel, IN USA
María Renedo, MD, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina

Marc Simon, MD, MS, University of California San Francisco, San Francisco, CA USA
Melissa Smallfield, MD, Virginia Commonwealth University, Richmond, VA USA
Pallavi Solanki, MD, FACC, Rutgers-NJMS, Montville, NJ USA
Swethika Sundaravel, MD, University of Pennsylvania, Philadelphia, PA USA
Sarumathi Thangavel, MD, Chennai, India
Melana Yuzefpolskaya, MD, Columbia University Medical Center, New York, NY USA

(1000) ***Acute Rejection Following Donation after Circulatory Death Versus Brain Death Heart Transplantation;*** M. Urban[1], A. Castleberry[1], J. Um[1], D. Stoller[1], S. Lundgren[1], M. Hyden[1], M. Moody[2], K. Oreschak[3], B. Lowes[1]. *[1]University of Nebraska Medical Center, Omaha, NE, [2]Nebraska Medical Center, Elkhorn, NE, [3]CareDx, Denver, CO*

(1001) ***Revisiting Hemodynamic Compromise Rejection in the Current Era of Heart Transplantation: Still Problematic;*** M. Stachel, J. Patel, M. Kittleson, D. Chang, N. Patel, T. Singer-Englar, V. Ross, F. De Leon, M. Hamilton, L. Czer, F. Esmailian, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(1002) ***Differences in Individual Blood Gene Expression Profile (GEP) Levels in T-Cell Mediated Rejection Assessed by Molecular Microscopy in Heart Transplant;*** D. Lee[1], A. Usmani[2], R. Wu[3], T. Wicks[4], J. Fernandez[3], J. Huang[3], L. Arroyo[4], D. Rinde-Hoffman[4], S. Kumar[4], J. Feliberti[4], G. Oliveira[1], P. Berman[4], B. Mackie[4]. *[1]Div of Cardiovascular Science, Univ of South Florida, Tampa, FL, [2]Morsani College of Medicine, Univ of South Florida, Tampa, FL, [3]Univ of South Florida, Tampa, FL, [4]Tampa General Hospital, Tampa, FL*

(1003) ***Endomyocardial Biopsy Microscopic Molecular Profiling Correlates with Donor Derived Cell Free DNA and Histopathology;*** S. Roberts[1], D. Stoller[1], S. Lundgren[1], R. Zolty[1], C. Dunbar Matos[1], M. Hyden[2], M. Urban[3], B. Lowes[4]. *[1]University of Nebraska Medical Center, Omaha, NE, [2]Univ of Nebraska Med Ctr, Omaha, NE, [3]UNMC, Omaha, NE, [4]U. Nebraksa Med Ctr, Omaha, NE*

(1004) ***Impact of Long-Term Donor Derived Cell Free DNA Variability on Clinical Events Following Heart Transplantation;*** N. Uriel[1], B. Lowes[2], S. Hall[3], K. M. Pinney[4], V. Tran[4], R. Cheng[5], E. Minami[6], H. Eisen[7], J. Teuteberg[8], K. Khush[9]. *[1]New York Presbyterian, Columbia University Irving Medical Center, New York, NY, [2]U. Nebraksa Med Ctr, Omaha, NE, [3]Baylor University Medical Center, Dallas, TX, [4]Biostatistics and Data Sciences, CareDx, Brisbane, CA, [5]University of Washington Medical Center, Kirkland, WA, [6]University of Washington, Seattle, WA, [7]Penn State Milton S. Hershey Medical Center, Hershey, PA, [8]Stanford University School of Medicine, Stanford, CA, [9]Stanford University, Stanford, CA*

(1005) ***Gene Expression Profiling and Steroid Weaning: Experience from One Transplant Center;*** J. L. Nickol[1], D. Stoller[2], B. Lowes[3], M. Urban[4], S. Lundgren[2]. *[1]Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, [2]University of Nebraska Medical Center, Omaha, NE, [3]U. Nebraksa Med Ctr, Omaha, NE, [4]UNMC, Omaha, NE*

(1006) ***Donor-Derived Cell-Free DNA as a Potential Biomarker for Acute Cellular Rejection Surveillance (FreeDNA-CAR Study);*** M. Jimenez-Blanco Bravo[1], M. Crespo-Leiro[2], M. Garcia-Cosio[3], L. Perez-Gomez[1], R. Lopez-Vilella[4], C. Ortiz Bautista[5], M. Farrero Torres[6], A. Maestro Benedicto[7], B. Diaz Molina[8], C. Diez-Lopez[9], D. Rangel Sousa[10], N. Salterain[11], I. Garrido Bravo[12], J. Segovia-Cubero[1]. *[1]Hospital Universitario Puerta de Hierro, Madrid, Spain, [2]Hospital Universitario A Coruña, A Coruña, Spain, [3]Hospital Universitario 12 de octubre, Madrid, Spain, [4]Hospital Universitario La Fe, Valencia, Spain, [5]Hospital Universitario Gregorio Marañon, Madrid, Spain, [6]Hospital Clinic de Barcelona, Barcelona, Spain, [7]Hospital de la Santa Creu i Sant Pau, Barcelona, B, Spain, [8]Hospital Universitario Central de Asturias, Oviedo, Spain, [9]Hospital Universitario Bellvitge, Barcelona, Spain, [10]Hospital Universitario Virgen del Rocío, Utrera, Spain, [11]Clinica Universitaria de Navarra, Pamplona, Spain, [12]H Virgen de la Arrixaca, Murcia, Spain*

(1007) ***Clinical Relevance and Outcome of Routine Endomyocardial Biopsy to Detect Rejection after Heart Transplantation;*** L. C. Kieviet, M. K. Szymanski, M. G. van der Meer, N. P. van der Kaaij, N. de Jonge, L. W. van Laake, M. I. Oerlemans. *Department of Cardiology, University Medical Center Utrecht, Utrecht, Netherlands*

(1008) ***Gene Expression Profiling and Dd-cfdna Performance in Heart Transplant Recipients with Neuromuscular Disorders;*** L. Holzhauser[1], M. Molina[2], P. Joshi[3], P. Atluri[4], L. Goldberg[1], R. McLean[1]. *[1]University of Pennsylvania, Philadelphia, PA, [2]Hospital of the University of Pennsylvania, Philadelphia, PA, [3]CareDx, Reading, MA, [4]Univ of Pennsylvania, Philadelphia, PA*

(1009) ***Post-Cardiac Transplant Rejection Surveillance Utilizing a Novel Low-Cost Liquid Biopsy Technique Analyzing Dd-cfDNA and Dd-cfRNA;*** T. Meeran, A. Gaur, S. Sinha, N. Kamat, A. Phadke, R. Bunage, A. Mulay. *Sir HN Reliance Foundation Hospital, Mumbai, India*

(1010) ***Donor-Derived Cell-Free DNA Correlates Well with NT-ProBNP in Heart Transplant Recipients Undergoing Routine Endomyocardial Biopsies During First Year Post-Heart Transplant;*** M. Jimenez-Blanco Bravo[1], M. Crespo-Leiro[2], M. Garcia-Cosio[3], L. Perez-Gomez[1], R. Lopez-Vilella[4], C. Ortiz Bautista[5], M. Farrero Torres[6], A. Maestro Benedicto[7], B. Diaz Molina[8], C. Diez-Lopez[9], D. Rangel Sousa[10], N. Salterain[11], I. Garrido Bravo[12], J. Segovia-Cubero[1]. *[1]Hospital Universitario Puerta de Hierro, Madrid, Spain, [2]Hospital Universitario A Coruña, A Coruña, Spain, [3]Hospital Universitario 12 de octubre, Madrid, Spain, [4]Hospital Universitario La Fe, Valencia, Spain, [5]Hospital Universitario Gregorio Marañon, Madrid, Spain, [6]Hospital Clinic de Barcelona, Barcelona, Spain, [7]Hospital de la Santa Creu i Sant Pau, Barcelona, B, Spain, [8]Hospital Universitario Central de Asturias, Oviedo, Spain, [9]Hospital Universitario Bellvitge, Barcelona, Spain, [10]Hospital Universitario Virgen del Rocío, Utrera, Spain, [11]Clinica Universitaria de Navarra, Pamplona, Spain, [12]H Virgen de la Arrixaca, Murcia, Spain*

(1011) ***Added Value of Molecular Microscope Diagnostic System (mmdx) to Established Indicators of Heart Transplant Rejection: A Single Center Experience;*** M. Cagliostro[1], A. Folch[2], S. Ali[3], A. Lala-Trindade[4], N. Moss[2], A. Parikh[5], J. Contreras[2], S. Mitter[6], M. Trivieri[2], C. Gidea[2], D. Mancini[7], M. H. Barghash[8]. *[1]Icahn School of Medicine at Mount Sinai, New York, NY, [2]Mount Sinai Hospital, New York, NY, [3]Mount Sinai Hospital, New York, NY, [4]Mount Sinai Hosp, New York, NY, [5]Icahn school fo Medicine at Mount Sinai, New York, NY, [6]New York, NY, [7]Mount Sinai, New York, NY, [8]The Mount Sinai Hospital, New York, NY*

(1012) ***The Role of High-Sensitive Troponin in Identifying Patients with Cardiac Allograft Rejection;*** A. A. Scussel, F. G. Marcondes-Braga, C. Espinoza, D. De Marchi, M. Avila, A. P. Duque, A. R. de Paulo, S. Mangini, I. W. de Campos, L. F. Seguro, F. A. Gaiotto, F. Bacal. *Heart Institute (InCor), Hospital das Clinicas, Universidade de Sao Paulo, São Paulo, Brazil*

(1013) ***The Dilemma of the Role of Non-HLA Antibodies in AMR;*** M. T. Gamero[1], S. Marek-Iannucci[1], M. Liotta[2], Y. Huang[1], Y. Brailovsky[3], P. Uber[4], R. Alvarez[5], J. Rame[1], G. Gibson[6], E. Storozynsky[7], V. Tchantchaleishvili[8], H. Massey[1], K. Rajagopal[9], I. Rajapreyar[1]. *[1]Thomas Jefferson University Hospital, Philadelphia, PA, [23]Lafayette Hill, PA, [4]Penn Highlands, Haverford, PA, [5]Thomas Jefferson University, Cherry Hill, NJ, [6]Northwell, West Deptford, NJ, [7]Strong Memorial Hospital, Rochester, NY, [8]Thomas Jefferson Univ, Philadelphia, PA, [9]University of Texas-Houston, Sugar Land, TX*

(1014) ***Super Accelerated Cardiac Allograft Vasculopathy;*** I. Forado Benatar[1], A. Sa[2], E. Sole[1], M. Castel[3], P. Caravaca[1], A. Garcia Alvarez[4], E. Sandoval[1], N. Ibarra Marquez[1], P. Canto[1], J. Rodriguez[1], P. Cepas[1], M. Sabate[5], J. Casal[5], L. Izquierdo[5], E. Torrecilla[5], M. Farrero Torres[6]. *[1]Hospital Clínic de Barcelona, Barcelona, Spain, [2]Cardiology, Hospital Clínic, Barcelona, Spain, [3]Hospital Clinic de Barcelona, Barcelona, Spain, [4]Hospital Clínic de Barcelona, Barcelona, Spain, [5]Hospital Clínic, Barcelona, Spain, [6]Hospital Clinic de Barcelona, Barcelona, Spain*

(1015) ***No Signs of Recovery: Durable LVAD Implantation for Cardiac Graft Dysfunction;*** L. Pi, V. Jayachandiran, S. De, S. Smith, R. Davey. *Division of Cardiology, Western University, London, ON, Canada*

(1016) ***Combined Plasmapheresis and Complement Inhibition in a Highly Allosensitized Cardiac Transplant Recipient;*** D. Tardo[1], L. Carlos[2], F. Burrows[3], R. Carroll[4], W. Tong[5], P. Patel[4], A. Taverniti[4], S. Wiltshire[6], S. Conte[7], S. Parvar[8], S. Emmanuel[9], R. Grealy[8], C. Hayward[10], N. Bart[11], E. Kotlyar[11], A. Jabbour[10], A. Keogh[10], J. Patel[12], P. Jansz[10], P. Macdonald[10], K. Muthiah[10]. *[1]St Vincent's Hospital Sydney, Victor Chang Cardiac Research Institute, School of Medicine, Univ of Notre Dame Australia, Sydney, Darlinghurst, Australia, [2]St Vincent's Hospital Sydney, Darlinghurst, Australia, [3]St Vincent's Hospital, Darlinghurst, Australia, [4]New South Wales Transplantation and Immunogenetics Services, Lifeblood, Sydney, Australia, [5]St Vincent's Hospital Sydney, New South Wales Transplantation and Immunogenetics Services, Lifeblood, Darlinghurst, Australia, [6]St Vincent's Hospital Sydney, Victor Chang Cardiac Research Institute, Darlinghurst, Australia, [7]St Vincent's Hospital Sydney, Victor Chang Cardiac*

Research Institute, School of Medicine, Univ of Notre Dame Australia, Sydney, School of Medicine, Univ of New South Wales, Redfern, Australia, [8]St Vincent's Hospital, Sydney, Darlinghurst, Australia, [9]St Vincent's Hospital Sydney, Victor Chang Cardiac Research Institute, School of Medicine, Univ of Notre Dame Australia, Sydney, School of Medicine, Univ of New South Wales, Australia, Surry Hills, Australia, [10]St Vincent's Hospital Sydney, Victor Chang Cardiac Research Institute, School of Medicine, Univ of New South Wales, Darlinghurst, Australia, [11]St Vincent's Hospital Sydney, Victor Chang Cardiac Research Institute, School of Medicine, Univ of Notre Dame Australia, Sydney, School of Medicine, Univ of New South Wales, Darlinghurst, Australia, [12]Cedars-Sinai Smidt Heart Institute, Los Angeles, CA

(1017) ***Against All Odds - Transplanting Against 100% Reactive Antibodies and the Role of Non-Invasive Monitoring***; D. Lotan, C. M. Moeller, G. Rubinstein, H. Rosenblum, E. M. DeFilippis, K. Clerkin, J. Raikhelkar, J. Batra, K. Oh, E. Lin, J. Fried, F. Latif, P. Kennel, J. McLeod, P. C. Colombo, S. Lee, V. Topkara, M. Yuzefpolskaya, G. Sayer, N. Uriel. *Division of Cardiology -Center for Advanced Cardiac Care, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY*

(1018) ***A Case for a Novel Use of Donor-Derived Cell-Free DNA in Heart Transplantation: Detecting AT1R Antibody-Associated Injury***; V. N. Chukwuma[1], C. Nguyen[2], I. Balanlayos[2], A. Roska[3], K. C. Benig[3], M. Snyder[3], T. Lawrecki[4], W. Cotts[3], N. Narang[5], V. Chau[3], M. Dela Cruz[5]. *[1]Internal Medicine, Advocate Christ Medical Center, Oak Lawn, IL, [2]Advocate Health Advocate Christ Medical Center, Oak Lawn, IL, [3]Advocate Christ Medical Center, Oak Lawn, IL, [4]Chicago, IL, [5]Advocate Christ Medical Center, Chicago, IL*

(1019) ***Multivessel Epicardial Coronary Artery Thrombosis after Heart Transplantation***; T. Teszak[1], A. Assabiny[1], A. Kiraly[1], Z. Tarjanyi[1], N. Parazs[1], Z. Szakal-Toth[1], S. Kugler[1], I. Hartyanszky[1], Z. Szabolcs[1], F. Suhai[1], I. Edes[1], A. Fintha[2], B. Merkely[1], B. Sax[1]. *[1]Semmelweis University Heart and Vascular Centre, Budapest, Hungary, [2]Semmelweis University Department of Pathology and Experimental Cancer Research, Budapest, Hungary*

(1020) ***Complete Heart Block as a Presentation of Antibody Medication Rejection Early Post Heart-Lung Transplant***; K. M. Stawiarski, G. Stevens, Z. Kon, C. Saikus, M. Avila. *Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Uniondale, NY*

(1021) ***Use of Daratumumab in Antibody Mediated Rejection in a Heart Transplant Recipient***; A. Agrawal[1], L. Bernth[2], L. Arroyo[3]. *[1]University of South Florida, Tampa, FL, [2]Tamap General Hospital, Tampa, FL, [3]Tampa General Hospital, Tampa, FL*

(1022) ***Coronary- Pulmonary Artery Fistula Post Heart Transplantation***; A. Agrawal[1], L. Fox[1], J. Feliberti[2]. *[1]Cardiology, University of South Florida, Tampa, FL, [2]Tampa General Hospital, Tampa, FL*

(1023) ***Investigating Genetic Variants in Patients with Left Ventricular Assist Devices for Nonischemic Cardiomyopathy***; C. Scott[1], J. Posey[1], A. Butac[1], H. Lamba[1], S. Oberton[1], A. Shafii[1], K. Liao[1], G. Loor[1], J. George[2], L. Simpson[1], R. Delgado[2], A. Civitello[2], A. Nair[1]. *[1]Baylor College of Medicine, Houston, TX, [2]Texas Heart Institute, Houston, TX*

(1024) ***Baseline Characteristics & Predictors of Cardiac Recovery in Patients with Left Ventricle Assist Device Implantation***; A. Malhotra[1], T. Dalia[2], P. Bhyan[2], J. Hu[3], J. Baker[3], M. Danter[4], S. Silvestry[5], C. Selzman[6], S. Drakos[6], A. Vidic[2], Z. Shah[2]. *[1]Internal Medicine, University of Kansas Medical Center, Kansas City, KS, [2]Dept of Cardiovascular Med, Univ of Kansas MC, Kansas City, KS, [3]Dept of Biostatistics and Data Science, Univ of Kansas MC, Kansas City, KS, [4]Dept of Cardiothoracic Surgery, Univ of Kansas MC, Kansas, KS, [5]AdventHealth Transplant Institute, Orlando, FL, [6]Univ of Utah, Salt Lake City, UT*

(1025) ***Myocardial Recovery Profile in Patients Following Left Ventricular Assist Device Explantation***; R. Crespo[1], C. Weaver[2], M. Bennett[3], B. Sun[1], P. Eckman[1], M. Samara[1], K. Hryniewicz[1]. *[1]Minneapolis Heart Institute, Minneapolis, MN, [2]Abbott Northwestern Hospital, Minneapolis, MN, [3]Abbott Northwestern Hosp, Minneapolis, MN*

(1026) ***What's The Best Regimen? Impact of Everolimus Use on Chronic Kidney Disease after Heart Transplant***; M. Dazo, J. Foland, C. M. Iler, L. Norris, S. Deshpande. *Children's National Hospital, Washington, DC*

(1027) ***Combined Heart Liver Transplant versus Heart Transplant Alone in Failed Fontan Adult Patients;*** R. Akbari[1], C. Valdes[1], D. Moguillansky[2], A. Saidi[3], J. Reid[4], M. Bleiweis[5], J. Jacobs[5], G. Peek[5], M. Al-Ani[6], A. Parker[3], J. Vilaro[7], J. Aranda[3], M. M. Ahmed[9]. *[1]CoM, Univ of Florida, Gainesville, FL, [2]Pediatrics, Univ of Florida, Gainesville, FL, [3]Univ of Florida, Gainesville, FL, [4]Shands Hosp, Gainesville, FL, [5]UF Health Congenital Heart Ctr, Gainesville, FL, [6]Gainesville, FL, [7]UF Hlth Shands Hospital, Gainesville, FL, [9]Div of Cardiovascular Medicine, Univ of Florida, Gainesville, FL*

(1028) ***Post-Transplantation Outcomes of Adult Congenital Heart Disease;*** K. Kearney[1], R. Cordina[2], P. Choudhary[3], D. Tanous[3], D. Celermajer[2], A. Keogh[1], N. Bart[1], A. Jabbour[4], E. Kotlyar[1], P. Jansz[1], C. Hayward[1], K. Muthiah[1], P. MacDonald[1]. *[1]St Vincent's Hospital, Darlinghurst, Australia, [2]Royal Prince Alfred Hospital, Camperdown, Australia, [3]Westmead Hospital, Sydney, Australia, [4]Victor Chang Cardiac Research Institute St Vincent's Hospital, Darlinghurst, Australia*

(1029) ***Donor-Derived Cell-Free DNA in Heart Transplant Recipients with a History of Congenital Heart Disease;*** Y. Mehlman[1], D. Lotan[1], G. Rubinstein[1], C. Moeller[1], D. Oren[1], S. Slomovich[1], F. Latif[1], S. Lee[1], K. Oh[1], E. Lin[1], J. Raikhelkar[1], K. Clerkin[1], J. Fried[1], M. Yuzefpolskaya[1], E. DeFilippis[1], P. Colombo[1], V. Topkara[1], M. Lewis[2], G. Sayer[1], K. Axsom[1], N. Uriel[1]. *[1]Div of Cardiology - Center for Advanced Cardiac Care, Columbia Univ Irving Medical Center - New York Presbyterian Hospital, New York, NY, [2]Div of Cardiology - Schneeweiss Adult Congenital Heart Center, Columbia Univ Irving Medical Center - New York Presbyterian Hospital, New York, NY*

(1030) ***Non-HLA Antibodies: The State of Current Practice in Pediatric Heart Transplant;*** C. M. Iler[1], J. Backowski[2], H. Bastardi[3], C. Boyle[4], M. Brickler[5], C. Buesking[2], S. Daneman[6], K. Gambetta[7], L. Ha[4], A. M. Huston[8], N. Sinicropi[9], R. White[4], S. Deshpande[1]. *[1]Children's National Hosp, Washington, DC, [2]St. Louis Children's Hosp, St. Louis, MO, [3]Children's Hosp of Boston, Boston, MA, [4]Children's Hosp of Philadelphia, Philadelphia, PA, [5]Children's Hosp of Wisconsin, East Troy, WI, [6]Children's Med Ctr, Dallas, TX, [7]Lurie Children's Hosp, Chicago, IL, [8]UPMC Children's Hosp, Pittsburgh, PA, [9]C.S. Mott Children's Hosp, Ann Arbor, MI*

(1031) ***Distribution of Gene Expression Profiling Scores in Pediatric Heart Transplant Recipients;*** L. D'Addese[1], V. Ravichandran[2], K. Oreschak[2]. *[1]Joe DiMaggio Children's Hospital, Hollywood, FL, [2]CareDx, Brisbane, CA*

(1032) ***Decreasing Endomyocardial Biopsy Frequency in Pediatric Heart Transplantation Using a Rejection Risk Prediction- A Single Center Study;*** D. Tolani[1], D. Sutcliffe[2], R. Butts[1], A. Power[1]. *[1]Children's Medical Center of Dallas/ University of Texas Southwestern, Dallas, TX, [2]Children's Mercy Hospital, Kansas City, MO*

(1033) ***Effect of Practice Variation Amongst Organ Procurement Organizations on Pediatric Donor Heart Utilization;*** F. Haregu[1], M. Porter[2], J. Dixon[3], M. McCulloch[4]. *[1]Pediatric Cardiology, University of Virginia Children's Hospital, Charlottesville, VA, [2]Systems Engineering, University of Virginia, Charlottesville, VA, [3]Data Science, University of Virginia, Charlottesville, VA, [4]University of Virginia Children's Hospital, Charlottesville, VA*

(1034) ***Racial and Geographic Disparities in Utilization of Listing by Exception Among US Children Listed for Heart Transplantation;*** D. M. Torpoco Rivera[1], K. Sweat[2], B. Kaufman[3], R. Kameny[4], A. Burgart[2], M. Miller[2], E. Profita[5], S. Hollander[6], C. Almond[2]. *[1]Pediatric Cardiology - Heart Transplant, Lucile Packard Children's Hospital at Stanford University, Palo Alto, CA, [2]Stanford University, Palo Alto, CA, [3]Stanford University, San Francisco, CA, [4]Menlo Park, CA, [5]Stanford University, San Carlos, CA, [6]San Carlos, CA*

(1035) ***Colocutaneous Fistula Following Pediatric Bivad Implantation, A Rare but Serious Complication;*** S. Rangu[1], J. Murray[2], A. Shiu[2], E. Martin[3], T. Nasirov[3], M. Bruzoni[4], S. Chen[1], D. Rosenthal[1], M. Ma[3], J. Dykes[1]. *[1]Pediatric Cardiology, Stanford University, Palo Alto, CA, [2]Lucile Packard Children's Hospital Stanford, Palo Alto, CA, [3]Cardiothoracic Surgery, Stanford University, Palo Alto, CA, [4]Pediatric Surgery, Stanford University, Palo Alto, CA*

(1036) ***Through the "Chimney": Berlin Heart Excor Pediatric Ventricular Assist Device Inflow Stenting via a Novel Direct Access to Inflow Tubing;*** A. C. Taylor[1], K. Lee[1], L. M. Felmly[2], A. Issapour[1], C. Almond[3], M. Ma[4], E. Martin[2]. *[1]Department of Pediatrics, Division of Pediatric Cardiology, Stanford University, Palo Alto, CA, [2]Department of Cardiothoracic Surgery, Stanford University, Palo Alto, CA, [3]Stanford University, Palo Alto, CA, [4]Stanford University, Stanford, CA*

(1037) ***What to Do with a Squeaky Wheel? Ventricular Assist Device Use in Children with Mechanical Valves in the Action Database;*** S. F. Hussain[1], O. Aljohani[2], S. Auerbach[3], D. Bearl[4], V. Benvenuto[5], E. Bonura[6], L. Crawford[7], J. Dyal[8], C. Hartje-Dunn[9], S. Jana[10], A. Joong[7], S. Kaushal[11], M. Lynn[11], E. Miller[1], L. Radel[12], A. Raskin[13], D. Rivera-Torpoco[14], J. Spinner[11], S. Wilkens[15], C. Villa[1]. *[1]Cincinnati Children's Hosp MC, Cincinnati, OH, [2]Benioff Children's Hosps, San Francisco, CA, [3]Univ of Colorado, Denver, [4]Monroe Carell Jr. Children's Hosp at Vanderbilt, Nashville, TN, [5]Boston Children's Hosp, Boston, MA, [6]St. Louis Children's Hosp, St Louis, MO, [7]Ann & Robert H. Lurie Children's Hosp, Chicago, IL, [8]Children's Healthcare of Atlanta, Atlanta, GA, [9]Boston Children's Hosp, Boston, MA, [10]Stollery Children's Hosp, Edmonton, Canada, [11]Texas Children's Hosp, Houston, TX, [12]Children's MC of Dallas, Dallas, TX, [13]Children's Wisconsin, Brookfield, WI, [14]Lucille Packard Children's Hosp, Palo Alto, CA, [15]Norton Children's Hosp, Louisville, KY*

(1038) ***Racial Disparities in the Use of Ventricular Assist Devices (VADs) in US Children Listed for Heart Transplantation;*** D. M. Torpoco Rivera[1], K. Sweat[2], B. Kaufman[3], J. Dykes[4], J. Murray[4], T. Nasirov[5], A. Burgart[2], M. Miller[2], R. Kameny[6], C. Almond[2]. *[1]Pediatric Cardiology, Lucile Packard Children's Hosp at Stanford Univ, Palo Alto, CA, [2]Stanford Univ, Palo Alto, CA, [3]Stanford Univ, San Francisco, CA, [4]Lucile Packard Children's Hosp, Stanford, CA, [5]Sacramento, CA, [6]Menlo Park, CA*

(1039) ***Glp-1 Receptor Agonists Among LVAD Patients with Diabetes and Obesity; Effect on Comorbid Conditions;*** M. Mekhaimar[1], A. Correa[1], C. Hamo[2], A. Doshi[3], A. Young[1], J. Roldan[1], A. Lala[1], S. Mitter[1], A. Parikh[1], D. Mancini[1], N. Moss[1]. *[1]Mount Sinai Hospital, New York, NY, [2]NYU Langone Health, New York, NY, [3]Sanger Heart & Vascular Institute, Charlotte, NC*

(1040) ***Impact of Lymphocyte-Depleting Induction on Graft Outcomes in Highly Sensitized Heart Transplant Recipients;*** M. Demehin[1], I. Booth[1], W. Cappuccio[2], B. Ravichandran[1], K. Huang[1], S. Asadi[3], A. Hicks[3], S. Cipriano[1], M. Oldsman[1], S. Joseph[3], M. Plazak[1]. *[1]University of Maryland Medical Center, Baltimore, MD, [2]University of Maryland School of Pharmacy, Baltimore, MD, [3]University of Maryland School of Medicine, Baltimore, MD*

(1041) ***Does Switching from Bactrim to Atovaquone Result in Less Hyperkalemia? A Single-Center Retrospective Analysis in Heart Transplant Patients;*** M. Novakovic[1], D. Nnani[2], O. Saeed[2], S. Vukelic[2], Y. Rochlani[2], S. Madan[2], D. Sims[2], J. Shin[2], S. Murthy[2], A. Bazarbachi[1], P. Chavez[2], U. Jorde[2], S. Patel[2]. *[1]Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, [2]Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY*

(1042) ***Safety and Tolerability of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients Supported with Left Ventricular Assist Devices;*** S. Chavali[1], S. Barua[1], A. Adjii[1], D. Robson[1], L. Raven[2], J. Greenfield[2], S. Parvar[1], P. MacDonald[1], C. Hayward[1], K. Muthiah[1]. *[1]Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Australia, [2]Department of Endocrinology, St Vincent's Hospital, Sydney, Australia*

(1043) ***SGLT2 Inhibitors are Associated with Improved Clinical and Hemodynamic Parameters in LVAD Patients;*** A. Fardman[1], A. Kodesh[2], A. Siegel[2], E. Regev[3], A. Berkovitch[3], A. Morgan[3], A. Grupper[4]. *[1]Chaim Sheba Medical Center, Ramat-Gan, Israel, [2]Tel-Aviv university, Tel-Aviv, Israel, [3]Sheba Medical Center, Ramat-Gan, Israel, [4]Sheba Med Ctr, Tel Aviv-Yafo, TA, Israel*

(1044) ***Characterization of Safety and Tolerance of SGLT2i Therapy in Adult LVAD Recipients;*** J. S. Hong[1], C. Doligalski[2], P. Chang[3], R. Watkins[4], M. Byku[1]. *[1]University of North Carolina School of Medicine, Chapel Hill, NC, [2]University of North Carolina Hospital, Chapel Hill, NC, [3]University of North Carolina at Chapel Hill, Chapel Hill, NC, [4]University of North Carolina Medical Center, Chapel Hill, NC*

(1045) ***Association of Neurohormonal Blockade with Clinical Outcomes Among Patients with Advanced Heart Failure on Left Ventricular Assist Device Support;*** G. Gallone[1], J. Ibero Valencia[2], A. Morley-Smith[1], O. Dar[1], M. Monteagudo Vela[1], F. Fiorelli[1], M. Konicoff[1], G. Edwards[1], B. Raj[1], M. Shanmuganathan[1], S. Frea[3], G. De Ferrari[3], V. Panoulas[1], U. Stock[1], C. Bowles[1], J. Dunning[1], F. Riesgo Gil[1]. *[1]Cardiothoracic Transplantation., Harefield Hospital. Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, [2]Hospital San Pedro, Logrono, Spain, [3]Division of Cardiology, Cardiovascular and Thoracic Department., "Citta della Salute e della Scienza" Hospital, Turin, Italy*

(1046) ***WITHDRAWN***

(1047) ***Sex Differences in Heart Transplantation: A National Cohort Study;*** N. Abdoul[1], C. Legeai[1], S. Varnous[2], M. Para[3], C. Goeminne[4], S. Pattier[5], F. Kerbaul[1], R. Dorent[1]. *[1]Agence de la Biomédecine, Saint-Denis La Plaine, France, [2]Hosp Pitie Salpetriere, Paris, 75, France, [3]Department of Cardiac Surgery, Bichat- Claude Bernard Hospital Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France, [4]Ctre Hosp Reg. Univ De Lille, Lille, France, [5]Hosp Nord G Et R Laennec, Herblain, France*

(1048) ***An Interactive Dashboard for Analyzing the Geographic Epidemiology of Cardiac Transplantation;*** P. Zhao[1], D. Drullinsky[2], D. Nagpal[2], R. Davey[3], K. Hornby[4], S. Smith[5]. *[1]London Health Sciences Centre, Western University, London, ON, Canada, [2]London Health Sciences Centre, London, ON, Canada, [3]Western University, London, ON, Canada, [4]Trillium Gift of Life Network, Ontario Health, Toronto, ON, Canada, [5]LHSC-University Hosp, London, ON, Canada*

(1049) ***The Utilities of Family Frailty Score as a Novel Social Support Assessment Tool for Patients Undergoing Advanced Heart Failure Therapies;*** D. Yaranov[1], V. Kittipibul[2], B. Snodgrass[1], O. Mahmoud[1], T. Edwards[1], A. Shirwany[3], K. Acheson[1], K. Wilson[1], S. Campbell[1], B. Bruckner[1], M. Fudim[4], W. Mullinax[1]. *[1]Baptist Memorial Hospital, Memphis, TN, [2]Duke University Medical Center, Durham, NC, [3]Stern CV Foundation, Memphis, TN, [4]Duke, Durham, NC*

(1050) ***Reproductive Health Awareness in Menstruating Individuals of Reproductive Age That Undergo Advanced Therapies for Stage D Heart Failure;*** Y. Daraz, D. Wolfe, A. Bortnick, P. Chavez. *Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY*

(1051) ***The Validation of Cardiac Rehabilitation after Heart Transplantation from Anonymized Patient-Reported Outcomes;*** I. Kim[1], J. Youn[2], D. Chang[3], K. Nishihara[3], E. Kransdorf[3], M. Kittleson[3], J. Patel[3], R. Cole[3], A. Nikolova[3], F. Esmailian[3], L. Czer[3], J. Kobashigawa[3]. *[1]Keimyung University Dongsan Hospital, Dalseo-Gu, South Korea, [2]Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea, [3]Cedars-Sinai Heart Institute, Los Angeles, CA*

(1052) ***Effect of an Advanced Heart Failure Program on Heart Failure Admissions in a Rural State;*** K. Chadwick[1], C. Clark[1], R. Veilleux[2], D. Sawyer[2], E. Shao[3]. *[1]Internal Medicine, Maine Medical Center, Portland, ME, [2]Cardiovascular Medicine, Maine Medical Center, Portland, ME, [3]Maine Health Cardiology, South Portland, ME*

(1053) ***Heart Failure Admissions Per 1000 Heart Failure Patients as a Better Indicator of Quality and Outcomes;*** C. H. Clark[1], K. Chadwick[2], E. Shao[3], R. Veilleux[1], D. Sawyer[1]. *[1]Maine Medical Center, Portland, ME, [23]Maine Health Cardiology, South Portland, ME*

(1054) ***Bioimpedance Analysis as a Screening Tool in Heart-Transplanted Patients;*** G. Lee[1], S. Park[1], S. Lee[1], K. Song[2], Y. Kim[2], W. Chang[2], J. Kim[2], N. Park[2], J. Kim[3], S. Park[4], I. Hwang[5], H. Kim[1], I. Kim[1]. *[1]Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, 1035, Dalgubeol-daero, Dalseo-gu, Daegu, South Korea, [2]Department of Cardiothoracic Surgery, Cardiovascular Center, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, 1035, Dalgubeol-daero, Dalseo-gu, Daegu, South Korea, [3]Department of Radiology, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, 1035, Dalgubeol-daero, Dalseo-gu, Daegu, South Korea, [4]Department of Laboratory Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, 1035, Dalgubeol-daero, Dalseo-gu, Daegu, South Korea, [5]Department of Pathology, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, 1035, Dalgubeol-daero, Dalseo-gu, Daegu, South Korea*

(1055) ***The Effect of Pulmonary Artery Pulsatility Index (PAPi) in Heart Failure and in LVADs is Mediated Through Different Mechanisms;*** R. Ratnagiri[1], K. G. Sureshrao[2], R. Krishnakumar[3], G. Rajagopalan[4], K. R. Balakrishnan[2]. *[1]Heart and Lung Transplant, MGM Healthcare Chennai India, Chennai, India, [2]Heart and Lung Transplant, MGM Healthcare, Chennai, India, [3]Department of Engineering Design, Indian Institute of Technology (IIT) Madras, Chennai, India, [4]Depart of Engineering Design, Indian Institute of Technology (IIT) Madras, Chennai, India*

(1056) ***Use of Induction Therapy Post Heart Transplantation - Clinical Practice Recommendations Based on Systematic Review and Network Meta-Analysis of Evidence;*** F. Foroutan[1], G. Guyatt[2], J. Stehlik[3], F. Gustafsson[4], D. Greig[5], M. McDonald[6], A. Bertolotti[7], L. Kugathasan[8], D. Rayner[9], A. Cook[10], D. Zlatanoski[10], S. Ram[10], P. Demas-Clarke[11], S. Kozuszko[6], A. Alba[6]. *[1]Ted Rogers Centre for Heart Research, Toronto, ON, Canada, [2]Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada, [3]University of Utah, Salt Lake City, UT, [4]Rigshospitalet, Copenhagen, Denmark, [5]P. Universidad Catolica de Chile, RM, Chile, [6]Toronto General Hospital, Toronto, ON, Canada, [7]Favaloro Foundation, Ciudad Autónoma Buenos Aires, Argentina, [8]University Health Network, Toronto, ON, Canada, [9]Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada, [10]None, Toronto, ON, Canada, [11]Toronto General Hospital, Toront, ON, Canada*

(1057) ***Remote Monitoring of Patients on Left Ventricular Assist Device (lvad) Support: A Proof-Of-concept Study;*** L. Numan[1], M. Moazeni[2], E. Aarts[2], M. Szymanski[1], N. P. Van der Kaaij[3], F. Asselbergs[4], L. Van Laake[3]. *[1]Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands, [2]Methodology & Statistics, University of Utrecht, Utrecht, Netherlands, [3]University Medical Centre Utrecht, Utrecht, Netherlands, [4]Cardiology, Amsterdam UMC, Amsterdam, Netherlands*

(1059) ***Peri-Perative Transfusion Requirements and ICU Length of Stay after Heart Transplantation for Patients with LVADs Anticoagulated with Apixaban - Initial Experience;*** S. Chavali[1], B. Schnegg[2], P. Lo[1], D. Robson[1], S. Emmanuel[3], P. Jansz[3], E. Granger[3], A. Watson[3], P. MacDonald[1], K. Muthiah[1], C. Hayward[1]. *[1]Heart Failure and Transplant Unit, St Vincent's Hosp, Sydney, Australia, [2]Inselspital, Univ Hosp Bern, CH, Wabern, BE, Switzerland, [3]Dept of Cardiothoracic Surgery, St Vincent's Hosp, Sydney, Australia*

(1060) ***The Hemodynamic Effects of Pump Speed Adjustments in Patients with Heartmate 3 Left Ventricular Assist Device;*** G. Rubinstein[1], D. Lotan[1], C. Moeller[1], S. Slomovich[1], D. Oren[1], J. Fried[1], K. Clerkin[1], V. Topkara[1], J. Raikhelkar[1], K. Oh[1], K. Takeda[2], Y. Naka[2], Y. Kaku[2], P. Colombo[1], M. Yuzefpolskaya[1], F. Latif[1], G. Sayer[1], N. Uriel[1]. *[1]Div of Cardiology, Ctr of Advanced Cardiac Care, Columbia Univ Irving MC, New York, NY, [2]Dept of Carthoracic Surgery, Columbia Univ Irving MC, New York, NY*

(1061) ***Long-Term Changes in Renal Function After Implantation of Left Ventricular Assist Device and Differences by Type of Devices from Japanese Registry for Mechanical Assisted Circulatory Support (J-MACS);*** N. Kikuchi, Y. Minami, Y. Asami, H. Hattori, Y. Ichihara, S. Saito, N. Hiroshi, J. Yamaguchi, S. Nunoda. *Tokyo Women's Medical University, Tokyo, Japan*

(1062) ***Beyond the Limits of Current Pump Monitoring - HeartMate 3 SNOOPY in Echocardiographic Speed Ramp Tests;*** T. Schloeglhofer[1], C. Gross[2], T. Abart[2], A. K. Schaefer[2], G. Widhalm[2], C. Marko[2], M. Röhrich[3], I. Weigel[2], F. Kaufmann[4], B. Karner[2], J. Riebandt[2], D. Wiedemann[2], G. Laufer[2], H. Schima[1], M. Granegger[2], D. Zimpfer[2]. *[1]Cardiac Surgery, Ctr for Med. Physics and Biomed. Eng, LBI Cardiovasc. Research, Med Univ of Vienna, Vienna, Austria, [2]Cardiac Surgery, Med Univ of Vienna, Vienna, Austria, [3]Anesthesia, Intensive Care Med and Pain Med, Med Univ of Vienna, Vienna, Austria, [4]German Hrt Inst, Berlin, Germany*

(1063) ***Clinical Prediction Model for Advanced Fibrosis in Heart Transplant Candidates;*** L. Cao[1], J. Rushakoff[1], J. Kobashigawa[1], J. Patel[1], M. Guindi[2], E. Kransdorf[1]. *[1]Cedars-Sinai Heart Institute, Los Angeles, CA, [2]Cedars-Sinai Medical Center, Los Angeles, CA*

(993) ***Prevalence of Incidental Amyloid on Cardiac Explants;*** N. Gorrie[1], P. MacDonald[1], V. Sivasubramaniam[1], A. Jabbour[2], K. Muthiah[1], D. Fatkin[3], E. Kotlyar[1], C. Hayward[1], N. Bart[1]. *[1]St Vincent's Hospital, Sydney, Australia, [2]Victor Chang Cardiac Research Institute St Vincent's Hospital, Darlinghurst, Australia, [3]Victor Chang Cardiac Research Institute, Sydney, Australia*

(994) ***Mixed Rejection in Orthotopic Heart Transplantation;*** P. Srivastava, E. Kransdorf, M. Kittleson, D. Chang, A. Nikolova, J. Patel, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(995) ***A Contemporary Analysis of Antibody-Mediated Rejection Following Heart Transplantation Based on the Presence or Absence of Donor-Specific Antibodies;*** S. Laux[1], B. Q. Yang[2], E. Deych[2], J. D. Schilling[2]. *[1]UMKC School of Medicine, Kansas City, MO, [2]Washington University School of Medicine in St. Louis, St. Louis, MO*

(996) ***Relationship Between Absolute Quantification of Donor-Derived Cell-Free DNA and Donor-Derived Cell-Free DNA Fraction for Detection of Allograft Rejection in Heart Transplant Patients;*** S. Patel[1], N. Uriel[2], A. Nguyen[3], B. Silvia[3], T. Wolf-Doty[3], W. Tian[3], K. Qu[3], S. Pinney[4]. *[1]Montefiore-Einstein, Bronx, NY, [2]New York Presbyterian, New York, NY, [3]CareDx, Brisbane, CA, [4]University of Chicago, Chicago, IL*

(997) ***Routine Donor Specific Antibody Monitoring in Heart Transplant Recipients - Is There a Role?;*** D. Buckley[1], D. Aspinall[2], R. Carroll[3], C. Hayward[1], E. Kotlyar[1], A. Jabbour[1], N. Bart[1], A. Keogh[1], P. MacDonald[1], K. Muthiah[1], W. Tong[3]. *[1]St. Vincent's Hospital, Sydney, Australia, [2]Australia Red Cross, Lifeblood, Sydney, Australia, [3]Australian Red Cross, Lifeblood, Sydney, Australia*

(998) ***Clinical Value of Newly Detected Donor-Specific HLA Antibodies for Predicting the Development of Pathological Antibody Mediated Rejection;*** H. Mochizuki[1], T. Watanabe[2], S. Komeyama[3], T. Hada[4], O. Seguchi[5], T. Fujita[6], Y. Tsukamoto[7]. *[1]National Cerebral and Cardiovascular Center, Osaka, Japan, [2]National cerebral and cardiovascular center, Japan, [3]National Cerebral and Cardiovascular Center, Japan, Suita, Japan, [4]National Cerebral and Cardiovascular Center, Osaka-Shi, 27, Japan, [5]Nat 'l Cerebral & CV Ctr, 27, Japan, [6]Nat'l Cerebral & CV Ctr, Suita-Shi, 27, Japan, [7]Osaka University, Suita-Shi, 27, Japan*

(999) ***Validation of the Clinical Utility of MicroRNA as Non-Invasive Biomarkers of Cardiac Allograft Rejection Monitoring: A Prospective Longitudinal Multicenter Study;*** G. Coutance[1], F. Tacafred[2], M. Racape[2], R. Dorent[3], P. Battistella[4], R. Guillemain[5], K. Blanchart[6], E. Epailly[7], A. Gay[8], S. Pattier[9], A. Boignard[10], E. Vermes[11], X. Jouven[2], A. Loupy[12], J. Duong-Van-Huyen[13]. *[1]Pitié-Salpetrière Hosp, Paris, France, [2]Paris Transplant Group, Paris, France, [3]Agence de la Biomédecine, Saint-Denis, France, [4]Hosp Arnaud De Villeneuve, Montpellier, France, [5]European Hosp Georges Pompidou, Paris, 75, France, [6]Caen Univ Hosp, Paris, France, [7]Univ Hosp, Strasbourg, France, [8]Rouen, France, [9]Hosp Nord G Et R Laennec, Herblain, France, [10]Hosp Albert Michallon, La Tronche, France, [11]Chu Trousseau, Tours, France, [12]Necker Hosp, Paris, France, [13]Paris, France*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

POSTER SESSION 03: CARDIOTHORACIC SURGERY

Location: Mile High Ballroom

Core Therapies: HEART, LUNG, MCS
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Nursing and Allied Health, Pathology, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Cardiothoracic Surgery. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Nathan Airhart, MD, Saint Alphonsus Medical Center, Boise, ID USA
Nael Aldweib, MD, Oregon Health Science University, Portland, Oregon USA
Kamal Ayyat, MD, PhD, Cleveland Clinic, Cleveland, OH USA
Yaron Barac, MD, PhD, Rabin Medical Center, Petah Tiqva, Israel
Stacey Brann, MD, MSc, FRCS(Ed), TransMedics, Inc., Andover, MA USA
Nicolas Brozzi, MD, Cleveland Clinic, Weston, FL USA
Gustavo Calado Ribeiro, Clinic Cardio Cirurgica Campinas, Campinas, Brazil
Philip Carrott, MD, University of Virginia, Charlottesville, VA USA
Alfred Casillan, MD, PhD, Johns Hopkins University, Baltimore, MD USA
Robert Chen, MD, MPH, Stanford University School of Medicine, Palo Alto, CA USA
Jenalee Coster, MD, UPMC, Pittsburgh, PA USA
Thomas Egan, MD, MSC, UNC at Chapel Hill, Chapel Hill, NC USA
Sam Emmanuel, MBBS, BHSc (Hons), St Vincent's Hospital, Sydney, NSW Australia
Julien Fessler, MD, Foch Lung Transplant Group, Paris, France
Miriam Freundt, MD, Hershey, PA USA
Claudia Gidea, MD, Newark Beth Israel Medical Center, New York, NY USA
Emily Granger, MBBS, St Vincent's Hospital Sydney, NSW Australia
Eric Griffiths, MD, University of Utah, Salt Lake City, UT USA
David Hormuth, MD, MBA, StarTeamsLLC, Jupiter, FL USA
Peter Ivak, MD, PhD, IKEM, Prague, Czech Republic
Mandisa-Maia Jones, MD, Weill Cornell NY Presbyterian, New York, NY USA
Darshak Karia, MD, Piedmont Augusta, Augusta, GA USA
Suresh Keshavamurthy, MD, FACS, FRCS, University of Kentucky, Lexington, KY USA
Sean Kiley, M.D., Mayo Clinic Florida, Jacksonville, FL USA
Ahmet Kilic, MD, The Johns Hopkins University, Baltimore, MD USA
Kevin Koomalsingh, MD, Providence St Vincent Medical Center, Portland, OR USA
Kewal Krishan, MD, Temple University Hospital, Philadelphia, PA USA
Lucian Lozonschi, MD, University of South Florida, Tampa General Hospital, Tampa, FL USA
Archer Martin, MD, Mayo Clinic, Jacksonville, FL USA
Aurelie Merlo, MD, University of North Carolina, Chapel Hill, NC USA
Ezequiel Molina, MD, Piedmont Heart Institute - Samsky Advanced Heart Failure Center, Atlanta, GA USA
Minoru Ono, MD, PhD, The University of Tokyo Hospital, Tokyo, Japan
Alessandro Palleschi, MD, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico of Milan, Milano, Italy
Siddharth Pahwa, MD, University of Louisville Physicians, Louisville, KY USA
Anthony Panos, MD, MSc, FRCSC, FACS, University of Iowa Hospital and Clinics, Iowa City, IA USA
Pedro Reck dos Santos, MD, MSc, PhD, Mayo Clinic Arizona, Phoenix, AZ USA
Elena Sandoval, MD, FEBCTS, Barcelona, Spain
Sia Saatee, MD, Northwestern Medicine, Chicago, IL USA

Tae Song, MD, University of Chicago, Chicago, IL USA
Stephan Schueler, MD, PhD, FRCS, Newcastle upon Tyne Hospitals, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Daniel Tang, MD, Inova, Falls Church, VA USA
Roh Yanagida, MD, PhD, Temple University Hospital, Philadelphia, PA USA

(1064) ***Economic Impact of Donation after Circulatory Death Heart Transplantation;*** T. Ryan, J. Um, A. Castleberry, B. Lowes, M. Moody, M. Urban. *University of Nebraska Medical Center, Omaha, NE*

(1065) ***Cardiac Transplant in Southeast Asia: Challenges and Opportunities;*** R. Sulague[1], N. Cruz[2], R. Ricardo[3], P. Alfonso[4], D. Vervoort[5]. *[1]Georgetown University School of Health, Washington, DC, [2]Our Lady of Fatima University College of Medicine, Valenzuela City, Philippines, [3]University of the Philippines-Philippine General Hospital, Manila, Philippines, [4]University of the Philippines College of Medicine, Manila, Philippines, [5]Institute of Health Policy, Management, and Evaluation, Univ of Toronto, Toronto, ON, Canada*

(1066) ***Procurement Delays Experienced by Specialized Thoracic Organ Recovery Teams: Areas for Improvement;*** H. A. Tetteh[1], P. Brandenhoff[2], J. Tessier[3], R. S. Higgins[4]. *[1]Uniformed Services University of the Health Sciences, Bethesda, MD, [2]Thoracic Transplant Consultants Inc, San Francisco, CA, [3]STAR Teams, Springfield, VA, [4]Mass General Brigham, Boston, MA*

(1067) ***Donation after Circulatory Death Heart Transplantation Reduces Length of Stay and Associated Costs: A Single Center Comparison;*** R. White[1], M. Kearns[1], K. Sharaf[1], D. Cookish[1], Y. Gernhofer[2], Q. Bui[1], A. Duran[1], K. Hong[1], A. Brann[1], M. Urey[1], V. Pretorius[1]. *[1]UC San Diego Health, La Jolla, CA, [2]University of the Incarnate Word School of Osteopathic Medicine, San Antonio, TX*

(1068) ***Successful Lung Re-Transplantation with Perioperative Desensitization for Sensitized Recipient with Donor Specific DQ Antibody;*** H. Choshi, K. Miyoshi, H. Ujike, S. Kawana, Y. Kubo, D. Shimizu, K. Matsubara, K. Hashimoto, S. Tanaka, K. Shien, K. Suzawa, H. Yamamoto, M. Okazaki, S. Sugimoto, S. Toyooka. *Okayama University Hospital, Okayama, Japan*

(1069) ***Lung Waitlist and Transplantation Outcomes after the Affordable Care Act's Medicaid Expansion;*** Q. Kern[1], K. Shorbaji[1], B. Gibney[1], L. Paoletti[2], T. Whelan[2], A. Kilic[1], Z. Hashmi[1]. *[1]Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC, [2]Pulmonary, Critical Care, Allergy & Sleep Medicine, Medical University of South Carolina, Charleston, SC*

(1070) ***Changes in Patient Selection and Outcomes in the New Lung Transplant Allocation Era;*** W. Blanding, K. Shorbaji, B. Welch, B. Gibney, L. Paoletti, T. Whelan, A. Kilic, Z. Hashmi. *Medical University of South Carolina, Charleston, SC*

(1071) ***Esophageal Clearance Issues Prevalent on Post-Lung Transplant Modified Barium Swallow Studies: A Pilot Study;*** E. L. Reedy[1], H. S. Bonilha[2], A. N. Simpson[3], A. K. O'Rourke[3], M. H. Khalaf[4], J. E. Pandolfino[1], B. Martin-Harris[5]. *[1]Northwestern Univ, Chicago, IL, [2]Emory Univ, Atlanta, GA, [3]MUSC, Charleston, SC, [4]East Carolina Univ, Greenville, NC, [5]Northwestern Univ, Evanston, IL*

(1072) ***A Retrospective Analysis of Concomitant Alfieri Stitch Mitral Valve Repair in Patients Undergoing Left Ventricular Assist Device Implantation;*** R. Chockalingam Jnr[1], K. Tang[1], K. Chew[1], Z. Abdul Aziz[1], J. Loh[1], V. Chao[1], T. Tan[2], K. Kerk[1], L. Teo[1], D. Sim[1], C. Sivathasan[1]. *[1]National Heart Centre, Singapore, Singapore, [2]National Heart Centre Singapore, Singapore, Singapore*

(1073) ***Prolonged Bridging to Transplantation with Impella 5.5;*** G. Faerber[1], H. Kirov[1], P. von Samson[2], I. Schwan[3], U. Schneider[3], M. Diab[3], T. Doenst[3]. *[1]University Hospital Jena, Jena, Germany, [2]n/a, [3]Cardiothoracic Surgery, University Hospital Jena, Jena, Germany*

(1074) ***Serial Assessment of Bronchial Anastomoses by Endobronchial Ultrasonography for Follow-Up in Lung Transplant Recipients;*** P. von Samson[1], T. Sandhaus[1], G. Faerber[1], H. Kirov[2], T. Siemeni[2], T. Doenst[1]. *[1]Cardio-Thoracic Surgery, University Hospital, Jena, Germany, [2]University Hospital, Jena, Germany*

(1075) ***The Crossroads in VAD - To Wean or Not to Wean: A Meta-Analysis on Predictors of Feasibility of Ventricular Assist Device Explantation with Stable Myocardial Recovery in Chronic Non-Ischemic Dilative Cardiomyopathy;*** M. Javier[1], E. Javier Delmo[2], M. Dandel[3], R. Hetzer[4]. *[1]Cardiac Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, [2]Charité Research Organisation, Charité -Universitätsmedizin Berlin, Berlin, Germany, [3]German Center for Cardiovascular Research (DZHK) Partner Site Berlin, Berlin, Germany, [4]Charité Universitätsmedizin Berlin, Berlin, Germany*

(1076) ***Longitudinal Analysis of Pump Settings Over Long-Term Support with the Heartmate3 Left Ventricular Assist Device;*** F. Consolo[1], M. Pieri[2], M. Scandroglio[2], F. Pappalardo[3]. *[1]Università Vita Salute San Raffaele, Milano, Italy, [2]Ospedale San Raffaele, Milano, Italy, [3]AO SS Antonio e Biagio e Cesare Arrigo, Milano, Italy*

(1077) ***De-Commissioning/ Explant of Durable LVAD can be Done Safely Using Manchester Criteria for LV Recovery;*** S. Das De, M. Jain, S. Kore, J. Hooper, V. Mehta, P. Callan, S. Shaw, R. Venkateswaran. *Wythenshawe Cardiothoracic Transplant Unit, Manchester Foundation Trust, Wythenshawe Hospital, Wythenshawe, Manchester, United Kingdom*

(1078) ***The Antibody Response of an MMF-Containing Immunosuppressive Regimen Aftercovid-19 Vaccination in Asian Heart Transplant Recipient;*** C. Tsao[1], N. Chou[2], Y. Yung[1], P. Hsieh[1], C. Wang[2], N. Chi[2], H. Yu[2], R. Hsu[2], S. Huang[2], Y. Chen[2]. *[1]Nursing, National Taiwan University Hospital, Taipei, Taiwan, [2]Surgery, National Taiwan University Hospital, Taipei, Taiwan*

(1079) ***Aseptic Meningitis and New-Onset Seizures with Concurrent Cefepime Administration in the Immediate Post-Lung Transplant Period;*** M. Olson[1], H. Abdelrazek[2], H. Mohamed[2], A. Arjuna[2]. *[1]University of Arizona, School of Medicine, Phoenix, AZ, [2]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(1080) ***Comparison of Alemtuzumab to Basiliximab on Post-Operative Pulmonary Function Following Lung Transplantation;*** A. Wu[1], M. Spisak[1], A. Kashem[1], H. Kehara[2], N. Shigemura[3], Y. Toyoda[1]. *[1]Temple Univ SoM, Philadelphia, PA, [2]Temple Univ, Philadelphia, PA, [3]Temple Univ Health System and Lewis Katz SoM, Philadelphia, PA*

(1081) ***Routine Use of Non-Heparin Purge Solution with Temporary Transvalvular Ventricular Assist Devices;*** K. Simonsen, A. Malhotra, G. Tavilla, R. Reddy. *Baylor Scott & White, Temple, TX*

(1082) ***Does Donor Smoking Status Impact the Development of Coronary Artery Vasculopathy;*** D. Blitzer[1], D. Baran[2], S. Lirette[3], A. Mohammed[4], H. Copeland[5]. *[1]Columbia University, New York, NY, [2]Cleveland Clinic Heart, Vascular and Thoracic Institute, Parkland, FL, [3]Fulcrum, Jackson, MS, [4]Lutheran Hospital Transplant Center, Fort Wayne, IN, [5]Lutheran Medical Group, Fort Wayne, IN*

(1083) ***Donor Simvastatin Treatment in Heart Transplantation: 5-Year Results of a Randomized Clinical Trial;*** S. O. Syrjala[1], E. Holmstrom[2], K. Dhaygude[3], J. Lommi[4], A. Nykanen[5], K. Lemstrom[3]. *[1]Helsinki Univ Hosp, Helsinki, Finland, [2]Univ of Helsinki, Helsinki, Finland, [3]Univ of Helsinki, Helsinki, 18, Finland, [4]Helsinki Univ Hosp, Helsinki, Finland, [5]Helsinki Univ Hosp, Helsinki, Finland*

(1084) ***Successful Heart Transplantation Using a Portable Normothermic Ex-Vivo Donor Heart Preservation System for Extended Criteria Donor after Circulatory Death: A Case Series with Extended Perfusion Times;*** C. Ruaengsri, Y. Shudo, A. Malki, D. Neto, R. Chen, D. Bethencourt, W. Hiesinger, J. MacArthur, M. Currie, J. Boyd, B. Guenthart, A. Lee, J. Woo. *Cardiothoracic Surgery, Stanford University, Stanford, CA*

(1085) ***Galectin-3 as an Early Marker of Renal Dysfunction in Heart Transplant Patients: Short-Term Results;*** L. Giovannico[1], A. d'Errico Ramirez[2], D. Parigino[3], G. Fischetti[4], V. Santeramo[4], L. Savino[4], A. Silva[4], A. Marzullo[5], T. Bottio[6], A. Milano[4]. *[1]Department of Emergency and Organ Transplants - Cardiac Surgery Unit, Università degli Studi di Bari, Bari, Italy, [2]Policlinico Hospital of Bari, Bari, BA, Italy, [3]Università degli Studi di Bari Aldo Moro, Lesina, FG, Italy, [4]Department of Emergency and Organ Transplants - Cardiac Surgery Unit, University of Bari Aldo Moro Medical School, Bari, Italy, [5]Department of Emergency and Organ Transplants - Dept of Pathology, University of Bari Aldo Moro Medical School, Bari, Italy, [6]University of Bari Aldo Moro Medical School, Bari, Italy*

(1086) ***Donor Cause of Death and Ejection Fraction in Heart Transplant Recipients***; F. Del Valle Diaz[1], M. Dean[2], C. Lemoine[3], L. Copeland[4], J. Silverman[5], C. Zoni[6], T. Raines[7], Y. Ravi[6], C. Sai-Sudhakar[6]. *[1]University of Puerto Rico School of Medicine, San Juan, Puerto Rico, [2]Virginia Commonwealth University Health System Internal Medicine Residency, Richmond, VA, [3]University of Connecticut Health Center, Farmington, CO, [4]Department of Population Health and Quantitative Health Sciences University of Massachusetts Medical School, Worcester, MA, [5]University of Connecticut Health Center, Farmington, CT, [6]Department of Cardiothoracic Surgery-Dept of Surgery UConn Health, Farmington, CT, [7]Univ of Tennessee Health Science Center, Memphis, TN*

(1087) ***Cerebral Venous Congestion in Patient with Oxyrvad V-V Ecmo Presenting as Blurred Vision***; A. J. Gorton[1], S. Nandavaram[2], S. Keshavamurthy[3]. *[1]Cardiothoracic Surgery, University of Kentucky, Lexington, KY, [2]University of Kentucky, Lexington, KY, [3]University Of Kentucky, Lexington, Lexington, KY*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

POSTER SESSION 03: NURSING AND ALLIED HEALTH

Location: Mile High Ballroom

Core Therapies: HEART, LUNG, MCS
Practice Areas: Nursing & Allied Health, Cardiology, Cardiothoracic Surgery

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Nursing and Allied Health. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Kelly Bryce, PhD, Henry Ford Hospital, Detroit, MI USA
Kevin Chan, MD, Michigan Medicine, Ann Arbor, MI USA
Meg Fregoso, MSN, NP-BC CCTC, Inova Fairfax Hospital, Fairfax, VA USA
Louise Fuller, PhD, BApp Sc (Physio), Alfred Hospital, Melbourne, VIC Australia
Kathleen Grady, PhD, RN, MS, FAAN, Northwestern University, Chicago, IL USA
Christiane Kugler, PhD, Albert-Ludwigs University Freiburg, Reute, Germany
Michael Petty, PhD, RN, APRN, CNS, CCNS, University of Minnesota MC, Minneapolis, MN USA
Melissa Sanchez, BSc Hons, PGDip, DClinPsy, MSc, Central and North West London NHS Foundation Trust, London, United Kingdom

(1088) ***Attitudes Toward Donated Organ Research;*** R. Hahn[1], L. Alarcon[2], H. Hayes[3], L. Dembo[3], S. Lawrence[4], M. Musk[4], R. Larbalestier[5], W. Pavey[2]. *[1]Dept of Cardiothoracic Surgery, Fiona Stanley Hosp, Perth, Australia, [2]Dept of Anaesthesia, Fiona Stanley Hosp, Perth, Australia, [3]Advanced Heart Failure, Fiona Stanley Hosp, Perth, Australia, [4]Advanced Lung Disease, Fiona Stanley Hosp, Perth, Australia, [5]Dept of Cardiothoracic and Transplant Surgery, Fiona Stanley Hosp, Perth, Australia*

(1089) ***Promoting Healthy Diet and Food Security in Patients with Heart Failure Through Novel Food4Health Clinic;*** M. Butler[1], D. Juros[2], A. Jaiswal[3]. *[1]Hartford Hospital, Hartford, CT, [2]DWJ Food Systems Consulting, Pleasantville, NY, [3]Hartford hospital, New Orleans, LA*

(1090) ***Sympathetic Dysfunction is Associated with Physical Symptoms Among Adults with Moderate to Advanced Heart Failure;*** N. Stutsman[1], N. Pavlovic[2], W. Woodward[1], B. Habecker[1], C. Lee[3], Q. Denfeld[1]. *[1]Oregon Health & Science University, Portland, OR, [2]Johns Hopkins University, Baltimore, MD, [3]Boston College, Hopkinton, MA*

(1091) ***Palliative Care Needs in Heart Transplant Candidates: A Comparison of the Edmonton Symptom Assessment Scale-Revised (ESAS-r) with Patient Expressed Needs;*** M. I. Owen[1], H. Groninger[2], N. Noorani[3], K. Esbensen[4]. *[1]College of Nursing, Seattle University, Seattle, WA, [2]Section of Palliative Care, MedStar Washington Hospital Center, Washington, DC, [3]Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, [4]Division of Hospital Medicine, Emory University, Atlanta, GA*

(1092) ***Use of Donor-Derived Cell Free Dna in Heart/Lung Transplant Recipients;*** M. Wahl, A. Cochrane, M. Fregoso, J. Kennedy, S. Aryal. *Inova Fairfax Hospital, Falls Church, VA*

(1093) ***Respiratory-Swallow Coordination in Patients Referred for Lung Transplant Evaluation;*** K. J. Graham[1], E. Reedy[2], A. Arunachalam[3], R. Tomic[4], B. Martin-Harris[1]. *[1]Northwestern University, Evanston, IL, [23]Northwestern Memorial Hospital, Chicago, IL, [4]Northwestern University, Chicago, IL*

(1094) ***Why We Stay: A National Study of Ventricular Assist Device Coordinators in the Role for 10+ Years;*** S. Schettle[1], J. Bennett[2], J. Hajj[3], B. Pambakian[4], T. Robbins[5], S. Schroeder[6], A. Rosenbaum[1]. *[1]Mayo Clinic, Rochester, MN, [2]Methodist Hospital, Helotes, TX, [3]Medical University of South Carolina, Charleston, SC, [4]International Consortium of Circulatory Assist Clinicians, N/A, NJ, [5]Philadelphia, PA, [6]Bryan Heart, Lincoln, NE*

(1095) ***Standardizing Initiation, Management, and Discontinuation of Temporary Mechanical Circulatory Support (T-MCS)***; J. B. Williams[1], L. Craig[2]. *[1]CVICU, Vanderbilt University Medical Center, Nashville, TN, [2]Vanderbilt University Medical Center, Nashville, TN*

(1096) ***Behavioral Risk Factors Linked to Adverse Events (AEs) after Left Ventricular Assist Device (LVAD) Implantation in Women and Men***; L. Maukel[1], G. Weidner[2], J. Beyersmann[3], H. Spaderna[1]. *[1]Health Psychology, Trier University, Trier, Germany, [2]Biology, San Francisco State University, Sausalito, CA, [3]Institute of Statistics, Ulm University, Ulm, Germany*

(1097) ***Impact of a Prehabilitation Program on Lvad Implantation Surgical Outcomes***; Y. Wu[1], S. Fanous[2], S. Baudart[1], A. Jannesen[1], A. Strehlow[1], A. J. Abad[1], K. Griswold[3], K. Mulcahy[3], L. Klein[1], G. Wieselthaler[1]. *[1]Advanced Heart Failure Comprehensive Care Center, University of California San Francisco, San Francisco, CA, [2]Department of Pharmacy, University of California San Francisco, San Francisco, CA, [3]Department of Rehabilitation, University of California San Francisco, San Francisco, CA*

5:00 – 6:00 p.m.

POSTER SESSION 03: PATHOLOGY

Location: Mile High Ballroom

Core Therapies: HEART
Practice Areas: Pathology, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Pharmacy, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Pathology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Fiorella Calabrese, MD, University of Padova, Padova, Italy
Anja Roden, MD, Mayo Clinic Rochester, Rochester, MN USA

(1098) ***Optimization and Safety of Lipoic Acid F127@pla Nanoparticles as New Therapeutic Vector for Rna Delivery in Cardiovascular Diseases;*** C. Castellani[1], L. Morillas Becerril[2], R. Luisetto[2], C. Radu[2], I. Barison[3], M. Fedrigo[4], A. Giarraputo[4], G. Virzì[5], M. Tomaz Do Nascimento[6], P. Simioni[6], E. Papini[6], R. Tavano[6], G. Vescovo[7], F. Mancin[6], A. Angelini[2]. *[1]University of Padova, Padova, Italy, [2]University of Padua, Padova, Italy, [3]University of Padua, Padova, VE, Italy, [4]University of Padova, Padova, PD, Italy, [5]San Bortolo Hospital, Vicenza, Italy, [6]University of Padua, Padua, Italy, [7]Padua University Hospital, Padova, Italy*

(1099) ***MicroRNA Microarray Analysis in Infections Post Heart-Transplantation;*** I. Barison[1], A. Giarraputo[2], E. Rossi[3], L. Vedovelli[4], S. Minuzzo[3], M. Fedrigo[5], C. Castellani[6], F. Tona[7], T. Bottio[8], G. Toscano[4], C. Basso[4], G. Gerosa[9], S. Mandruzzato[3], D. Abate[10], D. Gregori[4], A. Angelini[11]. *[1]Dept. of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padova, Italy, [2]Dept. of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Padova, Italy, [3]Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy, University of Padua, Padua, Italy, [4]Dept. of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy, [5]University of Padova, Padova, PD, Italy, [6]University of Padova, Padova, Italy, [7]Clinica Cardiologica Universita Padova, Padova, PD, Italy, [8]Az Osp. Di Padova, Padova, PD, Italy, [9]AZ. OSP. Padova, Padova, Italy, [10]Department of Molecular Medicine, University of Padua, Padua, Italy, [11]University of Padua, Padova, Italy*

(1100) ***Quantification of Histopathological Features in Masson Trichrome-Stained Endomyocardial Biopsies by Using a Deep-Learning Algorithm;*** A. J. Lahtiharju[1], K. Dhaygude[2], M. Mäyränpää[1], K. Lemstrom[2], S. Syrjala[3]. *[1]University of Helsinki, Helsinki, Finland, [2]University of Helsinki, Helsinki, 18, Finland, [3]Helsinki University Hospital, Helsinki, 18, Finland*

5:00 – 6:00 p.m.

POSTER SESSION 03: PEDIATRICS

Location: Mile High Ballroom

Core Therapies: HEART, MCS, PVD
Practice Areas: Pediatrics, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Pediatrics. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Shahnawaz Amdani, MD, Cleveland Clinic, Cleveland, OH USA
Nicholas Avdimiretz, MD, FRCPC, University of Alberta, Edmonton, AB Canada
Estela Azeka, MD, University of Sao Paulo, São Paulo, Brazil
Charles Canter, MD, St Louis Children's Hospital, Saint Louis, MO USA
Michael Carboni, MD, Duke Children's Hospital, Durham, NC USA
Kevin Daly, MD, Boston Children's Hospital, Boston, MA USA
Oliver Dewald, MD, University Hospital Erlangen, Erlangen, Germany
Josh Friedland-Little, MD, Seattle Children's Hospital, Seattle, WA, US
Jeffrey Gossett, MD, Northwell Health, New York, NY USA
Jonathan Johnson, MD, Mayo Clinic, Rochester, MN USA
Steven Kindel, MD, Children's Hospital of Wisconsin, Milwaukee, WI USA
Ken Knecht, MD, Arkansas Children's Hospital, Little Rock, AR USA
Jacqueline Lamour, MD, Mount Sinai Medical Center, New York, NY USA
Irene Lytrivi, MD, Columbia Presbyterian Hospital, New York, Larchmont, NY USA
David Moreno McNeill, MD, Texas Children's Hospital, Houston, TX USA
David Peng, MD, University of Michigan, Ann Arbor, MI USA
Adam Putschoegl, Minneapolis, MN USA
Joseph Rossano, MD, The Children's Hospital, Philadelphia, PA USA
Fawwaz Shaw, MD, Emory University/Children's Health Care of Atlanta, Atlanta, GA USA
David L. Sutcliffe, MD, Children's Mercy Hospital, Kansas City, MO USA
Madeleine Townsend, MD, Cleveland Clinic Children's, Cleveland, OH USA
Simon Urschel, MD, University of Alberta, Edmonton, AB Canada
Carol Wittlieb-Weber, MD, Media, PA USA
Warren Zuckerman, MD, New York Presbyterian Hospital/Columbia University MC, New York, NY USA

(1101) ***In-App Messaging by Adolescent Heart Transplant Patients During Mobile App-Based Video Directly Observed Therapy;*** M. Killian[1], L. Schelbe[2], M. L. Lustria[3], D. Gupta[4]. *[1]Florida State Univ, Tallahassee, FL, [2]Coll of Social Work, Florida State Univ, Tallahassee, FL, [3]Sch of Information, Coll of Communication and Information, Florida State Univ, Tallahassee, FL, [4]UF CoM, Gainesville, FL*

(1102) ***Daratumumab for Chronic Antibody Mediated Rejection and Subsequent Successful Pediatric Heart-Kidney Retransplantation;*** A. McCormick[1], A. Jarosz[2], H. Lim[1], D. Peng[1], K. Schumacher[1], D. G. Frame[2], M. Cusick[3]. *[1]Pediatrics, Mich Med, Ann Arbor, MI, [2]Clinical Pharmacy, Univ of Mich Coll of Pharmacy, Ann Arbor, MI, [3]Pathology, Mich Med, Ann Arbor, MI*

(1103) ***Pathological Remodeling and Metabolic Dysfunction in Peripheral Blood Mononuclear Cells are Associated with Heart Failure in Single Ventricle Heart Disease;*** A. N. Baybayon-Grandgeorge[1], P. M. Zegelbone[2], A. E. Pietra[2], S. D. Miyamoto[2], A. M. Garcia[2]. *[1]Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, [2]Department of Pediatrics, University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, CO*

(1104) ***Mucosal-Associated Invariant T (MAIT) Cell Frequency is Preserved in Pediatric Heart Transplant Recipients;*** L. Loh[1], L. Gapin[1], J. Abbott[2], S. J. Nakano[2]. *[1]Immunology and Microbiology, University of Colorado, Aurora, CO, [2]Pediatrics, University of Colorado, Aurora, CO*

(1105) ***Multisystem Inflammatory Syndrome in a Pediatric Heart Transplant Recipient: A Case Report;*** K. Shibbani[1], M. L. Staron-Ehlinger[1], A. Raskin[2], G. S. Beasley[1], R. S. Khan[1]. *[1]University of Iowa Stead Family Children's Hospital, Iowa City, IA, [2]Children's Wisconsin, Milwaukee, WI*

(1106) ***The Molecular Microscope Diagnostic System (MMDx) Fails to Detect Early Antibody Mediated Rejection after Flow Crossmatch Positive Pediatric Heart Transplantation;*** C. Milligan, T. Singh, G. Nava, R. Kobayashi, P. Esteso, K. Daly. *Department of Cardiology, Boston Children's Hospital, Boston, MA*

(1107) ***Percutaneous Mitral Valve Repair in Pediatric Patients;*** F. Haregu[1], M. McCulloch[2], N. Wong[3], D. S. Lim[3]. *[1]Pediatric Cardiology, University of Virginia Children's Hospital, Charlottesville, VA, [2]University of Virginia Children's Hospital, Charlottesville, VA, [3]Cardiology, University of Virginia, Charlottesville, VA*

(1108) ***New Desensitization Strategy: Daratumumab for Highly Sensitized Pediatric Heart Transplant Candidate;*** N. Baez Hernandez[1], L. Radel[1], R. Butts[1], M. Bano[1], J. Lantz[1], R. Davies[2], C. Lacelle[3], T. Ellimuttil[4]. *[1]Pediatric Cardiology, Children's Medical Center of Dallas/University of Texas Southwestern, Dallas, TX, [2]Cardiovascular and Thoracic Surgery, Children's Health, UT Southwestern, Dallas, TX, [3]Pathology, UT Southwestern Medical Center, Dallas, TX, [4]Pharmacy, Children's Health, Dallas, TX*

(1109) ***A Metabolic, Mechanical, Multi-Organ Masterpiece: Durable Device Support Bridge to Heart-Liver Transplantation in Propionic Acidemia;*** R. M. Juhl[1], B. F. Birnbaum[1], A. P. Barnes[1], W. Gibson[2], B. Mullapudi[3], B. Lang[1], M. Faseler[3], D. Heble[4], V. Urban[4], R. Fischer[5], J. L. Gannon[6], D. L. Sutcliffe[1]. *[1]Pediatric Heart Failure and Transplantation, Children's Mercy Hospital, Kansas City, MO, [2]Pediatric Cardiothoracic Surgery, Children's Mercy Hospital, Kansas City, MO, [3]Pediatric Surgery, Children's Mercy Hospital, Kansas City, MO, [4]Pharmacy, Children's Mercy Hospital, Kansas City, MO, [5]Pediatric Hepatology, Children's Mercy Hospital, Kansas City, MO, [6]Pediatric Clinical Genetics, Children's Mercy Hospital, Kansas City, MO*

(1110) ***Treatment of Antibody-Mediated Rejection in Adolescent Heart Transplant Recipients with Daratumumab;*** C. Milligan, A. Wong, H. Bastardi, K. Daly, T. Singh, P. Esteso. *Department of Cardiology, Boston Children's Hospital, Boston, MA*

(1111) ***Long-Term Experience with Heart Transplantation in Patients with Congenital Heart Disease - Focus on Single Ventricle Patients and Vad;*** J. Bruhs, E. Sandica, K. T. Laser, J. Grohmann, R. Goerg, J. Hummel, S. Molatta, S. Schubert. *Center of Congenital Heart Disease, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany*

(1112) ***For Patients with Congenital Heart Disease and Advanced Heart Failure: Is it Better to Be Listed for Heart Transplant as a Child or an Adult;*** L. Isaac Maximo[1], W. Liu[2], S. Amdani[3]. *[1]Pediatrics, Cleveland Clinic Children's, Cleveland, OH, [2]Quantitative Health Science, Cleveland Clinic, Cleveland, OH, [3]Pediatric Cardiology, Cleveland Clinic Children's, Cleveland, OH*

(1113) ***Lower Cardiac Index Precedes Clinically Recognizable Cardiac Allograft Vasculopathy in Children after Heart Transplant;*** H. J. Tadros[1], S. Denfield[2], K. Hope[3], K. Puri[4], A. Qureshi[5], J. Price[6], H. Tunuguntla[6], S. Choudhry[6], J. Heinle[6], I. Adachi[7], W. Dreyer[8], J. Spinner[2]. *[1]Texas Children's Hospital / Baylor College of Medicine, Houston, TX, [2]Baylor College of Medicine, Houston, TX, [3]Texas Children's Hospital, Baylor College of Medicine, Bellaire, TX, [4]Baylor College of Medicine, Bellaire, TX, [5]Texas Children's Hospital/Baylor College of Medicine, Houston, TX, [6]Texas Children's Hospital, Houston, TX, [7]Children's Hospital, Houston, TX, [8]Baylor College of Med, Houston, TX*

(1114) ***Regional Incidence of Pediatric Heart Failure, Cohort Characteristics, and Outcomes;*** L. J. May[1], A. Cabrera[2], J. Wilkes[3], Z. Ou[4], J. Stehlik[2], H. T. Keenan[5]. *[1]University of Utah, Cottonwood Heights, UT, [2]University of Utah, Salt Lake City, UT, [3]Intermountain Health Care, Salt Lake City, UT, [4]Internal Medicine, University of Utah, Salt Lake City, UT, [5]Pediatrics, University of Utah, Salt Lake City, UT*

(1115) ***SGLT2 Inhibitor Use in Pediatric Heart Failure;*** R. Butts[1], D. Nandi[2], B. Hong[3], A. Lorts[4], J. Spinner[5]. *[1]Children's Medical Center of Dallas/University of Texas Southwestern, Dallas, TX, [2]Nationwide Children's Hospital, Columbus, OH, [3]Seattle Children's Hospital, Seattle, WA, [4]Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [5]Baylor College of Medicine, Houston, TX*

(1116) ***Pediatric Heart Failure Program Development-Evaluation of a Single Center Experience;*** K. Nelson McMillan[1], J. Hoffman[2], C. Kriesberg[3], S. Kane[3], V. Dorsey[4], F. Yousaf[4], A. Waas[5], L. Vricella[6], S. Pophal[3]. *[1]Advocate Children's Heart Institute, University of Chicago/Chicagoland Children's Health Alliance, Oak Lawn, IL, [2]Advocate Children's Heart Institute/Chicagoland Children's Health Alliance, Oak Lawn, IL, [3]Advocate Children's Heart Institute/Chicagoland Children's Health Alliance, Oak Lawn, IL, [4]Advocate Children's Hospital, Oak Lawn, IL, [5]Advocate Children's Heart Institute, Oak Lawn, IL, [6]Advocate Children's Heart Institute, University of Chicago/Chicagoland Children's Health Alliance, Oak Lawn, IL*

(1117) ***Prolonged Inotrope Use after Surgery for Congenital Heart Disease: Risk Factors for Inpatient Mortality;*** A. M. Kamsheh[1], W. B. Bilker[2], O. Okunowo[1], D. S. Burstein[3], J. B. Edelson[1], K. Y. Lin[1], K. Maeda[1], C. D. Mavroudis[1], M. J. O'Connor[1], C. A. Wittlieb-Weber[1], H. R. Bogner[2], J. W. Rossano[1]. *[1]Children's Hospital of Philadelphia, Philadelphia, PA, [2]University of Pennsylvania, Philadelphia, PA, [3]University of Vermont, Burlington, VT*

(1118) ***Administrative Databases: Friend or Foe in Pediatric Cardiomyopathy;*** J. Conway[1], O. Barrett[2], T. Pidborochynski[3], K. Schroeder[1], C. Cunningham[3], A. Jeewa[4], K. Padma[3]. *[1]Stollery Children's Hospital, Edmonton, AB, Canada, [2]Alberta Health Services, Edmonton, AB, Canada, [3]University of Alberta, Edmonton, AB, Canada, [4]The Hospital for Sick Children, Markham, ON, Canada*

(1119) ***A Prospective Study of Sleep Disordered Breathing in Children with Heart Failure;*** M. Oglesby[1], K. Puri[2], J. Spinner[3], K. Hope[4], H. Tunuguntla[5], S. Choudhry[5], W. Dreyer[6], J. Price[5]. *[1]Pediatric Critical Care Medicine, Baylor CoM, Houston, TX, [2]Pediatric Critical Care Medicine and Cardiology, Baylor CoM, Houston, TX, [3]Baylor College of Medicine, Houston, TX, [4]Texas Children's Hospital, Baylor CoM, Bellaire, TX, [5]Texas Children's Hosp, Houston, TX, [6]Baylor CoM, Houston, TX*

(1120) ***Chasing the Dream (of Equipoise): Design and Execution Challenges of the Multicenter TITRE Trial of Indication-Based Red Blood Cell Transfusion in Pediatric ECMO;*** L. A. Sleeper[1], P. Alexander[1], D. P. Kelly[2], M. M. Bembea[3], D. C. Bellinger[4], A. Sadhwani[1], L. Sun[1], M. Shrivastava[1], G. L. Klein[1], J. W. Newburger[1], R. R. Thiagarajan[1]. *[1]Cardiology, Boston Children's Hospital, Boston, MA, [2]Medical Critical Care, Boston Children's Hospital, Boston, MA, [3]Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, [4]Neurology, Boston Children's Hospital, Boston, MA*

(1122) ***Relations Between Cardiac Magnetic Resonance Imaging and Cell Free Dna in Pediatric Heart Transplant - A Pilot Study for the Future of Heart Transplant Surveillance;*** K. Watanabe, A. Birjiniuk, R. L. Crawford, J. R. Robinson, D. Magnetta, C. Rigsby, C. Laternser, N. Husain. *Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL*

(1123) ***Association Between Donor-Derived Cell-Free DNA Levels and Cardiac Pressures in Pediatric Heart Transplant Recipients;*** M. L. Staron-Ehlinger[1], G. Beasley[2], T. Hardin[2], J. Baker[2], R. Khan[2]. *[1]University of Iowa Children's Hospital, Iowa City, IA, [2]University of Iowa Stead Family Children's Hospital, Iowa City, IA*

(1124) ***Predictors of Long-Term Renal Insufficiency in Repeat Pediatric Heart Transplants;*** M. Chan[1], L. Silveira[2], D. Patterson[3], M. Bock[3], B. Pietra[4], M. Everitt[5], K. Simpson[6], S. Miyamoto[7], S. Auerbach[8]. *[1]Department of Nephrology, University of Colorado and Children's Hospital Colorado, Denver, CO, [2]Colorado School of Public Health, Denver, CO, [3]University of Colorado and Children's Hospital Colorado, Denver, CO, [4]U FL Congenital Hrt Ctr, Gainesville, FL, [5]Children's Hospital Colorado, Englewood, CO, [6]University of Colorado Denver, Denver, CO, [7]Aurora, CO, [8]University of Colorado, Denver*

(1125) ***Use of Donor-Derived Cell Free DNA for Rejection Surveillance in Pediatric Heart Transplant Patients Undergoing Treatment for Post-Transplant Lymphoproliferative Disorder: A Pilot Study;*** D. Mokshagundam[1], J. Backowski[2], P. Rasp[2], E. Bonura[1], L. Gokanapudy Hahn[1], A. Ybarra[1], J. Scheel[1], C. Canter[1]. *[1]Wash Univ in St Louis, St Louis, MO, [2]St Louis Children's Hosp, St Louis, MO*

(1126) ***Use of Apixaban in Children Awaiting Heart Transplantation for Thromboprophylaxis;*** V. Benvenuto[1], C. Hartje-Dunn[2], L. Vo[1], A. Hellinger[3], P. Esteso[4], F. Fynn-Thompson[5], C. Vander Pluym[6]. *[1]Pediatric Cardiology, Boston Children's Hospital, Boston, MA, [2]Boston Children's Hospital, Boston, MA, [3]Pediatric Cardiology, Boston Childrens Hospital, Boston, MA, [4]Boston Children's Hospital, Brookline, MA, [5]Children's Hospital, Boston, MA, [6]Boston Children's Hospital, Boston, MA*

(1127) ***Utility of Allomap® in the Developing Immune System: A Single-Center Analysis;*** V. Ravichandran[1], T. Bueno[2], E. Ladich[2], I. Dumitru[3]. *[1]CareDx, Brisbane, CA, [2]Memorial Regional Hospital, Hollywood, FL, [3]Tampa General Hospital, Tampa, FL*

(1128) ***Donor Derived Cell Free DNA is Correlated with DSA and Rejection in Pediatric Heart Transplant Recipients;*** J. Edwards[1], E. Mejia[1], C. Boyle[1], L. Ha[1], M. O'Connor[2], P. Joshi[3], R. White[4], J. Rossano[5], J. Berger[6], C. Wittlieb-Weber[7], K. Lin[8], K. Maeda[9], J. Edelson[1]. *[1]Children's Hospital of Philadelphia, Philadelphia, PA, [2]Children's Hospital of Philadelphia, Wynnewood, PA, [3]CareDx, Reading, MA, [4]The Children's Hospital of Philadelphia, Havertown, PA, [5]The Children's Hospital, Philadelphia, PA, [6]Children's Hospital of Philadelphia, Merion Station, PA, [7]Media, PA, [8]Children's Hosp of Philadelphia, Philadelphia, PA, [9]Children's Hospital of Philadelphia, Penn Valley, PA*

(1129) ***Assessment of an Electronic Healthcare Transition Toolkit to Improve Successful Patient Care Transition;*** K. Beddows[1], K. Hudgins[1], A. Makinde[2], W. Rodriguez[3], D. Hsu[1]. *[1]Montefiore Einstein Heart and Vascular Care Center and Children's Hospital at Montefiore, Bronx, NY, [2]Nursing Informatics and Decision Support, Montefiore Medical Center, Bronx, NY, [3]Montefiore Information Technology, Montefiore Medical Center, Bronx, NY*

(1130) ***Training and Early Career Experience in Pediatric Heart Failure and Transplantation;*** M. R. Varma[1], W. A. Zuckerman[1], D. L. Sutcliffe[2], D. Mokshagundam[3], D. Magnetta[4], J. A. Laks[5], J. A. Spinner[6], N. Bansal[7], A. Butto[8], D. N. Rosenthal[9], R. K. Singh[10]. *[1]Morgan Stanley Children's Hospital of New York Presbyterian at Columbia University, New York, NY, [2]Children's Mercy Hospital, Kansas City, MO, [3]Washington University in St Louis, St Louis, MO, [4]Lurie Children's Hospital of Chicago, Chicago, IL, [5]Johns Hopkins All Children's Hospital, St Petersburg, FL, [6]Baylor College of Medicine, Houston, TX, [7]Mount Sinai Hospital, New York, NY, [8]Children's Healthcare of Atlanta, Atlanta, GA, [9]Stanford University, Stanford, CA, [10]NYU Langone, New York, NY*

(1131) ***Comparison of Functional Echocardiographic Parameters for Detection of Coronary Artery Vasculopathy in Pediatric Patients Following Heart Transplant: A Single-Center Retrospective Study;*** D. Tolani, H. Kim, A. Power, M. Gaitonde. *Pediatric Cardiology, Children's Medical Center of Dallas/University of Texas Southwestern, Dallas, TX*

(1132) ***Nutritional Risk Index - A Novel Objective Nutritional Assessment Tool That Identifies Children at Increased Risk for Worse Outcomes after Heart Transplant;*** R. Shahid, W. Liu, S. Amdani. *Pediatric Cardiology, Cleveland Clinic Children's, Cleveland, OH*

(1133) ***Bicaval Versus Biatrial Heart Transplantation in Pediatric Recipients: A United Network for Organ Sharing Database Analysis;*** C. S. Premananthan, G. Rowe, G. Gill, Q. Chen, J. Malas, M. Zubair, D. Emerson, R. Kim, M. Bowdish, J. Chikwe. *Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA*

(1134) ***Characteristics and Outcomes of Children Determined Not to be Candidates for Heart Transplantation;*** S. Bell, J. H. Berger, C. Boyle, J. B. Edelson, J. J. Edwards, L. Ha, K. Y. Lin, K. Maeda, J. W. Rossano, C. A. Wittlieb-Weber, R. White, M. J. O'Connor. *Children's Hospital of Philadelphia, Philadelphia, PA*

(1135) ***Procurement Distance Patterns and Relationship to Ischemic Time and Graft Survival in Pediatric Heart Transplantation;*** M. Jayaraman[1], L. Mirea[2], B. Wisotzkey[3], S. Zangwill[4]. *[1]Univ of Arizona CoM Phoenix, Phoenix, AZ, [2]Research, Phoenix Children's Hospital, Phoenix, AZ, [3]Cardiology, Phoenix Children's Hospital, Phoenix, AZ, [4]Cardiology, Phoenix Children's Hospital, Phoenix, AZ*

(1136) ***Genetic Testing Provides Anticipatory Guidance in Pediatric Heart Transplant Candidates;*** J. Stansauk, L. McCallen, M. Everitt, K. Chatfield. *Children's Hospital Colorado, Aurora, CO*

(1137) ***HLA Diversity Transcends Donor-Recipient Race Matching;*** J. Spinner[1], A. Fuentes-Baldemar[2], T. Tu[1], P. Robinsin[1], S. Nicholas[2], K. Hope[3], K. Puri[4], S. Denfield[1], H. Tunuguntla[2], J. Price[2], S. Choudhry[2], W. Dreyer[5], P. Jindra[6]. *[1]Baylor College of Medicine, Houston, TX, [2]Texas Children's Hospital, Houston, TX, [3]Texas Children's Hospital, Baylor College of Medicine, Bellaire, TX, [4]Baylor College of Medicine, Bellaire, TX, [5]Baylor College of Med, Houston, TX, [6]UCLA Innunogenetics Center, Los Angeles, CA*

(1138) ***A Report of the First Pediatric Total Artificial Heart Implant in Canada;*** A. Lynch, A. Jeewa, A. Maurich, M. Mazwi, E. Jean-St-Michel, O. Zaulan, A. Floh, S. Yoo, B. Langanecha, O. Honjo. *The Hospital for Sick Children, Toronto, ON, Canada*

(1139) ***WITHDRAWN***

(1140) ***Steroids Reduce Vad-Related Inflammation in Children;*** K. Puri[1], A. Ankola[2], K. Hope[3], B. Elias[4], I. Adachi[4], J. Spinner[2], S. Choudhry[4], J. Price[4], W. Dreyer[5], H. Tunuguntla[4]. *[1]Pediatric Critical Care Medicine and Cardiology, Baylor College of Medicine, Houston, TX, [2]Baylor College of Medicine, Houston, TX, [3]Texas Children's Hospital, Baylor College of Medicine, Bellaire, TX, [4]Texas Children's Hospital, Houston, TX, [5]Baylor College of Med, Houston, TX*

(1141) ***Ventricular Assist Device (VAD) Support Leads to Different Outcomes in Infants with Single Ventricle (SVAD) vs Two Ventricle (2VAD) Anatomy with Severe Heart Failure;*** E. D. Bonura[1], M. Mehegan[2], F. Wan[1], L. R. Gokanapudy Hahn[1], D. Mokshagundam[1], J. Scheel[1], A. M. Ybarra[1], A. Z. Gazit[1], J. R. Miller[1], D. S. Nath[1], P. Eghtesady[1], C. E. Canter[1]. *[1]Washington University, Saint Louis, MO, [2]St Louis Children's Hospital, Saint Louis, MO*

(1142) ***Preteen with Prenatal Agenesis of the Ductus Venosus Presenting with a Portosystemic Shunt and Severe Delayed-Onset Pulmonary Arterial Hypertension: A Rare Case Report;*** D. Youssef[1], S. Richards[1], C. Sheppard[1], L. Hornberger[1], M. Pietrosanu[2], A. Bates[1]. *[1]Department of Pediatric, Division of Pediatric Pulmonary Hypertension, Stollery Children's Hospital, Edmonton, AB, Canada, [2]Department of Mathematical and Statistical Sciences, University of Alberta, Edmonton, AB, Canada*

(1143) ***An Infant Presenting with Severe Pulmonary Hypertension Following Nitric Oxide Treatment: A Case Report;*** D. Youssef[1], S. Richards[1], C. Sheppard[1], C. Gerdung[2], M. Pietrosanu[3], A. Bates[1]. *[1]Department of Pediatric, Division of Pediatric Pulmonary Hypertension, Stollery Children's Hospital, Edmonton, AB, Canada, [2]Department of Pediatric, Division of Pediatric Respiratory Medicine, Stollery Children's Hospital, Edmonton, AB, Canada, [3]Department of Mathematical and Statistical Sciences, University of Alberta, Edmonton, AB, Canada*

(1144) ***Characteristics and Outcomes of Children with Pulmonary Hypertension Undergoing Lung Transplantation: A Single Center Experience;*** E. Seymour[1], M. Gazzaneo[2], R. Morales-Demori[1]. *[1]Pediatrics-Critical Care Medicine, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, [2]Pediatrics-Pulmonary Medicine and Critical Care Medicine, Baylor College of Medicine/Texas Children's Hospital, Houston, TX*

(1145) ***Liver Transplantation for Pediatric Portopulmonary Hypertension;*** J. Wacker, R. Joye, V. McLin, B. Wildhaber, C. Toso, L. Genecand, F. Lador, M. Beghetti. *University Hospitals of Geneva, Geneva, Switzerland*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

POSTER SESSION 03: PHARMACY

Location: Mile High Ballroom

Core Therapies: HEART, LUNG, MCS
Practice Areas: Pharmacy and Pharmacology, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Pharmacy and Pharmacology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Rayid Abdulqawi, MD, PhD, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Alexander Fardman, MD, Chaim Sheba Medical Center, Ramat-Gan, Israel
Livia Goldraich, MD, MSc, Hospital de Clínicas Porto Alegre, Porto Alegre, Brazil
Megan Greene, PharmD, BCPPS, Children's Hospital Colorado, Aurora, CO USA
Edward Horn, PharmD, University of Pittsburgh, Pittsburgh, PA USA
Jill Krisl, PharmD, Houston Methodist Hospital, Houston, TX USA
Amy Kiskaddon, PharmD, MBA, Johns Hopkins All Children's Hospital, St. Petersburg, FL USA

(1146) ***Desensitization Prior to Heart Transplantation;*** H. Brink[1], J. Cox[2], S. Lundgren[2]. *[1]Department of Pharmacy, Nebraska Medical Center, Omaha, NE, [2]University of Nebraska Medical Center, Omaha, NE*

(1147) ***Impact of Early Belatacept Use on 1-Year CAV Progression in Heart Transplant Recipients;*** R. Lavelle[1], A. Loethen[2], C. Murks[3], T. Riley[4], J. Powers[1], A. Jones[5], M. Belkin[3], A. Nguyen[1], J. Grinstein[6], B. Chung[7], S. Kalantari[8], B. Smith[9], N. Sarswat[10], G. Kim[3], S. Pinney[3]. *[1]University of Chicago Medicine, Chicago, IL, [2]University of Chicago Medicine, [3]University of Chicago, Chicago, IL, [4]University of Chicago Medical Center, Matteson, IL, [5]Univ of Chicago Med, Willow Springs, IL, [6]MedStar Heart and Vascular Institute, Chicago, IL, [7]Univ of Chicago, Chicago, IL, [8]University of Chicago University of Chicago, Chicago, IL, [9]University of Chicago Medical Center, Chicago, IL, [10]Univ of Chicago Hospital, Glencoe, IL*

(1148) ***Successful Use of Carfilzomib and Belatacept to Lower Alloantibodies Prior to Heart Transplant: A Case Series;*** A. Loethen[1], R. Lavelle[2], N. Sarswat[3], B. Chung[4], B. Smith[5], S. Kalantari[6], J. Grinstein[7], A. Nguyen[8], M. Belkin[9], G. Kim[9], S. Pinney[9]. *[1]Pharmacy, University of Chicago Medicine, Chicago, IL, [23]Univ of Chicago Hospital, Glencoe, IL, [4]Univ of Chicago, Chicago, IL, [5]University of Chicago Medical Center, Chicago, IL, [6]University of Chicago University of Chicago, Chicago, IL, [7]MedStar Heart and Vascular Institute, Chicago, IL, [8]University of Chicago Medicine, Chicago, IL, [9]University of Chicago, Chicago, IL*

(1149) ***Evaluation of the Tacrolimus Drug Interaction with Voriconazole vs. Clotrimazole in Heart Transplant Recipients;*** E. Posney[1], C. Konopka[1], N. Verlinden[1], M. Kanwar[2], T. Veasey[1]. *[1]Pharmacy, Allegheny General Hospital, Pittsburgh, PA, [2]Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA*

(1150) ***Conversion Between Sirolimus and Everolimus in Orthotopic Heart Transplant (OHT) Recipients;*** T. Wert[1], M. Morrison[1], S. Heeney[2]. *[1]Vanderbilt University Medical Center, Nashville, TN, [2]Yale New Haven Hospital, Killingworth, CT*

(1151) ***Impact of Steroid Withdrawal on Gene Expression Profiling, Donor Derived Cell-Free DNA, and Clinical Outcomes in the SHORE Registry;*** L. Bellumkonda[1], N. Uriel[2], Y. Fu[3], L. Shen[3], K. Qu[4], D. Baran[5]. *[1]Yale University, New Haven, CT, [2]New York Presbyterian, Columbia University Irving Medical Center, New York, NY, [3]Biostatistics and Data Sciences, CareDx, Brisbane, CA, [4]CareDx, Brisbane, CA, [5]Cleveland Clinic Heart, Vascular and Thoracic Institute, Parkland, FL*

(1152) ***Transplant Pharmacist Intervention During Transplant Center Transfer Among Pediatric Patients;*** S. A. Bernard, M. E. Wheeler, K. C. Kolbet, K. E. Schueler, M. D. DiCarlo, M. A. McCord, A. S. Rosier, J. N. Johnson, A. I. Lemke, R. K. Ameduri. *Mayo Clinic, Rochester, MN*

(1153) ***Characterization of CD3-Guided Anti-Thymocyte Globulin Dose Minimization for Renal Sparing Induction after Heart Transplant;*** J. Lange[1], G. Waldman[2], R. Scalzo[3], G. Lewis[4], L. Tsao[5], J. Clark[6]. *[1]Massachusetts General Hospital, Boston, MA, [2]Massachusetts General Hospital, Somerville, MA, [3]Massachusetts General, Boston, MA, [4]Massachusetts Gen Hosp, Boston, MA, [5]Massachusetts General Hospital, Newton, MA, [6]Massachusetts General Hospital, Braintree, MA*

(1154) ***Sirolimus in Heart Transplant Recipients - Review of Sirolimus Dosing Strategies and Conversions;*** K. Ho[1], M. Wai[1], V. Do[1], S. Sen[1], C. Maenza[1], M. Renauer[1], B. Landrum[2], S. Heeney[1]. *[1]Yale New Haven Hospital, New Haven, CT, [2]University of Health Sciences and Pharmacy in St. Louis, St. Louis, MO*

(1155) ***Safe and Effective Early Use of Betablockers after Pediatric Heart Transplantation;*** E. Sagray, L. Tomas, B. C. Cannon, P. L. Wackel, P. W. O'Leary, R. K. Ameduri, T. A. Brown, J. N. Johnson. *Mayo Clinic, Rochester, MN*

(1156) ***Evaluation of Anticoagulation Strategies Post-Heart Transplant;*** M. Borsh[1], S. Bowman[2], E. Lyden[2], M. Hyden[2]. *[1]The University of Kansas Health System, Kansas City, KS, [2]University of Nebraska Medical Center, Omaha, NE*

(1157) ***Evaluation of Hyperbilirubinemia During Glecaprevir/pibrentasvir and Azole Antifungal Coadministration after Cardiothoracic Transplant;*** J. E. Clark, G. Waldman. *Massachusetts General Hospital, Boston, MA*

(1158) ***Comparison of Anti-Mold Prophylaxis and Pharmacist Impact on Tacrolimus Drug Monitoring in Heart Recipients;*** T. Sprague[1], F. Bartlett[1], D. Taber[1], H. Meadows[2], C. Perez[1]. *[1]Medical University of South Carolina, Charleston, SC, [2]Med Univ of South Carolina, Charleston, SC*

(1159) ***Sirolimus and Tacrolimus Dosing Requirements in Pediatric Heart Transplant Recipients to Target Combined Trough Levels;*** A. Jarosz[1], M. Zamberlan[2], G. Owns[3]. *[1]Clinical Pharmacy, University of Michigan, Ann Arbor, MI, [2]University of Michigan, Ann Arbor, MI, [3]Department of Pediatrics, Pediatric Cardiology, University of Michigan, Ann Arbor, MI*

(1160) ***Sticks and Drugs May Break My Bones: A Case of Voriconazole Induced Periostitis;*** J. A. Villalpando[1], N. Narula[2], L. Chhatwani[3]. *[1]Pulmonary and Critical Care, Stanford University, Stanford, CA, [2]Stanford University, Redwood City, CA, [3]Stanford University, Stanford, CA*

(1161) ***Impact of Extended Mycophenolate Dose Modifications on Chronic Lung Allograft Dysfunction Incidence after Lung Transplant;*** K. Grieves, G. Waldman, B. Keller, J. E. Clark. *Massachusetts General Hospital, Boston, MA*

(1162) ***Outcomes and Immunosuppression of Combined Liver-Lung Transplantation: A Single Center Experience;*** S. Farghaly[1], S. Yun[1], A. Mansour[2], K. Stryker[2], J. Joseph[2], S. Forest[3], J. Borgi[3], S. Alsunaid[2]. *[1]Pharmacy, Montefiore Medical Center, Bronx, NY, [2]Pulmonary Failure and Lung Transplantation, Montefiore Medical Center, Bronx, NY, [3]Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY*

(1163) ***Tolerability of Posaconazole as Fungal Prophylaxis in Lung Transplant Patients Compared to Voriconazole;*** H. Hixson[1], S. McCullough[2], S. Haywood[1], C. Shoemaker[1], L. Donohue[1], S. Floyd[1], R. Anderson[1], H. Mannem[1]. *[1]University of Virginia Health, Charlottesville, VA, [2]Swedish Medical Center -HCA Healthcare, Englewood, CO*

(1164) ***A Pharmacogenetic-Based Integrated Limited Sampling Strategy for Mycophenolic Acid in Lung Transplant Recipients;*** L. K. Tague[1], H. Anthony[2], Y. Soo[3], B. Gage[4], A. Gelman[5]. *[1]Pulmonary & Critical Care Medicine, Washington Univ in St. Louis, Saint Louis, MO, [2]Pulmonary & Critical Care Medicine, Washington University, Saint Louis, MO, [3]Division of Biostatistics, Washington University, Saint Louis, MO, [4]General Medicine, Washington University, Saint Louis, MO, [5]Washington University School of Medicine, Saint Louis, MO*

(1165) ***Safety and Effectiveness of Extended Duration Cytomegalovirus Prophylaxis in High-Risk Lung Transplant Recipients: A Retrospective Cohort Study;*** C. J. Iasella[1], A. Smith[2], L. Sacha[3], M. Zhuang[1], P. Sanchez[4], C. Hage[5], J. McDyer[1], C. A. Moore[3]. *[1]University of Pittsburgh, Pittsburgh, PA, [2]West Virginia University, Morgantown, WV, [3]UPMC, Pittsburgh, PA, [4]University of Pittsburgh Medical Center, Pittsburgh, PA, [5]University of Pittsburgh- UPMC, Carmel, IN*

(1166) ***It Cuts Both Ways: Single-Center Retrospective Review Describing Three-Way Interaction Between Flucloxacillin, Voriconazole and Tacrolimus;*** F. S. Burrows, L. M. Carlos, J. Stojanova, D. Marriott. *St Vincent's Hospital, Sydney, Australia*

(1167) ***Weight It Out: Use of Semaglutide for Weight Loss in Patients Undergoing Lung Transplant Evaluation;*** K. Stryker[1], S. Farghaly[2], S. Alsunaid[1], J. Joseph[1], J. BORGI[3], S. Forest[3], A. Mansour[1]. *[1]Montefiore Medical Center, Bronx, NY, [2]Pharmacy, Montefiore Medical Center, Bronx, NY, [3]Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY*

(1168) ***Perioperative Tacrolimus Levels Do Not Impact Early Acute Rejection Rates in Lung Transplant Recipients Receiving Basiliximab Induction;*** S. E. Lawrence[1], K. Schoeppler[2], E. Sartain[1], J. Smith[3], M. P. Steele[3], A. Gray[3]. *[1]University of Colorado Hospital, Denver, CO, [2]Univeristy of Colorado Hospital, Denver, CO, [3]University of Colorado School of Medicine, Denver, CO*

(1169) ***Outcome of Enoxaparin Bridging in Left Ventricular Assist Devices (LVAD) in an Ambulatory Setting : A Continuation Study at Cedars Sinai Medical Center (CSMC);*** L. D. Lam[1], L. Czer[2], C. Runyan[3], I. Otarola[4], J. Jang[4], J. Lau[4], M. Gau[4], K. Hernandez[4], T. Ngo[4], R. Cole[2], J. Moriguchi[5]. *[1]Cedars Sinai Comprehensive Transplant Center, Los Angeles, CA, [2]Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, [3]Cedars Sinai Medical Center, Los Angeles, CA, [4]Pharmacy, Cedars Sinai Med Center, Los Angeles, CA, [5]California Heart Foundation, Los Angeles, CA*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

POSTER SESSION 03: PULMONOLOGY

Location: Mile High Ballroom

Core Therapies: LUNG
Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Pulmonology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Ambalavanan Arunachalam, MD, Northwestern Memorial Hospital, Chicago, IL USA
Christian Benden, MD, MBA, FCCP, University of Zürich, Zürich, Switzerland
David Bennett, MD, PhD, University Hospital of Siena, Siena, Italy,
Marie Budev, DO, MPH, Cleveland Clinic, Cleveland, OH USA
Silvia Campos, PhD, Heart Institute of Sao Paulo Medical School HCFMUSP, São Paulo, Brazil
Letizia Corinna Morlacchi, MD, Milano, Italy
Patrick Evrard, MD, CHU UCL Namur site Godinne, Yvoir, Belgium
Vicky Gerovasili, MD, PhD, Royal Brompton and Harefield Hospitals, Harefield, United Kingdom
Allan Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, NSW Australia
Laurent Godinas, MD, PhD, UZ Leuven, Leuven, Belgium
Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany
Kieran Halloran, MD, MSc, University of Alberta, Edmonton, AB Canada
Peter Hopkins, FRACP, The Prince Charles Hospital, Chermside, QLD Australia
Renea Jablonski, MD, The University of Chicago, Chicago, IL USA
Arun Jose, MD, MS, University of Cincinnati, Cincinnati, OH USA
Erin Lowery, MD, MS, University of Wisconsin-Madison, Madison, WI USA
Julia Maheshwari, MD, University of California, San Francisco, CA USA
Sravanthi Nandavaram, MD, FCCP, University of Kentucky, Lexington, KY USA
Michael Perch, MD, Rigshospitalet, Copenhagen, Denmark
Justin Rosenheck, PharmD, Janssen Pharmaceuticals, Powell, OH USA,
Marc Schecter, MD, University of Florida, Gainesville, FL USA
Laurie Snyder, MD, MHS, Duke University, Durham, NC USA
Grant Turner, MD, MHA, UCLA, Los Angeles, CA USA
Maryam Valapour, MD, MPP, Cleveland Clinic, Cleveland, OH USA
Rajat Walia, MD, St. Joseph's Hospital and Medical Center Norton Thoracic Institute, Phoenix, AZ USA
Chad Witt, MD, Washington University School of Med, Saint Louis, MO USA
Lorenzo Zaffiri, MD, PhD, West Hollywood, CA USA

(1170) ***Sex Differences in Lung Transplantation: A National Cohort Study;*** N. Abdoul[1], C. Legeai[1], A. Olland[2], J. Le Pavec[3], J. Jougon[4], F. Kerbaul[1], R. Dorent[1]. *[1]Agence de la Biomédecine, Saint-Denis la Plaine, France, [2]University Hospital Strasbourg, Strasbourg, France, [3]Hôpital Marie Lannelongue, Le Plessis-Robinson, France, [4]Bordeaux University Hospital CHU, Bordeaux, France*

(1171) ***Between-Center Disparities in Access to Lung Transplantation: Contribution of Candidate and Center Factors;*** N. Abdoul[1], C. Legeai[1], F. Bayer[1], E. Sage[2], H. Mal[3], G. Brioude[4], F. Kerbaul[1], R. Dorent[1]. *[1]Agence de la Biomédecine, Saint-Denis La Plaine, France, [2]Hospital Foch, Suresnes, France, [3]APHP, Bichat, Paris, 75, France, [4]Department of Thoracic Surgery, Hôpital Nord, Aix-Marseille University, Marseille, France*

(1172) ***Association of Ambient Air Pollution Exposure with Poor Outcomes in Lung Transplantation;*** O. Amubieya[1], S. Weigt[1], J. Belperio[2]. *[1]UCLA, Los Angeles, CA, [2]UCLA Pulmonary & C C Med, Los Angeles, CA*

(1173) ***Improving Enrollment and Adherence to the Lung Transplant Home Spirometry Program;*** A. Phero[1], T. Alamin[1], D. Blumenshine[1], H. Lim[2], A. Liu[2], A. Mello[2], O. Bigazzi[2], A. Maiorano[2], N. Madu[2], A. Odisho[2], L. Leard[3], S. Hays[3]. *[1]School of Medicine, University of California, San Francisco, San Francisco, CA, [2]Center for Digital Health Innovation, University of California, San Francisco, San Francisco, CA, [3]UCSF Department of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, San Francisco, CA*

(1174) ***Impact of Collaborative Weight Management: Single Center Study;*** N. Venishetty[1], L. Mahan[2], J. Schellinger[2], S. Bollineni[2], M. Mohanka[2], J. Joerns[2], F. Torres[2], A. Lawrence[2], I. Timofte[2], J. Almandoz[2], V. Kaza[2]. *[1]Texas Tech Health Sciences Center School of Medicine, El Paso, TX, [2]UT Southwestern Medical Center, Dallas, TX*

(1175) ***Gaps in Lung Transplant Training Curriculum in North America;*** H. A. Ali[1], L. Snyder[2]. *[1]Duke University Hospital, Durham, NC, [2]Duke University Medical Center*

(1176) ***Do We Know Patient Preferences? Improving Advance Care Planning in Post-Lung Transplant Patients;*** A. L. Park*, C. Sales*, A. Roland*, A. Venado, S. Hays, L. Leard, A. A. Perez. *University of California San Francisco, San Francisco, CA*

(1177) ***The Humanistic Burden of CLAD-BOS on Patients Undergoing Lung Transplant in the United States;*** M. E. Minshall[1], R. Kemp[1], E. Hofstetter[2], G. Boerner[3], J. McGrain[4], S. J. Siddiqui[4], D. J. Levine[5]. *[1]Market Access and HEOR, Zambon USA Ltd., Cambridge, MA, [2]HealthStrat Consulting, Munich, Germany, [3]HEOR, BREATH Therapeutics GmbH, a Zambon Company, Munich, Germany, [4]Medical Affairs, Zambon USA Ltd., Cambridge, MA, [5]Medicine, Pulmonary, and Critical Care Medicine, Stanford University, Palo Alto, CA*

(1178) ***Is the Third Time the Charm? Evaluating Rehabilitation Differences in Third Lung Transplant Recipients;*** A. R. Graham[1], V. F. Gupta[2], A. Pontula[3], R. Byrd[4], J. Haney[3], M. Hartwig[3], L. Snyder[1]. *[1]Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center, Durham, NC, [2]Duke University School of Medicine, Durham, NC, [3]Division of Cardiovascular and Thoracic Surgery, Duke University Medical Center, Durham, NC, [4]Department of Cardiology, Duke University Medical Center, Durham, NC*

(1179) ***Association of Pre-Transplant Health-Related Quality of Life and Mental Health with Post-Operative Delirium and Coma in Lung Transplant Recipients;*** A. Dragnich[1], I. Feurer[2], S. Rega[3], A. Goree[3], C. Shaver[4]. *[1]Pulmonary and Critical Care Medicine, Vanderbilt, Nashville, TN, [2]Departments of Surgery and Biostatistics, Vanderbilt, Nashville, TN, [3]Vanderbilt, Nashville, TN, [4]Vanderbilt University Medical Center, Nashville, TN*

(1180) ***A Case of Successful Lung Transplantation Following 10 Months of Mechanical Ventilator Dependence;*** A. Joudi[1], C. Myers[2], A. Arunachalam[3], M. Venkata Subramani[4], R. Tomic[5]. *[1]Pulmonary and Critical Care, Northwestern Memorial Hospital, Chicago, IL, [2]Northwestern Feinberg School of Medicine, Chicago, IL, [3]Northwestern Memorial Hospital, Chicago, IL, [4]Northwestern University Feinberg School of Medicine, Chicago, IL, [5]Northwestern University, Chicago, IL*

(1181) ***Successful Use of Percutaneous Right Ventricular Assist Device with Oxygentaor (Oxyrvad) as a Bridge to Lung Transplantation;*** S. Nandavaram[1], S. Keshavamurthy[2], J. Gurley[3]. *[1]University of Kentucky, Nicholasville, KY, [2]Lexington, KY, [3]University of Kentucky, Lexington, KY*

(1182) ***Curbing Disparities in Lung Transplant, One Patient at a Time;*** N. Narula[1], C. Doherty[2], J. Villalpando[3], L. Chhatwani[1], G. Dhillon[1]. *[1]Stanford University, Stanford, CA, [2]Social Work & Case Management Department, Stanford University, Stanford, CA, [3]UT Health San Antonio, San Antonio, TX*

(1183) ***Relative Change in %dd-cfdna Correlates with Allograft Dysfunction Better Than Absolute Values in Lung Allograft Recipients >2 Years Post-Transplant;*** A. J. Trindade[1], K. Chapin[1], A. Mullican[1], J. Gray[2], H. Hoy[1], C. Demarest[1], E. Lambright[1], K. A. McPherson[1], S. Norfolk[1], I. Robbins[1], M. Bacchetta[1], C. M. Shaver[1]. *[1]Vanderbilt University Medical Center, Nashville, TN, [2]CareDx, Brisbane, CA*

(1184) ***The Impact of Granulocyte Telomere Length and Telomere Gap on Early Post-Lung Transplant Outcomes;*** A. J. Trindade, C. M. Shaver, K. Chapin, L. E. Litfin, K. M. Nicholas, C. Demarest, E. Lambright, K. A. McPherson, S. G. Norfolk, I. M. Robbins, M. D. Bacchetta, D. B. Erasmus. *Vanderbilt University Medical Center, Nashville, TN*

(1185) ***Plasma Donor-Derived Cell-Free DNA as a Predictor of Freedom from Chronic Lung Allograft Dysfunction More Than 3 Years after Lung Transplant;*** D. Zhu, H. Mannem. *University of Virginia, Charlottesville, VA*

(1186) ***Donor Derived Cell Free Dna after Lung Transplantation: Marker for Acute and Chronic Lung Allograft Injury?;*** P. Jaksch[1], G. Muraközy[2], A. Benazzo[3], Z. Kovacs[2], K. Hoetzenecker[3], G. Fischer[4]. *[1]Medical University Vienna, Austria, Wien, Austria, [2]Division of Thoracic Surgery, Medical University Vienna, Vienna, Austria, [3]Medical University of Vienna, Wien, 9, Austria, [4]Department of Blood Group Serology and Transfusion Medicine, Medical University Vienna, Vienna, Austria*

(1187) ***Study Design for a Randomized Control Trial of Lung Allograft Monitoring with Blood Donor-Derived Cell-Free DNA Assessments (LAMBDA 001);*** M. Keller[1], D. Ross[2], S. Bhorade[3], S. Agbor-Enoh[4]. *[1]NIH, Bethesda, MD, [2]Natera, San Carlos, CA, [3]Natera, Oak Brook, IL, [4]National Institutes of Health, Bethesda, MD*

(1188) ***Assessment of Dd-cfDNA Between Stable Single and Double Lung Recipients;*** D. Levine[1], B. Saez Gimenez[2], C. Pham[3], S. Jyothula[4], S. Casas[3], C. Berastegui Garcia[2], V. Ruiz[5], M. Arjona Peris[2], C. Bravo Masgoret[2], A. Roman[2], S. Gomez[6]. *[1]Stanford University, Palo Alto, CA, [2]Pulmonology Service, Hospital Vall d'Hebron, Barcelona, Spain, [3]Medical Affairs, CareDx, Brisbane, CA, [4]UT Health, McGovern School of Medicine, Houston, TX, [5]Vall d'Hebron Research Institute, [6]Hospital Vall d'Hebron Research Institute, Barcelona, Spain*

(1189) ***Clinical Relevance of Donor-Derived Cell-Free Dna and Fragment Size Analysis During the First Month after Lung Transplantation;*** P. Pedini[1], B. Coiffard[2], S. Casas[3], F. Fina[4], A. Boutonnet-Rodat[4], J. Baudey[1], A. Basire[1], C. Frassati[1], J. Chiaroni[1], M. Gaubert[2], C. Picard[1]. *[1]Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France, [2]Lung Transplant Department, APHM, Marseille, France, [3]CareDx, Stockholm, Sweden, [4]ADELIS Tech, Labege, France*

(1190) ***Airway Epithelial Cell Apoptosis in Acute Cellular Rejection (ACR) and Chronic Lung Allograft Dysfunction (CLAD);*** B. Renaud-Picard[1], T. Daigneault[1], G. Berra[1], M. Olivia[1], J. Fortunato[1], D. Hwang[2], P. Pal[3], S. Juvet[1], T. Martinu[1]. *[1]Toronto General Hospital Research Institute, Toronto Lung Transplant Program, Toronto, ON, Canada, [2]Sunnybrook Health Sciences Centre, Toronto, ON, Canada, [3]Department of Pathology, Toronto General Hospital, Toronto, ON, Canada*

(1191) ***Diagnostic Utility of Surveillance Transbronchial Biopsies after the First Post-Lung Transplant Year;*** M. Dianti[1], T. Martinu[2], A. Sidhu[3], E. Huszti[4], R. Ghany[1], L. Singer[4], M. Aversa[1]. *[1]University of Toronto, Toronto, ON, Canada, [2]Toronto General Hospital/ UHN, Toronto, ON, Canada, [3]Toronto Lung Transplant Program, Toronto, ON, Canada, [4]University Health Network, Toronto, ON, Canada*

(1192) ***Role of BAL Lymphocytosis and Blood Eosinophils in the Prediction of Acute Rejection in Lung Transplant Patients;*** S. Aguado Ibáñez, R. Laporta Hernandez, M. Aguilar Perez, R. Sanabrias, C. García Fadul, G. Diaz Nuevo, C. Lopez Garcia-Gallo, M. Lázaro Carrasco de la Fuente, C. Salas Antón, A. Royuela Vicente, B. Jara Chinarro, P. Ussetti. *Hospital Universitario Puerta de Hierro, Majadahonda, Spain*

(1193) ***The Molecular Microscope Diagnostic System versus Histology in the Evaluation of Acute Cellular Rejection in Lung Transplant Recipients;*** A. Zajacova[1], M. Mackova[2], K. Halloran[2], D. Rakita[1], M. Svorcova[3], J. Vachtenheim[3], J. Pozniak[3], J. Simonek[3], L. Fila[1], R. Lischke[3], P. F. Halloran[2], J. Havlin[3]. *[1]Prague Lung Transplant Program, Department of Pneumology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic, [2]Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, [3]Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic*

(1194) ***The Presence of Activated Pepsin in Bronchoalveolar Lavage is Associated with Acute Cellular Rejection in Lung Transplant Recipients;*** A. R. Latorre-Rodríguez, D. Sindu, S. Tokman, A. Arjuna, S. K. Mittal. *Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(1195) ***Donor Derived Cell Free DNA Provides Insights Into DSA Characterization in Lung Transplantation;*** S. Jyothula[1], R. Hussain[1], C. Pham[2], M. Patel[1], J. Patel[1], J. Gray[2], K. Qu[3]. *[1]Memorial Hermann Hospital / University of Texas at Houston, Houston, TX, [2]Medical Affairs, CareDx, Brisbane, CA, [3]CareDx, Brisbane, CA*

(1196) ***Infectious Complications after Conversion to Belatacept in Lung Transplant Recipients;*** D. Rudym[1], T. Lewis[2], V. LaMaina[2], M. Lesko[1], J. Natalini[1], E. Fitzpatrick[2], A. Stiefel[2], J. Ohanian[2], T. Geraci[3], J. Chan[3], S. Chang[3], L. Angel[1]. *[1]Division of Pulmonary, Critical Care and Sleep Medicine, NYU Langone Health, New York, NY, [2]Transplant Institute, NYU Langone Health, New York, NY, [3]Department of Cardiothoracic Surgery, NYU Langone Health, New York, NY*

(1197) ***Guillain-Barré Syndrome after Mrna-1273 Covid-19 Vaccine Booster in an Immunosuppressed Double Lung Transplant Recipient;*** D. Sindu, A. Arjuna, K. Mcannally, B. Buddhdev, R. Walia, H. Mohamed, H. Abdelrazek, A. Omar, S. Tokman. *Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(1198) ***Magnetic Resonance-Guided Focused Ultrasound Thalamotomy for Treatment of Severe Essential Tremor in a Lung Transplant Recipient;*** P. Modi[1], L. Qiu[2], T. Fallah[3], A. Courtwright[1], C. Halpern[2]. *[1]Advanced Lung Diseases and Lung Transplantation, Hospital of the University of Pennsylvania, Philadelphia, PA, [2]Department of Neurosurgery, Pennsylvania Hospital, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, [3]Ohio State University Wexner Medical Center, Columbus, OH*

(1199) ***Immune Globulin Repletion for Hypogammaglobulinemia Does not Improve Outcomes Post-Lung Transplant;*** L. Sacha[1], T. Werner[1], C. Moore[1], J. McDyer[2], P. Sanchez[1], C. Iasella[2]. *[1]University of Pittsburgh Medical Center, Pittsburgh, PA, [2]University of Pittsburgh, Pittsburgh, PA*

(1200) ***Evusheld Protects Against SARS-CoV-2 in Lung Transplant Recipients;*** D. Eck, K. Chapin, A. Siedlecki, J. Barnes, A. Trindade, C. Shaver. *Vanderbilt University Medical Center, Nashville, TN*

(1201) ***Belatacept as a Novel Pharmacological Strategy to Preserve Renal Function without Allograft Dysfunction;*** A. R. Latorre-Rodríguez[1], D. Razia[2], T. Walia[1], L. Cherrier[1], K. J. Goodlet[3], R. Mosquito[3], A. Arjuna[1]. *[1]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, [2]Department of Internal Medicine, Creighton University School of Medicine, Phoenix, AZ, [3]Midwestern University College of Pharmacy, Glendale, AZ*

(1202) ***Alemtuzumab Induction Spares Donor Tissue Resident Memory T Cells after Lung Transplantation;*** A. Bondonese[1], A. Craig[1], R. Koshy[1], R. Burke[1], Y. Zhang[2], J. McDyer[1], M. E. Snyder[1]. *[1]Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, [2]Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittbsurgh, PA*

(1203) ***Unlike the US-LAS, the Eurotransplant-LAS is Not a Risk Factor for De-Novo Donor Specific Antibodies;*** S. Schwarz[1], N. Fruhmann[1], A. Benazzo[1], D. Koren[2], G. Fischer[2], P. Jaksch[1], K. Hoetzenecker[1]. *[1]Thoracic Surgery, Medical University of Vienna, Vienna, Austria, [2]Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria*

(1204) ***Increased Antibody Response to a Five-Dose Regime of Covid-19 Vaccine in Lung Transplant Patients;*** J. P. van Gemert[1], F. J. Steenberg[1], C. van Leer Buter[2], H. A. Kerstjens[1], O. W. Akkerman[1], E. A. Verschuuren[1], T. Gan[1]. *[1]Department of Respiratory Diseases, Tuberculosis and Lung Transplantation, University Medical Centre Groningen, Groningen, Netherlands, [2]Department of Virology, University Medical Centre Groningen, Groningen, Netherlands*

(1205) ***Effect of T3 on Lung Ischemia-Riperfusion Injury in an Evlp Rat Model: Results of Ad Interim Analyses;*** I. Righi[1], L. Rosso[2], M. Cattaneo[2], C. Lonati[1], L. Vivona[1], M. Pinti[3], M. Battistin[1], A. Lombardi[1], V. Selleri[3], L. Fugazzola[4], I. Campi[4], M. Nosotti[2]. *[1]Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milano, Milano, Italy, [2]University of Milan, Milano, Italy, [3]Dipartimento di Scienze della Vita, Modena, Modena, Italy, [4]Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS Milano, Milano, Italy*

(1206) ***Clinical Implications of Microbiome on Acute Rejection in Lung Transplant Recipients;*** M. Bing[1], C. M. Shedd[2], H. W. Lwin[1], V. Kaza[2], S. Bollineni[2], L. Mahan[2], M. Mohanka[2], A. Lawrence[2], J. Joerns[2], M. Wait[2], M. Peltz[2], L. Huffman[2], A. Hackmann[2], A. Iacono[3], C. Heid[2], F. Torres[2], S. Pham[4], I. Timofte[2]. *[1]University of Maryland, Baltimore, MD, [2]UT Southwestern Medical Center, Dallas, TX, [3]Northwell Health, Manhasset, NY, [4]Jacksonville, FL*

(1207) ***Anellovirus: A Novel Marker for Overimmunosuppression and Risk of Infection in Lung Transplant Recipients;*** Y. Hamad[1], A. Charya[2], H. Kong[3], M. Jang[4], T. Andargie[5], P. Shah[6], J. Mathew[7], J. Orens[8], S. Aryal[9], S. Nathan[10], S. Agbor-Enoh[1]. *[1]National Institutes of Health, Bethesda, MD, [2]NHLBI, Columbia, MD, [3]National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, [4]NHLBI/NIH, Bethesda, MD, [5]National Heart, Lung, and Blood Institute, Bethesda, MD, [6]Johns Hopkins University, Rockville, MD, [7]Johns Hopkins University, Sparrows Point, MD, [8]Johns Hopkins Univ, Baltimore, MD, [9]Inova, Falls Church, VA, [10]Inova Fairfax Hospital, Vienna, VA*

(1208) ***Generation of Personalized Donor-Specific Snv Maps from Cfdna in Ex Vivo Lung Perfusate Using Nanopore Sequencing;*** H. Yamamoto[1], J. Allen[1], G. W. Wilson[1], A. Akhter[1], P. C. Zuzarte[2], J. T. Simpson[2], S. Keshavjee[1], J. C. Yeung[1]. *[1]Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, [2]Ontario Institute for Cancer Research, Toronto, ON, Canada*

(1209) ***A Case of Dual Organ Lung-Kidney Transplant in a Highly Sensitized Patient;*** A. Joudi[1], C. Myers[2], A. Arunachalam[3], M. Venkata Subramani[4], R. Tomic[5]. *[1]Pulmonary and Critical Care, Northwestern Memorial Hospital, Chicago, IL, [2]Northwestern Feinberg School of Medicine, Chicago, IL, [3]Northwestern Memorial Hospital, Chicago, IL, [4]Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, IL, [5]Northwestern University, Chicago, IL*

(1210) ***Total Cell-Free Dna May Reflect Non-Rejection Causes of Lung Allograft Injury;*** S. Sultan[1], D. Ross[2], N. Ioannou[2], A. Betensley[1], N. De Oliveira[3]. *[1]Medical College of Wisconsin, Milwaukee, WI, [2]Natera, San Carlos, CA, [3]Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI*

(1211) ***Hyperacute Rejection of the Lung Allograft Despite Perioperative Desensitization. What's Next;*** M. Younis, C. Vahdatpour, A. Shahmohammadi, A. Emtiazjoo. *Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL*

(1212) ***Successful Lung Transplantation for Genetic Pulmonary Alveolar Proteinosis Caused by Methionyl-TRNA Synthetase (MARS) Mutation: 2 Cases;*** C. Roy[1], N. Allou[2], D. Grenet[1], C. Cerf[3], F. Parquin[3], R. Borie[4], B. Zuber[3], E. Sage[5], M. Glorion[5], A. Roux[1], C. Picard[1], S. De Miranda[1], L. Beaumont - Azuar[1], S. Colin de Verdière[1], M. Le Guen[6], A. Hamid[1], A. Hadchouel[7], O. Brugiere[1]. *[1]Pulmonology Dept, Foch Hospital, Suresnes, France, [2]University Hospital Centre of Réunion, Saint Denis, France, [3]Intensive Care Unit Department, Foch Hospital, Suresnes, France, [4]Pulmonology Dept, Bichat Hospital, AP-HP, Paris, France, [5]Thoracic Surgery Department, Foch Hospital, Suresnes, France, [6]Anesthesiology Dept, Foch Hospital, Suresnes, France, [7]Pulmonology Dept, Necker Hospital, AP-HP, Paris, France*

(1213) ***Brachytherapy Treatment for Bronchial Anastomosis Narrowing After Invasive Aspergillosis;*** O. M. Glueck[1], J. Kovacs[1], S. Corradini[2], J. M. Fertmann[1], W. G. Sienel[1], T. Kauke[1], R. Hatz[1], S. Michel[3], M. Irlbeck[4], N. Kneidinger[5], C. Schneider[1]. *[1]Thoracic Surgery, University Hospital of the Ludwig Maximilians University, Munich, Germany, [2]Radiation Therapy, University Hospital of the Ludwig Maximilians University, Munich, Germany, [3]Cardiac Surgery, University Hospital of the Ludwig Maximilians University, Munich, Germany, [4]Anaesthesiology and Intensive Care, University Hospital of the Ludwig Maximilians University, Munich, Germany, [5]Pulmonology, University Hospital of the Ludwig Maximilians University, Munich, Germany*

(1214) ***Phlegmasia Cerulea Dolens Post Lung Transplant: A Case Report;*** L. Marinak[1], D. G. Tang[2], S. Aryal[2], M. Mani[2]. *[1]Inova Fairfax Medical Campus, Falls Church, VA, [2]Inova, Falls Church, VA*

(1215) ***Think Inside The Box: Constrictive Pericarditis after Pediatric Lung Transplant;*** J. Spinner[1], G. Perumal[1], G. Mallory[2], E. Melicoff-Portillo[3], J. Heinle[3]. *[1]Baylor College of Medicine, Houston, TX, [2]Texas Children 's Hospital/Baylor College of Medicine, Houston, TX, [3]Texas Children's Hospital, Houston, TX*

(1216) ***A Novel Phenotype of Chronic Lung Allograft Dysfunction (CLAD);*** D. Sindu, A. Arjuna, K. Mcannaly, B. Buddhdev, H. Mohamed, H. Abdelrazek, R. Walia, A. Omar, S. Tokman. *Norton Thoracic Institute, St. Joseph's Hosp and MC, Phoenix, AZ*

(1217) ***Acute Fibrinous and Organizing Pneumonia (AFOP) in Lung Transplant Recipient: A Case Report of Successful Treatment with Infliximab® and Tocilizumab®;*** C. Abellan[1], F. Ioakeim[2], A. Casutt[2], Z. Balmpouzis[2], B. Lechartier[2], L. Noirez[2], J. Aubert[2], S. Rotman[3], A. Koutsokera[4]. *[1]Internal Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, [2]Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, [3]University Hospital, Lausanne, Switzerland, [4]Lausanne University Hospital, Lausanne, Switzerland*

(1218) ***Treating 2 Birds with 1 Stone: Lobectomy for Diagnosis of Lung Cancer and Lung Volume Reduction Surgery Post-Transplant;*** J. Pryor[1], N. Agarwal[1], S. Randhawa[2], N. Thomas[1], M. Steele[1], A. Gray[2], J. Smith[3]. *[1]University of Colorado, Aurora, CO, [2]University of Colorado, Denver, CO, [3]University of Colorado School of Medicine, Denver, CO*

(1219) ***CAR-T Treatment for Refractory PTLD after Lung Transplantation;*** K. Veit[1], T. Pena[1], J. Klesney-Tait[2]. *[1]University of Iowa, Iowa City, IA, [2]Univ of Iowas Hospitals, Iowa City, IA*

(1220) ***Pulmonary Vein Stenosis Mimicking Chronic Lung Allograft Dysfunction after Single Lung Transplantation;*** J. Taylor[1], G. Singh[2], B. Love[3], S. Scheinin[2], H. Seethamraju[1]. *[1]Pulmonary, Critical Care and Sleep Medicine, Mount Sinai Hospital, New York, NY, [2]Department of Cardiovascular Surgery, Mount Sinai Hospital, New York, NY, [3]Pediatrics, Mount Sinai Hospital, New York, NY*

(1221) ***Tacrolimus Induced Optic Neuritis in a Lung Transplant Recipient;*** A. Graham, C. Johnson. *Duke University, Durham, NC*

(1222) ***Identifying Imaging Biomarkers Before the Onset of Chronic Lung Allograft Dysfunction;*** K. Levin[1], B. Lavon[2], P. Muchmore[2], G. Westall[3], G. Snell[1]. *[1]Alfred Hospital, Melbourne, Australia, [2]Fluidda Inc., New York, NY, [3]Alfred Hospital, Prahran, Australia*

(1223) ***Diffusion Capacity and Six-Minute Walk Test in Lung Transplant Recipients as Tools to Assess Chronic Lung Allograft Dysfunction;*** N. Agarwal[1], R. Pomponio[1], R. Peterson[1], K. Likosky[1], J. Smith[2], A. Gray[3]. *[1]University of Colorado, Aurora, CO, [2]University of Colorado School of Medicine, Denver, CO, [3]University of Colorado, Denver, CO*

(1224) ***Peripheral Vesicular-Bound Hla-g as Predictor of Graft Tolerance after Lung Transplantation;*** O. Brugiere[1], D. Dreyfuss[2], R. Guilet[2], S. Hirschi[3], B. Renaud-Picard[4], M. Reynaud-Gaubert[5], A. Nieves[6], V. Bunel[7], J. Messika[8], X. Demant[9], L. Jérôme[10], G. Dauriat[11], C. Saint-Raymond[12], L. Falque[12], J. Mornex[13], A. Tissot[14], A. Foureau[15], A. Leborgne-Krams[16], V. Boussaud[17], A. MAgnan[18], C. Picard[19], A. Roux[19], E. Edgardo Carosella[20], A. Vallée[18], R. Rouas Freiss[20], J. Le MAoult[20]. *[1]Hôpital Foch, Suresnes, France, Suresnes, France, [2]Hopital Saint-Louis, Paris, France, [3]Hopitaux Universitaires de Strasbourg Nouvel Hopital Civil, Strasbourg, France, [4]Nouvel Hopital Civil, Strasbourg, France, [5]Sainte Marguerite Hospital, Marseille, France, [6]CHU de Marseille, MArseille, France, [7]APHP, Clichy, France, [8]Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, 92, France, [9]Boardeaux, Pessac, France, [10]Centre Chirurgical Marie-Lannelongue, Le Plessi-Robinson, France, [11]Centre Chirurgical MArie Lannelongue, Le Plessi-Robinson, France, [12]CHU Grenoble, Grenoble, France, [13]Hopital Louis Pradel, France, [14]CHU Nantes, Paris, France, [15]CHU Nantes, Nantes, France, [16]CHU Toulouse, Toulouse, France, [17]HEGP, Paris, France, [18]Hôpital Foch, Suresnes, France, [19]Foch Hospital, Suresnes, France, [20]Hôpital Saint-Louis, Paris, France*

(1225) ***Results from Randomized Trial of Pirfenidone in Patients with Chronic Rejection (STOP-CLAD Study);*** M. P. Combs[1], E. Belloli[1], N. Gargurevich[1], K. R. Flaherty[1], S. Murray[2], C. J. Galbán[1], V. Lama[1]. *[1]University of Michigan, Ann Arbor, MI, [2]Univ of Michigan, Ann Arbor, MI*

(1226) ***Serum Proteomics for Fibrotic Markers in Early Detection of Bronchiolitis Obliterans Syndrome after Lung Transplantation;*** E. A. van der Ploeg[1], A. Faiz[2], G. Teitsma[3], B. N. Melgert[4], P. Horvatovich[5], J. K. Burgess[3], T. Gan[6]. *[1]Department of Pulmonary Medicine, University Medical Centre Groningen, Groningen, Netherlands, [2]Respiratory Bioinformatics and Molecular Biology (RBMB), University of Technology Sydney, Sydney, Australia, [3]Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, Groningen, Netherlands, [4]Department of Molecular Pharmacology, University of Groningen, Groningen, Netherlands, [5]Department of Analytical Biochemistry, University of Groningen, Groningen, Netherlands, [6]Univ Med Center Groningen, Groningen, Netherlands*

(1227) ***Nonspecific Radiographic Patterns Predominate at Chronic Lung Allograft Dysfunction (CLAD) Onset;*** M. Dianti[1], G. Rani Karur[2], C. Houbois[2], L. Levy[1], M. Aversa[1], C. Chow[1], L. Singer[1], M. McInnis[2], T. Martinu[1]. *[1]Toronto Lung Tranplant Program, University Health Network, Toronto, ON, Canada, [2]Department of Medical Imaging, University Health Network, Toronto, ON, Canada*

(1228) ***The Interaction Between CfDNA and Gerd;*** A. Cochrane[1], M. Wahl[1], M. Fregoso[2], M. Schreffler[3], S. Nathan[4], S. Aryal[5]. *[1]Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA, [2]Inova Fairfax Hospital, Falls Church, VA, [34]Inova Fairfax Hospital, Vienna, VA, [5]Inova, Falls Church, VA*

(1229) ***Fibroblast Activation Protein Alpha (fapa) in Chronic Lung Allograft Dysfunction;*** I. Moneke[1], J. Burkle[2], E. Pfaffendorf[3], P. Bronsert[3], G. Zissel[4], S. Faendrich[4], B. Passlick[2], S. Diederichs[5], W. Jungraithmayr[2]. *[1]Thoracic Surgery, University of Freiburg - Medical Center, Freiburg, Germany, [2]Thoracic Surgery, University of Freiburg - Medical Center, Freiburg, Germany, [3]Pathology, University of Freiburg - Medical Center, Freiburg, Germany, [4]Pulmology, University of Freiburg - Medical Center, Freiburg, Germany, [5]University of Freiburg - Medical Center, Thoracic surgery, Germany*

(1231) ***Remote vs Local Ex-Vivo Lung Perfusion, a Single Center Experience;*** P. Balasubramanian[1], M. Thomas[2], I. Makey[2], F. Alvarez[3], T. Narula[3], S. Pham[2], K. Landolfo[4], M. El-Sayed Ahmed[2], S. Jacob[2], S. Shah[3], J. Mallea[5]. *[1]Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL, [2]Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, FL, [3]Department of transplantation, Mayo Clinic, Jacksonville, FL, [4]Thoracic Surgery, Mayo Clinic, Jacksonville, FL, [5]Division of Pulmonary, Allergy and Sleep Medicine, Department of Transplantation, Mayo Clinic, Jacksonville, FL*

(1232) ***Extending Cold Ischemic Time Using LUNGguard: A Single Center Experience in Time Shifting;*** M. Botros[1], A. Alsaghayer[2], C. Tanabe[1], K. Armas[3], M. Mabry[2], A. Goodarzi[3], S. Yau[2], J. Youssef[4], H. Huang[5], D. Ren[6], E. Suarez[7]. *[1]Medicine, Houston Methodist Hospital, Houston, TX, [2]Houston Methodist Hospital, Houston, TX, [3]Houston Methodist Hospital, Houston, MO, [4]Houston Methodist Hos, Sugar Land, TX, [5]Houston Methodist J.C. Walter Jr. Transplant Center, Houston, TX, [6]Cardiovascular Surgical Assoc, Houston, TX, [7]Houston, TX*

(1233) ***Utilization and Outcomes with Single Lung Transplantation Following Ex Vivo Lung Perfusion Using a Centralized Lung Evaluation System at a Dedicated Facility;*** J. Mallea[1], Z. Kon[2], A. Brown[3], M. Hartwig[4], P. Sanchez[5], C. Keller[6], D. Erasmus[7], D. Dilling[8], J. D'Cunha[9], M. Roberts[10], M. R. Sketch[11], D. Johnson[11], K. McCurry[12]. *[1]Mayo Clinic Florida, Jacksonville, FL, [2]Univ of MD Sch of Med, New York, NY, [3]Inova Fairfax Hospital, Fairfax, VA, [4]Duke University Medical Center, Durham, NC, [5]University of Pittsburgh Medical Center, Pittsburgh, PA, [6]Mayo Clinic Transplant Center, Jacksonville, FL, [7]Mayo Clinic, Nashville, TN, [8]Loyola University Chicago, Stritch School of Medicine, Maywood, IL, [9]Mayo Clinic Arizona, Phoenix, AZ, [10]Lung Bioengineering, Inc., Silver Spring, MD, [11]United Therapeutics Corporation, Durham, NC, [12]Cleveland Clinic, Solon, OH*

(1234) ***Comparison of Lung Utilization from Nrp-dcd vs Non-Nrp Dcd Using Evlp;*** S. A. Francois[1], S. Popa[2], C. M. Shaver[1], J. Mallea[3], M. Hartwig[4], Y. Patel[1], W. Tucker[1], B. Zofkie[5], R. Shelton[2], J. Benjamin[6], A. Brown[6], M. Bacchetta[7]. *[1]Vanderbilt University Medical Center, Nashville, TN, [2]Lung Bioengineering, Inc., Silver Spring, MD, [3]Mayo Clinic Florida, Jacksonville, FL, [4]Duke University Medical Center, Durham, NC, [5]Lung Bioengineering Inc., Jacksonville, FL, [6]Lung Bioengineering, Inc., Jacksonville, FL, [7]Vanderbilt University Medical Center, Mt Juliet, TN*

(1235) ***Lung Transplant Waitlist Outcomes Before and after 2021 LAS Revision;*** S. Greissman[1], K. Laothamatas[1], J. Costa[2], F. D'Ovidio[2], H. Grewal[2], P. Lemaitre[2], G. Magda[2], A. Miller[2], S. Patel[2], H. Robbins[2], L. Shah[2], J. Sonett[2], B. Stanifer[2], S. Arcasoy[2], L. Benvenuto[2]. *[1]New York Presbyterian - Columbia University Medical Center, New York, NY, [2]Columbia University Medical Center, New York, NY*

(1236) ***Moderately Prolonged Cold Ischemic Time. Does It Impact Outcome of Lung Transplantation;*** H. Ahmed, D. Garcia Saez, B. Zych, J. Dunning, E. Khoshbin. *Royal Brompton and Harefield Hospital as part of Guys and St Thomas NHS Foundation Trust, London, United Kingdom*

(1237) ***Pulmonary Physical Therapy Protocol to Evaluate Lung Transplant Candidates;*** C. Meirelles[1], A. Farnsworth[1], J. Rosenheck[2], V. Ramsammy[2], D. Nunley[2]. *[1]School of Health and Rehabilitation Sciences/Physical Therapy Division, The Ohio State University College of Medicine, Columbus, OH, [2]Division of Pulmonary, Critical Care & Sleep Medicine, The Ohio State University College of Medicine., Columbus, OH*

(1238) ***Quantitative Torque Teno Virus Plasma DNA Assessments May Complement Donor-Derived Cell-Free DNA for Detection of Immunologic Events after Lung Transplantation;*** J. P. Rosenheck[1], P. Van Hummelen[2], A. Butskova[2], N. Haque[2], S. M. Bhorade[2], B. C. Keller[3], D. J. Ross[2]. *[1]The Ohio State University, Columbus, OH, [2]Natera Inc, San Carlos, CA, [3]Massachusetts General Hospital, Boston, MA*

(1239) ***The Impact of Antifibrotic Medications on Lung Transplant Airway Dehiscence, Primary Graft Dysfunction, and 30-Day Survival: A Meta-Analysis;*** A. M. Courtwright[1], J. M. Diamond[2], H. J. Goldberg[3]. *[1]Hospital of the University of Pennsylvania, Philadelphia, PA, [2]Hospital of University of Pennsylvania, Philadelphia, PA, [3]Brigham & Women's Hospital, Boston, MA*

(1240) ***Association of Acute Kidney Injury Grade with Primary Graft Dysfunction Grade after Lung Transplantation: A Cohort Study;*** T. Toyoda, B. L. Thomae, V. Kandula, A. J. Manerikar, T. Kaiho, Y. Yagi, E. Cerier, A. Bharat, C. Kurihara. *Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL*

(1241) ***Association of Acute Kidney Injury Grade with Chronic Kidney Disease after Lung Transplantation: A Cohort Study;*** T. Toyoda, B. L. Thomae, V. Kandula, A. J. Manerikar, T. Kaiho, Y. Yagi, E. Cerier, A. Bharat, C. Kurihara. *Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL*

(1242) ***The High Incidence of Non-Melanoma Skin Cancer-Related Death in Australian Lung Transplant Recipients;*** H. Yeoh[1], H. Shingles[2], B. Levvey[2], G. Snell[2], M. C. Andrews[1]. *[1]Medical Oncology, Alfred Health, Melbourne, Australia, [2]Lung Transplant Service, Alfred Health, Melbourne, Australia*

(1243) ***Lung Transplant Airway Complications Treated with Biodegradable Stents; A Multi-Center Experience;*** R. van Pel[1], T. Gan[1], K. Klooster[1], J. M. Daniels[2], D. Ruigrok[3], M. Hellemons[4], D. Slebos[1]. *[1]University Medical Center Groningen, Groningen, Netherlands, [2]Amsterdam UMC, Amsterdam, Netherlands, [3]UMC Utrecht, Utrecht, Netherlands, [4]Erasmus MC, Rotterdam, Netherlands*

(1244) ***Outcomes of Flow Cytometry Crossmatch Positive Lung Transplant Recipients;*** B. M. Menachem, H. Ali. *Pulmonary and Critical Care, Duke University Hospital, Durham, NC*

(1245) ***Lack of Correlation Between Both Percent and Absolute Count Dd-CfDNA and Primary Graft Dysfunction;*** D. Levine[1], K. Noda[2], C. Pham[3], M. Zhou[4], P. Sanchez[2]. *[1]Stanford University, Palo Alto, CA, [2]University of Pittsburgh Medical Center, Pittsburgh, PA, [3]Medical Affairs, CareDx, Brisbane, CA, [4]CareDx, Brisbane, CA*

(1246) ***Novel Regional Ventilation Evaluation of Abnormalities of the Lung In Advanced Lung Disease (REVEAL Study);*** G. Snell[1], L. Holsworth[1], G. Westall[1], N. Punjabi[2], T. Siddharthan[2], J. Dusting[3], N. Eikelis[3], A. Fouras[3], J. Kirkness[3], V. Lui[3], P. Pirakalathanan[3]. *[1]Alfred Hospital, Melbourne, Australia, [2]Miller School of Medicine, University of Miami, Miami, FL, [3]4DMedical Limited, Melbourne, Australia*

(1247) ***Rapidly Declining Rates of Single Lung Transplant for COPD and ILD in the U.S;*** L. Benvenuto[1], H. Grewal[2], K. Laothamatas[3], M. Anderson[4], M. Snyder[5], S. Greissman[6], J. Costa[7], L. Shah[8], H. Robbins[1], G. Magda[9], J. Sonett[10], P. Lemaitre[11], F. D'Ovidio[1], S. Arcasoy[12]. *[1]Columbia University Medical Center, New York, NY, [2]Columbia University Irving MC, Edgewater, NJ, [3]Columbia University Irving MC, New York, NY, [4]University of Pennsylvania, New York, NY, [5]University of Pittsburgh, Pittsburgh, PA, [67]Columbia Univ MC, New York, NY, [8]New York, NY, [9]Columbia University Vagelos College of Physicians and Surgeons, New York, NY, [10]Columbia Presbyterian MC, New York, NY, [11]Columbia University MC, New York, NY, [12]Columbia University, Allendale, NJ*

(1248) ***Outcomes of Lung Transplantation in Patients with Hereditary Pulmonary Fibrosis - A Systematic Review;*** J. Bordas - Martinez[1], J. R. Miedema[2], R. A. Hoek[2], R. H. Galjaard[3], M. H. Raaijmakers[4], A. M. Aalbers[4], M. S. Wijsenbeek[2], M. Molina - Molina[1], M. E. Hellemons[2]. *[1]Dept of Respiratory Med, Bellvithe Univ Hosp, IDIBELL, Barcelona Univ, Barcelona, Spain, [2]Dept of Respiratory Med and Erasmus MC Transplant Inst, Erasmus MC Univ MC, Rotterdam, Netherlands, [3]Dept of Clinical Genetics, Erasmus MC University MC, Rotterdam, Netherlands, [4]Dept of Hematology, Erasmus MC Cancer Inst, Rotterdam, Netherlands*

(1249) ***Impact of Neutropenia and Granulocyte Colony-Stimulating Factor Treatment in Lung Transplant Recipients;*** R. Sanabrias, R. Laporta, M. Aguilar-Perez, L. María Teresa, C. García Fadul, S. Aguado, A. Royuela, P. Ussetti. *Hospital Universitario Puerta de Hierro, Majadahonda, Spain*

(1250) ***Association Between Acute Rejection Within First Year and Post-Transplant Mortality after Lung Transplantation;*** P. Shah[1], D. Neujahr[2], W. Cherikh[3], A. Lewis[3], J. Chan[4], G. Parilla[1], J. Javidfar[5], W. Hunt[6], M. Daneshmand[1], S. Chandrashekaran[1]. *[1]Emory University, Atlanta, GA, [2]Emory Univesity, Atlanta, GA, [3]United Network for Organ Sharing, Richmond, VA, [4]Emory University, Attlanta, GA, [5]Atlanta, GA, [6]Emory Univ, Decatur, GA*

(1251) ***Socioeconomic Position Does Not Account for Racial Disparities in Survival after Lung Transplant;*** C. J. Lehr[1], M. Valapour[1], P. R. Gunsalus[1], J. Rose[2], J. E. Dalton[1]. *[1]Cleveland Clinic, Cleveland, OH, [2]Case Western Reserve University, Cleveland, OH*

(1252) ***Effect of Age and Transplant Type on Survival and Hospital-Free Days in COPD Patients;*** Y. Zou[1], K. Laothamatas[1], J. Sonett[1], P. Lemaitre[1], B. Stanifer[1], G. Magda[1], H. Grewal[1], L. Shah[1], H. Robbins[1], S. Patel[1], A. Miller[1], M. Anderson[2], J. Costa[1], F. D'Ovidio[1], S. Arcasoy[1], L. Benvenuto[1]. *[1]Columbia University Medical Center, New York, NY, [2]University of Pennsylvania, Philadelphia, PA*

(1253) ***Comparison of Post-Transplant Survival Between Lung-Kidney and Lung Transplant Recipients;*** S. Greissman[1], K. Laothamatas[1], J. Costa[2], F. D'Ovidio[2], H. Grewal[3], P. Lemaitre[2], G. Magda[2], A. Miller[2], S. Patel[2], H. Robbins[2], L. Shah[2], J. Sonnett[2], B. Stanifer[2], S. Arcasoy[4], L. Benvenuto[2]. *[1]New York Presbyterian - Columbia University Medical Center, New York, NY, [2]Columbia University Medical Center, New York, NY, [3]Columbia University Irving Medical Center, New York, NY, [4]Columbia University, Allendale, NJ*

(1254) ***Prognostic Factors and Outcomes of Kidney Transplant after Lung Transplantion;*** R. Wilson[1], J. D'Cunha[1], B. Langlais[2], H. Khamash[3], P. Reck dos Santos[1]. *[1]Department of Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, [2]Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, AZ, [3]Division of Nephrology/Transplant, Mayo Clinic, Phoenix, AZ*

(1255) ***Impact of Race-Based Spirometric Equations on Lung Transplant Eligibility in Patients with Chronic Obstructive Pulmonary Disease (COPD);*** K. E. Lowe[1], L. Mourany[2], C. J. Lehr[2], P. R. Gunsalus[2], J. E. Dalton[2], M. Valapour[2]. *[1]Cleveland Clinic Lerner College of Medicine, Cleveland, OH, [2]Cleveland Clinic, Cleveland, OH*

(1256) ***Combined Lung Liver Transplantation (LLT) in Recipients with Telomeropathy;*** J. I. Tak, L. Benninger, K. Shen, J. Y. You, H. Carraway, J. Lum, C. Lane, O. Akindipe, S. Gadre, J. Yun, K. McCurry, M. Budev. *Cleveland Clinic, Cleveland, OH*

(1257) ***Lung Volume Change Analysis in Lung Transplantation Using a Three-Dimensional Image Analysis System;*** J. Park[1], H. Lee[1], Y. Kim[1], S. Choi[2], S. Park[1], J. Park[2], K. Na[1]. *[1]Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital Seoul National University College of Medicine, Seoul, South Korea, [2]Department of Pulmonary and Critical Care Medicine, Seoul National University Hospital Seoul National University College of Medicine, Seoul, South Korea*

(1258) ***A Single-Center Retrospective Study of Patients Undergoing Combined Liver-Lung Transplantation (LLT);*** K. Shen[1], J. You[2], Y. Wang[3], X. Wang[3], J. Modaresi Esfeh[4], K. Hashimoto[4], K. McCurry[5], J. Yun[5], M. Budev[2]. *[1]Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, [2]Department of Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, OH, [3]Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, [4]Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, Cleveland, OH, [5]Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH*

(1259) ***Outcomes of Double Lung and Combined Double Lung-Liver Transplant in Cystic Fibrosis Patients;*** N. Siddiqui[1], P. Charoenpong[2]. *[12]Shreveport, LA*

FRIDAY, 21 APRIL, 2023

5:00 – 6:00 p.m.

POSTER SESSION 03: RESEARCH AND IMMUNOLOGY

Location: Mile High Ballroom

Core Therapies: LUNG
Practice Areas: Research and Immunology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Diseases, Pathology, Pharmacy, Pulmonology

Session Summary: Posters in this session include presentations on multiple topics where the primary practice area of the research is focused in Research and Immunology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts.

Poster Discussants:
Daniel Calabrese, MD, University of California, San Francisco, CA USA
Christine Falk, PhD, Hannover Medical School, Hannover, Germany
Martin Goddard, FRCS, FRCPath, Papworth Hospital, Cambridge, United Kingdom
Dipankar Gupta, MBBS, Temple University, Philadelphia, PA USA
Christian Heim, MD, MHBA, University of Erlangen, Erlangen, Germany
Stephen Juvet, MD, PhD, University Health Network, Toronto, ON Canada
Benjamin Kopecky, MD, PhD, Washington University in St. Louis, St. Louis, MO USA
Kumi Mesaki, University Health Network, Toronto, ON Canada
Nandan Kumar Mondal, MSc, MPhil, PhD, Baylor College of Medicine, Houston, TX USA
Eric Morrell, MD, University of Washington, Seattle, WA USA
Kentaro Noda, PhD, University of Pittsburgh, Pittsburgh, PA USA
Chetan Pasrija, University of Maryland, Baltimore, MD USA
Gregor Poglajen, MD, PhD, Advanced Heart Failure and Transplantation Center, Ljubljana, Slovenia
Yazhini Ravi, MD, Scott & White, Temple, TX USA
Macé Matthew Schuurmans, MD, University Hospital Zurich, Zurich, Switzerland
Ashish Sharma, MD, Brigham & Women's Hospital, Boston, MA USA
Akira Shimamoto, MD, PhD, Mie U Grad Sch of Med, Tsu, Japan
Yoshito Yamada, MD, PhD, Kyoto University Hospital, Kyoto City, Japan

(1260) ***The Role of CXCL2 in Acute Cellular Rejection after Lung Transplantation;*** R. Novysedlák[1], J. Vachtenheim[1], J. Smetanová[2], A. Slavčev[3], K. Vychytilová[3], J. Tavandžis[1], J. Balko[4], R. Lischke[1], Z. Střížová[2]. *[1]Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic, [2]Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic, [3]Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, [4]Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic*

(1261) ***Immunological Overlap Between Rejection and Infection in Murine Lung Transplantation;*** J. Kaes[1], E. Vanhulle[1], L. Seldeslachts[1], C. Hooft[1], H. Beeckmans[1], X. Jin[1], P. Kerckhof[1], J. Van Slambrouck[1], D. Van Raemdonck[2], G. Vande Velde[1], L. Naesens[1], D. Schols[1], L. J. Ceulemans[2], R. Vos[3], K. Vermeire[1], B. M. Vanaudenaerde[1]. *[1]KU Leuven, Leuven, Belgium, [2]University Hospitals Leuven, Leuven, Belgium, [3]UZ Leuven, Leuven, Belgium*

(1262) ***Investigation of Pleural Cavity B Cells in a Minor Alloantigen-Mismatched Mouse Orthotopic Lung Transplant Model;*** S. Karunagaran, J. Oliver, S. Keshavjee, T. Martinu, S. Juvet. *University Health Network, Toronto, ON, Canada*

(1263) ***Single-Cell Rna Sequencing of the Mouse Isograft and Allograft Lung after Orthotopic Lung Transplantation;*** C. Hooft[1], J. Kaes[1], T. Heigl[2], H. Beeckmans[3], P. Kerckhof[4], A. Vanstapel[5], X. Jin[1], J. Slambrouck[6], C. Vandervelde[1], D. Van Raemdonck[6], N. Kaminski[7], J. McDonough[7], L. Ceulemans[6], R. Vos[8], B. Vanaudenaerde[1]. *[1]KU Leuven, Leuven, Belgium, [2]KU Leuven UZ Leuven, Leuven, Belgium, [3]., Leuven, Belgium, [45]Leuven, Belgium, [6]University Hospitals Leuven, Leuven, Belgium, [7]Yale School of Medicine, New Haven, CT, [8]UZ Leuven, Leuven, Belgium*

(1264) ***Recipients of Extended Criteria Ex Situ Preserved Lungs Display Higher Plasma Levels of Cytokines and Endothelial Markers after Lung Transplantation Without Higher PGD Scores;*** J. F. Kuehne[1], K. Beushausen[1], J. Keil[1], B. Wiegmann[2], F. Ius[2], L. Chacon[3], C. Kuehn[2], M. Avsar[2], A. Haverich[2], G. Loor[4], G. Warnecke[5], C. S. Falk[1]. *[1]Inst of Transplant Immunology, Hannover Medical School, Hannover, Germany, [2]Department for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, [3]Regenerative Med Research Dept, Texas Heart Institute, Houston, TX, [4]Baylor College of Medicine, Div of Cardiothoracic Transplantation and Circulatory Support, Houston, TX, [5]Dept of Cardiac Surgery, Heidelberg Univ Hosp, Heidelberg, Germany*

(1265) ***Exploration of Intragraft T Cell Phenotypes in Minimal Acute Cellular Rejection (ACR) Using Imaging Mass Cytometry (IMC);*** S. Beber[1], S. Moshkelgosha[2], M. Cheung[1], D. Hedley[1], L. Levy[3], J. Samuels[4], B. Renaud-Picard[5], D. Hwang[6], T. Martinu[7], S. Juvet[1]. *[1]University Health Network, Toronto, ON, Canada, [2]Toronto, ON, Canada, [3]Sheba Medical Center, Gealya, Israel, [4]Richmond, BC, Canada, [5]Nouvel Hopital Civil, Strasbourg, France, [6]Sunnybrook Health Sciences Centre, Toronto, ON, Canada, [7]Toronto General Hospital/UHN, Toronto, ON, Canada*

(1266) ***Isolation and Characterization of Osteopontin-Expressing Pulmonary Macrophages Associated with Chronic Lung Allograft Dysfunction in Humans;*** A. Duong[1], S. Moshkelgosha[2], R. Ramendra[3], M. Liu[4], B. Hinz[5], S. Keshavjee[6], S. Juvet[1], T. Martinu[7]. *[1]University Health Network, Toronto, ON, Canada, [2]Toronto, ON, Canada, [3]Ajmera Transplant, University Health Network, Brampton, ON, Canada, [4]Toronto Gen Hosp, Toronto, ON, Canada, [5]Faculty of Dentistry, University of Toronto, Toronto, ON, Canada, [6]UHN, Toronto, ON, Canada, [7]Toronto General Hospital/UHN, Toronto, ON, Canada*

(1267) ***A Novel Rapid Collagenase A-Based Dissociation Strategy of Human Lung Tissue Maximizes Cell Yield and Minimizes Cellular Stress Responses;*** A. Duong[1], A. Wong[1], R. Ramendra[2], S. Keshavjee[3], M. Liu[4], S. Juvet[1], T. Martinu[5]. *[1]University Health Network, Toronto, ON, Canada, [2]Ajmera Transplant, University Health Network, Brampton, ON, Canada, [3]UHN, Toronto, ON, Canada, [4]Toronto Gen Hosp, Toronto, ON, Canada, [5]Toronto General Hospital/UHN, Toronto, ON, Canada*

(1268) ***Administration of Exogenous Bmp9 Ameliorates Lung Transplant Ischemia Reperfusion Injury;*** B. Gill, Z. Tu, L. Langerude, D. Nord, A. Emtiazjoo, M. Rackauskas, C. Atkinson. *University of Florida, Gainesville, FL*

(1269) ***Increased Circulating Cell Junction Proteins are Associated with the Development of Primary Graft Dysfunction;*** D. Nord, L. Langerude, B. Gill, H. Moussa, A. Emtiazjoo, A. Shahmohammadi, M. Rackauskas, C. Atkinson. *University of Florida, Gainesville, FL*

(1270) ***Thermal Preconditioning During EVLP Reduces T Lymphocytes and Increases Monocytes and Neutrophils Contents in the Perfusion Solution;*** J. Lugrin[1], R. Parapanov[2], A. Debonneville[2], A. Ojanguren Arranz[3], L. Liaudet[4], T. Krueger[5]. *[1]Service of Thoracic Surgery and Service of Adult Intensive Care Medicine, Lausanne Univ Hosp And Univ of Lausanne, Epalinges, Switzerland, [2]Service of Thoracic Surgery, Lausanne Univ Hospital And Univ of Lausanne, Epalinges, Switzerland, [3]Hosp Univ Germans Trias i Pujol, Univ Autónoma de Barcelona, Barcelona, B, Spain, [4]Service of Adult Intensive Care Med, Lausanne Univ Hosp And Univ of Lausanne, Lausanne, Switzerland, [5]Service of Thoracic Surgery, Lausanne Univ Hosp And Univ of Lausanne, Lausanne, Switzerland*

(1271) ***Cell Death in Lung Transplantation. The Roles of Apoptosis, Necroptois, and Pyroptosis;*** A. Debonneville[1], R. Parapanov[1], J. Lugrin[1], M. Gonzalez[1], J. Perentes[1], L. Liaudet[2], T. Krueger[1]. *[1]Division of Thoracic Surgery, Lausanne University Hospital, Lausanne, Switzerland, [2]Service of Adult Intensive Care Medicine, Lausanne University Hospital, Lausanne, Switzerland*

(1272) ***Effect of Aging on the Progression of Pulmonary Ischemia-Reperfusion Injury in Clawn Miniature Swine;*** H. Sahara[1], Y. Ichinari[1], T. Iwanaga[1], M. Sekijima[1], K. Takeuchi[2], A. Shimizu[2]. *[1]Life Science and Laboratory Animal Research Unit, Center for Advanced Science Research and Promotion, Kagoshima University, Kagoshima, Japan, [2]Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan*

(1273) ***Anti-Alcohol Drug to Target Macrophages Attenuates Acute Rejection in Rat Lung Allografts;*** N. Yoshiyasu[1], R. Matsuki[2], M. Sato[3], H. Urushiyama[4], E. Toda[5], Y. Terasaki[5], M. Suzuki[6], A. Shinozaki-Ushiku[6], Y. Terashima[7], J. Nakajima[8]. *[1]Thoracic Surgery, Graduate SoM, Univ of Tokyo, Tokyo, Japan, [2]Respiratory Med, Graduate SoM, Univ of Tokyo, Tokyo, Japan, [3]Organ Transplantation Center, Univ of Tokyo Hosp, Tokyo, Japan, [4]Respiratory Med, Univ of Tokyo Hosp, Tokyo, Japan, [5]Analytic Human Pathology, Nippon Med Sch Hosp, Tokyo, Japan, [6]Pathology, Univ of Tokyo Hosp, Tokyo, Japan, [7]Molecular Regulation of Inflammatory and Immune Diseases, Research Inst for Biomedical Sci, Tokyo Univ of Science, Chiba, Japan, [8]Thoracic Surgery, Univ of Tokyo Hosp, Tokyo, Japan*

(1274) ***Eight Micro-Rnas Show Differential Expression Twelve Months after Lung Transplantation: Preliminary Data from a High Throughput Technology;*** B. Hatice Oya[1], S. Auner[2], P. Boehm[3], S. Schwarz[4], S. Nasrollahi[1], P. Jaksch[5], K. Hoetzenecker[2], A. Benazzo[6]. *[1]Lung Transplantation Research Lab, Medical University of Vienna, Vienna, Austria, [2]Medical University of Vienna, Wien, 9, Austria, [34]Medical University of Vienna, Linz, Austria, [5]Medical University Vienna, Austria, Wien, Austria, [6]Medical University of Vienna, Wien, Austria*

(1275) ***Epigenetic Risk for Diabetes Predicts New Onset Diabetes after Lung Transplantation;*** S. Lum[1], W. Guo[2], R. P. Mohanty[1], S. Hays[3], D. Calabrese[4], J. Singer[5], M. Pellegrini[2], J. R. Greenland[1]. *[1]University of California, San Francisco, San Francisco, CA, [2]University of California, Los Angeles, Los Angeles, CA, [3]UCSF Medical Center, San Francisco, CA, [4]Mill Valley, CA, [5]San Francisco, CA*

(1276) ***Development of Mini-Circuit Ex-Vivo Lung Perfusion to Accelerate Human Lung Translational Research;*** H. Yamamoto, A. Mariscal, O. Hough, K. Mesaki, D. Taniguchi, H. Gokhale, M. Chen, H. Shan, Y. Suzuki, N. Yoshiyasu, K. Yamanashi, T. Aujla, D. Bojic, L. Del Sorbo, J. Yeung, M. Liu, M. Cypel, S. Keshavjee. *Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada*

(1277) ***Bile Acids Are Not Only a Marker of Aspiration as They Stimulate Fibrosis and Derange Surfactant Homeostasis in Human Lung Cells;*** C. Camillo[1], S. Russum[2], L. Benvenuto[3], F. D'Ovidio[3]. *[1]Surgery, Columbia University, New York, NY, [2]Columbia University, New York, NY, [3]Columbia University Medical Center, New York, NY*

(1278) ***Circulating Exosomes with Distinct Immune and Molecular Markers in Lung Transplanted Recipients for Cystic Fibrosis;*** R. Ravichandran[1], V. Kaza[2], R. Bremner[3], M. Smith[4], T. Mohanakumar[5]. *[1]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, [2]UT Southwestern Medical Center, Coppell, TX, [3]Dignity Health, Phoenix, AZ, [4]St. Joseph's Hosp & Med Center Norton Thoracic Institute, Phoenix, AZ, [5]Norton Thoracic Institute, St. Joseph 's Hospital and Medical Center, Phoenix, AZ*

(1279) ***Biomarker Assessment During Portable Ex-Vivo Lung Perfusion to Predict Primary Graft Dysfunction;*** L. Chacon[1], G. Loor[2], M. King[1], M. Salan-Gomez[2], A. Leon-Pena[2], A. Mattar[2], A. Elsenousi[2], C. Hochman-Mendez[1], R. Fernandez[2]. *[1]Department of Regenerative Medicine Research, Texas Heart Institute, Houston, TX, [2]Div of Cardiothoracic Transplantation and MCS, Michael E. DeBakey Dept of Surgery, Baylor College of Medicine, Houston, TX*

(1280) ***Assessment of an Innovative Liposomal Preparations on Precision-Cut Lung Slices (PCLS): An Ex-Vivo Model of EMT;*** S. Bozzini[1], E. Bozza[1], C. Bagnera[1], M. Della Zoppa[2], S. Lettieri[2], V. Bincoletto[3], C. Del Fante[4], B. Stella[3], F. Briganti[1], C. Primiceri[5], P. Rinaldi[5], G. Baietto[5], S. Arpicco[3], F. Meloni[6]. *[1]Laboratory of Respiratory Disease, Section of Cell Biology, UOS Transplant Center IRCCS Policlinico San Matteo Foundation, Pavia, Italy, [2]Pneumology Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, Pavia, Italy, [3]Department of Drug Science and Technology, University of Turin, Turin, Italy, [4]Immunohaematology and Transfusion Service, Apheresis and Cell Therapy Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, [5]Department of Thoracic Surgery, IRCCS San Matteo Foundation, Pavia, Italy, [6]Policlinico San Matteo di Pavia, Pavia, PV, Italy*

(1281) ***HTK-N Versus Del Nido Cardioplegia for Hypothermic Machine Perfusion of Donation after Circulatory Death Hearts: Comparison of Left-Ventricular Contractility and Transcriptomics;*** L. Saemann[1], F. Hoorn[2], K. Wächter[1], S. Pohl[1], S. Korkmaz-Icöz[2], F. Wenzel[3], M. Karck[2], A. Simm[1], G. Szabó[1]. *[1]Department of Cardiac Surgery, University Hospital Halle, Halle (Saale), Germany, [2]Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany, [3]Faculty Medical and Life Sciences, Furtwangen University of Applied Sciences, Villingen-Schwenningen, Germany*

8:00 – 9:00 a.m.

SESSION 85: AS YOU LIKE IT: PREDICTORS OF POST TRANSPLANT MORTALITY BETWEEN DONOR AND RECIPIENT FACTORS

Location: Rooms 603-605

Core Therapies: HEART
Practice Areas: Research and Immunology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pathology

Session Summary: This session will include research related to various pre- and post-heart transplant factors and impact on outcomes.

Co-Chairs: Sung-Ho Jung, MD, Asan Medical Center, Seoul, South Korea
Dylan Miller, MD, Intermountain Central Lab, Murray, UT USA

8:00 a.m. **(169)** ***Incidence and Predictors of Vasoplegia after Heart Transplantation: Results from the International PGD Consortium***; J. Han[1], Y. Moayedi[2], L. Truby[3], F. Foroutan[4], J. Guzman Bofarull[5], S. Saha[2], P. Angleitner[6], M. Sabatino[7], E. Henricksen[8], H. Luikart[8], J. van Zyl[9], M. Tremblay-Gravel[10], P. Noly[10], J. Segovia-Cubero[11], E. Ródenas Alesina[2], L. Potena[12], K. Takeda[13], J. Felius[14], B. Clarke[15], A. DeVore[16], G. Kim[1], R. Miller[17], A. Zuckermann[6], M. Farr[3], M. Crespo-Leiro[18], S. Hall[14], M. Farrero Torres[19], C. Fan[2], H. Ross[2], K. Khush[20], S. Chih[21]. *[1]University of Chicago Medical Center, Chicago, IL, [2]University Health Network, Toronto, ON, Canada, [3]University of Texas Southwestern Medical Center, Dallas, TX, [4]Ted Rogers Centre for Heart Research, Toronto, ON, Canada, [5]Hospital Clínic of Barcelona, Barcelona, Spain, [6]Medical University of Vienna, Wien, Austria, [7]Institute of Cardiology, S.Orsola-Malpighi Hospital, Bologna, Italy, [8]Stanford Health Care, Stanford, CA, [9]Baylor Scott & White Health, Dallas, TX, [10]Montreal Heart Institute, Montreal, QC, Canada, [11]Hospital Puerta de Hierro, Madrid, Spain, Madrid, Spain, [12]Bologna University Hospital, Bologna, Italy, [13]Columbia University, New York, NY, [14]Baylor University Medical Center, Dallas, TX, [15]St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada, [16]Duke University, Durham, NC, [17]University of Calgary, Calgary, AB, Canada, [18]Hospital Universitario A Coruña, A Coruña, Spain, [19]Hospital Clinic de Barcelona, Barcelona, Spain, [20]Stanford University, Stanford, CA, [21]University of Ottawa Heart Institute, Ottawa, ON, Canada*

8:15 a.m. **(170)** ***Heart Transplant Survival and the Use of Donors with Intracranial Bleeding: Unos Registry Propensity Matched Analysis***; J. S. Meyer[1], N. Sweitzer[2], D. Aravot[1], C. Milano[3], Y. Barac[1]. *[1]Rabin Medical Center, Petah Tiqva, Israel, [2]Banner University Medical Center, University of Arizona, Tucson, Tucson, AZ, [3]Duke University Med Ctrr, Durham, NC*

8:30 a.m. **(171)** ***Predicting Survival in Heart Transplants at Time of Biopsy Using Gene-Based Risk Scores***; J. Reeve[1], K. S. Madill-Thomsen[1], P. F. Halloran[2], .. and the INTERHEART Study Group[3]. *[1]Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, [2]University of Alberta, Edmonton, AB, Canada, [3]AB, Canada*

8:45 a.m. **(172)** ***Right Ventricular Oversizing Mitigates Post-Transplant Mortality in Recipients with Pulmonary Hypertension***; N. Hess[1], Y. Hong[2], L. Ziegler[1], M. Keebler[3], J. Huston[1], M. Mathier[4], G. Hickey[5], D. Kaczorowski[6]. *[1]University of Pittsburgh Medical Center, Pittsburgh, PA, [2]University of Pittsburgh, Pittsburgh, PA, [3]UPMC, Pittsburgh, PA, [4]Heart and Vascular Institute, Pittsburgh, PA, [5]UPMC Pittsburgh, Murrysville, PA, [6]UPMC, Venetia, PA*

SATURDAY, 22 APRIL, 2023

8:00 – 9:00 a.m.

SESSION 86: MEDICINE IS A SCIENCE OF UNCERTAINTY AND AN ART OF PROBABILITY: PATIENT SELECTION FOR HEART TRANSPLANTATION

Location: Rooms 401-404

Core Therapies: HEART
Practice Areas: Cardiology, Cardiothoracic Surgery

Session Summary: Evaluation for heart transplant candidacy is a multidisciplinary endeavor. This session will provide tools that will help integrate the various variables involved in evaluating patients for transplantation, including indicators for poor prognosis without transplant and potential contraindications that may cause suboptimal outcomes post-transplant.

Co-Chairs: Michal Zembala, Prof., ETHP.pl, Zbroslawice, Poland
Ugolino Livi, MD, Az. Osp. S. Maria Della Misericordia, Udine, Italy

8:00 a.m. **(173)** ***Predictors of Survival after Heart Transplantation in the Current Era***; J. Trivedi[1], S. Pahwa[2], M. Slaughter[3], D. Abramov[4]. *[1]University of Louisville, Louisville, KY, [2]University of Louisville Physicians Cardiovascular and Thoracic Surgery, Louisville, KY, [3]University of Louisville School of Medicine, Louisville, KY, [4]Loma Linda University, Loma Linda, CA*

8:15 a.m. **(174)** ***Do Older LVAD Patients Have Compromised Outcome after Heart Transplantation: Should They Stay as Destination Therapy?***; M. Kittleson, J. Patel, J. Moriguchi, R. Cole, T. Singer-Englar, N. Patel, C. Runyan, M. Welton, L. Czer, P. Catarino, J. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

8:30 a.m. **(175)** ***Characteristics and Outcomes of Multiple Cardiac Re-Transplant Recipients***; J. Batra[1], H. Rosenblum[2], E. DeFilippis[3], E. Donald[4], K. Clerkin[5], V. Topkara[6], S. Lee[7], F. Latif[8], M. Yuzefpolskaya[1], P. Colombo[9], K. Oh[10], D. Lotan[9], J. Raikhelkar[9], G. Sayer[11], N. Uriel[12]. *[1]Columbia University Medical Center, New York, NY, [2]New York, NY, [3]Columbia University Irving Medical Center, Short Hills, NJ, [4]New York Presbyterian, Columbia University Medical Center, New York, NY, [5]Columbia University Irving Medical Center, Ridgewood, NJ, [6]Columbia University New York Presbyterian Hospital, New York, NY, [7]Columbia University Medical Center, Bronx, NY, [8]NY Presbyterian Hospital, New York, NY, [9]Columbia University, New York, NY, [10]Columbia University Irving Medical Center, Bronx, NY, [11]Columbia University Irving Medical Center, Hartsdale, NY, [12]New York Presbyterian, New York, NY*

8:45 a.m. **(176)** ***The Burden of Advanced Heart Failure in the Eastern Mediterranean Region: Time to Address the Unmet Need***; Y. Manla, G. Gabra, M. Soliman, F. Bader. *Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates*

SATURDAY, 22 APRIL, 2023

8:00 – 9:00 a.m.

SESSION 87: DURABLE MCS: STAYING ALIVE!

Location: Rooms 501-504

Core Therapies: MCS
Practice Areas: Cardiology, Cardiothoracic Surgery, Research and Immunology

Session Summary: This session highlights recent advances in the field of MCS including new devices and new insights in existing devices.

Co-Chairs: Francis Pagani, MD, PhD, University of Michigan, Ann Arbor, MI USA
J. Eduardo Rame, MD, MPhil, Thomas Jefferson University, Philadelphia, PA USA

8:00 a.m. **(177)** ***Initial Safety Cohort Analysis: Prospective Multi-Center Randomized Study for Evaluating The EVAHEART®2 Left Ventricular Assist System (The COMPETENCE Trial)***; M. Slaughter[1], M. Ahmed[2], S. Allen[3], G. Answini[4], C. Bartoli[5], R. Dhingra[6], R. Dowling[4], G. Egnaczyk[4], B. Griffith[7], S. Gulati[8], S. Hall[9], E. Jeng[2], S. Joseph[7], M. Kiernan[10], L. Lozonschi[11], C. Mahr[12], D. Meyer[9], M. Ono[13], A. Ravichandran[14], A. Shafii[15], B. Soleimani[3], Y. Toyoda[16], L. Yarboro[17]. *[1]University of Louisville School of Medicine, Louisville, KY, [2]UF Health Shands Hospital, Gainesville, FL, [3]Penn State Health, Hershey, PA, [4]The Christ Hospital, Cincinnati, OH, [5]Geisinger Medical Center, Danville, PA, [6]University of Wisconsin, Madison, WI, [7]University of Maryland Medical Center, Baltimore, MD, [8]Atrium Health, Charlotte, NC, [9]Baylor Scott and White, Dallas, TX, [10]Tufts Medical Center, Boston, MA, [11]University of South Florida, Tampa, FL, [12]Univ Washington Medical Center, Seattle, WA, [13]Methodist Hospital, San Antonio, TX, [14]St. Vincent Health, Indianapolis, IN, [15]Baylor College of Medicine, Houston, TX, [16]Univ of Virginia Medical Center, Charlottesville, VA, [17]Charlottesville, VA*

8:15 a.m. **(178)** ***uSTOP LVAD BLEED: Utilization of Umbilical Cord Lining Stem Cells to Prevent Left Ventricular Assist Device Associated Angiodysplastic Bleeding***; M. M. Ahmed[1], L. Meece[2], E. Handberg[1], C. J. Pepine[1]. *[1]Cardiovascular Medicine, University of Florida, Gainesville, FL, [2]UF Health and Shands Hospital, Gainesville, FL*

8:30 a.m. **(179)** ***Clinical Predictors of 5-year Outcomes Following Heartmate 3 Left Ventricular Assist Device Implant: The Momentum 3 Trial***; A. Nayak[1], S. Hall[2], N. Uriel[3], D. Goldstein[4], J. Cleveland[5], J. Cowger[6], C. Salerno[7], Y. Naka[8], D. Horstmanshof[9], S. Somo[10], A. Wang[10], M. R. Mehra[1]. *[1]Harvard Medical School, Boston, MA, [2]Baylor University Medical Center, Dallas, TX, [3]New York Presbyterian, New York, NY, [4]Montefiore, Bronx, NY, [5]University of Colorado School of Medicine, Aurora, CO, [6]Henry Ford Hospitals, Detroit, MI, [7]University of Chicago, Carmel, IN, [8]Weill Cornell Medical College, New York, NY, [9]Integris Baptist Medical Center, Oklahoma City, OK, [10]Abbott, Abbott Park, IL*

8:45 a.m. **(180)** ***Multicenter Analysis of Outcomes in Non-Trial versus Trial-Like Patients with Commercial Heartmate 3 LVAD***; L. Coyle[1], C. Gallagher[1], N. Graney[1], L. Kukla[1], R. Paliga[1], K. Hughes[1], K. Schultz[2], A. Schuldt[2], N. Sulemanjee[2], A. Joshi[1], G. Macaluso[1], S. Pauwaa[1], J. Pillarella[1], C. Sciamanna[1], J. Monaco[1], M. T. Kabbany[1], W. Cotts[1], N. Narang[1], P. Pappas[1], A. Tatooles[1], V. Q. Chau[1]. *[1]Advocate Christ Medical Center, Oak Lawn, IL, [2]Aurora St. Luke's Medical Center, Milwaukee, WI*

8:00 – 9:00 a.m.

SESSION 88: CONTAGION MEETS OUTBREAK: LESSONS LEARNED FROM COVID-19 IN LUNG TRANSPLANTATION

Location: Rooms 205-207

Core Therapies: LUNG
Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Diseases

Session Summary: Lung transplant for COVID-19 recipients will be discussed in this session: numbers, outcomes, use of ECMO, and COVID-19 positive donors.

Co-Chairs: Marie Budev, DO, MPH, Cleveland Clinic, Cleveland, OH USA
Cameron Wolfe, MD, Duke University Medical Center, Durham, NC USA

8:00 a.m. **(181)** ***A Single-Center Experience with More Than 200 Lung Transplant Recipients with COVID-19 Infection***; H. Kehara[1], A. Johnson-Whiting[2], S. Iturra[2], R. Raman[2], R. Yanagida[2], K. Krishan[2], A. Kashem[1], F. Cordova[2], G. Criner[2], Y. Toyoda[2], N. Shigemura[2]. *[1]Temple University, Philadelphia, PA, [2]Temple University Hospital, Philadelphia, PA*

8:15 a.m. **(182)** ***Ecmo as a Bridge to Lung Transplantation for Covid-19 Respiratory Failure: Outcomes and Risk Factors for Early Mortality***; M. Hunt[1], F. Bermudez[2], M. Crespo[1], A. Courtwright[1], J. Diamond[3], J. Christie[3], A. Spelde[1], A. Usman[3], E. Clausen[4], E. Cantu[3], M. Cevasco[5], T. Richards[1], C. Bermudez[6]. *[1]Hospital of the University of Pennsylvania, Philadelphia, PA, [2]Georgetown University School of Medicine, Washington, DC, [3]University of Pennsylvania, Philadelphia, PA, [4]Hospital University of Pennsylvania, Philadelphia, PA, [5]Hospital of the University of Pennsylvania, Villanova, PA, [6]Hosp of the U of Pennsylvania, Merion Station, PA*

8:30 a.m. **(183)** ***Lung Transplantation for Covid-19 Related Complications: Early Outcomes Across the United States***; P. Tasoudis[1], L. Lobo[2], J. Long[3]. *[1]Cardiothoracic Surgery, University of North Carolina, Chapell Hill, NC, [2]The University of North Carolina UNC Hospital at Chapel Hill, Chapel Hill, NC, [3]UNC School of Medicine, Chapel Hill, NC*

8:45 a.m. **(184)** ***Changing Patterns in Lung Transplant for Respiratory Failure Due to Covid-19 in the U.S***; K. Laothamatas, L. Benvenuto, L. Shah, H. Robbins, H. Grewal, G. Magda, P. Lemaitre, B. P. Stanifer, J. Sonett, F. D'Ovidio, S. Arcasoy. *Columbia University Medical Center, New York, NY*

8:00 – 9:00 a.m.

SESSION 89: MEDICATIONS AND MACHINES: WHICH ONES IMPROVE PEDIATRIC HEART TRANSPLANT OUTCOMES?

Location: Rooms 405-407

Core Therapies: HEART
Practice Areas: Pediatrics, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health

Session Summary: This session will explore the financial burdens associated with pediatric heart transplant. It will also explore how new technologies and medications affect post-heart transplant outcomes in children and young adults.

Co-Chairs: Benjamin Mantell, MD, PhD, NewYork-Presbyterian, New York, NY USA
Oliver Miera, MD, Deutsches Herzzentrum Berlin, Berlin, Germany

8:00 a.m. **(185)** ***Out-of-Pocket Expenses Associated with Pediatric Heart Transplantation***; W. W. Kaslow[1], C. Melchiorre[2], N. Jaworski[1], C. Crawford[2], K. Taylor[2], K. Wujcik[3], S. Hollander[3], D. Bearl[2], D. Dodd[2], J. Godown[2]. *[1]Pediatric Cardiology, Vanderbilt Children's Hospital, Nashville, TN, [2]Vanderbilt Children's Hospital, Nashville, TN, [3]Lucile Packard Children's Hospital at Stanford, Palo Alto, CA*

8:15 a.m. **(186)** ***Pediatric Experience Using the Sherpapak Cardiac Transport System: A Subgroup Analysis of the Guardian Heart Registry***; J. P. Jacobs[1], U. Boston[2], Y. Stukov[1], J. Schroder[3], J. Bustamante-Munguira[4], A. Zuckermann[5]. *[1]University of Florida, Gainesville, FL, [2]Le Bonheur Children's Hosp, Memphis, TN, [3]Duke University Medical Center, Durham, NC, [4]Hospital Clinico Universitario de Valladolid, Valladolid, Spain, [5]Medical University of Vienna, Wien, Austria*

8:30 a.m. **(187)** ***Steroid Avoidance in Pediatric Heart Transplant***; C. Hartje-Dunn[1], E. Blume[2], H. Bastardi[3], M. Clark[2], K. Daly[2], F. Fynn-Thompson[4], K. Gauvreau[2], T. Singh[2]. *[1]Pediatric Cardiology, Boston Children's Hospital, Boston, MA, [2]Boston Children's Hospital, Boston, MA, [3]Children's Hospital of Boston, Boston, MA, [4]Children's Hospital, Boston, MA*

8:45 a.m. **(188)** ***Statin Use May Not Benefit Pediatric Heart Transplant Recipients: A PHTS Analysis***; M. L. Townsend[1], M. Khoury[2], D. Koehl[3], R. Cantor[4], J. Kirklin[5], G. Beasley[6], C. Chen[7], G. Boyle[8], J. Parent[9], N. Baez Hernandez[10], N. Halnon[11]. *[1]Pediatric Cardiology, Cleveland Clinic Children's, Cleveland, OH, [2]University of Alberta, Edmonton, AB, Canada, [3]UAB Medicine, [4]University of Alabama at Birmingham (UAB), Portland, OR, [5]University of Alabama Birmingham, Birmingham, AL, [6]University of Iowa Stead Family Children's Hospital, Tiffin, IA, [7]Palo Alto, CA, [8]Cleveland Clinic Children's Hospital, Shaker Hts, OH, [9]Indiana Univ Sch of Med, Indianapolis, IN, [10]Children's Medical Center, Dallas TX, Dallas, TX, [11]UCLA Mattel Children's Hospital, Los Angeles, CA*

8:00 – 9:00 a.m.

SESSION 90: ALL'S WELL THAT ENDS WELL: THE THREE P'S TO TRANSPLANT SUCCESS: PROTECTION, PRESERVATION, AND (EM)POWERING THE DONOR HEART

Location: Rooms 201-203

Core Therapies: HEART
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Nursing and Allied Health, Research and Immunology

Session Summary: To preserve and protect the donor heart is the ultimate goal! This session looks at techniques to ensure donor heart quality, ex-situ protection and the impact of warm ischaemia. Breaking bad, or staying on the straight and narrow for our donor hearts?

Co-Chairs: Victor Pretorius, MD, University of California San Diego, La Jolla, CA USA
Filip Rega, MD, University Hospitals Leuven, Leuven, Belgium

8:00 a.m. **(189)** ***Non-Ischaemic Heart Preservation to Improve Donor Heart Quality***; L. Wang[1], N. Chilvers[1], M. Huang[2], L. Bates[1], C. Y. Pang[1], G. Chelsea[1], M. Brown[1], M. Murphy[2], G. MacGowan[3], S. Ali[4], J. Dark[1]. *[1]Newcastle University, Newcastle upon Tyne, United Kingdom, [2]University of Cambridge, Cambridge, United Kingdom, [3]Freeman Hospital, Newcastle Upon Tyne, United Kingdom, [4]Newcastle University, Newcastle Upon Tyne, United Kingdom*

8:15 a.m. **(190)** ***Superior Cardiac Protection in Combined Ex-Situ Perfusion of Heart and Liver: Lessons Learned***; S. Hatami[1], J. Hefler[2], M. Wagner[2], G. Mainardi[2], M. Khan[2], S. Himmat[3], J. Nagendran[4], D. Freed[5]. *[1]Department of Medicine, University of Alberta, Edmonton, AB, Canada, [2]Department of Surgery, University of Alberta, Edmonton, AB, Canada, [3]University of Alberta, [4]University of Alberta, Edmonton, AB, Canada, [5]Stollery Children's Hospital, Edmonton, AB, Canada*

8:30 a.m. **(191)** ***Impact of Functional Warm Ischemic Time on Short Term Outcomes in Donation after Circulatory Death Heart Transplantation***; A. Brann[1], B. Jackson[2], R. White[2], K. Sharaf[2], D. Cookish[2], Y. Gernhofer[2], E. Adler[1], M. Urey[1], V. Pretorius[2], M. Kearns[2]. *[1]Cardiovascular Medicine, UC San Diego, La Jolla, CA, [2]Cardiothoracic Surgery, UC San Diego, La Jolla, CA*

8:45 a.m. **(192)** ***Prolonged Warm Ischemic Time is Safe for Cardiac Donation after Circulatory Death***; C. Pasrija, A. DeBose-Scarlett, C. D. Keck, S. R. Scholl, H. K. Siddiqi, K. Amancherla, D. M. Brinkley, J. Lindenfeld, J. Menachem, H. Ooi, D. Pedrotty, L. Punnoose, A. Rali, S. Sacks, M. Wigger, S. Zalawadiya, W. McMaster, A. S. Shah, K. Schlendorf, J. Trahanas. *Vanderbilt University Medical Center, Nashville, TN*

SATURDAY, 22 APRIL, 2023

9:30 – 11:00 a.m.

GENERAL SESSION (PLENARY) III

Location: Four Seasons Ballroom

Core Therapies: ALL
Practice Areas: ALL

Co-Chairs: Goran Dellgren, MD, PhD, University Hospital Goteborg, Goteborg, Sweden
Jason Christie, MD, MS, University of Pennsylvania, Philadelphia, PA USA

9:30 a.m. ***Awards Presentations***
Kathleen Grady, PhD, RN, MS, FAAN, Northwestern University, Chicago, IL USA

9:50 a.m. ***Xenotransplantation: The Future is Now***
Robert Montgomery, MD, PhD, NYU Langone Transplant Institute, New York, NY USA

10:15 a.m. ***FEATURED PRESENTATION:* (4) *Comparing Long-Term Survival and Readmissions Between Heartmate 3 and Heart Transplant as Primary Treatment for Advanced Heart Failure***; M. Kirschner[1], V. Topkara[2], Y. Ning[3], P. Kurlansky[3], Y. Kaku[3], Y. Naka[4], H. Shih[5], M. Yuzefpolskaya[1], P. Colombo[3], G. Sayer[6], N. Uriel[7], K. Takeda[3].
[1]Columbia University Medical Center, New York, NY, [2]Columbia University New York Presbyterian Hospital, New York, NY, [3]Columbia University, New York, NY, [4]New York Presbyterian Hospital, New York, NY, [5]Columbia University Vagelos College of Physicians and Surgeons, New York, NY, [6]Columbia University Irving Medical Center, Hartsdale, NY, [7]New York Presbyterian, New York, NY

10:25 a.m. ***Q&A with Interactive Discussant***
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain

10:30-11:00 a.m. ***PRESIDENT'S DEBATE: Is the Future of Therapy for Advanced Heart and Lung Disease Biologic or Mechanical?***

The current era is one of rapid advances in management and reconditioning of allografts for example with EVLP, extended donor criteria, DCD, lung/heart scaffolds and recelluarization and xenotransplantation, all providing new options for organ transplantation. Advances in mechanical assist strategies raises the possibility of mechanical approaches offering compelling alternatives to organ transplantation in patients with advanced heart and lung transplantation without some of the downsides. This debate will provide an erudite, scholarly, informed and highly polite discussion of which option is the future of therapy for advanced heart and lung disease. All attending will be far more knowledgeable afterward.

10:30 a.m. ***Biologic Team: We Are Doctors, Not Mechanics***
David Baran, MD, Cleveland Clinic Heart, Vascular and Thoracic Institute, Parkland, FL USA
Emily Granger, MBBS, St Vincent's Hospital Sydney, Sydney, NSW Australia

This two-member team will address EVLP, heart box, treatment during ex-vivo heart or lung perfusion, xenotransplantation, DCD, gene therapy, future decellularization, recellularization and lung/heart scaffolds: Go Natural, Stay Natural. (Combined presentation with one slide set, 10 minutes total argument)

10:40 a.m. ***Mechanical Team: The Rise of The Machines***
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA USA
Konrad Hoetzenecker, MD, Medical University of Vienna, Vienna, Austria

Organs? Who needs them? We can do better. Machines are the future. This two-member team will discuss advances in MCS, ECMO and other mechanical solutions to advanced heart and lung disease. (Combined presentation with one slide set, 10 minutes total argument)

10:50 a.m. ***Rebuttals***

11:15 a.m. – 12:15 p.m.

SESSION 91: MULTI-ORGAN TRANSPLANT OUTCOMES: WHEN ARE TWO ORGANS BETTER THAN ONE IN HEART TRANSPLANTATION?

Location: Rooms 603-605

Core Therapies: HEART
Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Research and Immunology

Session Summary: Appropriate patient selection for dual-organ transplantation is critical. This session will elucidate strategies to facilitate dual-organ transplantation by identifying predictive risk scores, waitlist and post-transplant outcomes.

Co-Chairs: Eileen Hsich, MD, Cleveland Clinic Foundation, Cleveland, OH USA
Cristiano Amarelli, MD, Monaldl Hospital, Napoli, Italy

11:15 a.m. **(193)** ***Heart Retransplant Recipients with Borderline Renal Dysfunction Benefit from Combined Heart-Kidney Transplantation***; J. Malas[1], Q. Chen[1], D. Emerson[1], D. Megna[1], P. Catarino[1], L. Czer[2], J. Patel[2], M. Kittleson[2], J. Kobashigawa[2], J. Chikwe[1], M. Bowdish[1], F. Esmailian[1]. *[1]Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, [2]Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA*

11:30 a.m. **(194)** ***Predictors of Transplantation and Waitlist Mortality Among Patients Listed for Combined Heart-Lung Transplantation: A Unos Registry Analysis***; N. Hess[1], Y. Hong[2], L. Ziegler[1], M. Keebler[3], G. Hickey[4], J. Huston[1], M. Mathier[5], D. Kaczorowski[6]. *[1]University of Pittsburgh Medical Center, Pittsburgh, PA, [2]University of Pittsburgh, Pittsburgh, PA, [3]UPMC, Pittsburgh, PA, [4]UPMC Pittsburgh, Murrysville, PA, [5]Heart and Vascular Institute, Pittsburgh, PA, [6]UPMC, Venetia, PA*

11:45 a.m. **(195)** ***Comparison of CAV Development in Simultaneous Multi-Organ and Isolated Heart Transplant Recipients in the United States***; N. Shahandeh[1], J. S. Kim[2], D. Tehrani[1], J. J. Hsu[1], A. Nsair[1], K. Khush[3], W. F. Fearon[3], R. V. Parikh[1]. *[1]University of California, Los Angeles, Los Angeles, CA, [2]David Geffen School of Medicine, Los Angeles, CA, [3]Stanford University, Stanford, CA*

12:00 p.m. **(196)** ***A Novel Simultaneous Heart-Kidney (sHK) Transplantation Risk Calculator Predicts Chronic Dialysis or Death at 1-Year: A UNOS Analysis***; S. Kumar[1], D. T. Nguyen[2], E. A. Graviss[2], S. Patil[3], J. H. Kim[1], E. E. Suarez[1], I. Hussain[1], R. Yousefzai[1], S. A. Ahsan[1], J. Gorthi[1], M. Kassi[1], A. Bhimaraj[1], C. M. Martin[1], A. Guha[1]. *[1]Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, [2]Department of Pathology and Genomic Medicine, Institute for Academic Medicine, Houston Methodist Hospital, Houston, TX, [3]Department of Medicine, RajaRajeswari Medical College & Hospital, Bangalore, India*

11:15 a.m. – 12:15 p.m.

SESSION 92: A FUNGUS AMONG US: ADVANCES IN FUNGAL BIOLOGY

Location: Rooms 401-404

Core Therapies: LUNG
Practice Areas: Infectious Diseases, Pharmacy, Pulmonology, Research and Immunology

Session Summary: This session will discuss advances in fungal biology with focus on the identification, diagnosis and treatment of fungal infections after lung transplantation.

Co-Chairs: Ann Woolley, MD, MPH, Brigham & Women's Hospital, Boston, MA USA
Steven Ivulich, BPharm, Alfred Hospital, Melbourne, VIC Australia

11:15 a.m. **(197)** ***Aspergillus Droplet Digital PCR (ddPCR)in Exhaled Breath Condensate for the Diagnosis of Invasive Aspergillosis (IA) in Lung Transplant Recipients (LTRs)***; F. Runyo[1], S. Almansour[1], S. Arora[1], L. Singer[2], M. Aversa[2], S. Keshavjee[2], R. Bitterman[1], T. Mazzulli[3], S. Husain[1]. *[1]Division of Infectious Diseases, Toronto General Hospital, University Health Network, Toronto, ON, Canada, [2]Toronto Lung Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada, [3]Department of Microbiology, Mount Sinai Hospital, University Health Network, Toronto, ON, Canada*

11:30 a.m. **(198)** ***Non-Aspergillus Fumigatus Mold Infections (NAFMI) in Lung Transplant (LT) Recipients, Pathogens and Risk Factors***; L. N. Walti[1], B. Henry[2], C. G. Crone[3], A. Cano[4], S. Kothari[1], M. Perch[5], J. Torres Cisneros[4], D. Bennett[6], M. Aversa[7], S. Keshavjee[8], T. Martinu[9], S. Husain[1]. *[1]University Health Network, Toronto, ON, Canada, [2]Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France, [3]Rigshospitalet - University of Copenhagen, Copenhagen, Denmark, [4]Reina Sofia University Hospital-IMIBIC, Cordoba, Spain, [5]Rigshospitalet, Gentofte, Denmark, [6]Siena, Italy, [7]University of Toronto, Toronto, ON, Canada, [8]UHN, Toronto, ON, Canada, [9]Toronto General Hospital/ UHN, Toronto, ON, Canada*

11:45 a.m. **(199)** ***Serum Concentrations of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Recipients***; K. Neuhaus, X. Xhemali. *Cleveland Clinic, Cleveland, OH*

12:00 p.m. **(200)** ***Bronchopulmonary Penetration of Isavuconazole in Lung Transplant Recipients***; I. Darnaude-Ximénez[1], A. Caballero-Bermejo[1], M. Aguilar-Perez[2], A. Gómez-López[3], A. Sancho-López[1], C. López García-Gallo[2], G. Díaz Nuevo[2], E. Diago-Sempere[1], B. Ruiz-Antorán[1], P. Ussetti-Gil[2]. *[1]Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Madrid, Spain, [2]Respiratory Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Madrid, Spain, [3]Mycology Reference and Research Laboratory, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain*

11:15 a.m. – 12:15 p.m.

SESSION 93: A MIDSUMMER NIGHT'S DREAM: FROM MITOCHONDRIA TO XENOTRANSPLANTATION: NOVEL RESEARCH COMING TO YOU!

Location: Rooms 501-504

Core Therapies: HEART
Practice Areas: Cardiology, Cardiothoracic Surgery, Pathology, Research and Immunology

Session Summary: From the mighty mitochondria to xenotransplantation possibilities, this session covers basic science and novel research with a 60 minute "tour de force" presenting innovations in the field of heart transplantation.

Co-Chairs: Patricia Uber, PharmD, Thomas Jefferson University Hospital, Philadelphia, PA USA
Carlos Ortiz-Bautista, MD, PhD, Hospital Universitario Gregorio Marañón, Madrid, Spain

11:15 a.m. **(201)** ***Echocardiographic Evaluation of Two 10-Gene Modified Xenoheart Transplants into Brain Dead Decedents***; D. Bamira[1], A. F. Vainrib[1], M. Saric[1], T. Saraon[1], A. Reyentovich[1], I. S. Jaffe[2], L. James[1], J. Stern[1], K. Khalil[1], E. P. Weldon[1], D. Ayares[3], A. Griesemer[1], D. Smith[1], R. A. Montgomery[1], N. Moazami[1]. *[1]NYU Langone Health, New York, NY, [2]NYU Grossman School of Medicine, New York, NY, [3]Revivicor, Inc., Blacksburg, VA*

11:30 a.m. **(202)** ***Monitoring of Mitochondrial Function in Donation after Circulatory Death: A Porcine Ex-Situ Heart Perfusion Model***; L. Stastny[1], J. Hofmann[2], A. Meszaros[2], A. Ampferer[1], N. Huemer[1], G. Putzer[3], N. Hofmann[1], J. Martini[3], F. Sommerauer[1], M. Grimm[1], S. Schneeberger[2], J. Dumfarth[1]. *[1]Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria, [2]Department of Visceral-, Transplant-, and Thoracic-Surgery, Medical University of Innsbruck, Innsbruck, Austria, [3]Department of Anesthesiology and Intensive Care, Medical University of Innsbruck, Innsbruck, Austria*

11:45 a.m. **(203)** ***Two 10-Gene Modified Xenoheart Transplants into Brain Dead Decedents***; N. Moazami[1], D. Smith[1], J. Stern[2], J. I. Kim[1], K. Khalil[1], L. James[1], H. Kowalski[3], S. Bisen[3], D. Bamira[4], T. Saraon[1], A. Reyentovich[1], G. Piper[1], P. Sommer[1], J. Ngai[1], M. Mangiola[1], S. A. Mehta[1], A. Griesemer[1], D. Ayares[5], N. Narula[1], E. P. Weldon[1], R. Montgomery[1]. *[1]NYU Langone Health, New York, NY, [2]Transplant Institute, NYU Langone Health, New York, NY, [3]NYU Grossman School of Medicine, New York, NY, [4]Cardiology, NYU Langone Health, New York, NY, [5]Revivicor, Inc, Blacksburg, VA*

12:00 p.m. **(204)** ***Cardiac Mitochondrial Stress Burden and Impairment of Oxidative Phosphorylation are More Profound in Human Heart Donated after Circulatory Death Than Heart Donated after Brain Death***; N. K. Mondal[1], S. Li[1], A. E. Elsenousi[1], A. Mattar[1], K. V. Nordick[1], H. K. Lamba[1], C. Hochman-Mendez[2], T. Rosengart[1], K. K. Liao[1]. *[1]Department of Surgery, Baylor College of Medicine, Houston, TX, [2]Regenerative Medicine Research, Texas Heart Institute, Houston, TX*

11:15 a.m. – 12:15 p.m.

SESSION 94: FRIDAY NIGHT LIGHTS: LUNG TRANSPLANTATION PERI-OPERATIVE MEDICINE

Location: Rooms 205-207

Core Therapies: LUNG
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Pulmonology

Session Summary: This session will focus on new peri-operative developments that may improve patient outcomes as well as physician well-being! From clinical and experimental studies, the audience will learn new techniques in peri-operative lung transplantation and their impact on ischemia-reperfusion injury.

Co-Chairs: Edward Cantu, MD, MSCE, University of Pennsylvania, Philadelphia, PA USA
Brandi Bottiger, MD, Duke University Hospital, Durham, NC USA

11:15 a.m. **(205)** ***Temporary Diaphragm Pacing Wires in Lung Transplant Patients: Diagnostic and Therapeutic Utilization***; R. Onders[1], M. Elmo[1], N. Carl[1], Y. Elgudin[2], Y. Abu-Omar[1], M. Pelletier[1], R. Schilz[3]. *[1]University Hospitals Cleveland Medical Center, Cleveland, OH, [2]University Hospitals Cleveland Medcial Center, Cleveland, OH, [3]Case Western Reserve University, Cleveland, OH*

11:30 a.m. **(206)** ***Semi-Elective Lung Transplantation: Is It Possible? A Single Institution Prospective Study Using 10°C Cold Storage***; M. Gil Barturen, A. Romero Román, L. Hoyos Mejia, S. Crowley, J. Naranjo Gomez, M. Cordoba Pelaez, R. Laporta Hernandez, A. Romero Berrocal, J. Martín López, P. Cordero Iglesias, F. Alayza Avendaño, D. Gómez de Antonio, J. Campo-Cañaveral de la Cruz. *Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain*

11:45 a.m. **(207)** ***Pumpless Intra-Operative Circulatory Support During Lung Transplantation: Pulmonary Artery to Left Atrium Oxygenator in a Porcine Model of Pulmonary Ischemia-Reperfusion Injury***; M. Orlitova[1], D. Van Beersel[2], A. E. Frick[1], K. Van de Voorde[2], K. Degezelle[2], J. Hellinck[1], M. Nolmans[1], B. M. Vanaudenaerde[1], G. M. Verleden[2], R. Vos[2], P. Claus[1], D. E. Van Raemdonck[2], L. J. Ceulemans[2], T. Verbelen[2], A. P. Neyrinck[2]. *[1]KU Leuven, Leuven, Belgium, [2]University Hospitals Leuven, Leuven, Belgium*

12:00 p.m. **(208)** ***Minimally Invasive Lung Transplantation Improves Post-Operative Pulmonary Function and Reduces Opiate Requirements***; J. Thomas[1], Q. Chen[1], J. Malas[1], D. Barnes[2], A. Peiris[1], C. Premananthan[1], A. Krishnan[1], G. Rowe[1], G. Gill[1], D. Emerson[1], R. Rampolla[3], J. Chikwe[1], P. Catarino[1], D. Megna[1]. *[1]Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, [2]Department of Pharmacy, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, [3]Department of Pulmonary and Critical Care Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA*

11:15 a.m. – 12:15 p.m.

SESSION 95: BAD MEDICINE ON THE EDGE OF A BROKEN HEART: ADVERSE EVENTS IN MCS

Location: Rooms 405-407

Core Therapies: MCS
Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health, Pediatrics, Research and Immunology

Session Summary: This session will focus on adverse events in patients with durable mechanical assist devices including uniforming the definitions, early/late markers and--last but not least--prevalence.

Co-Chairs: Daniel J Goldstein, MD, Montefiore Medical Center, Bronx, NY USA
Julie Vishram-Nielsen, MD, PhD, Roskilde Hospital, Roskilde, Denmark

11:15 a.m. **(209)** ***Moving Toward Uniform Criteria for Adverse Event Definitions Across Mechanical Circulatory Support***; K. R. Ryan[1], C. Ozment[2], O. Jahadi[1], D. Bonadonna[2], J. Murray[1], J. Dykes[1], J. Sleasman[1], V. Yarlagadda[1], C. S. Almond[3]. *[1]Stanford University, Palo Alto, CA, [2]Duke University, Durham, NC, [3]Pediatrics, Stanford University, Palo Alto, CA*

11:30 a.m. **(210)** ***Early Markers for Hemocompatibility Related Adverse Events Based on Routinely Available Pump Parameters from HeartMate 3 Left Ventricular Assist Device Patients***; T. Abart[1], C. Gross[1], F. Kohout[1], A. Schaefer[1], J. Riebandt[1], G. Laufer[1], D. Wiedemann[1], D. Zimpfer[1], T. Schloeglhofer[2]. *[1]Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, [2]Department of Cardiac Surgery, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria*

11:45 a.m. **(211)** ***Retinal Microvascular Remodelling Predicts Adverse Events in Continuous-Flow Left Ventricular Assist Device Supported Patients***; S. Jeyakumar[1], H. Nguyen[2], D. Robson[3], N. Olsen[1], B. Schnegg[3], P. MacDonald[3], C. Fraser[4], G. Liew[2], C. Hayward[3], K. Muthiah[3]. *[1]University of New South Wales, Sydney, Australia, [2]Westmead Institute for Medical Research, Sydney, Australia, [3]St. Vincent's Hospital, Darlinghurst, Australia, [4]University of Sydney, Sydney, Australia*

12:00 p.m. **(212)** ***Five-Year Survival and Incidence of Adverse Events in Patients Implanted with HeartMate 3 Left Ventricular Assist Device at a High Volume Center***; G. Mondellini[1], A. Vinogradsky[1], M. Kirschner[1], P. A. Kurlansky[1], Y. Ning[1], J. Y. Sun[1], M. Tiburcio[1], A. Kleet[1], Y. Naka[2], Y. Kaku[1], G. T. Sayer[1], N. Uriel[2], M. Yuzefpolskaya[1], K. Takeda[1], P. C. Colombo[1]. *[1]Columbia University Irving Medical Center, New York, NY, [2]New York Presbyterian Hospital, New York, NY*

11:15 a.m. – 12:15 p.m.

SESSION 96: UNBREAK MY HEART: RECOVERY AND WEANING IN MCS PATIENTS

Location: Rooms 201-203

Core Therapies: MCS
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Pediatrics

Session Summary: This session will focus on MCS weaning strategies and on the evaluation of myocardial recovery.

Co-Chairs: Maryjane Farr, MD, UT Southwestern Medical Center, Dallas, TX USA
Cesar Guerrero-Miranda, MD, FACC, Baylor University MC, Baylor Scott and White, Dallas, TX USA

11:15 a.m. **(213)** ***Impella 5.0/5.5 Support in AMI CS Patients: How to Increase Myocardial Recovery Chances***; M. Pieri[1], A. Ortalda[1], S. Altizio[1], S. Ajello[2], L. Bertoglio[1], P. Nardelli[1], E. Fominskiy[1], E. Lapenna[1], A. Scandroglio[3]. *[1]IRCCS San Raffaele Scientific Institute, Milan, Italy, [2]Milano, Milano, Italy, [3]IRCCS San Raffaele Scientific Institute, Milano, Italy*

11:30 a.m. **(214)** ***Long-Term Clinical Trajectory after Durable Lvad Weaning: An International Registry Report***; S. R. Patel[1], J. Knierim[2], D. Goldstein[3], H. Lamba[4], B. Sun[5], J. Schmitto[6], B. Lowes[7], P. Shah[8], M. Kanwar[9], J. Wald[10], A. Ravichandran[11], G. MacGowan[12], V. Ton[13], S. Silvestry[14], F. Sera[15], M. Farooq[16], U. Jorde[16], J. Stehlik[17], C. Selzman[17], E. Potapov[18], S. Drakos[17]. *[1]Montefiore-Einstein, Bronx, NY, [2]Deutsches Herzzentrum Berlin, Berlin, BE, Germany, [3]Montefiore, Bronx, NY, [4]Houston, TX, [5]Minneapolis Heart Institute, Minneapolis, MN, [6]Hannover Medical School, Hannover, Germany, [7]U. Nebraksa Med Ctr, Omaha, NE, [8]Inova Heart and Vascular Institute, Falls Church, VA, [9]Allegheny General Hospital, Pittsburgh, PA, [10]Philadelphia, PA, [11]St. Vincent Heart Center of Indiana, 46074, IN, [12]Freeman Hospital, Newcastle Upon Tyne, United Kingdom, [13]., Boston, MA, [14]AdventHealth Transplant Institute, Orlando, FL, [15]Cardiovascular Medicine, Osaka University, Osaka, Japan, [16]Montefiore Medical Center, Bronx, NY, [17]University of Utah, Salt Lake City, UT, [18]German Heart Institute, Berlin, BE, Germany*

11:45 a.m. **(215)** ***Multicenter Development and Validation of a Machine Learning Model to Predict Myocardial Recovery During LVAD Support: The UCAR Score***; C. P. Kyriakopoulos[1], I. Taleb[1], O. Wever-Pinzon[1], C. Selzman[1], M. Bonios[1], E. Dranow[1], J. Wever-Pinzon[1], M. Yin[1], E. Tseliou[1], J. Stehlik[1], R. Alharethi[1], A. Kfoury[1], T. Hanff[1], J. Fang[1], A. Koliopoulou[1], K. Sideris[1], E. Krauspe[1], M. Nelson[1], A. Elmer[1], R. Singh[2], M. Psotka[2], E. Birks[3], M. Slaughter[3], S. Koenig[3], A. Kyvernitakis[4], K. Hoffman[4], M. Guglin[5], J. Kotter[5], K. Campbell[5], S. Silvestry[6], A. Vidic[6], N. Raval[6], M. Mehra[7], J. Cowger[8], M. Kanwar[4], P. Shah[2], S. G. Drakos[1]. *[1]Utah Cardiac Recovery (UCAR) Program (University of Utah Health and School of Medicine, Intermountain Medical Center, George E. Wahlen Department of Veterans Affairs Medical Center), Salt Lake City, UT, [2]Inova Heart and Vascular Institute, Falls Church, VA, [3]University of Louisville, Louisville, KY, [4]Cardiovascular Institute at Allegheny Health Network, Pittsburgh, PA, [5]University of Kentucky, Lexington, KY, [6]AdventHealth Transplant Institute, Orlando, FL, [7]Brigham and Women's Hospital and Harvard Medical School, Boston, MA, [8]Henry Ford Hospitals, Detroit, MI*

12:00 p.m. **(216)** ***Combined Strategy to Induce Myocardial Recovery in Children with Advanced Heart Failure: Single Center Retrospective Study***; R. Adorisio, N. Cantarutti, E. Bellettini, G. Ingrasciotta, E. Mencarelli, M. Grandinetti, R. Kirk, A. Amodeo. *Bambino Gesù Children's Hospital, IRCCS, Rome, Italy*

12:30 – 1:30 p.m.

SESSION 97: MEASURE FOR MEASURE: REJECTION SURVEILLANCE: ALL THAT GLITTERS IS NOT GOLD

Location: Rooms 603-605

Core Therapies: HEART
Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Pharmacy, Research and Immunology

Session Summary: This session includes some controversies in the diagnosis of rejection in heart transplant recipients.

Co-Chairs: Juan Ortega-Legaspi, MD, PhD, University of Pennsylvania, Philadelphia, PA USA
Marco Masetti, MD, PhD, IRCCS S. Orsola Malpighi, University of Bologna, Bologna, Italy

12:30 p.m. **(217)** ***Rejection Outcomes in Donation after Cardiac Death (DCD) Heart Transplants***; S. S. Li[1], M. Funamoto[2], A. Osho[1], D. Paneitz[1], R. Singh[1], G. Lewis[3], D. D'Alessandro[1]. *[1]Cardiac Surgery, Massachusetts General Hospital, Boston, MA, [2]Cardiac Surgery, Methodist Hospital, San Antonio, TX, [3]Cardiology, Massachusetts General Hospital, Boston, MA*

12:45 p.m. **(218)** ***A "Negative" Endomyocardial Biopsy after an Elevated Donor-Derived Cell Free DNA is Associated with Worse Survival after Heart Transplant***; J. Teuteberg[1], S. Pinney[2], K. Khush[3], M. Fei[4], J. Yue[4], L. Shen[4], S. Patel[5], M. Kanwar[6], P. Shah[7], N. Uriel[8]. *[1]Stanford University School of Medicine, Stanford, CA, [2]University of Chicago, Chicago, IL, [3]Stanford University, Stanford, CA, [4]Biostatistics and Data Sciences, CareDx, Brisbane, CA, [5]Montefiore-Einstein, Bronx, NY, [6]Allegheny General Hospital, Pittsburgh, PA, [7]Inova Heart and Vascular Institute, Falls Church, VA, [8]New York Presbyterian, New York, NY*

1:00 p.m. **(219)** ***How Age, Sex, and Time Influence Dd-Cfdna in Heart Transplant (HT) Recipients: A Real-World Experience***; S. Carey[1], K. Woodruff[1], E. Ahmed[1], M. Olymbios[1], S. Hall[2]. *[1]Natera, San Carlos, CA, [2]Baylor University Medical Center, Dallas, TX*

1:15 p.m. **(220)** ***Cell-Free DNA Enhances Pathologist Interrater Reliability at the Assessment of Acute Rejection on Endomyocardial Biopsy, on Behalf of the GRAfT Investigators***; A. Mehta[1], J. Goldberg[2], P. Bagchi[3], C. Marboe[4], K. Shah[5], S. Najjar[6], S. Hsu[7], M. Rodrigo[8], M. Jang[9], A. Cochrane[10], I. Tchoukina[5], H. Kong[11], B. Lohmar[12], E. Mcnair[12], H. Valantine[13], S. Agbor-Enoh[14], G. Berry[15], P. Shah[12]. *[1]Cardiovascular Disease, Inova Fairfax Medical Campus, Falls Church, VA, [2]Inova L.J. Murphy Children's Hospital, Germantown, TN, [3]Department of Statistics, George Mason University, Fairfax, VA, [4]Columbia University Vagelos College of Physicians & Surgeons, San Rafael, CA, [5]Virginia Commonwealth University, Richmond, VA, [6]MedStar Health, Baltimore, MD, [7]Johns Hopkins University School of Medicine, Baltimore, MD, [8]Medstar Washington Hospital Center, Potomac, MD, [9]NHLBI/NIH, Bethesda, MD, [10]Inova Fairfax Hospital, Potomac, MD, [11]National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, [12]Inova Heart and Vascular Institute, Falls Church, VA, [13]Stanford University School of Medicine, Portola Valley, CA, [14]National Institutes of Health, Bethesda, MD, [15]Stanford Univ, Palo Alto, CA*

12:30 – 1:30 p.m.

SESSION 98: ANDROMEDA STRAIN: HUMAN-VIRAL INTERACTIONS IN LUNG TRANSPLANTATION

Location: Rooms 401-404

Core Therapies: LUNG
Practice Areas: Pulmonology, Infectious Diseases, Research and Immunology

Session Summary: This session will discuss humoral and cellular immune responses to viral infections after lung transplantation.

Co-Chairs: Emily Blumberg, MD, University of Pennsylvania, Philadelphia, PA USA
Allan Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, NSW Australia

12:30 p.m. **(221)** ***CMV-Expanded, Phenotypically Heterogenous CD8 TEMRA Differentially Associate with Viral Control and Allograft Outcomes***; H. Pickering[1], J. Arakawa-Hoyt[2], M. Llamas[1], K. Ishiyama[2], Y. Sun[1], R. Parmar[1], S. Sen[1], J. Schaenman[1], L. L. Lanier[2], E. Reed[3], D. Calabrese[4], J. Greenland[5]. *[1]UCLA, Los Angeles, CA, [2]UCSF, San Francisco, CA, [3]UCLA Immunogenetics Center, Malibu, CA, [4]University of California, San Francisco, Mill Valley, CA, [5]University of California, San Francisco, San Francisco, CA*

12:45 p.m. **(222)** ***Discordance Between Humoral and Cellular Immune Responses to Cytomegalovirus Infection in CMV Seropositive Recipients (R+)***; M. Boada Pérez[1], C. Berastegui Garcia[2], M. Erro[3], P. Ussetti[3], E. Crespo[4], L. Donadeu[4], O. Bestard[5], G. Anguera[6], A. Sole[6], R. Ponz[7], B. Molloy[7], E. Revilla[2], V. Monforte[8], S. Gomez[9]. *[1]Department of Pulmonology, Vall d'Hebron Institut de Recerca, Barcelona, Spain; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain, [2]Department of Pulmonology, Lung Transplant Program, Hospital Universitari Vall Hebron, Barcelona, Spain, [3]Unidad de Trasplante pulmonar, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain, [4]Department of Nephrology and Renal Transplantation, Vall d'Hebron Institut de Recerca, Barcelona, Spain, [5]Department of Nephrology and Renal Transplantation, Hospital Universitari Vall d'Hebron, Barcelona, Spain, [6]Unidad de Trasplante Pulmonar, Hospital Universitario La Fe, Instituto de Investigación Sanitaria La Fe, Valencia, Spain, [7]MSD Spain, Madrid, Spain, [8]Department of Pulmonology, Lung Transplant Program, Hospital Universitari Vall Hebron, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain, [9]Department of Pulmonology, Vall d'Hebron Research Institute Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain*

1:00 p.m. **(223)** ***Parainfluenza Virus Infections in Lung Transplant Recipients: A Multicenter Comparison with Influenza Virus and Assessment of Ribavirin Efficacy***; A. De Zwart[1], A. Riezebos-Brilman[2], A. Rasoul[3], B. Luijk[4], H. Kerstjens[1], T. Gan[5], J. C. Alffenaar[6], E. Verschuuren[7]. *[1]University of Groningen, University Medical Center Groningen, Groningen, Netherlands, [2]Laboratory for Medical Microbiology and Public Health, Enschede, Netherlands, [3]University of Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, [4]UMC Utrecht, Utrecht, Netherlands, [5]Univ Med Center Groningen, Groningen, Netherlands, [6]Sydney Institute for Infectious Diseases, University of Sydney and Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, Australia, [7]University Medical Centre Groningen, Groningen, GR, Netherlands*

1:15 p.m. **(224)** ***Immunological and Molecular Characterization of Circulating Exosomes Induced by Lung Transplant Recipients with Covid-19***; S. Bansal[1], T. Fleming[1], M. Smith[2], R. Bremner[1], T. Mohanakumar[3]. *[1]St. Joseph's Hospital and Medical Center, Phoenix, AZ, [2]St. Joseph's Hosp & Med Center Norton Thoracic Institute, Phoenix, AZ, [3]St. Joseph 's Hospital and Medical Center, Phoenix, AZ*

12:30 – 1:30 p.m.

SESSION 99: ECMO IS A FOUR-LETTER WORD: STRATEGIES AND DESTINATIONS FOR PATIENTS ON SUPPORT

Location: Rooms 501-504

Core Therapies: MCS
Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Pediatrics, Pulmonology

Session Summary: This session will delve into high priority topics in ECMO support including physiology regarding left ventricular filling pressures, use of combination ECMO and Impella, and transition to durable MCS from ECMO.

Co-Chairs: Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN USA
Evgenij Potapov, MD, German Heart Institute, Berlin, Germany

12:30 p.m. **(225)** ***Afterload and LV Function, but Not Circuit Flow, Determine LV Filling Pressure During VA-ECMO***; J. Jiang[1], P. Jain[2], A. Adji[3], S. Barua[4], C. Hayward[4]. *[1]University of New South Wales, Darlinghurst, Australia, [2]Royal Prince Alfred Hospital, Sydney, Australia, [3]Victor Chang Cardiac Research Institute, Darlinghurst, Australia, [4]St Vincent's Hospital, Darlinghurst, Australia*

12:45 p.m. **(226)** ***Comparison of In-Hospital Outcomes in Acute Myocardial Infarction-Cardiogenic Shock (AMICS) versus Non-AMICS Following ECPELLA***; S. Mathai[1], K. Krupad[2], S. Sohal[3], A. Mehta[1], M. Montgomery[4], S. Murthy[5], G. Visveshwaran[3], D. Sims[6], U. Jorde[7]. *[1]Jacobi Medical Center/AECOM, Bronx, NY, NY, [2]Carle Foundation Hospital, Urbana, IL, [3]RWJ-BH Newark Beth Israel Medical Center, Newark, NJ, [4]., Jersey City, NJ, [5]Montefiore Medical Center, Nyack, NY, [6]Montefiore Medical Center NY, New York, NY, [7]Montefiore Medical Center, Bronx, NY*

1:00 p.m. **(227)** ***Impella 5.5 with Veno-Arterial Extracorporeal Membrane Oxygenation Support as Ecpella 5.5***; A. Isath[1], A. Gass[2], S. Pan[3], E. Levine[4], C. Gupta[5], G. Lanier[6], D. Spielvogel[3], M. Kai[3], S. Ohira[7]. *[1]Westchester Medical Center and New York Medical College, Valhalla, NY, [2]Westchester Medical Center, valhalla, NY, [3]Westchester Medical Center, Valhalla, NY, [4]Westchester Medical Center, Teaneck, NJ, [5]Westchester Medical Center, Pleasantville, NY, [6]Westchester Medical Center, New York, NY, [7]Westchester Medical Center, New York Medical College, Valhalla, NY*

1:15 p.m. **(228)** ***Optimal Patient Selection on Extra-Corporeal Life Support for Durable Mechanical Circulatory Support: Validation Study on Behalf of Durable MCS after ECLS Study Group***; D. Saeed[1], C. Stark[2], A. Loforte[3], D. Zimpfer[4], A. Bernhardt[5], D. Schibilsky[6], J. Riebandt[4], K. Jawad[1], A. Lichtenberg[7], A. Haneya[8], E. Potapov[9], A. Albert[10], W. Otto[1], K. Huenges[8], H. Aubin[7], D. Lewin[9], A. Raweh[10], M. Morshuis[11], U. Jorde[12], H. Reichenspurner[5], M. Borger[1], J. Gummert[11]. *[1]Leipzig Heart Center, Leipzig, Germany, [2]Helsinki University Central Hospital, Helsinki, Finland, [3]S. Orsola University Hospital, Università di Bologna, Bologna, BO, Italy, [4]Medical University Vienna, Vienna, Austria, [5]University Hospital Hamburg-Eppendorf, Hamburg, Germany, [6]Freiburg, Germany, [7]University Hospital Duesseldorf, Düsseldorf, Germany, [8]University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany, [9]German Heart Center, Berlin, Germany, [10]Klinikum Dortmund, Dortmund, Germany, [11]Herz und Diabeteszentrum NRW, Bad Oeynhausen, Germany, [12]Montefiore Medical Center, Bronx, NY*

12:30 – 1:30 p.m.

SESSION 100: CUTTING TO THE HEART OF THE MATTER: FROM PROCUREMENT TO IMPLANT

Location: Rooms 205-207

Core Therapies: HEART
Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Nursing and Allied Health, Pathology, Research and Immunology

Session Summary: Does surgical technique really impact donor heart function: from procurement to implant? This session looks not only at the "cutting and pasting" but also shines a light on the microscopic level. What is the myocardial impact of preservation solutions and warm ischaemia? Are we setting up donor hearts for success or sending them down the rocky road of graft dysfunction?

Co-Chairs: Amanda Vest, MBBS, MPH, Tufts Medical Center, Boston, MA USA
Nicolas Brozzi, MD, Cleveland Clinic, Weston, FL USA

12:30 p.m. **(229)** ***A Single Center Comparison of DCD Heart Transplantation Using Two Procurement Strategies: Direct Procurement and Perfusion versus Normothermic Regional Perfusion***; M. J. Kearns[1], A. Brann[2], R. White[2], B. Jackson[2], D. Cookish[2], K. Sharaf[2], D. Huynh[3], Y. Gernhofer[4], H. Tran[2], M. Urey[2], E. Adler[2], V. Pretorius[2]. *[1]UC San Diego Health, La Jolla, CA, [2]UC San Diego, La Jolla, CA, [3]UC San Diego Health Systems, San Diego, CA, [4]University of the Incarnate Word School of Osteopathic Medicine, San Antonio, TX*

12:45 p.m. **(230)** ***The Effect of Preservation Modality on Myocardial Injury - A Single Blinded Study***; D. Lotan[1], G. Rubinstein[1], C. M. Moeller[1], S. Slomovich[1], D. Oren[1], E. M. DeFilippis[1], J. Raikhelkar[1], K. Clerkin[1], J. Fried[1], D. Majure[2], Y. Naka[3], Y. Kaku[3], K. Takeda[3], K. Oh[1], E. Lin[1], S. Lee[1], V. Topkara[1], P. Colombo[1], M. Yuzefpolskaya[1], F. Latif[1], G. Sayer[1], N. Uriel[1], S. Miroslav[4]. *[1]Division of Cardiology -Center for Advanced Cardiac Care, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY, [2]Division of Cardiology -Center for Advanced Cardiac Care, Weill Cornell Medical College, New York, NY, [3]Division of Cardiac, Thoracic & Vascular Surgery - Department of Surgery, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY, [4]Department of Pathology and Cell Biology, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY*

1:00 p.m. **(231)** ***Impact of Surgical Techniques on Survival and Hemodynamics after Orthotopic Heart Transplantation***; A. Nemoto[1], M. Belkin[2], N. Sarswat[3], B. Chung[3], A. Nguyen[3], B. Smith[3], S. Kalantari[3], G. Kim[3], J. Grinstein[3], S. Pinney[2], D. Onsager[2], T. Song[2], C. Salerno[2], V. Jeevanandam[4], T. Ota[2]. *[1]Section of Cardiac Surgery, University of Chicago Medicine, Chicago, IL, [2]University of Chicago, Chicago, IL, [3]University of Chicago Medicine, Chicago, IL, [4]University of Chicago Medical Center, Chicago, IL*

1:15 p.m. **(232)** ***Temporal Changes in Myocardial Edema, Inflammation and Injury in Human Heart Donated after Circulatory Death: Impact of Warm Ischemia and Subsequent Cold Storage***; N. K. Mondal[1], S. Li[1], A. E. Elsenousi[1], A. Mattar[1], H. K. Lamba[1], C. Hochman-Mendez[2], T. Rosengart[1], K. K. Liao[1]. *[1]Department of Surgery, Baylor College of Medicine, Houston, TX, [2]Regenerative Medicine Research, Texas Heart Institute, Houston, TX*

12:30 – 1:30 p.m.

SESSION 101: BRAVE NEW WORLD: IMPROVING EVLP SCIENCE

Location: Rooms 405-407

Core Therapies: LUNG
Practice Areas: Research and Immunology, Cardiothoracic Surgery, Pulmonology

Session Summary: This session will highlight new developments in the clinical and translational science of ex vivo lung perfusion (EVLP).

Co-Chairs: Caitlin Demarest, MD, PhD, Vanderbilt University Medical Center, Nashville, TN USA
Jorge Mallea, MD, Mayo Clinic Florida, Jacksonville, FL USA

12:30 p.m. **(233)** ***Supervised Machine Learning Algorithm Reveals Human Lung EVLP Perfusate Cell Populations are Associated with Donor Mode of Death and Post-Transplant Primary Graft Dysfunction***; A. Duong[1], G. Madu[1], S. Moshkelgosha[2], J. Yeung[3], M. Cypel[1], S. Keshavjee[4], T. Martinu[5], S. Juvet[1]. *[1]University Health Network, Toronto, ON, Canada, [2]Toronto, ON, Canada, [3]University of Toronto, Toronto, ON, Canada, [4]UHN, Toronto, ON, Canada, [5]Toronto General Hospital/UHN, Toronto, ON, Canada*

12:45 p.m. **(234)** ***Human Pulmonary Endothelial Function is Improved by Nutrient Supplementation in Ex Vivo Lung Perfusion Perfusates***; D. Bojic[1], R. Vellanki[2], O. Hough[1], B. Wouters[2], A. Andreazza[3], S. Keshavjee[1], M. Liu[1]. *[1]Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, [2]Radiation Oncology, Princess Margaret Cancer Centre and Campbell Family Institute for Cancer Research, Toronto, ON, Canada, [3]Departments of Pharmacology & Toxicology and Psychiatry, University of Toronto, Toronto, ON, Canada*

1:00 p.m. **(235)** ***Neutrophil Extracellular Traps Removal During Ex Vivo Lung Perfusion Improves Lung Function in Aspiration Damaged Porcine Lungs***; M. Mittendorfer[1], L. Pierre[2], G. Kjellberg[3], J. Schofield[4], S. Abrams[4], G. Wang[5], C. Toh[6], A. Aswani[7], F. Olm[2], S. Lindstedt[8]. *[1]Lund University, Lund, Sweden, [2]Lund University Hospital, Lund, Sweden, [3]Uppsala University Hospital, Uppsala, Sweden, [4]University of Liverpool, Liverpool, United Kingdom, [5]Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom, [6]Royal Liverpool University Hospital, Liverpool, United Kingdom, [7]Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom, [8]Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden*

1:15 p.m. **(236)** ***Autologous Blood Re-Exposure Does Not Invoke Hyperacute Rejection in a Human Lung after Xenogeneic Cross-Circulation***; T. Harris[1], K. Tracy[1], S. Francois[1], W. Tucker[1], R. Ukita[2], C. Johnson[1], S. DeVries[1], M. Cortelli[1], N. Cardwell[1], N. Do[1], C. Pasrija[1], C. Demarest[2], S. Alexopoulos[3], C. Shaver[2], M. Bacchetta[4]. *[1]Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, [2]Vanderbilt University Medical Center, Nashville, TN, [3]Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, [4]Vanderbilt University Medical Center, Mt Juliet, TN*

12:30 – 1:30 p.m.

SESSION 102: LOVE, ACTUALLY: REJECTION IN LUNG TRANSPLANTATION

Location: Rooms 201-203

Core Therapies: LUNG
Practice Areas: Pulmonology, Cardiothoracic Surgery, Pathology, Research and Immunology

Session Summary: This session will highlight scientific advances in diagnosis and prevention of acute and chronic rejection after lung transplantation.

Co-Chairs: Kieran Halloran, MD, MSc, University of Alberta, Edmonton, AB Canada
Stephanie Chang, MD, NYU Langone Health, New York, NY USA

12:30 p.m. **(237)** ***The Ability of an Electronic Nose to Distinguish Between Acute Cellular Rejection and Infection in Lung Transplant Recipients***; N. Wijbenga[1], R. A. Hoek[1], B. J. Mathot[1], L. Seghers[1], D. Bos[2], O. C. Manintveld[3], M. E. Hellemons[1]. *[1]Department of Respiratory Medicine and Erasmus MC Transplant Institute, Erasmus MC University Medical Center, Rotterdam, Netherlands, [2]Department of Radiology & Nuclear Medicine and Epidemiology, Erasmus MC University Medical Center, Rotterdam, Netherlands, [3]Department of Cardiology and Erasmus MC Transplant Institute, Erasmus MC University Medical Center, Rotterdam, Netherlands*

12:45 p.m. **(238)** ***Downregulation of LKB1-Stradα Pathway in Circulating Exosomes as a Biomarker for Chronic Murine Lung Allograft Rejection***; M. Rahman[1], S. Bansal[2], R. Ravichandran[3], N. Sankpal[4], S. Angara[4], M. Smith[5], R. Bremner[6], T. Mohanakumar[7]. *[1]Norton Thoracic Institute, St. Joseph Hospital & Medical Center, Phoenix, AZ, [2]Phoenix, AZ, [3]St. Joseph's Hospital and Medical Center, Phoenix, AZ, [4]Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, [5]St. Joseph's Hosp & Med Center Norton Thoracic Institute, Phoenix, AZ, [6]Dignity Health, Phoenix, AZ, [7]Norton Thoracic Institute, St. Joseph's Hosp and Medical Center, Phoenix, AZ*

1:00 p.m. **(239)** ***CD26/Dipeptidyl Peptidase-4 Inhibitors as Prophylaxis of Chronic Lung Allograft Dysfunction after Lung Transplantation, a Clinicopathological Evaluation***; Y. Yamada, S. Tanaka, Y. Yutaka, M. Hamaji, D. Nakajima, A. Ohsumi, H. Date. *Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan*

1:15 p.m. **(240)** ***The Effect of CTLA-4-Ig on the Progression of Fibrosis from Acute Cellular Rejection in a Murine Model of Chronic Lung Allograft Dysfunction***; K. Mineura, S. Tanaka, Y. Goda, Y. Yamada, Y. Yutaka, A. Ohsumi, D. Nakajima, M. Hamaji, T. Menju, H. Date. *Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan*